Table of Contents

Index to Financial Statements

As filed with the Securities and Exchange Commission on June 3, 2016

Securities Act File No. 333-203511

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM N-2

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

(Check appropriate box or boxes)

 

 

Pre-Effective Amendment No.     

Post-Effective Amendment No. 5

Hercules Capital, Inc.

(formerly known as Hercules Technology Growth Capital, Inc.)

(Exact name of Registrant as specified in charter)

 

 

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

(Address of Principal Executive Offices)

Registrant’s Telephone Number, including Area Code: (650) 289-3060

Manuel A. Henriquez

Chief Executive Officer

Hercules Capital, Inc.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

(Name and address of agent for service)

 

 

COPIES TO:

William Bielefeld

Ian Hartman

Jay Alicandri

Dechert LLP

1095 Avenue of the Americas

New York, NY 10036

APPROXIMATE DATE OF PROPOSED PUBLIC OFFERING:

As soon as practicable after the effective date of this Registration Statement.

 

 

If any securities being registered on this form will be offered on a delayed or continuous basis in reliance on Rule 415 under the Securities Act of 1933, other than securities offered in connection with a dividend reinvestment plan, check the following box.  x

It is proposed that this filing will become effective (check appropriate box):  x  when declared effective pursuant to section 8(c).

 

 

CALCULATION OF REGISTRATION FEE UNDER THE SECURITIES ACT OF 1933

 

Title of Securities Being Registered		Amount Being Registered		Proposed Maximum Aggregate Offering Price(1)		Amount of Registration Fee(1)
Common Stock, $0.001 par value per share(2)
Preferred Stock, $0.001 par value per share(2)
Warrants(2)
Subscription Rights(3)
Debt Securities(4)
TOTAL(5)				$500,000,000		$58,100(6)

(1)

Estimated pursuant to Rule 457(o) solely for the purposes of determining the registration fee. The proposed maximum offering price per security will be determined, from time to time, by the Registrant in connection with the sale by the Registrant of the securities registered under this registration statement.

(2)	Subject to Note 5 below, there is being registered hereunder an indeterminate number of shares of common stock, preferred stock, or warrants as may be sold, from time to time. Warrants represent rights to purchase common stock, preferred stock or debt securities.

(3)	Subject to Note 5 below, there is being registered hereunder an indeterminate number of subscription rights as may be sold, from time to time, representing rights to purchase common stock.

(4)

Subject to Note 5 below, there is being registered hereunder an indeterminate principal amount of debt securities as may be sold, from time to time. If any debt securities are issued at an original issue discount, then the offering price shall be in such greater principal amount as shall result in an aggregate price to investors not to exceed $500,000,000.

(5)	In no event will the aggregate offering price of all securities issued from time to time pursuant to this registration statement exceed $500,000,000.

(6)	Previously paid.

 

 

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.

 

 

 

---

Table of Contents

Index to Financial Statements

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS (Subject to Completion)

June 3, 2016

$500,000,000

 

 

Common Stock

Preferred Stock

Warrants

Subscription Rights

Debt Securities

This prospectus relates to the offer, from time to time, in one or more offerings or series, up to $500,000,000 of shares of our common stock, par value $0.001 per share, preferred stock, par value $0.001 per share, warrants representing rights to purchase shares of our common stock, preferred stock or debt securities, subscription rights or debt securities, which we refer to, collectively, as the “securities.” The preferred stock, debt securities, subscription rights and warrants offered hereby may be convertible or exchangeable into shares of our common stock. We may sell our securities through underwriters or dealers, “at-the-market” to or through a market maker into an existing trading market or otherwise directly to one or more purchasers, including existing stockholders in a rights offering, or through agents or through a combination of methods of sale, including auctions. The identities of such underwriters, dealers, market makers or agents, as the case may be, will be described in one or more supplements to this prospectus. The securities may be offered at prices and on terms to be described in one or more supplements to this prospectus.

We may offer shares of common stock at a discount to net asset value per share in certain circumstances. On July 7, 2015, our common stockholders voted on a proposal to allow us to issue common stock at a price below net asset value per share, which was approved by our common stockholders and is effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of our common stockholders. Our Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of net asset value per share. Sales of common stock at prices below net asset value per share dilute the interests of existing stockholders, have the effect of reducing our net asset value per share and may reduce our market price per share. In the event we offer common stock, the offering price per share will not be less than the net asset value per share of our common stock at the time we make the offering except (1) in connection with a rights offering to our existing stockholders, (2) with the consent of the holders of the majority of our voting securities and approval of our Board of Directors, or (3) under such circumstances as the Securities and Exchange Commission may permit. See “Risk Factors” for more information.

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a broadly diversified variety of technology, life sciences and sustainable and renewable technology industries. We primarily finance privately-held companies backed by leading venture capital and private equity firms and publicly-traded companies that lack access to public capital or are sensitive to equity ownership dilution. We source our investments through our principal office located in Palo Alto, CA, as well as through additional offices in Boston, MA, New York, NY, McLean, VA, Santa Monica, CA and Hartford, CT. Our goal is to be the leading structured debt financing provider for venture capital-backed companies in technology-related industries requiring sophisticated and customized financing solutions. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company. We invest primarily in private companies but also have investments in public companies.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our equity-related investments. We are an internally-managed, non-diversified closed-end investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended.

Our common stock is traded on the New York Stock Exchange, or NYSE, under the symbol “HTGC.” On June 2, 2016, the last reported sale price of a share of our common stock on the NYSE, was $12.38. The net asset value per share of our common stock at March 31, 2016 (the last date prior to the date of this prospectus on which we determined net asset value) was $9.81.

 

 

An investment in our securities may be speculative and involves risks including a heightened risk of total loss of investment. In addition, the companies in which we invest are subject to special risks. See “Risk Factors” beginning on page 11 to read about risks that you should consider before investing in our securities, including the risk of leverage.

Please read this prospectus before investing and keep it for future reference. It contains important information about us that a prospective investor ought to know before investing in our securities. We file annual, quarterly and current reports, proxy statements and other information about us with the Securities and Exchange Commission. The information is available free of charge by contacting us at 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301 or by telephone calling collect at (650) 289-3060 or on our website at www.htgc.com. The SEC also maintains a website at www.sec.gov that contains such information.

 

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

This prospectus may not be used to consummate sales of any securities unless accompanied by a prospectus supplement.

The date of this prospectus is                     , 2016

---

Table of Contents

Index to Financial Statements

You should rely only on the information contained in this prospectus. We have not authorized any dealer, salesperson or other person to provide you with different information or to make representations as to matters not stated in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell, or a solicitation of an offer to buy, any securities by any person in any jurisdiction where it is unlawful for that person to make such an offer or solicitation or to any person in any jurisdiction to whom it is unlawful to make such an offer or solicitation. The information in this prospectus is accurate only as of its date, and under no circumstances should the delivery of this prospectus or the sale of any securities imply that the information in this prospectus is accurate as of any later date or that the affairs of Hercules Capital, Inc. have not changed since the date hereof. This prospectus will be updated to reflect material changes.

 

 

TABLE OF CONTENTS

 

		Page
Summary			1
Fees and Expenses			7
Selected Consolidated Financial Data			9
Risk Factors			11
Forward-Looking Statements			53
Use of Proceeds			54
Price Range of Common Stock and Distributions			55
Ratio of Earnings to Fixed Charges			59
Management’s Discussion and Analysis of Financial Condition and Results of Operations			60
Business			110
Portfolio Companies			123
Senior Securities			146
Management			149
Corporate Governance			160
Executive Compensation			165
Control Persons and Principal Stockholders			188
Certain Relationships and Related Transactions			190
Certain United States Federal Income Tax Considerations			191
Regulation			200
Determination of Net Asset Value			206
Sales of Common Stock Below Net Asset Value			210
Dividend Reinvestment Plan			215
Description of Capital Stock			216
Description of Our Preferred Stock			223
Description of Our Subscription Rights			225
Description of Warrants			227
Description of Our Debt Securities			229
Plan of Distribution			242
Brokerage Allocation and Other Practices			244
Custodian, Transfer and Dividend Paying Agent and Registrar			244
Legal Matters			244
Experts			244
Available Information			245
Index to Financial Statements			F-1

 

 

Hercules Capital, Inc., our logo and other trademarks of Hercules Capital, Inc. mentioned in this prospectus are the property of Hercules Capital, Inc. All other trademarks or trade names referred to in this prospectus are the property of their respective owners.

---

Table of Contents

Index to Financial Statements

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission using the “shelf” registration process. Under the shelf registration process, which constitutes a delayed offering in reliance on Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), we may offer, from time to time, up to $500,000,000 of our common stock, preferred stock, warrants representing rights to purchase shares of our common stock, preferred stock or debt securities, subscription rights or debt securities on the terms to be determined at the time of the offering. We may sell our securities through underwriters or dealers, “at-the-market” to or through a market maker, into an existing trading market or otherwise directly to one or more purchasers, including existing stockholders in a rights offering, or through agents or through a combination of methods of sale. The identities of such underwriters, dealers, market makers or agents, as the case may be, will be described in one or more supplements to this prospectus. The securities may be offered at prices and on terms described in one or more supplements to this prospectus. This prospectus provides you with a general description of the securities that we may offer. Each time we use this prospectus to offer securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. Please carefully read this prospectus and any such supplements together with the additional information described under “Where You Can Find Additional Information” in the “Summary” and “Risk Factors” sections before you make an investment decision.

A prospectus supplement may also add to, update or change information contained in this prospectus.

---

Table of Contents

Index to Financial Statements

 

1

---

Table of Contents

Index to Financial Statements

 

2

---

Table of Contents

Index to Financial Statements

 

3

---

Table of Contents

Index to Financial Statements

 

4

---

Table of Contents

Index to Financial Statements

 

5

---

Table of Contents

Index to Financial Statements

 

6

---

Table of Contents

Index to Financial Statements

FEES AND EXPENSES

The following table is intended to assist you in understanding the various costs and expenses that an investor in our common stock will bear directly or indirectly. However, we caution you that some of the percentages indicated in the table below are estimates and may vary. The footnotes to the fee table state which items are estimates. Except where the context suggests otherwise, whenever this prospectus contains a reference to fees or expenses paid by “you” or “us” or that “we” will pay fees or expenses, stockholders will indirectly bear such fees or expenses as investors in Hercules Capital, Inc.

 

Stockholder Transaction Expenses (as a percentage of the public offering price):
Sales load (as a percentage of offering price)(1)			—	%
Offering expenses			—	%(2)
Dividend reinvestment plan fees			—	%(3)
Total stockholder transaction expenses (as a percentage of the public offering price)			—	%(4)
Annual Expenses (as a percentage of net assets attributable to common stock):(5)
Operating expenses			6.02	%(6)(7)
Interest and fees paid in connection with borrowed funds			4.45	%(8)
Total annual expenses			10.47	%(9)

 

(1)	In the event that our securities are sold to or through underwriters, a corresponding prospectus supplement to this prospectus will disclose the applicable sales load.

(2)	In the event that we conduct an offering of our securities, a corresponding prospectus supplement to this prospectus will disclose the estimated offering expenses.

(3)

The expenses associated with the administration of our dividend reinvestment plan are included in “Operating expenses.” We pay all brokerage commissions incurred with respect to open market purchases, if any, made by the administrator under the plan. For more details about the plan, see “Dividend Reinvestment Plan”.

(4)	Total stockholder transaction expenses may include sales load and will be disclosed in a future prospectus supplement, if any.

(5)	“Net assets attributable to common stock” equals the weighted average net assets for the three-month period ended March 31, 2016, which is approximately $719.9 million.

(6)

“Operating expenses” represent our estimated operating expenses by annualizing our actual operating expenses incurred for the three-months ended March 31, 2016, including all fees and expenses of our consolidated subsidiaries and excluding interests and fees on indebtedness. This percentage for the year ended December 31, 2015 was 6.45%. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Management”.

(7)

We do not have an investment adviser and are internally managed by our executive officers under the supervision of our board of directors (“Board of Directors”). As a result, we do not pay investment advisory fees, but instead we pay the operating costs associated with employing investment management professionals.

(8)

“Interest and fees paid in connection with borrowed funds” represents our estimated interest, fees and credit facility expenses by annualizing our actual interest, fees and credit facility expenses incurred for the three-months ended March 31, 2016, including our Wells Facility, Union Bank Facility, the Convertible Senior Notes, the 2019 Notes, the 2024 Notes, the 2021 Asset-Backed Notes and the SBA debentures, each of which is defined herein. This percentage for the year ended December 31, 2015 was 5.10%.

(9)

“Total annual expenses” is the sum of “operating expenses,” and “interest and fees paid in connection with borrowed funds.” This percentage for the year ended December 31, 2015 was 11.55%. “Total annual expenses” is presented as a percentage of weighted average net assets attributable to common stockholders, because the holders of shares of our common stock (and not the holders of our debt securities or preferred stock, if any) bear all of our fees and expenses, including the fees and expenses of our wholly-owned consolidated subsidiaries, all of which are included in this fee table presentation.

 

7

---

Table of Contents

Index to Financial Statements

Example

The following example demonstrates the projected dollar amount of total cumulative expenses that would be incurred over various periods with respect to a hypothetical investment in our common stock. These amounts are based upon our payment of annual operating expenses at the levels set forth in the table above and assume no additional leverage.

 

		1 Year				3 Years				5 Years				10 Years
You would pay the following expenses on a $1,000 common stock investment, assuming a 5% annual return		$	102			$	290			$	458			$	806

The example and the expenses in the tables above should not be considered a representation of our future expenses, and actual expenses may be greater or lesser than those shown. Moreover, while the example assumes, as required by the applicable rules of the SEC, a 5% annual return, our performance will vary and may result in a return greater or lesser than 5%. In addition, while the example assumes reinvestment of all dividends and distributions at net asset value (“NAV”), participants in our dividend reinvestment plan may receive shares valued at the market price in effect at that time. This price may be at, above or below NAV. See “Dividend Reinvestment Plan” for additional information regarding our dividend reinvestment plan.

 

8

---

Table of Contents

Index to Financial Statements

SELECTED CONSOLIDATED FINANCIAL DATA

The selected consolidated financial data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Senior Securities” and the consolidated financial statements and related notes included elsewhere herein. The selected balance sheet data as of the end of fiscal year 2015, 2014, 2013, 2012 and 2011 and the financial statement of operations data for fiscal 2015, 2014, 2013, 2012 and 2011 has been derived from our audited financial statements, which have been audited by PricewaterhouseCoopers LLP, our independent registered public accounting firm, but not all of which are presented in this Form N-2.” The historical data are not necessarily indicative of results to be expected for any future period. The selected financial and other data for the three months ended March 31, 2016 and other quarterly financial information is derived from our unaudited financial statements, but in the opinion of management, reflects all adjustments (consisting only of normal recurring adjustments) that are necessary to present fairly the results of such interim periods. Interim results as of and for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

 

		For the Three Months Ended March 31 (unaudited)								For the Year Ended December 31,
(in thousands, except per share amounts)		2016				2015				2015				2014				2013				2012				2011
Investment income:
Interest		$	36,474			$	30,559			$	140,266			$	126,618			$	123,671			$	87,603			$	70,346
Fees			2,465				1,935				16,866				17,047				16,042				9,917				9,509
Total investment income			38,939				32,494				157,132				143,665				139,713				97,520				79,855
Operating expenses:
Interest			7,018				7,854				30,834				28,041				30,334				19,835				13,252
Loan fees			988				1,513				6,055				5,919				4,807				3,917				2,635
General and administrative			3,580				3,618				16,658				10,209				9,354				8,108				7,992
Employee Compensation:
Compensation and benefits			4,685				3,796				20,713				16,604				16,179				13,326				13,260
Stock-based compensation			2,571				2,719				9,370				9,561				5,974				4,227				3,128
Total employee compensation			7,256				6,515				30,083				26,165				22,153				17,553				16,388
Total operating expenses			18,842				19,500				83,630				70,334				66,648				49,413				40,267
Loss on debt extinguishment (Long-term Liabilities - Convertible Senior Notes)			—				(1	)			(1	)			(1,581	)			—				—				—
Net investment income			20,097				12,993				73,501				71,750				73,065				48,107				39,588
Net realized gain on investments			(4,468	)			3,312				5,147				20,112				14,836				3,168				2,741
Net change in unrealized appreciation (depreciation) on investments			(1,334	)			5,614				(35,732	)			(20,674	)			11,545				(4,516	)			4,607
Total net realized and unrealized gain (loss)			(5,802	)			8,926				(30,585	)			(562	)			26,381				(1,348	)			7,348
Net increase in net assets resulting from operations		$	14,295			$	21,919			$	42,916			$	71,188			$	99,446			$	46,759			$	46,936
Change in net assets per common share (basic)		$	0.20			$	0.33			$	0.60			$	1.12			$	1.67			$	0.93			$	1.08
Cash dividends declared per common share		$	0.31			$	0.31			$	1.24			$	1.24			$	1.11			$	0.95			$	0.88

 

9

---

Table of Contents

Index to Financial Statements

		For the Three Months Ended March 31 (unaudited)								For the Year Ended December 31,
(in thousands, except per share amounts)		2016				2015				2015				2014				2013				2012				2011
Balance sheet data:
Investments, at value		$	1,291,310			$	1,161,421			$	1,200,638			$	1,020,737			$	910,295			$	906,300			$	652,870
Cash and cash equivalents			13,478				171,756				95,196				227,116				268,368				182,994				64,474
Total assets			1,331,815				1,387,088				1,334,761				1,299,223				1,221,715				1,123,643				747,394
Total liabilities			613,435				623,762				617,627				640,359				571,708				607,675				316,353
Total net assets			718,380				763,326				717,134				658,864				650,007				515,968				431,041
Other Data:
Total debt investments, at value			1,205,673				1,058,032				1,110,209				923,906				821,988				827,540				585,767
Total warrant investments, at value			23,496				30,938				22,987				25,098				35,637				29,550				30,045
Total equity investments, at value			62,141				72,451				67,442				71,733				52,670				49,210				37,058
Unfunded Commitments(2)			64,640				145,113				75,402				147,689				69,091				19,265				76,128
Net asset value per share(1)		$	9.81			$	10.47			$	9.94			$	10.18			$	10.51			$	9.75			$	9.83

 

(1)	Based on common shares outstanding at period end.

(2)	Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request by the portfolio company.

The following tables set forth certain quarterly financial information for each of the eight quarters up to and ending December 31, 2015 and the quarter ending March 31, 2016. This information was derived from our unaudited consolidated financial statements. Results for any quarter are not necessarily indicative of results for the full year or for any future quarter.

 

(in thousands, except per share data)		March 31, 2016
Total investment income		$	38,939
Net investment income before investment gains and losses			20,097
Net increase (decrease) in net assets resulting from operations			14,295
Change in net assets per common share (basic)		$	0.20

 

		Quarter Ended
(in thousands, except per share data)		March 31, 2015				June 30, 2015				September 30, 2015				December 31, 2015
Total investment income		$	32,494			$	38,126			$	47,132			$	39,380
Net investment income before investment gains and losses			12,993				16,781				23,590				20,137
Net increase (decrease) in net assets resulting from operations			21,919				2,752				4,075				14,170
Change in net assets per common share (basic)		$	0.33			$	0.03			$	0.05			$	0.20

 

		Quarter Ended
		March 31, 2014				June 30, 2014				September 30, 2014				December 31, 2014
Total investment income		$	35,770			$	34,001			$	37,019			$	36,875
Net investment income before investment gains and losses			18,304				18,551				18,995				15,899
Net increase (decrease) in net assets resulting from operations			22,185				13,191				15,177				20,635
Change in net assets per common share (basic)		$	0.36			$	0.21			$	0.24			$	0.32

 

10

---

Table of Contents

Index to Financial Statements

RISK FACTORS

Investing in our securities may be speculative and involves a high degree of risk. You should consider carefully the risks described below and all other information contained in this prospectus, including our financial statements and the related notes and the schedules and exhibits to this prospectus. The risks set forth below are not the only risks we face. If any of the following risks occur, our business, financial condition and results of operations could be materially adversely affected. In such case, our NAV and the trading price of our securities could decline, and you may lose all or part of your investment.

Risks Related to our Business Structure

We are dependent upon key management personnel for their time availability and for our future success and if we are not able to hire and retain qualified personnel, or if we lose any member of our senior management team, our ability to implement our business strategy could be significantly harmed.

We depend upon the members of our senior management as well as other key personnel for the identification, final selection, structuring, closing and monitoring of our investments. These employees have critical industry experience and relationships on which we rely to implement our business plan. If we lose the services of any senior management members we may not be able to operate the business as we expect, and our ability to compete could be harmed, which could cause our operating results to suffer. Furthermore, we do not have an employment agreement with our senior management that restricts them from creating new investment vehicles subject to compliance with applicable law. We believe our future success will depend, in part, on our ability to identify, attract and retain sufficient numbers of highly skilled employees. If we do not succeed in identifying, attracting and retaining such personnel, we may not be able to operate our business as we expect.

Our business model depends to a significant extent upon strong referral relationships with venture capital and private equity fund sponsors, and our inability to develop or maintain these relationships, or the failure of these relationships to generate investment opportunities, could adversely affect our business.

We expect that members of our management team will maintain their relationships with venture capital and private equity firms, and we will rely to a significant extent upon these relationships to provide us with our deal flow. If we fail to maintain our existing relationships, our relationships become strained as a result of enforcing our rights with respect to non-performing portfolio companies in protecting our investments or we fail to develop new relationships with other firms or sources of investment opportunities, then we will not be able to grow our investment portfolio. In addition, persons with whom members of our management team have relationships are not obligated to provide us with investment opportunities and, therefore, there is no assurance that such relationships will lead to the origination of debt or other investments.

We operate in a highly competitive market for investment opportunities, and we may not be able to compete effectively.

A number of entities compete with us to make the types of investments that we plan to make in prospective portfolio companies. We compete with a large number of venture capital and private equity firms, as well as with other investment funds, business development companies, investment banks and other sources of financing, including traditional financial services companies such as commercial banks and finance companies. Many of our competitors are substantially larger and have considerably greater financial, technical, marketing and other resources than we do. For example, some competitors may have a lower cost of funds and/or access to funding sources that are not available to us. This may enable some competitors to make loans with interest rates that are comparable to or lower than the rates that we typically offer. A significant increase in the number and/or the size of our competitors, including traditional commercial lenders and other financing sources, in technology-related industries could force us to accept less attractive investment terms. We may be unable to capitalize on certain opportunities if we do not match competitors’ pricing, terms and structure. If we do match competitors’ pricing,

 

11

---

Table of Contents

Index to Financial Statements

terms or structure, we may experience decreased net interest income and increased risk of credit losses. In addition, some of our competitors may have higher risk tolerances or different risk assessments, which could allow them to consider a wider variety of investments, establish more relationships and build their market shares. Furthermore, many potential competitors are not subject to the regulatory restrictions that the 1940 Act imposes on us as a business development company or that the Code imposes on us as a RIC. If we are not able to compete effectively, our business, financial condition, and results of operations will be adversely affected. As a result of this competition, there can be no assurance that we will be able to identify and take advantage of attractive investment opportunities, or that we will be able to fully invest our available capital.

If we are unable to manage our future growth effectively, we may be unable to achieve our investment objective, which could adversely affect our financial condition and results of operations and cause the value of your investment to decline.

Our ability to achieve our investment objective will depend on our ability to sustain growth. Sustaining growth will depend, in turn, on our senior management team’s ability to identify, evaluate, finance and invest in suitable companies that meet our investment criteria. Accomplishing this result on a cost-effective basis is largely a function of our marketing capabilities, our management of the investment process, our ability to provide efficient services and our access to financing sources on acceptable terms. Organizational growth and scale-up of our investments could strain our existing managerial, investment, financial and other resources. Management of the Company’s growth divert financial resources from other projects. Failure to manage our future growth effectively could have a material adverse effect on our business, financial condition and results of operations.

Because we intend to distribute substantially all of our income to our stockholders in order to qualify as a RIC, we will continue to need additional capital to finance our growth. If additional funds are unavailable or not available on favorable terms, our ability to grow will be impaired.

In order to satisfy the tax requirements applicable to a RIC, to avoid payment of excise taxes and to minimize or avoid payment of income taxes, we intend to distribute to our stockholders substantially all of our net ordinary income and realized net capital gains except for certain realized net capital gains, which we may retain, pay applicable income taxes with respect thereto and elect to treat as deemed distributions to our stockholders. As a business development company, we generally are required to meet a coverage ratio of total assets to total borrowings and other senior securities, which includes all of our borrowings and any preferred stock that we may issue in the future, of at least 200%. This requirement limits the amount that we may borrow. This limitation may prevent us from incurring debt and require us to raise additional equity at a time when it may be disadvantageous to do so. We cannot assure you that debt and equity financing will be available to us on favorable terms, or at all, and debt financings may be restricted by the terms of any of our outstanding borrowings. If we are unable to incur additional debt, we may be required to raise additional equity at a time when it may be disadvantageous to do so. In addition, shares of closed-end investment companies have recently traded at discounts to their NAV. This characteristic of closed-end investment companies is separate and distinct from the risk that our NAV per share may decline. We cannot predict whether shares of our common stock will trade above, at or below our NAV. If our common stock trades below its NAV, we generally will not be able to issue additional shares of our common stock at its market price without first obtaining the approval for such issuance from our stockholders and our independent directors. If additional funds are not available to us, we could be forced to curtail or cease new lending and investment activities, and our NAV could decline. In addition, our results of operations and financial condition could be adversely affected.

Because most of our investments typically are not in publicly-traded securities, there is uncertainty regarding the value of our investments, which could adversely affect the determination of our NAV.

At March 31, 2016, portfolio investments, whose fair value is determined in good faith by the Board of Directors, were approximately 97.0% of our total assets. We expect our investments to continue to consist primarily of securities issued by privately-held companies, the fair value of which is not readily determinable. In

 

12

---

Table of Contents

Index to Financial Statements

addition, we are not permitted to maintain a general reserve for anticipated loan losses. Instead, we are required by the 1940 Act to specifically value each investment and record an unrealized gain or loss for any asset that we believe has increased or decreased in value.

There is no single standard for determining fair value in good faith. We value these securities at fair value as determined in good faith by our Board of Directors, based on the recommendations of our Audit Committee. In making a good faith determination of the value of these securities, we generally start with the cost basis of each security, which includes the amortized original issue discount, or OID, and payment-in-kind, or PIK, interest, if any. The Audit Committee uses its best judgment in arriving at the fair value of these securities. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment while applying a valuation process for the types of investments we make, which includes but is not limited to deriving a hypothetical exit price. However, the Board of Directors retains ultimate authority as to the appropriate valuation of each investment. Because such valuations are inherently uncertain and may be based on estimates, our determinations of fair value may differ materially from the values that would be assessed if a ready market for these securities existed. We adjust quarterly the valuation of our portfolio to reflect the Board of Directors’ determination of the fair value of each investment in our portfolio. Any changes in fair value are recorded in our statement of operations as net change in unrealized appreciation or depreciation. Our NAV could be adversely affected if our determinations regarding the fair value of our investments were materially higher than the values that we ultimately realize upon the disposal of such securities.

Because we have substantial indebtedness, there could be increased risk in investing in our company.

Lenders have fixed dollar claims on our assets that are superior to the claims of stockholders, and we have granted, and may in the future grant, lenders a security interest in our assets in connection with borrowings. In the case of a liquidation event, those lenders would receive proceeds before our stockholders. In addition, borrowings, also known as leverage, magnify the potential for gain or loss on amounts invested and, therefore, increase the risks associated with investing in our securities. Leverage is generally considered a speculative investment technique. If the value of our assets increases, then leverage would cause the NAV attributable to our common stock to increase more than it otherwise would have had we not leveraged. Conversely, if the value of our assets decreases, leverage would cause the NAV attributable to our common stock to decline more than it otherwise would have had we not used leverage. Similarly, any increase in our revenue in excess of interest expense on our borrowed funds would cause our net income to increase more than it would without the leverage. Any decrease in our revenue would cause our net income to decline more than it would have had we not borrowed funds and could negatively affect our ability to make distributions on common stock. Our ability to service any debt that we incur will depend largely on our financial performance and will be subject to prevailing economic conditions and competitive pressures. We and, indirectly, our stockholders will bear the cost associated with our leverage activity. If we are not able to service our substantial indebtedness, our business could be harmed materially.

Our secured credit facilities with Wells Fargo Capital Finance LLC (the “Wells Facility”) and MUFG Union Bank, N.A. (the “Union Bank Facility,” and together with the Wells Facility, our “Credit Facilities”) our Convertible Senior Notes, our 2019 Notes, our 2024 Notes and our 2021 Asset-Backed Notes (as each term is defined below) contain financial and operating covenants that could restrict our business activities, including our ability to declare dividends if we default under certain provisions.

As of March 31, 2016, we had approximately $61.0 million of indebtedness outstanding on the Wells Facility. In addition, as of March 31, 2016, we had approximately $190.2 million of indebtedness outstanding incurred by our SBIC subsidiaries, approximately $17.6 million in aggregate principal amount of 6.00% convertible senior notes (the “Convertible Senior Notes”), approximately $110.4 million in aggregate principal amount of 7.00% notes due 2019 (the “2019 Notes”), approximately $103.0 million in aggregate principal amount of 6.25% notes due 2024 (the “2024 Notes”) and approximately $129.3 million in aggregate principal

 

13

---

Table of Contents

Index to Financial Statements

amount of fixed rate asset-backed notes issued in November 2014 (the “2021 Asset-Backed Notes”) in connection with our $237.4 million debt securitization (the “2014 Debt Securitization”).

There can be no assurance that we will be successful in obtaining any additional debt capital on terms acceptable to us or at all. If we are unable to obtain debt capital, then our equity investors will not benefit from the potential for increased returns on equity resulting from leverage to the extent that our investment strategy is successful and we may be limited in our ability to make new commitments or fundings to our portfolio companies.

As a business development company, generally, we are not permitted to incur indebtedness unless immediately after such borrowing we have an asset coverage for total borrowings of at least 200% (i.e., the amount of debt may not exceed 50% of the value of our assets). In addition, we may not be permitted to declare any cash dividend or other distribution on our outstanding common shares, or purchase any such shares, unless, at the time of such declaration or purchase, we have asset coverage of at least 200% after deducting the amount of such dividend, distribution, or purchase price. If this ratio declines below 200%, we may not be able to incur additional debt and may need to sell a portion of our investments to repay some debt when it is disadvantageous to do so, and we may not be able to make distributions. As of March 31, 2016 our asset coverage ratio under our regulatory requirements as a business development company was 270.5% excluding our SBIC debentures as a result of our exemptive order from the SEC that allows us to exclude all SBA leverage from our asset coverage ratio.

Illustration. The following table illustrates the effect of leverage on returns from an investment in our common stock assuming various annual returns, net of expenses. The calculations in the table below are hypothetical and actual returns may be higher or lower than those appearing below.

 

		Annual Return on Our Portfolio (Net of Expenses)
		-10%				-5%				0%				5%				10%
Corresponding return to stockholder(1)			(23.26	%)			(13.99	%)			(4.72	%)			4.55	%			13.82	%

 

(1)

Assumes $1.3 billion in total assets, $611.5 million in debt outstanding, $718.4 million in stockholders’ equity, and an average cost of funds of 5.54%, which is the approximate average cost of borrowed funds, including our Credit Facilities, our Convertible Senior Notes, 2019 Notes, 2024 Notes, our SBA debentures and our 2021 Asset-Backed Notes for the period ended March 31, 2016. Actual interest payments may be different.

It is likely that the terms of any current or future long-term or revolving credit or warehouse facility we may enter into in the future could constrain our ability to grow our business.

Under our borrowings and our Credit Facilities, current lenders have, and any future lender or lenders may have, fixed dollar claims on our assets that are senior to the claims of our stockholders and, thus, will have a preference over our stockholders with respect to our assets pledged as collateral under the Credit Facilities. Our Credit Facilities and borrowings also subject us to various financial and operating covenants, including, but not limited to, maintaining certain financial ratios and minimum tangible net worth amounts. Future credit facilities and borrowings will likely subject us to similar or additional covenants. In addition, we may grant a security interest in our assets in connection with any such credit facilities and borrowings.

Our Credit Facilities generally contain customary default provisions such as a minimum net worth amount, a profitability test, and a restriction on changing our business and loan quality standards. In addition, our Credit Facilities require or are expected to require the repayment of all outstanding debt on the maturity which may disrupt our business and potentially the business of our portfolio companies that are financed through the facilities. An event of default under these facilities would likely result, among other things, in termination of the availability of further funds under the facilities and accelerated maturity dates for all amounts outstanding under the facilities, which would likely disrupt our business and, potentially, the business of the portfolio companies

 

14

---

Table of Contents

Index to Financial Statements

whose loans we finance through the facilities. This could reduce our revenues and, by delaying any cash payment allowed to us under our facilities until the lender has been paid in full, reduce our liquidity and cash flow and impair our ability to grow our business and our ability to make distributions sufficient to maintain our ability to be subject to tax as a RIC.

The terms of future available financing may place limits on our financial and operation flexibility. If we are unable to obtain sufficient capital in the future, we may be forced to reduce or discontinue our operations, not be able to make new investments, or otherwise respond to changing business conditions or competitive pressures.

In addition to regulatory requirements that restrict our ability to raise capital, our Credit Facilities, the Convertible Senior Notes, the 2019 Notes and the 2024 Notes contain various covenants which, if not complied with, could require accelerated repayment under the facility or require us to repurchase the Convertible Senior Notes, the 2019 Notes and the 2024 Notes thereby materially and adversely affecting our liquidity, financial condition, results of operations and ability to pay dividends.

The credit agreements governing our Credit Facilities, the Convertible Senior Notes, the 2019 Notes, and the 2024 Notes require us to comply with certain financial and operational covenants. These covenants require us to, among other things, maintain certain financial ratios, including asset coverage, debt to equity and interest coverage. Our ability to continue to comply with these covenants in the future depends on many factors, some of which are beyond our control. There are no assurances that we will be able to comply with these covenants. Failure to comply with these covenants would result in a default which, if we were unable to obtain a waiver from the lenders under our Credit Facilities or the trustee or holders under the Convertible Senior Notes and could accelerate repayment under the facilities or the Convertible Senior Notes, the 2019 Notes or 2024 Notes and thereby have a material adverse impact on our liquidity, financial condition, results of operations and ability to pay a sufficient amount of dividends and maintain our ability to be subject to tax as a RIC. In addition, holders of the Convertible Senior Notes will have the right to require us to repurchase the Convertible Senior Notes upon the occurrence of a fundamental change at a repurchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any. We may not have enough available cash or be able to obtain financing at the time we are required to make repurchases. See “Management’s Discussion and Analysis of Financial Condition of Results of Operations—Borrowings.”

We may be unable to obtain debt capital on favorable terms or at all, in which case we would not be able to use leverage to increase the return on our investments.

If we are unable to obtain debt capital, then our equity investors will not benefit from the potential for increased returns on equity resulting from leverage to the extent that our investment strategy is successful and we may be limited in our ability to make new commitments or fundings to our portfolio companies. An inability to obtain debt capital may also limit our ability to refinance existing indebtedness, particularly during periods of adverse credit market conditions when refinancing indebtedness may not be available under interest rates and other terms acceptable to us or at all.

We are subject to certain risks as a result of our interests in connection with the 2014 Debt Securitization and our equity interest in the 2014 Securitization Issuer.

On November 13, 2014, in connection with the 2014 Debt Securitization and the offering of the 2021 Asset-Backed Notes by Hercules Capital Funding Trust 2014-1 (the “2014 Securitization Issuer”), we sold and/or contributed to Hercules Capital Funding 2014-1 LLC, as trust depositor (the “2014 Trust Depositor”), certain senior loans made to certain of our portfolio companies (the “2014 Loans”), which the 2014 Trust Depositor in turn sold and/or contributed to the 2014 Securitization Issuer in exchange for 100% of the equity interest in the 2014 Securitization Issuer, cash proceeds and other consideration. Following these transfers, the 2014 Securitization Issuer, and not the 2014 Trust Depositor or us, held all of the ownership interest in the 2014 Loans.

 

15

---

Table of Contents

Index to Financial Statements

As a result of the 2014 Debt Securitization, we hold, indirectly through the 2014 Trust Depositor, 100% of the equity interests in the 2014 Securitization Issuer. As a result, we consolidate the financial statements of the 2014 Trust Depositor and the 2014 Securitization Issuer, as well as our other subsidiaries, in our consolidated financial statements. Because the 2014 Trust Depositor and the 2014 Securitization Issuer is disregarded as an entity separate from its owners for U.S. federal income tax purposes, the sale or contribution by us to the 2014 Trust Depositor, and by the 2014 Trust Depositor to the 2014 Securitization Issuer, as applicable, did not constitute a taxable event for U.S. federal income tax purposes. If the U.S. Internal Revenue Service (“IRS”) were to take a contrary position, there could be a material adverse effect on our business, financial condition, results of operations or cash flows.

Further, a failure of the 2014 Securitization Issuer to be treated as a disregarded entity for U.S. federal income tax purposes would constitute an event of default pursuant to the indenture under the 2014 Debt Securitization, upon which the trustee under the 2014 Debt Securitization (the “2014 Trustee”), may and will at the direction of a supermajority of the holders of the 2021 Asset-Backed Notes (the “2021 Noteholders”), declare the 2021 Asset-Backed Notes, to be immediately due and payable and exercise remedies under the applicable indenture, including (i) to institute proceedings for the collection of all amounts then payable on the 2021 Asset-Backed Notes, or under the applicable indenture, enforce any judgment obtained, and collect from the 2014 Securitization Issuer and any other obligor upon the 2021 Asset-Backed Notes monies adjudged due; (ii) institute proceedings from time to time for the complete or partial foreclosure of the applicable indenture with respect to the property of the 2014 Securitization Issuer; (iii) exercise any remedies as a secured party under the relevant Uniform Commercial Code and take other appropriate action under applicable law to protect and enforce the rights and remedies of the 2014 Trustee and the 2021 Noteholders; or (iv) sell the property of the 2014 Securitization Issuer or any portion thereof or rights or interest therein at one or more public or private sales called and conducted in any matter permitted by law. Any such exercise of remedies could have a material adverse effect on our business, financial condition, results of operations or cash flows.

An event of default in connection with the 2014 Debt Securitization could give rise to a cross-default under our other material indebtedness.

The documents governing our other material indebtedness contain customary cross-default provisions that could be triggered if an event of default occurs in connection with the 2014 Debt Securitization. An event of default with respect to our other indebtedness could lead to the acceleration of such indebtedness and the exercise of other remedies as provided in the documents governing such other indebtedness. This could have a material adverse effect on our business, financial condition, results of operations and cash flows and may result in our inability to make distributions sufficient to maintain our ability to be subject to tax as a RIC.

We may not receive cash distributions in respect of our indirect ownership interests in the 2014 Securitization Issuer.

Apart from fees payable to us in connection with our role as servicer of the 2014 Loans and the reimbursement of related amounts under the documents governing the 2014 Debt Securitization, we receive cash in connection with the 2014 Debt Securitization only to the extent that the 2014 Trust Depositor receives payments in respect of its equity interests in the 2014 Securitization Issuer. The respective holders of the equity interests in the 2014 Securitization Issuer are the residual claimants on distributions, if any, made by the 2014 Securitization Issuer after the respective 2014 Noteholders and other claimants have been paid in full on each payment date or upon maturity of the 2021 Asset-Backed Notes, subject to the priority of payments under the 2014 Debt Securitization documents governing the 2014 Debt Securitization. To the extent that the value of a 2014 Securitization Issuer’s portfolio of loans is reduced as a result of conditions in the credit markets (relevant in the event of a liquidation event), other macroeconomic factors, distressed or defaulted loans or the failure of individual portfolio companies to otherwise meet their obligations in respect of the loans, or for any other reason, the ability of the 2014 Securitization Issuer to make cash distributions in respect of the 2014 Trust Depositor’s equity interests would be negatively affected and consequently, the value of the equity interests in the 2014

 

16

---

Table of Contents

Index to Financial Statements

Securitization Issuer would also be reduced. In the event that we fail to receive cash indirectly from the 2014 Securitization Issuer, we could be unable to make distributions, if at all, in amounts sufficient to maintain our ability to be subject to tax as a RIC.

The interests of the 2014 Noteholders may not be aligned with our interests.

The 2021 Asset-Backed Notes are debt obligations ranking senior in right of payment to the rights of the holder of the equity interests in the 2014 Securitization Issuer, as residual claimants in respect of distributions, if any, made by the 2014 Securitization Issuer. As such, there are circumstances in which the interests of the 2014 Noteholders may not be aligned with the interests of holders of the equity interests in the 2014 Securitization Issuer. For example, under the terms of the documents governing the 2014 Debt Securitization, the 2014 Noteholders have the right to receive payments of principal and interest prior to holders of the equity interests.

For as long as the 2021 Asset-Backed Notes remain outstanding, the respective 2014 Noteholders have the right to act in certain circumstances with respect to the 2014 Loans in ways that may benefit their interests but not the interests of the respective holders of the equity interests in the 2014 Securitization Issuer, including by exercising remedies under the documents governing the 2014 Debt Securitization.

If an event of default occurs, the 2014 Noteholders will be entitled to determine the remedies to be exercised, subject to the terms of the documents governing the 2014 Debt Securitization. For example, upon the occurrence of an event of default with respect to the 2021 Asset-Backed Notes, the 2014 Trustee may and will at the direction of the holders of a supermajority of the applicable 2021 Asset-Backed Notes declare the principal, together with any accrued interest, of the notes to be immediately due and payable. This would have the effect of accelerating the principal on such notes, triggering a repayment obligation on the part of the 2014 Securitization Issuer. The 2021 Asset-Backed Notes then outstanding will be paid in full before any further payment or distribution on the equity interest is made. There can be no assurance that there will be sufficient funds through collections on the 2014 Loans or through the proceeds of the sale of the 2014 Loans in the event of a bankruptcy or insolvency to repay in full the obligations under the 2021 Asset-Backed Notes, or to make any distribution to holders of the equity interests in the 2014 Securitization Issuer.

Remedies pursued by the 2014 Noteholders could be adverse to our interests as the indirect holder of the equity interests in the 2014 Securitization Issuer. The 2014 Noteholders have no obligation to consider any possible adverse effect on such other interests. Thus, there can be no assurance that any remedies pursued by the 2014 Noteholders will be consistent with the best interests of the 2014 Trust Depositor or that we will receive, indirectly through the 2014 Trust Depositor, any payments or distributions upon an acceleration of the 2021 Asset-Backed Notes. Any failure of the 2014 Securitization Issuer to make distributions in respect of the equity interests that we indirectly hold, whether as a result of an event of default and the acceleration of payments on the 2021 Asset-Backed Notes or otherwise, could have a material adverse effect on our business, financial condition, results of operations and cash flows and may result in our inability to make distributions sufficient to maintain our ability to be subject to tax as a RIC.

Certain events related to the performance of 2014 Loans could lead to the acceleration of principal payments on the 2021 Asset-Backed Notes.

The following constitute rapid amortization events (“Rapid Amortization Events”) under the documents governing the 2014 Debt Securitization: (i) the aggregate outstanding principal balance of delinquent 2014 Loans, and restructured 2014 Loans that would have been delinquent 2014 Loans had such loans not become restructured loans exceeds 10% of the current aggregate outstanding principal balance of the 2014 Loans for a period of three consecutive months; (ii) the aggregate outstanding principal balance of defaulted 2014 Loans exceeds 5% of the initial outstanding principal balance of the 2014 Loans determined as November 13, 2014 for a period of three consecutive months; (iii) the aggregate outstanding principal balance of the 2021 Asset-Backed Notes exceeds the borrowing base for a period of three consecutive months; (iv) the 2014 Securitization Issuer’s

 

17

---

Table of Contents

Index to Financial Statements

pool of 2014 Loans contains 2014 Loans to ten or fewer obligors; and (v) the occurrence of an event of default under the documents governing the 2014 Debt Securitization. After a Rapid Amortization Event has occurred, subject to the priority of payments under the documents governing the 2014 Debt Securitization, principal collections on the 2014 Loans will be used to make accelerated payments of principal on the 2021 Asset-Backed Notes until the principal balance of the 2021 Asset-Back Notes is reduced to zero. Such an event could delay, reduce or eliminate the ability of the 2014 Securitization Issuer to make distributions in respect of the equity interests that we indirectly hold, which could have a material adverse effect on our business, financial condition, results of operations and cash flows and may result in our inability to make distributions sufficient to maintain our ability to be subject to tax as a RIC.

We have certain repurchase obligations with respect to the 2014 Loans transferred in connection with the 2014 Debt Securitization.

As part of the 2014 Debt Securitization, we entered into a sale and contribution agreement and a sale and servicing agreement under which we would be required to repurchase any 2014 Loan (or participation interest therein) which was sold to the 2014 Securitization Issuer in breach of certain customary representations and warranty made by us or by the 2014 Trust Depositors with respect to such 2014 Loan or the legal structure of the 2014 Debt Securitization. To the extent that there is a breach of such representations and warranties and we fail to satisfy any such repurchase obligation, a 2014 Trustee may, on behalf of the 2014 Securitization Issuer, bring an action against us to enforce these repurchase obligations.

Our investments in a portfolio company, whether debt, equity, or a combination thereof, may lead to our receiving material non-public information (“MNPI”) or obtaining ‘control’ of the target company. Our ability to exit an investment where we have MNPI or control could be limited and could result in a realized loss on the investment.

If we receive MNPI, or a controlling interest in a portfolio company, our ability to divest ourselves from a debt or equity investment could be restricted. Causes of such restriction could include market factors, such as liquidity in a private stock, or limited trading volume in a public company’s securities, or regulatory factors, such as the receipt of MNPI or insider blackout periods, where we are under legal obligation not to sell. Additionally, we may choose not to take certain actions to protect a debt investment in a control investment portfolio company. As a result, we could experience a decrease in the value of our portfolio company holdings and potentially incur a realized loss on the investment.

Regulations governing our operations as a business development company may affect our ability to, and the manner in which, we raise additional capital, which may expose us to risks.

Our business will require a substantial amount of capital. We may acquire additional capital from the issuance of senior securities, including borrowings, securitization transactions or other indebtedness, or the issuance of additional shares of our common stock. However, we may not be able to raise additional capital in the future on favorable terms or at all. We may issue debt securities, other evidences of indebtedness or preferred stock, and we may borrow money from banks or other financial institutions, which we refer to collectively as “senior securities,” up to the maximum amount permitted by the 1940 Act. Under the 1940 Act, we are not permitted to incur indebtedness unless immediately after such borrowing we have an asset coverage for total borrowings of at least 200% (i.e., the amount of debt may not exceed 50% of the value of our assets). In addition, we may not be permitted to declare any cash dividend or other distribution on our outstanding common shares, or purchase any such shares, unless, at the time of such declaration or purchase, we have asset coverage of at least 200% after deducting the amount of such dividend, distribution, or purchase price. Our ability to pay dividends or issue additional senior securities would be restricted if our asset coverage ratio were not at least 200%.

If the value of our assets declines, we may be unable to satisfy this test. If that happens, we may be required to liquidate a portion of our investments and repay a portion of our indebtedness at a time when such transaction

 

18

---

Table of Contents

Index to Financial Statements

may be disadvantageous. As a result of issuing senior securities, we would also be exposed to risks associated with leverage, including an increased risk of loss. If we issue preferred stock, the preferred stock would rank “senior” to common stock in our capital structure, preferred stockholders would have separate voting rights and might have rights, preferences, or privileges more favorable than those of our common stockholders and the issuance of preferred stock could have the effect of delaying, deferring, or preventing a transaction or a change of control that might involve a premium price for holders of our common stock or otherwise be in your best interest.

To the extent that we are constrained in our ability to issue debt or other senior securities, we will depend on issuances of common stock to finance operations. Other than in certain limited situations such as rights offerings, as a business development company, we are generally not able to issue our common stock at a price below NAV without first obtaining required approvals from our stockholders and our independent directors. If we raise additional funds by issuing more common stock or senior securities convertible into, or exchangeable for, our common stock, then the percentage ownership of our stockholders at that time will decrease, and you might experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on favorable terms or at all.

When we are a debt or minority equity investor in a portfolio company, we may not be in a position to control the entity, and management of the company may make decisions that could decrease the value of our portfolio holdings.

We make both debt and minority equity investments; therefore, we are subject to the risk that a portfolio company may make business decisions with which we disagree, and the stockholders and management of such company may take risks or otherwise act in ways that do not serve our interests. As a result, a portfolio company may make decisions that could decrease the value of our portfolio holdings.

If we do not invest a sufficient portion of our assets in qualifying assets, we could fail to qualify as a business development company or be precluded from investing according to our current business strategy.

As a business development company, we may not acquire any assets other than “qualifying assets” as defined under the 1940 Act, unless, at the time of and after giving effect to such acquisition, at least 70% of our total assets are qualifying assets. See “Regulation.”

We believe that most of the senior loans we make will constitute qualifying assets. However, we may be precluded from investing in what we believe are attractive investments if such investments are not qualifying assets for purposes of the 1940 Act. If we do not invest a sufficient portion of our assets in qualifying assets, we could lose our status as a business development company, which would have a material adverse effect on our business, financial condition and results of operations. Similarly, these rules could prevent us from making follow-on investments in existing portfolio companies (which could result in the dilution of our position) or could require us to dispose of investments at inappropriate times in order to comply with the 1940 Act. If we need to dispose of such investments quickly, it would be difficult to dispose of such investments on favorable terms. For example, we may have difficulty in finding a buyer and, even if we do find a buyer, we may have to sell the investments at a substantial loss.

A failure on our part to maintain our qualification as a business development company would significantly reduce our operating flexibility.

If we fail to continuously qualify as a business development company, we might be subject to regulation as a registered closed-end investment company under the 1940 Act, which would significantly decrease our operating flexibility, and lead to situations where we might have to restrict our borrowings, reduce our leverage, sell securities and pursue other activities that we are allowed to engage in as a business development company. In addition, failure to comply with the requirements imposed on business development companies by the 1940 Act could cause the SEC to bring an enforcement action against us. For additional information on the qualification requirements of a business development company, see “Regulation.”

 

19

---

Table of Contents

Index to Financial Statements

To the extent OID and PIK interest constitute a portion of our income, we will be exposed to risks associated with such income being required to be included in taxable and accounting income prior to receipt of cash representing such income.

Our investments may include OID instruments and contractual PIK interest arrangements, which represents contractual interest added to a loan balance and due at the end of such loan’s term. To the extent OID or PIK interest constitute a portion of our income, we are exposed to risks associated with such income being required to be included in taxable and accounting income prior to receipt of cash, including the following:

 

•

The higher interest rates of OID and PIK instruments reflect the payment deferral and increased credit risk associated with these instruments, and OID and PIK instruments generally represent a significantly higher credit risk than coupon loans.

 

•

Even if the accounting conditions for income accrual are met, the borrower could still default when our actual collection is supposed to occur at the maturity of the obligation.

 

•

OID and PIK instruments may have unreliable valuations because their continuing accruals require continuing judgments about the collectability of the deferred payments and the value of any associated collateral. OID and PIK income may also create uncertainty about the source of our cash distributions.

 

•

For accounting purposes, any cash distributions to shareholders representing OID and PIK income are not treated as coming from paid-in capital, even though the cash to pay them comes from the offering proceeds. As a result, despite the fact that a distribution representing OID and PIK income could be paid out of amounts invested by our stockholders, the 1940 Act does not require that stockholders be given notice of this fact by reporting it as a return of capital.

 

•

The deferral of PIK interest may have a negative impact on our liquidity as it represents non-cash income that may require cash distributions to our stockholders in order to maintain our ability to be subject to tax as a RIC.

If we are unable to satisfy Code requirements for qualification as a RIC, then we will be subject to corporate-level income tax, which would adversely affect our results of operations and financial condition.

We elected to be treated as a RIC for federal income tax purposes with the filing of our federal corporate income tax return for 2006. We will not qualify for the tax treatment allowable to RICs if we are unable to comply with the source of income, asset diversification and distribution requirements contained in Subchapter M of the Code, or if we fail to maintain our election to be regulated as a business development company under the 1940 Act. If we fail to qualify for the federal income tax benefits allowable to RICs for any reason and become subject to a corporate-level income tax, the resulting taxes could substantially reduce our net assets, the amount of income available for distribution as dividends to our stockholders and the actual amount of our distributions. Such a failure would have a material adverse effect on us, the NAV of our common stock and the total return, if any, obtainable from your investment in our common stock.

We may have difficulty paying our required distributions under applicable tax rules if we recognize income before or without receiving cash representing such income.

In accordance with U.S. federal tax requirements, we are required to include in income for tax purposes certain amounts that we have not yet received in cash, such as OID and contractual PIK interest arrangements, which represents contractual interest added to a loan balance and due at the end of such loan’s term. In addition to the cash yields received on our loans, in some instances, our loans generally include one or more of the following: end-of-term payments, exit fees, balloon payment fees, commitment fees, success fees or prepayment fees. In some cases our loans also include contractual PIK interest arrangements. The increases in loan balances as a result of contractual PIK arrangements are included in income for the period in which such PIK interest was accrued, which is often in advance of receiving cash payment, and are separately identified on our statements of cash flows. We also may be required to include in income for tax purposes certain other amounts prior to receiving the related cash.

 

20

---

Table of Contents

Index to Financial Statements

Any warrants that we receive in connection with our debt investments will generally be valued as part of the negotiation process with the particular portfolio company. As a result, a portion of the aggregate purchase price for the debt investments and warrants will be allocated to the warrants that we receive. This will generally result in OID for tax purposes, which we must recognize as ordinary income, increasing the amount that we are required to distribute to qualify for the federal income tax benefits applicable to RICs. Because these warrants generally will not produce distributable cash for us at the same time as we are required to make distributions in respect of the related OID, if ever, we would need to obtain cash from other sources or to pay a portion of our distributions using shares of newly issued common stock, consistent with IRS requirements, to satisfy such distribution requirements.

Other features of the debt instruments that we hold may also cause such instruments to generate OID, resulting in a dividend distribution requirement in excess of current cash interest received. Since in certain cases we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the RIC tax requirement to distribute dividends each taxable year to our shareholders generally of an amount equal to at least 90% of our investment company taxable income. Under such circumstances, we may have to sell some of our assets, raise additional debt or equity capital or reduce new investment originations to meet these distribution requirements. If we are unable to obtain cash from other sources and are otherwise unable to satisfy such distribution requirements, we may fail to qualify for the federal income tax benefits allowable to RICs and, thus, become subject to a corporate-level income tax on all our taxable income (including any net realized securities gains).

Furthermore, we may invest in the equity securities of non-U.S. corporations (or other non-U.S. entities classified as corporations for U.S. federal income tax purposes) that could be treated under the Code and U.S. Treasury regulations as “passive foreign investment companies” and/or “controlled foreign corporations.” The rules relating to investment in these types of non-U.S. entities are designed to ensure that U.S. taxpayers are either, in effect, taxed currently (or on an accelerated basis with respect to corporate level events) or taxed at increased tax rates at distribution or disposition. In certain circumstances, these rules also could require us to recognize taxable income or gains where we do not receive a corresponding payment in cash.

Our portfolio investments may present special tax issues.

Investments in below-investment grade debt instruments and certain equity securities may present special tax issues for us. U.S. federal income tax rules are not entirely clear about issues such as when we may cease to accrue interest, OID or market discount, when and to what extent deductions may be taken for bad debts or worthless debt in equity securities, how payments received on obligations in default should be allocated between principal and interest income, as well as whether exchanges of debt instruments in a bankruptcy or workout context are taxable. Such matters could cause us to recognize taxable income for U.S. federal income tax purposes, even in the absence of cash or economic gain, and require us to make taxable distributions to our stockholders to maintain our RIC status or preclude the imposition of either U.S. federal corporate income or excise taxation. Additionally, because such taxable income may not be matched by corresponding cash received by us, we may be required to borrow money or dispose of other investments to be able to make distributions to our stockholders. These and other issues will be considered by us, to the extent determined necessary, in order that we minimize the level of any U.S. federal income or excise tax that we would otherwise incur. See “Certain United States Federal Income Tax Considerations—Taxation as a Regulated Investment Company.”

Legislative or regulatory tax changes could adversely affect you.

At any time, the federal income tax laws governing RICs or the administrative interpretations of those laws or regulations may be amended. Any of those new laws, regulations or interpretations may take effect retroactively and could adversely affect the taxation of us or of you as a stockholder. Therefore, changes in tax laws, regulations or administrative interpretations or any amendments thereto could diminish the value of an investment in our shares or the value or the resale potential of our investments.

 

21

---

Table of Contents

Index to Financial Statements

There is a risk that you may not receive distributions or that our distributions may not grow over time.

We intend to make distributions on a quarterly basis to our stockholders. We cannot assure you that we will achieve investment results, or our business may not perform in a manner that will allow us to make a specified level of distributions or year-to-year increases in cash distributions. In addition, due to the asset coverage test applicable to us as a business development company, we may be limited in our ability to make distributions. Also, our Credit Facilities limit our ability to declare dividends if we default under certain provisions of our Credit Facilities.

We have and may in the future choose to pay dividends in our own stock, in which case you may be required to pay tax in excess of the cash you receive.

Under applicable Treasury regulations and other administrative authorities issued by the IRS, RICs are permitted to treat certain distributions payable in their stock, as taxable dividends that will satisfy their annual distribution obligations for federal income tax and excise tax purposes provided that shareholders have the opportunity to elect to receive all or a portion of such distribution in cash. Taxable stockholders receiving such dividends will be required to include the full amount of the dividend as ordinary income (or as long-term capital gain to the extent such distribution is properly designated as a capital gain dividend) to the extent of our current and accumulated earnings and profits for federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with respect to such dividends in excess of any cash received. If a U.S. stockholder sells the stock it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold federal income tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, then such sales may put downward pressure on the trading price of our stock. We may in the future determine to distribute taxable dividends that are partially payable in our common stock.

We are exposed to risks associated with changes in interest rates, including fluctuations in interest rates which could adversely affect our profitability or the value of our portfolio

General interest rate fluctuations may have a substantial negative impact on our investments and investment opportunities, and, accordingly, may have a material adverse effect on our investment objective and rate of return on investment capital. A portion of our income will depend upon the difference between the rate at which we borrow funds and the interest rate on the debt securities in which we invest. Because we will borrow money to make investments and may issue debt securities, preferred stock or other securities, our net investment income is dependent upon the difference between the rate at which we borrow funds or pay interest or dividends on such debt securities, preferred stock or other securities and the rate at which we invest these funds. Typically, we anticipate that our interest-earning investments will accrue and pay interest at both variable and fixed rates, and that our interest-bearing liabilities will generally accrue interest at fixed rates.

A significant increase in market interest rates could harm our ability to attract new portfolio companies and originate new loans and investments. We expect that most of our current initial investments in debt securities will be at floating rate with a floor. However, in the event that we make investments in debt securities at variable rates, a significant increase in market interest rates could also result in an increase in our non-performing assets and a decrease in the value of our portfolio because our floating-rate loan portfolio companies may be unable to meet higher payment obligations. As of March 31, 2016, approximately 93.1% of our loans were at floating rates or floating rates with a floor and 6.9% of the loans were at fixed rates.

In periods of rising interest rates, our cost of funds would increase, resulting in a decrease in our net investment income. In addition, a decrease in interest rates may reduce net income, because new investments may be made at lower rates despite the increased demand for our capital that the decrease in interest rates may

 

22

---

Table of Contents

Index to Financial Statements

produce. We may, but will not be required to, hedge against the risk of adverse movement in interest rates in our short-term and long-term borrowings relative to our portfolio of assets. If we engage in hedging activities, it may limit our ability to participate in the benefits of lower interest rates with respect to the hedged portfolio. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on our business, financial condition, and results of operations.

We may expose ourselves to risks if we engage in hedging transactions.

If we engage in hedging transactions, we may expose ourselves to risks associated with such transactions. We may utilize instruments such as forward contracts, currency options and interest rate swaps, caps, collars and floors to seek to hedge against fluctuations in the relative values of our portfolio positions from changes in currency exchange rates and market interest rates. Hedging against a decline in the values of our portfolio positions does not eliminate the possibility of fluctuations in the values of such positions or prevent losses if the values of such positions decline. However, such hedging can establish other positions designed to gain from those same developments, thereby offsetting the decline in the value of such portfolio positions. Such hedging transactions may also limit the opportunity for gain if the values of the underlying portfolio positions should increase. It may not be possible to hedge against an exchange rate or interest rate fluctuation that is so generally anticipated that we are not able to enter into a hedging transaction at an acceptable price. Moreover, for a variety of reasons, we may not seek to establish a perfect correlation between such hedging instruments and there can be no assurance that any such hedging arrangements will achieve the desired effect. During the three months ended March 31, 2016, we did not engage in any hedging activities.

Our realized gains are reduced by amounts paid pursuant to the warrant participation agreement.

Citigroup Global Markets Realty Corp. (“Citigroup”), a former credit facility provider to Hercules, has an equity participation right through a warrant participation agreement on the pool of loans and certain warrants formerly collateralized under its then existing credit facility (the “Citibank Credit Facility”). Pursuant to the warrant participation agreement, we granted to Citigroup a 10% participation in all warrants held as collateral under the Citibank Credit Facility. As a result, Citigroup is entitled to 10% of the realized gains on certain warrants until the realized gains paid to Citigroup pursuant to the agreement equals $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three months ended March 31, 2016, we recorded a decrease in participation liability and an increase in unrealized appreciation by a net amount of approximately $1,000 as a result of appreciation of fair value on the pool of warrants collateralized under the warrant participation agreement offset by the acquisition proceeds we received on our Atrenta, Inc. equity investment. The remaining value of their participation right on unrealized gains in the related equity investments was approximately $110,000 as of March 31, 2016 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, we have paid approximately $2.2 million under the warrant participation agreement thereby reducing our realized gains by this amount. We will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup warrant participation agreement are set to expire between April 2016 and January 2017.

Legislation may allow us to incur additional leverage.

As a business development company, under the 1940 Act generally we are not permitted to incur indebtedness unless immediately after such borrowing we have an asset coverage for total borrowings of at least

 

23

---

Table of Contents

Index to Financial Statements

200% (i.e., the amount of debt may not exceed 50% of the value of our assets). If recent legislation in the U.S. House of Representatives is passed, or similar legislation is introduced, it would modify this section of the 1940 Act and increase the amount of debt that business development companies may incur. As a result, we may be able to incur additional indebtedness in the future and therefore your risk of an investment in us may increase. However, the ultimate form and likely outcome of such legislation or any similar legislation cannot be predicted.

Two of our wholly-owned subsidiaries are licensed by the U.S. Small Business Administration, and as a result, we will be subject to SBA regulations, which could limit our capital or investment decisions.

Our wholly-owned subsidiaries HT II and HT III are licensed to act as SBICs and are regulated by the SBA. HT II and HT III hold approximately $111.6 million and $289.1 million in assets, respectively, and they accounted for approximately 6.6% and 17.1% of our total assets, respectively, prior to consolidation at March 31, 2016. The SBIC licenses allow our SBIC subsidiaries to obtain leverage by issuing SBA-guaranteed debentures, subject to the issuance of a capital commitment by the SBA and other customary procedures.

The SBA regulations require that a licensed SBIC be periodically examined and audited by the SBA to determine its compliance with the relevant SBA regulations. The SBA prohibits, without prior SBA approval, a “change of control” of an SBIC or transfers that would result in any person (or a group of persons acting in concert) owning 10.0% or more of a class of capital stock of a licensed SBIC. If either HT II or HT III fail to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/ or limit HT II or HT III from making new investments. Such actions by the SBA would, in turn, negatively affect us because HT II and HT III are our wholly owned subsidiaries.

HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2016 as a result of having sufficient capital as defined under the SBA regulations. Compliance with SBA requirements may cause HT II and HT III to forego attractive investment opportunities that are not permitted under SBA regulations. See “Regulation—Small Business Administration Regulations.”

SBA regulations limit the outstanding dollar amount of SBA guaranteed debentures that may be issued by an SBIC or group of SBICs under common control.

The SBA regulations currently limit the dollar amount of SBA-guaranteed debentures that can be issued by any one SBIC to $150.0 million or to a group of SBICs under common control to $350.0 million.

An SBIC may not borrow an amount in excess of two times (and in certain cases, up to three times) its regulatory capital. As of March 31, 2016, we have issued $190.2 million in SBA-guaranteed debentures in our SBIC subsidiaries, which is the maximum combined capacity for our SBIC subsidiaries under our existing licenses. During times that we reach the maximum dollar amount of SBA-guaranteed debentures permitted, and if we require additional capital, our cost of capital is likely to increase, and there is no assurance that we will be able to obtain additional financing on acceptable terms.

Moreover, the current status of our SBIC subsidiaries as SBICs does not automatically assure that our SBIC subsidiaries will continue to receive SBA-guaranteed debenture funding. Receipt of SBA leverage funding is dependent upon our SBIC subsidiaries continuing to be in compliance with SBA regulations and policies and available SBA funding. The amount of SBA leverage funding available to SBICs is dependent upon annual Congressional authorizations and in the future may be subject to annual Congressional appropriations. There can be no assurance that there will be sufficient debenture funding available at the times desired by our SBIC subsidiaries.

The debentures guaranteed by the SBA have a maturity of ten years and require semi-annual payments of interest. Our SBIC subsidiaries will need to generate sufficient cash flow to make required interest payments on

 

24

---

Table of Contents

Index to Financial Statements

the debentures. If our SBIC subsidiaries are unable to meet their financial obligations under the debentures, the SBA, as a creditor, will have a superior claim to our SBIC subsidiaries’ assets over our stockholders in the event we liquidate our SBIC subsidiaries or the SBA exercises its remedies under such debentures as the result of a default by us.

Our wholly-owned SBIC subsidiaries may be unable to make distributions to us that will enable us to maintain RIC status, which could result in the imposition of an entity-level tax.

In order for us to continue to qualify for RIC tax treatment and to minimize corporate-level taxes, we will be required to distribute substantially all of our investment company taxable income and net capital gains, including income from certain of our subsidiaries, which includes the income from our SBIC subsidiaries. We will be partially dependent on our SBIC subsidiaries for cash distributions to enable us to meet the RIC distribution requirements. Our SBIC subsidiaries may be limited by the Small Business Investment Act of 1958, as amended, and SBA regulations governing SBICs, from making certain distributions to us that may be necessary to maintain our ability to be subject to tax as a RIC. We may have to request a waiver of the SBA’s restrictions for our SBIC subsidiaries to make certain distributions to maintain our ability to be subject to tax as a RIC. We cannot assure you that the SBA will grant such waiver. If our SBIC subsidiaries are unable to obtain a waiver, compliance with the SBA regulations may result in loss of RIC tax treatment and a consequent imposition of an entity-level tax on us.

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm (when undertaken, as noted below), may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors and lenders to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.

Our Board of Directors may change our investment objective, operating policies and strategies without prior notice or stockholder approval, the effects of which may be adverse.

Our Board of Directors has the authority, except as otherwise provided in the 1940 Act, to modify or waive certain of our operating policies and strategies without prior notice and without stockholder approval. However, absent stockholder approval, we may not change the nature of our business so as to cease to be, or withdraw our election as, a business development company. We cannot predict the effect any changes to our current operating policies and strategies would have on our business, operating results and the market price of our common stock. Nevertheless, any such changes could materially and adversely affect our business and impair our ability to make distributions to our stockholders.

Changes in laws or regulations governing our business could negatively affect the profitability of our operations.

Changes in the laws or regulations, or the interpretations of the laws and regulations, which govern business development companies, SBICs, RICs or non-depository commercial lenders could significantly affect our

 

25

---

Table of Contents

Index to Financial Statements

operations and our cost of doing business. We are subject to federal, state and local laws and regulations, in addition to applicable foreign and international laws and regulations, and are subject to judicial and administrative decisions that affect our operations, including our loan originations maximum interest rates, fees and other charges, disclosures to portfolio companies, the terms of secured transactions, collection and foreclosure procedures, and other trade practices. If these laws, regulations or decisions change, or if we expand our business into jurisdictions that have adopted more stringent requirements than those in which we currently conduct business, then we may have to incur significant expenses in order to comply or we may have to restrict our operations. In addition, if we do not comply with applicable laws, regulations and decisions, then we may lose licenses needed for the conduct of our business and be subject to civil fines and criminal penalties, any of which could have a material adverse effect upon our business results of operations or financial condition.

Our business is subject to increasingly complex corporate governance, public disclosure and accounting requirements that could adversely affect our business and financial results.

We are subject to changing rules and regulations of federal and state government as well as the stock exchange on which our common stock is listed. These entities, including the Public Company Accounting Oversight Board, the SEC and the NYSE have issued a significant number of new and increasingly complex requirements and regulations over the course of the last several years and continue to develop additional regulations and requirements in response to laws enacted by Congress. On July 21, 2010, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act, and the SEC has adopted, and will continue to adopt, additional rules and regulations that may impact us. Our efforts to comply with these requirements have resulted in, and are likely to continue to result in, an increase in expenses and a diversion of management’s time from other business activities.

In addition, our failure to maintain compliance with such rules, or for our management to appropriately address issues relating to our compliance with such rules fully and in a timely manner, exposes us to an increasing risk of inadvertent non-compliance. While the Company’s management team takes reasonable efforts to ensure that the Company is in full compliance with all laws applicable to its operations, the increasing rate and extent of regulatory change increases the risk of a failure to comply, which may result in our ability to operate our business in the ordinary course or may subject us to potential fines, regulatory findings or other matters that may materially impact our business.

We incur significant costs as a result of being a publicly traded company.

As a publicly traded company, we incur legal, accounting and other expenses, including costs associated with the periodic reporting requirements applicable to a company whose securities are registered under the Exchange Act as well as additional corporate governance requirements, including requirements under the Sarbanes-Oxley Act and other rules implemented by the SEC.

Results may fluctuate and may not be indicative of future performance.

Our operating results may fluctuate and, therefore, you should not rely on current or historical period results to be indicative of our performance in future reporting periods. Factors that could cause operating results to fluctuate include, but are not limited to, variations in the investment origination volume and fee income earned, changes in the accrual status of our debt investments, variations in timing of prepayments, variations in and the timing of the recognition of net realized gains or losses and changes in unrealized appreciation or depreciation, the level of our expenses, the degree to which we encounter competition in our markets, and general economic conditions.

 

26

---

Table of Contents

Index to Financial Statements

We face cyber-security risks and the failure in cyber security systems, as well as the occurrence of events unanticipated in our disaster recovery systems and management continuity planning could impair our ability to conduct business effectively.

Our business operations rely upon secure information technology systems for data processing, storage and reporting. Despite careful security and controls design, implementation and updating, our information technology systems could become subject to cyber-attacks. Network, system, application and data breaches could result in operational disruptions or information misappropriation, which could have a material adverse effect on our business, results of operations and financial condition.

The occurrence of a disaster such as a cyber-attack, a natural catastrophe, an industrial accident, a terrorist attack or war, events unanticipated in our disaster recovery systems, or a support failure from external providers, could have an adverse effect on our ability to conduct business and on our results of operations and financial condition, particularly if those events affect our computer-based data processing, transmission, storage, and retrieval systems or destroy data. If a significant number of our managers were unavailable in the event of a disaster, our ability to effectively conduct our business could be severely compromised.

We depend heavily upon computer systems to perform necessary business functions. Despite our implementation of a variety of security measures, our computer systems could be subject to cyber-attacks and unauthorized access, such as physical and electronic break-ins or unauthorized tampering. Like other companies, we may experience threats to our data and systems, including malware and computer virus attacks, unauthorized access, system failures and disruptions. If one or more of these events occurs, it could potentially jeopardize the confidential, proprietary and other information processed and stored in, and transmitted through, our computer systems and networks, or otherwise cause interruptions or malfunctions in our operations, which could result in damage to our reputation, financial losses, litigation, increased costs, regulatory penalties and/or customer dissatisfaction or loss.

We are dependent on information systems and systems failures could significantly disrupt our business, which may, in turn, negatively affect the market price of our common stock and our ability to pay dividends.

Our business is dependent on our and third parties’ communications and information systems. Any failure or interruption of those systems, including as a result of the termination of an agreement with any third-party service providers, could cause delays or other problems in our activities. Our financial, accounting, data processing, backup or other operating systems and facilities may fail to operate properly or become disabled or damaged as a result of a number of factors including events that are wholly or partially beyond our control and adversely affect our business. There could be:

 

•

sudden electrical or telecommunication outages;

 

•

natural disasters such as earthquakes, tornadoes and hurricanes;

 

•

disease pandemics;

 

•

events arising from local or larger scale political or social matters, including terrorist acts; and

 

•

cyber-attacks.

These events, in turn, could have a material adverse effect on our operating results and negatively affect the market price of our common stock and our ability to pay dividends to our stockholders.

Risks Related to Current Economic and Market Conditions

Capital markets may experience periods of disruption and instability and we cannot predict when these conditions will occur. Such market conditions could materially and adversely affect debt and equity capital markets in the United States and abroad, which could have a negative impact on our business, financial condition and results of operations.

The global capital markets have experienced a period of disruption as evidenced by a lack of liquidity in the debt capital markets, write-offs in the financial services sector, the re-pricing of credit risk and the failure of

 

27

---

Table of Contents

Index to Financial Statements

certain major financial institutions. While the capital markets have improved, these conditions could deteriorate again in the future. During such market disruptions, we may have difficulty raising debt or equity capital, especially as a result of regulatory constraints.

Market conditions may in the future make it difficult to extend the maturity of or refinance our existing indebtedness and any failure to do so could have a material adverse effect on our business. The illiquidity of our investments may make it difficult for us to sell such investments if required. As a result, we may realize significantly less than the value at which we have recorded our investments. In addition, significant changes in the capital markets, including the disruption and volatility, have had, and may in the future have, a negative effect on the valuations of our investments and on the potential for liquidity events involving our investments. An inability to raise capital, and any required sale of our investments for liquidity purposes, could have a material adverse impact on our business, financial condition and results of operations.

Various social and political tensions in the United States and around the world, including in the Middle East, Eastern Europe and Russia, may continue to contribute to increased market volatility, may have long-term effects on the United States and worldwide financial markets, and may cause further economic uncertainties or deterioration in the United States and worldwide. Several European Union (“EU”) countries, including Greece, Ireland, Italy, Spain, and Portugal, continue to face budget issues, some of which may have negative long-term effects for the economies of those countries and other EU countries. There is also continued concern about national-level support for the euro and the accompanying coordination of fiscal and wage policy among European Economic and Monetary Union member countries. In July and August 2015, Greece reached agreements with its creditors for bailouts that provide aid in exchange for certain austerity measures. These and similar austerity measures may adversely affect world economic conditions and have an impact on our business and that of our portfolio companies. In the second quarter of 2015, stock prices in China experienced a significant drop, resulting primarily from continued sell-off of trading in Chinese markets. In August 2015, Chinese authorities sharply devalued China’s currency.

These market and economic disruptions affect, and these and other similar market and economic disruptions may in the future affect, the U.S. capital markets, which could adversely affect our business and that of our portfolio companies. We cannot predict the duration of the effects related to these or similar events in the future on the United States economy and securities markets or on our investments. We monitor developments and seek to manage our investments in a manner consistent with achieving our investment objective, but there can be no assurance that we will be successful in doing so.

Depending on funding requirements, we may need to raise additional capital to meet our unfunded commitments either through equity offerings or through additional borrowings.

As of March 31, 2016, we had approximately $64.6 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones. In addition, we had approximately $98.0 million of unavailable commitments to portfolio companies due to milestone and other covenant restrictions.

Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. Closed commitments generally fund 70-80% of the committed amount in aggregate over the life of the commitment. We believe that our assets provide adequate cover to satisfy all of our unfunded comments and we intend to use cash

 

28

---

Table of Contents

Index to Financial Statements

flow from normal and early principal repayments and proceeds from borrowings and notes to fund these commitments. However, there can be no assurance that we will have sufficient capital available to fund these commitments as they come due.

Our ability to secure additional financing and satisfy our financial obligations under indebtedness outstanding from time to time will depend upon our future operating performance, which is subject to the prevailing general economic and credit market conditions, including interest rate levels and the availability of credit generally, and financial, business and other factors, many of which are beyond our control. The prolonged continuation or worsening of current economic and capital market conditions could have a material adverse effect on our ability to secure financing on favorable terms, if at all.

Changes relating to the LIBOR calculation process may adversely affect the value of our portfolio of the LIBOR-indexed, floating-rate debt securities.

In the recent past, concerns have been publicized that some of the member banks surveyed by the British Bankers’ Association (“BBA”) in connection with the calculation of the London Interbank Offered Rate, or LIBOR, across a range of maturities and currencies may have been under-reporting or otherwise manipulating the inter-bank lending rate applicable to them in order to profit on their derivatives positions or to avoid an appearance of capital insufficiency or adverse reputational or other consequences that may have resulted from reporting inter-bank lending rates higher than those they actually submitted. A number of BBA member banks entered into settlements with their regulators and law enforcement agencies with respect to alleged manipulation of LIBOR, and investigations by regulators and governmental authorities in various jurisdictions are ongoing.

Actions by the BBA, regulators or law enforcement agencies as a result of these or future events, may result in changes to the manner in which LIBOR is determined. Potential changes, or uncertainty related to such potential changes may adversely affect the market for LIBOR-based securities, including our portfolio of LIBOR-indexed, floating-rate debt securities. In addition, any further changes or reforms to the determination or supervision of LIBOR may result in a sudden or prolonged increase or decrease in reported LIBOR, which could have an adverse impact on the market for LIBOR-based securities or the value of our portfolio of LIBOR-indexed, floating-rate debt securities.

Risks Related to Our Investments

Our investments are concentrated in certain industries and in a number of technology-related companies, which subjects us to the risk of significant loss if any of these companies default on their obligations under any of their debt securities that we hold, or if any of the technology-related industry sectors experience a downturn.

We have invested and intend to continue investing in a limited number of technology-related companies. A consequence of this limited number of investments is that the aggregate returns we realize may be significantly adversely affected if a small number of investments perform poorly or if we need to write down the value of any one investment. Beyond the asset diversification requirements to which we are subject as a business development company and a RIC, we do not have fixed guidelines for diversification or limitations on the size of our investments in any one portfolio company and our investments could be concentrated in relatively few issuers. In addition, we have invested in and intend to continue investing, under normal circumstances, at least 80% of the value of our total assets (including the amount of any borrowings for investment purposes) in technology-related companies.

As of March 31, 2016, approximately 63.1% of the fair value of our portfolio was composed of investments in four industries: 24.9% was composed of investments in the drug discovery and development industry, 13.8% was comprised of investments in the sustainable and renewable technology industry, 12.2% was composed of investments in the software industry, and 12.2% was composed of investments in the drug delivery industry.

 

29

---

Table of Contents

Index to Financial Statements

As a result, a downturn in technology-related industry sectors and particularly those in which we are heavily concentrated could materially adversely affect our financial condition.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at March 31, 2016 that represent greater than 5% of our net assets:

 

		March 31, 2016
(in thousands)		Fair Value				Percentage of Net Assets
Machine Zone, Inc.		$	101,469				14.1	%
Sungevity Development, LLC.		$	64,573				9.0	%
Actifio, Inc.		$	39,964				5.6	%

Machine Zone, Inc. is a technology company that is best known for building mobile Massively Multiplayer Online games with a focus on community-based gameplay.

Sungevity Development, LLC. is a global residential solar energy provider focused on making it easy and affordable for homeowners to benefit from solar power.

Actifio, Inc. is a software company that helps global enterprise customers and service provider partners virtualize their data in order to improve their data resiliency, agility, and mobility while reducing cost and operational complexity.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

Our investments may be in portfolio companies that have limited operating histories and resources.

We expect that our portfolio will continue to consist of investments that may have relatively limited operating histories. These companies may be particularly vulnerable to U.S. and foreign economic downturns may have more limited access to capital and higher funding costs, may have a weaker financial position and may need more capital to expand or compete. These businesses also may experience substantial variations in operating results. They may face intense competition, including from larger, more established companies with greater financial, technical and marketing resources. Furthermore, some of these companies do business in regulated industries and could be affected by changes in government regulation applicable to their given industry. Accordingly, these factors could impair their cash flow or result in other events, such as bankruptcy, which could limit their ability to repay their obligations to us, and may adversely affect the return on, or the recovery of, our investment in these companies. We cannot assure you that any of our investments in our portfolio companies will be successful. We may lose our entire investment in any or all of our portfolio companies.

Investing in publicly traded companies can involve a high degree of risk and can be speculative.

We have invested, and expect to continue to invest, a portion of our portfolio in publicly traded companies or companies that are in the process of completing their initial public offering (“IPO”). As publicly traded

 

30

---

Table of Contents

Index to Financial Statements

companies, the securities of these companies may not trade at high volumes, and prices can be volatile, particularly during times of general market volatility, which may restrict our ability to sell our positions and may have a material adverse impact on us.

Our ability to invest in public companies may be limited in certain circumstances.

To maintain our status as a business development company, we are not permitted to acquire any assets other than “qualifying assets” specified in the 1940 Act unless, at the time the acquisition is made, at least 70% of our total assets are qualifying assets (with certain limited exceptions). Subject to certain exceptions for follow-on investments and distressed companies, an investment in an issuer that has outstanding securities listed on a national securities exchange may be treated as a qualifying asset only if such issuer has a market capitalization that is less than $250 million at the time of such investment and meets the other specified requirements.

Our investment strategy focuses on technology-related companies, which are subject to many risks, including volatility, intense competition, shortened product life cycles, changes in regulatory and governmental programs and periodic downturns, and you could lose all or part of your investment.

We have invested and will continue investing primarily in technology-related companies, many of which may have narrow product lines and small market shares, which tend to render them more vulnerable to competitors’ actions and market conditions, as well as to general economic downturns. The revenues, income (or losses), and valuations of technology-related companies can and often do fluctuate suddenly and dramatically. In addition, technology-related industries are generally characterized by abrupt business cycles and intense competition. Overcapacity in technology-related industries, together with cyclical economic downturns, may result in substantial decreases in the market capitalization of many technology-related companies. Such decreases in market capitalization may occur again, and any future decreases in technology-related company valuations may be substantial and may not be temporary in nature. Therefore, our portfolio companies may face considerably more risk of loss than do companies in other industry sectors.

Because of rapid technological change, the average selling prices of products and some services provided by technology-related companies have historically decreased over their productive lives. As a result, the average selling prices of products and services offered by technology-related companies may decrease over time, which could adversely affect their operating results, their ability to meet obligations under their debt securities and the value of their equity securities. This could, in turn, materially adversely affect our business, financial condition and results of operations.

Our investments in sustainable and renewable technology companies are subject to substantial operational risks, such as underestimated cost projections, unanticipated operation and maintenance expenses, loss of government subsidies, and inability to deliver cost-effective alternative energy solutions compared to traditional energy products. In addition, sustainable and renewable technology companies employ a variety of means of increasing cash flow, including increasing utilization of existing facilities, expanding operations through new construction or acquisitions, or securing additional long-term contracts. Thus, some energy companies may be subject to construction risk, acquisition risk or other risks arising from their specific business strategies. Furthermore, production levels for solar, wind and other renewable energies may be dependent upon adequate sunlight, wind, or biogas production, which can vary from market to market and period to period, resulting in volatility in production levels and profitability. Demand for sustainable and renewable technology is also influenced by the available supply and prices for other energy products, such as coal, oil and natural gases. A change in prices in these energy products could reduce demand for alternative energy.

A natural disaster may also impact the operations of our portfolio companies, including our technology-related portfolio companies. The nature and level of natural disasters cannot be predicted and may be exacerbated by global climate change. A portion of our technology-related portfolio companies rely on items assembled or produced in areas susceptible to natural disasters, and may sell finished goods into markets susceptible to natural

 

31

---

Table of Contents

Index to Financial Statements

disasters. A major disaster, such as an earthquake, tsunami, flood or other catastrophic event could result in disruption to the business and operations of our technology-related portfolio companies.

We will invest in technology-related companies that are reliant on U.S. and foreign regulatory and governmental programs. Any material changes or discontinuation, due to change in administration or U.S. Congress or otherwise could have a material adverse effect on the operations of a portfolio company in these industries and, in turn, impair our ability to timely collect principal and interest payments owed to us to the extent applicable.

We have invested in and may continue investing in technology-related companies that do not have venture capital or private equity firms as equity investors, and these companies may entail a higher risk of loss than do companies with institutional equity investors, which could increase the risk of loss of your investment.

Our portfolio companies will often require substantial additional equity financing to satisfy their continuing working capital and other cash requirements and, in most instances, to service the interest and principal payments on our investment. Portfolio companies that do not have venture capital or private equity investors may be unable to raise any additional capital to satisfy their obligations or to raise sufficient additional capital to reach the next stage of development. Portfolio companies that do not have venture capital or private equity investors may be less financially sophisticated and may not have access to independent members to serve on their boards, which means that they may be less successful than portfolio companies sponsored by venture capital or private equity firms. Accordingly, financing these types of companies may entail a higher risk of loss than would financing companies that are sponsored by venture capital or private equity firms.

Sustainable and renewable technology companies are subject to extensive government regulation and certain other risks particular to the sectors in which they operate and our business and growth strategy could be adversely affected if government regulations, priorities and resources impacting such sectors change or if our portfolio companies fail to comply with such regulations.

As part of our investment strategy, we plan to invest in portfolio companies in sustainable and renewable technology sectors that may be subject to extensive regulation by foreign, U.S. federal, state and/or local agencies. Changes in existing laws, rules or regulations, or judicial or administrative interpretations thereof, or new laws, rules or regulations could have an adverse impact on the business and industries of our portfolio companies. In addition, changes in government priorities or limitations on government resources could also adversely impact our portfolio companies. We are unable to predict whether any such changes in laws, rules or regulations will occur and, if they do occur, the impact of these changes on our portfolio companies and our investment returns. Furthermore, if any of our portfolio companies fail to comply with applicable regulations, they could be subject to significant penalties and claims that could materially and adversely affect their operations. Our portfolio companies may be subject to the expense, delay and uncertainty of the regulatory approval process for their products and, even if approved, these products may not be accepted in the marketplace.

In addition, there is considerable uncertainty about whether foreign, U.S., state and/or local governmental entities will enact or maintain legislation or regulatory programs that mandate reductions in greenhouse gas emissions or provide incentives for sustainable and renewable technology companies. Without such regulatory policies, investments in sustainable and renewable technology companies may not be economical and financing for sustainable and renewable technology companies may become unavailable, which could materially adversely affect the ability of our portfolio companies to repay the debt they owe to us. Any of these factors could materially and adversely affect the operations and financial condition of a portfolio company and, in turn, the ability of the portfolio company to repay the debt they owe to us.

Cyclicality within the energy sector may adversely affect some of our portfolio companies.

Industries within the energy sector are cyclical with fluctuations in commodity prices and demand for, and production of commodities driven by a variety of factors. The highly cyclical nature of the industries within the

 

32

---

Table of Contents

Index to Financial Statements

energy sector may lead to volatile changes in commodity prices, which may adversely affect the earnings of energy companies in which we may invest and the performance and valuation of our portfolio.

Volatility of oil and natural gas prices could impair certain of our portfolio companies’ operations and ability to satisfy obligations to their respective lenders and investors, including us, which could negatively impact our financial condition.

Some of our portfolio companies’ businesses are heavily dependent upon the prices of, and demand for, oil and natural gas, which have recently declined significantly and such volatility could continue or increase in the future. A substantial or extended decline in oil and natural gas demand or prices may adversely affect the business, financial condition, cash flow, liquidity or results of operations of these portfolio companies and might impair their ability to meet capital expenditure obligations and financial commitments. A prolonged or continued decline in oil prices could therefore have a material adverse effect on our business, financial condition and results of operations.

Our investments in the life sciences industry are subject to extensive government regulation, litigation risk and certain other risks particular to that industry.

We have invested and plan to continue investing in companies in the life sciences industry that are subject to extensive regulation by the Food and Drug Administration, or the FDA, and to a lesser extent, other federal, state and other foreign agencies. If any of these portfolio companies fail to comply with applicable regulations, they could be subject to significant penalties and claims that could materially and adversely affect their operations. Portfolio companies that produce medical devices or drugs are subject to the expense, delay and uncertainty of the regulatory approval process for their products and, even if approved, these products may not be accepted in the marketplace. In addition, governmental budgetary constraints effecting the regulatory approval process, new laws, regulations or judicial interpretations of existing laws and regulations might adversely affect a portfolio company in this industry. Portfolio companies in the life sciences industry may also have a limited number of suppliers of necessary components or a limited number of manufacturers for their products, and therefore face a risk of disruption to their manufacturing process if they are unable to find alternative suppliers when needed. Any of these factors could materially and adversely affect the operations of a portfolio company in this industry and, in turn, impair our ability to timely collect principal and interest payments owed to us.

Our investments in the drug discovery industry are subject to numerous risks, including competition, extensive government regulation, product liability and commercial difficulties.

Our investments in the drug discovery industry are subject to numerous risks. The successful and timely implementation of the business model of our drug discovery portfolio companies depends on their ability to adapt to changing technologies and introduce new products. As competitors continue to introduce competitive products, the development and acquisition of innovative products and technologies that improve efficacy, safety, patient’s and clinician’s ease of use and cost-effectiveness are important to the success of such portfolio companies. The success of new product offerings will depend on many factors, including the ability to properly anticipate and satisfy customer needs, obtain regulatory approvals on a timely basis, develop and manufacture products in an economic and timely manner, obtain or maintain advantageous positions with respect to intellectual property, and differentiate products from those of competitors. Failure by our portfolio companies to introduce planned products or other new products or to introduce products on schedule could have a material adverse effect on our business, financial condition and results of operations.

Further, the development of products by drug discovery companies requires significant research and development, clinical trials and regulatory approvals. The results of product development efforts may be affected by a number of factors, including the ability to innovate, develop and manufacture new products, complete clinical trials, obtain regulatory approvals and reimbursement in the U.S. and abroad, or gain and maintain market approval of products. In addition, regulatory review processes by U.S. and foreign agencies may extend

 

33

---

Table of Contents

Index to Financial Statements

longer than anticipated as a result of decreased funding and tighter fiscal budgets. Further, patents attained by others can preclude or delay the commercialization of a product. There can be no assurance that any products now in development will achieve technological feasibility, obtain regulatory approval, or gain market acceptance. Failure can occur at any point in the development process, including after significant funds have been invested. Products may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, failure to achieve market adoption, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or the infringement of intellectual property rights of others.

Future legislation, and/or regulations and policies adopted by the FDA or other U.S. or foreign regulatory authorities may increase the time and cost required by some of our portfolio companies to conduct and complete clinical trials for the product candidates that they develop, and there is no assurance that these companies will obtain regulatory approval to market and commercialize their products in the U.S. and in foreign countries.

The FDA has established regulations, guidelines and policies to govern the drug development and approval process, as have foreign regulatory authorities, which affect some of our portfolio companies. Any change in regulatory requirements due to the adoption by the FDA and/or foreign regulatory authorities of new legislation, regulations, or policies may require some of our portfolio companies to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols and/or clinical trial applications or the need for new ones, may significantly impact the cost, timing and completion of the clinical trials.

In addition, increased scrutiny by the U.S. Congress of the FDA’s and other authorities approval processes may significantly delay or prevent regulatory approval, as well as impose more stringent product labeling and post-marketing testing and other requirements. Foreign regulatory authorities may also increase their scrutiny of approval processes resulting in similar delays. Increased scrutiny and approvals processes may limit the ability of our portfolio companies to market and commercialize their products in the U.S. and in foreign countries.

Life sciences companies, including drug development companies, device manufacturers, service providers and others, are also subject to material pressures when there are changes in the outlook for healthcare insurance markets. The ability for individuals, along with private and public insurers, to account for the costs of paying for healthcare insurance can place strain on the ability of new technology, devices and services to enter those markets, particularly when they are new or untested. As a result, it is not uncommon for changes in the insurance market place to lead to a slower rate of adoption, price pressure and other forces that may materially limit the success of companies bringing such technologies to market. Changes in the health insurance sector might then have an impact on the value of companies in our portfolio or our ability to invest in the sector generally.

Changes in healthcare laws and other regulations, or the enforcement or interpretation of such laws or regulations, applicable to some of our portfolio companies’ businesses may constrain their ability to offer their products and services.

Changes in healthcare or other laws and regulations, or the enforcement or interpretation of such laws or regulations, applicable to the businesses of some of our portfolio companies may occur that could increase their compliance and other costs of doing business, require significant systems enhancements, or render their products or services less profitable or obsolete, any of which could have a material adverse effect on their results of operations. There has also been an increased political and regulatory focus on healthcare laws in recent years, and new legislation could have a material effect on the business and operations of some of our portfolio companies.

Price declines and illiquidity in the corporate debt markets could adversely affect the fair value of our portfolio investments, reducing our NAV through increased net unrealized depreciation.

As a business development company, we are required to carry our investments at market value or, if no market value is ascertainable, at fair market value as determined in good faith by or under the direction of our

 

34

---

Table of Contents

Index to Financial Statements

board of directors. As part of the valuation process, we may take into account the following types of factors, if relevant, in determining the fair value of our investments: the enterprise value of a portfolio company (an estimate of the total fair value of the portfolio company’s debt and equity), the nature and realizable value of any collateral, the portfolio company’s ability to make payments and its earnings and discounted cash flow, the markets in which the portfolio company does business, a comparison of the portfolio company’s securities to similar publicly traded securities, changes in the interest rate environment and the credit markets generally that may affect the price at which similar investments may be made in the future and other relevant factors. When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, we use the pricing indicated by the external event to corroborate our valuation. While most of our investments are not publicly traded, applicable accounting standards require us to assume as part of our valuation process that our investments are sold in a principal market to market participants (even if we plan on holding an investment through its maturity). As a result, volatility in the capital markets can also adversely affect our investment valuations. Decreases in the market values or fair values of our investments are recorded as unrealized depreciation. The effect of all of these factors on our portfolio can reduce our NAV by increasing net unrealized depreciation in our portfolio.

Depending on market conditions, we could incur substantial realized losses and may suffer substantial unrealized depreciation in future periods, which could have a material adverse impact on our business, financial condition and results of operations.

Economic recessions or slowdowns could impair the ability of our portfolio companies to repay loans, which, in turn, could increase our non-performing assets, decrease the value of our portfolio, reduce our volume of new loans and have a material adverse effect on our results of operations.

Many of our portfolio companies may be susceptible to economic slowdowns or recessions in both the U.S. and foreign countries, and may be unable to repay our loans during such periods. Therefore, during such periods, our non-performing assets are likely to increase and the value of our portfolio is likely to decrease. Adverse economic conditions also may decrease the value of collateral securing some of our loans and the value of our equity investments. Economic slowdowns or recessions could lead to financial losses in our portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase our funding costs, limit our access to the capital markets or result in a decision by lenders not to extend credit to us. These events could prevent us from increasing investments and harm our operating results.

In particular, intellectual property owned or controlled by our portfolio companies may constitute an important portion of the value of the collateral of our loans to our portfolio companies. Adverse economic conditions may decrease the demand for our portfolio companies’ intellectual property and consequently its value in the event of a bankruptcy or required sale through a foreclosure proceeding. As a result, our ability to fully recover the amounts owed to us under the terms of the loans may be impaired by such events.

A portfolio company’s failure to satisfy financial or operating covenants imposed by us or other lenders could lead to defaults and, potentially, termination of the portfolio company’s loans and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the portfolio company’s ability to meet its obligations under the debt securities that we hold. We may incur expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a defaulting portfolio company.

Our portfolio companies may be unable to repay or refinance outstanding principal on their loans at or prior to maturity, and rising interests rates may make it more difficult for portfolio companies to make periodic payments on their loans.

Our portfolio companies may be unable to repay or refinance outstanding principal on their loans at or prior to maturity. This risk and the risk of default is increased to the extent that the loan documents do not require the portfolio companies to pay down the outstanding principal of such debt prior to maturity. In addition, if general

 

35

---

Table of Contents

Index to Financial Statements

interest rates rise, there is a risk that our portfolio companies will be unable to pay escalating interest amounts, which could result in a default under their loan documents with us. Any failure of one or more portfolio companies to repay or refinance its debt at or prior to maturity or the inability of one or more portfolio companies to make ongoing payments following an increase in contractual interest rates could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The disposition of our investments may result in contingent liabilities.

We currently expect that a portion of our investments will involve private securities. In connection with the disposition of an investment in private securities, we may be required to make representations about the business and financial affairs of the portfolio company typical of those made in connection with the sale of a business. We may also be required to indemnify the purchasers of such investment to the extent that any such representations turn out to be inaccurate or with respect to certain potential liabilities. These arrangements may result in contingent liabilities that ultimately yield funding obligations that must be satisfied through our return of certain distributions previously made to us.

The health and performance of our portfolio companies could be adversely affected by political and economic conditions in the countries in which they conduct business.

Some of the products of our portfolio companies are developed, manufactured, assembled, tested or marketed outside the U.S. Any conflict or uncertainty in these countries, including due to natural disasters, public health concerns, political unrest or safety concerns, among other things, could harm their business, financial condition and results of operations. In addition, if the government of any country in which their products are developed, manufactured or sold sets technical or regulatory standards for products developed or manufactured in or imported into their country that are not widely shared, it may lead some of their customers to suspend imports of their products into that country, require manufacturers or developers in that country to manufacture or develop products with different technical or regulatory standards and disrupt cross-border manufacturing, marketing or business relationships which, in each case, could harm their businesses.

Any unrealized depreciation we experience on our investment portfolio may be an indication of future realized losses, which could reduce our income available for distribution and could impair our ability to service our borrowings.

As a business development company, we are required to carry our investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by our Board of Directors. Decreases in the market values or fair values of our investments will be recorded as unrealized depreciation. Any unrealized depreciation in our investment portfolio could be an indication of a portfolio company’s inability to meet its repayment obligations to us with respect to the affected investments. This could result in realized losses in the future and ultimately in reductions of our income available for distribution in future periods and could materially adversely affect our ability to service our outstanding borrowings.

A lack of IPO or merger and acquisition opportunities may cause companies to stay in our portfolio longer, leading to lower returns, unrealized depreciation, or realized losses.

A lack of IPO or merger and acquisition (“M&A”) opportunities for venture capital-backed companies could lead to companies staying longer in our portfolio as private entities still requiring funding. This situation may adversely affect the amount of available funding for early-stage companies in particular as, in general, venture-capital firms are being forced to provide additional financing to late-stage companies that cannot complete an IPO or M&A transaction. In the best case, such stagnation would dampen returns, and in the worst case, could lead to unrealized depreciation and realized losses as some companies run short of cash and have to accept lower valuations in private fundings or are not able to access additional capital at all. A lack of IPO or M&A opportunities for venture capital-backed companies can also cause some venture capital firms to change

 

36

---

Table of Contents

Index to Financial Statements

their strategies, leading some of them to reduce funding of their portfolio companies and making it more difficult for such companies to access capital and to fulfill their potential, which can result in unrealized depreciation and realized losses in such companies by other companies such as ourselves who are co-investors in such companies.

The majority of our portfolio companies will need multiple rounds of additional financing to repay their debts to us and continue operations. Our portfolio companies may not be able to raise additional financing, which could harm our investment returns.

The majority of our portfolio companies will often require substantial additional equity financing to satisfy their continuing working capital and other cash requirements and, in most instances, to service the interest and principal payments on our investment. Each round of venture financing is typically intended to provide a company with only enough capital to reach the next stage of development. We cannot predict the circumstances or market conditions under which our portfolio companies will seek additional capital. It is possible that one or more of our portfolio companies will not be able to raise additional financing or may be able to do so only at a price or on terms unfavorable to us, either of which would negatively impact our investment returns. Some of these companies may be unable to obtain sufficient financing from private investors, public capital markets or traditional lenders. This may have a significant impact if the companies are unable to obtain certain federal, state or foreign agency approval for their products or the marketing thereof, of if regulatory review processes extend longer than anticipated, and the companies need continued funding for their operations during these times. Accordingly, financing these types of companies may entail a higher risk of loss than would financing companies that are able to utilize traditional credit sources.

If the assets securing the loans that we make decrease in value, then we may lack sufficient collateral to cover losses.

To attempt to mitigate credit risks, we will typically take a security interest in the available assets of our portfolio companies. There is no assurance that we will obtain or properly perfect our liens.

There is a risk that the collateral securing our loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise and may fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of a portfolio company to raise additional capital. In some circumstances, our lien could be subordinated to claims of other creditors. Consequently, the fact that a loan is secured does not guarantee that we will receive principal and interest payments according to the loan’s terms, or that we will be able to collect on the loan should we be forced to enforce our remedies.

In addition, because we invest in technology-related companies, a substantial portion of the assets securing our investment may be in the form of intellectual property, if any, inventory and equipment and, to a lesser extent, cash and accounts receivable. Intellectual property, if any, that is securing our loan could lose value if, among other things, the company’s rights to the intellectual property are challenged or if the company’s license to the intellectual property is revoked or expires, the technology fails to achieve its intended results or a new technology makes the intellectual property functionally obsolete. Inventory may not be adequate to secure our loan if our valuation of the inventory at the time that we made the loan was not accurate or if there is a reduction in the demand for the inventory.

Similarly, any equipment securing our loan may not provide us with the anticipated security if there are changes in technology or advances in new equipment that render the particular equipment obsolete or of limited value, or if the company fails to adequately maintain or repair the equipment. Any one or more of the preceding factors could materially impair our ability to recover earned interest and principal in a foreclosure.

At March 31, 2016, approximately 40.4% of our portfolio company debt investments were secured by a first priority security in all of the assets of the portfolio company, including their intellectual property, 48.1% of the debt investments were to portfolio companies that were prohibited from pledging or encumbering their

 

37

---

Table of Contents

Index to Financial Statements

intellectual property, or subject to a negative pledge, 8.2% of the our portfolio company debt investments were secured by a second priority security interest in all of the portfolio company’s assets, other than intellectual property and 3.3% of our portfolio company debt investments were subordinated secured by all of the portfolio company’s assets, including intellectual property. At March 31, 2016 we had no equipment only liens on any of our portfolio companies.

We may suffer a loss if a portfolio company defaults on a loan and the underlying collateral is not sufficient.

In the event of a default by a portfolio company on a secured loan, we will only have recourse to the assets collateralizing the loan. If the underlying collateral value is less than the loan amount, we will suffer a loss. In addition, we sometimes make loans that are unsecured, which are subject to the risk that other lenders may be directly secured by the assets of the portfolio company. In the event of a default, those collateralized lenders would have priority over us with respect to the proceeds of a sale of the underlying assets. In cases described above, we may lack control over the underlying asset collateralizing our loan or the underlying assets of the portfolio company prior to a default, and as a result the value of the collateral may be reduced by acts or omissions by owners or managers of the assets.

In the event of bankruptcy of a portfolio company, we may not have full recourse to its assets in order to satisfy our loan, or our loan may be subject to “equitable subordination.” This means that depending on the facts and circumstances, including the extent to which we actually provided significant “managerial assistance,” if any, to that portfolio company, a bankruptcy court might re-characterize our debt holding and subordinate all or a portion of our claim to that of other creditors. In addition, certain of our loans are subordinate to other debt of the portfolio company. If a portfolio company defaults on our loan or on debt senior to our loan, or in the event of a portfolio company bankruptcy, our loan will be satisfied only after the senior debt receives payment. Where debt senior to our loan exists, the presence of intercreditor arrangements may limit our ability to amend our loan documents, assign our loans, accept prepayments, exercise our remedies (through “standstill” periods) and control decisions made in bankruptcy proceedings relating to the portfolio company. Bankruptcy and portfolio company litigation can significantly increase collection losses and the time needed for us to acquire the underlying collateral in the event of a default, during which time the collateral may decline in value, causing us to suffer losses.

If the value of collateral underlying our loan declines or interest rates increase during the term of our loan, a portfolio company may not be able to obtain the necessary funds to repay our loan at maturity through refinancing. Decreasing collateral value and/or increasing interest rates may hinder a portfolio company’s ability to refinance our loan because the underlying collateral cannot satisfy the debt service coverage requirements necessary to obtain new financing. If a borrower is unable to repay our loan at maturity, we could suffer a loss which may adversely impact our financial performance.

The inability of our portfolio companies to commercialize their technologies or create or develop commercially viable products or businesses would have a negative impact on our investment returns.

The possibility that our portfolio companies will not be able to commercialize their technology, products or business concepts presents significant risks to the value of our investment. Additionally, although some of our portfolio companies may already have a commercially successful product or product line when we invest, technology-related products and services often have a more limited market- or life-span than have products in other industries. Thus, the ultimate success of these companies often depends on their ability to continually innovate, or raise additional capital, in increasingly competitive markets. Their inability to do so could affect our investment return. In addition, the intellectual property held by our portfolio companies often represents a substantial portion of the collateral, if any, securing our investments. We cannot assure you that any of our portfolio companies will successfully acquire or develop any new technologies, or that the intellectual property the companies currently hold will remain viable. Even if our portfolio companies are able to develop commercially viable products, the market for new products and services is highly competitive and rapidly changing. Neither our portfolio companies nor we

 

38

---

Table of Contents

Index to Financial Statements

have any control over the pace of technology development. Commercial success is difficult to predict, and the marketing efforts of our portfolio companies may not be successful.

An investment strategy focused on privately-held companies presents certain challenges, including the lack of available information about these companies, a dependence on the talents and efforts of only a few key portfolio company personnel and a greater vulnerability to economic downturns.

We invest primarily in privately-held companies. Generally, very little public information exists about these companies, and we are required to rely on the ability of our management and investment teams to obtain adequate information to evaluate the potential returns from investing in these companies. Such small, privately held companies as we routinely invest in may also lack quality infrastructures, thus leading to poor disclosure standards or control environments. If we are unable to uncover all material information about these companies, then we may not make a fully informed investment decision, and we may not receive the expected return on our investment or lose some or all of the money invested in these companies.

Also, privately-held companies frequently have less diverse product lines and a smaller market presence than do larger competitors. Privately-held companies are, thus, generally more vulnerable to economic downturns and may experience more substantial variations in operating results than do larger competitors. These factors could affect our investment returns and our results of operations and financial condition.

In addition, our success depends, in large part, upon the abilities of the key management personnel of our portfolio companies, who are responsible for the day-to-day operations of our portfolio companies. Competition for qualified personnel is intense at any stage of a company’s development, and high turnover of personnel is common in technology-related companies. The loss of one or more key managers can hinder or delay a company’s implementation of its business plan and harm its financial condition. Our portfolio companies may not be able to attract and retain qualified managers and personnel. Any inability to do so may negatively impact our investment returns and our results of operations and financial condition.

If our portfolio companies are unable to protect their intellectual property rights, or are required to devote significant resources to protecting their intellectual property rights, then our investments could be harmed.

Our future success and competitive position depend in part upon the ability of our portfolio companies to obtain and maintain proprietary technology used in their products and services, which will often represent a significant portion of the collateral, if any, securing our investment. The portfolio companies will rely, in part, on patent, trade secret and trademark law to protect that technology, but competitors may misappropriate their intellectual property, and disputes as to ownership of intellectual property may arise. Portfolio companies may, from time to time, be required to institute litigation in order to enforce their patents, copyrights or other intellectual property rights, to protect their trade secrets, to determine the validity and scope of the proprietary rights of others or to defend against claims of infringement. Such litigation could result in substantial costs and diversion of resources. Similarly, if a portfolio company is found to infringe upon or misappropriate a third party’s patent or other proprietary rights, that portfolio company could be required to pay damages to such third party, alter its own products or processes, obtain a license from the third party and/or cease activities utilizing such proprietary rights, including making or selling products utilizing such proprietary rights. Any of the foregoing events could negatively affect both the portfolio company’s ability to service our debt investment and the value of any related debt and equity securities that we own, as well as any collateral securing our investment.

Our financial condition, results of operations and cash flows could be negatively affected if we are unable to recover our principal investment as a result of a negative pledge or lack of a security interest on the intellectual property of our venture growth stage companies.

In some cases, we collateralize our loans with a secured collateral position in a portfolio company’s assets, which may include a negative pledge or, to a lesser extent, no security on their intellectual property. In the event

 

39

---

Table of Contents

Index to Financial Statements

of a default on a loan, the intellectual property of the portfolio company will most likely be liquidated to provide proceeds to pay the creditors of the company. There can be no assurance that our security interest, if any, in the proceeds of the intellectual property will be enforceable in a court of law or bankruptcy court or that there will not be others with senior or pari passu credit interests.

Our relationship with certain portfolio companies may expose us to our portfolio companies’ trade secrets and confidential information which may require us to be parties to non-disclosure agreements and restrict us from engaging in certain transactions.

Our relationship with some of our portfolio companies may expose us to our portfolio companies’ trade secrets and confidential information (including transactional data and personal data about their employees and clients) which may require us to be parties to non-disclosure agreements and restrict us from engaging in certain transactions. Unauthorized access or disclosure of such information may occur, resulting in theft, loss or other misappropriation. Any theft, loss, improper use, such as insider trading or other misappropriation of confidential information could have a material adverse impact on our competitive positions, our relationship with our portfolio companies and our reputation and could subject us to regulatory inquiries, enforcement and fines, civil litigation (which may cause us to incur significant expense or expose us to losses) and possible financial liability or costs.

Portfolio company litigation could result in additional costs, the diversion of management time and resources and have an adverse impact on the fair value of our investment.

To the extent that litigation arises with respect to any of our portfolio companies, we may be named as a defendant, which could result in additional costs and the diversion of management time and resources. Furthermore, if we are providing managerial assistance to the portfolio company or have representatives on the portfolio company’s board of directors, our costs and diversion of our management’s time and resources in assessing the portfolio company could be substantial in light of any such litigation regardless of whether we are named as a defendant. In addition, litigation involving a portfolio company may be costly and affect the operations of the portfolio company’s business, which could in turn have an adverse impact on the fair value of our investment in such company.

We may not be able to realize our entire investment on equipment-based loans, if any, in the case of default.

We may from time-to-time provide loans that will be collateralized only by equipment of the portfolio company. If the portfolio company defaults on the loan we would take possession of the underlying equipment to satisfy the outstanding debt. The residual value of the equipment at the time we would take possession may not be sufficient to satisfy the outstanding debt and we could experience a loss on the disposition of the equipment.

Our investments in foreign securities may involve significant risks in addition to the risks inherent in U.S. investments.

Our investment strategy contemplates that a portion of our investments may be in securities of foreign companies. Our total investments at value in foreign companies were approximately $47.9 million or 3.7% of total investments at March 31, 2016. Investing in foreign companies may expose us to additional risks not typically associated with investing in U.S. companies. These risks include changes in exchange control regulations, political and social instability, expropriation, imposition of foreign taxes, less liquid markets and less available information than is generally the case in the U.S., higher transaction costs, less government supervision of exchanges, brokers and issuers, less developed bankruptcy laws, difficulty in enforcing contractual obligations, lack of uniform accounting and auditing standards and greater price volatility, among other things.

If our investments do not meet our performance expectations, you may not receive distributions.

We intend to make distributions on a quarterly basis to our stockholders. We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these

 

40

---

Table of Contents

Index to Financial Statements

distributions from time to time. In addition, due to the asset coverage test applicable to us as a business development company, we may be limited in our ability to make distributions. Also, restrictions and provisions in any future credit facilities may limit our ability to make distributions. As a RIC, if we do not distribute a certain percentage of our income each taxable year, we will suffer adverse tax consequences, including failure to obtain, or possible loss of, the federal income tax benefits allowable to RICs. We cannot assure you that you will receive distributions at a particular level or at all.

We may not have sufficient funds to make follow-on investments. Our decision not to make a follow-on investment may have a negative impact on a portfolio company in need of such an investment or may result in a missed opportunity for us.

After our initial investment in a portfolio company, we may be called upon from time to time to provide additional funds to such company or have the opportunity or need to increase our investment in a successful situation, for example, the exercise of a warrant to purchase common stock, or a negative situation, to protect an existing investment. Any decision we make not to make a follow-on investment or any inability on our part to make such an investment may have a negative impact on a portfolio company in need of such an investment or may result in a missed opportunity for us to increase our participation in a successful operation and may dilute our equity interest or otherwise reduce the expected yield on our investment. Moreover, a follow-on investment may limit the number of companies in which we can make initial investments. In determining whether to make a follow-on investment, our management will exercise its business judgment and apply criteria similar to those used when making the initial investment. There is no assurance that we will make, or will have sufficient funds to make, follow-on investments and this could adversely affect our success and result in the loss of a substantial portion or all of our investment in a portfolio company.

The lack of liquidity in our investments may adversely affect our business and, if we need to sell any of our investments, we may not be able to do so at a favorable price. As a result, we may suffer losses.

We generally invest in debt securities with terms of up to seven years and hold such investments until maturity, and we do not expect that our related holdings of equity securities will provide us with liquidity opportunities in the near-term. We invest and expect to continue investing in companies whose securities have no established trading market and whose securities are and will be subject to legal and other restrictions on resale or whose securities are and will be less liquid than are publicly-traded securities. The illiquidity of these investments may make it difficult for us to sell these investments when desired. In addition, if we are required to liquidate all or a portion of our portfolio quickly, we may realize significantly less than the value at which we had previously recorded these investments. As a result, we do not expect to achieve liquidity in our investments in the near-term. However, to maintain our qualification as a business development company and as a RIC, we may have to dispose of investments if we do not satisfy one or more of the applicable criteria under the respective regulatory frameworks.

Our portfolio companies may incur debt or issue equity securities that rank equally with, or senior to, our investments in such companies.

We invest primarily in debt securities issued by our portfolio companies. In some cases, portfolio companies will be permitted to incur other debt, or issue other equity securities, that rank equally with, or senior to, our investment. Such instruments may provide that the holders thereof are entitled to receive payment of dividends, interest or principal on or before the dates on which we are entitled to receive payments in respect of our investments. These debt instruments would usually prohibit the portfolio companies from paying interest on or repaying our investments in the event and during the continuance of a default under such debt. Also, in the event of insolvency, liquidation, dissolution, reorganization or bankruptcy of a portfolio company, holders of securities ranking senior to our investment in that portfolio company would typically be entitled to receive payment in full before we receive any distribution in respect of our investment. After repaying such holders, the portfolio company might not have any remaining assets to use for repaying its obligation to us. In the case of securities ranking equally

 

41

---

Table of Contents

Index to Financial Statements

with our investments, we would have to share on a pari passu basis any distributions with other security holders in the event of an insolvency, liquidation, dissolution, reorganization or bankruptcy of the relevant portfolio company.

The rights we may have with respect to the collateral securing any junior priority loans we make to our portfolio companies may also be limited pursuant to the terms of one or more intercreditor agreements that we enter into with the holders of senior debt. Under such an intercreditor agreement, at any time that senior obligations are outstanding, we may forfeit certain rights with respect to the collateral to the holders of the senior obligations. These rights may include the right to commence enforcement proceedings against the collateral, the right to control the conduct of such enforcement proceedings, the right to approve amendments to collateral documents, the right to release liens on the collateral and the right to waive past defaults under collateral documents. We may not have the ability to control or direct such actions, even if as a result our rights as junior lenders are adversely affected.

Our warrant and equity-related investments are highly speculative, and we may not realize gains from these investments. If our warrant and equity-related investments do not generate gains, then the return on our invested capital will be lower than it would otherwise be, which could result in a decline in the value of shares of our common stock.

When we invest in debt securities, we generally expect to acquire warrants or other equity-related securities as well. Our goal is ultimately to dispose of these equity interests and realize gains upon disposition of such interests. Over time, the gains that we realize on these equity interests may offset, to some extent, losses that we experience on defaults under debt securities that we hold. However, the equity interests that we receive may not appreciate in value and, in fact, may decline in value. Accordingly, we may not be able to realize gains from our equity interests, and any gains that we do realize on the disposition of any equity interests may not be sufficient to offset any other losses that we experience.

Prepayments of our debt investments by our portfolio companies could adversely impact our results of operations and reduce our return on equity.

During the three-months ended March 31, 2016, we received debt investment early repayments and pay down of working capital debt investments of approximately $76.4 million. We are subject to the risk that the investments we make in our portfolio companies may be repaid prior to maturity. When this occurs, we will generally reinvest these proceeds in temporary investments, pending their future investment in new portfolio companies. These temporary investments will typically have substantially lower yields than the debt being prepaid and we could experience significant delays in reinvesting these amounts. Any future investment in a new portfolio company may also be at lower yields than the debt that was repaid. As a result, our results of operations could be materially adversely affected if one or more of our portfolio companies elect to prepay amounts owed to us. Additionally, prepayments could negatively impact our return on equity, which could result in a decline in the market price of our common stock.

We may choose to waive or defer enforcement of covenants in the debt securities held in our portfolio, which may cause us to lose all or part of our investment in these companies.

We structure the debt investments in our portfolio companies to include business and financial covenants placing affirmative and negative obligations on the operation of the company’s business and its financial condition. However, from time to time we may elect to waive breaches of these covenants, including our right to payment, or waive or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular portfolio company. These actions may reduce the likelihood of receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could negatively impact our ability to pay dividends, could adversely affect our results of operation and financial condition and cause the loss of all or part of your investment.

 

42

---

Table of Contents

Index to Financial Statements

We may also be subject to lender liability claims for actions taken by us with respect to a borrower’s business or instances where we exercise control over the borrower. It is possible that we could become subject to a lender’s liability claim, including as a result of actions taken in rendering significant managerial assistance or actions to compel and collect payments from the borrower outside the ordinary course of business.

Our loans could be subject to equitable subordination by a court which would increase our risk of loss with respect to such loans or we could be subject to lender liability claims.

Courts may apply the doctrine of equitable subordination to subordinate the claim or lien of a lender against a borrower to claims or liens of other creditors of the borrower, when the lender or its affiliates is found to have engaged in unfair, inequitable or fraudulent conduct. The courts have also applied the doctrine of equitable subordination when a lender or its affiliates is found to have exerted inappropriate control over a client, including control resulting from the ownership of equity interests in a client or providing of significant managerial assistance. We have made direct equity investments or received warrants in connection with loans. These investments represent approximately 6.6% of the outstanding value of our investment portfolio as of March 31, 2016. Payments on one or more of our loans, particularly a loan to a client in which we also hold an equity interest, may be subject to claims of equitable subordination. If we were deemed to have the ability to control or otherwise exercise influence over the business and affairs of one or more of our portfolio companies resulting in economic hardship to other creditors of that company, this control or influence may constitute grounds for equitable subordination and a court may treat one or more of our loans as if it were unsecured or common equity in the portfolio company. In that case, if the portfolio company were to liquidate, we would be entitled to repayment of our loan on a pro-rata basis with other unsecured debt or, if the effect of subordination was to place us at the level of common equity, then on an equal basis with other holders of the portfolio company’s common equity only after all of its obligations relating to its debt and preferred securities had been satisfied.

In addition to these risks, in the event we elect to convert our debt position to equity, or otherwise take control of a portfolio company (such as through placing a member of our management team on its board of directors), as part of a restructuring, we face additional risks acting in that capacity. It is not uncommon for unsecured, or otherwise unsatisfied creditors, to sue parties that elect to use their debt positions to later control a company following a restructuring or bankruptcy. Apart from lawsuits, key customers and suppliers might act in a fashion contrary to the interests of a portfolio company if they were left unsatisfied in a restructuring or bankruptcy. Any combination of these factors might lead to the loss in value of a company subject to such activity and may divert the time and attention of our management team and investment team to help to address such issues in a portfolio company.

Risks Related to Our Securities

Investing in shares of our common stock involves an above average degree of risk.

The investments we make in accordance with our investment objective may result in a higher amount of risk, volatility or loss of principal than alternative investment options. Our investments in portfolio companies may be highly speculative and aggressive, and therefore, an investment in our common stock may not be suitable for investors with lower risk tolerance.

Our common stock may trade below its NAV per share, which limits our ability to raise additional equity capital.

If our common stock is trading below its NAV per share, we will generally not be able to issue additional shares of our common stock at its market price without first obtaining the approval for such issuance from our stockholders and our independent directors. If our common stock trades below NAV, the higher cost of equity capital may result in it being unattractive to raise new equity, which may limit our ability to grow. The risk of trading below NAV is separate and distinct from the risk that our NAV per share may decline. We cannot predict whether shares of our common stock will trade above, at or below our NAV.

 

43

---

Table of Contents

Index to Financial Statements

Provisions of our charter and bylaws could deter takeover attempts and have an adverse impact on the price of our common stock.

Our charter and bylaws contain provisions that may have the effect of discouraging, delaying, or making difficult a change in control of our company or the removal of our incumbent directors. Under our charter, our Board of Directors is divided into three classes serving staggered terms, which will make it more difficult for a hostile bidder to acquire control of us. In addition, our Board of Directors may, without stockholder action, authorize the issuance of shares of stock in one or more classes or series, including preferred stock. Subject to compliance with the 1940 Act, our Board of Directors may, without stockholder action, amend our charter to increase the number of shares of stock of any class or series that we have authority to issue. The existence of these provisions, among others, may have a negative impact on the price of our common stock and may discourage third party bids for ownership of our company. These provisions may prevent any premiums being offered to you for shares of our common stock in connection with a takeover.

Sales of substantial amounts of our common stock in the public market may have an adverse effect on the market price of our common stock.

Sales of substantial amounts of our common stock, or the availability of such common stock for sale, could adversely affect the prevailing market prices for our common stock. If this occurs and continues, it could impair our ability to raise additional capital through the sale of securities should we desire to do so.

We may periodically obtain the approval of our stockholders to issue shares of our common stock at prices below the then current NAV per share of our common stock. If we receive such approval from the stockholders, we may issue shares of our common stock at a price below the then current NAV per share of common stock. Any such issuance could materially dilute your interest in our common stock and reduce our NAV per share.

We may periodically obtain the approval of our stockholders to issue shares of our common stock at prices below the then current NAV per share of our common stock. Such approval has allowed and may again allow us to access the capital markets in a way that we typically are unable to do as a result of restrictions that, absent stockholder approval, apply to business development companies under the 1940 Act. Any decision to sell shares of our common stock below the then current NAV per share of our common stock is subject to the determination by our board of directors that such issuance and sale is in our and our stockholders’ best interests.

Any sale or other issuance of shares of our common stock at a price below NAV per share has resulted and will continue to result in an immediate dilution to your interest in our common stock and a reduction of our NAV per share. This dilution would occur as a result of a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting interest in us than the increase in our assets resulting from such issuance. Because the number of future shares of common stock that may be issued below our NAV per share and the price and timing of such issuances are not currently known, we cannot predict the actual dilutive effect of any such issuance. We also cannot determine the resulting reduction in our NAV per share of any such issuance at this time. We caution you that such effects may be material, and we undertake to describe all the material risks and dilutive effects of any offering that we make at a price below our then current NAV in the future in a prospectus supplement issued in connection with any such offering. We cannot predict whether shares of our common stock will trade above, at or below our NAV.

If we conduct an offering of our common stock at a price below NAV, investors are likely to incur immediate dilution upon the closing of the offering.

We are not generally able to issue and sell our common stock at a price below NAV per share. We may, however, sell our common stock, at a price below the current NAV of the common stock, or sell warrants, options or other rights to acquire such common stock, at a price below the current NAV of the common stock if

 

44

---

Table of Contents

Index to Financial Statements

our board of directors determines that such sale is in our best interests and the best interests of our stockholders and our stockholders have approved the practice of making such sales.

At the 2015 Annual Meeting of Stockholders, our common stockholders approved a proposal to allow us to issue common stock at a discount from its then current NAV per share, which is effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of stockholders. In connection with the receipt of such stockholder approval, we will limit the number of shares that it issues at a price below NAV pursuant to this authorization so that the aggregate dilutive effect on our then outstanding shares will not exceed 20%. Our Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share. If we were to issue shares at a price below NAV, such sales would result in an immediate dilution to existing common stockholders, which would include a reduction in the NAV per share as a result of the issuance. This dilution would also include a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting interest in us than the increase in our assets resulting from such issuance.

In addition, if we determined to conduct additional offerings in the future there may be even greater dilution if we determine to conduct such offerings at prices below NAV. As a result, investors will experience further dilution and additional discounts to the price of our common stock. Because the number of shares of common stock that could be so issued and the timing of any issuance is not currently known, the actual dilutive effect of an offering cannot be predicted. We did not sell any of our securities at a price below NAV during the three-months ended March 31, 2016.

We may allocate the net proceeds from an offering in ways with which you may not agree.

We have significant flexibility in investing the net proceeds of an offering and may use the net proceeds from an offering in ways with which you may not agree or for purposes other than those contemplated at the time of the offering.

If we issue preferred stock, debt securities or convertible debt securities, the NAV and market value of our common stock may become more volatile.

We cannot assure you that the issuance of preferred stock and/or debt securities would result in a higher yield or return to the holders of our common stock. The issuance of preferred stock, debt securities or convertible debt would likely cause the NAV and market value of our common stock to become more volatile. If the dividend rate on the preferred stock, or the interest rate on the debt securities, were to approach the net rate of return on our investment portfolio, the benefit of leverage to the holders of our common stock would be reduced. If the dividend rate on the preferred stock, or the interest rate on the debt securities, were to exceed the net rate of return on our portfolio, the use of leverage would result in a lower rate of return to the holders of common stock than if we had not issued the preferred stock or debt securities. Any decline in the NAV of our investment would be borne entirely by the holders of our common stock. Therefore, if the market value of our portfolio were to decline, the leverage would result in a greater decrease in NAV to the holders of our common stock than if we were not leveraged through the issuance of preferred stock. This decline in NAV would also tend to cause a greater decline in the market price for our common stock.

There is also a risk that, in the event of a sharp decline in the value of our net assets, we would be in danger of failing to maintain required asset coverage ratios which may be required by the preferred stock, debt securities, convertible debt or units or of a downgrade in the ratings of the preferred stock, debt securities, convertible debt or our current investment income might not be sufficient to meet the dividend requirements on the preferred stock or the interest payments on the debt securities. If we do not maintain our required asset coverage ratios, we may not be permitted to declare dividends. In order to counteract such an event, we might need to liquidate investments in order to fund redemption of some or all of the preferred stock, debt securities or convertible debt. In addition, we would pay (and the holders of our common stock would bear) all costs and

 

45

---

Table of Contents

Index to Financial Statements

expenses relating to the issuance and ongoing maintenance of the preferred stock, debt securities, convertible debt or any combination of these securities. Holders of preferred stock, debt securities or convertible debt may have different interests than holders of common stock and may at times have disproportionate influence over our affairs.

Holders of any preferred stock that we may issue will have the right to elect members of the board of directors and have class voting rights on certain matters.

The 1940 Act requires that holders of shares of preferred stock must be entitled as a class to elect two directors at all times and to elect a majority of the directors if dividends on such preferred stock are in arrears by two years or more, until such arrearage is eliminated. In addition, certain matters under the 1940 Act require the separate vote of the holders of any issued and outstanding preferred stock, including changes in fundamental investment restrictions and conversion to open-end status and, accordingly, preferred stockholders could veto any such changes. Restrictions imposed on the declarations and payment of dividends or other distributions to the holders of our common stock and preferred stock, both by the 1940 Act and by requirements imposed by rating agencies, might impair our ability to maintain our ability to be subject to tax as a RIC for U.S. federal income tax purposes.

Terms relating to redemption may materially adversely affect your return on any debt securities that we may issue.

If your debt securities are redeemable at our option, we may choose to redeem your debt securities at times when prevailing interest rates are lower than the interest rate paid on your debt securities. In addition, if your debt securities are subject to mandatory redemption, we may be required to redeem your debt securities also at times when prevailing interest rates are lower than the interest rate paid on your debt securities. In this circumstance, you may not be able to reinvest the redemption proceeds in a comparable security at an effective interest rate as high as your debt securities being redeemed.

Our shares may trade at discounts from NAV or at premiums that are unsustainable over the long term.

Shares of business development companies may trade at a market price that is less than the NAV that is attributable to those shares. Our shares have historically traded above and below our NAV. The possibility that our shares of common stock will trade at a discount from NAV or at a premium that is unsustainable over the long term is separate and distinct from the risk that our NAV may decrease. It is not possible to predict whether our shares will trade at, above or below NAV in the future.

Our credit ratings may not reflect all risks of an investment in our debt securities.

Our credit ratings are an assessment by third parties of our ability to pay our obligations. Consequently, real or anticipated changes in our credit ratings will generally affect the market value of our debt securities. Our credit ratings, however, may not reflect the potential impact of risks related to market conditions generally or other factors discussed herein on the market value of or trading market for the publicly issued debt securities.

A downgrade, suspension or withdrawal of the credit rating assigned by a rating agency to us or our debt securities, if any, or change in the debt markets could cause the liquidity or market value of our debt securities to decline significantly.

Our credit ratings are an assessment by rating agencies of our ability to pay our debts when due. Consequently, real or anticipated changes in our credit ratings will generally affect the market value of our outstanding debt securities. These credit ratings may not reflect the potential impact of risks relating to the structure or marketing of such debt securities. Credit ratings are not a recommendation to buy, sell or hold any security, and may be revised or withdrawn at any time by the issuing organization in its sole discretion.

 

46

---

Table of Contents

Index to Financial Statements

Neither we nor any underwriter undertakes any obligation to maintain our credit ratings or to advise holders of our debt securities of any changes in our credit ratings. There can be no assurance that a credit rating will remain for any given period of time or that such credit ratings will not be lowered or withdrawn entirely if future circumstances relating to the basis of the credit rating, such as adverse changes in our company, so warrant. The conditions of the financial markets and prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future.

Investors in offerings of our common stock will likely incur immediate dilution upon the closing of an offering pursuant to this prospectus.

We generally expect the public offering price of any offering of shares of our common stock to be higher than the book value per share of our outstanding common stock (unless we offer shares pursuant to a rights offering or after obtaining prior approval for such issuance from our stockholders and our independent directors). Accordingly, investors purchasing shares of common stock in offerings pursuant to this prospectus may pay a price per share that exceeds the tangible book value per share after such offering.

Our stockholders will experience dilution in their ownership percentage if they opt out of our dividend reinvestment plan.

All dividends declared in cash payable to stockholders that are participants in our dividend reinvestment plan are automatically reinvested in shares of our common stock. As a result, our stockholders that opt out of our dividend reinvestment plan will experience dilution in their ownership percentage of our common stock over time.

Our stockholders may experience dilution upon the repurchase of common shares.

On February 24, 2015, our Board of Directors authorized a stock repurchase plan permitting us to repurchase up to $50.0 million of our common stock. This plan expired on August 24, 2015. On August 27, 2015, our Board of Directors authorized a replacement stock repurchase plan permitting us to repurchase up to $50.0 million of our common stock. We may repurchase shares of our common stock in the open market, including block purchases, at prices that may be above or below the NAV as reported in the most recently published financial statements. We expect that the share repurchase program will be in effect until August 23, 2016, or until the approved dollar amount has been used to repurchase shares. If we were to repurchase shares at a price above NAV, such repurchases would result in an immediate dilution to existing common stockholders due to a reduction in the our earnings and assets due to the repurchase that is greater than the reduction in total shares outstanding.

Our distribution proceeds may exceed our earnings. Therefore, portions of the distributions that we make may represent a return of capital to stockholders, which will lower their tax basis in their shares.

The tax treatment and characterization of our distributions may vary significantly from time to time due to the nature of our investments. The ultimate tax characterization of our distributions made during a taxable year may not finally be determined until after the end of that taxable year. We may make distributions during a taxable year that exceed our investment company taxable income and net capital gains for that taxable year. In such a situation, the amount by which our total distributions exceed investment company taxable income and net capital gains generally would be treated as a return of capital up to the amount of a stockholder’s tax basis in the shares, with any amounts exceeding such tax basis treated as a gain from the sale or exchange of such shares. A return of capital generally is a return of a stockholder’s investment rather than a return of earnings or gains derived from our investment activities. Moreover, we may pay all or a substantial portion of our distributions from the proceeds of the sale of shares of our common stock or from borrowings in anticipation of future cash flow, which could constitute a return of stockholders’ capital and will lower such stockholders’ tax basis in our shares, which may result in increased tax liability to stockholders when they sell such shares.

 

47

---

Table of Contents

Index to Financial Statements

Our common stock price has been and continues to be volatile and may decrease substantially.

As with any company, the price of our common stock will fluctuate with market conditions and other factors, which include, but are not limited to, the following:

 

•

price and volume fluctuations in the overall stock market from time to time;

 

•

significant volatility in the market price and trading volume of securities of RICs, business development companies or other financial services companies;

 

•

any inability to deploy or invest our capital;

 

•

fluctuations in interest rates;

 

•

any shortfall in revenue or net income or any increase in losses from levels expected by investors or securities analysts;

 

•

the financial performance of specific industries in which we invest in on a recurring basis;

 

•

announcement of strategic developments, acquisitions, and other material events by us or our competitors, or operating performance of companies comparable to us;

 

•

changes in regulatory policies or tax guidelines with respect to RICs, SBICs or business development companies;

 

•

losing RIC status;

 

•

actual or anticipated changes in our earnings or fluctuations in our operating results, or changes in the expectations of securities analysts;

 

•

changes in the value of our portfolio of investments;

 

•

realized losses in investments in our portfolio companies;

 

•

general economic conditions and trends;

 

•

inability to access the capital markets;

 

•

loss of a major funded source; or

 

•

departure of key personnel.

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. Due to the potential volatility of our stock price, we may be the target of securities litigation in the future. Securities litigation could result in substantial costs and could divert management’s attention and resources from our business.

Your interest in us may be diluted if you do not fully exercise your subscription rights in any rights offering. In addition, if the subscription price is less than our NAV per share, then you will experience an immediate dilution of the aggregate NAV of your shares.

In the event we issue subscription rights, stockholders who do not fully exercise their subscription rights should expect that they will, at the completion of a rights offering pursuant to this prospectus, own a smaller proportional interest in us than would otherwise be the case if they fully exercised their rights. We cannot state precisely the amount of any such dilution in share ownership because we do not know at this time what proportion of the shares will be purchased as a result of such rights offering.

In addition, if the subscription price is less than the NAV per share of our common stock, then our stockholders would experience an immediate dilution of the aggregate NAV of their shares as a result of the

 

48

---

Table of Contents

Index to Financial Statements

offering. The amount of any decrease in NAV is not predictable because it is not known at this time what the subscription price and NAV per share will be on the expiration date of a rights offering or what proportion of the shares will be purchased as a result of such rights offering. Such dilution could be substantial.

The trading market or market value of our publicly issued debt securities may fluctuate.

Our publicly issued debt securities may or may not have an established trading market. We cannot assure you that a trading market for our publicly issued debt securities will ever develop or be maintained if developed. In addition to our creditworthiness, many factors may materially adversely affect the trading market for, and market value of, our publicly issued debt securities. These factors include, but are not limited to, the following:

 

•

the time remaining to the maturity of these debt securities;

 

•

the outstanding principal amount of debt securities with terms identical to these debt securities;

 

•

the ratings assigned by national statistical ratings agencies;

 

•

the general economic environment;

 

•

the supply of debt securities trading in the secondary market, if any;

 

•

the redemption or repayment features, if any, of these debt securities;

 

•

the level, direction and volatility of market interest rates generally; and

 

•

market rates of interest higher or lower than rates borne by the debt securities. You should also be aware that there may be a limited number of buyers when you decide to sell your debt securities. This too may materially adversely affect the market value of the debt securities or the trading market for the debt securities.

The 2019 Notes and 2024 Notes are unsecured and therefore are effectively subordinated to any secured indebtedness we have currently incurred or may incur in the future.

The 2019 Notes and 2024 Notes are not secured by any of our assets or any of the assets of our subsidiaries. As a result, the 2019 Notes and 2024 Notes are effectively subordinated to any secured indebtedness we or our subsidiaries have currently incurred and may incur in the future (or any indebtedness that is initially unsecured to which we subsequently grant security) to the extent of the value of the assets securing such indebtedness. In any liquidation, dissolution, bankruptcy or other similar proceeding, the holders of any of our existing or future secured indebtedness and the secured indebtedness of our subsidiaries may assert rights against the assets pledged to secure that indebtedness in order to receive full payment of their indebtedness before the assets may be used to pay other creditors, including the holders of the 2019 Notes and 2024 Notes.

The 2019 Notes and 2024 Notes are structurally subordinated to the indebtedness and other liabilities of our subsidiaries.

The 2019 Notes and 2024 Notes are obligations exclusively of Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) and not of any of our subsidiaries. None of our subsidiaries are or act as guarantors of the 2019 Notes and 2024 Notes and neither the 2019 Notes nor the 2024 Notes is required to be guaranteed by any subsidiaries we may acquire or create in the future. Our secured indebtedness with respect to the SBA debentures is held through our SBIC subsidiaries. The assets of any such subsidiaries are not directly available to satisfy the claims of our creditors, including holders of the 2019 Notes and 2024 Notes.

Except to the extent we are a creditor with recognized claims against our subsidiaries, all claims of creditors (including holders of preferred stock, if any, of our subsidiaries) will have priority over our equity interests in such subsidiaries (and therefore the claims of our creditors, including holders of the 2019 Notes and 2024 Notes)

 

49

---

Table of Contents

Index to Financial Statements

with respect to the assets of such subsidiaries. Even if we are recognized as a creditor of one or more of our subsidiaries, our claims would still be structurally subordinated to any security interests in the assets of any such subsidiary and to any indebtedness or other liabilities of any such subsidiary senior to our claims. Consequently, the 2019 Notes and 2014 Notes are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our subsidiaries and any subsidiaries that we may in the future acquire or establish as financing vehicles or otherwise. In addition, our subsidiaries may incur substantial additional indebtedness in the future, all of which would be structurally senior to the 2019 Notes and 2024 Notes.

The indenture under which the 2019 Notes and 2024 Notes were issued contains limited protection for their respective holders.

The indenture under which the 2019 Notes and 2024 Notes were issued offers limited protection to their respective holders. The terms of the indenture and the 2019 Notes and 2024 Notes do not restrict our or any of our subsidiaries’ ability to engage in, or otherwise be a party to, a variety of corporate transactions, circumstances or events that could have an adverse impact on an investment in the 2019 Notes and 2024 Notes. In particular, the terms of the indentures and the 2019 Notes and 2024 Notes do not place any restrictions on our or our subsidiaries’ ability to:

 

•

issue securities or otherwise incur additional indebtedness or other obligations, including (1) any indebtedness or other obligations that would be equal in right of payment to the 2019 Notes and 2024 Notes, (2) any indebtedness or other obligations that would be secured and therefore rank effectively senior in right of payment to the 2019 Notes and 2024 Notes to the extent of the values of the assets securing such debt, (3) indebtedness of ours that is guaranteed by one or more of our subsidiaries and which therefore would rank structurally senior to the 2019 Notes and 2024 Notes and (4) securities, indebtedness or other obligations issued or incurred by our subsidiaries that would be senior in right of payment to our equity interests in our subsidiaries and therefore would rank structurally senior in right of payment to the 2019 Notes and 2024 Notes with respect to the assets of our subsidiaries, in each case other than an incurrence of indebtedness or other obligation that would cause a violation of Section 18(a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act or any successor provisions;

 

•

pay dividends on, or purchase or redeem or make any payments in respect of, capital stock or other securities ranking junior in right of payment to the 2019 Notes and 2024 Notes, in each case other than dividends, purchases, redemptions or payments that would cause a violation of Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act or any successor provisions giving effect to any exemptive relief granted to us by the SEC (these provisions generally prohibit us from declaring any cash dividend or distribution upon any class of our capital stock, or purchasing any such capital stock if our asset coverage, as defined in the 1940 Act, is below 200% at the time of the declaration of the dividend or distribution or the purchase and after deducting the amount of such dividend, distribution or purchase);

 

•

sell assets (other than certain limited restrictions on our ability to consolidate, merge or sell all or substantially all of our assets);

 

•

enter into transactions with affiliates;

 

•

create liens (including liens on the shares of our subsidiaries) or enter into sale and leaseback transactions;

 

•

make investments; or

 

•

create restrictions on the payment of distributions or other amounts to us from our subsidiaries.

In the indenture and the 2019 Notes and 2024 Notes do not require us to offer to purchase the 2019 Notes and 2024 Notes in connection with a change of control or any other event.

 

50

---

Table of Contents

Index to Financial Statements

Furthermore, the terms of the indenture and the 2019 Notes and 2024 Notes do not protect their respective holders in the event that we experience changes (including significant adverse changes) in our financial condition, results of operations or credit ratings, as they do not require that we or our subsidiaries adhere to any financial tests or ratios or specified levels of net worth, revenues, income, cash flow or liquidity, except as required under the 1940 Act.

Our ability to recapitalize, incur additional debt and take a number of other actions that are not limited by the terms of the 2019 Notes and 2024 Notes may have important consequences for their holders, including making it more difficult for us to satisfy our obligations with respect to the 2019 Notes and 2024 Notes or negatively affecting their trading value.

Certain of our current debt instruments include more protections for their respective holders than the indenture and the 2019 Notes and 2024 Notes. In addition, other debt we issue or incur in the future could contain more protections for its holders than the indenture and the 2019 Notes and 2024 Notes, including additional covenants and events of default. The issuance or incurrence of any such debt with incremental protections could affect the market for and trading levels and prices of the 2019 Notes and 2024 Notes.

An active trading market for the Notes may not develop or be sustained, which could limit the market price of the Notes or your ability to sell them.

Although the 2019 Notes are listed on the NYSE under the symbol “HTGZ,” in the case of the April 2019 Notes, “HTGY” in the case of the September 2019 Notes and “HTGX,” in the case of the 2024 Notes, we cannot provide any assurances that an active trading market will develop or be sustained for the April 2019 Notes, the September 2019 Notes, or the 2024 Notes or that any of the notes will be able to be sold. At various times, the 2019 Notes and 2024 Notes may trade at a discount from their initial offering price depending on prevailing interest rates, the market for similar securities, our credit ratings, general economic conditions, our financial condition, performance and prospects and other factors. To the extent an active trading market is not sustained, the liquidity and trading price for the 2019 Notes and 2024 Notes may be harmed.

 

51

---

Table of Contents

Index to Financial Statements

If we default on our obligations to pay our other indebtedness, we may not be able to make payments on the 2019 Notes and 2024 Notes.

Any default under the agreements governing our indebtedness, including a default under the Wells Facility, the Union Bank Facility and the Convertible Senior Notes or other indebtedness to which we may be a party that is not waived by the required lenders or holders, and the remedies sought by the holders of such indebtedness could make us unable to pay principal, premium, if any, and interest on the 2019 Notes and 2024 Notes and substantially decrease the market value of the 2014 Notes and 2024 Notes. If we are unable to generate sufficient cash flow and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our indebtedness, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our indebtedness, we could be in default under the terms of the agreements governing such indebtedness. In the event of such default, the holders of such indebtedness could elect to declare all the funds borrowed thereunder to be due and payable, together with accrued and unpaid interest, the lenders under the Wells Facility and the Union Bank Facility or other debt we may incur in the future could elect to terminate their commitments, cease making further loans and institute foreclosure proceedings against our assets, and we could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to seek to obtain waivers from the required lenders under the Wells Facility or Union Bank Facility or the required holders of our Convertible Senior Notes or other debt that we may incur in the future to avoid being in default. If we breach our covenants under the Wells Facility or Union Bank Facility or the Convertible Senior Notes or other debt and seek a waiver, we may not be able to obtain a waiver from the required lenders or holders. If this occurs, we would be in default under the Wells Facility or Union Bank Facility or the Convertible Senior Notes or other debt, the lenders or holders could exercise their rights as described above, and we could be forced into bankruptcy or liquidation. If we are unable to repay debt, lenders having secured obligations, including the lenders under the Wells Facility and the Union Bank Facility, could proceed against the collateral securing the debt. Because the Wells Facility, the Union Bank Facility and the Convertible Senior Notes have, and any future credit facilities will likely have, customary cross-default provisions, if the indebtedness under the 2019 Notes, 2024 Notes, the Wells Facility, Union Bank Facility, the Convertible Senior Notes or under any future credit facility is accelerated, we may be unable to repay or finance the amounts due.

 

52

---

Table of Contents

Index to Financial Statements

FORWARD-LOOKING STATEMENTS

The matters discussed in this prospectus, as well as in future oral and written statements by management of Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this prospectus should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this prospectus include statements as to:

 

•

our future operating results;

 

•

our business prospects and the prospects of our prospective portfolio companies;

 

•

the impact of investments that we expect to make;

 

•

our informal relationships with third parties including in the venture capital industry;

 

•

the expected market for venture capital investments and our addressable market;

 

•

the dependence of our future success on the general economy and its impact on the industries in which we invest;

 

•

our ability to access debt markets and equity markets;

 

•

the ability of our portfolio companies to achieve their objectives;

 

•

our expected financings and investments;

 

•

our regulatory structure and tax status;

 

•

our ability to operate as a business development company, a SBIC and a RIC;

 

•

the adequacy of our cash resources and working capital;

 

•

the timing of cash flows, if any, from the operations of our portfolio companies;

 

•

the timing, form and amount of any dividend distributions;

 

•

the impact of fluctuations in interest rates on our business;

 

•

the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and

 

•

our ability to recover unrealized losses.

For a discussion of factors that could cause our actual results to differ from forward-looking statements contained in this prospectus, please see the discussion under “Risk Factors.” You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this prospectus relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this prospectus.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this prospectus. In addition to historical information, the following discussion and other parts of this prospectus contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under “Risk Factors” and “Forward-Looking Statements.”

 

53

---

Table of Contents

Index to Financial Statements

USE OF PROCEEDS

We intend to use the net proceeds from selling our securities for funding investments in debt and equity securities in accordance with our investment objective and other general corporate purposes. The supplement to this prospectus relating to an offering will more fully identify the use of proceeds from such offering.

We anticipate that substantially all of the net proceeds from any offering of our securities will be used as described above within twelve months, but in no event longer than two years. Pending such uses and investments, we will invest the net proceeds primarily in cash, cash equivalents, U.S. government securities or high-quality debt securities maturing in one year or less from the time of investment. Our ability to achieve our investment objective may be limited to the extent that the net proceeds of any offering, pending full investment, are held in lower yielding short-term instruments.

 

54

---

Table of Contents

Index to Financial Statements

PRICE RANGE OF COMMON STOCK AND DISTRIBUTIONS

Our common stock is traded on the NYSE under the symbol “HTGC.”

The following table sets forth the range of high and low sales prices of our common stock, the sales price as a percentage of NAV and the dividends declared by us for each fiscal quarter. The stock quotations are interdealer quotations and do not include markups, markdowns or commissions.

 

						Price Range								Premium/ Discount of High Sales Price to NAV				Premium/ Discount of Low Sales Price to NAV				Cash Dividend per Share
		NAV(1)				High				Low
2014
First quarter		$	10.58			$	15.27			$	13.24				44.3	%			25.1	%		$	0.310
Second quarter		$	10.42			$	15.54			$	12.75				49.1	%			22.4	%		$	0.310
Third quarter		$	10.22			$	16.24			$	14.16				58.9	%			38.6	%		$	0.310
Fourth quarter		$	10.18			$	15.82			$	13.16				55.4	%			29.3	%		$	0.310
2015
First quarter		$	10.47			$	15.27			$	13.47				45.8	%			28.7	%		$	0.310
Second quarter		$	10.26			$	13.37			$	11.25				30.3	%			9.6	%		$	0.310
Third quarter		$	10.02			$	12.23			$	9.99				22.1	%			-0.3	%		$	0.310
Fourth quarter		$	9.94			$	12.44			$	10.23				25.2	%			2.9	%		$	0.310
2016
First quarter		$	9.81			$	12.39			$	10.03				26.3	%			2.2	%		$	0.310
Second quarter (through June 2, 2016)			*			$	12.43			$	11.74				*				*				**

 

(1)	Net asset value per share is generally determined as of the last day in the relevant quarter and therefore may not reflect the NAV per share on the date of the high and low sales prices. The NAVs shown are based on outstanding shares at the end of each period.

*	Net asset value has not yet been calculated for this period.

**	Cash dividend per share has not yet been determined for this period.

The last reported price for our common stock on June 2, 2016 was $12.38 per share.

Shares of business development companies may trade at a market price that is less than the value of the net assets attributable to those shares. The possibility that our shares of common stock will trade at a discount from NAV or at premiums that are unsustainable over the long term are separate and distinct from the risk that our NAV will decrease. At times, our shares of common stock have traded at a premium to NAV and at times our shares of common stock have traded at a discount to the net assets attributable to those shares. It is not possible to predict whether the shares offered hereby will trade at, above, or below NAV.

 

55

---

Table of Contents

Index to Financial Statements

Dividends

The following table summarizes dividends declared and paid or to be paid or reinvested on all shares, including restricted stock, to date:

 

Date Declared

Record Date

Payment Date

Amount Per Share

October 27, 2005

November 1, 2005

November 17, 2005

$

0.03

December 9, 2005

January 6, 2006

January 27, 2006

0.30

April 3, 2006

April 10, 2006

May 5, 2006

0.30

July 19, 2006

July 31, 2006

August 28, 2006

0.30

October 16, 2006

November 6, 2006

December 1, 2006

0.30

February 7, 2007

February 19, 2007

March 19, 2007

0.30

May 3, 2007

May 16, 2007

June 18, 2007

0.30

August 2, 2007

August 16, 2007

September 17, 2007

0.30

November 1, 2007

November 16, 2007

December 17, 2007

0.30

February 7, 2008

February 15, 2008

March 17, 2008

0.30

May 8, 2008

May 16, 2008

June 16, 2008

0.34

August 7, 2008

August 15, 2008

September 19, 2008

0.34

November 6, 2008

November 14, 2008

December 15, 2008

0.34

February 12, 2009

February 23, 2009

March 30, 2009

0.32

*

May 7, 2009

May 15, 2009

June 15, 2009

0.30

August 6, 2009

August 14, 2009

September 14, 2009

0.30

October 15, 2009

October 20, 2009

November 23, 2009

0.30

December 16, 2009

December 24, 2009

December 30, 2009

0.04

February 11, 2010

February 19, 2010

March 19, 2010

0.20

May 3, 2010

May 12, 2010

June 18, 2010

0.20

August 2, 2010

August 12, 2010

September 17,2010

0.20

November 4, 2010

November 10, 2010

December 17, 2010

0.20

March 1, 2011

March 10, 2011

March 24, 2011

0.22

May 5, 2011

May 11, 2011

June 23, 2011

0.22

August 4, 2011

August 15, 2011

September 15, 2011

0.22

November 3, 2011

November 14, 2011

November 29, 2011

0.22

February 27, 2012

March 12, 2012

March 15, 2012

0.23

April 30, 2012

May 18, 2012

May 25, 2012

0.24

July 30, 2012

August 17, 2012

August 24, 2012

0.24

October 26, 2012

November 14, 2012

November 21, 2012

0.24

February 26, 2013

March 11, 2013

March 19, 2013

0.25

April 29, 2013

May 14, 2013

May 21, 2013

0.27

July 29, 2013

August 13, 2013

August 20, 2013

0.28

November 4, 2013

November 18, 2013

November 25, 2013

0.31

February 24, 2014

March 10, 2014

March 17, 2014

0.31

April 28, 2014

May 12, 2014

May 19, 2014

0.31

July 28, 2014

August 18, 2014

August 25, 2014

0.31

October 29, 2014

November 17, 2014

November 24, 2014

0.31

February 24, 2015

March 12, 2015

March 19, 2015

0.31

May 4, 2015

May 18, 2015

May 25, 2015

0.31

July 29, 2015

August 17, 2015

August 24, 2015

0.31

October 28, 2015

November 16, 2015

November 23, 2015

0.31

February 17, 2016

March 7, 2016

March 14, 2016

0.31

April 27, 2016

May 16, 2016

May 23, 2016

0.31

$

11.85

 

*	Dividend paid in cash and stock.

On April 27, 2016 the Board of Directors declared a cash dividend of $0.31 per share to be paid on May 23, 2016 to shareholders of record as of May 16, 2016. This dividend represents our forty-third consecutive dividend declaration since our initial public offering, bringing the total cumulative dividend declared to date $11.85 per share.

 

56

---

Table of Contents

Index to Financial Statements

Our Board of Directors maintains a variable dividend policy with the objective of distributing four quarterly distributions in an amount that approximates 90—100% of our taxable quarterly income or potential annual income for a particular year. In addition, at the end of the year, our Board of Directors may choose to pay an additional special dividend or fifth dividend, so that we may distribute approximately all of our annual taxable income in the year it was earned, or may elect to maintain the option to spill over our excess taxable income into the coming year for future dividend payments.

Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of the stockholder’s tax basis, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and distributions paid for the full taxable year. 100% of the distributions declared and paid during the fiscal years ended December 31, 2015, 2014, and 2013 were derived from our current and accumulated earnings and profits. There can be no certainty to stockholders that this determination is representative of the tax attributes of our 2016 distributions to stockholders.

We maintain an “opt out” dividend reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board of Directors authorizes, and we declare a cash dividend, then our stockholders who have not “opted out” of our dividend reinvestment plan will have their cash dividend automatically reinvested in additional shares of our common stock, rather than receiving the cash dividends. During 2015, 2014, and 2013, the Company issued approximately 199,894, 96,976 and 159,000 shares, respectively, of common stock to shareholders in connection with the dividend reinvestment plan.

Each year, we or the applicable withholding agent will mail to our U.S. stockholders a statement on Form 1099 identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution). To the extent our taxable earnings fall below the total amount of our distributions for that fiscal year, a portion of those distributions may be deemed a tax return of capital to our stockholders.

We operate to qualify to be taxed as a RIC under the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders from its income to determine “taxable income” for U.S. federal income tax purposes. Taxable income includes our taxable interest, dividend and fee income, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized. In addition, gains realized for financial reporting purposes may differ from gains included in taxable income as a result of our election to recognize gains using installment sale treatment, which generally results in the deferment of gains for tax purposes until notes or other amounts, including amounts held in escrow, received as consideration from the sale of investments are collected in cash. Taxable income includes non-cash income, such as changes in accrued and reinvested interest and dividends, which includes contractual PIK interest, and the amortization of discounts and fees. Cash collections of income resulting from contractual PIK interest or the amortization of discounts and fees generally occur upon the repayment of the loans or debt securities that include such items. Non-cash taxable income is reduced by non-cash expenses, such as realized losses and depreciation and amortization expense.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless we distribute in a timely manner an amount at least equal to the sum of (1) 98% of our ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of our capital gains in excess of our capital losses, or “capital gain net income” (adjusted for certain ordinary losses) for the 1-year period ending October 31 in that calendar year and (3) any ordinary income or capital gain net income realized, but not distributed, in the preceding calendar year (the “Excise Tax Avoidance Requirements”). We will not be

 

57

---

Table of Contents

Index to Financial Statements

subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains). Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and pay a 4% excise tax on such income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of dividends paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next taxable year, dividends declared and paid by us in a taxable year may differ from taxable income for that taxable year as such dividends may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our borrowings. See “Regulation”.

Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.

 

58

---

Table of Contents

Index to Financial Statements

RATIO OF EARNINGS TO FIXED CHARGES

The following contains our ratio of earnings to fixed charges for the periods indicated, computed as set forth below. You should read these ratios of earnings to fixed charges in connection with our consolidated financial statements, including the notes to those statements, included in this prospectus.

 

		For the three months ended March 31, 2016				For the year ended December 31, 2015				For the year ended December 31, 2014				For the year ended December 31, 2013				For the year ended December 31, 2012				For the year ended December 31, 2011
Earnings to Fixed Charges(1)			2.79				2.16				3.10				3.83				2.97				3.95

 

For purposes of computing the ratios of earnings to fixed charges, earnings represent net increase in stockholders’ equity resulting from operations plus fixed charges. Fixed charges include interest and credit facility fees expense and amortization of debt issuance costs.

 

(1)	Earnings include net realized and unrealized gains or losses. Net realized and unrealized gains or losses can vary substantially from period to period.

 

59

---

Table of Contents

Index to Financial Statements

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this prospectus. In addition to historical information, the following discussion and other parts of this prospectus contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under “Risk Factors” and “Forward-Looking Statements” appearing elsewhere herein.

Overview

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, McLean, VA, Santa Monica, CA and Hartford, CT.

Our goal is to be the leading structured debt financing provider for venture capital-backed companies in technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We invest primarily in private companies but also have investments in public companies.

We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our warrant and equity-related investments. Our primary business objectives are to increase our net income, net operating income and NAV by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related industries with attractive current yields and the potential for equity appreciation and realized gains. Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related industries is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.

We also make investments in qualifying small businesses through our two wholly-owned SBICs. Our SBIC subsidiaries, HT II and HT III, hold approximately $111.6 million and $289.1 million in assets, respectively, and accounted for approximately 6.6% and 17.1% of our total assets, respectively, prior to consolidation at March 31, 2016. As of March 31, 2016, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $350.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2016, with our net investment of $118.5 million, HT II and HT III have the capacity to issue a total of $190.2 million of SBA-guaranteed debentures, subject to SBA approval. At March 31, 2016, we have issued $190.2 million in SBA-guaranteed debentures in our SBIC subsidiaries.

We have qualified as and have elected to be treated for tax purposes as a RIC under Subchapter M of the Code. Pursuant to this election, we generally will not have to pay corporate-level taxes on any income and gains

 

60

---

Table of Contents

Index to Financial Statements

that we distribute as dividends to our stockholders. However, our qualification and election to be treated as a RIC requires that we comply with provisions contained in Subchapter M of the Code. For example, as a RIC we must earn 90% or more of our gross income for each taxable year from qualified earnings, typically referred to as “good income,” as well as satisfy certain quarterly asset diversification and annual income distribution requirements.

We are an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a business development company under the 1940 Act. As a business development company, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents and high-quality debt investments that mature in one year or less.

Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology related companies at various stages of their development. Consistent with requirements under the 1940 Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies.

We regularly engage in discussions with third parties with respect to various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We, our subsidiaries or our affiliates may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and required regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

Portfolio and Investment Activity

The total fair value of our investment portfolio was $1.3 billion at March 31, 2016, as compared to $1.2 billion at December 31, 2015. The fair value of our debt investment portfolio at March 31, 2016 was approximately $1.2 billion, compared to a fair value of approximately $1.1 billion at December 31, 2015. The fair value of the equity portfolio at March 31, 2016 was approximately $62.1 million, compared to a fair value of approximately $67.4 million at December 31, 2015. The fair value of the warrant portfolio at March 31, 2016 was approximately $23.5 million, compared to a fair value of approximately $23.0 million at December 31, 2015.

Portfolio Activity

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. From time to time, unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. Not all debt commitments represent future cash requirements. Similarly, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final

 

61

---

Table of Contents

Index to Financial Statements

investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Our portfolio activity for the three months ended March 31, 2016 and the year ended December 31, 2015 was comprised of the following:

 

(in millions)		March 31, 2016				December 31, 2015
Debt Commitments(1)
New portfolio company		$	204.5			$	544.0
Existing portfolio company			15.4				181.7
Total		$	219.9			$	725.7
Funded and Restructured Debt Investments(3)
New portfolio company		$	146.0			$	352.5
Existing portfolio company			23.9				341.6
Total		$	169.9			$	694.1
Funded Equity Investments
New portfolio company		$	—			$	1.0
Existing portfolio company			1.0				17.6
Total		$	1.0			$	18.6
Unfunded Contractual Commitments(2)
Total		$	64.6			$	75.4
Non-Binding Term Sheets
New portfolio company		$	45.5			$	81.0
Existing portfolio company			15.0				5.0
Total		$	60.5			$	86.0

 

(1)	Includes restructured loans and renewals in addition to new commitments.

(2)	Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company and unencumbered by milestones.

(3)	Funded amounts include borrowings on revolving facilities.

We receive payments in our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the three months ended March 31, 2016, we received approximately $76.4 million in aggregate principal repayments. Of the approximately $76.4 million of aggregate principal repayments, approximately $21.4 million were scheduled principal payments and approximately $55.0 million were early principal repayments related to 16 portfolio companies. Of the approximately $55.0 million early principal repayments, none were early repayments due to merger and acquisition transactions or IPOs.

 

62

---

Table of Contents

Index to Financial Statements

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable, escrow receivables and Citigroup warrant participation) as of and for the three months ended March 31, 2016 and the year ended December 31, 2015 was as follows:

 

(in millions)		March 31, 2016				December 31, 2015
Beginning portfolio		$	1,200.6			$	1,020.7
New fundings and restructures			170.9				712.3
Warrants not related to current period fundings			0.1				0.1
Principal payments received on investments			(21.4	)			(115.1	)
Early payoffs			(55.0	)			(388.5	)
Accretion of loan discounts and paid-in-kind principal			10.1				31.7
Net acceleration of loan discounts and loan fees due to early payoff or restructure			(1.1	)			(1.7	)
New loan fees			(2.5	)			(9.5	)
Warrants converted to equity			—				0.4
Sale of investments			(2.4	)			(5.2	)
Loss on investments due to write offs			(6.7	)			(7.5	)
Net change in unrealized depreciation			(1.3	)			(37.1	)
Ending portfolio		$	1,291.3			$	1,200.6

The following table shows the fair value of our portfolio of investments by asset class as of March 31, 2016 and December 31, 2015:

 

		March 31, 2016								December 31, 2015
(in thousands)		Investments at Fair Value				Percentage of Total Portfolio				Investments at Fair Value				Percentage of Total Portfolio
Senior Secured Debt with Warrants		$	1,007,751				78.0	%		$	961,464				80.1	%
Senior Secured Debt			221,418				17.1	%			171,732				14.3	%
Preferred Stock			35,542				2.8	%			35,245				2.9	%
Common Stock			26,599				2.1	%			32,197				2.7	%
Total		$	1,291,310				100.0	%		$	1,200,638				100.0	%

A summary of our investment portfolio as of March 31, 2016 and December 31, 2015 at value by geographic location is as follows:

 

		March 31, 2016								December 31, 2015
(in thousands)		Investments at Fair Value				Percentage of Total Portfolio				Investments at Fair Value				Percentage of Total Portfolio
United States		$	1,243,362				96.3	%		$	1,167,281				97.2	%
Netherlands			20,158				1.6	%			20,112				1.7	%
England			18,553				1.4	%			8,884				0.8	%
Canada			5,507				0.4	%			595				0.0	%
Israel			3,730				0.3	%			3,764				0.3	%
India			—				0.0	%			2				0.0	%
Total		$	1,291,310				100.0	%		$	1,200,638				100.0	%

As of March 31, 2016, we held warrants or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings. All four companies filed confidentially under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.

 

63

---

Table of Contents

Index to Financial Statements

Changes in Portfolio

We generate revenue in the form of interest income, primarily from our investments in debt securities, and commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity-related securities that we acquire from our portfolio companies. Our investments generally range from $12.0 million to $25.0 million, although we may make investments in amounts above or below that range. As of March 31, 2016, our debt investments have a term of between two and seven years and typically bear interest at a rate ranging from approximately 4.0% to approximately 15.0%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: end-of-term payments, exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, certain of our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. We had approximately $26.8 million of unamortized fees at March 31, 2016, of which approximately $24.3 million was included as an offset to the cost basis of our current debt investments and approximately $2.5 million was deferred contingent upon the occurrence of a funding or milestone. At December 31, 2015 we had approximately $26.1 million of unamortized fees, of which approximately $23.6 million was included as an offset to the cost basis of our current debt investments and approximately $2.5 million was deferred contingent upon the occurrence of a funding or milestone.

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At March 31, 2016 we had approximately $26.0 million in exit fees receivable, of which approximately $20.8 million was included as a component of the cost basis of our current debt investments and approximately $5.2 million was a deferred receivable related to expired commitments. At December 31, 2015 we had approximately $22.7 million in exit fees receivable, of which approximately $17.4 million was included as a component of the cost basis of our current debt investments and approximately $5.3 million was a deferred receivable related to expired commitments.

We have debt investments in our portfolio that contain a PIK provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our ability to be subject to tax as a RIC, this non-cash source of income must be paid out to stockholders with other sources of income in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $1.7 million and $907,000 in PIK income in the three months ended March 31, 2016 and 2015, respectively.

The core yield on our debt investments, which excludes any benefits from the fees and income related to early loan repayment acceleration of unamortized fees and income as well as prepayment of fees and includes income from expired commitments, was 12.9% and 12.8% during the three months ended March 31, 2016 and 2015, respectively. The effective yield on our debt investments, which includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications and other one-time event fees, was 13.2% and 12.9% for the three months ended March 31, 2016 and 2015, respectively. The effective yield is

 

64

---

Table of Contents

Index to Financial Statements

derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter, excluding non-interest earning assets such as warrants and equity investments. Both the core yield and effective yield may be higher than what our common stockholders may realize as the core yield and effective yield do not reflect our expenses and any sales load paid by our common stockholders.

The total return for our investors was approximately 1.2% and -7.4% during the three months ended March 31, 2016 and 2015, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus dividends paid per share during the period, divided by the beginning price assuming the dividend is reinvested on the date of the distribution. The total return does not reflect any sales load that must be paid by investors. See “Note 9—Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this prospectus.

Portfolio Composition

Our portfolio companies are primarily privately held companies and public companies which are active in the drug discovery and development, sustainable and renewable technology, software, drug delivery, medical devices and equipment, media/content/info, internet consumer and business services, specialty pharmaceuticals, communications and networking, consumer and business products, semiconductors, healthcare services, surgical devices, electronics and computer hardware, biotechnology tools, information services, and diagnostic industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.

As of March 31, 2016, approximately 63.1% of the fair value of our portfolio was composed of investments in four industries: 24.9% was composed of investments in the drug discovery and development industry, 13.8% was comprised of investments in the sustainable and renewable technology industry, 12.2% was composed of investments in the software industry, and 12.2% was composed of investments in the drug delivery industry.

The following table shows the fair value of our portfolio by industry sector at March 31, 2016 and December 31, 2015:

 

		March 31, 2016								December 31, 2015
(in thousands)		Investments at Fair Value				Percentage of Total  Portfolio				Investments at Fair Value				Percentage of Total  Portfolio
Drug Discovery & Development		$	321,359				24.9	%		$	284,266				23.7	%
Sustainable and Renewable Technology			178,532				13.8	%			159,487				13.3	%
Software			157,769				12.2	%			147,237				12.3	%
Drug Delivery			157,756				12.2	%			164,665				13.7	%
Medical Devices & Equipment			110,312				8.6	%			90,560				7.5	%
Media/Content/Info			106,652				8.3	%			95,488				7.9	%
Internet Consumer & Business Services			102,571				8.0	%			88,377				7.4	%
Specialty Pharmaceuticals			50,416				3.9	%			52,088				4.3	%
Communications & Networking			25,055				1.9	%			33,213				2.8	%
Consumer & Business Products			23,016				1.8	%			26,611				2.2	%
Semiconductors			16,711				1.3	%			22,705				1.9	%
Healthcare Services, Other			15,289				1.2	%			15,131				1.3	%
Surgical Devices			10,874				0.8	%			11,185				0.9	%
Electronics & Computer Hardware			6,936				0.5	%			6,928				0.6	%
Biotechnology Tools			6,690				0.5	%			719				0.1	%
Information Services			1,308				0.1	%			1,657				0.1	%
Diagnostic			64				0.0	%			321				0.0	%
Total		$	1,291,310				100.0	%		$	1,200,638				100.0	%

 

65

---

Table of Contents

Index to Financial Statements

Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrants or other equity-related interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies.

For the three months ended March 31, 2016 and the year ended December 31, 2015, our ten largest portfolio companies represented approximately 31.6% and 32.1% of the total fair value of our investments in portfolio companies, respectively. At March 31, 2016 and December 31, 2015, we had three and two investments, respectively, that represented 5% or more of our net assets. At March 31, 2016, we had four equity investments representing approximately 53.6% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. At December 31, 2015, we had four equity investments which represented approximately 53.2% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments.

As of March 31, 2016 approximately 93.1% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime or LIBOR-based interest rate floor. As a result, we believe we are well positioned to benefit should market interest rates rise in the near future.

As of March 31, 2016, 91.8% of our debt investments were in a senior secured first lien position with the remaining 8.2% secured by a senior second priority security interest in all of the portfolio company’s assets, other than intellectual property. In the majority of cases, we collateralize our investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, we may obtain a negative pledge covering a company’s intellectual property. At March 31, 2016, of the approximately 91.8% of our debt investments in a senior secured first lien position, 40.4% were secured by a first priority security in all of the assets of the portfolio company, including its intellectual property; 48.1% were secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property, or subject to a negative pledge; and 3.3% were secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, with a second lien on the portfolio company’s cash and accounts receivable. At March 31, 2016 we had no equipment only liens on material investments in our portfolio companies.

Our investments in senior secured debt with warrants have detachable equity enhancement features, typically in the form of warrants or other equity-related securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of March 31, 2016, we held warrants in 135 portfolio companies, with a fair value of approximately $23.5 million. The fair value of our warrant portfolio increased by approximately $509,000, as compared to a fair value of $23.0 million at December 31, 2015 primarily related to the addition of warrants in 10 new and 4 existing portfolio companies during the period.

Our existing warrant holdings would require us to invest approximately $91.8 million to exercise such warrants as of March 31, 2016. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. Of the warrants that we have monetized since inception, we have realized multiples in the range of approximately 1.02x to 14.93x based on the historical rate of return on our investments. However, our warrants may not appreciate in value and, in fact, may decline in value. Accordingly, we may experience losses from our warrant portfolio.

As required by the 1940 Act, we classify our investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that we are deemed to “control”, which, in general, includes a company in which we own 25% or more of the voting securities of such company or have greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated

 

66

---

Table of Contents

Index to Financial Statements

companies” of ours, as defined in the 1940 Act, which are not control investments. We are deemed to be an “affiliate” of a company in which we have invested if we own 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes our realized and unrealized gain and loss and changes in our unrealized appreciation and depreciation on affiliate investments for the three months ended March 31, 2016 and 2015. We did not hold any Control investments at either March 31, 2016 or March 31, 2015.

 

(in thousands)										For the Three Months Ended March 31, 2016
Portfolio Company		Type				Fair Value at March  31, 2016				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation / (Depreciation)				Realized Gain/ (Loss)
Optiscan BioMedical, Corp.			Affiliate			$	6,991			$	7			$	(413	)		$	—			$	—
Stion Corporation			Affiliate				1,106				58				539				—				—
Total						$	8,097			$	65			$	126			$	—			$	—
(in thousands)										For the Three Months Ended March 31, 2015
Portfolio Company		Type				Fair Value at March 31, 2015				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation / (Depreciation)				Realized Gain/ (Loss)
Gelesis, Inc.			Affiliate			$	2,414			$	—			$	2,087			$	—			$	—
Optiscan BioMedical, Corp.			Affiliate				6,768				—				695				—				—
Stion Corporation			Affiliate				1,600				101				(469	)			—				—
Total						$	10,782			$	101			$	2,313			$	—			$	—

As of December 31, 2015, changes to the capitalization structure of the portfolio company Gelesis, Inc. reduced the Company’s investment below the threshold for classification as an affiliate investment.

Portfolio Grading

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of March 31, 2016 and December 31, 2015, respectively:

 

(in thousands)		March 31, 2016												December 31, 2015
Investment Grading		Number of Companies				Debt Investments at Fair Value				Percentage of Total Portfolio				Number of Companies				Debt Investments at Fair Value				Percentage of Total Portfolio
1			16			$	287,343				23.8	%			18			$	215,202				19.4	%
2			47				636,013				52.7	%			47				759,274				68.4	%
3			16				202,243				16.8	%			6				44,837				4.0	%
4			5				40,391				3.4	%			4				34,153				3.1	%
5			8				39,683				3.3	%			10				56,743				5.1	%
			92			$	1,205,673				100.0	%			85			$	1,110,209				100.0	%

As of March 31, 2016, our debt investments had a weighted average investment grading of 2.17, as compared to 2.16 at December 31, 2015. Our policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade our portfolio companies if they are not meeting our financing criteria or are underperforming relative to their respective business plans. Various companies in our portfolio will require additional funding in the near term or have not met their business plans and therefore have been downgraded until their funding is complete or their operations improve.

 

67

---

Table of Contents

Index to Financial Statements

The change in weighted average investment grading at March 31, 2016 from December 31, 2015 is due to the addition of fourteen new portfolio investments at a 2 rating per our policy, offset by the downgrade of twelve existing portfolio companies to a 3 rating primarily due to impending capital needs.

At March 31, 2016, we had four debt investments on non-accrual with a cumulative investment cost and fair value of approximately $49.8 million and $27.2 million, respectively. At December 31, 2015, we had five debt investments on non-accrual with cumulative investment cost and fair value of approximately $47.4 million and $23.2 million, respectively. In addition, at December 31, 2015, we had one debt investment with an investment cost and fair value of approximately $20.1 million and $14.9 million, respectively, for which only the PIK interest was on non-accrual. During the three months ended March 31, 2016, we recognized a realized loss of approximately $6.2 million on the settlement of one debt investment that was on non-accrual at December 31, 2015. In addition, we recognized a realized loss of $430,000 on the partial write off of one debt investment that was on non-accrual as of December 31, 2015.

Results of Operations

Comparison of the three months ended March 31, 2016 and 2015

Investment Income

Total investment income for the three months ended March 31, 2016 was approximately $38.9 million as compared to approximately $32.5 million for the three months ended March 31, 2015.

Interest income for the three months ended March 31, 2016 totaled approximately $36.5 million as compared to approximately $30.6 million for the three months ended March 31, 2015. The increase in interest income for the three months ended March 31, 2016 as compared to the same period ended March 31, 2015 is primarily attributable to debt investment portfolio growth, specifically an increase in the weighted average principal outstanding between the periods.

Of the $36.5 million in interest income for the three months ended March 31, 2016, approximately $35.8 million represents recurring income from the contractual servicing of our loan portfolio and approximately $728,000 represents income related to the acceleration of income due to early loan repayments and other one-time events during the period. Income from recurring interest and the acceleration of interest income due to early loan repayments represented $30.3 million and $294,000, respectively, of the $30.6 million interest income for the three months ended March 31, 2015.

Income from commitment, facility and loan related fees for the three months ended March 31, 2016 totaled approximately $2.5 million as compared to approximately $1.9 million for the three months ended March 31, 2015. The increase in fee income for the three months ended March 31, 2016 is primarily attributable to an increase in normal fee amortization due to a higher debt investment portfolio between the periods.

Of the $2.5 million in income from commitment, facility and loan related fees for the three months ended March 31, 2016, approximately $2.2 million represents income from recurring fee amortization and approximately $275,000 represents income related to the acceleration of unamortized fees due to early repayments and one-time fees for the period. Income from recurring fee amortization and the acceleration of unamortized fees due to early loan repayments represented $1.4 million and $525,000, respectively, of the $1.9 million income for the three months ended March 31, 2015.

 

68

---

Table of Contents

Index to Financial Statements

The following table shows the PIK-related activity for the three months ended March 31, 2016 and 2015, at cost:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Beginning PIK loan balance		$	5,149			$	6,250
PIK interest income during the period			1,709				907
PIK capitalized to principal but not recorded as income			550				—
Payments received from PIK loans			(20	)			(1,356	)
Realized loss			(266	)			—
Ending PIK loan balance		$	7,122			$	5,801

The decrease in payments received from PIK loans and increase in PIK interest income during the three months ended March 31, 2016 as compared to the three months ended March 31, 2015 is due to an increase in the weighted average principal outstanding for loans which bear PIK interest and a reduction in the number of PIK loans which paid off during the period.

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the three months ended March 31, 2016 or 2015.

Operating Expenses

Our operating expenses are comprised of interest and fees on our borrowings, general and administrative expenses and employee compensation and benefits. Our operating expenses totaled approximately $18.8 million and $19.5 million during the three months ended March 31, 2016 and 2015, receptively.

Interest and Fees on our Borrowings

Interest and fees on our borrowings totaled approximately $8.0 million and $9.4 million for the three months ended March 31, 2016 and 2015, respectively. Interest and fee expense for the three months ended March 31, 2016 as compared to March 31, 2015 decreased due to lower weighted average principal balances outstanding on our Asset Backed Notes, 2019 Notes and 2024 Notes (together with the 2019 Notes, the “Baby Bonds”) along with lower debt issuance costs amortization on our Asset Backed Notes, slightly offset by an increase in the weighted average principal balance outstanding on the Wells Facility.

We had a weighted average cost of debt, comprised of interest and fees and loss on debt extinguishment (long-term liabilities—convertible senior notes), of approximately 5.5% and 6.1% for the three months ended March 31, 2016 and 2015, respectively. The decrease between comparative periods was primarily driven by a reduction in the weighted average principal outstanding on our higher yielding debt instruments compared to the prior period, specifically due to redemptions of our 2019 Notes which occurred in 2015.

General and Administrative Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments and various other expenses. Our general and administrative expenses remained constant at $3.6 million for both the three months ended March 31, 2016 and 2015.

Employee Compensation

Employee compensation and benefits totaled approximately $4.7 million for the three months ended March 31, 2016 as compared to approximately $3.8 million for the three months ended March 31, 2015. The increase between comparative periods was primarily due to changes in variable compensation expense.

 

69

---

Table of Contents

Index to Financial Statements

Employee stock-based compensation totaled approximately $2.6 million for the three months ended March 31, 2016 as compared to approximately $2.7 million for the three months ended March 31, 2015. The decrease between comparative periods was primarily due to restricted stock award vesting and forfeitures, slightly offset by new grants issued related to incentive compensation and strategic hiring objectives.

Loss on Extinguishment of Convertible Senior Notes

Upon meeting the stock trading price conversion requirement during the three months ended June 30, 2014, September 30, 2014 and December 31, 2014, the Convertible Senior Notes became convertible on July 1, 2014 and continued to be convertible during each of the three months ended September 30, 2014, December 31, 2014 and March 31, 2015, respectively. During this period and as of March 31, 2016, holders of approximately $57.4 million of our Convertible Senior Notes have exercised their conversion rights and these Convertible Senior Notes were settled with a combination of cash equal to the outstanding principal amount of the Convertible Senior Notes and approximately 1.5 million shares of the Company’s common stock, or $24.3 million.

We recorded a loss on extinguishment of debt for the proportionate amount of unamortized debt issuance costs and original issue discount. The loss was partially offset by a gain in the amount of the difference between the outstanding principal balance of the converted notes and the fair value of the debt instrument. The net loss on extinguishment of debt we recorded for the year ended December 31, 2015 was $1,000. We did not record a loss on extinguishment of debt in the three months ended March 31, 2016. The loss on extinguishment of debt was classified as a component of net investment income in our Consolidated Statement of Operations.

Net Investment Realized Gains and Losses and Net Unrealized Appreciation and Depreciation

Realized gains or losses are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Net change in unrealized appreciation or depreciation primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of realized gains and losses for the three months ended March 31, 2016 and 2015 is as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Realized gains		$	2,789			$	4,330
Realized losses			(7,257	)			(1,018	)
Net realized gains		$	(4,468	)		$	3,312

During the three months ended March 31, 2016 and 2015, we recognized net realized losses of approximately $4.5 million and net realized gains of $3.3 million, respectively. During the three months ended March 31, 2016, we recorded gross realized gains of approximately $2.8 primarily from the sale of investments in two portfolio companies, including Celator Pharmaceuticals, Inc. ($1.5 million) and the sale of options on Box, Inc. ($1.1 million). These gains were offset by gross realized losses of approximately $7.3 primarily from the liquidation or write off of our investments in six portfolio companies, including the settlement of our outstanding debt investment in The Neat Company ($6.2 million).

During the three months ended March 31, 2015, we recorded gross realized gains of approximately $4.3 million primarily from the sale of investments in four portfolio companies, including Cempra, Inc. ($2.0 million),

 

70

---

Table of Contents

Index to Financial Statements

Celladon Corporation ($1.4 million), Everyday Health, Inc. ($387,000) and Identiv, Inc. ($304,000).These gains were partially offset by gross realized losses of approximately $1.0 million from the liquidation of our investments in three portfolio companies.

The net unrealized appreciation and depreciation of our investments is based on the fair value of each investment determined in good faith by our Board of Directors. The following table summarizes the change in net unrealized appreciation (depreciation) of investments for the three months ended March 31, 2016 and 2015:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Gross unrealized appreciation on portfolio investments		$	13,317			$	21,155
Gross unrealized depreciation on portfolio investments			(24,885	)			(13,239	)
Reversal of prior period net unrealized appreciation upon a realization event			—				(3,708	)
Reversal of prior period net unrealized depreciation upon a realization event			10,197				1,005
Net unrealized appreciation (depreciation) attributable to taxes payable			36				442
Citigroup warrant participation			1				(41	)
Net unrealized appreciation (depreciation) on portfolio investments		$	(1,334	)		$	5,614

During the three months ended March 31, 2016, we recorded approximately $1.3 million of net unrealized depreciation, of which $1.3 million is net unrealized depreciation from our debt, equity and warrant investments. Approximately $6.2 million is attributed to net unrealized depreciation on our equity investments which primarily relates to approximately $5.2 million unrealized depreciation on our public equity portfolio with the largest concentration in our investment in Box, Inc. and $1.1 million of unrealized depreciation on our private portfolio companies related to declining industry performance. Approximately $1.1 million is attributed to net unrealized depreciation on our public warrant portfolio. This unrealized depreciation is partially offset by approximately $6.0 million of net unrealized appreciation on our debt investments which primarily relates to the reversal of $12.2 million unrealized depreciation upon payoff or settling of our debt investments offset by $6.6 million unrealized depreciation for collateral based impairments on eleven portfolio companies.

Net unrealized depreciation was offset by approximately $36,000 as a result of decreased estimated taxes payable for the three months ended March 31, 2016.

Net unrealized depreciation was further offset by approximately $1,000 as a result of net depreciation of fair value on the pool of warrants collateralized under the warrant participation during the three months ended March 31, 2016.

During the three months ended March 31, 2015, we recorded approximately $5.6 million of net unrealized appreciation, of which $5.2 million is net unrealized appreciation from our debt, equity and warrant investments. Approximately $704,000 is attributed to net unrealized appreciation on our debt investments which primarily related to the reversal of $2.4 million unrealized depreciation for prior period collateral based impairments on two portfolio companies offset by $1.8 million unrealized depreciation for collateral based impairments on six portfolio companies. In addition, approximately $419,000 is attributed to the reversal of approximately $419,000 of unrealized depreciation upon payoff of our debt investments. Approximately $1.0 million is attributed to net unrealized appreciation on our equity investments which primarily related to approximately $3.0 million unrealized appreciation on three private portfolio companies and $1.5 million unrealized appreciation on our public equity portfolio related to portfolio company performance offset by the reversal of $3.7 million of prior period net unrealized appreciation upon being realized as a gain for our sale of shares of Cempra, Inc. Celladon Corporation, Everyday Health, and Identiv, Inc. as discussed above. Finally, approximately $3.1 million is attributed to net unrealized appreciation on our warrant investments which primarily related to $1.2 million of unrealized appreciation on our public portfolio company investments and the reversal of $1.0 million of unrealized depreciation upon being realized as a loss due to the liquidation of our warrant investments in three portfolio companies.

 

71

---

Table of Contents

Index to Financial Statements

Net unrealized appreciation increased by approximately $442,000 as a result of decreased estimated taxes payable for the three months ended March 31, 2015.

During three months ended March 31, 2015, net unrealized appreciation was offset by approximately $41,000 of net appreciation of fair value on the pool of warrants collateralized under the warrant participation.

The following table summarizes the change in net unrealized appreciation (depreciation) in the investment portfolio by category, excluding net unrealized appreciation (depreciation) on taxes payable, escrow receivables and Citigroup warrant participation, for the three months ended March 31, 2016 and 2015:

 

		Three Months Ended March 31, 2016
(in millions)		Debt				Equity				Warrants				Total
Collateral Based Impairments		$	(6.6	)		$	—			$	(0.1	)		$	(6.7	)
Reversals of Prior Period Collateral Based Impairments			—				—				—				—
Reversals due to Debt Payoffs & Warrant/Equity Sales			12.2				0.1				—				12.3
Fair Value Market/Yield Adjustments*
Level 1 & 2 Assets			(0.1	)			(5.2	)			(1.1	)			(6.4	)
Level 3 Assets			0.5				(1.1	)			0.1				(0.5	)
Total Fair Value Market/Yield Adjustments			0.4				(6.3	)			(1.0	)			(6.9	)
Total Unrealized Appreciation/(Depreciation)		$	6.0			$	(6.2	)		$	(1.1	)		$	(1.3	)
		Three Months Ended March 31, 2015
(in millions)		Debt				Equity				Warrants				Total
Collateral Based Impairments		$	(1.8	)		$	—			$	—			$	(1.8	)
Reversals of Prior Period Collateral Based Impairments			2.4				—				0.2				2.6
Reversals due to Debt Payoffs & Warrant/Equity Sales			0.4				(3.7	)			1.0				(2.3	)
Fair Value Market/Yield Adjustments*
Level 1 & 2 Assets			—				1.5				1.2				2.7
Level 3 Assets			0.1				3.2				0.7				4.0
Total Fair Value Market/Yield Adjustments			0.1				4.7				1.9				6.7
Total Unrealized Appreciation/(Depreciation)		$	1.1			$	1.0			$	3.1			$	5.2

 

*

Level 1 assets are generally equities listed in active markets and level 2 assets are generally warrants held in a public company. Observable market prices are typically the primary input in valuing level 1 and 2 assets. Level 3 asset valuations require inputs that are both significant and unobservable. Generally, level 3 assets are debt investments and warrants and equities held in a private company. See Note 2 to the financial statements discussing ASC 820 (“Fair Value Measurements”).

Income and Excise Taxes

We account for income taxes in accordance with the provisions of Topic 740 of the Financial Accounting Standards Board’s (“FASB’s”) Accounting Standards Codification, as amended (“ASC”) Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. Based upon our previous election and anticipated continued qualification to be subject to taxation as a RIC, we are typically not subject to a material level of federal income taxes. We intend to distribute approximately $8.2 million of spillover earnings from ordinary income from the year ended December 31, 2015 to our shareholders in 2016.

 

72

---

Table of Contents

Index to Financial Statements

Net Increase in Net Assets Resulting from Operations and Earnings Per Share

For the three months ended March 31, 2016 and 2015, the net increase in net assets resulting from operations totaled approximately $14.3 million and approximately $21.9 million, respectively. These changes are made up of the items previously described.

Both the basic and fully diluted net change in net assets per common share were $0.20 per share for the three months ended March 31, 2016 and both the basic and fully diluted net change in net assets per common share for the three months ended March 31, 2015 were $0.33 per share.

For the purpose of calculating diluted earnings per share for three months ended March 31, 2016 and 2015, the dilutive effect of the Convertible Senior Notes under the treasury stock method is included in this calculation as our share price was greater than the conversion price in effect ($10.94 as of March 31, 2016 and $11.28 as of March 31, 2015) for the Convertible Senior Notes for such periods.

Comparison of periods ended December 31, 2015 and 2014

Investment Income

Interest Income

Total investment income for the year ended December 31, 2015 was approximately $157.1 million as compared to approximately $143.7 million for the year ended December 31, 2014.

Interest income for the year ended December 31, 2015 totaled approximately $140.3 million as compared to approximately $126.6 million for the year ended December 31, 2014. The increase in interest income for the year ended December 31, 2015 as compared to the year ended December 31, 2014 is primarily attributable to debt investment portfolio growth, specifically an increase in the weighted average principal outstanding between the periods.

Of the $140.3 million in interest income for the year ended December 31, 2015, approximately $130.4 million represents recurring income from the contractual servicing of our loan portfolio and approximately $9.9 million represents income related to the acceleration of income due to early loan repayments and other one-time events during the period. Income from recurring interest and the acceleration of interest income due to early loan repayments represented $106.8 million and $19.8 million, respectively, of the $126.6 million interest income for the year ended December 31, 2014.

The following table shows the PIK-related activity, for the years ended December 31, 2015 and 2014, at cost:

 

		Year Ended December 31,
(in thousands)		2015				2014
Beginning PIK loan balance		$	6,250			$	5,603
PIK interest income during the period			4,658				3,346
Payments received from PIK loans			(5,483	)			(2,699	)
Realized loss			(276	)			—
Ending PIK loan balance		$	5,149			$	6,250

The increase in payments received from PIK loans and the increase in PIK interest capitalized during the year ended December 31, 2015 as compared to the year ended December 31, 2014 is due to an increase in the weighted average principal outstanding for loans which bear PIK interest and the number of PIK loans which paid-off during the period.

 

73

---

Table of Contents

Index to Financial Statements

Fee Income

Income from commitment, facility and loan related fees for the year ended December 31, 2015 totaled approximately $16.9 million as compared to approximately $17.0 million for the year ended December 31, 2014. The decrease in fee income is primarily attributable to the acceleration of early loan repayments and restructures, slightly offset by an increase in normal fee amortization due to a higher weighted average debt investment portfolio outstanding during the period.

Of the $16.9 million in income from commitment, facility and loan related fees for the year ended December 31, 2015, approximately $5.8 million represents income from recurring fee amortization and approximately $11.1 million represents income related to the acceleration of unamortized fees for the period. Income from recurring fee amortization and the acceleration of unamortized fees due to early loan repayments represented $5.2 million and $11.8 million, respectively, of the $17.0 million income for the year ended December 31, 2014.

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the years ended December 31, 2015 and 2014, respectively.

Operating Expenses

Our operating expenses are comprised of interest and fees on our borrowings, general and administrative expenses and employee compensation and benefits. Operating expenses totaled approximately $83.6 million and $70.3 million during the years ended December 31, 2015 and 2014, respectively.

Interest and Fees on our Borrowings

Interest and fees on our borrowings totaled approximately $36.9 million and $34.0 million for the years ended December 31, 2015 and 2014, respectively. Interest and fee expense for the year ended December 31, 2015 as compared to December 31, 2014 increased primarily due to higher weighted average principal balances outstanding on our Asset Backed Notes, Credit Facilities, 2019 Notes and 2024 Notes (together with the 2019 Notes, the “Baby Bonds”), slightly offset by a reduction in weighted average principal balances outstanding on our SBA debentures, Convertible Senior Notes and lower debt issuance cost amortization related to our Convertible Senior Notes and Asset Backed Notes.

We had a weighted average cost of debt, comprised of interest and fees and loss on debt extinguishment (long-term liabilities – convertible senior notes), of approximately 6.0% and 6.6% for the years ended December 31, 2015 and 2014, respectively. The decrease between comparative periods was primarily driven by a reduction in the weighted average principal outstanding on our higher yielding debt instruments and a reduction in non-cash acceleration of debt issuance costs related to our SBA Debentures, Convertible Senior Notes and Asset Backed Notes as compared to the prior period, slightly offset by non-cash accelerations of debt issuance costs due to early pay downs on our Baby Bonds.

General and Administrative Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments and various other expenses. Our general and administrative expenses increased to $16.7 million from $10.2 million for the years ended December 31, 2015 and 2014, respectively. This increase was primarily due to increased recruiting costs related to strategic hiring objectives, corporate legal expenses and outside consulting services.

Employee Compensation

Employee compensation and benefits totaled approximately $20.7 million for the year ended December 31, 2015 as compared to approximately $16.6 million for the year ended December 31, 2014. The increase between comparative periods was primarily due to changes in variable incentive compensation.

 

74

---

Table of Contents

Index to Financial Statements

Employee stock-based compensation totaled approximately $9.4 million for the year ended December 31, 2015 as compared to approximately $9.6 million for the year ended December 31, 2014. The decrease between comparative periods was primarily due to new grants issued related to incentive compensation and strategic hiring objectives, slightly offset by vesting and forfeitures.

Loss on Extinguishment of Convertible Senior Notes

Upon meeting the stock trading price conversion requirement during the three months ended June 30, 2014, September 30, 2014 and December 31, 2014, the Convertible Senior Notes became convertible on July 1, 2014 and continued to be convertible during each of the three months ended September 30, 2014, December 31, 2014 and March 31, 2015, respectively. During this period and as of December 31, 2015, holders of approximately $57.4 million of our Convertible Senior Notes have exercised their conversion rights and these Convertible Senior Notes were settled with a combination of cash equal to the outstanding principal amount of the Convertible Senior Notes and approximately 1.5 million shares of the Company’s common stock, or $24.3 million.

We recorded a loss on extinguishment of debt for the proportionate amount of unamortized debt issuance costs and OID. The loss was partially offset by a gain in the amount of the difference between the outstanding principal balance of the converted notes and the fair value of the debt instrument. The net loss on extinguishment of debt we recorded for the years ended December 31, 2015 and 2014 was approximately $1,000 and $1.6 million, respectively. The loss on extinguishment of debt was classified as a component of net investment income in our Consolidated Statements of Operations.

Net Investment Realized Gains and Losses and Net Unrealized Appreciation and Depreciation

Realized gains or losses are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Net change in unrealized appreciation or depreciation primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of realized gains and losses for the years ended December 31, 2015 and 2014 is as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Realized gains		$	12,677			$	24,027
Realized losses			(7,530	)			(3,915	)
Net realized gains		$	5,147			$	20,112

During the year ended December 31, 2015, we recognized net realized gains of approximately $5.1 million on the portfolio. These net realized gains included gross realized gains of approximately $12.6 million from the sale of investments in seven portfolio companies, including Box, Inc. ($3.2 million), Atrenta, Inc. ($2.6 million), Cempra, Inc. ($2.0 million), Celladon Corporation ($1.4 million), Egalet Corporation ($652,000), Everyday Health, Inc. ($387,000) and Identiv, Inc. ($304,000), and $1.5 million from subsequent recoveries received on two previously written-off debt investments. These gains were partially offset by gross realized losses of approximately $7.5 million primarily from the liquidation or write off of our investments in sixteen portfolio companies.

During the year ended December 31, 2014, we recognized net realized gains of approximately $20.1 million on the portfolio. These net realized gains included gross realized gains of approximately $24.0 million primarily from the sale of investments in seven portfolio companies including Acceleron Pharma, Inc., ($7.9 million),

 

75

---

Table of Contents

Index to Financial Statements

Merrimack Pharmaceuticals, Inc., ($4.3 million), Neuralstem, Inc., ($2.7 million), IPA Holdings, LLC., ($1.5 million), Cell Therapeutics, Inc., ($1.3 million), Trulia, Inc. ($1.0 million), and Portola Pharmaceuticals, Inc. ($700,000). These gains were partially offset by gross realized losses of approximately $3.9 million primarily from the liquidation of our investments in fifteen portfolio companies.

The net unrealized appreciation and depreciation of our investments is based on the fair value of each investment determined in good faith by our Board of Directors. The following table summarizes the change in net unrealized appreciation/depreciation of investments for the years ended December 31, 2015 and 2014:

 

		Year Ended December 31,
(in thousands)		2015				2014
Gross unrealized appreciation on portfolio investments		$	78,991			$	72,968
Gross unrealized depreciation on portfolio investments			(111,926	)			(79,412	)
Reversal of prior period net unrealized appreciation upon a realization event			(8,707	)			(15,335	)
Reversal of prior period net unrealized depreciation upon a realization event			4,599				3,182
Net unrealized appreciation (depreciation) attributable to taxes payable			1,322				(1,882	)
Net unrealized depreciation on escrow receivables			—				(465	)
Citigroup warrant participation			(11	)			270
Net unrealized appreciation (depreciation) on portfolio investments		$	(35,732	)		$	(20,674	)

During the year ended December 31, 2015, we recorded approximately $35.7 million of net unrealized depreciation, of which $37.1 million is net unrealized depreciation from our debt, equity and warrant investments. Of the $37.1 million, approximately $14.0 million is attributed to net unrealized depreciation on our debt investments which primarily related to $20.4 million unrealized depreciation for collateral based impairments on ten portfolio companies offset by the reversal of collateral based impairments of $5.6 on three portfolio companies. Approximately $19.1 million is attributed to net unrealized depreciation on our equity investments which primarily relates to approximately $11.4 million unrealized depreciation on our public equity portfolio with the largest concentration in our investment in Box, Inc. and the reversal of $7.8 million of prior period net unrealized appreciation upon being realized as a gain for our sale of shares of Box, Inc., Atrenta, Inc., Cempra, Inc. Celladon Corporation, Egalet Corporation, Everyday Health, and Identiv, Inc. as discussed above. Finally, approximately $4.0 million is attributed to net unrealized depreciation on our warrant investments which primarily related to $6.0 million of unrealized depreciation on our private portfolio companies related to declining industry performance offset by the reversal of $3.2 million of prior period net unrealized depreciation upon being realized as a loss on the liquidation of our investments in thirteen portfolio companies.

Net unrealized depreciation was offset by approximately $1.3 million as a result of decreased estimated taxes payable for the year ended December 31, 2015.

Net unrealized depreciation increased by approximately $11,000 due to appreciation of fair value on the pool of warrants collateralized under the warrant participation agreement offset by a decrease in the liability for the acquisition proceeds we received on our Atrenta, Inc. equity investment, which had been exercised from warrants that were included in the collateral pool.

During the year ended December 31, 2014, we recorded approximately $20.7 million of net unrealized depreciation, of which $18.6 million is net unrealized depreciation from our debt, equity and warrant investments. Of the $18.6 million, approximately $14.2 million is attributed to net unrealized depreciation on our debt investments which primarily related to $23.2 million unrealized depreciation for collateral based impairments on 12 portfolio companies offset by the reversal of collateral based impairments of $4.1 on two portfolio companies. Approximately $15.8 million is attributed to net unrealized depreciation on our warrant investments which primarily related to $8.3 million of net unrealized depreciation due to the exercise of our

 

76

---

Table of Contents

Index to Financial Statements

warrants in Box, Inc. to equity and $2.4 million of net unrealized depreciation due to the reversal of prior period net unrealized appreciation upon being realized as a gain. This unrealized depreciation was offset by approximately $11.4 million attributed to net unrealized appreciation on our equity investments, including approximately $13.0 million of net unrealized appreciation on Box, Inc., including the exercise of our remaining warrants in Box, Inc. to equity and approximately $7.7 million of net unrealized appreciation on our public equity portfolio. This was offset by approximately $12.7 million unrealized depreciation due to reversal of prior period net unrealized appreciation upon being realized as a gain.

Net unrealized appreciation decreased by approximately $1.9 million as a result of estimated taxes payable for the year ended December 31, 2014.

Net unrealized appreciation further decreased by approximately $465,000 as a result of reducing escrow receivables for the year ended December 31, 2014 related to merger and acquisition transactions closed on former portfolio companies.

During the year ended December 31, 2014, net unrealized depreciation was offset by approximately $270,000 due to net depreciation of fair value on the pool of warrants collateralized under the Citigroup warrant participation agreement as a result of the sale of shares in Acceleron Pharma, Inc., Merrimack Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc. and Everyday Health, Inc. that were subject to the Citigroup warrant participation agreement.

The following table summarizes the change in net unrealized appreciation/(depreciation) in the investment portfolio by investment type, excluding net unrealized appreciation (depreciation) on taxes payable, escrow receivables and Citigroup warrant participation, for the years ended December 31, 2015 and December 31, 2014.

 

		Year Ended December 31, 2015
(in millions)		Debt				Equity				Warrants				Total
Collateral based impairments		$	(20.4	)		$	(0.2	)		$	(0.4	)		$	(21.0	)
Reversals of Prior Period Collateral based impairments			5.6				—				0.4				6.0
Reversals due to Debt Payoffs & Warrant/Equity sales			6.2				(7.8	)			3.2				1.6
Fair Value Market/Yield Adjustments*
Level 1 & 2 Assets			(1.1	)			(11.4	)			(1.2	)			(13.7	)
Level 3 Assets			(4.3	)			0.3				(6.0	)			(10.0	)
Total Fair Value Market/Yield Adjustments			(5.4	)			(11.1	)			(7.2	)			(23.7	)
Total Unrealized Appreciation/(Depreciation)		$	(14.0	)		$	(19.1	)		$	(4.0	)		$	(37.1	)
		Year Ended December 31, 2014
(in millions)		Debt				Equity				Warrants				Total
Collateral based impairments		$	(23.2	)		$	(1.2	)		$	(3.3	)			(27.7	)
Reversals of Prior Period Collateral based impairments			4.1				0.6				—				4.7
Reversals due to Debt Payoffs & Warrant/Equity sales			—				(11.1	)			(9.7	)			(20.8	)
Fair Value Market/Yield Adjustments*
Level 1 & 2 Assets			—				7.6				(2.9	)			4.7
Level 3 Assets			4.9				15.5				0.1				20.5
Total Fair Value Market/Yield Adjustments			4.9				23.1				(2.8	)			25.2
Total Unrealized Appreciation/(Depreciation)		$	(14.2	)		$	11.4			$	(15.8	)		$	(18.6	)

 

*

Level 1 assets are generally equities listed in active markets and Level 2 assets are generally warrants held in a public company. Observable market prices are typically the primary input in valuing Level 1 and 2 assets. Level 3 asset valuations require inputs that are both significant and unobservable. Generally, level 3 assets are debt investments and warrants and equities held in a private company. See Note 2 to the financial statements discussing FASB ASC Topic 820.

 

77

---

Table of Contents

Index to Financial Statements

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC Topic 740, Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. Based upon our qualification and election to be subject to taxation as a RIC, we are typically not subject to a material level of federal income taxes. We intend to distribute approximately $0.2 million of spillover earnings from ordinary income and approximately $8.0 million from net capital gains from our taxable year ended December 31, 2015 to our shareholders during 2016.

Net Increase in Net Assets Resulting from Operations and Earnings Per Share

For the years ended December 31, 2015 and 2014, the net increase in net assets resulting from operations totaled approximately $42.9 million and approximately $71.2 million, respectively. These changes are made up of the items previously described.

The basic and fully diluted net change in net assets per common share for the year ended December 31, 2015 were $0.60 and $0.59, respectively, whereas the basic and fully diluted net change in net assets per common share for the year ended December 31, 2014 was $1.12 and $1.10, respectively.

For the purpose of calculating diluted earnings per share for years ended December 31, 2015 and 2014, the dilutive effect of the Convertible Senior Notes under the treasury stock method is included in this calculation as our share price was greater than the conversion price of $11.03 in effect as of December 31, 2015 and $11.36 as of December 31, 2014 for the Convertible Senior Notes for such periods.

Financial Condition, Liquidity and Capital Resources

Our liquidity and capital resources are derived from our Credit Facilities, SBA debentures, Convertible Senior Notes, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our borrowings and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may raise additional equity or debt capital through both registered offerings off a shelf registration, “At-The-Market”, or ATM, and private offerings of securities, by securitizing a portion of our investments or borrowing, including from the SBA through our SBIC subsidiaries.

On August 16, 2013, we entered into an ATM equity distribution agreement (the “Equity Distribution Agreement” with JMP Securities LLC (“JMP”) and on March 7, 2016 we renewed the Equity Distribution Agreement. The Equity Distribution Agreement provides that we may offer and sell up to 8.0 million shares of our common stock from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended March 31, 2016 we sold 1.1 million shares of common stock for total accumulated net proceeds of approximately $12.4 million. We did not sell any shares under the program during the year ended December 31, 2015. We generally use the net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2016, approximately 6.2 million shares remained available for issuance and sale under the Equity Distribution Agreement.

 

78

---

Table of Contents

Index to Financial Statements

On February 24, 2015, our Board of Directors authorized a stock repurchase plan permitting us to repurchase up to $50.0 million of our common stock. This plan expired on August 24, 2015. On August 27, 2015, our Board of Directors authorized a replacement stock repurchase plan permitting us to repurchase up to $50.0 million of our common stock and on February 17, 2016, our Board of Directors extended the program until August 23, 2016. We may repurchase shares of our common stock in the open market, including block purchases, at prices that may be above or below the NAV as reported in the most recently published financial statements. We expect that the share repurchase program will be in effect until August 23, 2016, or until the approved dollar amount has been used to repurchase shares. During the three months ended March 31, 2016 we repurchased 449,588 shares of our common stock at an average price per share of $10.64 per share and a total cost of approximately $4.8 million. As of March 31, 2016, approximately $40.6 million of common stock remains eligible for repurchase under the stock repurchase plan.

At the 2015 Annual Meeting of Stockholders on July 7, 2015, our common stockholders approved a proposal to allow us to issue common stock at a discount from our then current NAV per share, which is effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of stockholders. In connection with the receipt of such stockholder approval, we will limit the number of shares that we issue at a price below NAV pursuant to this authorization so that the aggregate dilutive effect on our then outstanding shares will not exceed 20%. Our Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share. During the three months ended March 31, 2016, we have not issued common stock at a discount to NAV. We did not issue common stock at a discount to NAV during the year ended December 31, 2015.

As of March 31, 2016, approximately $57.4 million of our Convertible Senior Notes had been converted and were settled with a combination of cash equal to the outstanding principal amount of the converted notes and approximately 1.5 million shares of our common stock, or $24.3 million. By not meeting the stock trading price conversion requirement during the three months ended March 31, 2015, June 30, 2015, or September 30, 2015 the Convertible Senior Notes were not convertible for the period between April 1, 2015 and October 14, 2015. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time.

At March 31, 2016, we had $17.6 million in principal outstanding of Convertible Senior Note, $110.4 million of 2019 Notes, $103.0 million of 2024 Notes, $129.3 million of 2021 Asset-Backed Notes, $190.2 million of SBA debentures payable, and $61.0 million on the Wells Facility. We had no borrowings outstanding under the Union Bank Facility.

At March 31, 2016, we had $122.5 million in available liquidity, including $13.5 million in cash and cash equivalents. We had available borrowing capacity of approximately $34.0 million under the Wells Facility after the March 2016 expansion of the available facility to $95.0 million and we had available borrowing capacity of $75.0 million under the Union Bank Facility, subject to existing terms and advance rates and regulatory requirements. We primarily invest cash on hand in interest bearing deposit accounts.

At March 31, 2016, we had $118.5 million of cash in restricted accounts related to our SBIC that we may use to fund new investments in the SBIC. With our net investments of $44.0 million and $74.5 million in HT II and HT III, respectively, we have the combined capacity to issue a total of $190.2 million of SBA guaranteed debentures, subject to SBA approval. At March 31, 2016, we have issued $190.2 million in SBA guaranteed debentures in our SBIC subsidiaries.

At March 31, 2016, we had approximately $3.6 million of restricted cash, which consists of collections of interest and principal payments on assets that are securitized. In accordance with the terms of the related securitized 2021 Asset-Backed Notes, based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt and are not distributed to us or available for our general operations. During the three months ended March 31, 2016, we

 

79

---

Table of Contents

Index to Financial Statements

principally funded our operations from (i) cash receipts from interest, dividend and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments.

During the three months ended March 31, 2016, our operating activities used $82.4 million of cash and cash equivalents, compared to $114.1 million used during the three months ended March 31, 2015. This $31.7 million decrease in cash used by operating activities resulted primarily from a decrease in investment purchases of approximately $38.5 million, offset by a decrease in net assets resulting from operations of $7.6 million.

During the three months ended March 31, 2016, our investing activities provided approximately $5.4 million of cash, compared to approximately $9.3 million used during the three months ended March 31, 2015. This $14.7 million increase in cash provided by investing activities was primarily due to a reduction of approximately $14.8 million in cash, classified as restricted cash, on assets that are securitized.

During the three months ended March 31, 2016, our financing activities used $4.8 million of cash, compared to $68.0 million provided during the three months ended March 31, 2015. This $72.8 million decrease in cash provided by financing activities was primarily due to decreases in proceeds from issuance of common stock of $87.7 million as a result of a public offering of 7,590,000 shares on March 27, 2015 as compared to the issuance of 1.1 million shares under the ATM program during the three months ended March 31, 2016. This increase was partially offset by proceeds received from borrowings under the Wells Facility during the three months ended March 31, 2016.

As of March 31, 2016, net assets totaled $718.4 million, with a NAV per share of $9.81. We intend to generate additional cash primarily from cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

As required by the 1940 Act, our asset coverage must be at least 200% after each issuance of senior securities. As of March 31, 2016 our asset coverage ratio under our regulatory requirements as a business development company was 270.5% excluding our SBA debentures as a result of our exemptive order from the SEC that allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 200%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total leverage when including our SBA debentures was 217.5% at March 31, 2016.

 

80

---

Table of Contents

Index to Financial Statements

Outstanding Borrowings

At March 31, 2016 and December 31, 2015, we had the following available borrowings and outstanding amounts:

 

		March 31, 2016												December 31, 2015
(in thousands)		Total Available				Principal				Carrying Value(1)				Total Available				Principal				Carrying Value(1)
SBA Debentures(2)		$	190,200			$	190,200			$	186,997			$	190,200			$	190,200			$	186,829
2019 Notes			110,364				110,364				108,339				110,364				110,364				108,179
2024 Notes			103,000				103,000				100,211				103,000				103,000				100,128
2021 Asset-Backed Notes			129,300				129,300				127,227				129,300				129,300				126,995
Convertible Senior Notes			17,604				17,604				17,572				17,604				17,604				17,478
Wells Facility(3)			95,000				61,003				61,003				75,000				50,000				50,000
Union Bank Facility(3)			75,000				—				—				75,000				—				—
Total		$	720,468			$	611,471			$	601,349			$	700,468			$	600,468			$	589,609

 

(1)

Except for the Wells Facility and Union Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted discount, if any, associated with the loan as of the balance sheet date. See below for the amount of debt issuance cost associated with each borrowing.

(2)	At both March 31, 2016 and December 31, 2015, the total available borrowings under the SBA debentures were $190.2 million, of which $41.2 million was available in HT II and $149.0 million was available in HT III.

(3)	Availability subject to us meeting the borrowing base requirements.

Our NAV may decline as a result of economic conditions in the United States. Our continued compliance with the covenants under our Credit Facilities, Convertible Senior Notes, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes and SBA debentures depend on many factors, some of which are beyond our control. Material net asset devaluation could have a material adverse effect on our operations and could require us to reduce our borrowings in order to comply with certain covenants, including the ratio of total assets to total indebtedness. We believe that our current cash and cash equivalents, cash generated from operations, and funds available from our Credit Facilities will be sufficient to meet our working capital and capital expenditure commitments for at least the next 12 months.

Debt issuance costs are fees and other direct incremental costs we incur in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the straight line method, which closely approximates the effective yield method. In accordance with Accounting Standards Update (“ASU”) 2015-03 debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statement of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements. Debt issuance costs, net of accumulated amortization, as of March 31, 2016 and December 31, 2015 were as follows:

 

(in thousands)		March 31, 2016				December 31, 2015
SBA Debentures		$	3,203			$	3,371
2019 Notes			2,025				2,185
2024 Notes			2,789				2,872
2021 Asset-Backed Notes			2,073				2,305
Convertible Senior Notes			12				44
Wells Facility(1)			737				669
Union Bank Facility(1)			190				229
Total		$	11,029			$	11,675

 

(1)	As the Wells Facility and Union Bank Facility are line-of-credit arrangements, the debt issuance costs associated with these instruments are presented separately as an asset on the Consolidated Statement of Assets and Liabilities in accordance with ASU 2015-15.

 

81

---

Table of Contents

Index to Financial Statements

As of January 1, 2016, we adopted ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs” and ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which require debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability, except for debt issuance costs associated with line-of-credit arrangements. Adoption of these standards results in the reclassification of debt issuance costs from Other Assets and the presentation of our SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes net of the associated debt issuance costs for each instrument in the liabilities section on the Consolidated Statement of Assets and Liabilities. There is no impact to the Consolidated Statement of Operations. In addition, there is no change to the presentation of the Wells Facility as debt issuance costs are presented separately as an asset on the Consolidated Statement of Assets and Liabilities. Refer to “—Critical Accounting Policies”.

Refer to “Note 4—Borrowings” included in the notes to our consolidated financial statements appearing elsewhere in this prospectus for a discussion of the contract terms, interest expense, and fees associated with each outstanding borrowing as of and for the three months ended March 31, 2016.

Commitments

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commits includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At March 31, 2016, we had approximately $64.6 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones. In addition, we had approximately $98.0 million of unavailable commitments to portfolio companies due to milestone and other covenant restrictions. We intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments.

We also had approximately $60.5 million of non-binding term sheets outstanding to three new and existing companies, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of our unfunded commitments are considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to a market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

 

82

---

Table of Contents

Index to Financial Statements

As of March 31, 2016, our unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones are as follows:

 

(in thousands) Portfolio Company
		Total  Unfunded Commitments
Paratek Pharmaceuticals, Inc.		$	20,000
NewVoiceMedia Limited			15,000
Aquantia Corp.			11,500
Bellicum Pharmaceuticals, Inc.			5,000
Genocea Biosciences, Inc.			5,000
Druva, Inc.			3,000
Flowonix Medical			2,000
Quanterix Corporation			2,000
Achronix Semiconductor Corporation			740
Cranford Pharmaceuticals, LLC			400
Total		$	64,640

Contractual Obligations

The following table shows our contractual obligations as of March 31, 2016:

 

		Payments due by period (in thousands)
Contractual Obligations(1)(2)		Total				Less than 1 year				1 - 3 years				3 - 5 years				After 5 years
Borrowings(3)(4)		$	611,471			$	17,604			$	147,700			$	232,917			$	213,250
Operating Lease Obligations(5)			4,427				1,598				2,593				236				—
Total		$	615,898			$	19,202			$	150,293			$	233,153			$	213,250

 

(1)	Excludes commitments to extend credit to our portfolio companies.

(2)	We also have a warrant participation agreement with Citigroup. See Note 4 to our consolidated financial statements.

(3)

Includes $190.2 million in principal outstanding under the SBA debentures, $110.4 million of the 2019 Notes, $103.0 million of the 2024 Notes, $129.3 million of the 2021 Asset-Backed Notes, $17.6 million of the Convertible Senior Notes, and $61.0 million under the Wells Facility as of March 31, 2016.

(4)	Amounts represent future principal repayments and not the carrying value of each liability. See “—Outstanding Borrowings”.

(5)	Long-term facility leases.

Certain premises are leased under agreements which expire at various dates through March 2020. Total rent expense amounted to approximately $436,000 during the three months ended March 31, 2016, respectively. Total rent expense amounted to approximately $408,000 during the same period ended March 31, 2015.

Indemnification Agreements

We have entered into indemnification agreements with our directors. The indemnification agreements are intended to provide our directors the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the director who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act.

We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

 

83

---

Table of Contents

Index to Financial Statements

Borrowings

Long-Term SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. Under the Small Business Investment Company Act and current SBA policy applicable to SBICs, a SBIC can have outstanding at any time SBA guaranteed debentures up to twice the amount of its regulatory capital. With the Company’s net investment of $44.0 million in HT II as of March 31, 2016, HT II has the capacity to issue a total of $41.2 million of SBA guaranteed debentures, subject to SBA approval, of which $41.2 million was outstanding as of March 31, 2016. As of March 31, 2016, HT II has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2016 the Company held investments in HT II in 35 companies with a fair value of approximately $98.7 million, accounting for approximately 7.6% of the Company’s total portfolio at March 31, 2016. HT II held approximately $111.6 million in assets and accounted for approximately 6.6% of the Company’s total assets prior to consolidation at March 31, 2016.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With the Company’s net investment of $74.5 million in HT III as of March 31, 2016, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, of which $149.0 million was outstanding as of March 31, 2016. As of March 31, 2016, HT III has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2016, the Company held investments in HT III in 49 companies with a fair value of approximately $272.5 million, accounting for approximately 21.1% of the Company’s total portfolio at March 31, 2016. HT III held approximately $289.1 million in assets and accounted for approximately 17.1% of the Company’s total assets prior to consolidation at March 31, 2016.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $19.5 million and have average annual fully taxed net income not exceeding $6.5 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through the Company’s wholly-owned subsidiaries HT II and HT III, the Company plans to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to the Company if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect the Company because HT II and HT III are the Company’s wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2016 as a result of having sufficient capital as defined under the SBA regulations.

The rates of borrowings under various draws from the SBA beginning in March 2009 are set semiannually in March and September and range from 2.25% to 4.62% excluding annual fees. Interest payments on SBA

 

84

---

Table of Contents

Index to Financial Statements

debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of March 2009, the initial maturity of SBA debentures will occur in March 2019. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees on other debentures have been set at 0.906%. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.515%. The rates of borrowings on the Company’s SBA debentures range from 3.05% to 5.53% when including these annual fees.

The average amount of debentures outstanding for the three months ended March 31, 2016 for HT II was approximately $41.2 million with an average interest rate of approximately 4.52%. The average amount of debentures outstanding for the three months ended March 31, 2016 for HT III was approximately $149.0 million with an average interest rate of approximately 3.43%.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the SBA debentures are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,738			$	1,718
Amortization of debt issuance cost (loan fees)			168				165
Total interest expense and fees		$	1,906			$	1,883
Cash paid for interest expense and fees		$	3,461			$	3,442

As of March 31, 2016, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $350.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2016, with the Company’s net investment of $118.5 million, HT II and HT III have the capacity to issue a total of $190.2 million of SBA-guaranteed debentures, subject to SBA approval. At March 31, 2016, the Company has issued $190.2 million in SBA-guaranteed debentures in the Company’s SBIC subsidiaries.

The Company reported the following SBA debentures outstanding principal balances as of March 31, 2016 and December 31, 2015:

 

(in thousands) Issuance/Pooling Date		Maturity Date		Interest  Rate(1)				March 31, 2016				December 31, 2015
SBA Debentures:
March 25, 2009		March 1, 2019			5.53	%		$	18,400			$	18,400
September 23, 2009		September 1, 2019			4.64	%			3,400				3,400
September 22, 2010		September 1, 2020			3.62	%			6,500				6,500
September 22, 2010		September 1, 2020			3.50	%			22,900				22,900
March 29, 2011		March 1, 2021			4.37	%			28,750				28,750
September 21, 2011		September 1, 2021			3.16	%			25,000				25,000
March 21, 2012		March 1, 2022			3.28	%			25,000				25,000
March 21, 2012		March 1, 2022			3.05	%			11,250				11,250
September 19, 2012		September 1, 2022			3.05	%			24,250				24,250
March 27, 2013		March 1, 2023			3.16	%			24,750				24,750
Total SBA Debentures								$	190,200			$	190,200

 

(1)	Interest rate includes annual charge

 

85

---

Table of Contents

Index to Financial Statements

2019 Notes

On March 6, 2012, the Company and U.S. Bank National Association (the “2019 Trustee”) entered into an indenture (the “Base Indenture”). On April 17, 2012, the Company and the 2019 Trustee entered into the First Supplemental Indenture to the Base Indenture (the “First Supplemental Indenture”), dated April 17, 2012, relating to the Company’s issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

In July 2012, the Company reopened the Company’s April 2019 Notes and issued an additional $41.5 million in aggregate principal amount of April 2019 Notes, which included the exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

On September 24, 2012, the Company and the 2019 Trustee, entered into the Second Supplemental Indenture to the Base Indenture (the “Second Supplemental Indenture”), dated as of September 24, 2012, relating to the Company’s issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% notes due 2019 (the “September 2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

In October 2012, the underwriters exercised their over-allotment option for an additional $10.9 million of the September 2019 Notes, bringing the total amount of the September 2019 Notes issued to approximately $85.9 million in aggregate principal outstanding.

In April 2015, the Company redeemed $20.0 million of the $84.5 million issued and outstanding aggregate principal amount of April 2019 Notes, as previously approved by the Board of Directors. In December 2015 the Company redeemed $40.0 million of the $85.9 million issued and outstanding aggregate principal amount of September 2019 Notes, as previously approved by the Board of Directors.

As of March 31, 2016 and December 31, 2015, the 2019 Notes payable outstanding principal balance consists of:

 

(in thousands)		March 31, 2016				December 31, 2015
April 2019 Notes		$	64,490			$	64,490
September 2019 Notes			45,874				45,874
Total 2019 Notes Principal Outstanding		$	110,364			$	110,364

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the NYSE under the trading symbol “HTGZ.”

The April 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively

 

86

---

Table of Contents

Index to Financial Statements

subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grant security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring the Company’s compliance with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the 2019 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the First Supplemental Indenture. The Base Indenture provides for customary events of default and further provides that the 2019 Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The April 2019 Notes were sold pursuant to an underwriting agreement dated April 11, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the NYSE under the trading symbol “HTGY.”

The September 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the 2019 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the Second Supplemental Indenture. The Base Indenture provides for customary events of default and further provides that the 2019 Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

 

87

---

Table of Contents

Index to Financial Statements

The September 2019 Notes were sold pursuant to an underwriting agreement dated September 19, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the April 2019 Notes and September 2019 Notes are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,932			$	2,981
Amortization of debt issuance cost (loan fees)			160				240
Total interest expense and fees		$	2,092			$	3,221
Cash paid for interest expense and fees		$	1,932			$	2,981

As of March 31, 2016, the Company was in compliance with the terms of the Base Indenture, and respective supplemental indentures thereto, governing the April 2019 Notes and September 2019 Notes.

2024 Notes

On July 14, 2014, the Company and U.S. Bank, N.A. (the “2024 Trustee”), entered into the Third Supplemental Indenture (the “Third Supplemental Indenture”) to the Base Indenture between the Company and the 2024 Trustee, dated July 14, 2014, relating to the Company’s issuance, offer and sale of $100.0 million aggregate principal amount of 2024 Notes. On August 6, 2014, the underwriters issued notification to exercise their over-allotment option for an additional $3.0 million in aggregate principal amount of the 2024 Notes. The sale of the 2024 Notes generated net proceeds of approximately $99.9 million.

The 2024 Notes will mature on July 30, 2024 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after July 30, 2017, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The 2024 Notes bear interest at a rate of 6.25% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2014, and trade on the NYSE under the trading symbol “HTGX.”

The 2024 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2024 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the Third Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the Third Supplemental Indenture. The Base Indenture, as supplemented by the Third Supplemental Indenture, also contains certain reporting requirements, including a requirement that the Company provide financial information to the holders of the 2024 Notes and the 2024 Trustee if the Company should no longer be subject to the

 

88

---

Table of Contents

Index to Financial Statements

reporting requirements under the Exchange Act. The Base Indenture provides for customary events of default and further provides that the 2024 Trustee or the holders of 25% in aggregate principal amount of the outstanding 2024 Notes in a series may declare such 2024 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period. As of March 31, 2016, the Company was in compliance with the terms of the Base Indenture as supplemented by the Third Supplemental Indenture.

At both March 31, 2016 and December 31, 2015, the 2024 Notes had an outstanding principal balance of $103.0 million.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the 2024 Notes are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,609			$	1,609
Amortization of debt issuance cost (loan fees)			83				83
Total interest expense and fees		$	1,692			$	1,692
Cash paid for interest expense and fees		$	1,609			$	1,609

2021 Asset-Backed Notes

On November 13, 2014, the Company completed a $237.4 million term debt securitization in connection with which an affiliate of the Company made an offer of $129.3 million in aggregate principal amount of fixed rate asset-backed notes (the “2021 Asset-Backed Notes”), which were rated A(sf) by Kroll Bond Rating Agency, Inc. (“KBRA”). The 2021 Asset-Backed Notes were sold by Hercules Capital Funding Trust 2014-1 pursuant to a note purchase agreement, dated as of November 13, 2014, by and among the Company, 2014 Trust Depositor, 2014 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, and are backed by a pool of senior loans made to certain of the Company’s portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has an 18-month reinvestment period during which time principal collections may be reinvested into additional eligible loans. Interest on the 2021 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.524% per annum. The 2021 Asset-Backed Notes have a stated maturity of April 16, 2021.

As part of this transaction, the Company entered into a sale and contribution agreement with the 2014 Trust Depositor under which the Company has agreed to sell or have contributed to the 2014 Trust Depositor the 2014 Loans. The Company has made customary representations, warranties and covenants in the sale and contribution agreement with respect to the 2014 Loans as of the date of their transfer to the 2014 Trust Depositor.

In connection with the issuance and sale of the 2021 Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the note purchase agreement. The 2021 Asset-Backed Notes are secured obligations of the 2014 Securitization Issuer and are non-recourse to the Company. The 2014 Securitization Issuer also entered into an indenture governing the 2021 Asset-Backed Notes, which includes customary representations, warranties and covenants. The 2021 Asset-Backed Notes were sold without being registered under the Securities Act (A) in the United States to “qualified institutional buyers” as defined in Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rules 501(a)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” as defined in Sec. 2 (a)(51)(A) of the 1940 Act and pursuant to an exemption under the Securities Act and (B) to non-U.S. purchasers acquiring interest in the 2021 Asset-Backed Notes outside the United States in accordance with Regulation S under the Securities Act. The 2014 Securitization Issuer is not registered under the 1940 Act in reliance on an exemption provided by Section 3(c)(7) thereof and Rule 3a-7 thereunder. In addition, the 2014 Trust Depositor entered into an amended and restated trust agreement in respect of the 2014 Securitization Issuer, which includes customary representation, warranties and covenants.

 

89

---

Table of Contents

Index to Financial Statements

The 2014 Loans are serviced by the Company pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. The Company performs certain servicing and administrative functions with respect to the 2014 Loans. The Company is entitled to receive a monthly fee from the 2014 Securitization Issuer for servicing the 2014 Loans. This servicing fee is equal to the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including October 5, 2014 through and including December 5, 2014 over 360) of 2.00% and the aggregate outstanding principal balance of the 2014 Loans plus collections on deposit in the 2014 Securitization Issuer’s collections account, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including October 5, 2014, to the close of business on December 5, 2014).The Company also serves as administrator to the 2014 Securitization Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At both March 31, 2016 and December 31, 2015, the 2021 Asset-Backed Notes had an outstanding principal balance of $129.3 million.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the 2021 Asset-Backed Notes are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,139			$	1,139
Amortization of debt issuance cost (loan fees)			232				222
Total interest expense and fees		$	1,371			$	1,361
Cash paid for interest expense and fees		$	1,139			$	1,139

Under the terms of the 2021 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2021 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. There was approximately $3.6 million and $9.2 million of restricted cash as of March 31, 2016 and December 31, 2015, respectively, funded through interest collections.

Convertible Senior Notes

In April 2011, the Company issued $75.0 million in aggregate principal amount of 6.00% convertible senior notes due 2016 (the “Convertible Senior Notes”). As of March 31, 2016, the outstanding principal balance of the Convertible Senior Notes is $17.6 million and the carrying value, comprised of the aggregate principal amount outstanding less the remaining unamortized debt issuance costs associated with the borrowing and the remaining unaccreted discount initially recorded upon issuance of the Convertible Senior Notes, is approximately $17.6 million.

The Convertible Senior Notes mature on April 15, 2016, unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are the Company’s senior unsecured obligations and rank senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

 

90

---

Table of Contents

Index to Financial Statements

Prior to the close of business on the business day immediately preceding October 15, 2015, holders could convert their Convertible Senior Notes only under certain circumstances set forth in the indenture governing the Convertible Senior Notes. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at the Company’s election, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. The conversion rate was initially 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate is subject to adjustment in some events but is not adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the conversion rate is increased for converting holders. As of March 31, 2016, the conversion rate was 91.3937 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $10.94 per share of common stock).

The Company may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require the Company to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

The Convertible Senior Notes are accounted for in accordance with ASC Subtopic 470-20 (“Debt Instruments with Conversion and Other Options”). In accounting for the Convertible Senior Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes was recorded in “capital in excess of par value” in the Consolidated Statement of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 8.1%.

Upon meeting the stock trading price conversion requirement as set forth in the indenture governing the Convertible Senior Notes, dated April 15, 2011, between the Company and U.S. Bank National Association, during the three months ended June 30, 2014, September 30, 2014 and December 31, 2014, the Convertible Senior Notes became convertible on July 1, 2014 and continued to be convertible during each of the three months ended September 30, 2014, December 31, 2014 and March 31, 2015, respectively. During this period and as of March 31, 2016, approximately $57.4 million of the Convertible Senior Notes were converted and were settled with a combination of cash equal to the outstanding principal amount of the converted notes and approximately 1.5 million shares of the Company’s common stock, or $24.3 million. By not meeting the stock trading price conversion requirement during the three months ended March 31, 2015, June 30, 2015, or September 30, 2015 the Convertible Senior Notes were not convertible for the period between April 1, 2015 and October 14, 2015. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time as described above.

The Company recorded a loss on extinguishment of debt for the proportionate amount of unamortized debt issuance costs and original issue discount. The loss was partially offset by a gain in the amount of the difference between the outstanding principal balance of the Convertible Senior Notes and the fair value of the debt instrument. The net loss on extinguishment of debt the Company recorded for the year ended December 31, 2015 was $1,000. The Company did not record a loss on extinguishment of debt in the three months ended March 31, 2016. The loss on extinguishment of debt was classified as a component of net investment income in the Company’s Consolidated Statement of Operations.

 

91

---

Table of Contents

Index to Financial Statements

As of March 31, 2016 and December 31, 2015, the components of the carrying value of the Convertible Senior Notes were as follows:

 

(in thousands)		March 31, 2016				December 31, 2015
Principal amount of debt		$	17,604			$	17,604
Unamortized debt issuance cost			(12	)			(44	)
Original issue discount, net of accretion			(20	)			(82	)
Carrying value of Convertible Senior Notes		$	17,572			$	17,478

For the three months ended March 31, 2016 and 2015, the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	264			$	215
Accretion of original issue discount			61				62
Amortization of debt issuance cost (loan fees)			32				33
Total interest expense and fees		$	357			$	310
Cash paid for interest expense and fees		$	—			$	—

The estimated effective interest rate of the debt component of the Convertible Senior Notes, equal to the stated interest of 6.0% plus the accretion of the original issue discount, was approximately 8.1% for the three months ended March 31, 2016 and 2015. As of March 31, 2016, the Company is in compliance with the terms of the indentures governing the Convertible Senior Notes.

Wells Facility

On June 29, 2015, the Company, through a special purpose wholly-owned subsidiary, Hercules Funding II LLC (“Hercules Funding II”), entered into the Wells Facility with Wells Fargo Capital Finance, LLC, as a lender and as the arranger and the administrative agent, and the lenders party thereto from time to time. The Wells Facility amends, restates, and otherwise replaces the Loan and Security Agreement, which was originally entered into on August 25, 2008, with Wells Fargo Capital Finance, LLC, and had been amended from time to time. The Wells Facility was amended and restated to, among other things, consolidate prior amendments and update certain provisions to reflect current operations and personnel of the Company and Hercules Funding II. Many other terms and provisions of the Wells Facility remain the same or substantially similar to the terms and provisions of the original Wells Facility.

On December 16, 2015, the Company entered into an amendment to the Wells Facility that extended the revolving credit availability period and maturity date of the facility. As amended, the revolving credit availability period ends on August 1, 2018 and the Wells Facility matures on August 2, 2019, unless terminated sooner in accordance with its terms.

On March 8, 2016, the Company entered into a further amendment to the Wells Facility that amended the minimum interest coverage ratio covenant and added Alostar Bank of Commerce as a lender of the facility, expanding the available commitment to $95.0 million under the accordion feature.

Under the Wells Facility, Wells Fargo Capital Finance, LLC has made commitments of $75.0 million and Alostar Bank of Commerce has made commitments of $20.0 million. The Wells Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the facility; however, there can be no assurances that additional lenders will join the Wells Facility. Borrowings under the Wells Facility

 

92

---

Table of Contents

Index to Financial Statements

generally bear interest at a rate per annum equal to LIBOR plus 3.25%, and the Wells Facility has an advance rate of 50% against eligible debt investments. The Wells Facility is secured by all of the assets of Hercules Funding II. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% depending on the average monthly outstanding balance under the facility relative to the maximum amount of commitments at such time. For the three months ended March 31, 2016, this non-use fee was approximately $66,000. For the three months ended March 31, 2015, this non-use fee was approximately $94,000.

The Wells Facility also includes various financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding II, including covenants relating to certain changes of control of the Company and Hercules Funding II. Among other things, these covenants also require the Company to maintain certain financial ratios, including a maximum debt to worth ratio, minimum interest coverage ratio, minimum portfolio funding liquidity, and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $500.0 million plus 90% of the cumulative amount of equity raised after June 30, 2014. As of March 31, 2016, the minimum tangible net worth covenant has increased to $601.9 million as a result of the March 2015 follow-on public offering of 7.6 million shares of common stock for total gross proceeds of approximately $100.4 million and the 1.1 million shares of common stock issued under the ATM equity distribution agreement with JMP for gross proceeds of $12.8 million during the three months ended March 31, 2016. The Wells Facility provides for customary events of default, including, without limitation, with respect to payment defaults, breach of representations and covenants, certain key person provisions, cross acceleration provisions to certain other debt, lien and judgment limitations, and bankruptcy.

On June 20, 2011 the Company paid $1.1 million in structuring fees in connection with the original Wells Facility. In connection with an amendment to the original Wells Facility in August 2014, the Company paid an additional $750,000 in structuring fees and in connection with the amendment in December 2015, the Company paid an additional $188,000 in structuring fees. These fees are being amortized through the end of the term of the Wells Facility.

The Company had aggregate draws of $106.7 million on the available facility during the three months ended March 31, 2016 offset by repayments of $95.7 million. At March 31, 2016 and December 31, 2015 there was $61.0 million and $50.0 million, respectively, of borrowings outstanding on this facility.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the Wells Facility are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	275			$	—
Amortization of debt issuance cost (loan fees)			104				86
Total interest expense and fees		$	379			$	86
Cash paid for interest expense and fees		$	244			$	—

See Note 4 to our consolidated financial statements for more detail on the Wells Facility.

Union Bank Facility

On May 5, 2016, the “Company, through a special purpose wholly-owned subsidiary, Hercules Funding III, LLC (“Hercules Funding III”), as borrower, entered into the Union Bank Facility with MUFG Union Bank, N.A. (“MUFG Union Bank”), as the arranger and administrative agent, and the lenders party to the Union Bank Facility from time to time.

Under the Union Bank Facility, MUFG Union Bank has made commitments of $75.0 million. The Union Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate

 

93

---

Table of Contents

Index to Financial Statements

of $200.0 million, funded by additional lenders and with the agreement of MUFG Union Bank and subject to other customary conditions. Borrowings under the Union Bank Facility generally bear interest at either (i) if such borrowing is a base rate loan, a base rate per annum equal to the federal funds rate plus 1.00%, LIBOR plus 1.00% or MUFG Union Bank’s prime rate, in each case, plus a margin of 1.25% or (ii) if such borrowing is a LIBOR loan, a rate per annum equal to LIBOR plus 3.25%, and the Union Bank Facility generally has an advance rate of 50% against eligible debt investments. The Union Bank Facility is secured by all of the assets of HT III. The Union Bank Facility requires payment of a non-use fee during the revolving credit availability period on a scale of 0.25% to 0.50% depending on the average monthly outstanding balance under the facility relative to the maximum amount of commitments at such time. The Company paid a one-time $562,500 structuring fee in connection with the Union Bank Facility.

The Union Bank Facility also includes various financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to HT III, including covenants relating to certain changes of control of the Company and HT III. Among other things, these covenants also require the Company to maintain certain financial ratios, including a maximum debt to worth ratio, minimum interest coverage ratio, minimum portfolio funding liquidity, and a minimum tangible net worth in an amount that is in excess of $500.0 million plus 90% of the cumulative amount of equity raised after June 30, 2014. The Union Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.

The Union Bank Facility matures on May 5, 2020, unless sooner terminated in accordance with its terms.

In connection with the Union Bank Facility, the Company and HT III also entered into the Sale and Servicing Agreement, dated as of May 5, 2016 (“the Sale Agreement”), by and among HT III, as borrower, the Company, as originator and servicer, and MUFG Union Bank, as agent. Under the Sale Agreement, the Company agrees to (i) sell or transfer certain loans to HT III under the Union Bank Facility and (ii) act as servicer for the loans sold or transferred.

Citibank Credit Facility

The Company, through Hercules Funding Trust I, an affiliated statutory trust, entered into the Citibank Credit Facility with Citigroup, which expired under normal terms. During the first quarter of 2009, the Company paid off all principal and interest owed under the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of debt investments and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, the Company granted to Citigroup a 10% participation in all warrants held as collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal the Maximum Participation Limit. The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three months ended March 31, 2016, the Company recorded a decrease in participation liability and an increase in unrealized appreciation by a net amount of approximately $1,000 primarily due to depreciation of fair value on the pool of warrants collateralized under the warrant participation. The remaining value of Citigroup’s participation right on unrealized gains in the related equity investments is approximately $110,000 as of March 31, 2016 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, the Company has paid Citigroup approximately $2.2 million under the warrant participation agreement thereby reducing realized gains by this amount. The Company will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between April 2016 and January 2017.

 

94

---

Table of Contents

Index to Financial Statements

Dividends

The following table summarizes our dividends declared and paid, to be paid or reinvested on all shares, including restricted stock, to date:

 

Date Declared		Record Date		Payment Date		Amount Per Share
October 27, 2005		November 1, 2005		November 17, 2005		$	0.03
December 9, 2005		January 6, 2006		January 27, 2006			0.30
April 3, 2006		April 10, 2006		May 5, 2006			0.30
July 19, 2006		July 31, 2006		August 28, 2006			0.30
October 16, 2006		November 6, 2006		December 1, 2006			0.30
February 7, 2007		February 19, 2007		March 19, 2007			0.30
May 3, 2007		May 16, 2007		June 18, 2007			0.30
August 2, 2007		August 16, 2007		September 17, 2007			0.30
November 1, 2007		November 16, 2007		December 17, 2007			0.30
February 7, 2008		February 15, 2008		March 17, 2008			0.30
May 8, 2008		May 16, 2008		June 16, 2008			0.34
August 7, 2008		August 15, 2008		September 19, 2008			0.34
November 6, 2008		November 14, 2008		December 15, 2008			0.34
February 12, 2009		February 23, 2009		March 30, 2009			0.32	*
May 7, 2009		May 15, 2009		June 15, 2009			0.30
August 6, 2009		August 14, 2009		September 14, 2009			0.30
October 15, 2009		October 20, 2009		November 23, 2009			0.30
December 16, 2009		December 24, 2009		December 30, 2009			0.04
February 11, 2010		February 19, 2010		March 19, 2010			0.20
May 3, 2010		May 12, 2010		June 18, 2010			0.20
August 2, 2010		August 12, 2010		September 17,2010			0.20
November 4, 2010		November 10, 2010		December 17, 2010			0.20
March 1, 2011		March 10, 2011		March 24, 2011			0.22
May 5, 2011		May 11, 2011		June 23, 2011			0.22
August 4, 2011		August 15, 2011		September 15, 2011			0.22
November 3, 2011		November 14, 2011		November 29, 2011			0.22
February 27, 2012		March 12, 2012		March 15, 2012			0.23
April 30, 2012		May 18, 2012		May 25, 2012			0.24
July 30, 2012		August 17, 2012		August 24, 2012			0.24
October 26, 2012		November 14, 2012		November 21, 2012			0.24
February 26, 2013		March 11, 2013		March 19, 2013			0.25
April 29, 2013		May 14, 2013		May 21, 2013			0.27
July 29, 2013		August 13, 2013		August 20, 2013			0.28
November 4, 2013		November 18, 2013		November 25, 2013			0.31
February 24, 2014		March 10, 2014		March 17, 2014			0.31
April 28, 2014		May 12, 2014		May 19, 2014			0.31
July 28, 2014		August 18, 2014		August 25, 2014			0.31
October 29, 2014		November 17, 2014		November 24, 2014			0.31
February 24, 2015		March 12, 2015		March 19, 2015			0.31
May 4, 2015		May 18, 2015		May 25, 2015			0.31
July 29, 2015		August 17, 2015		August 24, 2015			0.31
October 28, 2015		November 16, 2015		November 23, 2015			0.31
February 17, 2016		March 7, 2016		March 14, 2016			0.31
April 27, 2016		May 16, 2016		May 23, 2016			0.31
						$	11.85

 

*	Dividend paid in cash and stock.

 

95

---

Table of Contents

Index to Financial Statements

On April 27, 2016 the Board of Directors declared a cash dividend of $0.31 per share to be paid on May 23, 2016 to shareholders of record as of May 16, 2016. This dividend represents our forty-third consecutive dividend declaration since our initial public offering, bringing the total cumulative dividend declared to date $11.85 per share.

Our Board of Directors maintains a variable dividend policy with the objective of distributing four quarterly distributions in an amount that approximates 90—100% of our taxable quarterly income or potential annual income for a particular taxable year. In addition, at the end of our taxable year, our Board of Directors may choose to pay an additional special dividend, or fifth dividend, so that we may distribute approximately all of our annual taxable income in the taxable year in which it was earned, or may elect to maintain the option to spill over our excess taxable income into the following taxable year as part of any future dividend payments.

Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of the stockholder’s tax basis in our shares, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and distributions paid for the full taxable year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full taxable year. Of the dividends declared during the year ended December 31, 2015, 100% were distributions derived from our current and accumulated earnings and profits.

During the three months ended March 31, 2016, we declared a distribution of $0.31 per share. If we had determined the tax attributes of our distributions year-to-date as of March 31, 2016, 100% would be from our current and accumulated earnings and profits. However, there can be no certainty to shareholders that this determination is representative of what the tax attributes of our 2016 distributions to shareholders will actually be.

Shortly after the close of each calendar year a statement on Form 1099-DIV identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution) is mailed to our stockholders subject to information reporting. To the extent our taxable earnings fall below the total amount of our distributions for any taxable year, a portion of those distributions may be deemed a tax return of capital to our stockholders.

We expect to qualify to be taxed as a RIC under Subchapter M of the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders in determining “taxable income.” Taxable income includes our taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses and generally excludes net unrealized appreciation or depreciation as such gains or losses are not included in taxable income until they are realized.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we distribute dividends in respect of each calendar year in a timely manner to our shareholders of an amount generally at least equal to the sum of (1) 98% of our ordinary income for each calendar year, (2) 98.2% of our capital gain net income for the 1-year period ending October 31 in that calendar year and (3) any income realized, but not distributed, in the preceding year (the “Excise Tax Avoidance Requirements”). We will not be subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains).

Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year dividend distributions from such taxable income into the next taxable year and pay a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable

 

96

---

Table of Contents

Index to Financial Statements

income that may be carried over for distribution as dividends in the next taxable year under the Code is the total amount of dividends paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next taxable year, dividends declared and paid by us in a taxable year may differ from taxable income for that taxable year as such dividends may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our borrowings. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.

We intend to distribute approximately $8.2 million of spillover earnings from ordinary income from the year ended December 31, 2015 to our shareholders in 2016.

We maintain an “opt-out” dividend reinvestment plan for our common stockholders. As a result, if we declare a dividend, cash dividends will be automatically reinvested in additional shares of our common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash dividends.

Critical Accounting Policies

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

Reclassification

Certain balances from prior years have been reclassified in order to conform to the current year presentation.

Change in Accounting Principle

As of January 1, 2016, we adopted ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs” and ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”. Adoption of these standards results in the reclassification of debt issuance costs from Other Assets and the presentation of our SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes net of the associated debt issuance costs for each instrument in the liabilities section on the Consolidated Statement of Assets and Liabilities. In addition, the comparative Consolidated Statement of Assets and Liabilities as of December 31, 2015 has been adjusted to apply the change in accounting principle retrospectively. Specifically, the presentation of our Other Assets, SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes line items were adjusted by the amount of unamortized debt issuance costs for each instrument. There is no impact to the Consolidated Statement of Operations. In addition, there is no change to the presentation of the Wells Facility as debt issuance costs are presented separately as an asset on the Consolidated Statement of Assets and Liabilities. Refer to “—Outstanding Borrowings” for the amount of unamortized debt issuance costs for each instrument.

 

97

---

Table of Contents

Index to Financial Statements

Valuation of Investments

The most significant estimate inherent in the preparation of our consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At March 31, 2016, approximately 97.0% of our total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. Our investments are carried at fair value in accordance with the 1940 Act and ASC 946 and measured in accordance with ASC 820. Our debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of our investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, we value substantially all of our investments at fair value as determined in good faith pursuant to a consistent valuation policy by our Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of our investments determined in good faith by our Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

See “Determination of Net Asset Value” for a discussion of our investment valuation process.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2016 and as of December 31, 2015. We transfer investments in and out of Level 1, 2 and 3 securities as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period. During the three months ended March 31, 2016, there were no transfers between Levels 1 or 2.

 

(in thousands)		Balance March 31,				Quoted Prices In Active Markets For Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
Description		2016				(Level 1)				(Level 2)				(Level 3)
Senior Secured Debt		$	1,205,673			$	—			$	5,475			$	1,200,198
Preferred Stock			35,542				—				—				35,542
Common Stock			26,599				25,531				—				1,068
Warrants			23,496				—				3,641				19,855
Escrow Receivable			2,967				—				—				2,967
Total		$	1,294,277			$	25,531			$	9,116			$	1,259,630

 

(in thousands)		Balance December 31,				Quoted Prices In Active Markets For Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
Description		2015				(Level 1)				(Level 2)				(Level 3)
Senior Secured Debt		$	1,110,209			$	—			$	7,813			$	1,102,396
Preferred Stock			35,245				—				—				35,245
Common Stock			32,197				30,670				—				1,527
Warrants			22,987				—				4,422				18,565
Escrow Receivable			2,967				—				—				2,967
Total		$	1,203,605			$	30,670			$	12,235			$	1,160,700

 

98

---

Table of Contents

Index to Financial Statements

The table below presents a reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three months ended March 31, 2016 and the year ended December 31, 2015.

 

(in thousands)		Balance January  1, 2016				Net Realized Gains (Losses)(1)				Net Change in Unrealized Appreciation (Depreciation)(2)				Purchases(5)				Sales				Repayments(6)				Gross Transfers into Level 3(3)				Gross Transfers out of Level 3(3)				Balance March  31, 2016
Senior Debt		$	1,102,396			$	(6,451	)		$	6,112			$	175,552			$	—			$	(77,411	)		$	—			$	—			$	1,200,198
Preferred Stock			35,245				(150	)			156				1,000				—				—				52				(761	)			35,542
Common Stock			1,527				—				(1,220	)			—				—				—				761				—				1,068
Warrants			18,565				(106	)			(91	)			1,539				—				—				—				(52	)			19,855
Escrow Receivable			2,967				—				—				—				—				—				—				—				2,967
Total		$	1,160,700			$	(6,707	)		$	4,957			$	178,091			$	—			$	(77,411	)		$	813			$	(813	)		$	1,259,630

 

(in thousands)		Balance January 1, 2015				Net Realized Gains (Losses)(1)				Net Change in Unrealized Appreciation (Depreciation)(2)				Purchases(5)				Sales				Repayments(6)				Gross Transfers into Level 3(4)				Gross Transfers out of Level 3(4)				Balance December  31, 2015
Senior Debt		$	923,906			$	(2,295	)		$	(12,930	)		$	699,555			$	—			$	(505,274	)		$	—			$	(566	)		$	1,102,396
Preferred Stock			57,548				2,598				(1,539	)			15,076				(4,542	)			—				685				(34,581	)			35,245
Common Stock			1,387				(298	)			743				—				(305	)			—				—				—				1,527
Warrants			21,923				(3,849	)			(4,749	)			5,311				1,220				—				—				(1,291	)			18,565
Escrow Receivable			3,598				71				—				511				(1,032	)			(181	)			—				—				2,967
Total		$	1,008,362			$	(3,773	)		$	(18,475	)		$	720,453			$	(4,659	)		$	(505,455	)		$	685			$	(36,438	)		$	1,160,700

 

(1)	Included in net realized gains or losses in the accompanying Consolidated Statement of Operations.

(2)	Included in change in net unrealized appreciation (depreciation) in the accompanying Consolidated Statement of Operations.

(3)

Transfers out of Level 3 during the three months ended March 31, 2016 relate to the exercise of warrants in Ping Identity Corporation to preferred stock and the conversion of the Company’s preferred shares to common shares in SCIEnergy, Inc. Transfers into Level 3 during the three months ended March 31, 2016 relate to the acquisition of preferred stock as a result of the exercise of warrants in Ping Identity Corporation and the conversion of the Company’s preferred shares to common shares in SCIEnergy, Inc..

(4)

Transfers out of Level 3 during the year ended December 31, 2015 relate to the IPOs of Box, Inc., ZP Opco, Inc. (p.k.a. Zosano Pharma, Inc), Neos Therapeutics, Edge Therapeutics Inc., ViewRay, Inc., and Cerecor, Inc. in addition to the exercise of warrants in both Forescout, Inc. and Atrenta, Inc. to preferred stock. Transfers into Level 3 during the year ended December 31, 2015 relate to the acquisition of preferred stock as a result of the exercise of warrants in both Forescout, Inc. and Atrenta, Inc and the conversion of debt to equity in Home Dialysis Plus and Gynesonics.

(5)	Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period.

(6)	Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures.

 

99

---

Table of Contents

Index to Financial Statements

For three months ended March 31, 2016, approximately $104,000 in net unrealized appreciation and $1.2 in net unrealized depreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $6.1 million in net unrealized depreciation and $45,000 in net unrealized appreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

For the year ended December 31, 2015, approximately $179,000 in net unrealized depreciation and $745,000 in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $13.7 million and $5.9 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

The following tables provides quantitative information about our Level 3 fair value measurements of our investments as of March 31, 2016 and December 31, 2015. In addition to the techniques and inputs noted in the table below, according to our valuation policy we may also use other valuation techniques and methodologies when determining our fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to our fair value measurements.

The significant unobservable input used in the fair value measurement of our escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.

 

100

---

Table of Contents

Index to Financial Statements

Investment Type - Level Three Debt Investments		Fair Value at March  31, 2016 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(b)
Pharmaceuticals		$	92,845			Originated Within 6 Months		Origination Yield		12.00% - 14.48%			13.15	%
			430,402			Market Comparable Companies		Hypothetical Market Yield		8.86% - 16.81%			12.39	%
								Premium/(Discount)		(0.75%) - 1.00%
Technology			55,262			Originated Within 6 Months		Origination Yield		11.00% - 15.73%			13.78	%
			273,064			Market Comparable Companies		Hypothetical Market Yield		10.75% - 17.85%			13.38	%
								Premium/(Discount)		(0.50%) - 0.50%
			28,591			Liquidation(c)		Probability weighting of alternative outcomes		5.00% - 100.00%
Sustainable and Renewable			22,270			Originated Within 6 Months		Origination Yield		12.74% - 16.13%			15.00	%
Technology			102,890			Market Comparable Companies		Hypothetical Market Yield		7.54% - 25.68%			17.60	%
								Premium/(Discount)		(0.50%) - 0.00%
			1,106			Liquidation(c)		Probability weighting of alternative outcomes		100.00%
Medical Devices			8,253			Originated Within 6 Months		Origination Yield		15.34%			15.34	%
			77,067			Market Comparable Companies		Hypothetical Market Yield		10.73% - 19.86%			14.67	%
								Premium/(Discount)		0.00% - 0.50%
			5,110			Liquidation(c)		Probability weighting of alternative outcomes		25.00% - 75.00%
Lower Middle Market			5,436			Originated Within 6 Months		Origination Yield		13.61% - 14.50%			14.10	%
			14,723			Market Comparable Companies		Hypothetical Market Yield		13.78%			13.78	%
								Premium/(Discount)		0.25%
			15,761			Liquidation(c)		Probability weighting of alternative outcomes		20.00% - 60.00%
						Debt Investments Where Fair Value Approximates Cost
			14,074			Imminent Payoffs(d)
			53,344			Debt Investments Maturing in Less than One Year
		$	1,200,198			Total Level Three Debt Investments

 

(a)

The significant unobservable inputs used in the fair value measurement of our debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in our Consolidated Schedule of Investments are included in the industries noted above as follows:

 

•

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery and Biotechnology Tools industries in the Consolidated Schedule of Investments.

 

•

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Consumer and Business Products, Information Services, and Communications and Networking industries in the Consolidated Schedule of Investments.

 

•

Sustainable and Renewable Technology, above, aligns with the Sustainable and Renewable Technology Industry in the Consolidated Schedule of Investments.

 

•

Medical Devices, above, is comprised of debt investments in the Surgical Devices and Medical Devices and Equipment industries in the Consolidated Schedule of Investments.

 

•

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services—Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Consolidated Schedule of Investments.

 

(b)	The weighted averages are calculated based on the fair market value of each investment.

 

(c)	The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

 

(d)	Imminent payoffs represent debt investments that we expect to be fully repaid within the next three months, prior to their scheduled maturity date.

 

101

---

Table of Contents

Index to Financial Statements

Investment Type - Level Three Debt Investments		Fair Value at December 31, 2015 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(b)
Pharmaceuticals		$	72,981			Originated Within 6 Months		Origination Yield		10.35% - 16.16%			12.29	%
			406,590			Market Comparable Companies		Hypothetical Market Yield		9.55% - 16.75%			12.67	%
								Premium/(Discount)		(0.75%) - 0.00%
Technology			6,873			Originated Within 6 Months		Origination Yield		15.19%			15.19	%
			283,045			Market Comparable Companies		Hypothetical Market Yield		6.57% - 23.26%			13.22	%
								Premium/(Discount)		(0.25%) - 0.50%
			36,815			Liquidation(c)		Probability weighting of alternative outcomes		10.00% - 100.00%
Sustainable and Renewable			11,045			Originated Within 6 Months		Origination Yield		19.74%			19.74	%
Technology			105,382			Market Comparable Companies		Hypothetical Market Yield		10.62% - 27.31%			15.91	%
								Premium/(Discount)		0.00%
			1,013			Liquidation(c)		Probability weighting of alternative outcomes		100.00%
Medical Devices			80,530			Market Comparable Companies		Hypothetical Market Yield		11.65% - 19.90%			15.26	%
								Premium/(Discount)		0.00% - 0.50%
			3,764			Liquidation(c)		Probability weighting of alternative outcomes		50.00%
Lower Middle Market			17,811			Originated Within 6 Months		Origination Yield		12.70% - 14.50%			13.00	%
			15,151			Liquidation(c)		Probability weighting of alternative outcomes		25.00% - 75.00%
						Debt Investments Where Fair Value Approximates Cost
			12,434			Imminent Payoffs(d)
			48,962			Debt Investments Maturing in Less than One Year
		$	1,102,396			Total Level Three Debt Investments

 

(a)

The significant unobservable inputs used in the fair value measurement of our debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in our Consolidated Schedule of Investments are included in the industries noted above as follows:

 

•

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, and Drug Delivery industries in the Consolidated Schedule of Investments.

 

•

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Consumer and Business Products, Information Services, and Communications and Networking industries in the Consolidated Schedule of Investments.

 

•

Sustainable and Renewable Technology, above, aligns with the Sustainable and Renewable Technology Industry in the Consolidated Schedule of Investments.

 

•

Medical Devices, above, is comprised of debt investments in the Surgical Devices and Medical Devices and Equipment industries in the Consolidated Schedule of Investments.

 

•

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services—Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Consolidated Schedule of Investments.

 

(b)	The weighted averages are calculated based on the fair market value of each investment.

 

(c)	The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

 

(d)	Imminent payoffs represent debt investments that we expect to be fully repaid within the next three months, prior to their scheduled maturity date.

 

102

---

Table of Contents

Index to Financial Statements

Investment Type - Level Three Equity and Warrant  Investments		Fair Value at March  31, 2016 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(e)
Equity Investments		$	5,518			Market Comparable Companies		EBITDA Multiple(b)		4.3x - 20.8x		7.5x
								Revenue Multiple(b)		0.7x - 3.8x		2.0x
								Discount for Lack of Marketability(c)		15.08% - 26.98%		17.22%
								Average Industry Volatility(d)		40.32% - 111.12%		64.44%
								Risk-Free Interest Rate		0.56% - 0.74%		0.60%
								Estimated Time to Exit (in months)		10 - 23		12
			31,092			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 82.81%		66.30%
								Risk-Free Interest Rate		0.54% - 1.36%		0.72%
								Estimated Time to Exit (in months)		10 - 47		17
Warrant Investments			9,115			Market Comparable Companies		EBITDA Multiple(b)		5.4x - 50.0x		11.3x
								Revenue Multiple(b)		0.5x - 7.3x		1.9x
								Discount for Lack of Marketability(c)		15.15% - 32.23%		20.70%
								Average Industry Volatility(d)		36.84% - 98.38%		56.47%
								Risk-Free Interest Rate		0.54% - 1.11%		0.59%
								Estimated Time to Exit (in months)		10 - 50		16
			10,740			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 111.12%		65.82%
								Risk-Free Interest Rate		0.44% - 1.43%		0.78%
								Estimated Time to Exit (in months)		7 - 47		21
Total Level Three Warrant and Equity Investments		$	56,465

 

(a)

The significant unobservable inputs used in the fair value measurement of our warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model (“OPM”) include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when we have determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when we have determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

(e)	Weighted averages are calculated based on the fair market value of each investment.

 

103

---

Table of Contents

Index to Financial Statements

Investment Type - Level Three Equity and Warrant Investments		Fair Value at December 31, 2015 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(e)
Equity Investments		$	5,898			Market Comparable Companies		EBITDA Multiple(b)		3.3x - 19.5x		7.6x
								Revenue Multiple(b)		0.7x - 3.7x		2.1x
								Discount for Lack of Marketability(c)		14.31% - 25.11%		18.05%
								Average Industry Volatility(d)		37.72% - 109.64%		60.27%
								Risk-Free Interest Rate		0.61% - 1.09%		0.74%
								Estimated Time to Exit (in months)		10 - 26		15
			30,874			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 86.41%		65.40%
								Risk-Free Interest Rate		0.36% - 1.51%		0.80%
								Estimated Time to Exit (in months)		10 - 47		17
Warrant Investments			7,904			Market Comparable Companies		EBITDA Multiple(b)		5.1x - 57.9x		16.0x
								Revenue Multiple(b)		0.4x - 9.6x		3.0x
								Discount for Lack of Marketability(c)		10.09% - 31.37%		23.11%
								Average Industry Volatility(d)		39.51% - 73.36%		41.19%
								Risk-Free Interest Rate		0.32% - 1.51%		0.87%
								Estimated Time to Exit (in months)		4 - 47		23
			10,661			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 109.64%		64.31%
								Risk-Free Interest Rate		0.36% - 1.45%		0.85%
								Estimated Time to Exit (in months)		10 - 44		20
Total Level Three Warrant and Equity Investments		$	55,337

 

(a)

The significant unobservable inputs used in the fair value measurement of our warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes OPM include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when we have determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when we have determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

(e)	Weighted averages are calculated based on the fair market value of each investment.

Income Recognition

We record interest income on an accrual basis and we recognize it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect that principal, interest, and other obligations due will be collected in full, we will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal and interest due has been paid or we believe the portfolio company has demonstrated the ability to repay our current and future contractual obligations. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, we may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

At March 31, 2016, the Company had four debt investments on non-accrual with a cumulative investment cost and approximate fair value of $49.8 million and $27.2 million, respectively. At December 31, 2015, the Company had five debt investments on non-accrual with cumulative investment cost and fair value of approximately $47.4 million and $23.2 million, respectively. In addition, at December 31, 2015, the Company had one debt investment with an investment cost and fair value of approximately $20.1 million and $14.9 million, respectively, for which only the PIK interest is on non-accrual. During the three months ended March 31, 2016, the Company recognized a realized loss of approximately $6.2 million on the settlement of one debt investment that was on non-accrual at December 31, 2015. In addition, the Company recognized a realized loss of $430,000 on the partial write off of one debt investment that was on non-accrual as of December 31, 2015.

 

104

---

Table of Contents

Index to Financial Statements

Paid-In-Kind and End of Term Income

Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We will generally cease accruing PIK interest if there is insufficient value to support the accrual or we do not expect the portfolio company to be able to pay all principal and interest due. In addition, we may also be entitled to an end-of-term payment that we amortize into income over the life of the loan. To maintain our ability to be subject to tax as a RIC, PIK and end-of-term income must be paid out to stockholders in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $1.7 million and $907,000 in PIK income during the three months ended March 31, 2016 and 2015, respectively.

Fee Income

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and deal structuring, as well as fees for transaction services and management services rendered by us to portfolio companies and other third parties. Loan and commitment fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees.

We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fees, including prepayment penalties, fees related to select covenant default waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding.

Equity Offering Expenses

Our offering costs are charged against the proceeds from equity offerings when received.

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by us in obtaining debt financing. Debt issuance costs are recognized as prepaid expenses and amortized over the life of the related debt instrument using the straight line method, which closely approximates the effective yield method.

Cash and Cash Equivalents

Cash and cash equivalents consists solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value.

Other Assets

Other Assets generally consists of prepaid expenses, deferred financing costs net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivable. The escrow receivable balance as of March 31, 2016 was approximately $3.0 million and was fair valued and held in accordance with ASC 820.

Stock Based Compensation

We have issued and may, from time to time, issue additional stock options and restricted stock to employees under our 2004 Equity Incentive Plan and members of the Board of Directors under our 2006 Equity Incentive

 

105

---

Table of Contents

Index to Financial Statements

Plan. We follow ASC 718, formally known as FAS 123R “Share-Based Payments” to account for stock options granted. Under ASC 718, compensation expense associated with stock based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life.

Income Taxes

We operate to qualify to be taxed as a RIC under the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders in determining its “taxable income.” Taxable income includes our taxable interest, dividend and fee income, reduced by deductible expenses, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized.

As a RIC, we will be subject to a 4% U.S. nondeductible federal excise tax on certain undistributed income and gains unless we distribute dividends in a timely manner an amount at least equal to the Excise Tax Avoidance Requirements. We will not be subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains). Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year dividend distributions from such taxable income into the next taxable year and pay a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of dividends paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next taxable year, dividends declared and paid by us in a taxable year may differ from taxable income for that taxable year as such dividends may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

We intend to distribute approximately $8.2 million of spillover earnings from ordinary income from the year ended December 31, 2015 to our shareholders in 2016. We distributed 100% of our spillover dividends from long term capital gains from the taxable year ended December 31, 2014 to our shareholders during 2015.

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

Recent Accounting Pronouncements

In February 2015, the FASB issued ASU 2015-02, “Consolidation (Topic 810)—Amendments to the Consolidation Analysis”. The new guidance applies to entities in all industries and provides a new scope exception to registered money market funds and similar unregistered money market funds. It makes targeted amendments to the current consolidation guidance and ends the deferral granted to investment companies from applying the variable interest entities (“VIE”) guidance. There is not a material impact from adopting this standard on our financial statements. We have adopted this standard for three months ended March 31, 2016.

In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”, which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability and in August 2015, the FASB issued ASU 2015-15 “Presentation and Subsequent Measurement of

 

106

---

Table of Contents

Index to Financial Statements

Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the application of ASU 2015-03 to debt issuance costs associated with line-of-credit arrangements and allows presentation of debt issuance costs on these instruments as assets that are amortized over the term of the instrument. Adoption of these standards results in the reclassification of debt issuance costs from Other Assets and the presentation of our SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes net of the associated debt issuance costs for each instrument in the liabilities section on the Consolidated Statement of Assets and Liabilities. There is no impact to the Consolidated Statement of Operations. In addition, there is no change to the presentation of the Wells Facility as debt issuance costs are presented separately as an asset on the Consolidated Statement of Assets and Liabilities. We have adopted this standard for three months ended March 31, 2016. Refer to “—Critical Accounting Policies”.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which, among other things, requires that (i) all equity investments, other than equity-method investments, in unconsolidated entities generally be measured at fair value through earnings and (ii) an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. Additionally, the ASU changes the disclosure requirements for financial instruments. ASU 2016-01 is effective for annual reporting periods, and the interim periods within those periods, beginning after December 15, 2017. Early adoption is permitted for certain provisions. We are currently evaluating the impact that ASU 2016-01 will have on our consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which, among other things, requires recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Additionally the ASU requires the classification of all cash payments on leases within operating activities in the Consolidated Statement of Cash Flows. ASU 2016-02 is effective for annual reporting periods, and the interim periods within those periods, beginning after December 15, 2018. Early adoption is permitted. We are currently evaluating the impact that ASU 2016-02 will have on our consolidated financial statements and disclosures.

In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which, among other things, simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods, and the interim periods within those periods, beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact that ASU 2016-09 will have on our consolidated financial statements and disclosures.

Quantitative and Qualitative Disclosure About Market Risk

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle funds investments. Our investment income will be affected by changes in various interest rates, including LIBOR and Prime rates, to the extent our debt investments include variable interest rates. As of March 31, 2016, approximately 93.1% of the loans in our portfolio had variable rates based on floating Prime or LIBOR rates with a floor. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

 

107

---

Table of Contents

Index to Financial Statements

Based on our Consolidated Statement of Assets and Liabilities as of March 31, 2016, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and borrowings.

 

(in thousands)		Interest				Interest				Net
Basis Point Change		Income				Expense				Income
(100)		$	(2,604	)		$	(170	)		$	(2,434	)
100		$	7,441			$	293			$	7,148
200		$	17,055			$	586			$	16,469
300		$	27,646			$	879			$	26,767
400		$	38,446			$	1,172			$	37,274
500		$	49,437			$	1,465			$	47,972

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations (and foreign currency) by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates (and foreign currency), they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the three months ended March 31, 2016 we did not engage in interest rate (or foreign currency) hedging activities.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including borrowings under our Credit Facilities, SBA debentures, Convertible Senior Notes, 2019 Notes, 2024 Notes and 2021 Asset-Backed Notes that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from borrowers. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio.

For additional information regarding the interest rate associated with each of our Credit Facilities, SBA debentures, Convertible Senior Notes, 2019 Notes, 2024 Notes and 2021 Asset-Backed Notes please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Financial Condition, Liquidity and Capital Resources—Borrowings” in this prospectus.

Disclosure Controls and Procedures

The Company’s chief executive and chief financial officers, under the supervision and with the participation of the Company’s management, conducted an evaluation of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. As of the end of the period covered by this prospectus, the Company’s chief executive and chief financial officers have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

108

---

Table of Contents

Index to Financial Statements

Internal Control Over Financial Reporting

a. Management’s Report on Internal Control over Financial Reporting

The Company is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the SEC, internal control over financial reporting is a process designed under the supervision of the Company’s principal executive and principal financial and accounting officer, approved and monitored by the Company’s Board of Directors, and implemented by management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP.

The Company’s internal control over financial reporting is supported by written policies and procedures, that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Company’s management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management of the Company conducted an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2015 based on criteria established in Internal Control— Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2015.

Report of the Independent Registered Public Accounting Firm

The effectiveness of the Company’s internal control over financial reporting as of December 31, 2015 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm who also audited the Company’s consolidated financial statements, as stated in their report, which is included in this prospectus.

Changes in Internal Control over Financial Reporting in 2015

There have been no changes in the Company’s internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, which occurred during the Company’s most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

109

---

Table of Contents

Index to Financial Statements

BUSINESS

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a broadly diversified variety of technology, life sciences and sustainable and renewable technology industries. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, McLean, VA, Santa Monica, CA and Hartford, CT.

Our goal is to be the leading structured debt financing provider for venture capital-backed companies in technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products. We focus our investments in companies active in the technology industry sub-sectors characterized by products or services that require advanced technologies, including, but not limited to, computer software and hardware, networking systems, semiconductors, semiconductor capital equipment, information technology infrastructure or services, internet consumer and business services, telecommunications, telecommunications equipment, renewable or alternative energy, media and life sciences. Within the life sciences sub-sector, we generally focus on medical devices, bio-pharmaceutical, drug discovery, drug delivery, health care services and information systems companies. Within the sustainable and renewable technology sub-sector, we focus on sustainable and renewable energy technologies and energy efficiency and monitoring technologies. We refer to all of these companies as “technology-related” companies and intend, under normal circumstances, to invest at least 80% of the value of our assets in such businesses.

We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We invest primarily in private companies but also have investments in public companies. We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our warrant and equity-related investments. Our primary business objectives are to increase our net income, net operating income and NAV by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related industries with attractive current yields and the potential for equity appreciation and realized gains. Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related industries is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.

We also make investments in qualifying small businesses through our two wholly-owned SBICs. Our SBIC subsidiaries, HT II and HT III, hold approximately $111.6 million and $289.1 million in assets, respectively, and accounted for approximately 6.6% and 17.1% of our total assets, respectively, prior to consolidation at March 31, 2016. As of March 31, 2016, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $350.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2016, with our net investment of $118.5 million, HT II and HT III have the capacity to issue a total of $190.2 million of SBA-guaranteed debentures, subject to SBA approval. At March 31, 2016, we have issued $190.2 million in SBA-guaranteed debentures in our SBIC subsidiaries. See “Regulation—Small Business Administration Regulations” for additional information regarding our SBIC subsidiaries.

We regularly engage in discussions with third parties with respect to various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We, our subsidiaries or our affiliates may also agree to manage certain other funds that invest

 

110

---

Table of Contents

Index to Financial Statements

in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will typically be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and required regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

CORPORATE HISTORY AND OFFICES

We are a Maryland corporation formed in December 2003 that began investment operations in September 2004. On February 25, 2016, we changed our name from “Hercules Technology Growth Capital, Inc.” to “Hercules Capital, Inc.” We are an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company under the 1940 Act. As a business development company, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” including securities of private U.S. companies, cash, cash equivalents, U.S. government securities and high-quality debt investments that mature in one year or less. A business development company also must meet a coverage ratio of total net assets to total senior securities, which include all of our borrowings (including accrued interest payable) except for debentures issued by the SBA and any preferred stock we may issue in the future, of at least 200% subsequent to each borrowing or issuance of senior securities. See “Regulation.”

Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology-related companies at various stages of their development. Consistent with regulatory requirements, we invest primarily in United States based companies and, to a lesser extent, in foreign companies.

Effective January 1, 2006, we elected to be treated for tax purposes as a RIC under the Code. Pursuant to this election, we generally will not have to pay corporate-level taxes on any income that we distribute to our stockholders. However, our qualification and election to be treated as a RIC requires that we comply with provisions contained in the Code. For example, as a RIC we must receive 90% or more of our income from qualified earnings, typically referred to as “good income,” as well as satisfy asset diversification and income distribution requirements. As an investment company, we follow accounting and reporting guidance as set forth in Topic 946 of FASB’s ASC.

Our principal executive offices are located at 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301, and our telephone number is (650) 289-3060. We also have offices in Boston, MA, New York, NY, McLean, VA, Santa Monica, CA, and Hartford, CT. We maintain a website on the Internet at www.htgc.com. We make available, free of charge, on our website our proxy statement, annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider that information to be part of this prospectus.

We file annual, quarterly and current periodic reports, proxy statements and other information with the SEC under the Exchange Act. This information is available at the SEC’s public reference room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information about the operation of the SEC’s public reference room by calling the SEC at (202) 551-8090. In addition, the SEC maintains an Internet website, at www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers, including us, who file documents electronically with the SEC.

 

111

---

Table of Contents

Index to Financial Statements

OUR MARKET OPPORTUNITY

We believe that technology-related companies compete in one of the largest and most rapidly growing sectors of the U.S. economy and that continued growth is supported by ongoing innovation and performance improvements in technology products as well as the adoption of technology across virtually all industries in response to competitive pressures. We believe that an attractive market opportunity exists for a specialty finance company focused primarily on investments in structured debt with warrants in technology- related companies for the following reasons:

 

•

technology-related companies have generally been underserved by traditional lending sources;

 

•

unfulfilled demand exists for structured debt financing to technology-related companies due to the complexity of evaluating risk in these investments; and

 

•

structured debt with warrants products are less dilutive and complement equity financing from venture capital and private equity funds.

Technology-Related Companies are Underserved by Traditional Lenders. We believe many viable technology-related companies backed by financial sponsors have been unable to obtain sufficient growth financing from traditional lenders, including financial services companies such as commercial banks and finance companies because traditional lenders have continued to consolidate and have adopted a more risk-averse approach to lending. More importantly, we believe traditional lenders are typically unable to underwrite the risk associated with these companies effectively.

The unique cash flow characteristics of many technology-related companies typically include significant research and development expenditures and high projected revenue growth thus often making such companies difficult to evaluate from a credit perspective. In addition, the balance sheets of these companies often include a disproportionately large amount of intellectual property assets, which can be difficult to value. Finally, the speed of innovation in technology and rapid shifts in consumer demand and market share add to the difficulty in evaluating technology-related companies.

Due to the difficulties described above, we believe traditional lenders generally refrain from entering the structured debt financing marketplace, instead preferring the risk-reward profile of asset based lending. Traditional lenders generally do not have flexible product offerings that meet the needs of technology-related companies. The financing products offered by traditional lenders typically impose on borrowers many restrictive covenants and conditions, including limiting cash outflows and requiring a significant depository relationship to facilitate rapid liquidation.

Unfulfilled Demand for Structured Debt Financing to Technology-Related Companies. Private debt capital in the form of structured debt financing from specialty finance companies continues to be an important source of funding for technology-related companies. We believe that the level of demand for structured debt financing is a function of the level of annual venture equity investment activity.

We believe that demand for structured debt financing is currently underserved. The venture capital market for the technology-related companies in which we invest has been active. Therefore, to the extent we have capital available, we believe this is an opportune time to be active in the structured lending market for technology-related companies.

Structured Debt with Warrants Products Complement Equity Financing From Venture Capital and Private Equity Funds. We believe that technology-related companies and their financial sponsors will continue to view structured debt securities as an attractive source of capital because it augments the capital provided by venture capital and private equity funds. We believe that our structured debt with warrants product provides access to growth capital that otherwise may only be available through incremental investments by existing equity investors. As such, we provide portfolio companies and their financial sponsors with an opportunity to diversify their capital sources. Generally, we believe many technology-related companies at all stages of development

 

112

---

Table of Contents

Index to Financial Statements

target a portion of their capital to be debt in an attempt to achieve a higher valuation through internal growth. In addition, because financial sponsor-backed companies have reached a more mature stage prior to reaching a liquidity event, we believe our investments could provide the debt capital needed to grow or recapitalize during the extended period sometimes required prior to liquidity events.

OUR BUSINESS STRATEGY

Our strategy to achieve our investment objective includes the following key elements:

Leverage the Experience and Industry Relationships of Our Management Team and Investment Professionals. We have assembled a team of experienced investment professionals with extensive experience as venture capitalists, commercial lenders, and originators of structured debt and equity investments in technology-related companies. Our investment professionals have, on average, more than 15 years of experience as equity investors in, and/or lenders to, technology-related companies. In addition, our team members have originated structured debt, debt with warrants and equity investments in over 350 technology-related companies, representing almost $5.9 billion in commitments from inception to March 31, 2016, and have developed a network of industry contacts with investors and other participants within the venture capital and private equity communities. In addition, members of our management team also have operational, research and development and finance experience with technology-related companies. We have established contacts with leading venture capital and private equity fund sponsors, public and private companies, research institutions and other industry participants, which we believe will enable us to identify and attract well-positioned prospective portfolio companies.

We concentrate our investing activities generally in industries in which our investment professionals have investment experience. We believe that our focus on financing technology-related companies will enable us to leverage our expertise in structuring prospective investments, to assess the value of both tangible and intangible assets, to evaluate the business prospects and operating characteristics of technology-related companies and to identify and originate potentially attractive investments with these types of companies.

Mitigate Risk of Principal Loss and Build a Portfolio of Equity-Related Securities. We expect that our investments have the potential to produce attractive risk-adjusted returns through current income, in the form of interest and fee income, as well as capital appreciation from warrant and equity-related securities. We believe that we can mitigate the risk of loss on our debt investments through the combination of loan principal amortization, cash interest payments, relatively short maturities, security interests in the assets of our portfolio companies, and on select investment covenants requiring prospective portfolio companies to have certain amounts of available cash at the time of our investment and the continued support from a venture capital or private equity firm at the time we make our investment.

Historically our structured debt investments to technology-related companies typically include warrants or other equity interests, giving us the potential to realize equity-like returns on a portion of our investment. In addition, in some cases, we receive the right to make additional equity investments in our portfolio companies, including the right to convert some portion of our debt into equity, in connection with future equity financing rounds. We believe these equity interests will create the potential for meaningful long-term capital gains in connection with the future liquidity events of these technology-related companies.

Provide Customized Financing Complementary to Financial Sponsors’ Capital. We offer a broad range of investment structures and possess expertise and experience to effectively structure and price investments in technology-related companies. Unlike many of our competitors that only invest in companies that fit a specific set of investment parameters, we have the flexibility to structure our investments to suit the particular needs of our portfolio companies. We offer customized financing solutions ranging from senior debt to equity capital, with a focus on structured debt with warrants.

 

113

---

Table of Contents

Index to Financial Statements

We use our relationships in the financial sponsor community to originate investment opportunities. Because venture capital and private equity funds typically invest solely in the equity securities of their portfolio companies, we believe that our debt investments will be viewed as an attractive and complimentary source of capital, both by the portfolio company and by the portfolio company’s financial sponsor. In addition, we believe that many venture capital and private equity fund sponsors encourage their portfolio companies to use debt financing for a portion of their capital needs as a means of potentially enhancing equity returns, minimizing equity dilution and increasing valuations prior to a subsequent equity financing round or a liquidity event.

Invest at Various Stages of Development. We provide growth capital to technology-related companies at all stages of development, including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancings and established-stage companies. We believe that this provides us with a broader range of potential investment opportunities than those available to many of our competitors, who generally focus their investments on a particular stage in a company’s development. Because of the flexible structure of our investments and the extensive experience of our investment professionals, we believe we are well positioned to take advantage of these investment opportunities at all stages of prospective portfolio companies’ development.

Benefit from Our Efficient Organizational Structure. We believe that the perpetual nature of our corporate structure enables us to be a long-term partner for our portfolio companies in contrast to traditional investment funds, which typically have a limited life. In addition, because of our access to the equity markets, we believe that we may benefit from a lower cost of capital than that available to private investment funds. We are not subject to requirements to return invested capital to investors nor do we have a finite investment horizon. Capital providers that are subject to such limitations are often required to seek a liquidity event more quickly than they otherwise might, which can result in a lower overall return on an investment.

Deal Sourcing Through Our Proprietary Database. We have developed a proprietary and comprehensive SQL database system to track various aspects of our investment process including sourcing, originations, transaction monitoring and post-investment performance. As of March 31, 2016, our proprietary SQL-based database system included approximately 45,000 technology-related companies and approximately 9,200 venture capital firms, private equity sponsors/investors, as well as various other industry contacts. This proprietary SQL system allows us to maintain, cultivate and grow our industry relationships while providing us with comprehensive details on companies in the technology-related industries and their financial sponsors.

OUR INVESTMENTS AND OPERATIONS

We principally invest in debt securities and, to a lesser extent, equity securities, with a particular emphasis on structured debt with warrants.

We generally seek to invest in companies that have been operating for at least six to 12 months prior to the date of our investment. We anticipate that such entities may, at the time of investment, be generating revenues or will have a business plan that anticipates generation of revenues within 24 to 48 months. Further, we anticipate that on the date of our investment we will generally obtain a lien on available assets, which may or may not include intellectual property, and these companies will have sufficient cash on their balance sheet to operate as well as potentially amortize their debt for at least three to nine months following our investment. We generally require that a prospective portfolio company, in addition to having sufficient capital to support leverage, demonstrate an operating plan capable of generating cash flows or raising the additional capital necessary to cover its operating expenses and service its debt, for an additional six to twelve months subject to market conditions.

We expect that our investments will generally range from $12.0 million to $25.0 million, although we may make investments in amounts above or below this range. We typically structure our debt securities to provide for amortization of principal over the life of the loan, but may include a period of interest-only payments. Our loans

 

114

---

Table of Contents

Index to Financial Statements

will typically be collateralized by a security interest in the borrower’s assets, although we may not have the first claim on these assets and the assets may not include intellectual property. As of March 31, 2016, approximately 93.1% of our loans were at floating rates or floating rates with a floor and 6.9% of the loans were at fixed rates.

In addition to the cash yields received on our loans, in some instances, our loans generally include one or more of the following: end-of-term payments, exit fees, balloon payment fees, commitment fees, success fees or prepayment fees. In some cases our loans also include contractual PIK interest arrangements. The increases in loan balances as a result of contractual PIK arrangements are included in income for the period in which such PIK interest was accrued, which is often in advance of receiving cash payment, and are separately identified on our statements of cash flows. We also may be required to include in income for tax purposes certain other amounts prior to receiving the related cash.

In addition, the majority of our investments in the structured debt of venture capital-backed companies generally have equity enhancement features, typically in the form of warrants or other equity-related securities that are considered OID to our loans and are designed to provide us with an opportunity for potential capital appreciation. The warrants typically will be immediately exercisable upon issuance and generally will remain exercisable for the lesser of five to ten years or three to five years after completion of an IPO. The exercise prices for the warrants varies from nominal exercise prices to exercise prices that are at or above the current fair market value of the equity for which we receive warrants. We may structure warrants to provide minority rights provisions or on a very select basis put rights upon the occurrence of certain events. We generally target a total annualized return (including interest, fees and value of warrants) of 12% to 25% for our debt investments.

Typically, our structured debt and equity investments take one of the following forms:

 

•

Structured Debt with Warrants. We seek to invest a majority of our assets in structured debt with warrants of prospective portfolio companies. Our investments in structured debt with warrants may be the only debt capital on the balance sheet of our portfolio companies, and in many cases we have a first priority security interest in all of our portfolio company’s assets, or in certain investments we may have a negative pledge on intellectual property. Our structured debt with warrants typically has a maturity of between two and seven years, and they may provide for full amortization after an interest only period. Our structured debt with warrants generally carries a contractual interest rate up to 15.0% and may include an additional end-of-term payment or contractual PIK interest arrangements. We may structure our structured debt with warrants with restrictive affirmative and negative covenants, default penalties, prepayment penalties, lien protection, equity calls, change-in-control provisions or board observation rights.

 

•

Senior Debt. We seek to invest a limited portion of our assets in senior debt. Senior debt may be collateralized by accounts receivable and/or inventory financing of prospective portfolio companies. Senior debt has a senior position with respect to a borrower’s scheduled interest and principal payments and holds a first priority security interest in the assets pledged as collateral. Senior debt also may impose covenants on a borrower with regard to cash flows and changes in capital structure, among other items. We generally collateralize our investments by obtaining security interests in our portfolio companies’ assets, which may include their intellectual property. In other cases we may obtain a negative pledge covering a company’s intellectual property. Our senior loans, in certain instances, may be tied to the financing of specific assets. In connection with a senior debt investment, we may also provide the borrower with a working capital line-of-credit that will carry an interest rate ranging from Prime or LIBOR plus a spread with a floor, generally maturing in one to three years, and typically secured by accounts receivable and/or inventory.

 

•

Equipment Loans. We intend to invest a limited portion of our assets in equipment-based loans to early-stage prospective portfolio companies. Equipment-based loans are secured by a first priority security interest in only the specific assets financed. These loans are generally for amounts up to $3.0 million but may be up to $15.0 million, carry a contractual interest rate between Prime and Prime plus 9.0%, and have an average term between three and four years. Equipment loans may also include end of term payments.

 

115

---

Table of Contents

Index to Financial Statements

•

Equity-Related Securities. The equity-related securities we hold consist primarily of warrants or other equity interests generally obtained in connection with our structured debt investments. In addition to the warrants received as a part of a structured debt financing, we typically receive the right to make equity investments in a portfolio company in connection with that company’s next round of equity financing. We may also on certain debt investments have the right to convert a portion of the debt investment into equity. These rights will provide us with the opportunity to further enhance our returns over time through opportunistic equity investments in our portfolio companies. These equity-related investments are typically in the form of preferred or common equity and may be structured with a dividend yield, providing us with a current return, and with customary anti-dilution protection and preemptive rights. We may achieve liquidity through a merger or acquisition of a portfolio company, a public offering of a portfolio company’s stock or by exercising our right, if any, to require a portfolio company to buy back the equity-related securities we hold. We may also make stand-alone direct equity investments into portfolio companies in which we may not have any debt investment in the company. As of December 31, 2015, we held warrant and equity-related securities in 150 portfolio companies.

A comparison of the typical features of our various investment alternatives is set forth in the chart below.

 

		Structured Debt with Warrants		Senior Debt		Equipment Loans		Equity-Related Securities
Typical Structure		Term debt with warrants		Term or revolving debt		Term debt with warrants		Preferred stock or common stock
Investment Horizon		Long-term, ranging from 2 to 7 years, with an average of 3 years		Usually under 3 years		Ranging from 3 to 4 years		Ranging from 3 to 7 years
Ranking/Security		Senior secured, either first out or last out, or second lien		Senior / First lien		Secured only by underlying equipment		None/unsecured
Covenants		Less restrictive; mostly financial		Generally borrowing base and financial		None		None
Risk Tolerance		Medium / High		Low		High		High
Coupon/Dividend		Cash pay—fixed and floating rate; PIK in limited cases		Cash pay—fixed or floating rate		Cash pay—fixed or floating rate and may include PIK		Generally none
Customization or Flexibility		More flexible		Little to none		Little to none		Flexible
Equity Dilution		Low to medium		None to low		Low		High

 

116

---

Table of Contents

Index to Financial Statements

Investment Criteria

We have identified several criteria, among others, that we believe are important in achieving our investment objective with respect to prospective portfolio companies. These criteria, while not inclusive, provide general guidelines for our investment decisions.

Portfolio Composition. While we generally focus our investments in venture capital-backed companies in technology-related industries, we seek to invest across various financial sponsors as well as across various stages of companies’ development and various technology industry sub-sectors and geographies. As of March 31, 2016, approximately 63.1% of the fair value of our portfolio was composed of investments in four industries: 24.9% was composed of investments in the drug discovery and development industry, 13.8% was comprised of investments in the sustainable and renewable technology industry, 12.2% was composed of investments in the software industry, and 12.2% was composed of investments in the drug delivery industry.

Continuing Support from One or More Financial Sponsors. We generally invest in companies in which one or more established financial sponsors have previously invested and continue to make a contribution to the management of the business. We believe that having established financial sponsors with meaningful commitments to the business is a key characteristic of a prospective portfolio company. In addition, we look for representatives of one or more financial sponsors to maintain seats on the Board of Directors of a prospective portfolio company as an indication of such commitment.

Company Stage of Development. While we invest in companies at various stages of development, we generally require that prospective portfolio companies be beyond the seed stage of development and generally have received or anticipate having commitments for their first institutional round of equity financing for early stage companies. We expect a prospective portfolio company to demonstrate progress in its product development or demonstrate a path towards revenue generation or increase its revenues and operating cash flow over time. The anticipated growth rate of a prospective portfolio company is a key factor in determining the value that we ascribe to any warrants or other equity securities that we may acquire in connection with an investment in debt securities.

Operating Plan. We generally require that a prospective portfolio company, in addition to having potential access to capital to support leverage, demonstrate an operating plan capable of generating cash flows or the ability to potentially raise the additional capital necessary to cover its operating expenses and service its debt for a specific period. Specifically, we require that a prospective portfolio company demonstrate at the time of our proposed investment that in addition to having sufficient capital to support leverage, it has an operating plan capable of generating cash flows or raising the additional capital necessary to cover its operating expenses and service its debt for an additional six to twelve months subject to market conditions.

Security Interest. In many instances we seek a first priority security interest in all of the portfolio companies’ tangible and intangible assets as collateral for our debt investment, subject in some cases to permitted exceptions. In other cases we may obtain a negative pledge prohibiting a company from pledging or otherwise encumbering their intellectual property. Although we do not intend to operate as an asset-based lender, the estimated liquidation value of the assets, if any, collateralizing the debt securities that we hold is an important factor in our credit analysis and subject to assumptions that may change over the life of the investment especially when attempting to estimate the value of intellectual property. We generally evaluate both tangible assets, such as accounts receivable, inventory and equipment, and intangible assets, such as intellectual property, customer lists, networks and databases.

Covenants. Our investments may include one or more of the following covenants: cross-default; material adverse change provisions; requirements that the portfolio company provide periodic financial reports and operating metrics; and limitations on the portfolio company’s ability to incur additional debt, sell assets, dividend recapture, engage in transactions with affiliates and consummate an extraordinary transaction, such as a merger or recapitalization without our consent. In addition, we may require other performance or financial based covenants, as we deem appropriate.

 

117

---

Table of Contents

Index to Financial Statements

Exit Strategy. Prior to making a debt investment that is accompanied by an equity-related security in a prospective portfolio company, we analyze the potential for that company to increase the liquidity of its equity through a future event that would enable us to realize appreciation in the value of our equity interest. Liquidity events may include an initial public offering, a private sale of our equity interest to a third party, a merger or an acquisition of the company or a purchase of our equity position by the company or one of its stockholders.

Investment Process

We have organized our management team around the four key elements of our investment process:

 

•

Origination;

 

•

Underwriting;

 

•

Documentation; and

 

•

Loan and Compliance Administration.

Our investment process is summarized in the following chart:

 

 

Origination

The origination process for our investments includes sourcing, screening, preliminary due diligence and deal structuring and negotiation, all leading to an executed non-binding term sheet. As of March 31, 2016, our investment origination team, which consists of approximately 34 investment professionals, is headed by our Chief Investment Officer and our Chief Executive Officer. The origination team is responsible for sourcing potential investment opportunities and members of the investment origination team use their extensive relationships with various leading financial sponsors, management contacts within technology-related companies, trade sources, technology conferences and various publications to source prospective portfolio companies. Our investment origination team is divided into special opportunity lower middle market, technology, sustainable and renewable technology, and life sciences sub-teams to better source potential portfolio companies.

 

118

---

Table of Contents

Index to Financial Statements

In addition, we have developed a proprietary and comprehensive SQL-based database system to track various aspects of our investment process including sourcing, originations, transaction monitoring and post-investment performance. This proprietary SQL system allows our origination team to maintain, cultivate and grow our industry relationships while providing our origination team with comprehensive details on companies in the technology-related industries and their financial sponsors.

If a prospective portfolio company generally meets certain underwriting criteria, we perform preliminary due diligence, which may include high level company and technology assessments, evaluation of its financial sponsors’ support, market analysis, competitive analysis, identifying key management, risk analysis and transaction size, pricing, return analysis and structure analysis. If the preliminary due diligence is satisfactory, and the origination team recommends moving forward, we then structure, negotiate and execute a non-binding term sheet with the potential portfolio company. Upon execution of a term sheet, the investment opportunity moves to the underwriting process to complete formal due diligence review and approval.

Underwriting

The underwriting review includes formal due diligence and approval of the proposed investment in the portfolio company.

Due Diligence. Our due diligence on a prospective investment is typically completed by two or more investment professionals whom we define as the underwriting team. The underwriting team for a proposed investment consists of the deal sponsor who typically possesses general industry knowledge and is responsible for originating and managing the transaction, other investment professional(s) who perform due diligence, credit and corporate financial analyses and, as needed, our legal professionals. To ensure consistent underwriting, we generally use our standardized due diligence methodologies, which include due diligence on financial performance and credit risk as well as an analysis of the operations and the legal and applicable regulatory framework of a prospective portfolio company. The members of the underwriting team work together to conduct due diligence and understand the relationships among the prospective portfolio company’s business plan, operations and financial performance.

As part of our evaluation of a proposed investment, the underwriting team prepares an investment memorandum for presentation to the investment committee. In preparing the investment memorandum, the underwriting team typically interviews select key management of the company and select financial sponsors and assembles information necessary to the investment decision. If and when appropriate, the investment professionals may also contact industry experts and customers, vendors or, in some cases, competitors of the company.

Approval Process. The sponsoring managing director or principal presents the investment memorandum to our investment committee for consideration. The approval of a majority of our investment committee and an affirmative vote by our Chief Executive Officer is required before we proceed with any investment. The members of our investment committee are our Chief Executive Officer, our Chief Financial Officer, and our Chief Investment Officer. The investment committee generally meets weekly and more frequently on an as-needed basis.

Documentation

Our legal department administers the documentation process for our investments. This department is responsible for documenting the transactions approved by our investment committee with a prospective portfolio company. This department negotiates loan documentation and, subject to appropriate approvals, final documents are prepared for execution by all parties. The legal department generally uses the services of external law firms to complete the necessary documentation.

Loan and Compliance Administration

Our investment team, credit team, and finance department, headed by our investment committee, administer loans and track covenant compliance, if applicable, of our investments and oversees periodic reviews of our

 

119

---

Table of Contents

Index to Financial Statements

critical functions to ensure adherence with our internal policies and procedures. After funding of a loan in accordance with the investment committee’s approval, the loan is recorded in our loan administration software and our SQL-based database system. The investment team, credit team, and finance department are responsible for ensuring timely interest and principal payments and collateral management as well as advising the investment committee on the financial performance and trends of each portfolio company, including any covenant violations that occur, to aid us in assessing the appropriate course of action for each portfolio company and evaluating overall portfolio quality. In addition, the investment team and credit team advise the investment committee and the Audit Committee of our Board of Directors, accordingly, regarding the credit and investment grading for each portfolio company as well as changes in the value of collateral that may occur.

The investment team and credit team monitor our portfolio companies in order to determine whether the companies are meeting our financing criteria and their respective business plans and also monitors the financial trends of each portfolio company from its monthly or quarterly financial statements to assess the appropriate course of action for each company and to evaluate overall portfolio quality. In addition, our management team closely monitors the status and performance of each individual company through our SQL-based database system and periodic contact with our portfolio companies’ management teams and their respective financial sponsors.

Credit and Investment Grading System. Our investment team and credit team use an investment grading system to characterize and monitor our outstanding loans. Our investment team and credit team monitors and, when appropriate, recommends changes to investment grading. Our investment committee reviews the recommendations and/or changes to the investment grading, which are submitted on a quarterly basis to the Audit Committee and our Board of Directors for approval.

From time to time, we will identify investments that require closer monitoring or become workout assets. We develop a workout strategy for workout assets and our investment committee monitors the progress against the strategy. We may incur losses from our investing activities, however, we work with our troubled portfolio companies in order to recover as much of our investments as is practicable, including possibly taking control of the portfolio company. There can be no assurance that principal will be recovered.

We use the following investment grading system approved by our Board of Directors:

 

Grade 1.

Loans involve the least amount of risk in our portfolio. The borrower is performing above expectations, and the trends and risk profile is generally favorable.

 

Grade 2.

The borrower is performing as expected and the risk profile is neutral to favorable. All new loans are initially graded 2.

 

Grade 3.

The borrower may be performing below expectations, and the loan’s risk has increased materially since origination. We increase procedures to monitor a borrower that may have limited amounts of cash remaining on the balance sheet, is approaching its next equity capital raise within the next three to six months, or if the estimated fair value of the enterprise may be lower than when the loan was originated. We will generally lower the loan grade to a level 3 even if the company is performing in accordance to plan as it approaches the need to raise additional cash to fund its operations. Once the borrower closes its new equity capital raise, we may increase the loan grade back to grade 2 or maintain it at a grade 3 as the company continues to pursue its business plan.

 

Grade 4.

The borrower is performing materially below expectations, and the loan risk has substantially increased since origination. Loans graded 4 may experience some partial loss or full return of principal but are expected to realize some loss of interest which is not anticipated to be repaid in full, which, to the extent not already reflected, may require the fair value of the loan to be reduced to the amount we anticipate will be recovered. Grade 4 investments are closely monitored.

 

Grade 5.

The borrower is in workout, materially performing below expectations and a significant risk of principal loss is probable. Loans graded 5 will experience some partial principal loss or full loss of remaining principal outstanding is expected. Grade 5 loans will require the fair value of the loans be reduced to the amount, if any, we anticipate will be recovered.

 

120

---

Table of Contents

Index to Financial Statements

As of March 31, 2016, our debt investments had a weighted average investment grading of 2.17

Managerial Assistance

As a business development company, we are required to offer, and provide upon request, managerial assistance to our portfolio companies. This assistance could involve, among other things, monitoring the operations of our portfolio companies, participating in board and management meetings, consulting with and advising officers of portfolio companies and providing other organizational and financial guidance. We may, from time to time, receive fees for these services. In the event that such fees are received, they are incorporated into our operating income and are passed through to our shareholders, given the nature of our structure as an internally managed business development company. See “Regulation—Significant Managerial Assistance” for additional information.

COMPETITION

Our primary competitors provide financing to prospective portfolio companies and include non-bank financial institutions, federally or state chartered banks, venture debt funds, financial institutions, venture capital funds, private equity funds, investment funds and investment banks. Many of these entities have greater financial and managerial resources than we have, and the 1940 Act imposes certain regulatory restrictions on us as a business development company to which many of our competitors are not subject. However, we believe that few of our competitors possess the expertise to properly structure and price debt investments to venture capital-backed companies in technology-related industries. We believe that our specialization in financing technology-related companies will enable us to determine a range of potential values of intellectual property assets, evaluate the business prospects and operating characteristics of prospective portfolio companies and, as a result, identify investment opportunities that produce attractive risk-adjusted returns. For additional information concerning the competitive risks we face, see “Risk Factors—Risks Related to our Business and Structure—We operate in a highly competitive market for investment opportunities, and we may not be able to compete effectively.”

BROKERAGE ALLOCATIONS AND OTHER PRACTICES

Because we generally acquire and dispose of our investments in privately negotiated transactions, we typically do not use brokers in the normal course of business. However, from time to time, we may work with brokers to sell positions we have acquired in the securities of publicly listed companies or to acquire positions (principally equity) in companies where we see a market opportunity to acquire such securities at attractive valuations. In cases where we do use a broker, we do not execute transactions through any particular broker or dealer, but will seek to obtain the best net results for the Company, taking into account such factors as price (including the applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm and the firm’s risk and skill in positioning blocks of securities. While we generally seek reasonably competitive execution costs, we may not necessarily pay the lowest spread or commission available. Subject to applicable legal requirements, we may select a broker based partly upon brokerage or research services provided to us. In return for such services, we may pay a higher commission than other brokers would charge if we determine in good faith that such commission is reasonable in relation to the services provided.

EMPLOYEES

As of March 31, 2016, we had 65 employees, including approximately 34 investment and portfolio management professionals, all of whom have extensive experience working on financing transactions for technology-related companies.

 

121

---

Table of Contents

Index to Financial Statements

Legal Proceedings

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

 

122

---

Table of Contents

Index to Financial Statements

PORTFOLIO COMPANIES

(dollars in thousands)

The following tables set forth certain information as of March 31, 2016 regarding each portfolio company in which we had a debt or equity investment. The general terms of our loans and other investments are described in “Business—Our Investments and Operations.” Other than these investments, our only formal relationship with our portfolio companies is the offer to make available significant managerial assistance. In addition, we may receive rights to observe the Board of Directors’ meetings of our portfolio companies. Amounts are presented in thousands.

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Debt Investments
Biotechnology Tools
1-5 Years Maturity
Exicure, Inc.(11)(13) 8045 Lamon Avenue Suite 410 Skokie, IL 60077		Biotechnology Tools		Senior Secured		September 2019		Interest rate PRIME + 6.45% or Floor rate of 9.95%		$	6,000			$	5,862			$	5,862
Subtotal: 1-5 Years Maturity															5,862				5,862
Subtotal: Biotechnology Tools (0.82%)*															5,862				5,862
Communications & Networking
1-5 Years Maturity
Avanti Communications Group(4)(9) Cobham House, 20 Black Friars Lane London, EC4V 6EB		Communications & Networking		Senior Secured		October 2019		Interest rate FIXED 10.00%		$	7,500				6,693				5,475
OpenPeak, Inc.(7) 1750 Clint Moore Road Boca Raton, FL 33487		Communications & Networking		Senior Secured		April 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	12,370				9,134				4,379
SkyCross, Inc.(7)(12)(13)(14) 2025 Gateway Place Suite 385 San Jose, CA 95110		Communications & Networking		Senior Secured		January 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%, PIK Interest 5.00%		$	19,674				20,529				7,050
Spring Mobile Solutions, Inc.(13) 11710 Plaza America Drive Suite 2000 Reston, VA 20190		Communications & Networking		Senior Secured		January 2019		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	3,000				2,959				2,959
Subtotal: 1-5 Years Maturity															39,315				19,863
Subtotal: Communications & Networking (2.76%)*															39,315				19,863
Consumer & Business Products
Under 1 Year Maturity
Antenna79 (p.k.a. Pong Research Corporation)(14) 1010 S. Coast Highway 101 Suite 105 Encinitas, CA 92024		Consumer & Business Products		Senior Secured		June 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	158				158				158
Miles, Inc. (p.k.a. Fluc, Inc.)(8) 1259 El Camino Real Menlo Park, CA 94025		Consumer & Business Products		Convertible Debt		March 2017		Interest rate FIXED 4.00%		$	100				100				—
Subtotal: Under 1 Year Maturity															258				158
1-5 Years Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(13)(14) 1010 S. Coast Highway 101 Suite 105 Encinitas, CA 92024		Consumer & Business Products		Senior Secured		December 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.50%		$	4,433				4,359				4,359

 

123

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Nasty Gal(13)(14) 523 W. 6th Street Suite 330 Los Angeles, CA 90014		Consumer & Business Products		Senior Secured		May 2019		Interest rate PRIME + 5.45% or Floor rate of 8.95%		$	15,000			$	14,996			$	14,723
Second Time Around (Simplify Holdings, LLC)(13)(14) 560 Harrison Ave Suite 501 Boston, MA 02118		Consumer & Business Products		Senior Secured		February 2019		Interest rate PRIME + 7.25% or Floor rate of 10.75%		$	2,500				2,477				2,477
Subtotal: 1-5 Years Maturity															21,832				21,559
Subtotal: Consumer & Business Products (3.02%)*															22,090				21,717
Drug Delivery
1-5 Years Maturity
AcelRx Pharmaceuticals, Inc.(9)(10)(13)(14) 351 Galveston Drive Redwood City, CA 94063		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 3.85% or Floor rate of 9.10%		$	20,466				20,914				20,892
Agile Therapeutics, Inc.(10)(13) 101 Poor Farm Road Princeton, NJ 08540		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 4.75% or Floor rate of 9.00%		$	16,500				16,347				16,304
BIND Therapeutics, Inc.(13)(14) 325 Vassar St Cambridge, MA 02139		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 5.10% or Floor rate of 8.35%		$	13,691				13,919				13,754
BioQ Pharma Incorporated(10)(13) 185 Berry St Ste 160 San Francisco, CA 94107		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	10,000				10,237				10,174
		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 7.00% or Floor rate of 10.50%		$	3,000				2,983				2,983
Total BioQ Pharma Incorporated										$	13,000				13,220				13,157
Celator Pharmaceuticals, Inc.(10)(13) 200 PrincetonSouth Corporate Center Suite 180 Ewing, NJ 08628		Drug Delivery		Senior Secured		June 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	13,276				13,349				13,510
Celsion Corporation(10)(13) 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648		Drug Delivery		Senior Secured		June 2017		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	5,364				5,575				5,603
Dance Biopharm, Inc.(13)(14) 150 North Hill Drive, Suite 24 Brisbane, CA 94005		Drug Delivery		Senior Secured		November 2017		Interest rate PRIME + 7.40% or Floor rate of 10.65%		$	2,384				2,475				1,380
Edge Therapeutics, Inc.(10)(13) 200 Connell Dr. Suite 1600 Berkeley Heights, NJ 07922		Drug Delivery		Senior Secured		March 2018		Interest rate PRIME + 5.45% or Floor rate of 9.95%		$	4,919				4,915				4,942
Egalet Corporation(11)(13) 460 E. Swedesford Road Suite 1050 Wayne, PA 19087		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.15% or Floor rate of 9.40%		$	15,000				15,059				15,170
Neos Therapeutics, Inc.(10)(13)(14) 2940 N. Highway 360 Suite 400 Grand Prarie, TX 75050		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 9.00%		$	10,000				10,000				10,063
		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 10.50%		$	10,000				10,109				10,123
		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 9.00%		$	5,000				5,017				5,027
Total Neos Therapeutics, Inc.										$	25,000				25,126				25,213

 

124

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Pulmatrix Inc.(8)(10)(13) 99 Hayden Avenue, Suite 390 Lexington, MA 2421		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	7,000			$	6,924			$	6,935
ZP Opco, Inc (p.k.a. Zosano Pharma)(10)(13) 34790 Ardentech Court Fremont, CA 94555		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 2.70% or Floor rate of 7.95%		$	15,000				14,996				14,936
Subtotal: 1-5 Years Maturity															152,819				151,796
Subtotal: Drug Delivery (21.13%)*															152,819				151,796
Drug Discovery & Development
1-5 Years Maturity
Aveo Pharmaceuticals, Inc.(9)(13) One Broadway, 14th Floor Cambridge, MA 02142		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 6.65% or Floor rate of 11.90%		$	10,000				10,149				10,067
Bellicum Pharmaceuticals, Inc.(13)(14) 2130 West Holcombe Boulevard Suite 800 Houston, TX 77030		Drug Discovery & Development		Senior Secured		March 2020		Interest rate PRIME + 5.85% or Floor rate of 9.35%		$	15,000				14,893				14,893
Brickell Biotech, Inc.(11)(13) 2600 SW 3rd Avenue Suite 300 Miami, FL 33129		Drug Discovery & Development		Senior Secured		September 2019		Interest rate PRIME + 5.70% or Floor rate of 9.20%		$	7,500				7,321				7,321
Cerecor, Inc.(11)(13) 400 East Pratt Street Suite 604 Baltimore, MD 21202		Drug Discovery & Development		Senior Secured		August 2017		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	4,884				4,928				4,980
Cerulean Pharma, Inc.(11)(13) 35 Gatehouse Drive Waltham, MA 02451		Drug Discovery & Development		Senior Secured		July 2018		Interest rate PRIME + 1.55% or Floor rate of 7.30%		$	19,072				19,432				19,454
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(10)(13) 3101 Western Avenue Seattle, WA 98121		Drug Discovery & Development		Senior Secured		December 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%		$	25,000				25,607				25,778
CytRx Corporation(10)(13)(14) 11726 San Vicente Blvd. Suite 650 Los Angeles, CA 90049		Drug Discovery & Development		Senior Secured		February 2020		Interest rate PRIME + 6.00% or Floor rate of 9.50%		$	25,000				24,436				24,436
Epirus Biopharmaceuticals, Inc.(11)(13) 699 Boylston Street 8th Floor Boston, MA 02116		Drug Discovery & Development		Senior Secured		April 2018		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	15,000				14,944				15,061
Genocea Biosciences, Inc.(10)(13) 161 First Street, Suite 2C Cambridge, MA 02142		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 2.25% or Floor rate of 7.25%		$	17,000				17,081				17,147
Immune  Pharmaceuticals(10)(13) 708 Third Avenue Suite 210 New York, NY 10017		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 4.75% or Floor rate of 10.00%		$	4,500				4,429				4,388
Insmed, Incorporated(10)(13) 10 Finderne Avenue Building 10 Bridgewater, NJ 08807		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 4.75% or Floor rate of 9.25%		$	25,000				24,776				24,764
Mast Therapeutics, Inc.(13)(14) 3611 Valley Centre Dr. Suite 500 San Diego, CA 92130		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 5.70% or Floor rate of 8.95%		$	15,000				14,890				14,920
Melinta Therapeutics(11)(13) 300 TriState International Suite 272 Lincolnshire, IL 60069		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 3.75% or Floor rate of 8.25%		$	30,000				30,010				30,013
Merrimack Pharmaceuticals, Inc.(9) One Kendall Square Suite B7201 Cambridge, MA 02139		Drug Discovery & Development		Senior Secured		December 2022		Interest rate FIXED 11.50%		$	25,000				25,000				25,000
Neothetics, Inc. (p.k.a. Lithera, Inc)(13)(14) 9171 Towne Centre Drive Suite 270 San Diego, CA 92122		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	4,000				4,132				4,137

 

125

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Neuralstem, Inc.(13)(14) 20271 Goldenrod Lane 2nd floor Germantown, MD 20876		Drug Discovery & Development		Senior Secured		April 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	7,235			$	7,364			$	7,341
Paratek Pharmaceuticals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(13)(14) 75 Park Plaza 4th Floor Boston, MA 02116		Drug Discovery & Development		Senior Secured		September 2020		Interest rate PRIME + 2.75% or Floor rate of 8.50%		$	20,000				19,893				19,890
uniQure B.V.(4)(9)(10)(13) Tafelbergweg 51 Amsterdam, The Netherlands 1105 BD		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.00% or Floor rate of 10.25%		$	20,000				20,002				20,053
XOMA Corporation(9)(13)(14) 2910 Seventh Street Berkeley, CA 94710		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 2.15% or Floor rate of 9.40%		$	20,000				20,129				20,067
Subtotal: 1-5 Years Maturity															309,416				309,710
Subtotal: Drug Discovery & Development (43.11%)*															309,416				309,710
Electronics & Computer Hardware
1-5 Years Maturity
Persimmon  Technologies(11)(13) 200 Harvard Mill Square Suite 110 Wakefield, MA 01880		Electronics & Computer Hardware		Senior Secured		June 2019		Interest rate PRIME + 7.50% or Floor rate of 11.00%		$	7,000				6,928				6,855
Subtotal: 1-5 Years Maturity															6,928				6,855
Subtotal: Electronics & Computer Hardware (0.95%)*															6,928				6,855
Healthcare Services, Other
1-5 Years Maturity
Chromadex Corporation(13)(14) 10005 Muirlands Boulevard Suite G, First Floor Irvine, CA 92618		Healthcare Services, Other		Senior Secured		April 2018		Interest rate PRIME + 6.10% or Floor rate of 9.35%		$	5,000				4,952				4,977
InstaMed Communications, LLC(13)(14) 1880 John F Kennedy Blvd 12th Floor Philadelphia, PA 19103		Healthcare Services, Other		Senior Secured		February 2019		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	10,000				10,127				10,111
Subtotal: 1-5 Years Maturity															15,079				15,088
Subtotal: Healthcare Services, Other (2.10%)*															15,079				15,088
Information Services
Under 1 Year Maturity
InXpo, Inc.(13)(14) 770 N Halsted Street Suite 6s Chicago, IL 60642		Information Services		Senior Secured		October 2016		Interest rate PRIME + 7.50% or Floor rate of 10.75%		$	1,247				1,304				1,304
Subtotal: Under 1 Year Maturity															1,304				1,304
Subtotal: Information Services (0.18%)*															1,304				1,304
Internet Consumer & Business Services
Under 1 Year Maturity
NetPlenish(7)(8)(14) 505 Poli Street Suite 308 Ventura, CA 93001		Internet Consumer & Business Services		Convertible Debt		September 2016		Interest rate FIXED 10.00%		$	381				373				—
		Internet Consumer & Business Services		Senior Secured		April 2016		Interest rate FIXED 10.00%		$	44				44				—
Total NetPlenish										$	425				417				—
Subtotal: Under 1 Year Maturity															417				—

 

126

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
1-5 Years Maturity
Aria Systems, Inc.(10)(12) 575 Market Street, 10th Floor San Francisco, CA 94105		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 3.20% or Floor rate of 6.95%, PIK Interest 1.95%		$	2,031			$	2,008			$	1,983
		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 5.20% or Floor rate of 8.95%, PIK Interest 1.95%		$	18,191				17,962				17,767
Total Aria Systems, Inc.										$	20,222				19,970				19,750
CloudOne, Inc.(13) 8626 E 116th Street Suite 300 Fishers, IN 46038		Internet Consumer & Business Services		Senior Secured		April 2019		Interest rate PRIME + 6.35% or Floor rate of 9.85%		$	5,000				4,927				4,927
LogicSource(13)(14) 20 Marshall Street Sourth Norwalk, CT 06854		Internet Consumer & Business Services		Senior Secured		October 2019		Interest rate PRIME + 6.25% or Floor rate of 9.75%		$	8,500				8,371				8,371
One Planet Ops Inc. (p.k.a. Reply! Inc.) 12667 Alcosta Blvd. Suite 200 San Ramon, CA 94583		Internet Consumer & Business Services		Senior Secured		March 2019		Interest rate PRIME + 4.25% or Floor rate of 7.50%		$	6,168				5,725				5,262
ReachLocal(13) 21700 Oxnard St Suite 1600 Woodland Hills, CA 91367		Internet Consumer & Business Services		Senior Secured		April 2018		Interest rate PRIME + 8.50% or Floor rate of 11.75%		$	25,000				25,147				25,007
Tapjoy, Inc.(11)(13) 111 Sutter Street 12th Floor San Francisco, CA 94104		Internet Consumer & Business Services		Senior Secured		July 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	20,000				19,653				19,555
Tectura Corporation(7)(12)(15) 951 Old County Road Suite 2-317 Belmont, CA 94002		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR +10.00% or Floor rate of 13.00%		$	6,468				6,468				5,175
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%		$	7,670				7,670				6,136
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR +10.00% or Floor rate of 13.00%		$	563				563				450
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR +10.00% or Floor rate of 13.00%		$	5,000				5,000				4,000
Total Tectura Corporation										$	19,701				19,701				15,761
Subtotal: 1-5 Years Maturity															103,494				98,633
Subtotal: Internet Consumer & Business Services (13.73%)*															103,911				98,633
Media/Content/Info
1-5 Years Maturity
Machine Zone, Inc.(12) 1050 Page Mill Road Palo Alto, CA 94304		Media/ Content/Info		Senior Secured		May 2018		Interest rate PRIME + 2.50% or Floor rate of 6.75%, PIK Interest 3.00%		$	101,437				99,395				98,647
WP Technology, Inc. (Wattpad, Inc.)(4)(9)(13) 4950 Yonge Street Suite 801 Toronto, Canada M2N 6K1		Media/ Content/Info		Senior Secured		April 2020		Interest rate PRIME + 4.75% or Floor rate of 8.25%		$	5,000				4,943				4,943
Subtotal: 1-5 Years Maturity															104,338				103,590
Subtotal: Media/Content/Info (14.42%)*															104,338				103,590
Medical Devices & Equipment
Under 1 Year Maturity
InspireMD, Inc.(4)(9)(13) 4 Menorat Hamaor Street Tel Aviv, Israel 67448		Medical Devices & Equipment		Senior Secured		February 2017		Interest rate PRIME + 5.00% or Floor rate of 10.50%		$	3,992				4,412				3,730

 

127

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Optiscan Biomedical, Corp.(5)(8)(14) 24590 Clawiter Road Hayward, CA 94545		Medical Devices & Equipment		Convertible Debt		December 2016		Interest Rate FIXED 8.00%		$	431			$	431			$	431
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)(13) 10130 Perimeter Parkway Suite 250 Charlotte, NC 28216		Medical Devices & Equipment		Senior Secured		April 2016		Interest rate PRIME +7.75% or Floor rate of 11.00%		$	73				481				481
Subtotal: Under 1 Year Maturity															5,324				4,642
1-5 Years Maturity
Amedica Corporation(8)(13)(14) 1885 West 2100 South Salt Lake City, UT 84119		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME +9.20% or Floor rate of 12.45%		$	15,218				16,015				15,753
Aspire Bariatrics, Inc.(13)(14) 3200 Horizon Drive Suite 100 King of Prussia, PA 19406		Medical Devices & Equipment		Senior Secured		October 2018		Interest rate PRIME + 4.00% or Floor rate of 9.25%		$	7,000				6,860				6,827
Avedro, Inc.(13)(14) 230 Third Avenue Waltham, MA 02451		Medical Devices & Equipment		Senior Secured		June 2018		Interest rate PRIME +6.00% or Floor rate of 9.25%		$	11,761				11,688				11,675
Flowonix Medical Incorporated(11)(13) 500 International Drive Suite 200 Mount Olive, NJ 07828		Medical Devices & Equipment		Senior Secured		May 2018		Interest rate PRIME + 4.75% or Floor rate of 10.00%		$	15,000				15,179				15,092
Gamma Medica, Inc.(10)(13) 12 Manor Parkway Unit 3 Salem, NH 3079		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	2,500				2,567				2,549
Micell Technologies, Inc.(11)(13) 801 Capitola Drive Suite 1 Durham, NC 27713		Medical Devices & Equipment		Senior Secured		August 2019		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	8,500				8,253				8,253
Quanta Fluid Solutions(4)(9)(13) Tything Road Alcester, UK B49 6EU		Medical Devices & Equipment		Senior Secured		April 2020		Interest rate PRIME + 8.05% or Floor rate of 11.55%		$	12,500				12,351				12,351
Quanterix Corporation(10)(13) 113 Hartwell Avenue Lexington, MA 02421		Medical Devices & Equipment		Senior Secured		February 2018		Interest rate PRIME + 2.75% or Floor rate of 8.00%		$	12,661				12,757				12,707
SynergEyes, Inc.(13)(14) 2232 Rutherford Road Carlsbad, CA 92008		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	3,804				4,104				4,036
Subtotal: 1-5 Years Maturity															89,774				89,243
Subtotal: Medical Devices & Equipment (13.07%)*															95,098				93,885
Semiconductors
Under 1 Year Maturity
Achronix Semiconductor Corporation(14) 2953 Bunker Hill Lane Suite 101 Santa Clara, CA 95054		Semiconductors		Senior Secured		July 2016		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	4,260				4,260				4,260
Subtotal: Under 1 Year Maturity															4,260				4,260
1-5 Years Maturity
Achronix Semiconductor Corporation(13)(14) 2953 Bunker Hill Lane Suite 101 Santa Clara, CA 95054		Semiconductors		Senior Secured		July 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	4,710				4,787				4,728
Avnera Corporation(10)(13) 1600 NW Compton Drive Ste 300. Beaverton, OR 97006		Semiconductors		Senior Secured		April 2018		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	7,500				7,527				7,596
Subtotal: 1-5 Years Maturity															12,314				12,324
Subtotal: Semiconductors (2.31%)*															16,574				16,584

 

128

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Software
Under 1 Year Maturity
Clickfox, Inc.(14)(16) 3445 Peachtree Road Suite 450 Atlanta, GA 30326		Software		Senior Secured		March 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	2,600			$	2,600			$	2,600
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.)(12)(13)(14) 21250 Hawthorne Boulevard Suite 380 Torrance, CA 90503		Software		Senior Secured		October 2016		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	1,483				1,444				815
Message Systems, Inc.(14) 9130 Guilford Road Columbia, MD 21046		Software		Senior Secured		February 2017		Interest rate PRIME + 2.75% or Floor rate of 6.00%		$	318				318				318
Neos, Inc.(13)(14) 6210 Stoneridge Mall Suite 450 Pleasanton, CA 94588		Software		Senior Secured		May 2016		Interest rate PRIME + 6.75% or Floor rate of 10.50%		$	446				616				616
Touchcommerce, Inc.(14) 29903 Agoura Road Agoura Hills, CA 91301		Software		Senior Secured		August 2016		Interest rate PRIME + 2.25% or Floor rate of 6.50%		$	6,000				6,000				6,000
Subtotal: Under 1 Year Maturity															10,978				10,349
1-5 Years Maturity
Actifio, Inc.(12)(13) 333 Wyman Street, Waltham Waltham, MA 2451		Software		Senior Secured		January 2019		Interest rate PRIME + 4.25% or Floor rate of 8.25%, PIK Interest 2.25%		$	30,434				30,216				29,898
		Software		Senior Secured		January 2019		Interest rate PRIME + 4.75% or Floor rate of 8.75%, PIK Interest 2.50%		$	10,000				9,533				9,533
Total Actifio, Inc.										$	40,434				39,749				39,431
Clickfox, Inc.(13)(14) 3445 Peachtree Road Suite 450 Atlanta, GA 30326		Software		Senior Secured		March 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	4,935				4,988				4,979
Druva, Inc.(10)(13) 150 Mathilda Place Suite 450 Sunnyvale, CA 94041		Software		Senior Secured		March 2018		Interest rate PRIME + 4.60% or Floor rate of 7.85%		$	12,000				12,173				12,113
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.)(12)(13)(14) 21250 Hawthorne Boulevard Suite 380 Torrance, CA 90503		Software		Senior Secured		March 2018		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	12,308				11,640				6,568
Message Systems, Inc.(14) 9130 Guilford Road Columbia, MD 21046		Software		Senior Secured		February 2019		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	17,500				17,141				16,960
OneLogin, Inc.(12)(14) 150 Spear Street Suite 1400 San Francisco, CA 94105		Software		Senior Secured		August 2019		Interest rate PRIME + 6.45% or Floor rate of 9.95%, PIK Interest 3.25%		$	13,033				12,880				12,880
RedSeal Inc.(13)(14) 940 Stewart Drive Suite 101 Sunnyvale, CA 94085		Software		Senior Secured		June 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	5,000				5,038				4,992
Signpost, Inc.(12)(13)(14) 333 Hudson Street New York, NY 10014		Software		Senior Secured		February 2020		Interest rate PRIME + 4.15% or Floor rate of 8.15%, PIK Interest 1.75%		$	15,035				14,609				14,609
Touchcommerce, Inc.(13)(14) 29903 Agoura Road Agoura Hills, CA 91301		Software		Senior Secured		February 2018		Interest rate PRIME + 6.00% or Floor rate of 10.25%		$	12,000				11,957				11,872
Subtotal: 1-5 Years Maturity															130,175				124,404
Subtotal: Software (18.76%)*															141,153				134,753

 

129

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Specialty Pharmaceuticals
Under 1 Year Maturity
Cranford Pharmaceuticals, LLC(14) 11 Commerce Dr Cranford, NJ 07016		Specialty Pharmaceuticals		Senior Secured		August 2016		Interest rate LIBOR + 8.25% or Floor rate of 9.50%		$	1,100			$	1,100			$	1,100
Subtotal: Under 1 Year Maturity															1,100				1,100
1-5 Years Maturity
Alimera Sciences, Inc.(10)(13) 6120 Windward Parkway Suite 290 Alpharetta, GA 30005		Specialty Pharmaceuticals		Senior Secured		May 2018		Interest rate PRIME + 7.65% or Floor rate of 10.90%		$	35,000				34,137				34,090
Cranford Pharmaceuticals, LLC(10)(12)(13)(14) 11 Commerce Dr Cranford, NJ 07016		Specialty Pharmaceuticals		Senior Secured		August 2017		Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%		$	8,874				9,071				9,071
Jaguar Animal Health, Inc.(10)(13) 201 Mission Street Suite 2375 San Francisco, CA 94105		Specialty Pharmaceuticals		Senior Secured		August 2018		Interest rate PRIME + 5.65% or Floor rate of 9.90%		$	5,821				5,897				5,842
Subtotal: 1-5 Years Maturity															49,105				49,003
Subtotal: Specialty Pharmaceuticals (6.97%)*															50,205				50,103
Surgical Devices
1-5 Years Maturity
Transmedics, Inc.(13) 200 Minuteman Road Suite 302 Andover, MA 01810		Surgical Devices		Senior Secured		March 2019		Interest rate PRIME + 5.30% or Floor rate of 9.55%		$	8,500				8,491				8,428
Subtotal: 1-5 Years Maturity															8,491				8,428
Subtotal: Surgical Devices (1.17%)*															8,491				8,428
Sustainable and Renewable Technology
Under 1 Year Maturity
Agrivida, Inc.(13)(14) 200 Boston Avenue Medford, MA 02155		Sustainable and Renewable Technology		Senior Secured		December 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	3,786				4,034				4,034
American Superconductor Corporation(10)(13) 64 Jackson Rd Devens, MA 01434		Sustainable and Renewable Technology		Senior Secured		November 2016		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	2,667				3,135				3,135
Amyris, Inc.(9)(11)(13) Lesya Kulchenko 5885 Hollis Street, Ste. 100 Emeryville, CA 94608		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	17,543				17,543				17,543
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	3,497				3,497				3,497
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	10,960				11,224				11,224
Total Amyris, Inc.										$	32,000				32,264				32,264
Modumetal, Inc.(11)(13) Northlake R&D Center 1443 N. Northlake Way Seattle, WA 98103		Sustainable and Renewable Technology		Senior Secured		March 2017		Interest rate PRIME + 8.70% or Floor rate of 11.95%		$	1,429				1,805				1,805
Stion Corporation (5)(13) 6321 San Ignacio Avenue San Jose, CA 95119		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	1,754				1,754				1,106
Subtotal: Under 1 Year Maturity															42,992				42,344

 

130

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
1-5 Years Maturity
American Superconductor Corporation(10)(13) 64 Jackson Rd Devens, MA 01434		Sustainable and Renewable Technology		Senior Secured		June 2017		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	1,500			$	1,509			$	1,500
Modumetal, Inc.(11)(13) Northlake R&D Center 1443 N. Northlake Way Seattle, WA 98103		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	6,170				6,415				6,362
Proterra, Inc.(10)(13) 1 Whitlee Ct. Greenville, SC 29607		Sustainable and Renewable Technology		Senior Secured		December 2018		Interest rate PRIME + 6.95% or Floor rate of 10.20%		$	25,000				25,140				24,592
Rive Technology, Inc.(13)(14) 1 Deer Park Drive Suite A Monmouth Junction, NJ 08852		Sustainable and Renewable Technology		Senior Secured		January 2019		Interest rate PRIME + 6.20% or Floor rate of 9.45%		$	7,500				7,450				7,450
Sungevity, Inc.(11)(13)(14) 66 Franklin Street Suite 310 Oakland, CA 94607		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	35,000				35,969				35,879
		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	20,000				20,000				19,975
Total Sungevity, Inc.										$	55,000				55,969				55,854
Tendril Networks(11)(13) 2580 55th Street Suite 100 Boulder, CO 80301		Sustainable and Renewable Technology		Senior Secured		June 2019		Interest rate FIXED 7.25%		$	15,000				14,908				14,580
Verdezyne, Inc.(13)(14) 2715 Loker Avenue West Carlsbad, CA 92010		Sustainable and Renewable Technology		Senior Secured		April 2019		Interest rate PRIME + 8.25% or Floor rate of 11.75%		$	15,000				14,820				14,820
Subtotal: 1-5 Years Maturity															126,211				125,158
Subtotal: Sustainable and Renewable Technology (23.32%)*															169,203				167,502
Total Debt Investments (167.83%)*															1,241,786				1,205,673

 

131

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Equity Investments
Biotechnology Tools
NuGEN Technologies, Inc.(14) 201 Industrial Road Suite 310 San Carlos, CA 94070		Biotechnology Tools			Equity				0.88	%		Preferred Series C			189,394			$	500			$	538
Subtotal: Biotechnology Tools (0.07%)*																			500				538
Communications & Networking
GlowPoint, Inc.(3) 430 Mountain Avenue, Suite 301 Murray Hill, NJ 07974		Communications & Networking			Equity				0.32	%		Common Stock			114,192				102				45
Peerless Network, Inc. 222 South Riverside Plaza Suite 2730 Chicago, IL 60606		Communications & Networking			Equity				3.16	%		Preferred Series A			1,000,000				1,000				4,304
Ping Identity Corporation 1001 17th Street Suite 100 Denver, CO 80202		Communications & Networking			Equity				0.27	%		Preferred Series B			684,004				52				391
Subtotal: Communications & Networking (0.66%)*																			1,154				4,740
Consumer & Business Products
Market Force Information, Inc. PO Box 270355 Louisville, CO 80027		Consumer & Business Products			Equity				0.66	%		Common Stock			480,261				—				192
		Consumer & Business Products			Equity				0.26	%		Preferred Series B-1			187,970				500				3
Total Market Force Information, Inc.															668,231				500				195
Subtotal: Consumer & Business Products (0.03%)*																			500				195
Diagnostic
Singulex, Inc. 1701 Harbor Way Parkway Suite 200 Alameda, CA 94502		Diagnostic			Equity				0.70	%		Common Stock			937,998				750				60
Subtotal: Diagnostic (0.01%)*																			750				60
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9) 351 Galveston Drive Redwood City, CA 94063		Drug Delivery			Equity				0.12	%		Common Stock			54,240				108				168
BioQ Pharma Incorporated(14) 185 Berry St Ste 160 San Francisco, CA 94107		Drug Delivery			Equity				0.60	%		Preferred Series D			165,000				500				650
Edge Therapeutics, Inc.(3) 200 Connell Dr. Suite 1600 Berkeley Heights, NJ 07922		Drug Delivery			Equity				0.55	%		Common Stock			157,190				1,000				1,438
Merrion Pharmaceuticals, Plc(3)(4)(9) 3200 Lake Drive Citywest Business Campus Dublin, Ireland 24		Drug Delivery			Equity				0.11	%		Common Stock			20,000				9				—
Neos Therapeutics, Inc.(3)(14) 2940 N. Highway 360 Suite 400 Grand Prarie, TX 75050		Drug Delivery			Equity				0.78	%		Common Stock			125,000				1,500				1,349
Revance Therapeutics, Inc.(3) 7555 Gateway Blvd. Newark, CA 94560		Drug Delivery			Equity				0.08	%		Common Stock			22,765				557				397
Subtotal: Drug Delivery (0.56%)*																			3,674				4,002
Drug Discovery & Development
Aveo Pharmaceuticals, Inc.(3)(9)(14) One Broadway, 14th Floor Cambridge, MA 02142		Drug Discovery & Development			Equity				0.29	%		Common Stock			167,864				842				153

 

132

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Cerecor, Inc.(3) 400 East Pratt Street Suite 604 Baltimore, MD 21202		Drug Discovery & Development			Equity				1.38	%		Common Stock			119,087			$	1,000			$	444
Cerulean Pharma, Inc.(3) 35 Gatehouse Drive Waltham, MA 02451		Drug Discovery & Development			Equity				0.50	%		Common Stock			135,501				1,000				367
Dicerna Pharmaceuticals, Inc.(3)(14) 87 Cambridge Park Dr Cambridge, MA 02140		Drug Discovery & Development			Equity				0.69	%		Common Stock			142,858				1,000				766
Dynavax Technologies(3)(9) 2929 Seventh Street, Suite 100 Berkley, CA 94710		Drug Discovery & Development			Equity				0.05	%		Common Stock			20,000				550				385
Epirus Biopharmaceuticals, Inc.(3) 699 Boylston Street 8th Floor Boston, MA 02116		Drug Discovery & Development			Equity				0.76	%		Common Stock			200,000				1,000				538
Genocea Biosciences, Inc.(3) 161 First Street, Suite 2C Cambridge, MA 02142		Drug Discovery & Development			Equity				0.79	%		Common Stock			223,463				2,000				1,730
Inotek Pharmaceuticals Corporation(3) 131 Hartwell Ave., Suite 105 Lexington, MA 02421		Drug Discovery & Development			Equity				0.01	%		Common Stock			3,778				1,500				28
Insmed, Incorporated(3) 10 Finderne Avenue Building 10 Bridgewater, NJ 08807		Drug Discovery & Development			Equity				0.11	%		Common Stock			70,771				1,000				897
Melinta Therapeutics 300 TriState International Suite 272 Lincolnshire, IL 60069		Drug Discovery & Development			Equity				0.68	%		Preferred Series 4			1,914,448				2,000				2,040
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3) 75 Park Plaza 4th Floor Boston, MA 02116		Drug Discovery & Development			Equity				0.43	%		Common Stock			76,362				2,744				1,158
Subtotal: Drug Discovery & Development (1.18%)*																			14,636				8,506
Electronics & Computer Hardware
Identiv, Inc.(3) 1900-B Carnegie Avenue, Building B Santa Ana, CA 92705		Electronics & Computer Hardware			Equity				0.06	%		Common Stock			6,700				34				14
Subtotal: Electronics & Computer Hardware (0.00%)*																			34				14
Internet Consumer & Business Services
Blurb, Inc.(14) 580 California St Suite 300 San Francisco, CA 94104		Internet Consumer & Business Services			Equity				0.43	%		Preferred Series B			220,653				175				223
Lightspeed POS, Inc.(4)(9) 700 St-Antoine Est Suite 300 Montreal, Canada H2Y1A6		Internet Consumer & Business Services			Equity				0.09	%		Preferred Series C			230,030				250				254
		Internet Consumer & Business Services			Equity				0.08	%		Preferred Series D			198,677				250				241
Total Lightspeed POS, Inc.															428,707				500				495
Oportun (p.k.a. Progress Financial) 1600 Seaport Blvd. Suite 250 Redwood City, CA 94063		Internet Consumer & Business Services			Equity				0.09	%		Preferred Series G			218,351				250				374
		Internet Consumer & Business Services			Equity				0.03	%		Preferred Series H			87,802				250				245
Total Oportun (p.k.a. Progress Financial)															306,153				500				619
Philotic, Inc. 548 4th Street San Francisco, CA 94107		Internet Consumer & Business Services			Equity				0.05	%		Common Stock			9,023				93				—

 

133

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
RazorGator Interactive Group, Inc. 4216 3/4 Glencoe Ave Marina Del Rey, CA 90292		Internet Consumer & Business Services			Equity				0.13	%		Preferred Series AA			34,783			$	15			$	28
Subtotal: Internet Consumer & Business Services (0.19%)*																			1,283				1,365
Medical Devices & Equipment
AtriCure, Inc.(3)(14) 7555 Innovation Way Mason, Ohio 45040		Medical Devices & Equipment			Equity				0.02	%		Common Stock			7,536				266				116
Flowonix Medical Incorporated 500 International Drive Suite 200 Mount Olive, NJ 07828		Medical Devices & Equipment			Equity				1.03	%		Preferred Series E			221,893				1,500				1,913
Gelesis, Inc.(14) 500 Boylston Street Suite 1600 Boston, MA 02116		Medical Devices & Equipment			Equity				1.31	%		Common Stock			198,202				—				815
		Medical Devices & Equipment			Equity				1.27	%		Preferred Series A-1			191,210				425				859
		Medical Devices & Equipment			Equity				1.27	%		Preferred Series A-2			191,626				500				823
Total Gelesis, Inc.															581,038				925				2,497
Medrobotics Corporation(14) 475 Paramount Drive Raynham, MA 02767		Medical Devices & Equipment			Equity				0.14	%		Preferred Series E			136,798				250				207
		Medical Devices & Equipment			Equity				0.07	%		Preferred Series F			73,971				155				192
		Medical Devices & Equipment			Equity				0.16	%		Preferred Series G			163,934				500				504
Total Medrobotics Corporation															374,703				905				903
Novasys Medical, Inc. 39684 Eureka Drive Newark, CA 94560		Medical Devices & Equipment			Equity				1.48	%		Preferred Series D-1			4,118,444				1,000				—
Optiscan Biomedical, Corp.(5)(14) 24590 Clawiter Road Hayward, CA 94545		Medical Devices & Equipment			Equity				0.71	%		Preferred Series B			6,185,567				3,000				520
		Medical Devices & Equipment			Equity				0.22	%		Preferred Series C			1,927,309				655				156
		Medical Devices & Equipment			Equity				6.35	%		Preferred Series D			55,103,923				5,257				5,628
Total Optiscan Biomedical, Corp.															63,216,799				8,912				6,304
Oraya Therapeutics, Inc. 7999 Gateway Blvd Suite 100 Newark, CA 94560		Medical Devices & Equipment			Equity				1.02	%		Preferred Series 1			1,086,969				500				267
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.) 1830 Bering Drive San Jose, CA 95112		Medical Devices & Equipment			Equity				0.25	%		Preferred Series B			232,061				527				503
Quanterix Corporation 113 Hartwell Avenue Lexington, MA 02421		Medical Devices & Equipment			Equity				0.49	%		Preferred Series D			272,479				1,000				1,216
Subtotal: Medical Devices & Equipment (1.91%)*																			15,535				13,719
Software
Box, Inc.(3)(14) 4440 El Camino Real Los Altos, CA 94022		Software			Equity				1.03	%		Common Stock			1,287,347				5,654				15,532
CapLinked, Inc. 2221 Park Place El Segundo, CA 90245		Software			Equity				0.36	%		Preferred Series A-3			53,614				50				82
Druva, Inc. 150 Mathilda Place Suite 450 Sunnyvale, CA 94041		Software			Equity				0.41	%		Preferred Series 2			458,841				1,000				1,056

 

134

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
ForeScout Technologies, Inc . 900 E. Hamilton Avenue Suite 300 Campbell, CA 95008		Software			Equity				0.40	%		Preferred Series D			319,099			$	398			$	1,363
		Software			Equity				0.10	%		Preferred Series E			80,587				131				348
Total ForeScout Technologies, Inc.															399,686				529				1,711
HighRoads, Inc. 3 Burlington Woods Dr Burlington, MA 01803		Software			Equity				0.69	%		Preferred Series B			190,170				307				—
NewVoiceMedia Limited(4)(9) Belvedere, Basing View Basingstoke, UK RG21 4NG		Software			Equity				0.31	%		Preferred Series E			669,173				963				699
WildTangent, Inc.(14) 18578 NE 67th Court Building 5 Redmond, WA 98052		Software			Equity				0.17	%		Preferred Series 3			100,000				402				171
Subtotal: Software (2.68%)*																			8,905				19,251
Specialty Pharmaceuticals
QuatRx Pharmaceuticals Company 777 East Eisenhower Parkway Suite 100 Ann Arbor, MI 48108		Specialty Pharmaceuticals			Equity				0.24	%		Preferred Series E			241,829				750				—
		Specialty Pharmaceuticals			Equity				0.03	%		Preferred Series E-1			26,955				—				—
		Specialty Pharmaceuticals			Equity				4.62	%		Preferred Series G			4,667,636				—				—
Total QuatRx Pharmaceuticals Company															4,936,420				750				—
Subtotal: Specialty Pharmaceuticals (0.00%)*																			750				—
Surgical Devices
Gynesonics, Inc.(14) 301 Galveston Drive Redwood City, CA 94063		Surgical Devices			Equity				0.05%			Preferred Series B			219,298				250				26
		Surgical Devices			Equity				0.14%			Preferred Series C			656,538				282				36
		Surgical Devices			Equity				0.43%			Preferred Series D			1,991,157				712				602
		Surgical Devices			Equity				0.60%			Preferred Series E			2,785,402				429				390
Total Gynesonics, Inc.															5,652,395				1,673				1,054
Transmedics, Inc. 200 Minuteman Road Suite 302 Andover, MA 01810		Surgical Devices			Equity				0.21%			Preferred Series B			88,961				1,100				105
		Surgical Devices			Equity				0.29%			Preferred Series C			119,999				300				59
		Surgical Devices			Equity				0.62%			Preferred Series D			260,000				650				427
		Surgical Devices			Equity				0.24%			Preferred Series F			100,200				500				470
Total Transmedics, Inc.															569,160				2,550				1,061
Subtotal: Surgical Devices (0.29%)*																			4,223				2,115
Sustainable and Renewable Technology
Glori Energy, Inc.(3) 4315 South Drive Houston, TX 77053		Sustainable and Renewable Technology			Equity				0.06	%		Common Stock			18,208				165				4
Modumetal, Inc. Northlake R&D Center 1443 N. Northlake Way Seattle, WA 98103		Sustainable and Renewable Technology			Equity				0.94	%		Preferred Series C			3,107,520				500				483
SCIEnergy, Inc. 4100 Alpha Road Suite 900 Dallas, TX 75244		Sustainable and Renewable Technology			Equity				0.00	%		Common Stock			19,250				761				—
Sungevity, Inc.(14) 66 Franklin Street Suite 310 Oakland, CA 94607		Sustainable and Renewable Technology			Equity				1.68	%		Preferred Series D			68,807,339				6,750				7,149
Subtotal: Sustainable and Renewable Technology (1.06%)*																			8,176				7,636
Total: Equity Investments (8.65%)*																			60,120				62,141

 

135

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Warrant Investments
Biotechnology Tools
Exicure, Inc. 8045 Lamon Avenue Suite 410 Skokie, IL 60077		Biotechnology Tools			Warrant				0.20	%		Preferred Series C			104,348			$	107			$	109
Labcyte, Inc.(14) 1190 Borregas Avenue Sunnyvale, CA 94089		Biotechnology Tools			Warrant				0.85	%		Preferred Series C			1,127,624				323				181
Subtotal: Biotechnology Tools (0.04%)*																			430				290
Communications & Networking
Intelepeer, Inc.(14) 177 Bovet Road Suite 400 San Mateo, CA 94402		Communications & Networking			Warrant				0.23	%		Common Stock			117,958				102				—
OpenPeak, Inc. 1750 Clint Moore Road Boca Raton, FL 33487		Communications & Networking			Warrant				0.41	%		Common Stock			108,982				149				—
PeerApp, Inc. 29 Crafts Street Suite 260 Newton, MA 02458		Communications & Networking			Warrant				0.39	%		Preferred Series B			298,779				61				37
Peerless Network, Inc. 222 South Riverside Plaza Suite 2730 Chicago, IL 60606		Communications & Networking			Warrant				0.43	%		Preferred Series A			135,000				95				360
SkyCross, Inc.(14) 2025 Gateway Place Suite 385 San Jose, CA 95110		Communications & Networking			Warrant				1.61	%		Preferred Series F			9,762,777				394				—
Spring Mobile Solutions, Inc. 11710 Plaza America Drive Suite 2000 Reston, VA 20190		Communications & Networking			Warrant				0.78	%		Preferred Series D			2,834,375				418				55
Subtotal: Communications & Networking (0.06%)*																			1,219				452
Consumer & Business Products
Antenna79 (p.k.a. Pong Research Corporation)(14) 1010 S. Coast Highway 101 Suite 105 Encinitas, CA 92024		Consumer & Business Products			Warrant				1.01	%		Preferred Series A			1,662,441				228				—
Intelligent Beauty, Inc.(14) 2301 Rosecrans Ave Suite 4100 El Segundo, CA 90245		Consumer & Business Products			Warrant				0.35	%		Preferred Series B			190,234				230				281
IronPlanet, Inc. 3825 Hopyard Rd Suite 250 Pleasanton, CA 94588		Consumer & Business Products			Warrant				1.26	%		Preferred Series D			1,155,821				1,076				805
Nasty Gal(14) 523 W. 6th Street Suite 330 Los Angeles, CA 90014		Consumer & Business Products			Warrant				0.48	%		Preferred Series C			845,194				23				18
The Neat Company(14) 1601 Market Street Suite 3500 Philadelphia, PA 19103		Consumer & Business Products			Warrant				0.01	%		Preferred Series C-1			540,540				365				—
Subtotal: Consumer & Business Products (0.15%)*																			1,922				1,104
Diagnostic
Navidea Biopharmaceuticals, Inc. (p.k.a. Neoprobe)(3)(14) 5600 Blazer Pkwy Suite 200 Dublin, OH 43017		Diagnostic			Warrant				0.21	%		Common Stock			333,333				244				4
Subtotal: Diagnostic (0.00%)*																			244				4
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)(14) 351 Galveston Drive Redwood City, CA 94063		Drug Delivery			Warrant				0.39	%		Common Stock			176,730				785				154

 

136

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Agile Therapeutics, Inc.(3) 101 Poor Farm Road Princeton, NJ 08540		Drug Delivery			Warrant				0.63	%		Common Stock			180,274			$	730			$	204
BIND Therapeutics, Inc.(3)(14) 325 Vassar St Cambridge, MA 02139		Drug Delivery			Warrant				0.73	%		Common Stock			152,586				488				5
BioQ Pharma Incorporated 185 Berry St Ste 160 San Francisco, CA 94107		Drug Delivery			Warrant				1.67	%		Common Stock			459,183				1				354
Celsion Corporation(3) 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648		Drug Delivery			Warrant				0.83	%		Common Stock			194,986				428				10
Dance Biopharm, Inc.(14) 150 North Hill Drive, Suite 24 Brisbane, CA 94005		Drug Delivery			Warrant				0.16	%		Common Stock			43,813				74				—
Edge Therapeutics, Inc.(3) 200 Connell Dr. Suite 1600 Berkeley Heights, NJ 07922		Drug Delivery			Warrant				0.27	%		Common Stock			78,595				390				228
Kaleo, Inc. (p.k.a. Intelliject, Inc.) 111 Virginia St Ste 300 Richmond, VA 23219		Drug Delivery			Warrant				0.48	%		Preferred Series B			82,500				594				877
Neos Therapeutics, Inc.(3)(14) 2940 N. Highway 360 Suite 400 Grand Prarie, TX 75050		Drug Delivery			Warrant				0.44	%		Common Stock			70,833				285				122
Pulmatrix Inc.(3) 99 Hayden Avenue, Suite 390 Lexington, MA 2421		Drug Delivery			Warrant				0.17	%		Common Stock			25,150				116				2
ZP Opco, Inc (p.k.a. Zosano Pharma)(3) 34790 Ardentech Court Fremont, CA 94555		Drug Delivery			Warrant				0.60	%		Common Stock			72,379				266				2
Subtotal: Drug Delivery (0.27%)*																			4,157				1,958
Drug Discovery & Development
ADMA Biologics, Inc.(3) 465 Route 17 South Ramsey, NJ 07446		Drug Discovery & Development			Warrant				0.84	%		Common Stock			89,750				295				123
Anthera Pharmaceuticals, Inc.(3)(14) 25801 Industrial Blvd Suite B Hayward, CA 94545		Drug Discovery & Development			Warrant				0.10	%		Common Stock			40,178				984				—
Aveo Pharmaceuticals, Inc.(3)(9)(14) One Broadway, 14th Floor Cambridge, MA 02142		Drug Discovery & Development			Warrant				1.05	%		Common Stock			608,696				194				117
Brickell Biotech, Inc. 2600 SW 3rd Avenue Suite 300 Miami, FL 33129		Drug Discovery & Development			Warrant				0.47	%		Preferred Series C			26,086				119				125
Cerecor, Inc.(3) 400 East Pratt Street Suite 604 Baltimore, MD 21202		Drug Discovery & Development			Warrant				0.26	%		Common Stock			22,328				70				11
Cerulean Pharma, Inc.(3) 35 Gatehouse Drive Waltham, MA 02451		Drug Discovery & Development			Warrant				0.63	%		Common Stock			171,901				369				9
Chroma Therapeutics, Ltd.(4)(9) 93 Innovation Drive Milton Park Abingdon Oxon, UK OX14 4RZ		Drug Discovery & Development			Warrant				0.61	%		Preferred Series D			325,261				490				—
Cleveland BioLabs, Inc.(3)(14) 73 High Street Buffalo, NY 14203		Drug Discovery & Development			Warrant				0.07	%		Common Stock			7,813				105				2

 

137

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Concert Pharmaceuticals, Inc.(3) 99 Hayden Avenue Suite 500 Lexington, MA 02421-7966		Drug Discovery & Development			Warrant				0.32	%		Common Stock			70,796			$	367			$	158
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(3) 3101 Western Avenue Seattle, WA 98121		Drug Discovery & Development			Warrant				0.10	%		Common Stock			292,398				165				20
CytRx Corporation (3)(14) 11726 San Vicente Blvd. Suite 650 Los Angeles, CA 90049		Drug Discovery & Development			Warrant				0.95	%		Common Stock			634,146				416				773
Dicerna Pharmaceuticals, Inc.(3)(14) 87 Cambridge Park Dr Cambridge, MA 02140		Drug Discovery & Development			Warrant				0.00	%		Common Stock			200				28				—
Epirus Biopharmaceuticals, Inc.(3) 699 Boylston Street 8th Floor Boston, MA 02116		Drug Discovery & Development			Warrant				0.25	%		Common Stock			64,194				276				42
Fortress Biotech, Inc. (p.k.a. Coronado Biosciences, Inc.)(3) 95 Sawyer Road Suite 110 Waltham, MA 02453		Drug Discovery & Development			Warrant				0.15	%		Common Stock			73,009				142				15
Genocea Biosciences, Inc.(3) 161 First Street, Suite 2C Cambridge, MA 02142		Drug Discovery & Development			Warrant				0.26	%		Common Stock			73,725				266				219
Immune Pharmaceuticals(3) 708 Third Avenue Suite 210 New York, NY 10017		Drug Discovery & Development			Warrant				0.59	%		Common Stock			214,853				164				13
Mast Therapeutics, Inc.(3)(14) 3611 Valley Centre Dr. Suite 500 San Diego, CA 92130		Drug Discovery & Development			Warrant				1.18	%		Common Stock			2,272,724				203				185
Melinta Therapeutics 300 TriState International Suite 272 Lincolnshire, IL 60069		Drug Discovery & Development			Warrant				0.49	%		Preferred Series 3			1,382,323				626				100
Nanotherapeutics, Inc.(14) 13859 Progress Blvd. Suite 300 Alachua, FL 32615		Drug Discovery & Development			Warrant				2.67	%		Common Stock			171,389				838				1,035
Neothetics, Inc. (p.k.a. Lithera, Inc)(3)(14) 9171 Towne Centre Drive Suite 270 San Diego, CA 92122		Drug Discovery & Development			Warrant				0.34	%		Common Stock			46,838				266				8
Neuralstem, Inc.(3)(14) 20271 Goldenrod Lane 2nd floor Germantown, MD 20876		Drug Discovery & Development			Warrant				0.08	%		Common Stock			75,187				77				10
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)(14) 75 Park Plaza 4th Floor Boston, MA 02116		Drug Discovery & Development			Warrant				0.12	%		Common Stock			21,467				129				20
uniQure B.V.(3)(4)(9) Tafelbergweg 51 Amsterdam, The Netherlands 1105 BD		Drug Discovery & Development			Warrant				0.15	%		Common Stock			37,174				218				105
XOMA Corporation(3)(9)(14) 2910 Seventh Street Berkeley, CA 94710		Drug Discovery & Development			Warrant				0.15	%		Common Stock			181,268				279				53
Subtotal: Drug Discovery & Development (0.44%)*																			7,086				3,143
Electronics & Computer Hardware
Clustrix, Inc. 201 Mission Street Suite 800 San Francisco, CA 94105		Electronics & Computer Hardware			Warrant				0.23	%		Common Stock			50,000				12				—

 

138

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)				Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Persimmon Technologies 200 Harvard Mill Square Suite 110 Wakefield, MA 01880		Electronics & Computer Hardware			Warrant				0.62	%		Preferred Series C			43,076			$	40			$	67
Subtotal: Electronics & Computer Hardware (0.01%)*																			52				67
Healthcare Services, Other
Chromadex Corporation(3)(9)(14) 10005 Muirlands Boulevard Suite G, First Floor Irvine, CA 92618		Healthcare Services, Other			Warrant				1.16	%		Common Stock			419,020				157				201
Subtotal: Healthcare Services, Other (0.03%)*																			157				201
Information Services
Cha Cha Search, Inc.(14)		Information Services			Warrant				0.21	%		Preferred Series G			48,232				58				—
14550 Clay Terrace Blvd. Suite 130 Carmel, IN 46032
INMOBI Inc.(4)(9)		Information Services			Warrant				0.11	%		Common Stock			46,874				82				—
475 Brannan St, Suite 410 San Francisco, CA 94107
InXpo, Inc.(14) 770 N Halsted Street Suite 6s Chicago, IL 60642		Information Services			Warrant				0.59	%		Preferred Series C			648,400				98				2
		Information Services			Warrant				1.07	%		Preferred Series C-1			1,165,183				74				2
Total InXpo, Inc.															1,813,583				172				4
RichRelevance, Inc.(14)		Information Services			Warrant				0.13	%		Preferred Series E			112,612				98				—
633 Folsom Street 4th Floor
San Francisco, CA 94107
Subtotal: Information Services (0.00%)*																			410				4
Internet Consumer & Business Services
Aria Systems, Inc. 575 Market Street, 10th Floor San Francisco, CA 94105		Internet Consumer & Business Services			Warrant				0.12	%		Preferred Series E			239,692				73				74
Blurb, Inc.(14) 580 California St Suite 300 San Francisco, CA 94104		Internet Consumer & Business Services			Warrant				0.45	%		Preferred Series C			234,280				636				130
CashStar, Inc.(14) 25 Pearl Street Portland, ME 04101		Internet Consumer & Business Services			Warrant				0.44	%		Preferred Series C-2			727,272				130				37
CloudOne, Inc. 8626 E 116th Street Suite 300 Fishers, IN 46038		Internet Consumer & Business Services			Warrant				0.64	%		Preferred Series E			968,992				19				19
Just Fabulous, Inc. 2301 Rosecrans Avenue Suite 5000 El Segundo, CA 90245		Internet Consumer & Business Services			Warrant				0.39	%		Preferred Series B			206,184				1,102				1,417
Lightspeed POS, Inc.(4)(9) 700 St-Antoine Est Suite 300 Montreal, Canada H2Y1A6		Internet Consumer & Business Services			Warrant				0.10	%		Preferred Series C			245,610				20				67
LogicSource(14) 20 Marshall Street Sourth Norwalk, CT 06854		Internet Consumer & Business Services			Warrant				0.41	%		Preferred Series C			79,625				30				55
Oportun (p.k.a. Progress Financial) 1600 Seaport Blvd. Suite 250 Redwood City, CA 94063		Internet Consumer & Business Services			Warrant				0.07	%		Preferred Series G			174,562				78				134
Prism Education Group, Inc.(14) 3 Executive Campus Suite 280 Cherry Hill, NJ 08002		Internet Consumer & Business Services			Warrant				0.81	%		Preferred Series B			200,000				43				—

 

139

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Percentage Ownership				Series		Shares				Cost(2)				Value(3)
ReachLocal(3) 21700 Oxnard St Suite 1600 Woodland Hills, CA 91367		Internet Consumer & Business Services		Warrant			1.00	%		Common Stock			300,000			$	155			$	315
ShareThis, Inc.(14) 4005 Miranda Avenue Suite 100 Palo Alto, CA 94304		Internet Consumer & Business Services		Warrant			0.93	%		Preferred Series C			493,502				547				127
Tapjoy, Inc. 111 Sutter Street 12th Floor San Francisco, CA 94104		Internet Consumer & Business Services		Warrant			0.41	%		Preferred Series D			748,670				316				198
Tectura Corporation 951 Old County Road Suite 2-317 Belmont, CA 94002		Internet Consumer & Business Services		Warrant			0.52	%		Preferred Series B-1			253,378				51				—
Subtotal: Internet Consumer & Business Services (0.36%)*																	3,200				2,573
Media/Content/Info
Machine Zone, Inc. 1050 Page Mill Road Palo Alto, CA 94304		Media/ Content/Info		Warrant			0.13	%		Common Stock			155,271				1,959				2,822
Rhapsody International, Inc.(14) 701 5th Ave Suite 3100 Seattle, WA 98104		Media/ Content/Info		Warrant			0.58	%		Common Stock			715,755				384				221
WP Technology, Inc. (Wattpad, Inc.) (4) 4950 Yonge Street Suite 801 Toronto, Canada M2N 6K1		Media/ Content/Info		Warrant			0.06	%		Common Stock			127,909				1				1
Zoom Media Group, Inc. 345 7th Avenue Suite 1501 New York, NY 10001		Media/ Content/Info		Warrant			0.45	%		Preferred Series A			1,204				348				18
Subtotal: Media/Content/Info (0.43%)*																	2,692				3,062
Medical Devices & Equipment
Amedica Corporation(3)(14) 1885 West 2100 South Salt Lake City, UT 84119		Medical Devices & Equipment		Warrant			0.90	%		Common Stock			103,225				459				65
Aspire Bariatrics, Inc.(14) 3200 Horizon Drive Suite 100 King of Prussia, PA 19406		Medical Devices & Equipment		Warrant			0.90	%		Preferred Series D			395,000				455				220
Avedro, Inc.(14) 230 Third Avenue Waltham, MA 02451		Medical Devices & Equipment		Warrant			1.37	%		Preferred Series AA			300,000				401				128
Flowonix Medical Incorporated 500 International Drive Suite 200 Mount Olive, NJ 07828		Medical Devices & Equipment		Warrant			0.52	%		Preferred Series E			110,947				203				450
Gamma Medica, Inc. 12 Manor Parkway Unit 3 Salem, NH 3079		Medical Devices & Equipment		Warrant			1.27	%		Preferred Series A			357,500				170				183
Gelesis, Inc. (1419)		Medical Devices & Equipment		Warrant			0.49	%		Preferred Series A-1			74,784				78				336
500 Boylston Street Suite 1600 Boston, MA 02116
InspireMD, Inc.(3)(4)(9) 4 Menorat Hamaor Street Tel Aviv, Israel 67448		Medical Devices & Equipment		Warrant			0.16	%		Common Stock			16,835				242				—
Medrobotics Corporation(14) 475 Paramount Drive Raynham, MA 02767		Medical Devices & Equipment		Warrant			0.45	%		Preferred Series E			455,539				370				232

 

140

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Micell Technologies, Inc. 801 Capitola Drive Suite 1 Durham, NC 27713		Medical Devices & Equipment		Warrant			0.46	%		Preferred Series D-2			84,955			$	262			$	280
NetBio, Inc. 266 Second Avenue Waltham, MA 02451		Medical Devices & Equipment		Warrant			0.86	%		Common Stock			2,568				408				17
NinePoint Medical, Inc.(14) 1 Kendall Square B7501 Cambridge, MA 02139		Medical Devices & Equipment		Warrant			0.34	%		Preferred Series A-1			587,840				170				67
Novasys Medical, Inc. 39684 Eureka Drive Newark, CA 94560		Medical Devices & Equipment		Warrant			0.04	%		Common Stock			109,449				2				—
		Medical Devices & Equipment		Warrant			0.19	%		Preferred Series D			526,840				125				—
		Medical Devices & Equipment		Warrant			0.02	%		Preferred Series D-1			53,607				6				—
Total Novasys Medical, Inc.													689,896				133				—
Optiscan Biomedical, Corp.(5)(14) 24590 Clawiter Road Hayward, CA 94545		Medical Devices & Equipment		Warrant			1.21	%		Preferred Series D			10,535,275				1,252				256
Oraya Therapeutics, Inc. 7999 Gateway Blvd Suite 100 Newark, CA 94560		Medical Devices & Equipment		Warrant			0.00	%		Common Stock			954				66				—
		Medical Devices & Equipment		Warrant			1.53	%		Preferred Series 1			1,632,084				676				57
Total Oraya Therapeutics, Inc.													1,633,038				742				313
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.) 1830 Bering Drive San Jose, CA 95112		Medical Devices & Equipment		Warrant			0.54	%		Preferred Series A			500,000				402				243
Quanterix Corporation 113 Hartwell Avenue Lexington, MA 02421		Medical Devices & Equipment		Warrant			0.31	%		Preferred Series C			173,428				180				144
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)		Medical Devices & Equipment		Warrant			0.02	%		Preferred Series A			6,464				188				—
10130 Perimeter Parkway Suite 250 Charlotte, NC 28216
Strata Skin Sciences, Inc. (p.k.a. MELA Sciences, Inc.)(3)		Medical Devices & Equipment		Warrant			0.66	%		Common Stock			69,320				402				—
100 Lakeside Drive Suite 100 Horsham, PA 19044
ViewRay, Inc.(3)(14) 815 E. Middlefield Rd Mountain View, CA 94043		Medical Devices & Equipment		Warrant			0.34	%		Common Stock			128,231				333				30
Subtotal: Medical Devices & Equipment (0.38%)*																	6,850				2,708
Semiconductors
Achronix Semiconductor Corporation(14)		Semiconductors		Warrant			0.18	%		Preferred Series C			360,000				160				18
2953 Bunker Hill Lane Suite 101 Santa Clara, CA 95054
		Semiconductors		Warrant			0.24	%		Preferred Series D-1			500,000				6				4
Total Achronix Semiconductor Corporation													860,000				166				22
Aquantia Corp.		Semiconductors		Warrant			0.07	%		Preferred Series G			196,831				4				38
105 E. Tasman Drive San Jose, CA 95134
Avnera Corporation		Semiconductors		Warrant			0.29	%		Preferred Series E			141,567				47				67
1600 NW Compton Drive Ste 300. Beaverton, OR 97006
Subtotal: Semiconductors (0.02%)*																	217				127

 

141

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Percentage Ownership				Series		Shares				Cost(2)				Value(3)
Software
Actifio, Inc.		Software		Warrant			0.08	%		Common Stock			73,584			$	249			$	190
333 Wyman Street, Waltham Waltham, MA 2451		Software		Warrant			0.03	%		Preferred Series F			31,673				343				343
Total Actifio, Inc.													105,257				592				533
Braxton Technologies, LLC		Software		Warrant			0.63	%		Preferred Series A			168,750				188				—
6 North Tejon Street Suite 200 Colorado Springs, CO 80903
CareCloud Corporation(14)		Software		Warrant			0.93	%		Preferred Series B			413,433				258				609
5200 Blue Lagoon Drive, Suite 900 Miami, FL 33126
Clickfox, Inc.(14)		Software		Warrant			1.48	%		Preferred Series B			1,038,563				330				193
3445 Peachtree Road Suite 450 Atlanta, GA 30326		Software		Warrant			0.84	%		Preferred Series C			592,019				730				161
		Software		Warrant			0.07	%		Preferred Series C-A			46,109				13				9
Total Clickfox, Inc.													1,676,691				1,073				363
Hillcrest Laboratories, Inc.(14) 15245 Shady Grove Road Suite 400 Rockville, MD 20850		Software		Warrant			0.70	%		Preferred Series E			1,865,650				55				183
JumpStart Games, Inc. (p.k.a Knowledge Holdings, Inc.)(14)		Software		Warrant			0.46	%		Preferred Series E			614,333				16				—
21250 Hawthorne Boulevard Suite 380 Torrance, CA 90503
Message Systems, Inc.(14)		Software		Warrant			1.21	%		Preferred Series C			503,718				334				434
9130 Guilford Road Columbia, MD 21046
Mobile Posse, Inc.(14)		Software		Warrant			1.08	%		Preferred Series C			396,430				130				80
1320 Old Chain Bridge Rd Suite 240 McLean, VA 22101
Neos, Inc.(14)		Software		Warrant			0.11	%		Common Stock			221,150				22				110
6210 Stoneridge Mall Suite 450
Pleasanton, CA 94588
NewVoiceMedia Limited(4)(9)		Software		Warrant			0.10	%		Preferred Series E			225,586				33				28
Belvedere, Basing View Basingstoke, UK RG21 4NG
OneLogin, Inc.(14)		Software		Warrant			0.45	%		Common Stock			228,972				150				148
150 Spear Street Suite 1400 San Francisco, CA 94105
Poplicus, Inc.(14)		Software		Warrant			0.54	%		Preferred Series C			2,595,230				—				98
542 Brannan Street San Francisco, CA 94107
Signpost, Inc.(14)		Software		Warrant			0.88	%		Preferred Series C			324,005				314				305
333 Hudson Street New York, NY 10014
Soasta, Inc.(14)		Software		Warrant			0.39	%		Preferred Series E			410,800				691				273
444 Castro Street 4th Floor Mountain View, CA 94041
Sonian, Inc.(14)		Software		Warrant			0.52	%		Preferred Series C			185,949				106				26
3 Allied Drive Suite 155 Dedham, MA 02026
Touchcommerce, Inc.(14)		Software		Warrant			1.52	%		Preferred Series E			2,282,968				446				575
29903 Agoura Road Agoura Hills, CA 91301
Subtotal: Software (0.52%)*																	4,408				3,765

 

142

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Percentage Ownership		Series		Shares				Cost(2)				Value(3)
Specialty Pharmaceuticals
Alimera Sciences, Inc.(3) 6120 Windward Parkway Suite 290 Alpharetta, GA 30005		Specialty Pharmaceuticals		Warrant		1.92%		Common Stock			862,069			$	729			$	313
QuatRx Pharmaceuticals Company 777 East Eisenhower Parkway Suite 100 Ann Arbor, MI 48108		Specialty Pharmaceuticals		Warrant		0.15%		Preferred Series E			155,324				307				—
Subtotal: Specialty Pharmaceuticals (0.04%)*															1,036				313
Surgical Devices
Gynesonics, Inc.(14) 301 Galveston Drive Redwood City, CA 94063		Surgical Devices		Warrant		0.04%		Preferred Series C			180,480				75				8
		Surgical Devices		Warrant		0.34%		Preferred Series D			1,575,965				320				200
Total Gynesonics, Inc.											1,756,445				395				208
Transmedics, Inc.		Surgical Devices		Warrant		0.10%		Preferred Series B			40,436				224				—
200 Minuteman Road Suite 302 Andover, MA 01810		Surgical Devices Surgical Devices		Warrant Warrant		0.42% 0.04%		Preferred Series D Preferred Series F			175,000 16,476				100 3				121 2
Total Transmedics, Inc.											231,912				327				123
Subtotal: Surgical Devices (0.05%)*															722				331
Sustainable and Renewable Technology
Agrivida, Inc.(14) 200 Boston Avenue Medford, MA 02155		Sustainable and Renewable Technology		Warrant		0.63%		Preferred Series D			471,327				120				79
Alphabet Energy, Inc.(14) 26225 Eden Landing Road Suite D Hayward, CA 94545		Sustainable and Renewable Technology		Warrant		0.30%		Preferred Series A			86,329				82				149
American Superconductor Corporation(3) 64 Jackson Rd Devens, MA 01434		Sustainable and Renewable Technology		Warrant		0.42%		Common Stock			58,823				39				103
Brightsource Energy, Inc. 1999 Harrison Street Suite 2150 Oakland, CA 94612		Sustainable and Renewable Technology		Warrant		0.22%		Preferred Series 1			116,667				104				7
Calera, Inc.(14) 485 Alberto Way#210 Los Gatos, CA 95032		Sustainable and Renewable Technology		Warrant		0.17%		Preferred Series C			44,529				513				—
EcoMotors, Inc.(14) 17000 Federal Dr. Suite 200 Allen Park, MI 48101		Sustainable and Renewable Technology		Warrant		0.68%		Preferred Series B			437,500				308				134
Fluidic, Inc. 8455 North 90th Street Suite 4 Scottsdale, AZ 85258		Sustainable and Renewable Technology		Warrant		0.11%		Preferred Series D			61,804				102				38
Fulcrum Bioenergy, Inc. 4900 Hopyard Road Suite 220 Pleasanton, CA 94588		Sustainable and Renewable Technology		Warrant		0.25%		Preferred Series C-1			280,897				275				207
GreatPoint Energy, Inc.(14) 2215 W. Harrison St. Chicago, IL 60612		Sustainable and Renewable Technology		Warrant		0.12%		Preferred Series D-1			393,212				548				—
Polyera Corporation(14) 8045 Lamon Avenue#140 Skokie, IL 60077		Sustainable and Renewable Technology		Warrant		0.97%		Preferred Series C			311,609				338				12
Proterra, Inc. 1 Whitlee Ct. Greenville, SC 29607		Sustainable and Renewable Technology		Warrant		0.69%		Preferred Series 4			397,931				37				55

 

143

---

Table of Contents

Index to Financial Statements

Portfolio Company		Sub-Industry		Type of Investment(1)		Percentage Ownership		Series		Shares				Cost(2)				Value(3)
Rive Technology, Inc.(14) 1 Deer Park Drive Suite A Monmouth Junction, NJ 08852		Sustainable and Renewable Technology		Warrant		0.38%		Preferred Series E			234,477			$	12			$	24
SCIEnergy, Inc. 4100 Alpha Road Suite 900 Dallas, TX 75244		Sustainable and Renewable Technology		Warrant		0.05%		Common Stock			530,811				181				—
		Sustainable and Renewable Technology		Warrant		0.00%		Preferred Series 2-A			6,229				50				—
Total SCIEnergy, Inc.											537,040				231				—
Solexel, Inc.(14) 1530 McCarthy Blvd. Milpitas, CA 95035		Sustainable and Renewable Technology		Warrant		0.54%		Preferred Series C			1,171,625				1,162				649
Stion Corporation (5) 6321 San Ignacio Avenue San Jose, CA 95119		Sustainable and Renewable Technology		Warrant		7.89%		Preferred Series Seed			2,154				1,378				—
Sungevity, Inc. 66 Franklin Street Suite 310 Oakland, CA 94607		Sustainable and Renewable Technology		Warrant		0.49%		Common Stock			20,000,000				543				763
		Sustainable and Renewable Technology		Warrant		0.79%		Preferred Series C			32,472,222				902				807
Total Sungevity, Inc.											52,472,222				1,445				1,570
TAS Energy, Inc. 6110 Cullen Blvd. Houston, TX 77021		Sustainable and Renewable Technology		Warrant		0.10%		Preferred Series AA			428,571				299				—
Tendril Networks 2580 55th Street Suite 100 Boulder, CO 80301		Sustainable and Renewable Technology		Warrant		0.50%		Preferred Series 3-A			1,019,793				189				208
TPI Composites, Inc. 8501 N Scottsdale Rd Gainey Center II, Suite 280 Scottsdale, AZ 85253		Sustainable and Renewable Technology		Warrant		0.64%		Preferred Series B			160				273				108
Trilliant, Inc.(14) 1100 Island Drive#201 Redwood City, CA 94065		Sustainable and Renewable Technology		Warrant		0.13%		Preferred Series A			320,000				162				51
Subtotal: Sustainable and Renewable Technology (0.47%)*															7,617				3,394
Total: Warrant Investments (3.27%)*															42,419				23,496
Total Investments (179.75%)*														$	1,344,325			$	1,291,310

 

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $24.3 million, $77.2 million and $52.9 million respectively. The tax cost of investments is $1.3 billion.

(3)

Except for warrants in 37 publicly traded companies and common stock in 20 publicly traded companies, all investments are restricted at March 31, 2016 and were valued at fair value as determined in good faith by the Company’s board of directors (the “Board of Directors”). No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Non-U.S. company or the company’s principal place of business is outside the United States.

(5)	Affiliate investment as defined under the Investment Company Act of 1940, as amended, (the “1940 Act”) in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.

(6)	Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. There were no control investments at March 31, 2016.

(7)	Debt is on non-accrual status at March 31, 2016, and is therefore considered non-income producing.

(8)	Denotes that all or a portion of the debt investment is convertible debt.

 

144

---

Table of Contents

Index to Financial Statements

(9)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(10)	Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).

(11)	Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility (as defined in Note 4).

(12)	Denotes that all or a portion of the debt investment principal includes accumulated PIK, or payment-in-kind, interest and is net of repayments.

(13)	Denotes that all or a portion of the debt investment includes an exit fee receivable. This fee ranges from 1.0% to 19.4% of the total debt commitment based on the contractual terms of our loan servicing agreements.

(14)	Denotes that all or a portion of the investment in this portfolio company is held by Hercules Technology II, L.P., or HT II, or Hercules Technology III, L.P., or HT III, the Company’s wholly-owned SBIC subsidiaries.

(15)

The stated ‘maturity date’ for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company’s investment team and Investment Committee continue to closely monitor developments at the borrower company.

(16)	Repayment of debt investment is delinquent of the contractual maturity date.

 

145

---

Table of Contents

Index to Financial Statements

SENIOR SECURITIES

Information about our senior securities is shown in the following table for the periods as of December 31, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007 and 2006 and as of March 31, 2016. The information as of December 31, 2015, 2014, 2013, 2012, 2011 and 2010 has been derived from our audited financial statements for these periods, which have been audited by PricewaterhouseCoopers LLP, our independent registered public accounting firm. The report of PricewaterhouseCoopers LLP on the senior securities table as of December 31, 2015 is attached as an exhibit to the registration statement of which this prospectus is a part. The “—” indicates information that the SEC expressly does not require to be disclosed for certain types of senior securities.

 

Class and Year		Total Amount Outstanding Exclusive of Treasury Securities(1)				Asset Coverage per Unit(2)				Average Market Value per Unit(3)
Securitized Credit Facility with Wells Fargo Capital Finance
December 31, 2006		$	41,000,000			$	7,230				N/A
December 31, 2007		$	79,200,000			$	6,755				N/A
December 31, 2008		$	89,582,000			$	6,689				N/A
December 31, 2009(6)			—				—				N/A
December 31, 2010(6)			—				—				N/A
December 31, 2011		$	10,186,830			$	73,369				N/A
December 31, 2012(6)			—				—				N/A
December 31, 2013(6)			—				—				N/A
December 31, 2014(6)			—				—				N/A
December 31, 2015		$	50,000,000			$	26,352				N/A
December 31, 2016 (as of March 31, 2016, unaudited)		$	61,003,303			$	21,800				N/A
Securitized Credit Facility with Union Bank, NA
December 31, 2009(6)			—				—				N/A
December 31, 2010(6)			—				—				N/A
December 31, 2011(6)			—				—				N/A
December 31, 2012(6)			—				—				N/A
December 31, 2013(6)			—				—				N/A
December 31, 2014(6)			—				—				N/A
December 31, 2015(6)			—				—				N/A
December 31, 2016 (as of March 31, 2016, unaudited)(6)			—				—				N/A
Small Business Administration Debentures (HT II)(4)
December 31, 2007		$	55,050,000			$	9,718				N/A
December 31, 2008		$	127,200,000			$	4,711				N/A
December 31, 2009		$	130,600,000			$	3,806				N/A
December 31, 2010		$	150,000,000			$	3,942				N/A
December 31, 2011		$	125,000,000			$	5,979				N/A
December 31, 2012		$	76,000,000			$	14,786				N/A
December 31, 2013		$	76,000,000			$	16,075				N/A
December 31, 2014		$	41,200,000			$	31,535				N/A
December 31, 2015		$	41,200,000			$	31,981				N/A
December 31, 2016 (as of March 31, 2016, unaudited)		$	41,200,000			$	32,278				N/A
Small Business Administration Debentures (HT III)(5)
December 31, 2010		$	20,000,000			$	29,564				N/A
December 31, 2011		$	100,000,000			$	7,474				N/A
December 31, 2012		$	149,000,000			$	7,542				N/A
December 31, 2013		$	149,000,000			$	8,199				N/A
December 31, 2014		$	149,000,000			$	8,720				N/A
December 31, 2015		$	149,000,000			$	8,843				N/A
December 31, 2016 (as of March 31, 2016, unaudited)		$	149,000,000			$	8,925				N/A

 

146

---

Table of Contents

Index to Financial Statements

Class and Year		Total Amount Outstanding Exclusive of Treasury Securities(1)				Asset Coverage per Unit(2)				Average Market Value per Unit(3)
Senior Convertible Notes
December 31, 2011		$	75,000,000			$	10,623			$	885
December 31, 2012		$	75,000,000			$	15,731			$	1,038
December 31, 2013		$	75,000,000			$	16,847			$	1,403
December 31, 2014		$	17,674,000			$	74,905			$	1,290
December 31, 2015		$	17,604,000			$	74,847			$	1,110
December 31, 2016 (as of March 31, 2016, unaudited)(9)		$	17,604,000			$	75,543			$	1,086
April 2019 Notes
December 31, 2012		$	84,489,500			$	13,300			$	986
December 31, 2013		$	84,489,500			$	14,460			$	1,021
December 31, 2014		$	84,489,500			$	15,377			$	1,023
December 31, 2015		$	64,489,500			$	20,431			$	1,017
December 31, 2016 (as of March 31, 2016, unaudited)		$	64,489,500			$	20,621			$	1,024
September 2019 Notes
December 31, 2012		$	85,875,000			$	13,086			$	1,003
December 31, 2013		$	85,875,000			$	14,227			$	1,016
December 31, 2014		$	85,875,000			$	15,129			$	1,026
December 31, 2015		$	45,875,000			$	28,722			$	1,009
December 31, 2016 (as of March 31, 2016, unaudited)		$	45,875,000			$	28,989			$	1,013
2024 Notes
December 31, 2014		$	103,000,000			$	12,614			$	1,010
December 31, 2015		$	103,000,000			$	12,792			$	1,014
December 31, 2016 (as of March 31, 2016, unaudited)(10)		$	103,000,000			$	12,911			$	1,005
2017 Asset-Backed Notes
December 31, 2012		$	129,300,000			$	8,691			$	1,000
December 31, 2013		$	89,556,972			$	13,642			$	1,004
December 31, 2014		$	16,049,144			$	80,953			$	1,375
December 31, 2015			—				—				—
December 31, 2016 (as of March 31, 2016, unaudited)			—				—				—
2021 Asset-Backed Notes
December 31, 2014		$	129,300,000			$	10,048			$	1,000
December 31, 2015		$	129,300,000			$	10,190			$	996
December 31, 2016 (as of March 31, 2016, unaudited)		$	129,300,000			$	10,285			$	991
Total Senior Securities(7)
December 31, 2006		$	41,000,000			$	7,230				N/A
December 31, 2007		$	134,250,000			$	3,985				N/A
December 31, 2008		$	216,782,000			$	2,764				N/A
December 31, 2009		$	130,600,000			$	3,806				N/A
December 31, 2010		$	170,000,000			$	3,478				N/A
December 31, 2011		$	310,186,830			$	2,409				N/A
December 31, 2012		$	599,664,500			$	1,874	(8)			N/A
December 31, 2013		$	559,921,472			$	2,182				N/A
December 31, 2014		$	626,587,644			$	2,073				N/A
December 31, 2015		$	600,468,500			$	2,194				N/A
December 31, 2016 (as of March 31, 2016, unaudited)		$	611,471,803			$	2,175				N/A

 

(1)	Total amount of each class of senior securities outstanding at the end of the period presented.

(2)

The asset coverage ratio for a class of senior securities representing indebtedness is calculated as our consolidated total assets, less all liabilities and indebtedness not represented by senior securities, including senior securities not subject to asset coverage requirements under the 1940 Act due to exemptive relief from the SEC, divided by senior securities representing indebtedness. This asset coverage ratio is multiplied by $1,000 to determine the Asset Coverage per Unit.

 

147

---

Table of Contents

Index to Financial Statements

(3)	Not applicable because senior securities are not registered for public trading.

(4)	Issued by HT II, one of our SBIC subsidiaries, to the SBA. These categories of senior securities were not subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by the SEC.

(5)	Issued by HT III, one of our SBIC subsidiaries, to the SBA. These categories of senior securities were not subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by the SEC.

(6)	The Company’s Wells Facility and Union Bank Facility had no borrowings outstanding during the periods noted above.

(7)

The total senior securities and Asset Coverage per Unit shown for those securities do not represent the asset coverage ratio requirement under the 1940 act because the presentation includes senior securities not subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by the SEC. As of March 31, 2016 our asset coverage ratio under our regulatory requirements as a business development company was 270.5% excluding our SBA debentures as a result of our exemptive order from the SEC which allows us to exclude all SBA leverage from our asset coverage ratio.

(8)

As noted in footnote 7 above, the total senior securities and Asset Coverage per Unit shown does not represent the asset coverage ratio requirement under the 1940 Act because the presentation includes senior securities not subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by the SEC. Including our SBA debentures, in accordance with our exemption order from the SEC, our asset coverage ratio as of December 31, 2012 was 296.8%.

(9)

The Convertible Senior Notes were convertible into shares of the Company’s common stock beginning October 15, 2015 until the close of business on the scheduled trading day immediately preceding the April 15, 2016 maturity date. Subsequent to March 31, 2016, approximately $17.4 million of the Convertible Senior Notes were converted pursuant to the conversion procedures as set forth in the indenture governing the Convertible Senior Notes and were settled in April 2016 with a combination of cash equal to the outstanding principal amount of the converted notes and approximately 137,854 shares of the Company’s common stock. The remaining Convertible Senior Notes outstanding were fully repaid at maturity on April 15, 2016.

(10)	On May 2, 2016, the Company closed an underwritten public offering of an additional $72.9 million in aggregate principal amount of its 6.25% unsecured notes due 2024 (the “Additional 2024 Notes”)

 

148

---

Table of Contents

Index to Financial Statements

MANAGEMENT

Our business and affairs are managed under the direction of our Board of Directors. Our Board of Directors elects our officers who serve at the discretion of the Board of Directors. Our Board of Directors currently consists of seven members, one who is an “interested person” of the Company as defined in Section 2(a)(19) of the 1940 Act and five who are not interested persons and who we refer to as our independent directors.

Directors, Executive Officers and Key Employees

Our executive officers, directors and key employees and their positions are set forth below. The address for each executive officer, director and key employee is c/o Hercules Capital, Inc., 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301.

 

Name		Age				Positions
Interested Director:
Manuel A. Henriquez(1)			51			Chairman of the Board of Directors, President and Chief Executive Officer
Independent Directors:
Robert P. Badavas			62			Director
Allyn C. Woodward, Jr.			74			Director
Thomas J. Fallon			54			Director
Dr. Rodney A. Ferguson, Ph.D			59			Director
Susanne D. Lyons			58			Director
Joseph F. Hoffman			66			Director
Executive Officers:
Mark Harris			45			Chief Financial Officer and Chief Accounting Officer
Melanie Grace			46			General Counsel and Chief Compliance Officer
Scott Bluestein			37			Chief Investment Officer
Andrew Olson			32			Controller

 

(1)	Mr. Henriquez is an interested person, as defined in section 2(a)(19) of the 1940 Act, of the Company due to his position as an executive officer of the Company.

Set forth below is information regarding our current directors, including each director’s (i) name and age; (ii) a brief description of their recent business experience, including present occupations and employment during at least the past five years; (iii) directorships, if any, that each director holds and has held during the past five years; and (iv) the year in which each person became a director of the Company. As the information that follows indicates, the nominee and each continuing director brings strong and unique experience, qualifications, attributes, and skills to the Board of Directors. This provides the Board of Directors, collectively, with competence, experience, and perspective in a variety of areas, including: (i) corporate governance and Board service; (ii) executive management, finance, and accounting; (iii) venture capital financing with a technology-related focus; (iv) business acumen; and (v) an ability to exercise sound judgment.

Moreover, the nominating and corporate governance committee believes that it is important to seek a broad diversity of experience, professions, skills, geographic representation and backgrounds. The nominating and corporate governance committee does not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees. We believe that the backgrounds and qualifications of the directors, considered as a group, should provide a significant composite mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Our Board of Directors does not have a specific diversity policy, but considers diversity of race, religion, national origin, gender, sexual orientation, disability, cultural background and professional experiences in evaluating candidates for Board membership.

 

149

---

Table of Contents

Index to Financial Statements

For each director, we have highlighted certain key areas of experience that qualify him or her to serve on the Board of Directors in each of their respective biographies below.

 

Name, Address, and Age(1)		Position(s) held with Company		Term of Office and Length of Time Served		Principal Occupation(s) During Past 5 Years		Other Directorships Held by Director or Nominee for Director During the past 5 years(2)
Independent Directors
Susanne D. Lyons (59)		Director		Class I Director since 2015		Retired. Chief Marketing Officer, VISA from 2005-2007.		None.
Robert P. Badavas (63)		Director		Class I Director since 2006		Chairman and Chief Executive Officer of PlumChoice, provider of remote technical services and support, since December 2011; President, Petros Ventures, Inc., a private venture investing and management advisory firm, from 2009-2011.		Constant Contract, Inc., an online marketing company, from 2007-2016.
Thomas J. Fallon (54)		Director		Class II Director since 2014		Chief Executive Officer of Infinera Corporation, manufacturer of high capacity optical transmission equipment, since 2010;		Infinera Corporation since 2014.
Allyn C. Woodward, Jr. (75)		Director		Class II Director since 2004		Retired. Vice Chairman and Director of Adams Harkness Financial Group, an institutional investment bank, from 2001-2006.		None.
Joseph F. Hoffman (67)		Director Nominee		Class IIII Director since 2015		Retired. SEC Reviewing Partner and Silicon Valley Professional for KPMG from 1998-2009.		None.
Rodney A. Ferguson (59)		Director		Class III Director since 2015		Panorama Capital, a life sciences venture capital firm, since 2006.		None.
Interested Director
Manuel A. Henriquez (52)(3)		Director Nominee Chief Executive Officer and Chairman of the Board of Directors		Class III since 2004		Hercules Capital, Inc. since 2004.		None.

 

(1)	The address for each officer and director is c/o Hercules Capital, Inc., 400 Hamilton Avenue., Suite 310, Palo Alto, California 94301.

(2)	No director otherwise serves as a director of an investment company subject to the 1940 Act.

(3)	Mr. Henriquez is an interested director due to his position as an officer of the Company.

 

150

---

Table of Contents

Index to Financial Statements

Interested Director

 

Manuel A. Henriquez		Board Committee:		Independent:
		N/A		No

Mr. Henriquez, age 52, is a co-founder of Hercules and has been our Chairman and Chief Executive Officer since 2004 and our President (since 2005).

 

Prior Business Experience:		•        Partner, VantagePoint Venture Partners, a $2.5 billion multi-stage technology venture fund (2000-2003) •        President and Chief Investment Officer, Comdisco Ventures, a division of Comdisco, Inc., a leading technology and financial services company (1999-2000) •        Managing Director, Comdisco Ventures (1997-1999) •        Senior Member, Investment Team, Comdisco Ventures (1997-2000)
Private Directorships/ Memberships:		•        Northeastern University, a global, experiential research university •        Lucile Packard Foundation for Children’s Health, the sole fundraising entity for Lucile Packard Children’s Hospital and the child health programs at Stanford University School of Medicine •        Children’s Health Council, a diagnostic and treatment center for children and adolescents facing developmental and behavioral challenges
Education:		•        Bachelor’s degree in Business Administration from Northeastern University
Skills/ Qualifications:		In particular, Mr. Henriquez’ key areas of skills/qualifications include, but are not limited to:   •        Client Industries—vast array of knowledge in venture capital financing, including software, life sciences and clean tech •        Banking/Financial Services—extensive experience with equity and debt financings as well SEC rules and regulations and business development companies •        Leadership/Strategy—current role as chairman and CEO as well as officer and director experience in several private and public companies and knowledge of financial risk assessment •        Finance/IT and Other Business Processes—extensive experience in IT and supervising IT internal control and procedures

 

151

---

Table of Contents

Index to Financial Statements

Independent Directors

 

Joseph F. Hoffman		Board Committee:		Independent:
		•       Nominating, Chair		Yes
		•       Audit

Mr. Hoffman, age 67, is retired from KPMG LLP after 26 years as a partner and senior executive with that firm. He has served as a director on our Board of Directors since April 2015.

 

Prior Business Experience:		•        SEC Reviewing Partner and Silicon Valley Professional Practice Partner, KPMG LLP (1998-2009) •        Audit Partner and Business Unit Partner in Charge, KPMG LLP (1983-1998)
Private Directorships:		•        LiveOps, Inc., a cloud based contact center (since 2013) •        KPMG LLP, an audit, tax, and advisory professional services firm. (2005-2009)
Audit Committees:		•        LiveOps, Inc. (since 2013) •        KPMG LLP (2005-2009) •        Willamette University (since 2014)
Non-Profit Leadership:		•        Board of Trustees, Willamette University (since 2011)
Memberships:		•        California Society of Certified Public Accountants •        National Association of Corporate Directors •        American College of Corporate Directors •        Association of Governing Boards of Universities and Colleges
Education:		•        Bachelor’s degree in Mathematics and Economics, Willamette University •        Master’s degree in Business Administration, Stanford Graduate School of Business •        Certified public accountant, State of California
Skills/ Qualifications:		In particular, Mr. Hoffman’s key areas of skill/qualifications include, but are not limited to:   •        Client Industries—extensive experience in the technology, manufacturing, and financial services industries •        Finance and Enterprise Risk Management—extensive experience as an advisor to senior management and audit committees on complex accounting, financial reporting, internal controls, and enterprise risk management •        Leadership/Strategy—significant experience as a business executive and director

 

152

---

Table of Contents

Index to Financial Statements

Allyn C. Woodward, Jr.		Board Committee:		Independent:
		•       Audit •       Compensation		Yes–Lead Director

Mr. Woodward, age 75, has extensive experience and qualifications in banking and financial services. He has served as a director on our Board of Directors since February 2004 and his term expires in 2018.

 

Business Experience:		•        Vice Chairman and Director, Adams Harkness Financial Group (formerly Adams, Harkness & Hill), an independent institutional research, brokerage and investment banking firm (2001-2006) •        President and Director, Adams Harkness Financial Group (1995-2001) •        Silicon Valley Bank •        Vice President, Founder, Wellesley, Massachusetts office •        Senior Vice President (1990-1992) •        Chief Operating Officer (California) (1992-1995) •        Senior Vice President and Group Manager of Technology Group, Bank of New England (1963-1990)
Private Directorships:		•        Union Specialties, manufacturer of waterbased polyurethane dispersions and specialty products
Current Advisory Board Directorships:		•        Fletcher Spaght Venture Capital •        Boston Millennia Partners •        Ampersand Venture Capital
Prior Directorships:		•        AH&H Venture Capital •        Square 1 Bank •        Lecroy Corporation, Chairman •        Viewlogic Systems •        Cayenne Software, Inc.
Non-Profit Leadership:		•        Member of Finance Committee and Board of Overseers, Newton Wellesley Hospital   •        Babson College, Member of: •        Investment Committee •        Finance Committee •        Private Equity Committee (co-founder)
Education:		•        Bachelor’s degree in Finance and Accounting from Babson College •        Banking degree, Stonier Graduate School of Banking at Rutgers University
Memberships		•        National Association of Corporate Directors •        Board Leaders Group
Certifications:		•        Executive Masters Professional Director Certification, American College of Corporate Directors
Skills/ Qualifications:		•        In particular, Mr. Woodward’s key areas of skill/qualifications include, but are not limited to: •        Client Industries and Banking/Financial Services—extensive leadership, management and director experience in financial services, banking and technology-related companies •        Leadership/Strategy—significant executive and board experience for both private and public companies in business, finance and investments with a special emphasis on best policies regarding compensation and governance and service as Lead Independent Director

 

153

---

Table of Contents

Index to Financial Statements

Robert P. Badavas		Board Committee:		Independent:
		•      Audit, Chair		Yes

Mr. Badavas, aged 63, currently serves as Chairman and Chief Executive Officer of PlumChoice, a venture-backed technology, software and services company (since December 2011). He has served as a director on our Board of Directors since March 2006 and his term expires in 2017.

 

Business Experience:		•        President, Petros Ventures, Inc., a management and advisory services firm (2009-2011) •        President and Chief Executive Officer of TAC Worldwide, a multi-national technical workforce management and business services company (2005-2009) •        Executive Vice President and Chief Financial Officer, TAC Worldwide (2003-2005) •        Senior Partner and Chief Operating Officer, Atlas Venture, an international venture capital firm (2001-2003) •        Chief Executive Officer at Cerulean Technology, Inc., a venture capital backed wireless application software company (1995-2001) •        Certified Public Accountant, PwC (1974-1983)
Public Directorships:		•        Constant Contact, Inc., including chairman of the audit committee, a provider of email and other engagement marketing products and services for small and medium sized organizations, acquired by Endurance International Group Holdings, Inc., (2007-2016)
Prior Directorships:		•        Arivana, Inc; a telecommunications infrastructure company—publicly traded until its acquisition by SAC Capital •        RSA Security; an IT security company—publicly traded until its acquisition by EMC •        On Technology; an IT software infrastructure company—publicly traded until its acquisition by Symantec •        Renaissance Worldwide; an IT services and solutions company—publicly traded until its acquisition by Aquent
Private Directorships:		•        PlumChoice (since 2010)
Other Experience:		•        Vice-Chairman, Board of Trustees. Bentley University (since 2005) •        Board of Trustees Executive Committee and Corporate Treasurer, Hellenic College/Holy Cross School of Theology, including positions on the executive committee and corporate treasurer (since 2000) •        Chairman Emeritus, The Learning Center for the Deaf (1995-2005) •        Professional Director Certification, American College of Corporate Directors •        National Association of Corporate Directors
Education:		•        Bachelor’s degree in Accounting and Finance from Bentley University
Skills/ Qualifications:		In particular, Mr. Badavas’ key areas of skill/qualifications include, but are not limited to:   •        Client Industries—extensive experience in software, business and technology enabled services and venture capital •        Leadership/Strategy—significant experience as a senior corporate executive in private and public companies, including tenure as chief executive officer, chief financial officer and chief operating officer •        Finance, IT and Other Business Strategy and Enterprise Risk Management—prior experience as a CEO directing business strategy and as a CFO directing IT, financing and accounting, strategic alliances and human resources and evaluation of enterprise risk in such areas •        Governance—extensive experience as an executive and director of private and public companies with governance matters

 

154

---

Table of Contents

Index to Financial Statements

Thomas J. Fallon		Board Committee:		Independent:
		•      Nominating		Yes

Mr. Fallon, aged 54, currently serves as Chief Executive Officer of Infinera Corporation (since 2010) and a member of Infinera’s board of directors (since 2009). He has served as a director on our Board of Directors since July 2014 and his term expires in 2018.

 

Infinera Corporation Experience:		•        President and Chief Executive Officer, Infinera Corporation (2010-Current) •        Chief Operating Officer, Infinera Corporation (2006-2009) •        Vice President of Engineering and Operations, Infinera Corporation (2004-2006)
Other Business Experience		•        Vice President, Corporate Quality and Development Operations of Cisco Systems, Inc. (2003-2004) •        General Manager of Cisco Systems’ Optical Transport Business Unit, VP Operations, VP Supply, various executive positions (1991-2003)
Private Directorships:		•        Piccaro, a leading provider of solutions to measure greenhouse gas concentrations, trace gases and stable isotopes (since 2010)
Other Experience:		•        Member, Engineering Advisory Board of the University of Texas at Austin •        Member, President’s Development Board University of Texas
Education:		•        Bachelor’s degree in Mechanical Engineering from the University of Texas at Austin •        Master’s degree in Business Administration from the University of Texas at Austin
Skills/ Qualifications:		In particular, Mr. Fallon’s key areas of skill/qualifications include, but are not limited to:   •        Client Industries—significant experience in venture capital and technology •        Banking/Finance services—experience in finance and audit functions •        Leadership/Strategy—extensive experience as a director and executive in both public and private companies •        Enterprise Risk Management—experience in managing enterprise risk •        Governance—experienced in both corporate governance and executive compensation for both public and private companies

 

155

---

Table of Contents

Index to Financial Statements

Rodney A. Ferguson, Ph.D.		Board Committee:		Independent:
		•      None		Yes

Dr. Ferguson, age 59, is a co-founder of Panorama Capital, a venture capital firm that spun off from JPMorgan Partners, where he focuses primarily on life science investments (since 2006). He has served as a director on our board since July 2015.

 

Prior Business Experience:		•        Managing Director, JPMorgan Partners, life sciences venture practice (2001-2006) •        Partner, InterWest Partners, a venture capital firm, where he focused on life sciences investments (1999-2001) •        Various management positions, Genentech, Inc., most recently as Senior Director of Business and Corporate Development responsible for worldwide licensing transactions for both technology and pharmaceutical products (1988-1999) •        Associate, McCutchen, Doyle, Brown & Enersen (1984-1988)
Private Directorships:		•        Itero BioPharmaceuticals, Inc. (since 2008) CardioKinetix, Inc. (since 2008) Alvine Pharmaceuticals, Inc. (since 2013)
Advisory:		•        Locust Walk Partners Advisory Board (since 2014)
Education:		•        Bachelor’s degree in Biochemistry from the University of Illinois •        Doctorate degree in Biochemistry from the State University of New York at Buffalo •        Juris Doctor from Northwestern University
Skills/ Qualifications:		In particular, Dr. Ferguson’s key areas of skills/qualifications include, but are not limited to:   •        Client Industries—vast knowledge and experience in the life sciences industry •        Leadership/Strategy—senior management and director experience in private companies •        Banking/Financial Services—significant experience in venture capital financings, particularly in life sciences

 

156

---

Table of Contents

Index to Financial Statements

Susanne D. Lyons		Board Committee:		Independent:
		•      Compensation, Chair		Yes
		•      Nominating

Ms. Lyons, aged 59, is a retired senior executive who has held top marketing and general management roles at some of the largest financial services companies in America. She has served as a director on our Board of Directors since March 2015 and her term expires in 2017.

 

Prior Business Experience:		•        Chief Marketing Officer, VISA (USA) (2004-2007) •        Various marketing and general management positions, including enterprise president of retail client service, Charles Schwab & Co., Inc. (1992-2001) •        Chief Marketing Officer, Charles Schwab & Co., Inc. (2000-2001) •        Senior positions in marketing, product development and business strategy, Fidelity Investments (1982-1992)
Private Directorships:		•        U.S. Olympic Committee (since December 2010) •        Wildcare, a non-for-profit organization (since 2008)
Prior Directorships:		•        CNET Networks until its acquisition by CBS Corp. (2007-2008) •        Gain Capital Holdings, Inc. (2008-2013)
Other Experience:		•        Advisory Board, Marketo, Inc., a marketing automation software company (2008-2011)
Education:		•        Bachelor’s degree in French from Vassar College •        Master’s degree in Business Administration from Boston University
Skills/ Qualifications:		In particular, Ms. Lyon’s key areas of skill/qualifications include, but are not limited to:   •        Banking/Financial Services—held a variety of key executive and management positions at large global financial institutions, including 1940-Act regulated companies •        Leadership/Strategy—extensive experience as a director and executive with broad operational experience in investments, finance, human resources, and marketing •        Human Resources—expertise in Human Resources, including extensive experience in public company compensation governance •        Governance—experienced executive and director for public companies, including extensive experience in public company compensation and governance

 

157

---

Table of Contents

Index to Financial Statements

Executives

Our executive officers perform policy-making functions for us within the meaning of applicable SEC rules. They may also serve as officers of our other subsidiaries. There are no family relationships among our directors or executive officers.

The following information outlines the name and age of our executive officers (as of the date of this prospectus) and his or her principal occupation with the Company, followed by the biographical information of each of such executive officer:

 

Name		Age				Principal Occupation
Manuel A. Henriquez			52			Chairman and Chief Executive Officer
Mark R. Harris			45			Chief Financial Officer and Chief Accounting Officer
Scott Bluestein			37			Chief Investment Officer
Melanie Grace			47			General Counsel, Chief Compliance Officer and Secretary
Andrew Olson			33			Controller

Executive Biographies

Mr. Manuel A. Henriquez’ biography can be found under “Interested Director” above.

Mark Harris joined us in 2015 as Chief Financial Officer and Chief Accounting Officer. Mr. Harris has over 20 years of experience working with public companies, as well as the mezzanine and direct lending space. Mr. Harris oversees the financial and accounting functions of the Company.

 

Other Prior Experience		•        Chief Financial Officer, Asia Strategy and Senior Managing Director/Head of Asia, Avenue Capital, where he lead the Asia strategy (2007-2015) •        Corporate Financial Controller, Hutchinson Capital (2004-2006) •        Vice President of Finance, Vsource (2001-2004) •        Manager, Global Capital Markets Group, PricewaterhouseCoopers (1995-2001)
Education/Other:		•        Master’s of Business Administration from the University of Chicago, Booth School of Business •        Bachelor’s in Business Administration with an emphasis in Accounting from California Polytechnic State University, San Luis Obispo •        Active Certified Public Accountant in California •        Member, Foundation Board of California Polytechnic State University, San Luis Obispo

Scott Bluestein joined us in 2010 as Chief Credit Officer. He was promoted to Chief Investment Officer in 2014. Mr. Bluestein is responsible for managing the investment teams and investments made by the Company.

 

Other Prior Experience		•        Founder and Partner, Century Tree Capital Management (2009-2010) •        Managing Director, Laurus-Valens Capital Management, an investment firm specializing in financing small and microcap growth-oriented businesses through debt and equity securities (2003-2010) •        Member of Financial Institutions Coverage Group focused on Financial Technology, UBS Investment Bank (2000-2003)
Education/Other:		•        Bachelor’s in Business Administration from Emory University

 

158

---

Table of Contents

Index to Financial Statements

Melanie Grace joined us in 2015 as General Counsel, Chief Compliance Officer and Secretary. She has over 15 years of experience representing public and private companies in securities, compliance and transactional matters. Ms. Grace oversees the legal and compliance function for the Company and serves as secretary for the Company and select subsidiaries.

 

Other Prior Experience		•        Chief Legal Officer and Corporate Secretary, WHV Investments, Inc. where she also served as interim Chief Compliance Officer (2011-2015) •        Member, Management, Operations and Proxy Committees, WHV Investments, Inc. (2013-2015) •        Chair, Ethics Committee, WHV Investments, Inc. (2013-2015) •        Chief Counsel, Corporate, NYSE Euronext (2005-2008) •        Associate, Fenwick & West LLP (2000-2005)
Education/Other:		•        Bachelor’s and Master’s in History from the University of California, Riverside •        Juris Doctor from Boston University School of Law •        Member, State Bar of California •        Designated Investment Adviser Certified Compliance Professional®

Andrew Olson joined us in 2014 as Corporate Controller. He has served as our Interim Chief Financial Officer (June 9, 2015 to August 1, 2015). Currently, Mr. Olson is our Vice President of Finance and Senior Controller and is responsible for financial and regulatory reporting, financial planning and analysis, and financial systems design and implementation.

 

Other Prior Experience		•        Senior Manager in Financial Services practice of PricewaterhouseCoopers, LLP San Francisco and Hong Kong where he developed extensive experience providing audit and consulting services to both regional and international institutions (2006-2014)
Education/Other:		•        Bachelor’s in Business Economics from the University of California •        Active Certified Public Accountant in California

Board of Directors

The number of directors is currently fixed at seven directors.

Our Board of Directors is divided into three classes. Class I directors hold office for a term expiring at the annual meeting of stockholders to be held in 2017, Class II directors hold office for a term expiring at the annual meeting of stockholders to be held in 2018 and Class III directors hold office for a term expiring at the annual meeting of stockholders to be held in 2019. Each director holds office for the term to which he or she is elected and until his or her successor is duly elected and qualifies. Messrs. Woodward and Fallon’s terms expire in 2018, Messrs. Henriquez, Ferguson and Hoffman’s terms expire in 2019 and Mr. Badavas and Ms. Lyons’ terms expire in 2017. At each annual meeting of our stockholders, the successors to the class of directors whose terms expire at such meeting will be elected to hold office for a term expiring at the annual meeting of stockholders held in the third year following the year of their election and until their successors are duly elected and qualify.

 

159

---

Table of Contents

Index to Financial Statements

CORPORATE GOVERNANCE

Our business, property and affairs are managed under the direction of our Board of Directors. Members of our Board of Directors are kept informed of our business through discussions with our chairman and chief executive officer, our chief financial officer, our chief investment officer, our secretary, and our other officers and employees, and by reviewing materials provided to them and participating in meetings of our Board of Directors and its committees.

Because our Board of Directors is committed to strong and effective corporate governance, it regularly monitors our corporate governance policies and practices to ensure we meet or exceed the requirements of applicable laws, regulations and rules, and the NYSE’s listing standards. The Board of Directors has approved corporate governance guidelines that provide a framework for the operation of the Board of Directors and address key governance practices. The Board of Directors has adopted a number of policies to support our values and good corporate governance, including corporate governance guidelines, Board of Directors’ committee charters, insider trading policy, code of ethics, code of business conduct and ethics, and related person transaction approval policy.

During 2015, as part of its on-going review of our corporate governance policies, our Board of Directors undertook the following relating to our corporate governance practices:

 

•

reviewed our compliance manual and made changes, where required, with the approval of our Board of Directors; and

 

•

as a result of the ongoing plan to integrate our comprehensive compliance program, conducted training sessions in 2015 to remind employees of their obligations as employees and officers of a business development company and the specific policies and procedures that have been designed by us to reasonably ensure that the our employees are in compliance with federal securities laws and other laws.

Our Board of Directors will continue to review and update the corporate governance guidelines, corporate governance practices, and our corporate governance framework, including the potential expansion of the size of our Board of Directors.

Board Leadership Structure

Chairman and Chief Executive Officer

Our Board of Directors currently combines the role of chairman of the Board of Directors with the role of chief executive officer, coupled with a lead independent director position to further strengthen our governance structure. Our Board of Directors believes this provides an efficient and effective leadership model for our company. Combining the chairman and chief executive officer roles fosters clear accountability, effective decision-making, and alignment on corporate strategy. Since 2004, Mr. Henriquez has served as both chairman of the Board of Directors and as our chief executive officer. Mr. Henriquez is an interested director.

No single leadership model is right for all companies at all times. Our Board of Directors recognizes that depending on the circumstances, other leadership models, such as a separate independent chairman of the Board of Directors, might be appropriate. Accordingly, our Board of Directors periodically reviews its leadership structure.

Moreover, our Board of Directors believes that its governance practices provide adequate safeguards against any potential risks that might be associated with having a combined chairman and chief executive officer. Specifically:

 

•

six of our seven current directors are independent directors;

 

160

---

Table of Contents

Index to Financial Statements

•

all of the members of our Audit Committee, Compensation Committee, and NCG Committee are independent directors;

 

•

our Board of Directors and its committees regularly conduct scheduled meetings in executive session, out of the presence of Mr. Henriquez and other members of management;

 

•

our Board of Directors and its committees regularly conduct meetings which specifically include Mr. Henriquez;

 

•

our Board of Directors and its committees remain in close contact with, and receive reports on various aspects of Hercules’s management and enterprise risk directly from our senior management and independent auditors.

Lead Independent Director

Our Board of Directors has instituted the lead independent director position to provide an additional measure of balance, ensure our Board of Directors’ independence, and enhance its ability to fulfill its management oversight responsibilities. Allyn C. Woodward, Jr. currently serves as our lead independent director. The lead independent director:

 

•

presides over all meetings of the independent directors at which our chairman is not present, including executive sessions of the independent directors;

 

•

has the authority to call meetings of the independent directors;

 

•

frequently consults with our chairman and chief executive officer about strategic policies;

 

•

provides our chairman and chief executive officer with input regarding Board of Directors meetings;

 

•

serves as a liaison between the chairman and chief executive officer and the independent directors; and

 

•

otherwise assumes such responsibilities as may be assigned to him by the independent directors.

Having a combined chairman and chief executive officer, coupled with a substantial majority of independent, experienced directors, including a lead independent director with specified responsibilities on behalf of the independent directors, provides the right leadership structure for our company and is best for us and our stockholders at this time.

Board Oversight of Risk

While risk management is primarily the responsibility of our management team, our Board of Directors is responsible for oversight of the material risks faced by us at both the full board level and at the committee level.

Our Audit Committee has oversight responsibility not only for financial reporting with respect to our major financial exposures and the steps management has taken to monitor and control such exposures, but also for the effectiveness of management’s enterprise risk management process that monitors and manages key business risks facing our company. In addition to our Audit Committee, the other committees of our Board of Directors consider the risks within their areas of responsibility. For example, our Compensation Committee considers the risks that may be posed by our executive compensation program.

Management provides regular updates throughout the year to our Board of Directors regarding the management of the risks they oversee at each regular meeting of our Board of Directors. Also, our Board of Directors receives presentations throughout the year from various department and business group heads that include discussion of significant risks as necessary. Additionally, our full Board of Directors reviews our short and long-term strategies, including consideration of significant risks facing our business and their potential impact.

 

161

---

Table of Contents

Index to Financial Statements

During 2015, in addition to unanimous written consents, the Board of Directors held the following meetings:

 

Type of Meeting		Number
Regular Meetings to address regular, quarterly business matters			4
Other Meetings to address business matters that arise between quarters			10

Each director makes a diligent effort to attend all Board of Directors and committee meetings, as well as our annual meeting of stockholders. All directors attended at least 75% of the aggregate number of meetings of the Board of Directors and of the respective committees on which they served. Each of our then-serving directors attended our 2015 annual meeting of stockholders in person

Board Committees

Our Board of Directors has established an Audit Committee, a Compensation Committee, and a NCG Committee. A brief description of each committee is included in this prospectus and the charters of the Audit, Compensation, and NCG Committees are available on the Investor Relations section of our website at http://investor.htgc.com/corporate-governance.cfm.

As of the date of this prospectus, the members of each of our Board of Directors committees are as follows (the names of the respective committee chairperson are bolded):

 

Audit		Compensation		Nominating and Governance
Robert Badavas Joseph Hoffman Allyn Woodward, Jr.		Susanne Lyons Allyn Woodward, Jr.		Joseph Hoffman Susanne Lyons Thomas Fallon

Each of our directors who sits on a committee satisfies the independence requirements for purposes of the rules promulgated by the NYSE and the requirements to be a non-interested director as defined in Section 2(a)(19) of the 1940 Act. Messrs. Badavas and Hoffman, Chairman and member of the Audit Committee, respectively, are each an “audit committee financial expert” as defined by applicable SEC rules.

Committee Governance

Each committee is governed by a charter that is approved by the Board of Directors, which sets forth each committee’s purpose and responsibilities. The Board of Directors reviews the committees’ charters, and each committee reviews its own charter, on at least an annual basis, to assess the charters’ content and sufficiency, with final approval of any proposed changes required by the full Board of Directors.

Committee Responsibilities and Meetings

The key oversight responsibilities of the Board of Directors committees, and the number of meetings held by each committee during 2015, are as follows:

 

Audit Committee		Number of meetings held in 2015:    5

 

•

Appointing, overseeing and replacing, if necessary, our independent auditor.

 

•

Overseeing the accounting and financial reporting processes and the integrity of the financial statements.

 

•

Establishing procedures for complaints relating to accounting, internal accounting controls or auditing matters.

 

•

Examining the independence qualifications of our auditors.

 

162

---

Table of Contents

Index to Financial Statements

•

Assisting our Board of Directors’ oversight of our compliance with legal and regulatory requirements and enterprise risk management.

 

•

Assisting our Board of Directors in fulfilling its oversight responsibilities related to the systems of internal controls and disclosure controls which management has established regarding finance, accounting, and regulatory compliance.

 

•

Reviewing and recommending to the Board of Directors the valuation of the Company’s portfolio.

 

Compensation Committee		Number of meetings held in 2015:    7

 

•

Oversees our overall compensation strategies, plans, policies and programs.

 

•

The approval of director and executive compensation.

 

•

The assessment of compensation-related risks.

 

Nominating and Corporate Governance Committee		Number of meetings held in 2015:    2

 

•

Our general corporate governance practices, including review of our Corporate Governance Guidelines.

 

•

The annual performance evaluation of our Board of Directors and its committees.

 

•

The identification and nomination of director candidates.

 

•

Succession planning for management.

 

•

Criteria considered by the NCG Committee in evaluating qualifications of individuals for election as members of the Board of Directors consist of the independence and other applicable NYSE corporate governance requirements; the 1940 Act and all other applicable laws, rules, regulations and listing standards; and the criteria, polices and principles set forth in the NCG Committee charter.

 

•

Considers nominees properly recommended by a stockholder. Nominations for directors may be made by stockholders if notice is timely given and if the notice contains the information required in our Bylaws. Except as noted below, to be timely, proposals and nominations of stockholders must be delivered to our secretary no earlier than November 30, 2016 and not later than 5:00 p.m., Eastern Time, on December 30, 2016. Proposals must comply with the other requirements contained in our Bylaws, including supporting documentation and other information.

Director Independence

The NYSE’s listing standards and Section 2(a)(19) of the 1940 Act require that a majority of our Board of Directors and every member of our Audit, Compensation, and NCG Committees are “independent.” Under the NYSE’s listing standards and our corporate governance guidelines, no director will be considered to be independent unless and until our Board of Directors affirmatively determines that such director has no direct or indirect material relationship with our company or our management. Our Board of Directors reviews the independence of its members annually.

In determining that Ms. Lyons and Messrs. Badavas, Woodward, Fallon, Ferguson and Hoffman are independent, our Board of Directors, through the NCG Committee, considered the financial services, commercial, family and other relationships between each director and his or her immediate family members or affiliated entities, on the one hand, and Hercules and its subsidiaries, on the other hand.

 

163

---

Table of Contents

Index to Financial Statements

Communication with the Board

We believe that communications between our Board of Directors, our stockholders and other interested parties are an important part of our corporate governance process. Stockholders with questions about Hercules are encouraged to contact our Investor Relations department at (650) 289-3060. However, if stockholders believe that their questions have not been addressed, they may communicate with our Board of Directors by sending their communications to Hercules Capital, Inc., c/o Melanie Grace, Secretary, 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301. All stockholder communications received in this manner will be delivered to one or more members of our Board of Directors.

Mr. Woodward currently serves as the lead independent director, and he presides over executive sessions of the independent directors. Parties may communicate directly with Mr. Woodward by sending their communications to Hercules Capital, Inc., c/o Melanie Grace, Secretary at the above address. All communications received in this manner will be delivered to Mr. Woodward.

All communications involving accounting, internal accounting controls and auditing matters, possible violations of, or non-compliance with, applicable legal and regulatory requirements or our code of ethics, or retaliatory acts against anyone who makes such a complaint or assists in the investigation of such a complaint, will be referred to Melanie Grace, Secretary. The communication will be forwarded to the chair of our Audit Committee if our secretary determines that the matter has been submitted in conformity with our whistleblower procedures or otherwise determines that the communication should be so directed.

The acceptance and forwarding of a communication to any director does not imply that the director owes or assumes any fiduciary duty to the person submitting the communication, all such duties being only as prescribed by applicable law.

Code of Business Conduct and Ethics

Our code of business conduct and ethics requires that our directors and executive officers avoid any conflict, or the appearance of a conflict, between an individual’s personal interests and the interests of Hercules. Pursuant to our code of business conduct and ethics, which is available on our website at http://investor.htgc.com/corporate-governance.cfm, each director and executive officer must disclose any conflicts of interest, or actions or relationships that might give rise to a conflict, to our Audit Committee. Certain actions or relationships that might give rise to a conflict of interest are reviewed and approved by our Board of Directors.

Availability of Corporate Governance Documents

To learn more about our corporate governance and to view our corporate governance guidelines, code of business conduct and ethics, and the charters of our Audit Committee, Compensation Committee, and NCG Committee, please visit the Investor Relations page of our website at http://investor.htgc.com/corporate-governance.cfm, under “Corporate Governance.” Copies of these documents are also available in print free of charge by writing to Hercules Capital, Inc., c/o Melanie Grace, secretary, 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301.

Compensation Committee Interlocks and Insider Participation

All members of our Compensation Committee are independent directors and none of the members are present or past employees of the Company. No member of our Compensation Committee: (i) has had any relationship with the Company requiring disclosure under Item 404 of Regulation S-K under the Securities Exchange Act of 1934, as amended, referred to as the Exchange Act; or (ii) is an executive officer of another entity, at which one of our executive officers serves on our Board of Directors.

 

164

---

Table of Contents

Index to Financial Statements

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

The Compensation and Discussion Analysis discusses our 2015 executive compensation program, as it relates to the following executive officers:

 

Manuel A. Henriquez		Chairman of the Board of Directors and Chief Executive Officer (“CEO”)
Mark R. Harris		Chief Financial Officer (“CFO”)
Scott Bluestein		Chief Investment Officer
Melanie Grace		General Counsel, Chief Compliance Officer and Secretary
Andrew Olson		Controller
Jessica Baron		Former Chief Financial Officer1

 

1	Ms. Baron separated from employment with the Company on June 9, 2015.

We refer to Messrs. Henriquez, Harris, Bluestein and Olson and Ms. Grace as our “named executive officers,” or “NEOs” and Ms. Baron as our “former NEO”.

Executive Summary

Under the oversight of our Compensation Committee, the Company’s executive compensation program is designed to attract, incent and retain talented individuals who are critical to our continued success and our corporate growth and who will deliver sustained strong performance over the longer term. Our executive compensation program is designed to motivate the Company’s executive officers to maintain the financial strength of the Company while avoiding any inappropriate focus on short-term profits that would impede the Company’s long-term growth and encourage excessive risk-taking.

For 2015, the Company continued to review and enhance our compensation practices in accordance with our executive compensation philosophy with respect to company performance on a five-year period from 2011 to 2015 and relative peer performance on the one and three-year and occasionally five-year periods (the “Performance Periods”). (See “Compensation Philosophy and Objectives” below). The Company’s incentive compensation practices are significantly limited by the requirements imposed on us as an internally managed business development company pursuant to the 1940 Act. (See “Limitations Imposed by the 1940 Act Relating to Implementation of Non-Equity Incentive Plans” below). The Company believes that compensation paid to our NEOs for 2015 was commensurate with the Company’s overall absolute performance as well as our performance relative to peers during the relevant Performance Periods. As discussed further below, our NEOs were compensated to reflect the Company’s performance during the relevant Performance Periods (See “Performance Highlights and Assessment of Company Performance” below) as well as individual performance.

In addition to key factors involved in the 2015 decisions made by the Compensation Committee, we also discuss changes to our executive officer compensation program (See “2016 Changes to Executive Compensation” below). For example, we have enhanced and expanded the scope of our clawback policy to include all Section 16 officers, not only the CEO and CFO pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (See “Clawback Policy” below).

Further information relating to our financial performance during 2015 is provided in our annual report on Form 10-K for the fiscal year ending December 31, 2015. You are encouraged to read our 2015 annual report on Form 10-K.

 

165

---

Table of Contents

Index to Financial Statements

Compensation Philosophy and Objectives

As an internally managed business development company, the Company’s compensation program is designed to encourage the NEOs to think and act like stockholders. The structure of the NEOs’ compensation program is designed to encourage and reward the following factors, among other things:

 

•

sourcing and pursuing attractively priced investment opportunities to venture-backed companies;

 

•

achieving the Company’s dividend objectives (which focus on stability and potential growth);

 

•

maintaining credit quality, monitoring financial performance and ultimately managing a successful exit of the Company’s investment portfolio;

 

•

providing compensation and incentives necessary to attract, motivate and retain key executives critical to our continued success and growth;

 

•

focusing management behavior and decision-making on goals that are consistent with the overall strategy of the business;

 

•

ensuring a linkage between NEO compensation and individual contributions to our performance; and

 

•

risk management.

We believe that our continued success during 2015 was attributable to our ability to attract, motivate and retain the Company’s outstanding executive team through the use of both short- and long-term incentive compensation programs, especially in a difficult business environment and against strong competition for top-quality executive talent in the venture debt industry.

The Company’s compensation objectives are achieved through its executive compensation program, which for 2015 consisted of the following:

 

ELEMENTS OF EXECUTIVE COMPENSATION
Compensation Element		Form of Compensation		Compensation Objective
Annual Base Salary		Cash paid on a regular basis throughout the year		Provide a level of fixed income that is competitive to allow the Company to retain and attract executive talent
Annual Cash Bonus Awards		Cash awards paid on an annual basis following year-end		Reward NEOs who contribute to our financial performance and strategic success during the year, and reward individual achievements
Long-Term Equity Incentive Awards		Equity incentive awards vest 1/3 on a one-year cliff with remaining 2/3 vesting quarterly over two years based on continued employment with the Company		Reward NEOs who contribute to our success through the creation of shareholder value and to provide meaningful retention incentives, and reward individual achievements

 

166

---

Table of Contents

Index to Financial Statements

The compensation program is designed to reflect best practices in executive compensation:

 

2015 GOVERNANCE “BEST PRACTICES” HIGHLIGHTS OF EXECUTIVE COMPENSATION
No employment agreements for NEOs.		No cash severance payments.
No guaranteed retirement benefits.		No executive perquisite allowances beyond the benefit programs offered to all employees.
No tax gross ups for NEOs.		No repricing of stock options without stockholder approval, as required under applicable NYSE rules (and subject to other requirements under the 1940 Act).
Maintain stock ownership guidelines for NEOs to own at least two times his or her salary.		Routinely engage an independent compensation consultant to review NEO compensation.
Clawback policy for CEO and CFO pursuant to Section 304 of Sarbanes-Oxley of 2002.		No change in control benefits.
No pension.

Executive Compensation Governance

The Company’s executive compensation program is supported by strong corporate governance and Board-level oversight. The Compensation Committee provides primary oversight of our compensation programs, including the design and administration of executive compensation plans, assessment and setting of corporate performance, as well as individual performance, metrics, and the approval of executive compensation. In addition, the Compensation Committee retains an independent compensation consultant, and where appropriate, discusses compensation-related matters with our CEO, as it relates to the other NEOs. The Compensation Committee developed our 2015 compensation program, and the compensation paid to our NEOs during and in respect of 2015 was approved by the Compensation Committee as well as all of our independent directors.

 

•

Role of Compensation Committee: The Compensation Committee is comprised entirely of independent directors who are also non-employee directors as defined in Rule 16b-3 under the Exchange Act, independent directors as defined by the NYSE rules, and are not “interested persons” of the Company, as defined by Section 2(a)(19) of the 1940 Act. Ms. Lyons and Mr. Woodward comprise the Compensation Committee. Ms. Lyons chairs the Compensation Committee.

The Compensation Committee operates pursuant to a charter that sets forth its mission, specific goals and responsibilities. A key component of the Compensation Committee’s goals and responsibilities is to evaluate, approve and/or make recommendations to our Board of Directors regarding the compensation of our NEOs, and to review their performance relative to their compensation to assure that they are compensated in a manner consistent with the compensation philosophy discussed above. In addition, the Compensation Committee evaluates and makes recommendations to our Board of Directors regarding the compensation of the directors for their services. Annually, the Compensation Committee:

 

•

evaluates our CEO’s performance,

 

•

reviews our CEO’s evaluation of the other NEOs’ performance,

 

•

determines and approves the compensation paid to our CEO, and

 

•

with input from our CEO, reviews and approves the compensation of the other NEOs.

The Compensation Committee periodically reviews our compensation programs and equity incentive plans to ensure that such programs and plans are consistent with our corporate objectives and appropriately align our NEOs’ interests with those of our stockholders. The Compensation Committee also administers our stock incentive program. The Compensation Committee may not delegate its responsibilities discussed above.

 

167

---

Table of Contents

Index to Financial Statements

•

Role of Compensation Consultant: The Compensation Committee has engaged Frederic W. Cook & Co., Inc., or F.W. Cook, as an independent outside compensation consultant to assist the Compensation Committee and provide advice on a variety of compensation matters relating to CEO compensation, compensation paid to our other NEOs, peer group selection, compensation program design, market and industry compensation trends, director compensation levels and regulatory developments. F.W. Cook was hired by and reports directly to the Compensation Committee. Our compensation consultant does not provide any other services to the Company. The Compensation Committee has assessed the independence of F.W. Cook pursuant to the NYSE rules, and it has been concluded that the consultant’s work for the Compensation Committee does not raise any conflict of interest.

 

•

Role of Chief Executive Officer: From time to time and at the Compensation Committee’s request, our CEO will attend the Compensation Committee’s meetings to discuss the Company’s performance and compensation-related matters. Our CEO does not attend executive sessions of the Compensation Committee, unless invited by the Compensation Committee. While our CEO does not participate in any deliberations relating to his own compensation, our CEO reviews on at least an annual basis the performance of each of the other NEOs and other executive officers. Based on these performance reviews and the Company’s overall absolute and relative performance, our CEO makes recommendations to the Compensation Committee on any changes to base salaries, annual bonuses and equity awards. The Compensation Committee considers the recommendations submitted by our CEO, as well as data and analysis provided by management and F.W. Cook, but retains full discretion to approve and/or recommend for Board approval all executive and director compensation.

Competitive Benchmarking Against Peers

To determine the competitiveness of executive compensation levels, the Compensation Committee analyzes a group of internally and externally managed business development companies as set forth below (the “Peer Group”). However, the Compensation Committee does not specifically benchmark the compensation of our NEOs against that paid by other companies. Moreover, many of these entities do not publicly report the compensation of their executive officers nor do they typically report publicly information on their corporate performance. While various salary surveys from other private sources may become available to the Company with regard to these private entities, the Company believes that, among other reasons, without accurate, publicly disclosed information that would serve as benchmarks, it is not appropriate for the Company to set formal benchmarking procedures.

During 2015, the Compensation Committee, based on the advice of F.W. Cook, reviewed the peer group used in connection with prior compensation decisions. Based on this review, and the advice of F.W. Cook, the Compensation Committee updated our Peer Group to better align it to our business. Our Peer Group was used as a factor in determining the annual cash bonus awards made with respect to 2015 (but paid in 2016), along with the various performance metrics outlined below under “Performance Highlights and Assessment of Company Performance,” as well as the further considerations further described below under “Annual Cash Bonus Awards”. We emphasize that the list below is not one of exact peers. There are few internally managed business development companies and none of them are directly comparable to the Company in business strategies, assets under management, typical investment size and market capitalization. Items reviewed, among others, were certain corporate and executive performance measures established to achieve total returns for stockholders and our expense “efficiency ratio” compared to other business development companies in our Peer Group (which is calculated by taking total general and administrative expenses and dividing it by the company’s total revenue).

 

HERCULES PEER GROUP
Internally Managed BDCs		Externally Managed BDCs
American Capital		Apollo Investment		Ares Capital
KCAP Financial		BlackRock Kelso Capital		Fifth Street Finance
Main Street Capital		FS Investment Corporation		Goldman Sachs BDC
Triangle Capital		Golub Capital BDC		Medley Capital
		New Mountain Finance		PennantPark Investment
		Prospect Capital		Solar Capital
		TCP Capital		THL Credit
		TICC Capital		TPG Specialty

 

168

---

Table of Contents

Index to Financial Statements

The items taken into account by the Compensation Committee in relation to other internally managed business development companies include, but are not limited to, base compensation, bonus compensation, restricted stock awards, and other compensation. In relation to externally managed business development companies, fees charged, including the base management fee (1.375% to 2.00%), administration fee (if applicable), incentive fee (17.5% to 20.0%) and capital gains fee (17.50% to 20.0%), are also taken into consideration.

Limitations Imposed by the 1940 Act Relating to Implementation of Non-Equity Incentive Plans

We are an internally-managed, non-diversified, closed-end investment company that has elected to be regulated as a business development company under the 1940 Act. As a business development company, we are required to comply with certain regulatory requirements, including the 1940 Act Requirements. The 1940 Act Requirements provide that the Company may maintain either an equity incentive plan or a “profit sharing plan”. A “profit sharing plan” as defined under the 1940 Act is any written or oral plan, contract, authorization or arrangement, or any practice, understanding or undertaking whereby amounts payable under the compensation plan are dependent upon or related to the profits of the company. The SEC has stated that compensation plans possess profit-sharing characteristics if an investment company is obligated to make payments under such a plan based on the level of income, realized gains or loss on investments or unrealized appreciation or depreciation of assets of such investment company.

The Company believes that equity incentives strongly align the interests of our stockholders with our NEOs, and, accordingly, an equity incentive plan was adopted in 2004. Since the Company has adopted the 2004 equity incentive plan (the “Equity Plan”), the 1940 Act Requirements prohibit us from also implementing a “profit sharing plan”.

Why is this important to the Company’s executive compensation? The 1940 Act Requirements that restrict the Company to sponsoring either an equity incentive plan or a “profit sharing plan” limit the Company’s use of formulas or non-discretionary objective performance goals or criteria in its incentive plans. This means that the Compensation Committee is not permitted to use a nondiscretionary formulaic application of any performance criteria for corporate and individual goals to determine compensation. Rather, the Compensation Committee must take into consideration all factors and use its discretion to determine the appropriate amount of compensation for our NEOs. The Compensation Committee’s objective is to work within this regulatory framework to maintain and motivate pay-for-performance alignment, to establish appropriate compensation levels relative to our Peer Group and to implement compensation best practices.

2015 Advisory Vote on Executive Compensation

At our 2015 annual meeting of stockholders, our advisory vote on say-on-pay received support from our stockholders (approximately 58.8% of votes cast). In response to our 2014 and 2015 say-on-pay votes, the Company made certain structural changes to its compensation program. Please see “2016 Changes to Executive Compensation” below.

The Company believes that the continuing dialogue with our stockholders on company performance, compensation and other governance matters is important. In advance of our 2016 annual meeting of stockholders, management engaged in numerous direct dialogues with our largest institutional 4shareholders, as well as a number of other institutional shareholders, to gain broad-based and/or specific insights into the Company’s overall performance, operating expenses, including executive compensation and corporate governance practices. In addition, we invited each of our institutional stockholders holding more than 1% of the Company’s stock to speak directly with management specifically on executive compensation and corporate governance practices.

The Company anticipates continuing our stockholder engagement efforts following the 2016 annual meeting and in advance of our future annual meetings.

 

 

169

---

Table of Contents

Index to Financial Statements

Performance Highlights and Assessment of Company Performance

In determining the compensation for our NEOs, the Compensation Committee evaluates our performance relative to our Peer Group (See “Competitive Benchmarking Against Peers” above), as well as Company-specific absolute performance factors over the relevant Performance Periods. In 2015, relative and company-specific factors included:

 

		Metric		Performance Period Outcomes
				2015				2014				2013				2012				2011
Key Performance Indicators		Total of New Fundings (in $ millions)			712.3				621.3				500.7				554.9				449.9
		Total Investments at Cost (in $ millions)			1,252.3				1,035.3				906.3				914.3				656.5
		Net Interest Margin (in $ million)			120.2				108.1				104.6				73.8				64.0

 

 

 

•

Total New Fundings: Debt and equity fundings grew from $449.9 million in 2011 to $712.3 million in 2015 or a CAGR of 12.2%, as we continue to expand our origination team, increase our market share and organically grow our business via a record funding year for Hercules.

 

•

Total Investments: Total investments increased to $1,252.3 million in 2015 from $656.5 million in 2011, a CAGR of 14.9% due to record new fundings, combined with the monetization of our warrants and equity positions.

 

•

Net Interest Margin: We continue to grow our net interest margin due to strong portfolio growth and effectively managing our weighted average cost of debt.

 

		Metric		Performance Period Outcomes
				2015				2014				2013				2012				2011
Execution Across Performance Metrics		Liquidity Levels (in $ millions)			195.2				377.1				373.4				288.0				184.3
		Available Unfunded Commitments (in $ millions)			75.4				147.7				69.1				19.3				76.1
		Cumulative Net Realized Losses (in $ millions)			6.9				12.0				32.1				47.0				50.1
		Dividend Yield (%)(1)			10.2				8.3				6.8				8.5				9.3

 

170

---

Table of Contents

Index to Financial Statements

 

 

 

•

Liquidity Levels: The use of our credit facilities has been an integral component of our treasury management as we minimize our cash drag on our assets via the use of our warehouse facilities. These facilities have a low interest cost and allow us to build up our asset base for future offerings at competitive rates.

 

•

Available Unfunded Commitments: We have done an outstanding job on managing our Available Unfunded Commitments. Our Available Unfunded Commitments was 6.5% of our loan portfolio at the end of 2015, where as in 2014 it was 15.5%.

 

•

Cumulative Net Realized Losses: We continue to demonstrate strong credit management and nothing shows this more than our cumulative net loan losses, where we finished in 2015 at $6.9 million on commitments of $5.7 billion. In 2011, our cumulative net realized losses were $50.1 million since inception, demonstrating our ability to manage our portfolio effectively over the last 5 years.

 

•

Dividend Yield: We saw our Dividend Yield grow to 10.2% at the end of 2015, which is above our target of 6% and 8%. We believe that our continued strong performance will be recognized and our Dividend Yields will adjust to the range we believe is representative of our stock price.

 

(1)	Dividend Yield: Dividend Yield is a financial ratio that indicates the amount of dividends paid by the Company relative to its share price and is calculated as annual dividends per share divided by price per share as of measurement date.

 

171

---

Table of Contents

Index to Financial Statements

		Metric		Performance Period Outcomes
				2015								2014								2013
				HTGC				Peer Group(1)				HTGC				Peer Group				HTGC				Peer Group
Superior Relative Performance		Return on Average Assets (ROAA) excl. Cash			6.4	%			6.0	%			7.2	%			6.3	%			7.7	%			6.6	%
		Return on Average Equity (ROAE)			10.7	%			10.5	%			11.2	%			10.1	%			12.5	%			10.2	%
		Net Interest Margin % (NIM)			9.5	%			9.5	%			9.0	%			9.5	%			9.2	%			10.2	%
					Performance Period Outcomes
				1-Year								3-Year								5-Year
				HTGC				Peer Group				HTGC				Peer Group				HTGC				Peer Group
		Total Shareholder Return (TSR)(2)			-9.7	%			-2.1	%			41.8	%			-0.2	%			70.0	%			26.2	%

 

 

 

•

2015 Return on Average Assets (excl. cash): We exceeded the performance of 70% of our Peer Group by generating a 6.4% return on average assets (excl. cash).

 

•

2015 Return on Average Equity: We generated a 10.7% return on average equity, outperforming 55% of our Peer Group, while maintaining less leverage in relation to our peers.

 

•

Net Interest Margin: We improved net interest margin by 300 basis points from 2013 to 2015, in contrast to a 700 basis point decline in the median net interest margin of the Peer Group.

 

•

Three-Year and Five-Year Average Total Shareholder Return: We outperformed the majority of our Peer Group by generating an average total shareholder return of 41.8% compared to the peer group median of -0.2% over three years and 70.0% over 5 years compared to the peer group median of 26.2%.

 

(1)	Peer Group is defined in “Competitive Benchmarking Against Peers.”

(2)

Total Shareholder Return: Total Shareholder Return is a measure of shareholder performance over time and is calculated as the share price at the beginning of the performance period minus the share price at the end of such performance period plus dividends divided by the share price at the beginning of the performance period.

 

172

---

Table of Contents

Index to Financial Statements

Assessment of Company Performance

In determining annual compensation for our NEOs, the Compensation Committee analyzes and evaluates the individual achievements and performance of our NEOs as well as the overall relative and absolute operating performance and achievements of the Company. We believe that the alignment of (i) our business plan, (ii) stockholder expectations and (iii) our employee compensation is essential to long-term business success and the interests of our stockholders and employees and to our ability to attract and retain executive talent, especially in a competitive environment for top-quality executive talent in the venture debt industry. Our business plan involves taking on credit risk over an extended period of time, and a premium is placed on our ability to maintain stability and growth of NAVs as well as continuity of earnings growth to pass through to stockholders in the form of recurring dividends over the long term. Our strategy is to generate income and capital gains from our investments in the debt with warrant securities, and to a lesser extent direct equity, of our portfolio companies. This income supports the anticipated payment of dividends to our stockholders. Therefore, a key element of our return to stockholders is current income through the payment of dividends. This recurring payout requires a methodical asset acquisition analyses as well as highly active monitoring and management of our investment portfolio over time. To accomplish these functions, our business requires implementation and oversight by management and key employees with highly specialized skills and experience in the venture debt industry. A substantial part of our employee base is dedicated to the generation of new investment opportunities to allow us to sustain dividends and to the maintenance of asset values in our portfolio. In addition to the performance factors above, the Company considered the following Company-specific performance factors over the relevant Performance Periods: overall credit performance, performance against annual gross funding goals, overall yields, efficiency ratios, total and net investment income and realized and unrealized gains and losses.

Elements of Executive Compensation and 2015 Compensation Determinations

Base Salary

We believe that base salaries are a fundamental element of our compensation program. The Compensation Committee establishes base salaries for each NEO to reflect (i) the scope of the NEO’s industry experience, knowledge and qualifications, (ii) the NEO’s position and responsibilities and contributions to our business growth and (iii) salary levels and pay practices of those companies with whom we compete for executive talent.

The Compensation Committee considers base salary levels at least annually as part of its review of the performance of NEOs and from time to time upon a promotion or other change in job responsibilities. During its review of base salaries for our executives, the Compensation Committee primarily considers: individual performance of the executive, including leadership and execution of strategic initiatives and the accomplishment of business results for our company; market data provided by our compensation consultant; our NEOs total compensation, both individually and relative to our other NEOs; and for NEOs other than the CEO, the base salary recommendations of our CEO. Mr. Olson’s base salary was increased to $186,250 effective June 1, 2015, reflecting a $45,000 increase. Such increase was related to Mr. Olson’s assumption of additional responsibilities as well as service as Interim CFO after Jessica Baron left the Company.

 

NEO		2015 Base Salary(1)
Manuel Henriquez		$	779,762
Mark Harris		$	166,667
Scott Bluestein		$	420,000
Melanie Grace		$	79,167
Andrew Olson		$	186,250

 

(1)

Mr. Harris became employed by the Company on August 3, 2015. The base salary amount reported above reflects the base salary paid to Mr. Harris between August 3, 2015 and December 31, 2015. Ms. Grace became employed by the Company on September 17, 2015. The base salary amount reported above reflects the base salary paid to Ms. Grace between September 17, 2015 and December 31, 2015.

 

173

---

Table of Contents

Index to Financial Statements

Annual Cash Bonus Awards

The Compensation Committee, together with input from our CEO, developed a specific bonus pool for the 2015 operating year to be available for our annual cash bonus program. The amount determined to be available for our annual cash program was dependent upon many factors, including those outlined previously under “Performance Highlights and Assessment of Company Performance.”

The Compensation Committee designs our annual cash bonuses to motivate our NEOs to achieve financial and non-financial objectives consistent with our operating plan. The Compensation Committee generally targets cash bonuses to 50% to 100% of an NEO’s base salary; however, such bonus amounts may exceed these targets in the event of exceptional company and individual performance.

The Compensation Committee retains complete discretion in the sizing and awarding of cash bonuses for each NEO to ensure that individual bonus determinations appropriately balance the interests of our stockholders, while rewarding an NEO’s contributions to our performance. Accordingly, should actual company and NEO performance exceed expectations the Compensation Committee may adjust individual cash bonuses to take such superior performance into account. Conversely, if company and NEO performance is below expectations, the Compensation Committee will consider such performance in determining the NEO’s actual cash bonus.

In evaluating the performance of our NEOs to arrive at their 2015 cash bonus awards, the Compensation Committee considered the performance factor achievements discussed above under “Performance Highlights and Assessment of Company Performance,” and the Compensation Committee specifically compared our performance and the returns of our stockholders against the performance and shareholder returns of other business development companies.

When sizing our cash bonus pool and allocating bonus awards, the total compensation paid to our NEOs and other employees is evaluated against the expense ratios of other business development companies. With respect to 2015, company-wide compensation expense as a percentage of average assets among the peers in the Peer Group was considered. For the fiscal year ended December 31, 2015, the ratio of our compensation expense divided by total revenue was below the median of the our Peer Group.

Based on the foregoing considerations and analysis, and after due deliberation, the Compensation Committee awarded our current NEOs the following annual cash bonuses with respect to 2015.

 

NEO		2015 Cash Bonus Award(1)
Manuel Henriquez		$	1,000,000
Mark Harris		$	200,000
Scott Bluestein		$	525,000
Melanie Grace		$	50,000
Andrew Olson		$	195,000

 

(1)	Mr. Harris’ and Ms. Grace’s 2015 bonuses were paid on a prorated basis due to their August 3, 2015 and September 17, 2015 employment dates, respectively.

Long-Term Equity Incentive Compensation

2004 Equity Incentive Plan

Our long-term equity incentive compensation is designed to develop a strong linkage between pay and our strategic goals and performance, as well as to align the interests of our NEOs, and other executives and key employees, with those of our stockholders by awarding long-term equity incentives in the form of stock options and restricted stock. These awards are made pursuant to our Equity Plan, which permits both options and restricted stock awards.

 

174

---

Table of Contents

Index to Financial Statements

We believe that annual restricted stock awards to our NEOs are a critical part of our compensation program as they allow us to:

 

•

align our business plan, stockholder interests and employee concerns,

 

•

manage dilution associated with equity-based compensation,

 

•

match the return expectations of the business more closely with our equity-based compensation plan, and

 

•

retain key management talent.

We believe that restricted stock motivates performance that is more consistent with the type of return expectations that we have established for our stockholders. Accordingly, the Company awards restricted stock award grants to our NEOs. These awards, if granted, typically vest over three (3) years.

Grant Practices for Executive Officers

In 2015, the Compensation Committee and all independent directors of the Board of Directors approved restricted stock awards to executive officers and all newly-hired executive officers. Annual equity compensation grants to executive officers have typically been granted in the first quarter of the year. The Company does not grant stock options to executive officers. As a result, there were no option grants to our NEOs in 2015.

Restricted Stock Awards

In January 2016, the Compensation Committee assessed each current NEO’s individual performance for 2015, our overall company performance in 2015 (including the performance factors detailed above under “Performance Highlights and Assessment of Company Performance” and “Annual Cash Bonus Awards”) and the levels of equity compensation paid by other companies with whom we compete for executive talent. Based on this assessment, the Compensation Committee determined that the following restricted stock awards be made to our current NEOs with respect to 2015, in the amounts and on the dates set forth below to reward them for services performed in 2015. These restricted stock awards vest as to one-third of the shares underlying the awards on the first anniversary of the grant date, and they vest as to the remaining shares in equal quarterly installments over the next two years.

 

NEO		Grant Date				Restricted Stock Awards				Fair Value of Restricted Stock Awards(1)
Manuel Henriquez			1/10/2016				333,500			$	4,005,335
Scott Bluestein			1/10/2016				104,000			$	1,249,040
Mark Harris			1/10/2016				33,000			$	396,330
Melanie Grace			1/10/2016				9,400			$	112,894
Andrew Olson			1/10/2016				6,000			$	72,060

 

(1)	Based on the closing price per share of our common stock of $12.01 on January 8, 2016.

Other Elements of Compensation

 

•

Severance: No NEO or employee of the Company has a written severance agreement or other arrangement providing for payments or benefits upon a termination of employment.

 

•

Benefits and Perquisites: Our NEOs receive the same benefits and perquisites as other full-time employees. Our benefits program is designed to provide competitive benefits and is not based on performance. Our NEOs and other full-time employees receive health and welfare benefits, which consist of life, long-term and short-term disability, health, dental, vision insurance benefits and the opportunity to participate in our defined contribution 401(k) plan. During 2015, our 401(k) plan provided for a match of contributions by the company for up to $18,000 per full-time employee. Other than the benefits set forth immediately above, our NEOs are not entitled to any other benefits or perquisites.

 

175

---

Table of Contents

Index to Financial Statements

•

Potential Payments Upon Termination or Change of Control: No NEO or employee of the Company has a written employment agreement, or other agreement, providing for payments or other benefits in connection with a change of control of the Company. Further, no NEO or any other employee is entitled to any tax gross-up payments.

Pay-for-Performance Alignment

The Company believes that there exists an alignment between the compensation of our NEOs and our performance over the relevant Performance Periods. As noted above, a broad range of individual performance factors and company performance factors are analyzed each year, including total shareholder return and relative performance to our Peer Group. The objective in analyzing these key performance factors is to align NEO compensation to our performance relative to our Peer Group and our absolute corporate performance.

Finally, in measuring our relative performance for 2015 compensation decisions, the Compensation Committee considered several factors against our Peer Group, including return on average assets, return on average equity, net interest margin and total shareholder return.

The Company’s annual bonus and equity awards constitute an effective mix of short- and long-term compensation components and reflect key measures of our performance and the returns enjoyed by our stockholders. Consistent with our pay-for-performance philosophy, the Compensation Committee will make future compensation decisions taking into account our absolute and relative performance, and, if our future performance were to fall significantly below our peers, the Compensation Committee would consider adjusting NEO compensation prospectively.

Total Compensation Expense Relative to other Internally Managed BDCs

In determining annual bonus awards, the total compensation paid to our NEOs and other employees against the expense ratios of other internally managed business development companies was considered.

Internal Pay Equity Analysis

Our compensation program is designed with the goal of providing compensation to our NEOs that is fair, reasonable, and competitive. To achieve this goal, the Company believes it is important to compare compensation paid to each NEO not only with compensation in our comparative group companies, as discussed above, but also with compensation paid to each of our other NEOs. Such an internal comparison is important to ensure that compensation is equitable among our NEOs.

As part of the Compensation Committee’s review, we made a comparison of our CEO’s total compensation paid for the year ending December 31, 2015 against that paid to our other NEOs during the same year. Upon review, the Compensation Committee determined that our CEO’s compensation relative to that of our other NEOs was appropriate because of his level and scope of responsibilities, expertise and performance history, and other factors deemed relevant by the Compensation Committee. The Compensation Committee also reviewed the mix of the individual elements of compensation paid to our NEOs for this period, the individual performance of each NEO and any changes in responsibilities of the NEO.

Stock Ownership Guidelines

The Company maintains stock ownership guidelines, which are outlined in our corporate governance guidelines, because we believe that material stock ownership by our executives plays a role in effectively aligning the interests of these employees with those of our stockholders and strongly motivates our executives to build long-term shareholder value. Pursuant to our stock ownership guidelines, each member of senior management is required to beneficially own at least two times the individual’s annual salary in Company common stock, based on market value, within three years of joining the Company. Our Board of Directors may make exceptions to this requirement based on particular circumstances; however, no exceptions have been made for our current NEOs. Messrs. Henriquez and Bluestein have met their minimum guidelines as of April 15, 2016.

 

176

---

Table of Contents

Index to Financial Statements

Tax and Accounting Matters

Stock-Based Compensation. We account for stock-based compensation, including options and shares of restricted stock granted pursuant to our Equity Plan and 2006 Non-Employee Director Plan in accordance with the requirements of FASB ASC Topic 718. Under the FASB ASC Topic 718, we estimate the fair value of our option awards at the date of grant using the Black-Scholes-Merton option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates on the expected term, volatility and forfeiture rates of the awards. Forfeitures are not estimated due to our limited history but are reversed in the period in which forfeiture occurs. As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, are likely to change our valuation assumptions used to value stock-based awards granted in future periods. We estimate the fair value of our restricted stock awards based on the grant date market closing price.

Deductibility of Executive Compensation. When analyzing both total compensation and individual elements of compensation paid to our NEOs, the Company considers the income tax consequences to the Company of its compensation policies and procedures. In particular, the Company considers Section 162(m) of the Code, which limits the deductibility of non-performance-based compensation paid to certain of the NEOs to $1,000,000 per affected NEO. The Compensation Committee intends to balance its objective of providing compensation to our NEOs that is fair, reasonable, and competitive with the Company’s ability to claim compensation expense deductions. Our Board of Directors believes that the best interests of the Company and our stockholders are served by executive compensation programs that encourage and promote our principal compensation philosophy, enhancement of shareholder value, and permit the Compensation Committee to exercise discretion in the design and implementation of compensation packages. Accordingly, we may from time to time pay compensation to our NEOs that may not be fully tax deductible, including certain bonuses and restricted stock. Stock options granted under our stock plan are intended to qualify as performance-based compensation under Section 162(m) of the Code. The Company will continue to review its executive compensation plans periodically to determine what changes, if any, should be made as a result of any deduction limitations.

Clawback Policy

The Company has a clawback policy pursuant to Section 304 of the Sarbanes-Oxley Act. Section 304 of Sarbanes-Oxley Act requires our CEO and CFO to reimburse the Company for certain compensation and stock sale profits received if the Company is required to restate financial statements due to material noncompliance, as a result of misconduct, with any financial reporting requirement under the securities laws. Beginning in 2016, the Company has expanded this policy to include all Section 16 officers and made other changes to the policy as well (See “2016 Changes to Executive Compensation, below).

2016 Changes to Executive Compensation

In response to our 2014 and 2015 say-on-pay votes, the Compensation Committee consulted with our compensation consultant, F.W. Cook, to revise the Company’s 2016 executive compensation in order to alleviate stockholder concerns and more directly align all elements of NEO compensation to individual performance. The following changes will be implemented for 2016:

 

•

Clawback Policy for Section 16 Officers

With respect to the Company’s clawback policy, beginning in 2016, the Company has

 

•

broadened its clawback policy to apply to all Section 16 officers; and

 

•

broadened the scope of its clawback policy beyond financial restatements.

Pursuant to this expanded clawback policy, for payments that are predicated on financial results augmented by fraud, embezzlement, gross negligence or deliberate disregard of applicable rules resulting in significant

 

177

---

Table of Contents

Index to Financial Statements

monetary loss, damage or injury to the Company (“Excess Compensation”), the Compensation Committee has the authority to seek repayment of any Excess Compensation, including:

 

•

cancellation of unvested, unexercised or unreleased equity incentive awards; and

 

•

repayment of any compensation earned on previously exercised or released equity incentive awards

whether or not such activity resulted in a financial restatement. The Compensation Committee will have sole discretion under this policy, consistent with any applicable statutory requirements, to seek reimbursement of any Excess Compensation paid or received by the Section 16 officer or director for up to a 12-month period prior to the date of the Compensation Committee action to require reimbursement of the Excess Compensation. Any clawback of Excess Compensation must be based upon fraud adjudicated by a court of competent jurisdiction or a financial restatement. Further, following a restatement of our financial statements, we will recover any compensation received by the CEO and CFO that is required to be recovered by Section 304 of the Sarbanes-Oxley Act.

For purposes of this policy, Excess Compensation will be measured as the positive difference, if any, between the compensation earned by a Section 16 officer or director and the compensation that would have been earned by the Section 16 officer or director had the fraud, embezzlement, gross negligence or deliberate disregard of applicable rules resulting from significant monetary loss, damage or injury to the Company not occurred.

 

•

Corporate Goals (50% of Executive Officer Incentive Compensation)

For 2016, the Compensation Committee will develop corporate goals that must be achieved in order for all executive officers to receive up to 50% of their incentive compensation. These goals include operational performance as well as performance relative to the Company’s peer group. While the criteria may not be weighted, the Compensation Committee will take into consideration each of these factors to determine whether the executive officers are eligible for up to 50% of the proposed incentive compensation. The Compensation Committee believes that the corporate goals applicable to all executive officers create an alignment not only with shareholders but also to the Company’s business strategy and performance goals.

 

•

Defined Individual Goals (50% of Executive Officer Incentive Compensation)

For 2016, the Compensation Committee will develop individual goals for each executive officer based on conversations with both the CEO and the respective executive officer. Each set of individual goals will be unique to the executive officer’s responsibilities and position within the Company. While each of the factors may not be weighted, the Compensation Committee will take into consideration each of these factors to determine whether the executive officers are eligible for up to 50% of the executive officer’s incentive compensation.

Risk Assessment of the Compensation Programs

Our Board of Directors believe that risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on the Company. The Company has designed our compensation programs, including our incentive compensation plans, with specific features to address potential risks while rewarding employees for achieving long-term financial and strategic objectives through prudent business judgment and appropriate risk taking. We use common variable compensation designs, with a significant focus on individual contributions to our performance and the achievement of absolute and relative corporate objectives, as generally described in this Compensation Discussion and Analysis.

In view of the current economic and financial environment, the Compensation Committee and the Board of Directors reviewed our compensation programs to assess whether any aspect of the programs would encourage any of our employees to take any unnecessary or inappropriate risks that could threaten the value of the Company. The Company has designed our compensation programs to reward our employees for achieving annual profitability and long-terms increase shareholder value.

 

178

---

Table of Contents

Index to Financial Statements

Our Board of Directors recognizes that the pursuit of corporate objectives possibly leads to behaviors that could weaken the link between pay and performance, and, therefore, the correlation between the compensation delivered to employees and the long-term return realized by stockholders. Accordingly, our executive compensation program is designed to mitigate these possibilities and to ensure that our compensation practices are consistent with our risk profile. These features include the following:

 

•

bonus payouts and equity incentive awards that are not based solely on corporate performance objectives, but are also based on individual performance levels,

 

•

the financial opportunity in our long-term equity incentive program that is best realized through long-term appreciation of our stock price, which mitigates excessive short-term risk-taking,

 

•

annual cash bonuses that are paid after the end of the fiscal year to which the bonus payout relates,

 

•

the engagement and use of a compensation consultant,

 

•

the institution of stock ownership guidelines applicable to our executive officers, and

 

•

final decision making by our Compensation Committee and our Board of Directors on all awards.

Additionally, the Company performed an assessment of compensation-related risks for all of our employees. Based on this assessment, we concluded that our compensation programs do not create risks that are reasonably likely to have a material adverse effect on the Company. In making this evaluation, the Company reviewed the key design elements of our compensation programs in relation to industry “best practices,” as well as the means by which any potential risks may be mitigated. In addition, management completed an inventory of incentive programs below the executive level and reviewed the design of these incentives and concluded that such incentive programs do not encourage excessive risk-taking.

 

179

---

Table of Contents

Index to Financial Statements

EXECUTIVE COMPENSATION TABLES

Summary Compensation Table

 

Name and Principal Position		Year		Salary($)(1)				Bonus($)(2)				Stock Awards($)(3)				Option Awards($)(3)				All Other Compensation($)(4)				Total($)
Manuel Henriquez		2015		$	779,762			$	1,000,000			$	4,472,142							$	1,635,353			$	7,887,257
Chairman & Chief Executive Officer		2014		$	779,762			$	692,500			$	5,992,250				—			$	804,675			$	8,269,187
		2013		$	757,050			$	1,136,000			$	3,819,994				—			$	639,950			$	6,352,994
Mark R. Harris		2015		$	166,667			$	200,000			$	400,001				—			$	26,404			$	793,072
Chief Financial Officer
Scott Bluestein		2015		$	420,000			$	525,000			$	670,212							$	193,370			$	1,808,582
Chief Investment Officer		2014		$	420,000			$	233,750			$	967,100				—			$	144,396			$	1,765,146
		2013		$	300,000			$	360,000			$	699,994				—			$	107,645			$	1,467,640
Melanie Grace		2015		$	79,167			$	50,000			$	112,500				—			$	36,466			$	278,133
General Counsel, Chief Compliance Officer and Secretary
Andrew Olson		2015		$	186,250			$	195,000			$	53,332				—			$	22,717			$	457,299
Controller
Jessica Baron		2015		$	130,096				—			$	267,838				—			$	63,168			$	461,102
Former Chief Financial Officer		2014		$	293,550			$	123,750			$	517,825				—			$	109,841			$	1,044,966
		2013		$	285,000			$	287,442			$	410,004				—			$	106,821			$	1,089,267

 

(1)	Salary column amounts represent base salary compensation received by each NEO for the listed fiscal year. The amount presented for Mr. Harris and Ms. Grace is the pro rata portion of their annual base salary paid through December 31, 2015.

(2)	Bonus column amounts represent the annual cash bonus earned during the fiscal year and awarded and paid out during the first quarter of the following fiscal year.

(3)

The amounts reflect the aggregate grant date fair value of restricted stock and stock option awards made to our NEOs and former NEOs during the applicable year computed in accordance with FASB ASC Topic 718. The grant date fair value of each restricted stock award is measured based on the closing price of our common stock on the date of grant.

(4)	All Other Compensation column includes the following:

•

We made matching contributions under our 401(k) plan of (a) $18,000 in 2015 to Messrs. Henriquez, Bluestein and Olson and Ms. Baron; (b) $17,000 in 2014 to Messrs. Henriquez and Bluestein and Ms. Baron; and (c) $17,000 in 2013 to Messrs. Henriquez and Bluestein and Ms. Baron.

•

Dividends to Messrs. Henriquez, Harris, Bluestein and Olson and Ms. Grace in the amount of $845,550, $22,587, $134,985, $4,717 and $3,100, respectively, were paid on unvested restricted stock awards during 2015.

•

Dividends to Messrs. Henriquez and Bluestein and Ms. Baron in the amount of $787,675, $127,396 and $92,841, respectively, were paid on unvested restricted stock awards during 2014.

•

Dividends to Messrs. Henriquez, Bluestein and Ms. Baron in the amount of $622,950, $90,645, and $89,821, respectively, were paid on unvested restricted stock awards during 2013.

•

Due to a change in the vacation policy of NEOs, Messrs. Henriquez, Harris, Bluestein and Ms. Grace were each paid out of all of their accrued vacation through August 30, 2015 in the amount of $771,803, $3,817, $40,385 and $1,007, respectively. NEOs no longer accrue vacation effective September 1, 2015.

•

Ms. Grace began as a contractor on August 3, 2015 until she was approved by the Board of Directors as an executive officer on September 17, 2015. During this period, Ms. Grace earned $32,359 in compensation.

 

180

---

Table of Contents

Index to Financial Statements

Grants of Plan Based Awards in 2015

 

NEO		Grant Date				All Other Stock Awards: Number of Shares of Stock or Units(1)				All Other Option Awards: Number of Securities Underlying Options(1)				Grant Date Fair Value of Stock and Option Awards(2)
Manuel Henriquez			3/10/2015				318,983				—			$	4,472,142
Mark Harris			8/06/2015				36,430				—			$	400,001
Scott Bluestein			3/10/2015				47,804				—			$	670,212
Melanie Grace			9/17/2015				10,000				—			$	112,500
Jessica Baron(3)			3/10/2015				19,104				—			$	267,838

 

(1)	Restricted stock awards vest as to one-third of the award on the one year anniversary of the date of the grant and quarterly over the succeeding 24 months. When payable, dividends are paid on a current basis on the unvested shares.

(2)	The amounts reflect the aggregate grant date fair value of computed in accordance with FASB ASC Topic 718.

(3)	Ms. Baron resigned effective June 9, 2015. Upon her resignation, Ms. Baron forfeited all of her unvested restricted stock.

 

181

---

Table of Contents

Index to Financial Statements

Outstanding Equity Awards at Fiscal Year End, December 31, 2015

 

		Option Awards																Stock Awards
Name and Principal Position		Number of Securities Underlying Unexercised Options Exercisable				Number of Securities Underlying Unexercised Options Unexercisable				Option Exercise Price ($)				Option Expiration Date				Number of Shares or Units of Stock That Have Not Vested				Market Value of Shares or Units of Stock That Have Not Vested(1)
Manuel Henriquez			—				—				—				—				15,313	(3)		$	186,665
			—				—				—				—				61,419	(4)		$	748,698
			—				—				—				—				68,750	(5)		$	838,063
			—				—				—				—				40,000	(7)		$	487,600
			—				—				—				—				318,983	(8)		$	3,888,403
Mark Harris			—				—				—				—				36,430	(9)		$	444,082
Scott Bluestein			—				—				—				—				2,188	(3)		$	26,672
			—				—				—				—				12,284	(4)		$	76,188
			—				—				—				—				6,250	(5)		$	149,742
			—				—				—				—				11,250	(6)		$	137,138
			—				—				—				—				47,804	(8)		$	582,731
Melanie Grace			—				—				—				—				10,000	(10)		$	121,900
Andrew Olson			6,666	(11)			13,334			$	15.12				12/3/2021				3,804	(8)		$	46,371
Jessica Baron(2)			—				—				—				—				—				—

 

(1)	Market value is computed by multiplying the closing market price of the Company’s stock at December 31, 2015 by the number of shares.

(2)	Ms. Baron resigned effective June 10, 2015. Upon her resignation, Ms. Baron forfeited all of her unvested restricted stock.

(3)	Restricted stock granted on 3/9/12 that vests as to one-fourth of the total award on the one-year anniversary of the date of the grant and ratably over the succeeding 36 months

(4)	Restricted stock granted on 3/4/13 that vests as to one-fourth of the total award on the one-year anniversary of the date of the grant and quarterly over the succeeding 36 months

(5)	Restricted stock granted on 4/10/14 that vests as to one-half of the total award on the one-year anniversary of the date of the grant and quarterly over the succeeding 12 months.

(6)	Restricted stock granted on 4/14/14 that vests as to one half of the total award on the one-year anniversary of the date of the grant and quarterly over the succeeding 12 months.

(7)	Restricted stock granted on 4/15/14 that vests as to one-half of the total award on the one-year anniversary of the date of the grant and quarterly over the succeeding 12 months.

(8)	Restricted stock granted on 3/10/15 that vests as to one-third of the total award on the one-year anniversary of the date of the grant and quarterly over the succeeding 24 months.

(9)	Restricted stock granted on 8/6/15 that vests as to one-third of the total award on the one-year anniversary of the date of the grant and quarterly over the succeeding 24 months

(10)	Restricted stock granted on 9/17/15 that vests as to one-third of the total award on the one year anniversary of the date of the grant and quarterly over the succeeding 24 months.

(11)	Options granted on 12/03/2014 that vest as to one-third of the total underlying shares on the one year anniversary of the date of the grant and on a monthly basis over the succeeding 24 months.

Options Exercised and Stock Vested in 2015

 

		Option Awards								Stock Awards
Name and Principal Position		Number of Shares Acquired on Exercise				Value Realized on Exercise				Number of Shares Acquired on Vesting				Value Realized  on Vesting
Manuel Henriquez			—				—				457,420			$	5,894,175
Scott Bluestein			—				—				73,512			$	946,463
Jessica Baron			—				—				30,541			$	423,669

 

182

---

Table of Contents

Index to Financial Statements

COMPENSATION OF DIRECTORS

Our Compensation Committee has the authority from our Board of Directors for the appointment, compensation and oversight of our outside compensation consultant. Our Compensation Committee generally engages a compensation consultant every other year to assist it with its responsibilities related to our director compensation program.

The following table discloses the cash, equity awards and other compensation earned, paid or awarded, as the case may be, to each of our current directors during the fiscal year ended December 31, 2015. We provide further information relating to equity awards made to our non-employee directors below under “—2006 Non-Employee Director Plan.”

 

Name		Fees Earned or Paid in Cash ($)(1)				Stock Awards ($)(2)				Option Awards ($)(3)				All Other Compensation ($)(4)				Total ($)
Robert P. Badavas		$	170,500				—				—			$	4,133			$	174,633
Thomas J. Fallon		$	146,500			$	57,200			$	4,696			$	5,166			$	213,562
Rodney A. Ferguson		$	75,000			$	38,130			$	3,131			$	2,583			$	118,844
Joseph F. Hoffman		$	103,250			$	45,395			$	3,548			$	2,583			$	154,776
Susanne D. Lyons		$	124,250			$	48,662			$	4,110			$	4,133			$	181,155
Allyn C. Woodward, Jr.		$	179,250			$	57,200			$	4,696			$	18,111			$	259,257
Manuel A. Henriquez(5)			—				—				—				—				—

 

(1)

Messrs. Badavas, Fallon, Ferguson, Hoffman and Woodward and Ms. Lyons earned $120,500, $96,500, $25,000, $53,250, $129,250 and $74,250, respectively, and each elected to receive an additional retainer fee of 4,522 shares of our common stock in lieu of cash. The total value of the shares issued to each of Messrs. Badavas, Fallon, Ferguson, Hoffman and Woodward and Ms. Lyons services in fiscal 2015 was $50,000.

(2)

During 2015, in connection their re-election to our Board of Directors, we granted Messrs. Fallon and Woodward each a restricted stock award for 5,000 shares of common stock, and we granted Messrs. Ferguson and Hoffman and Ms. Lyons each a restricted stock award for 3,333 shares of common stock upon their appointment to our Board of Directors. The amounts presented reflect the aggregate grant date fair value of the stock awards, as computed in accordance with FASB ASC Topic 718. The grant date fair value of each restricted stock award is measured based on the closing price of our common stock on the date of grant.

(3)

During 2015, in connection with their re-election to our Board of Directors, we granted Messrs. Fallon and Woodward each a stock option award with respect to 15,000 shares of our common stock, and, in connection with their appointment to our Board of Directors, we granted Messrs. Ferguson and Hoffman and Ms. Lyons a stock option award with respect to 10,000 shares of our common stock. The amounts presented reflect the aggregate grant date fair value of option awards computed in accordance with FASB ASC Topic 718. The fair value of each stock option grant is estimated based on the fair market value of the option on the date of grant using the Black-Scholes-Merton option pricing model. For a further discussion on the valuation model and the assumptions used to calculate the fair value of our stock options, please see Note 7 to the consolidated financial statements included in our annual report on Form 10-K for the 2015 fiscal year.

(4)	Represents dividends paid during 2015 on unvested common stock under restricted stock awards.

(5)	As an employee director, Mr. Henriquez does not receive any compensation for his service as a director. The compensation Mr. Henriquez receives as our chief executive officer is disclosed in the Summary Compensation Table and elsewhere under “EXECUTIVE COMPENSATION.”

As of December 31, 2015, Messrs. Badavas, Fallon, Ferguson, Hoffman and Woodward and Ms. Lyons had outstanding options in the amount of 20,000, 25,000, 10,000, 10,000, 25,000 and 10,000, respectively. As of December 31, 2015, Messrs. Badavas, Fallon, Ferguson, Hoffman and Woodward and Ms. Lyons held unvested shares of restricted stock in the amount of 3,333, 6,666, 3,333, 3,333, 5,000 and 3,333, respectively.

 

183

---

Table of Contents

Index to Financial Statements

Upon his appointment to our Board of Directors in July 2015, Mr. Ferguson received a restricted stock award with respect to 3,333 shares of our common stock and a stock option to purchase 10,000 shares of our common stock.

From January 1, 2015 through June 30, 2015, the compensation for serving on our Board of Directors as an independent director included the following:

 

Annual Director Retainer Fee		$	50,000
Committee Chairperson Fee		$	15,000
Board Meeting Fee		$	2,000
(in person or telephonically)
Committee Meeting Fee		$	2,000
(in person or telephonically)

On July 7, 2015, the Board of Directors approved a change to director compensation. From July 1, 2015 through December 31, 2015, the compensation for serving on our Board of Directors as an independent director included the following:

 

Annual Director Retainer Fee		$100,000
Annual Chairperson Fee		$25,000, Audit Committee
		$25,000, Compensation Committee
		$15,000, NCG Committee
Annual Lead Director Fee		$25,000

In 2015, we granted each independent director an additional retainer of $50,000, which was distributed as shares of common stock in lieu of cash. In addition, upon re-election to the Board of Directors, each independent director is granted an option to purchase 15,000 shares and an additional award of 5,000 shares of restricted stock. Employee directors do not receive compensation for serving on our Board of Directors. In addition, we reimburse our directors for their reasonable out-of-pocket expenses incurred in attending Board meetings.

Under current SEC rules and regulations applicable to business development companies, a business development company may not grant options or restricted stock to non-employee directors unless it receives exemptive relief from the SEC. We filed an exemptive relief request with the SEC to allow options and restricted stock to be issued to our non-employee directors, which was approved on October 10, 2007. On June 22, 2010, we received approval from the SEC regarding our exemptive relief request permitting its employees to exercise their stock options and restricted stock and pay any related income taxes using a cashless exercise program.

On June 21, 2007, our stockholders approved amendments to the Equity Plan and the 2006 Non-Employee Director Plan allowing for the grant of restricted stock. The Equity Plan and 2006 Non-Employee Director Plan limit the combined maximum amount of restricted stock that may be issued under both of the Equity Plan and 2006 Non-Employee Director Plan to 10% of the outstanding shares of our common stock on the effective date of the Equity Plan and 2006 Non-Employee Director Plan plus 10% of the number of shares of common stock issued or delivered by us during the terms of the Equity Plan and 2006 Non-Employee Director Plan.

 

184

---

Table of Contents

Index to Financial Statements

EQUITY COMPENSATION PLAN INFORMATION

The following table sets forth information as of December 31, 2015, with respect to compensation plans under which the Company’s equity securities are authorized for issuance:

 

Plan Category		(a) Number of Securities to be issued upon exercise of outstanding options, restricted stock and warrants				(b) Weighted- average exercise price of outstanding options, restricted stock and warrants				(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by stockholders:
2004 Equity Incentive Plan			628,171			$	13.97				4,241,172
2006 Non-Employee Director Plan			100,000			$	13.07				740,000
Equity compensation plans not approved by stockholders:											—
Total			728,171			$	13.52				4,981,172

2004 Equity Incentive Plan

Our board and our stockholders have approved our Equity Plan to align our employees’ interest with the performance of our Company and to attract and retain the services of executive officers and other key employees. Under our Equity Plan our Compensation Committee may award incentive stock options, referred to as ISOs, within the meaning of Section 422 of the Code, and non-qualified stock options to employees and employee directors. The following is a summary of the material features of our Equity Plan.

Under our Equity Plan, we had 3,745,060 shares of common stock available for issuance as of April 15, 2016. Participants in our Equity Plan may receive awards of options to purchase our common stock and/or restricted shares, as determined by our Compensation Committee. Options granted under our Equity Plan generally may be exercised for a period of no more than ten years from the date of grant unless the option agreement provides for an earlier expiration. Unless sooner terminated by our Board of Directors, our Equity Plan will terminate on the tenth anniversary of the date it was last approved by our stockholders. Such approval was last given by our stockholders on July 7, 2015. Our Equity Plan provides that all awards granted under the plan are subject to modification as required to ensure that such awards do not conflict with the requirements of the 1940 Act applicable to us.

Options granted under our Equity Plan will entitle the optionee, upon exercise, to purchase shares of common stock from us at a specified exercise price per share. ISOs must have a per share exercise price of no less than the fair market value of a share of stock on the date of the grant or, if the optionee owns or is treated as owning (under Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of our stock, 110% of the fair market value of a share of stock on the date of the grant. Nonstatutory stock options granted under our Equity Plan must have a per share exercise price of no less than the fair market value of a share of stock on the date of the grant. Options will not be transferable other than by laws of descent and distribution, or in the case of nonstatutory stock options, by gift, and will generally be exercisable during an optionee’s lifetime only by the optionee.

Under our Equity Plan, we are permitted to issue shares of restricted stock to all key employees of the Company and its affiliates consistent with such terms and conditions as the Board of Directors shall deem appropriate. Our Board of Directors determines the time or times at which such shares of restricted stock will become exercisable and the terms on which such shares will remain exercisable. Any shares of restricted stock for which forfeiture restrictions have not vested at the point at which the participant terminates his employment will terminate immediately and such shares will be returned to Hercules and will be available for future awards under this plan.

 

185

---

Table of Contents

Index to Financial Statements

Our Board of Directors administers our Equity Plan and has the authority, subject to the provisions of the Equity Plan, to determine who will receive awards under the Equity Plan and the terms of such awards. Our Board of Directors has the authority to adjust the number of shares available for awards, the number of shares subject to outstanding awards and the exercise price for awards following the occurrence of events such as stock splits, dividends, distributions and recapitalizations. The exercise price of an option may be paid in the form of shares of stock that are already owned by such option holder.

Upon specified covered transactions (as defined in the Equity Plan), all outstanding awards under our Equity Plan may either be assumed or substituted for by the surviving entity. If the surviving entity does not assume or substitute similar awards, the awards held by the participants will be accelerated in full and then terminated to the extent not exercised prior to the covered transaction.

2006 Non-Employee Director Plan

Our Board of Directors and our stockholders have approved our 2006 Non-Employee Director Plan. Under current SEC rules and regulations applicable to business development companies, absent exemptive relief, a business development company may not grant options or shares of restricted stock to non-employee directors. On February 15, 2007, we received exemptive relief from the SEC to permit us to grant options to non-employee directors as a portion of their compensation for service on our Board of Directors. On May 23, 2007, we received exemptive relief from the SEC to permit us to grant shares of restricted stock to non-employee directors as a portion of their compensation for service on our Board of Directors. The following is a summary of the material features of the 2006 Non-Employee Director Plan.

We instituted our 2006 Non-Employee Director Plan for the purpose of advancing our interests by providing for the grant of awards under our 2006 Non-Employee Director Plan to eligible non-employee directors. Under our 2006 Non-Employee Director Plan, we have authorized for issuance up to 1,000,000 shares of common stock of which 740,000 shares were available for issuance as of April 15, 2016.

Our 2006 Non-Employee Director Plan authorizes the issuance to non-employee directors of non-statutory stock options, referred to as NSOs, to purchase shares of our common stock at a specified exercise price per share and/or restricted stock. NSOs granted under our 2006 Non-Employee Director Plan will have a per share exercise price of no less than the current market value of a share of stock as determined in good faith by our Board of Directors on the date of the grant. The amount of the options that may be granted are limited by the terms of our 2006 Non-Employee Director Plan, which prohibits any grant that would cause us to be in violation of Section 61(a)(3) of the 1940 Act.

Under our 2006 Non-Employee Director Plan, non-employee directors will each receive an initial grant of an option to purchase 10,000 shares of stock upon initial election to such position. The options granted will vest over two years, in equal installments on each of the first two anniversaries of the date of grant, provided that the non-employee director remains in service on such dates. In addition, each non-employee director shall automatically be granted an option to purchase 15,000 shares of stock on the date of such non-employee director’s re-election to our Board of Directors and such grant will vest over three years, in equal installments on each of the first three anniversaries of the date of grant, provided that the non-employee director remains in service on such dates. Our Compensation Committee has, subject to SEC approval, the authority to determine from time to time which of the persons eligible under our 2006 Non-Employee Director Plan shall be granted awards; when and how each award shall be granted, including the time or times when a person shall be permitted to exercise an award; and the number of shares of stock with respect to which an award shall be granted to such person. The exercise price of options granted under our 2006 Non-Employee Director Plan is set at the closing price of our common stock on the NYSE as of the date of grant and will not be adjusted unless we receive an exemptive order from the SEC or written confirmation from the staff of the SEC that we may do so (except for adjustments resulting from changes in our capital structure, such as stock dividends, stock splits and reverse stock splits).

 

186

---

Table of Contents

Index to Financial Statements

Unless sooner terminated by our Board of Directors, our 2006 Non-Employee Director Plan will terminate on June 21, 2017 and no additional awards may be made under our 2006 Non-Employee Director Plan after that date. Our 2006 Non-Employee Director Plan provides that all awards granted under our 2006 Non-Employee Director Plan are subject to modification as required to ensure that such awards do not conflict with the requirements of the 1940 Act. Our Compensation Committee will determine the period during which any options granted under our 2006 Non-Employee Director Plan shall remain exercisable, provided that no option will be exercisable after the expiration of ten years from the date on which it was granted. Options granted under our 2006 Non-Employee Director Plan are not transferable other than by will or the laws of descent and distribution, or by gift, and will generally be exercisable during a non-employee director’s lifetime only by such non-employee director. In general, any portion of any options that are not then exercisable will terminate upon the termination of the non-employee director’s services to Hercules. Generally, any portion of any options that are exercisable at the time of the termination of the non-employee director’s services to Hercules will remain exercisable for the lesser of (i) a period of three months (or one year if the non-employee director’s services to Hercules terminated by reason of the non-employee director’s death) or (ii) the period ending on the latest date on which such options could have been exercised had the non-employee director’s services to Hercules not terminated. In addition, if our Board of Directors determines that a non-employee director’s service to Hercules terminated for reasons that cast such discredit on the non-employee director as to justify immediate termination of the non-employee director’s options, then all options then held by the non-employee director will immediately terminate.

Under our 2006 Non-Employee Director Plan, we also are permitted to issue shares of restricted stock to our non-employee directors. Upon initial election to such position, non-employee directors will automatically be granted 3,333 shares of restricted stock. The forfeiture restrictions for such initial shares of restricted stock will vest as to one-half of such shares on the first anniversary of the date of grant and as to an additional one-half of the restricted stock on the second anniversary of the date of grant. In addition, each non-employee director shall automatically be granted 5,000 shares of restricted stock on the date of such non-employee director’s re-election to our Board of Directors and the forfeiture restrictions on such shares will vest as to one-third of such shares on the anniversary of such grant over three years, provided that the non-employee director remains in service on such dates.

Our Compensation Committee administers our 2006 Non-Employee Director Plan. If there is a change in our capital structure by reason of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure, our Board of Directors will make appropriate adjustments to the number and class of shares of stock subject to our 2006 Non-Employee Director Plan and each option outstanding under it. In the event of a consolidation, merger, stock sale, a sale of all or substantially all of our assets, our dissolution or liquidation or other similar events, referred to as a Covered Transaction, our Board of Directors may provide for the assumption of some or all outstanding options or for the grant of new substitute options by the acquirer or survivor. If no such assumption or substitution occurs, all outstanding options will become exercisable prior to the Covered Transaction and will terminate upon consummation of the Covered Transaction.

Our Board of Directors may, subject to SEC prior approval, at any time or times amend our 2006 Non-Employee Director Plan or any outstanding award for any purpose which may at the time be permitted by law, and may at any time terminate our 2006 Non-Employee Director Plan as to any future grants of awards; provided, that except as otherwise expressly provided in our 2006 Non-Employee Director Plan, our Board of Directors may not, without the participant’s consent, alter the terms of an award so as to affect adversely the participant’s rights under the award, unless our Board of Directors expressly reserved the right to do so at the time of the grant of the award.

 

187

---

Table of Contents

Index to Financial Statements

CONTROL PERSONS AND PRINCIPAL STOCKHOLDERS

The following table sets forth, as of May 26, 2016, the beneficial ownership of each current director, each nominee for director, our NEOs, each person known to us to beneficially own 5% or more of the outstanding shares of our common stock, and our executive officers and directors as a group.

Beneficial ownership is determined in accordance with the rules of the SEC. Common stock subject to options or warrants that are currently exercisable or exercisable within 60 days of May 26, 2016 are deemed to be outstanding and beneficially owned by the person holding such options or warrants. Such shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. Percentage of ownership is based on 73,853,379 shares of common stock outstanding as of May 26, 2016.

Unless otherwise indicated, to our knowledge, each stockholder listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder, except to the extent authority is shared by their spouses under applicable law. Unless otherwise indicated, the address of all executive officers and directors is c/o Hercules Capital, Inc., 400 Hamilton Avenue, Suite 310, Palo Alto, California 94301.

Our directors are divided into two groups—interested directors and independent directors. Interested directors are “interested persons” as defined in Section 2(a)(19) of the 1940 Act, and independent directors are all other directors.

 

Name and Address of Beneficial Owner		Type of Ownership		Number of Shares Owned Beneficially(1)				Percentage of Class
Interested Director
Manuel A. Henriquez(2)		Record/Beneficial			2,061,318				2.8	%
Independent Directors
Robert B. Badavas(3)		Beneficial			151,205				*
Allyn C. Woodward, Jr.(4)		Record/Beneficial			257,901				*
Thomas J. Fallon(5)		Beneficial			38,855				*
Susanne D. Lyons(6)		Beneficial			12,855				*
Joseph F. Hoffman(7)		Beneficial			12,855				*
Rodney A. Ferguson, Ph.D.(8)		Record			12,855				*
Other Named Executive Officers
Mark R. Harris(9)		Record			69,430				*
Scott Bluestein(10)		Record			239,414				*
Melanie Grace(11)		Record			19,400				*
Andrew Olson(12)		Record			19,894				*
Executive officers and directors as a group (11 persons)(13)									3.9	%

 

(1)	Beneficial ownership has been determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

(2)

Includes 595,301 shares of restricted stock. 1,244,491 shares of common stock held by the Manuel A. Henriquez and Elizabeth H. Henriquez TTEE The Henriquez Family Trust U/A 5/11/99 of which 706,104 shares are pledged as a security; 154,954 shares of common stock held in The Henriquez Trust, U/A 05/11/99; 27,174 shares of common stock held in the Isabelle Irrev Trust, EH Trustee; 27,174 shares of common stock held in the Natalie Irrev Trust, EH Trustee; and 12,224 shares of common stock held in the Manuel Henriquez-Roth IRA. Mr. Henriquez disclaims any beneficial ownership interest of such shares except to the extent of his pecuniary interest therein.

(3)

Includes 15,000 shares of common stock that can be acquired upon the exercise of outstanding options and 3,333 shares of restricted common stock. All shares are held of record by the Robert P. Badavas Trust of 2007, and Mr. Badavas disclaims any beneficial ownership interest of such shares except to the extent of his pecuniary interest therein.

(4)

Includes 15,000 shares of common stock that can be acquired upon the exercise of outstanding options, 5,000 shares of restricted common stock, and 35,000 shares of common stock held by Mr. Woodward’s spouse in her name. Mr. Woodward disclaims any beneficial ownership interest of such shares held by his spouse except to the extent of his pecuniary interest therein.

 

188

---

Table of Contents

Index to Financial Statements

(5)

Includes 15,000 shares of common stock that can be acquired upon the exercise of outstanding options and 6,666 shares of restricted common stock. All shares are held of record by the Fallon Family Revocable Trust, and Mr. Fallon disclaims any beneficial ownership interest of such shares except to the extent of his pecuniary interest therein.

(6)

Includes 5,000 shares of common stock that can be acquired upon the exercise of outstanding options and 1,666 shares of restricted common stock. All shares are held of record by the Lyons Family Trust, and Ms. Lyons disclaims any beneficial ownership interest of such shares except to the extent of her pecuniary interest therein.

(7)

Includes 5,000 shares of common stock that can be acquired upon the exercise of outstanding options and 1,666 shares of restricted common stock. All shares are held of record by the Hoffman Trust, and Mr. Hoffman disclaims any beneficial ownership interest of such shares except to the extent of his pecuniary interest therein.

(8)	Dr. Ferguson was appointed to our Board effective July 7, 2015. Includes 5,000 shares of common stock that can be acquired upon the exercise of outstanding options and 3,333 shares of restricted common stock.

(9)	Includes 69,430 shares of restricted common stock.

(10)	Includes 145,698 shares of restricted common stock.

(11)	Includes 19,400 shares of restricted common stock.

(12)	Includes 10,555 shares of common stock that can be acquired upon the exercise of outstanding options and 8,537 shares of restricted common stock.

(13)	Includes 70,555 shares of common stock that can be acquired upon the exercise of outstanding options and 860,030 shares of restricted common stock.

*	Less than 1%.

The following table sets forth as of May 26, 2016, the dollar range of our securities owned by our directors and executive officers.

 

Name		Dollar Range of Equity Securities Beneficially Owned
Interested Director
Manuel A. Henriquez		Over $100,000
Independent Directors
Robert B. Badavas		Over $100,000
Allyn C. Woodward, Jr.		Over $100,000
Thomas J. Fallon		Over $100,000
Susanne D. Lyons		Over $100,000
Joseph F. Hoffman		Over $100,000
Rodney A. Ferguson, Ph.D.		Over $100,000
Other Named Executive Officers
Mark R. Harris(1)		Over $100,000
Scott Bluestein		Over $100,000
Melanie Grace(1)		Over $100,000
Andrew Olson		Over $100,000

 

(1)	Mr. Harris and Ms. Grace did not have vested restricted common stock or exercisable stock options as of May 26, 2016.

 

189

---

Table of Contents

Index to Financial Statements

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

We have established a written policy to govern the review, approval and monitoring of transactions involving the Company and certain persons related to Hercules. As a business development company, the 1940 Act restricts us from participating in transactions with any persons affiliated with Hercules, including our officers, directors, and employees and any person controlling or under common control with us.

In order to ensure that we do not engage in any prohibited transactions with any persons affiliated with Hercules, our officers screen each of our transactions for any possible affiliations, close or remote, between the proposed portfolio investment, Hercules, companies controlled by us and our employees and directors.

We will not enter into any agreements unless and until we are satisfied that no affiliations prohibited by the 1940 Act exist or, if such affiliations exist, we have taken appropriate actions to seek Board of Directors’ review and approval or exemptive relief from the SEC for such transaction.

 

190

---

Table of Contents

Index to Financial Statements

CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

The following discussion is a general summary of certain material U.S. federal income tax considerations relating to our qualification and taxation as a RIC and the acquisition, ownership and disposition of our preferred stock or common stock, but does not purport to be a complete description of the income tax considerations relating thereto.

Election to be Taxed as a RIC

Through December 31, 2005, we were subject to federal income tax as an ordinary corporation under Subchapter C of the Code. Effective beginning on January 1, 2006 we met the criteria specified below to qualify as a RIC, and elected to be treated as a RIC under Subchapter M of the Code with the filing of our federal income tax return for 2006. To qualify as a RIC we must, among other things, meet certain source of income and asset diversification requirements (as described below). In addition, we must distribute to our stockholders, in respect of each taxable year, dividends of an amount generally at least equal to 90% of our “investment company taxable income,” which is generally the sum of our net ordinary income plus the excess of our realized net short-term capital gains over our realized net long-term capital losses, determined without regard to any deduction for dividends paid, or the “Annual Distribution Requirement.” Upon satisfying these requirements in respect of a taxable year, we generally will not have to pay corporate taxes on any income we distribute to our stockholders as dividends, which will allows us to reduce or eliminate our corporate level tax.

Taxation as a Regulated Investment Company

For any taxable year in which we:

 

•

qualify as a RIC; and

 

•

distribute dividends to our shareholders of an amount at least equal to the Annual Distribution Requirement; we generally will not be subject to federal income tax on the portion of our investment company taxable income and net capital gain (i.e., net realized long-term capital gains in excess of net realized short-term capital losses) we distribute (or are deemed to distribute) as dividends to stockholders with respect to that taxable year. As described above, we made the election to recognize built-in gains as of the effective date of our election to be treated as a RIC and therefore were not subject to built-in gains tax when we sold those assets. However, if we subsequently acquire built-in gain assets from a C corporation in a carryover basis transaction, then we may be subject to tax on the gains recognized by us on dispositions of such assets unless we make a special election to pay corporate-level tax on such built-in gain at the time the assets are acquired. We will be subject to U.S. federal income tax at the regular corporate rates on any income or capital gains not distributed (or deemed distributed) as dividends to our stockholders.

In order to qualify as a RIC for federal income tax purposes and obtain the tax benefits of RIC status, in addition to satisfying the Annual Distribution Requirement, we must, among other things:

 

•

have in effect at all times during each taxable year an election to be regulated as a business development company under the 1940 Act;

 

•

derive in each taxable year at least 90% of our gross income from (a) dividends, interest, payments with respect to certain securities loans, gains from the sale of stock or other securities, or other income derived with respect to our business of investing in such stock or securities and (b) net income derived from an interest in a “qualified publicly traded partnership” (the “90% Income Test”); and diversify our holdings so that at the end of each quarter of the taxable year:

 

•

at the close of each quarter of each taxable year, at least 50% of the value of our assets consists of cash, cash equivalents, U.S. government securities, securities of other RICs, and other securities if such other

 

191

---

Table of Contents

Index to Financial Statements

securities of any one issuer do not represent more than 5% of the value of our assets or more than 10% of the outstanding voting securities of such issuer; and

 

•

at the close of each quarter of each taxable year, no more than 25% of the value of our assets is invested in (i) securities (other than U.S. government securities or securities of other RICs) of one issuer, (ii) securities of two or more issuers that are controlled, as determined under applicable tax rules, by us and that are engaged in the same or similar or related trades or businesses or (iii) securities of one or more “qualified publicly traded partnerships” (the “Diversification Tests”).

We may invest in partnerships which may result in our being subject to state, local or foreign income, franchise or other tax liabilities. In addition, some of the income and fees that we may recognize will not satisfy the 90% Income Test. In order to mitigate the risk that such income and fees would disqualify us as a RIC as a result of a failure to satisfy the 90% Income Test, we may be required to recognize such income and fees indirectly through one or more entities classified as corporations for U.S. federal income tax purposes. Such corporations will be subject to U.S. corporate income tax on their earnings, which ultimately will reduce our return on such income and fees.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we distribute in respect of each calendar year in a timely manner dividends of an amount at least equal to the sum of the Excise Tax Avoidance Requirements. We will not be subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains). Depending on the level of our investment company taxable income and net capital gains earned in a taxable year, we may choose to carry over all or a portion of such investment company taxable income and net capital gains in excess of current year dividend distributions from such investment company taxable income and net capital gains into the next taxable year and pay a 4% excise tax on such investment company taxable income and net capital gains, as required. The maximum amount of such excess investment company taxable income and net capital gains that may be carried over for distribution in the next taxable year under the Code is the total amount of dividends paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over investment company taxable income or net capital gains into the next taxable year, dividends declared and paid by us in a taxable year may differ from investment company taxable income or net capital gains for that taxable year as such dividends may include the distribution of dividends derived from the current taxable year’s investment company taxable income or net capital gains, the distribution of prior taxable year’s investment company taxable income or net capital gains carried over into and distributed in the current taxable year, or returns of capital.

Under applicable Treasury regulations and other administrative guidance issued by the IRS, we are permitted to treat certain distributions payable in our stock as taxable dividends that will satisfy the Annual Distribution Requirement as well as the Excise Tax Avoidance Requirement provided that shareholders have the opportunity to elect to receive the distribution in cash. Taxable stockholders receiving such dividends will be required to include the full amount of the dividend as ordinary income (or as long-term capital gain to the extent such distribution is properly designated as a capital gain dividend) to the extent of our current and accumulated earnings and profits for United States federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with respect to such dividends in excess of any cash received. If a U.S. stockholder sells the stock it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, then such sales may put downward pressure on the trading price of our stock. We may in the future determine to distribute taxable dividends that are payable in part in our common stock.

We may be required to recognize taxable income in circumstances in which we do not receive a corresponding payment in cash. For example, if we hold debt obligations that are treated under applicable tax

 

192

---

Table of Contents

Index to Financial Statements

rules as having OID (such as debt instruments with PIK interest provisions or, in certain cases, increasing interest rates or debt instruments that were issued with warrants), we must include in income each taxable year a portion of the OID that accrues over the life of the obligation, regardless of whether cash representing such income is received by us in the same taxable year. Because any OID accrued will be included in our investment company taxable income for the taxable year of accrual, we may be required to make a distribution to our stockholders in order to satisfy the Annual Distribution Requirement and the Excise Tax Avoidance Requirement, even though we will not have received any corresponding cash amount.

Gain or loss realized by us from the sale or exchange of warrants acquired by us as well as any loss attributable to the lapse of such warrants generally will be treated as capital gain or loss. Such gain or loss generally will be long-term or short-term, depending on how long we held a particular warrant.

We are authorized to borrow funds and to sell assets in order to satisfy the Annual Distribution Requirement and the Excise Tax Avoidance Requirement (collectively, the “Distribution Requirements”). However, under the 1940 Act, we are not permitted to make distributions to our stockholders while our debt obligations and other senior securities are outstanding unless certain “asset coverage” tests are met. See “Regulation—Senior Securities; Coverage Ratio.” We may be restricted from making distributions under the terms of our debt obligations themselves unless certain conditions are satisfied. Moreover, our ability to dispose of assets to meet the Distribution Requirements may be limited by (1) the illiquid nature of our portfolio, or (2) other requirements relating to our status as a RIC, including the Diversification Tests. If we dispose of assets in order to meet the Distribution Requirements, we may make such dispositions at times that, from an investment standpoint, are not advantageous. If we are prohibited from making distributions or are unable to obtain cash from other sources to make the distributions, we may fail to be subject to tax as a RIC, which would result in us becoming subject to corporate-level federal income tax.

In addition, we will be partially dependent on our SBIC subsidiaries for cash distributions to enable us to meet the RIC Distribution Requirements. Our SBIC subsidiaries may be limited by the Small Business Investment Act of 1958, as amended, and SBA regulations governing SBICs, from making certain distributions to us that may be necessary to maintain our status as a RIC. We may have to request a waiver of the SBA’s restrictions for our SBIC subsidiaries to make certain distributions to maintain our RIC status. We cannot assure you that the SBA will grant such waiver. If our SBIC subsidiaries are unable to obtain a waiver, compliance with the SBA regulations may cause us to fail to be subject to tax as a RIC, which would result in us becoming subject to corporate-level federal income tax.

Certain of our investment practices are subject to special and complex U.S. federal income tax provisions that may, among other things, (i) convert dividends that would otherwise constitute qualified dividend income into ordinary income, (ii) treat dividends that would otherwise be eligible for deductions available to certain U.S. corporations under the Code as ineligible for such treatment, (iii) disallow, suspend or otherwise limit the allowance of certain losses or deductions, (iv) convert long-term capital gains into short-term capital gains or ordinary income, (v) convert short-term capital losses into long-term capital losses, (vi) convert an ordinary loss or deduction into a capital loss (the deductibility of which is more limited), (vii) cause us to recognize income or gain without a corresponding receipt of cash, (viii) adversely alter the characterization of certain complex financial transactions, and (ix) produce gross income that will not constitute qualifying gross income for purposes of the 90% Income Test. These rules also could affect the amount, timing and character of distributions to stockholders.

A RIC is limited in its ability to deduct expenses in excess of its “investment company taxable income” (which is, generally, ordinary income plus net realized short-term capital gains in excess of net realized long-term capital losses). If our expenses in a given taxable year exceed gross taxable income (e.g., as the result of large amounts of equity-based compensation), we would incur a net operating loss for that year. However, a RIC is not permitted to carry forward net operating losses to subsequent taxable years and such net operating losses do not pass through to the RIC’s stockholders. In addition, deductible expenses can be used only to offset

 

193

---

Table of Contents

Index to Financial Statements

investment company taxable income, not net capital gain. A RIC may not use any net capital losses (that is, realized capital losses in excess of realized capital gains) to offset the RIC’s investment company taxable income, but may carry forward such net capital losses, and generally use them to offset capital gains indefinitely. Due to these limits on the deductibility of expenses and net capital losses, we may for tax purposes have aggregate taxable income for several taxable years that we are required to distribute and that is taxable to our stockholders even if such taxable income is greater than the aggregate net income we actually earned during those taxable years. Such required distributions may be made from our cash assets or by liquidation of investments, if necessary. We may realize gains or losses from such liquidations. In the event we realize net capital gains from such transactions, you may receive a larger capital gain distribution than you would have received in the absence of such transactions.

Investment income received from sources within foreign countries, or capital gains earned by investing in securities of foreign issuers, may be subject to foreign income taxes withheld at the source. In this regard, withholding tax rates in countries with which the United States does not have a tax treaty are often as high as 35% or more. The United States has entered into tax treaties with many foreign countries that may entitle us to a reduced rate of tax or exemption from tax on this related income and gains. The effective rate of foreign tax cannot be determined at this time since the amount of our assets to be invested within various countries is not now known. We do not anticipate being eligible for the special election that allows a RIC to treat foreign income taxes paid by such RIC as having been paid by its shareholders.

If we acquire stock in certain foreign corporations that receive at least 75% of their annual gross income from passive sources (such as interest, dividends, rents, royalties or capital gain) or hold at least 50% of their total assets in investments producing such passive income (“passive foreign investment companies”), we could be subject to federal income tax and additional interest charges on “excess distributions” received from such companies or gain from the sale of stock in such companies, even if all income or gain actually received by us is timely distributed to our shareholders. We would not be able to pass through to our shareholders any credit or deduction for such a tax. Certain elections may, if available, ameliorate these adverse tax consequences, but any such election requires us to recognize taxable income or gain without the concurrent receipt of cash. We intend to limit and/or manage our holdings in passive foreign investment companies to minimize our liability for any such taxes and related interest charges.

Foreign exchange gains and losses realized by us in connection with certain transactions involving foreign currencies, or payables or receivables denominated in a foreign currency, as well as certain non-U.S. dollar denominated debt securities, certain foreign currency futures contracts, foreign currency option contracts, foreign currency forward contracts, and similar financial instruments are subject to Code provisions that generally treat such gains and losses as ordinary income and losses and may affect the amount, timing and character of distributions to our stockholders. Any such transactions that are not directly related to our investment in securities (possibly including speculative currency positions or currency derivatives not used for hedging purposes) also could, under future Treasury regulations, produce income not among the types of “qualifying income” from which a RIC must derive at least 90% of its annual gross income.

Taxation of U.S. Stockholders

A “U.S. stockholder” generally is a beneficial owner of shares of our common stock who is for United States federal income tax purposes:

 

•

a citizen or individual resident of the United States including an alien individual who is a lawful permanent resident of the United States or meets the “substantial presence” test under Section 7701(b) of the Code;

 

•

a corporation or other entity taxable as a corporation, for United States federal income tax purposes, created or organized in or under the laws of the United States or any political subdivision thereof;

 

194

---

Table of Contents

Index to Financial Statements

•

a trust if (1) a court in the United States has primary supervision over its administration and one or more U.S. persons has the authority to control all substantial decisions of such trust or (2) if such trust validly elects to be treated as a U.S. person for federal income tax purposes; or

 

•

an estate, the income of which is subject to United States federal income taxation regardless of its source.

For federal income tax purposes, distributions by us generally are taxable to U.S. stockholders as ordinary income or capital gains. Distributions of our “investment company taxable income” (which is, generally, our ordinary income plus net realized short-term capital gains in excess of net realized long-term capital losses) will be taxable as ordinary income to U.S. stockholders to the extent of our current or accumulated earnings and profits, whether paid in cash or reinvested in additional common stock. To the extent such distributions are attributable to dividends from U.S. corporations and certain qualified foreign corporations, such distributions may be reported by us as “qualified dividend income” eligible to be taxed in the hands of non-corporate stockholders (including individuals) at the rates applicable to long-term capital gains, provided certain holding period and other requirements are met at both the stockholder and company levels. In this regard, it is anticipated that distributions paid by us generally will not be attributable to dividends and, therefore, generally will not be qualified dividend income. Distributions of our net capital gains (which is generally our realized net long-term capital gains in excess of realized net short-term capital losses) properly reported by us as “capital gain dividends” will be taxable to a U.S. stockholder as long-term capital gains (currently at a maximum rate of 20%, in the case of individuals, trusts or estates), regardless of the U.S. stockholder’s holding period for his, her or its common stock and regardless of whether paid in cash or reinvested in additional common stock. Distributions in excess of our current and accumulated earnings and profits first will reduce a U.S. stockholder’s adjusted tax basis in such stockholder’s common stock and, after the adjusted basis is reduced to zero, will constitute capital gains to such U.S. stockholder.

We currently intend to retain some or all of our realized net long-term capital gains in excess of realized net short-term capital losses. In that case, among other consequences, we will pay tax on the retained amount, each U.S. stockholder will be required to include his, her or its share of the deemed distribution in income as if it had been actually distributed to the U.S. stockholder, and the U.S. stockholder will be entitled to claim a tax credit equal to his, her or its allocable share of the tax paid thereon by us. Since we expect to pay tax on any retained net capital gains at our regular corporate tax rate, and since that rate is in excess of the maximum rate currently payable by non-corporate stockholders on long-term capital gains, the amount of tax that non-corporate stockholders will be treated as having paid and for which they will receive a credit will exceed the tax they owe on the retained net capital gain. Such excess generally may be claimed as a credit against the U.S. stockholder’s other federal income tax obligations or may be refunded to the extent it exceeds a stockholder’s liability for federal income tax. A stockholder that is not subject to federal income tax or otherwise required to file a federal income tax return would be required to file a federal income tax return on the appropriate form in order to claim a refund for the taxes we paid. For federal income tax purposes, the tax basis of shares owned by a U.S. stockholder will be increased by an amount equal under current law to the difference between the amount of undistributed capital gains included in the U.S. stockholder’s gross income and the tax deemed paid by the U.S. stockholder as described in this paragraph. In order to utilize the deemed distribution approach, we must provide written notice to our stockholders prior to the expiration of 60 days after the close of the relevant taxable year. We cannot treat any of our investment company taxable income as a “deemed distribution.”

Under applicable Treasury regulations and certain administrative guidance issued by the IRS, RICs are permitted to treat certain distributions payable in up to 80% in their stock, as taxable dividends that will satisfy their Distribution Requirements provided that shareholders have the opportunity to elect to receive the distribution in cash. Taxable stockholders receiving such dividends will be required to include the full amount of the dividend as ordinary income (or as long-term capital gain to the extent such distribution is properly designated as a capital gain dividend) to the extent of our current and accumulated earnings and profits for United States federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with

 

195

---

Table of Contents

Index to Financial Statements

respect to such dividends in excess of any cash received. If a U.S. stockholder sells the stock it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, then such sales may put downward pressure on the trading price of our stock. We previously determined to pay a portion of our first quarter 2009 dividend in shares of newly issued common stock, and we may in the future determine to distribute taxable dividends that are payable in part in our common stock.

For purposes of determining (1) whether the Annual Distribution Requirement is satisfied for any taxable year and (2) the amount of the deduction for ordinary income and capital gain dividends paid for that taxable year, we may, under certain circumstances, elect to treat a dividend that is paid during the following taxable year as if it had been paid during the taxable year in question. If we make such an election, the U.S. stockholder will still be treated as receiving the dividend in the taxable year in which the distribution is made. However, any dividend declared by us in October, November or December of any calendar year, payable to stockholders of record on a specified date in such a month and actually paid during January of the following calendar year, will be treated as if it had been received by our U.S. stockholders on December 31 of the calendar year in which the dividend was declared.

If an investor purchases shares of our or common stock shortly before the record date of a distribution, the price of the shares will include the value of the distribution and the investor will be subject to tax on the distribution even though economically it may represent a return of his, her or its investment.

A U.S. stockholder generally will recognize taxable gain or loss if the U.S. stockholder sells or otherwise disposes of his, her or its shares of our common stock. Any gain arising from such sale or disposition generally will be treated as long-term capital gain or loss if the U.S. stockholder has held his, her or its shares for more than one year. Otherwise, it will be classified as short-term capital gain or loss. However, any capital loss arising from the sale or disposition of shares of our common stock held for six months or less will be treated as long-term capital loss to the extent of the amount of capital gain dividends received, or undistributed capital gain deemed received, with respect to such shares. In addition, all or a portion of any loss recognized upon a disposition of shares of our common stock may be disallowed if other shares of our common stock are purchased (whether through reinvestment of distributions or otherwise) within 30 days before or after the disposition. In such a case, the basis of the newly purchased shares will be adjusted to reflect the disallowed loss.

In general, individual U.S. stockholders currently are subject to a reduced maximum U.S. federal income tax rate of 20% on their net capital gain (i.e. , the excess of realized net long-term capital gain over realized net short-term capital loss for a taxable year) including any long-term capital gain derived from an investment in our shares. Such rate is lower than the maximum rate on ordinary income currently payable by individuals. In addition, individuals with income in excess of certain threshold amounts and certain estates and trusts are subject to an additional 3.8% tax on their “net investment income,” which generally includes net income from interest, dividends, annuities, royalties, and rents, and net capital gains (other than certain amounts earned from trades or businesses). Corporate U.S. stockholders currently are subject to U.S. federal income tax on net capital gain at the maximum 35% rate also applied to ordinary income. Non-corporate U.S. stockholders with net capital losses for a taxable year (i.e., capital losses in excess of capital gains) generally may deduct up to $3,000 of such losses against their ordinary income each taxable year; any net capital losses of a non-corporate stockholder in excess of $3,000 generally may be carried forward and used in subsequent taxable years as provided in the Code. Corporate U.S. stockholders generally may not deduct any net capital losses for a taxable year, but may carry back such losses for three taxable years or carry forward such losses for five taxable years.

We or the applicable withholding agent will send to each of our U.S. stockholders, as promptly as possible after the end of each calendar year, a notice reporting the amounts includible in such U.S. stockholder’s taxable

 

196

---

Table of Contents

Index to Financial Statements

income for such calendar year as ordinary income and as long-term capital gain. In addition, the federal tax status of each calendar year’s distributions generally will be reported to the IRS (including the amount of dividends, if any, eligible for the 20% “qualified dividend income” rate). Distributions may also be subject to additional state, local, and foreign taxes depending on a U.S. stockholder’s particular situation. Dividends distributed by us generally will not be eligible for the corporate dividends-received deduction or the preferential rate applicable to “qualified dividend income.”

In some taxable years, we may be subject to the alternative minimum tax (“AMT”). If we have tax items that are treated differently for AMT purposes than for regular tax purposes, we may apportion those items between us and our stockholders, and this may affect our stockholder’s AMT liabilities. Although regulations explaining the precise method of apportionment have not yet been issued by the IRS, we may apportion these items in the same proportion that dividends paid to each stockholder bear to our taxable income (determined without regard to the dividends paid deduction), unless we determine that a different method for a particular item is warranted under the circumstances. You should consult your own tax advisor to determine how an investment in our stock could affect your AMT liability.

We or the applicable withholding agent may be required to withhold federal income tax (“backup withholding”) from all distributions to any non-corporate U.S. stockholder (1) who fails to furnish us with a correct taxpayer identification number or a certificate that such stockholder is exempt from backup withholding, or (2) with respect to whom the IRS notifies us or the applicable withholding agent that such stockholder has failed to properly report certain interest and dividend income to the IRS and to respond to notices to that effect. An individual’s taxpayer identification number is his or her social security number. Any amount withheld under backup withholding is allowed as a credit against the U.S. stockholder’s federal income tax liability, provided that proper information is timely provided to the IRS.

Dividend Reinvestment Plan We have adopted a dividend reinvestment plan through which all dividend distributions are paid to our common stockholders in the form of additional shares of our common stock, unless a stockholder elects to receive cash in accordance with the terms of the plan. See “Dividend Reinvestment Plan”. Any distributions made to a U.S. stockholder that are reinvested under the plan will nevertheless remain taxable to the U.S. stockholder. The U.S. stockholder will have an adjusted tax basis in the additional shares of our common stock purchased through the plan equal to the amount of the reinvested distribution. The additional shares will have a new holding period commencing on the day following the day on which the shares are credited to the U.S. stockholder’s account.

Taxation of Non-U.S. Stockholders

A “Non-U.S. stockholder” is a beneficial owner of shares of our common stock that is not a U.S. stockholder or a partnership (including an entity treated as a partnership) for U.S. federal income tax purposes.

Whether an investment in our shares is appropriate for a Non-U.S. stockholder will depend upon that person’s particular circumstances. An investment in the shares by a Non-U.S. stockholder may have adverse tax consequences. Non-U.S. stockholders should consult their tax advisors before investing in our common stock.

In general, dividend distributions (other than certain distributions derived from net long-term capital gains) paid by us to a Non-U.S. stockholder are subject to U.S. federal withholding tax at a rate of 30% (or lower applicable treaty rate) even if they are funded by income or gains (such as portfolio interest, short-term capital gains, or foreign-source dividend and interest income) that, if paid to a Non-U.S. stockholder directly, would not be subject to withholding. If the distributions are effectively connected with a U.S. trade or business of the Non-U.S. stockholder (and, if an income tax treaty applies, attributable to a permanent establishment maintained by the Non-U.S. stockholder in the United States), we will not be required to withhold tax if the Non-U.S. stockholder complies with applicable certification and disclosure requirements, although the distributions will be

 

197

---

Table of Contents

Index to Financial Statements

subject to federal income tax at the rates applicable to U.S. stockholders. (Special certification requirements apply to a Non-U.S. stockholder that is a foreign partnership or a foreign trust, and such entities are urged to consult their own tax advisors.)

However, no withholding is required with respect to certain distributions if (i) the distributions are properly reported to our stockholders as “interest-related dividends” or “short-term capital gain dividends” in written statements to our stockholders, (ii) the distributions are derived from sources specified in the Code for such dividends and (iii) certain other requirements are satisfied. Currently, we do not anticipate that any significant amount of our distributions would be reported as eligible for this exemption from withholding. No assurance can be provided as to whether any amount of our distributions will be eligible for this exemption from withholding or if eligible, will be reported as such by us.

Actual or deemed distributions of our net capital gains to a Non-U.S. stockholder, and gains realized by a Non-U.S. stockholder upon the sale of our common stock, will not be subject to U.S. federal withholding tax and generally will not be subject to U.S. federal income tax unless the distributions or gains, as the case may be, are effectively connected with a U.S. trade or business of the Non-U.S. stockholder (and, if an income tax treaty applies, are attributable to a permanent establishment maintained by the Non-U.S. stockholder in the United States), or in the case of an individual stockholder, the stockholder is present in the United States for a period or periods aggregating 183 days or more during the year of the sale or capital gain dividend and certain other conditions are met.

If we distribute our net capital gains in the form of deemed rather than actual distributions, a Non-U.S. stockholder will be entitled to a federal income tax credit or tax refund equal to the stockholder’s allocable share of the tax we pay on the capital gains deemed to have been distributed. In order to obtain the refund, the Non-U.S. stockholder must obtain a U.S. taxpayer identification number and file a federal income tax return even if the Non-U.S. stockholder would not otherwise be required to obtain a U.S. taxpayer identification number or file a federal income tax return. For a corporate Non-U.S. stockholder, distributions (both actual and deemed), and gains realized upon the sale of our common stock that are effectively connected to a U.S. trade or business may, under certain circumstances, be subject to an additional “branch profits tax” at a 30% rate (or at a lower rate if provided for by an applicable treaty). Accordingly, investment in the shares may not be appropriate for a Non-U.S. stockholder.

A Non-U.S. stockholder who is a non-resident alien individual, and who is not otherwise subject to withholding of federal income tax, may be subject to information reporting and backup withholding of U.S. federal income tax on dividends unless the Non-U.S. stockholder provides us or the dividend paying agent with an IRS Form W-8BEN or IRS Form W-8BEN-E, (or an acceptable substitute or successor form) or otherwise meets documentary evidence requirements for establishing that it is a Non-U.S. stockholder or otherwise establishes an exemption from backup withholding.

The “Foreign Account Tax Compliance Act,” or “FATCA,” provisions of the Code, generally imposes a 30% withholding tax on payments of certain types of income to foreign financial institutions that fail to enter into an agreement with the U.S. Treasury to report certain required information with respect to accounts held by U.S. persons (or held by foreign entities that have U.S. persons as substantial owners). The types of income subject to the tax include U.S. source interest and dividends and the gross proceeds from the sale of any property that could produce U.S.-source interest or dividends paid after December 31, 2018. The information required to be reported includes the identity and taxpayer identification number of each account holder that is a U.S. person and transaction activity within the holder’s account. In addition, subject to certain exceptions, this legislation also imposes a 30% withholding on payments to foreign entities that are not financial institutions unless the foreign entity certifies that it does not have a greater than 10% U.S. owner or provides the withholding agent with identifying information on each greater than 10% U.S. owner. Depending on the status of a Non-U.S. Holder and the status of the intermediaries through which they hold their shares, Non-U.S. Holders could be subject to this

 

198

---

Table of Contents

Index to Financial Statements

30% withholding tax with respect to distributions on their shares and proceeds from the sale of their shares. Under certain circumstances, a Non-U.S. Holders might be eligible for refunds or credits of such taxes.

Non-U.S. persons should consult their own tax advisors with respect to the U.S. federal income tax and withholding tax, and state, local and foreign tax consequences of an investment in the shares.

Failure to Qualify as a Regulated Investment Company

If we fail to satisfy the 90% Income Test or the Diversification Tests for any taxable year, we may nevertheless continue to qualify as a RIC for such taxable year if certain relief provisions are applicable (which may, among other things, require us to pay certain corporate-level federal taxes or to dispose of certain assets).

If we were unable to qualify for treatment as a RIC and the foregoing relief provisions are not applicable, we would be subject to tax on all of our taxable income at regular corporate rates. We would not be able to deduct distributions to stockholders, nor would they be required to be made. Such distributions would be taxable to our stockholders and provided certain holding period and other requirements were met, could qualify for treatment as “qualified dividend income” eligible for the 20% maximum rate to the extent of our current and accumulated earnings and profits. Subject to certain limitations under the Code, corporate distributions generally would be eligible for the dividends-received deduction with respect to distributions from our earnings and profits. Distributions in excess of our current and accumulated earnings and profits would be treated first as a return of capital to the extent of the stockholder’s tax basis, and any remaining distributions would be treated as a capital gain. To requalify as a RIC in a subsequent taxable year, we would be required to satisfy the RIC qualification requirements for that taxable year and dispose of any earnings and profits from any taxable year in which we failed to qualify as a RIC. Subject to a limited exception applicable to RICs that qualified as such under Subchapter M of the Code for at least one taxable year prior to disqualification and that requalify as a RIC no later than the second taxable year following the nonqualifying taxable year, we could be subject to tax on any unrealized net built-in gains in the assets held by us during the period in which we failed to qualify as a RIC that are recognized within the subsequent five taxable years, unless we made a special election to pay corporate-level tax on such built-in gain at the time of our requalification as a RIC.

 

199

---

Table of Contents

Index to Financial Statements

REGULATION

The following discussion is a general summary of the material prohibitions and descriptions governing business development companies. It does not purport to be a complete description of all of the laws and regulations affecting business development companies.

A business development company primarily focuses on investing in or lending to private companies and making managerial assistance available to them, while providing its stockholders with the ability to retain the liquidity of a publicly-traded stock. The 1940 Act contains prohibitions and restrictions relating to transactions between business development companies and their directors and officers and principal underwriters and certain other related persons and requires that a majority of the directors be persons other than “interested persons,” as that term is defined in the 1940 Act. In addition, the 1940 Act provides that we may not change the nature of our business so as to cease to be, or to withdraw our election as, a business development company unless approved by a majority of our outstanding voting securities as defined in the 1940 Act. A majority of the outstanding voting securities of a company is defined under the 1940 Act as the lesser of: (i) 67% or more of such company’s shares present at a meeting if more than 50% of the outstanding shares of such company are present or represented by proxy, or (ii) more than 50% of the outstanding shares of such company.

Qualifying Assets

Under the 1940 Act, a business development company may not acquire any asset other than assets of the type listed in Section 55(a) of the 1940 Act, which are referred to as qualifying assets, unless, at the time the acquisition is made, qualifying assets represent at least 70% of the company’s total assets. The principal categories of qualifying assets relevant to our proposed business are the following:

 

(1)

Securities purchased in transactions not involving any public offering from the issuer of such securities, which issuer (subject to certain limited exceptions) is an eligible portfolio company, or from any person who is, or has been during the preceding 13 months, an affiliated person of an eligible portfolio company, or from any other person, subject to such rules as may be prescribed by the SEC. An eligible portfolio company is defined in the 1940 Act as any issuer which:

 

(a)

is organized under the laws of, and has its principal place of business in, the United States;

 

(b)

is not an investment company (other than a small business investment company wholly owned by the business development company) or a company that would be an investment company but for certain exclusions under the 1940 Act; and

 

(c)

does not have any class of securities listed on a national securities exchange; or if it has securities listed on a national securities exchange such company has a market capitalization of less than $250 million; is controlled by the business development company and has an affiliate of a business development company on its board of directors; or meets such other criteria as may be established by the SEC.

 

(2)

Securities of any portfolio company which we control.

 

(3)

Securities purchased in a private transaction from a U.S. issuer that is not an investment company or from an affiliated person of the issuer, or in transactions incident thereto, if the issuer is in bankruptcy and subject to reorganization or if the issuer, immediately prior to the purchase of its securities was unable to meet its obligations as they came due without material assistance other than conventional lending or financing arrangements.

 

(4)

Securities of an eligible portfolio company purchased from any person in a private transaction if there is no ready market for such securities and we already own 60% of the outstanding equity of the eligible portfolio company.

 

(5)

Securities received in exchange for or distributed on or with respect to securities described in (1) through (4) above, or pursuant to the exercise of warrants or rights relating to such securities.

 

200

---

Table of Contents

Index to Financial Statements

(6)

Cash, cash equivalents, U.S. Government securities or high-quality debt securities maturing in one year or less from the time of investment.

Control, as defined by the 1940 Act, is presumed to exist where a business development company beneficially owns more than 25% of the outstanding voting securities of the portfolio company.

We do not intend to acquire securities issued by any investment company, including other business development companies, that exceed the limits imposed by the 1940 Act. Under these limits, we generally cannot acquire more than 3% of the voting stock of any investment company (as defined in the 1940 Act), invest more than 5% of the value of our total assets in the securities of one such investment company or invest more than 10% of the value of our total assets in the securities of such other investment companies in the aggregate. With regard to that portion of our portfolio invested in securities issued by investment companies, it should be noted that such investments might subject our stockholders to additional expenses.

Significant Managerial Assistance

Business development companies generally must offer to make available to the issuer of the securities significant managerial assistance, except in circumstances where either (i) the business development company controls such issuer of securities or (ii) the business development company purchases such securities in conjunction with one or more other persons acting together and one of the other persons in the group makes available such managerial assistance. Making available significant managerial assistance means, among other things, any arrangement whereby the business development company, through its directors, officers or employees, offers to provide and, if accepted, does so provide, significant guidance and counsel concerning the management, operations or business objectives and policies of a portfolio company through monitoring of portfolio company operations, selective participation in board and management meetings, consulting with and advising a portfolio company’s officers or other organizational or financial guidance.

Temporary Investments

Pending investment in other types of qualifying assets, as described above, our investments may consist of cash, cash equivalents, U.S. government securities or high quality debt securities maturing in one year or less from the time of investment, which we refer to, collectively, as temporary investments, so that 70% of our assets are qualifying assets. We may invest in U.S. treasury bills or in repurchase agreements, provided that such agreements are fully collateralized by cash or securities issued by the U.S. government or its agencies. A repurchase agreement involves the purchase by an investor, such as us, of a specified security and the simultaneous agreement by the seller to repurchase it at an agreed upon future date and at a price which is greater than the purchase price by an amount that reflects an agreed-upon interest rate. There is no percentage restriction on the proportion of our assets that may be invested in such repurchase agreements. However, if more than 25% of our total assets constitute repurchase agreements from a single counterparty, we generally would not meet the diversification tests imposed on us by the Code in order to qualify as a RIC for federal income tax purposes. Thus, we do not intend to enter into repurchase agreements with a single counterparty in excess of this limit. We will monitor the creditworthiness of the counterparties with which we enter into repurchase agreement transactions.

Warrants and Options

Under the 1940 Act, a business development company is subject to restrictions on the amount of warrants, options, restricted stock or rights to purchase shares of capital stock that it may have outstanding at any time. In particular, the amount of capital stock that would result from the conversion or exercise of all outstanding warrants, options or other rights to purchase capital stock cannot exceed 25% of the business development company’s total outstanding shares of capital stock. This amount is reduced to 20% of the business development company’s total outstanding shares of capital stock if the amount of warrants, options or rights issued pursuant to an executive compensation plan would exceed 15% of the business development company’s total outstanding

 

201

---

Table of Contents

Index to Financial Statements

shares of capital stock. We have received exemptive relief from the SEC permitting us to issue stock options and restricted stock to our employees and directors subject to the above conditions, among others. For a discussion regarding the conditions of this exemptive relief, see “—Exemptive Relief” below and Note 7 to our consolidated financial statements.

Senior Securities; Coverage Ratio

We will be permitted, under specified conditions, to issue multiple classes of indebtedness and one class of stock senior to our common stock if our asset coverage, as defined in the 1940 Act, is at least equal to 200% immediately after each such issuance. In addition, we may not be permitted to declare any cash dividend or other distribution on our outstanding common shares, or purchase any such shares, unless, at the time of such declaration or purchase, we have asset coverage of at least 200% after deducting the amount of such dividend, distribution, or purchase price. We may also borrow amounts up to 5% of the value of our total assets for temporary or emergency purposes. For a discussion of the risks associated with the resulting leverage, see “Risk Factors—Risks Related to Our Business Structure—Because we have substantial indebtedness, there could be increased risk in investing in our company.” On April 5, 2007, we received approval from the SEC on our request for exemptive relief that permits us to exclude the indebtedness of our wholly-owned subsidiaries that are small business investment companies from the 200% asset coverage requirement applicable to us.

Capital Structure

We are not generally able to issue and sell our common stock at a price below NAV per share. We may, however, sell our common stock, at a price below the current NAV of the common stock, or sell warrants, options or other rights to acquire such common stock, at a price below the current NAV of the common stock if our board of directors determines that such sale is in the best interests of the Company and our stockholders have approved the practice of making such sales.

At the 2015 Annual Meeting of Stockholders on July 7, 2015, our common stockholders approved a proposal to allow us to issue common stock at a discount from its then current NAV per share, which is effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of stockholders. In connection with the receipt of such stockholder approval, we will limit the number of shares that we issue at a price below NAV pursuant to this authorization so that the aggregate dilutive effect on our then outstanding shares will not exceed 20%. Our Board of Directors of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share. During the year ended December 31, 2015, we have not issued common stock at a discount to NAV.

Code of Ethics

We have adopted and will maintain a code of ethics that establishes procedures for personal investments and restricts certain personal securities transactions. Personnel subject to the code may invest in securities for their personal investment accounts, including securities that may be purchased or held by us, so long as such investments are made in accordance with the code’s requirements. Our code of ethics will generally not permit investments by our employees in securities that may be purchased or held by us. We may be prohibited under the 1940 Act from conducting certain transactions with our affiliates without the prior approval of our directors who are not interested persons and, in some cases, the prior approval of the SEC.

Our current code of ethics is posted on our website at www.htgc.com and was filed with the SEC as an exhibit to a Form 8-K filing on July 13, 2015. You may read and copy the code of ethics at the SEC’s Public Reference Room in Washington, D.C. You may obtain information on the operation of the Public Reference Room by calling the SEC at (202) 551-8090. In addition, the code of ethics is available on the EDGAR Database on the SEC’s Internet site at http://www.sec.gov. You may also obtain copies of the code of ethics, after paying a duplicating fee, by electronic request at the following e-mail address: publicinfo@sec.gov, or by writing the SEC’s Public Reference Section, 100 F Street, N.E., Washington, D.C. 20549.

 

202

---

Table of Contents

Index to Financial Statements

Privacy Principles

We are committed to maintaining the privacy of our stockholders and safeguarding their non-public personal information. The following information is provided to help you understand what personal information we collect, how we protect that information and why, in certain cases, we may share information with select other parties.

Generally, we do not receive any non-public personal information relating to our stockholders, although certain non-public personal information of our stockholders may become available to us. We do not disclose any non-public personal information about our stockholders or former stockholders, except as permitted by law or as is necessary in order to service stockholder accounts (for example, to a transfer agent).

We restrict access to non-public personal information about our stockholders to our employees with a legitimate business need for the information. We maintain physical, electronic and procedural safeguards designed to protect the non-public personal information of our stockholders.

Proxy Voting Policies and Procedures

We vote proxies relating to our portfolio securities in the best interest of our stockholders. We review on a case-by-case basis each proposal submitted to a stockholder vote to determine its impact on the portfolio securities held by us. Although we generally vote against proposals that may have a negative impact on our portfolio securities, we may vote for such a proposal if there exists compelling long-term reasons to do so.

Our proxy voting decisions are made by our investment committee, which is responsible for monitoring each of our investments. To ensure that our vote is not the product of a conflict of interest, we require that: (i) anyone involved in the decision making process disclose to our Chief Compliance Officer any potential conflict that he or she is aware of and any contact that he or she has had with any interested party regarding a proxy vote; and (ii) employees involved in the decision making process or vote administration are prohibited from revealing how we intend to vote on a proposal in order to reduce any attempted influence from interested parties.

Exemptive Relief

On June 21, 2005, we filed a request with the SEC for exemptive relief to allow us to take certain actions that would otherwise be prohibited by the 1940 Act, as applicable to business development companies. Specifically, we requested that the SEC permit us to issue stock options to our non-employee directors as contemplated by Section 61(a)(3)(B)(i)(II) of the 1940 Act. On February 15, 2007, we received approval from the SEC on this exemptive request. In addition, in June 2007, we filed an amendment to the February 2007 order to adjust the number of shares issued to the non-employee directors. On October 10, 2007, we received approval from the SEC on this amended exemptive request.

On April 5, 2007, we received approval from the SEC on our request for exemptive relief that permits us to exclude the indebtedness of our wholly-owned subsidiaries that are small business investment companies from the 200% asset coverage requirement applicable to us.

On May 23, 2007, we received approval from the SEC on our request for exemptive relief that permits us to issue restricted stock to our employees, officers and directors. On June 21, 2007, our shareholders approved amendments to the 2004 Equity Incentive Plan and 2006 Non-Employee Incentive Plan (collectively, the “Plans”) permitting such restricted grants. The maximum amount of shares that may be issued under the Plans will be 10% of the outstanding shares of our common stock on the effective date of the Plans plus 10% of the outstanding number of shares of our common stock issued or delivered by us (other than pursuant to compensation plans) during the term of the Plans. The amount of voting securities that would result from the exercise of all of our outstanding warrants, options, and rights, if any, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 25% of our outstanding voting securities, except

 

203

---

Table of Contents

Index to Financial Statements

that if such amount would exceed 15% of our outstanding voting securities, then the total amount of voting securities that would result from the exercise of all outstanding warrants, options, and rights, if any, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 20% of our outstanding voting securities.

On June 22, 2010 we received approval from the SEC on our request for exemptive relief that permits our employees to exercise their stock options and restricted stock and pay any related income taxes using a cashless exercise program.

Other

We will be periodically examined by the SEC for compliance with the Exchange Act and the 1940 Act.

We are required to provide and maintain a bond issued by a reputable fidelity insurance company to protect us against larceny and embezzlement. Furthermore, as a business development company, we are prohibited from protecting any director or officer against any liability to our stockholders arising from willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such person’s office.

We are required to adopt and implement written policies and procedures reasonably designed to prevent violation of the federal securities laws, review these policies and procedures annually for their adequacy and the effectiveness of their implementation. Our Chief Compliance Officer is responsible for administering these policies and procedures.

Small Business Administration Regulations

We make investments in qualifying small businesses through our two wholly-owned SBIC subsidiaries, HT II and HT III. With our net investments of $44.0 million and $74.5 million in HT II and HT III, respectively, we have the combined capacity to issue a total of $190.2 million of SBA guaranteed debentures, subject to SBA approval. At March 31, 2016, we have issued $190.2 million in SBA guaranteed debentures in our SBIC subsidiaries.

We intend to seek an additional SBIC license to ensure continued access to the maximum statutory limit of SBA guaranteed debentures under the SBIC program, which currently is $350.0 million for a group of SBICs under common control, subject to periodic adjustments by the SBA. We have formed Hercules Technology IV, L.P. for that purpose. There can be no assurance of when or if we will receive SBA approval for another SBIC license.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $19.5 million and have average annual fully taxed net income not exceeding $6.5 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through our wholly-owned subsidiaries HT II and HT III, we plan to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare

 

204

---

Table of Contents

Index to Financial Statements

outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to the Company if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect the Company because HT II and III are our wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2016 as a result of having sufficient capital as defined under the SBA regulations.

HT II and HT III hold approximately $111.6 million and $289.1 million in assets, respectively, and accounted for approximately 6.6% and 17.1% of our total assets prior to consolidation at March 31, 2015.

The SBA restricts the ability of SBICs to repurchase their capital stock. SBA regulations also include restrictions on a “change of control” or transfer of an SBIC and require that SBICs invest idle funds in accordance with SBA regulations. In addition, HT II and HT III may also be limited in their ability to make distributions to us if they do not have sufficient capital and/or distributed earnings, in accordance with SBA regulations.

Our SBIC subsidiaries are subject to regulation and oversight by the SBA, including requirements with respect to maintaining certain minimum financial ratios and other covenants. Receipt of an SBIC license does not assure that our SBIC subsidiaries will receive SBA guaranteed debenture funding, which is dependent upon our SBIC subsidiaries continuing to be in compliance with SBA regulations and policies. The SBA, as a creditor, will have a superior claim to our SBIC subsidiaries’ assets over our stockholders in the event we liquidate our SBIC subsidiaries or the SBA exercises its remedies under the SBA-guaranteed debentures issued by our SBIC subsidiaries upon an event of default.

 

205

---

Table of Contents

Index to Financial Statements

DETERMINATION OF NET ASSET VALUE

We determine the NAV per share of our common stock quarterly. The NAV per share is equal to the value of our total assets minus liabilities and any preferred stock outstanding divided by the total number of shares of common stock outstanding. As of the date of this prospectus, we do not have any preferred stock outstanding.

At March 31, 2016, 97.0% of the Company’s total assets represented investments in portfolio companies whose fair value is determined by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. The Company’s investments are carried at fair value in accordance with the 1940 Act and Accounting Standards Codification Topic 946 Financial Services—Investment Companies (“ASC 946”) and measured in accordance with Accounting Standards Codification Topic 820 Fair Value Measurements and Disclosures (“ASC 820”). The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy by the Company’s Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

The Company may from time to time engage an independent valuation firm to provide the Company with valuation assistance with respect to certain portfolio investments on a quarterly basis. The Company engages independent valuation firms on a discretionary basis. Specifically, on a quarterly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm.

The Company intends to continue to engage an independent valuation firm to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of services rendered by an independent valuation firm is at the discretion of the Board of Directors. The Company’s Board of Directors is ultimately, and solely, responsible for determining the fair value of the Company’s investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Company’s Board of Directors has approved a multi-step valuation process each quarter, as described below:

(1) the Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with the Company’s investment committee;

(3) the Audit Committee of the Board of Directors reviews the preliminary valuation of the investments in the portfolio as provided by the investment committee, which incorporates the results of the independent valuation firm as appropriate; and

 

206

---

Table of Contents

Index to Financial Statements

(4) the Board of Directors, upon the recommendation of the Audit Committee, discusses valuations and determines the fair value of each investment in our portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the investment committee.

ASC 820 establishes a framework for measuring the fair value of the assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also enhances disclosure requirements for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Debt Investments

The Company follows the guidance set forth in ASC 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. In addition, the Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives. These investments are considered Level 2 assets.

In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the OID, if any, and PIK interest or other receivables which have been accrued to principal as earned. The Company then applies the valuation methods as set forth below.

The Company applies a procedure for debt investments that assumes the sale of each investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment.

 

207

---

Table of Contents

Index to Financial Statements

The Company then uses senior secured, leveraged loan yields provided by third party providers to determine the change in market yields between inception of the debt security and the measurement date. Industry specific indices and other relevant market data are used to benchmark/assess market based movements.

Under this process, the Company also evaluates the collateral for recoverability of the debt investment. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated loans using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt security is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt security is greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Debt investments that are traded on a public exchange will be valued at the prevailing market price at period end.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes option pricing model. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

 

208

---

Table of Contents

Index to Financial Statements

Determinations In Connection With Offerings

In connection with each offering of shares of our common stock, the Board of Directors or a committee thereof is required to make the determination that we are not selling shares of our common stock at a price below our then current NAV at the time at which the sale is made, unless it is determined by the Board of Directors that such sale is in the best interests of our stockholders and such sale is otherwise approved by our stockholders. The Board of Directors considers the following factors, among others, in making such determination:

 

•

the NAV of our common stock disclosed in the most recent periodic report we filed with the SEC;

 

•

our management’s assessment of whether any material change in the NAV has occurred (including through the realization of net gains on the sale of our portfolio investments) from the period beginning on the date of the most recently disclosed NAV to the period ending two days prior to the date of the sale of our common stock; and

 

•

the magnitude of the difference between (i) a value that our Board of Directors or an authorized committee thereof has determined reflects the current NAV of our common stock, which is generally based upon the NAV of our common stock disclosed in the most recent periodic report that we filed with the SEC, as adjusted to reflect our management’s assessment of any material change in the NAV of our common stock since the date of the most recently disclosed NAV of our common stock, and (ii) the offering price of the shares of our common stock in the proposed offering.

Importantly, this determination does not require that we calculate NAV in connection with each offering of shares of our common stock, but instead it involves the determination by the Board of Directors or a committee thereof that we are not selling shares of our common stock at a price below the then current NAV at the time at which the sale is made.

Moreover, to the extent that there is a possibility that we may (i) issue shares of our common stock at a price below the then current NAV of our common stock at the time at which the sale is made or (ii) trigger the undertaking (which we will provide to the SEC in a registration statement to which a prospectus will be a part) to suspend the offering of shares of our common stock pursuant to a prospectus if the NAV fluctuates by certain amounts in certain circumstances until such prospectus is amended, the Board of Directors or a committee thereof will elect, in the case of clause (i) above, either to postpone the offering until such time that there is no longer the possibility of the occurrence of such, events or to undertake to determine NAV within two days prior to any such sale to ensure that such sale will not be below our then current NAV, and, in the case of clause (ii) above, to comply with such undertaking or to undertake to determine NAV to ensure that such undertaking has not been triggered.

These processes and procedures are part of our compliance policies and procedures. Records will be made contemporaneously with all determinations described in this section and these records will be maintained with other records we are required to maintain under the 1940 Act.

 

209

---

Table of Contents

Index to Financial Statements

SALES OF COMMON STOCK BELOW NET ASSET VALUE

At our 2015 Annual Meeting of Stockholders on July 7, 2015, our common stockholders voted to allow us to issue common stock at a discount from our NAV per share, effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of our stockholders. In connection with the receipt of such stockholder approval, we will agree to limit the number of shares that we issue at a price below NAV pursuant to this authorization so that the aggregate dilutive effect on our then outstanding shares will not exceed 20%. Our Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share.

In order to sell shares pursuant to this authorization:

 

•

a majority of our independent directors who have no financial interest in the sale must have approved the sale; and

 

•

a majority of such directors, who are not interested persons of the Company, in consultation with the underwriter or underwriters of the offering if it is to be underwritten, must have determined in good faith, and as of a time immediately prior to the first solicitation by us or on our behalf of firm commitments to purchase such shares or immediately prior to the issuance of such shares, that the price at which such shares are to be sold is not less than a price which closely approximates the market value of those shares, less any underwriting commission or discount; and

Any offering of common stock below NAV per share will be designed to raise capital for investment in accordance with our investment objectives and business strategies.

In making a determination that an offering below NAV per share is in our and our stockholders’ best interests, our Board of Directors would consider a variety of factors including:

 

•

The effect that an offering below NAV per share would have on our stockholders, including the potential dilution they would experience as a result of the offering;

 

•

The amount per share by which the offering price per share and the net proceeds per share are less than the most recently determined NAV per share;

 

•

The relationship of recent market prices of our common stock to NAV per share and the potential impact of the offering on the market price per share of our common stock;

 

•

Whether the proposed offering price would closely approximate the market value of our shares;

 

•

The potential market impact of being able to raise capital during the current financial market difficulties;

 

•

The nature of any new investors anticipated to acquire shares in the offering;

 

•

The anticipated rate of return on and quality, type and availability of investments to be funded with the proceeds from the offering, if any; and

 

•

The leverage available to us, both before and after any offering, and the terms thereof.

Sales by us of our common stock at a discount from NAV pose potential risks for our existing stockholders whether or not they participate in the offering, as well as for new investors who participate in the offering.

The following three headings and accompanying tables will explain and provide hypothetical examples on the impact of an offering at a price less than NAV per share on three different sets of investors:

 

•

existing stockholders who do not purchase any shares in the offering;

 

•

existing stockholders who purchase a relatively small amount of shares in the offering or a relatively large amount of shares in the offering; and

 

210

---

Table of Contents

Index to Financial Statements

Impact on Existing Stockholders who do not Participate in the Offering

Our existing stockholders who do not participate in an offering below NAV per share or who do not buy additional shares in the secondary market at the same or lower price we obtain in the offering (after expenses and commissions) face the greatest potential risks. All stockholders will experience an immediate decrease (often called dilution) in the NAV of the shares they hold. Stockholders who do not participate in the offering will also experience a disproportionately greater decrease in their participation in our earnings and assets and their voting power than stockholders who do participate in the offering. All stockholders may also experience a decline in the market price of their shares, which often reflects to some degree announced or potential decreases in NAV per share. This decrease could be more pronounced as the size of the offering and level of discount to NAV increases.

The following table illustrates the level of NAV dilution that would be experienced by a nonparticipating stockholder in different hypothetical offerings of different sizes and levels of discount from NAV per share. Actual sales prices and discounts may differ from the presentation below.

The examples assume that Company XYZ has 3,000,000 common shares outstanding, $40,000,000 in total assets and $10,000,000 in total liabilities. The current NAV and NAV are thus $30,000,000 and $10.00, respectively. The table illustrates the dilutive effect on nonparticipating Stockholder A of (1) an offering of 300,000 shares (10% of the outstanding shares) with proceeds to the Company XYZ at $9.00 per share after offering expenses and commissions, and (2) an offering of 600,000 shares (20% of the outstanding shares) with proceeds to the Company at $0.001 per share after offering expenses and commissions (a 100% discount from NAV).

 

		Prior to Sale Below NAV				Example 1 10% Offering at 10% Discount								Example 2 20% Offering at 100% Discount
						Following Sale				% Change				Following Sale				% Change
Offering Price
Price per Share to Public(1)			—			$	9.47				—			$	0.001				—
Net Proceeds per Share to Issuer			—			$	9.00				—			$	0.001				—
Decrease to NAV
Total Shares Outstanding			3,000,000				3,300,000				10.00	%			3,600,000				20.00	%
NAV per Share		$	10.00			$	9.91				(0.90	)%		$	8.33				(16.67	)%
Share Dilution to Stockholder
Shares Held by Stockholder A			30,000				30,000				—				30,000				—
Percentage of Shares Held by Stockholder A			1.00	%			0.91	%			(9.09	)%			0.83	%			(16.67	)%
Total Asset Values
Total NAV Held by Stockholder A		$	300,000			$	297,273				(0.90	)%		$	250,005				(16.67	)%
Total Investment by Stockholder A (Assumed to Be $10.00 per Share)		$	300,000			$	300,000				—			$	300,000				—
Total Dilution to Stockholder A (Change in Total NAV Held By Stockholder)						$	(2,727	)			—			$	(49,995	)			—
Per Share Amounts
NAV per Share Held by Stockholder A			—			$	9.91				—			$	8.33				—
Investment per Share Held by Stockholder A (Assumed to be $10.00 per Share on Shares Held Prior to Sale)		$	10.00			$	10.00				—			$	10.00				—
Dilution per Share Held by Stockholder A			—			$	(0.09	)			—			$	(1.67	)			—
Percentage Dilution per Share Held by Stockholder A			—				—				(0.90	)%			—				(16.67	)%

 

(1)	Assumes 5% in selling compensation and expenses paid by Company XYZ.

 

211

---

Table of Contents

Index to Financial Statements

Impact on Existing Stockholders who do Participate in the Offering

Our existing stockholders who participate in an offering below NAV per share or who buy additional shares in the secondary market at the same or lower price as we obtain in the offering (after expenses and commissions) will experience the same types of NAV dilution as the nonparticipating stockholders, albeit at a lower level, to the extent they purchase less than the same percentage of the discounted offering as their interest in our shares immediately prior to the offering. The level of NAV dilution on an aggregate basis will decrease as the number of shares such stockholders purchase increases. Existing stockholders who buy more than their proportionate percentage will experience NAV dilution but will, in contrast to existing stockholders who purchase less than their proportionate share of the offering, experience an increase (often called accretion) in NAV per share over their investment per share and will also experience a disproportionately greater increase in their participation in our earnings and assets and their voting power than our increase in assets, potential earning power and voting interests due to the offering. The level of accretion will increase as the excess number of shares purchased by such stockholder increases. Even a stockholder who over-participates will, however, be subject to the risk that we may make additional discounted offerings in which such stockholder does not participate, in which case such a stockholder will experience NAV dilution as described above in such subsequent offerings. These stockholders may also experience a decline in the market price of their shares, which often reflects to some degree announced or potential decreases in NAV per share. This decrease could be more pronounced as the size of the offering and the level of discount to NAV increases.

 

212

---

Table of Contents

Index to Financial Statements

The following chart illustrates the level of dilution and accretion in the hypothetical 20% discount offering from the prior chart (Example 3) for a stockholder that acquires shares equal to (1) 50% of its proportionate share of the offering (i.e., 3,000 shares, which is 0.5% of an offering of 600,000 shares rather than its 1.0% proportionate share) and (2) 150% of such percentage (i.e., 9,000 shares, which is 1.5% of an offering of 600,000 shares rather than its 1.0% proportionate share). The prospectus supplement pursuant to which any discounted offering is made will include a chart for this example based on the actual number of shares in such offering and the actual discount from the most recently determined NAV per share.

 

		Prior to Sale Below NAV				50% Participation								150% Participation
						Following Sale				% Change				Following Sale				% Change
Offering Price
Price per Share to Public(1)			—			$	8.42				—			$	8.42				—
Net Proceeds per Share to Issuer			—			$	8.00				—			$	8.00				—
Increase in Shares and Decrease to NAV
Total Shares Outstanding			3,000,000				3,600,000				20.00	%			3,600,000				20.00	%
NAV per Share		$	10.00			$	9.67				(3.33	)%		$	9.67				(3.33	)%
Dilution/Accretion to Participating Stockholder A
Share Dilution/Accretion
Shares Held by Stockholder A			30,000				33,000				10.00	%			39,000				30.00	%
Percentage Outstanding Held by Stockholder A			1.00	%			0.92	%			(8.33	)%			1.08	%			8.33	%
NAV Dilution/Accretion
Total NAV Held by Stockholder A		$	300,000			$	319,110				6.33	%		$	377,130				25.67	%
Total Investment by Stockholder A (Assumed to be $10.00 per Share on Shares Held Prior to Sale)			—			$	325,260				—			$	375,780				—
Total Dilution/Accretion to Stockholder A (Total NAV Less Total Investment)			—			$	(6,150	)			—			$	1,350				—
NAV Dilution/Accretion per Share
NAV per Share Held by Stockholder A			—			$	9.67				—			$	9.67				—
Investment per Share Held by Stockholder A (Assumed to be $10.00 per Share on Shares Held Prior to Sale)		$	10.00			$	9.86				(1.44	)%		$	9.64				(3.65	)%
NAV Dilution/Accretion per Share Experienced by Stockholder A (NAV per Share Less Investment per Share)			—			$	(0.19	)			—			$	0.03				—
Percentage NAV Dilution/Accretion Experienced by Stockholder A (NAV Dilution/Accretion per Share Divided by Investment per Share)			—				—				(1.93	)%			—				0.31	%

 

(1)	Assumes 5% in selling compensation and expenses paid by Company XYZ.

Impact on New Investors

Investors who are not currently stockholders, but who participate in an offering below NAV and whose investment per share is greater than the resulting NAV per share (due to selling compensation and expenses paid by us) will experience an immediate decrease, albeit small, in the NAV of their shares and their NAV per share compared to the price they pay for their shares. Investors who are not currently stockholders and who participate in an offering below NAV per share and whose investment per share is also less than the resulting NAV per share will experience an immediate increase in the NAV of their shares and their NAV per share compared to the price they pay for their shares. All these investors will experience a disproportionately greater participation in our earnings and assets and their voting power than our increase in assets, potential earning power and voting interests. These investors will, however, be subject to the risk that we may make additional discounted offerings

 

213

---

Table of Contents

Index to Financial Statements

in which such new stockholder does not participate, in which case such new stockholder will experience dilution as described above in such subsequent offerings. These investors may also experience a decline in the market price of their shares, which often reflects to some degree announced or potential decreases in NAV per share. This decrease could be more pronounced as the size of the offering and level of discount to NAV increases.

The following chart illustrates the level of dilution or accretion for new investors that would be experienced by a new investor in the same hypothetical 10% and 100% discounted offerings as described in the first chart above. The illustration is for a new investor who purchases the same percentage (1.00%) of the shares in the offering as Stockholder A in the prior examples held immediately prior to the offering. The prospectus supplement pursuant to which any discounted offering is made will include a chart for these examples based on the actual number of shares in such offering and the actual discount from the most recently determined NAV per share.

 

		Prior to Sale Below NAV				Example 1 10% Offering at 10% Discount								Example 2 20% Offering at 100% Discount
						Following Sale				% Change				Following Sale				% Change
Offering Price
Price per Share to Public(1)			—			$	9.47				—			$	0.001				—
Net Proceeds per Share to Issuer			—			$	9.00				—			$	0.001				—
Increase in Shares and Decrease to NAV
Total Shares Outstanding			3,000,000				3,300,000				10.00	%			3,600,000				20.00	%
NAV per Share		$	10.00			$	9.91				(0.90	)%		$	8.33				(16.67	)%
Dilution/Accretion to New Investor A
Share Dilution
Shares Held by Investor A			—				3,000				—				6,000				—
Percentage Outstanding Held by Investor A			0.00	%			0.09	%			—				0.17	%			—
NAV Dilution
Total NAV Held by Investor A			—			$	29,730				—			$	50,001				—
Total Investment by Investor A (At Price to Public)			—			$	28,410				—			$	6				—
Total Dilution/Accretion to Investor A (Total NAV Less Total Investment)			—			$	1,320				—			$	49,995				—
NAV Dilution per Share
NAV per Share Held by Investor A						$	9.91				—			$	8.33				—
Investment per Share Held by Investor A			—			$	9.47				—			$	0.001				—
NAV Dilution/Accretion per Share Experienced by Investor A (NAV per Share Less Investment per Share)			—			$	0.44				—			$	8.33				—
Percentage NAV Dilution/Accretion Experienced by Investor A (NAV Dilution/Accretion per Share Divided by Investment per Share)			—				—				4.65	%			—				99.99	%

 

(1)	Assumes 5% in selling compensation and expenses paid by Company XYZ.

 

214

---

Table of Contents

Index to Financial Statements

DIVIDEND REINVESTMENT PLAN

We have adopted a dividend reinvestment plan (the “DRP”), through which all dividend distributions are paid to our stockholders in the form of additional shares of our common stock, unless a stockholder elects to receive cash as provided below. In this way, a stockholder can maintain an undiluted investment in our common stock and still allow us to pay out the required distributable income.

No action is required on the part of a registered stockholder to receive a dividend distribution in shares of our common stock. A registered stockholder may elect to receive an entire dividend distribution in cash by notifying American Stock Transfer & Trust Company, the plan administrator and our transfer agent and registrar, so that such notice is received by the plan administrator no later than three days prior to the payment date for dividend distributions to stockholders. The plan administrator will set up an account for shares acquired through the DRP for each stockholder who has not elected to receive distributions in cash (each a “Participant”) and hold such shares in non-certificated form. Upon request by a Participant, received not less than three days prior to the payment date, the plan administrator will, instead of crediting shares to the Participant’s account, issue a certificate registered in the Participant’s name for the number of whole shares of our common stock and a check for any fractional share.

Those stockholders whose shares are held by a broker or other financial intermediary may receive distributions in cash by notifying their broker or other financial intermediary of their election.

We expect to use primarily newly-issued shares to implement the DRP, whether our shares are trading at a premium or at a discount to NAV, although we have the option under the DRP to purchase shares in the market to fulfill DRP requirements. The number of shares to be issued to a stockholder is determined by dividing the total dollar amount of the dividend distribution payable to such stockholder by the market price per share of our common stock at the close of regular trading on the NYSE on the valuation date for such dividend distribution. Market price per share on that date will be the closing price for such shares on the NYSE or, if no sale is reported for such day, at the average of their electronically-reported bid and asked prices. The number of shares of our common stock to be outstanding after giving effect to payment of the distribution cannot be established until the value per share at which additional shares will be issued has been determined and elections of our stockholders have been tabulated.

There is no charge to our stockholders for receiving their dividend distributions in the form of additional shares of our common stock. The plan administrator’s fees for handling dividend distributions in stock are paid by us. There are no brokerage charges with respect to shares we have issued directly as a result of dividend distributions payable in stock. If a Participant elects by internet or by written or telephonic notice to the plan administrator to have the plan administrator sell part or all of the shares held by the plan administrator in the Participant’s account and remit the proceeds to the Participant, the plan administrator is authorized to deduct a $15.00 transaction fee plus brokerage commissions from the proceeds.

Any shares issued in connection with a stock split or stock dividend will be added to a Participant’s account with the Plan Administrator. The Plan Administrator may curtail or suspend transaction processing until the completion of such stock split or payment of such stock dividend.

Stockholders who receive dividend distributions in the form of stock generally are subject to the same federal, state and local tax consequences as are stockholders who elect to receive their dividend distributions in cash. A stockholder’s basis for determining gain or loss upon the sale of stock received in a dividend distribution from us will be equal to the total dollar amount of the dividend distribution payable to the stockholder.

The DRP may be terminated by us upon notice in writing mailed to each Participant at least 30 days prior to any record date for the payment of any dividend distribution by us. All correspondence concerning the DRP, including requests for additional information, should be directed to the plan administrator by mail at American Stock Transfer & Trust Company, Attn: Dividend Reinvestment Department, P.O. Box 922, Wall Street Station, New York, NY 10269-0560 or by phone at 1-866-669-9888.

 

215

---

Table of Contents

Index to Financial Statements

DESCRIPTION OF CAPITAL STOCK

The following description is based on relevant portions of the Maryland General Corporation Law and on our charter and bylaws. This summary may not contain all of the information that is important to you, and we refer you to the Maryland General Corporation Law and our charter and bylaws for a more detailed description of the provisions summarized below.

Under the terms of our charter, our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, of which 73,890,579 shares are outstanding as of June 2, 2016. Under our charter, our Board of Directors is authorized to classify and reclassify any unissued shares of stock into other classes or series of stock, and to cause the issuance of such shares, without obtaining stockholder approval. In addition, as permitted by the Maryland General Corporation Law, but subject to the 1940 Act, our charter provides that the Board of Directors, without any action by our stockholders, may amend the charter from time to time to increase or decrease the aggregate number of shares of stock or the number of shares of stock of any class or series that we have authority to issue. Under Maryland law, our stockholders generally are not personally liable for our debts or obligations.

Common Stock

All shares of our common stock have equal rights as to earnings, assets, dividends and voting privileges, except as described below and, when they are issued, will be duly authorized, validly issued, fully paid and nonassessable.

Distributions may be paid to the holders of our common stock if, as and when authorized by our Board of Directors and declared by us out of assets legally available therefor. Shares of our common stock have no conversion, exchange, preemptive or redemption rights. In the event of a liquidation, dissolution or winding up of Hercules each share of our common stock would be entitled to share ratably in all of our assets that are legally available for distribution after we pay all debts and other liabilities and subject to any preferential rights of holders of our preferred stock, if any preferred stock is outstanding at such time. Each share of our common stock is entitled to one vote on all matters submitted to a vote of stockholders, including the election of directors. Except as provided with respect to any other class or series of stock, the holders of our common stock will possess exclusive voting power. There is no cumulative voting in the election of directors, which means that holders of a majority of the outstanding shares of common stock will elect all of our directors, and holders of less than a majority of such shares will be unable to elect any director.

 

Title of Class

Amount Authorized

Amount Held by Company for its Account

Amount Outstanding

Common Stock, $0.001 par value per share

200,000,000

—

73,890,579

Preferred Stock

Our charter authorizes our Board of Directors to classify and reclassify any unissued shares of stock into other classes or series of stock, including preferred stock. Prior to issuance of shares of each class or series, the Board of Directors is required by Maryland law and by our charter to set the terms, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications and terms or conditions of redemption for each class or series. Thus, the Board of Directors could authorize the issuance of shares of preferred stock with terms and conditions which could have the effect of delaying, deferring or preventing a transaction or a change in control that might involve a premium price for holders of our common stock or otherwise be in their best interest. You should note, however, that any issuance of preferred stock must comply with the requirements of the 1940 Act. The 1940 Act requires, among other things, that (1) immediately after issuance and before any dividend or other distribution is made with respect to our common stock and before

 

216

---

Table of Contents

Index to Financial Statements

any purchase of common stock is made, such preferred stock together with all other senior securities must not exceed an amount equal to 50% of our total assets after deducting the amount of such dividend, distribution or purchase price, as the case may be, and (2) the holders of shares of preferred stock, if any are issued, must be entitled as a class to elect two directors at all times and to elect a majority of the directors if dividends on such preferred stock are in arrears by two years or more. Certain matters under the 1940 Act require the separate vote of the holders of any issued and outstanding preferred stock. We believe that the availability for issuance of preferred stock will provide us with increased flexibility in structuring future financings and acquisitions.

Limitation on Liability of Directors and Officers; Indemnification and Advance of Expenses

Maryland law permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (a) actual receipt of an improper benefit or profit in money, property or services or (b) active and deliberate dishonesty established by a final judgment as being material to the cause of action. Our charter contains such a provision which eliminates directors’ and officers’ liability to the maximum extent permitted by Maryland law, subject to the requirements of the 1940 Act.

Our charter authorizes us, to the maximum extent permitted by Maryland law and subject to the requirements of the 1940 Act, to indemnify any present or former director or officer or any individual who, while a director or officer and at our request, serves or has served another corporation, real estate investment trust, partnership, joint venture, trust, employee benefit plan or other enterprise as a director, officer, partner or trustee, from and against any claim or liability to which such person may become subject or which such person may incur by reason of his or her service in any such capacity, except with respect to any matter as to which such person shall have been finally adjudicated in any proceeding not to have acted in good faith in the reasonable belief that their action was in our best interest or to be liable to us or our stockholders by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such person’s office. Our charter also provides that, to the maximum extent permitted by Maryland law, with the approval of our Board of Directors and provided that certain conditions described in our charter are met, we may pay certain expenses incurred by any such indemnified person in advance of the final disposition of a proceeding upon receipt of an undertaking by or on behalf of such indemnified person to repay amounts we have so paid if it is ultimately determined that indemnification of such expenses is not authorized under our charter. Our bylaws obligate us, to the maximum extent permitted by Maryland law and subject to the requirements of the 1940 Act, to indemnify any present or former director or officer or any individual who, while a director or officer and at our request, serves or has served another corporation, real estate investment trust, partnership, joint venture, trust, employee benefit plan or other enterprise as a director, officer, partner or trustee and who is made, or threatened to be made, a party to the proceeding by reason of his or her service in any such capacity from and against any claim or liability to which that person may become subject or which that person may incur by reason of his or her service in any such capacity, except with respect to any matter as to which such person shall have been finally adjudicated in any proceeding not to have acted in good faith in the reasonable belief that their action was in our best interest or to be liable to us or our stockholders by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such person’s office. Our bylaws also provide that, to the maximum extent permitted by Maryland law, with the approval of our Board of Directors and provided that certain conditions described in our bylaws are met, we may pay certain expenses incurred by any such indemnified person in advance of the final disposition of a proceeding upon receipt of an undertaking by or on behalf of such indemnified person to repay amounts we have so paid if it is ultimately determined that indemnification of such expenses is not authorized under our bylaws.

Maryland law requires a corporation (unless its charter provides otherwise, which our charter does not) to indemnify a director or officer who has been successful in the defense of any proceeding to which he or she is made, or threatened to be made, a party by reason of his or her service in that capacity. Maryland law permits a corporation to indemnify its present and former directors and officers, among others, against judgments,

 

217

---

Table of Contents

Index to Financial Statements

penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they may be made, or threatened to be made, a party by reason of their service in those or other capacities unless it is established that (a) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (1) was committed in bad faith or (2) was the result of active and deliberate dishonesty, (b) the director or officer actually received an improper personal benefit in money, property or services or (c) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. However, under Maryland law, a Maryland corporation may not indemnify for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal benefit was improperly received, unless in either case a court orders indemnification, and then only for expenses. In addition, Maryland law permits a corporation to advance reasonable expenses to a director or officer upon the corporation’s receipt of (a) a written affirmation by the director or officer of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification by the corporation and (b) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately determined that the standard of conduct was not met.

We currently have in effect a directors’ and officers’ insurance policy covering our directors and officers and us for any acts and omissions committed, attempted or allegedly committed by any director or officer during the policy period. The policy is subject to customary exclusions.

Provisions of the Maryland General Corporation Law and Our Charter and Bylaws

The Maryland General Corporation Law and our charter and bylaws contain provisions that could make it more difficult for a potential acquiror to acquire us by means of a tender offer, proxy contest or otherwise. These provisions are expected to discourage certain coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to negotiate first with our Board of Directors. We believe that the benefits of these provisions outweigh the potential disadvantages of discouraging any such acquisition proposals because, among other things, the negotiation of such proposals may improve their terms.

Classified Board of Directors

Our Board of Directors is divided into three classes of directors serving staggered three-year terms. The terms of the first, second and third classes will expire in 2017, 2015 and 2016, respectively. Upon expiration of their current terms, directors of each class are eligible to serve for three-year terms or until their successors are duly elected and qualify. Each year one class of directors will be elected by the stockholders. A classified board may render a change in control or removal of our incumbent management more difficult. We believe, however, that the longer time required to elect a majority of a classified Board of Directors will help to ensure the continuity and stability of our management and policies.

Election of Directors

Our charter provides that, except as otherwise provided in the bylaws, the affirmative vote of the holders of a majority of the outstanding shares of stock entitled to vote in the election of directors will be required to elect each director. Our bylaws currently provide that directors are elected by a plurality of the votes cast in the election of directors. Pursuant to our charter and bylaws, our Board of Directors may amend the bylaws to alter the vote required to elect directors.

Number of Directors; Vacancies; Removal

Our charter provides that the number of directors will be set only by the Board of Directors in accordance with our bylaws. Our bylaws provide that a majority of our entire Board of Directors may at any time increase or decrease the number of directors. However, unless the bylaws are amended, the number of directors may never

 

218

---

Table of Contents

Index to Financial Statements

be less than one nor more than 12. We have elected to be subject to the provision of Subtitle 8 of Title 3 of the Maryland General Corporation Law regarding the filling of vacancies on the Board of Directors. Accordingly, at such time, except as may be provided by the Board of Directors in setting the terms of any class or series of preferred stock, any and all vacancies on the Board of Directors may be filled only by the affirmative vote of a majority of the remaining directors in office, even if the remaining directors do not constitute a quorum, and any director elected to fill a vacancy shall serve for the remainder of the full term of the directorship in which the vacancy occurred and until a successor is elected and qualifies, subject to any applicable requirements of the 1940 Act.

Our charter provides that a director may be removed only for cause, as defined in the charter, and then only by the affirmative vote of at least two-thirds of the votes entitled to be cast in the election of directors.

Action by Stockholders

Under the Maryland General Corporation Law, stockholder action may be taken only at an annual or special meeting of stockholders or by unanimous consent in lieu of a meeting (unless the charter provides for stockholder action by less than unanimous written consent, which our charter does not). These provisions, combined with the requirements of our bylaws regarding the calling of a stockholder-requested special meeting of stockholders discussed below, may have the effect of delaying consideration of a stockholder proposal until the next annual meeting.

Advance Notice Provisions for Stockholder Nominations and Stockholder Proposals

Our bylaws provide that with respect to an annual meeting of stockholders, nominations of persons for election to the Board of Directors and the proposal of business to be considered by stockholders may be made only (1) pursuant to our notice of the meeting, (2) by the Board of Directors or (3) by a stockholder who is entitled to vote at the meeting and who has complied with the advance notice procedures of the bylaws. With respect to special meetings of stockholders, only the business specified in our notice of the meeting may be brought before the meeting. Nominations of persons for election to the Board of Directors at a special meeting may be made only (1) pursuant to our notice of the meeting, (2) by the Board of Directors or (3) provided that the Board of Directors has determined that directors will be elected at the meeting, by a stockholder who is entitled to vote at the meeting and who has complied with the advance notice provisions of the bylaws.

The purpose of requiring stockholders to give us advance notice of nominations and other business is to afford our Board of Directors a meaningful opportunity to consider the qualifications of the proposed nominees and the advisability of any other proposed business and, to the extent deemed necessary or desirable by our Board of Directors, to inform stockholders and make recommendations about such qualifications or business, as well as to provide a more orderly procedure for conducting meetings of stockholders. Although our bylaws do not give our Board of Directors any power to disapprove stockholder nominations for the election of directors or proposals recommending certain action, they may have the effect of precluding a contest for the election of directors or the consideration of stockholder proposals if proper procedures are not followed and of discouraging or deterring a third party from conducting a solicitation of proxies to elect its own slate of directors or to approve its own proposal without regard to whether consideration of such nominees or proposals might be harmful or beneficial to us and our stockholders.

Calling of Special Meeting of Stockholders

Our bylaws provide that special meetings of stockholders may be called by our Board of Directors and certain of our officers. Additionally, our bylaws provide that, subject to the satisfaction of certain procedural and informational requirements by the stockholders requesting the meeting, a special meeting of stockholders shall be called by our secretary upon the written request of stockholders entitled to cast not less than a majority of all of the votes entitled to be cast at such meeting.

 

219

---

Table of Contents

Index to Financial Statements

Approval of Extraordinary Corporate Action; Amendment of Charter and Bylaws

Under Maryland law, a Maryland corporation generally cannot dissolve, amend its charter, merge, sell all or substantially all of its assets, engage in a share exchange or engage in similar transactions outside the ordinary course of business, unless approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter. However, a Maryland corporation may provide in its charter for approval of these matters by a lesser percentage, but not less than a majority of all of the votes entitled to be cast on the matter. Our charter generally provides for approval of charter amendments and extraordinary transactions by the stockholders entitled to cast at least a majority of the votes entitled to be cast on the matter. Our charter also provides that certain charter amendments and any proposal for our conversion, whether by merger or otherwise, from a closed-end company to an open-end company or any proposal for our liquidation or dissolution requires the approval of the stockholders entitled to cast at least 75% of the votes entitled to be cast on such matter. However, if such amendment or proposal is approved by at least 75% of our continuing directors (in addition to approval by our Board of Directors), such amendment or proposal may be approved by the stockholders entitled to cast a majority of the votes entitled to be cast on such a matter. The “continuing directors” are defined in our charter as our current directors, as well as those directors whose nomination for election by the stockholders or whose election by the directors to fill vacancies is approved by a majority of the continuing directors then on the Board of Directors.

Our charter and bylaws provide that the Board of Directors will have the exclusive power to make, alter, amend or repeal any provision of our bylaws.

No Appraisal Rights

Except with respect to appraisal rights arising in connection with the Control Share Act discussed below, as permitted by the Maryland General Corporation Law, our charter provides that stockholders will not be entitled to exercise appraisal rights.

Control Share Acquisitions

The Maryland Control Share Acquisition Act (the “Control Share Act”) provides that control shares of a Maryland corporation acquired in a control share acquisition have no voting rights except to the extent approved by a vote of two-thirds of the votes entitled to be cast on the matter. Shares owned by the acquiror, by officers or by directors who are employees of the corporation are excluded from shares entitled to vote on the matter. Control shares are voting shares of stock which, if aggregated with all other shares of stock owned by the acquiror or in respect of which the acquiror is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquiror to exercise voting power in electing directors within one of the following ranges of voting power:

 

•

one-tenth or more but less than one-third;

 

•

one-third or more but less than a majority; or

 

•

a majority or more of all voting power.

The requisite stockholder approval must be obtained each time an acquiror crosses one of the thresholds of voting power set forth above. Control shares do not include shares the acquiring person is then entitled to vote as a result of having previously obtained stockholder approval. A control share acquisition means the acquisition of control shares, subject to certain exceptions.

A person who has made or proposes to make a control share acquisition may compel the Board of Directors of the corporation to call a special meeting of stockholders to be held within 50 days of demand to consider the voting rights of the shares. The right to compel the calling of a special meeting is subject to the satisfaction of certain conditions, including an undertaking to pay the expenses of the meeting. If no request for a meeting is made, the corporation may itself present the question at any stockholders meeting.

 

220

---

Table of Contents

Index to Financial Statements

If voting rights are not approved at the meeting or if the acquiring person does not deliver an acquiring person statement as required by the statute, then the corporation may repurchase for fair value any or all of the control shares, except those for which voting rights have previously been approved. The right of the corporation to repurchase control shares is subject to certain conditions and limitations. Fair value is determined, without regard to the absence of voting rights for the control shares, as of the date of the last control share acquisition by the acquiror or of any meeting of stockholders at which the voting rights of the shares are considered and not approved. If voting rights for control shares are approved at a stockholders meeting and the acquiror becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal rights. The fair value of the shares as determined for purposes of appraisal rights may not be less than the highest price per share paid by the acquiror in the control share acquisition.

The Control Share Act does not apply (a) to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction or (b) to acquisitions approved or exempted by the charter or bylaws of the corporation.

Our bylaws contain a provision exempting from the Control Share Act any and all acquisitions by any person of our shares of stock.

Business Combinations

Under the Maryland Business Combination Act (the “Business Combination Act”), “business combinations” between a Maryland corporation and an interested stockholder or an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These business combinations include a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities. An interested stockholder is defined as:

 

•

any person who beneficially owns 10% or more of the voting power of the corporation’s shares; or

 

•

an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner of 10% or more of the voting power of the then outstanding voting stock of the corporation.

A person is not an interested stockholder under this statute if the Board of Directors approved in advance the transaction by which such stockholder otherwise would have become an interested stockholder. However, in approving a transaction, the Board of Directors may provide that its approval is subject to compliance, at or after the time of approval, with any terms and conditions determined by the board.

After the 5-year prohibition, any business combination between the Maryland corporation and an interested stockholder generally must be recommended by the Board of Directors of the corporation and approved by the affirmative vote of at least:

 

•

80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and

 

•

two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder.

These super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price, as defined under Maryland law, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares.

The statute permits various exemptions from its provisions, including business combinations that are exempted by the Board of Directors before the time that the interested stockholder becomes an interested stockholder. Our Board of Directors has adopted a resolution exempting any business combination between us

 

221

---

Table of Contents

Index to Financial Statements

and any other person from the provisions of the Business Combination Act, provided that the business combination is first approved by the Board of Directors, including a majority of the directors who are not interested persons as defined in the 1940 Act.

Conflict with 1940 Act

Our bylaws provide that, if and to the extent that any provision of the Maryland General Corporation Law, or any provision of our charter or bylaws conflicts with any provision of the 1940 Act, the applicable provision of the 1940 Act will control.

Regulatory Restrictions

Our wholly-owned subsidiaries, HT II and HT III, have obtained SBIC licenses. The SBA prohibits, without prior SBA approval, a “change of control” or transfers which would result in any person (or group of persons acting in concert) owning 10% or more of any class of capital stock of a SBIC. A “change of control” is any event which would result in a transfer of the power, direct or indirect, to direct the management and policies of a SBIC, whether through ownership, contractual arrangements or otherwise.

 

222

---

Table of Contents

Index to Financial Statements

DESCRIPTION OF OUR PREFERRED STOCK

In addition to shares of common stock, our charter authorizes the issuance of preferred stock. We may issue preferred stock from time to time in one or more classes or series, without stockholder approval. If we offer preferred stock under this prospectus we will issue an appropriate prospectus supplement. Prior to issuance of shares of each class or series, our board of directors is required by Maryland law and by our charter to set the terms, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications and terms or conditions of redemption for each class or series. Thus, the board of directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of delaying, deferring or preventing a transaction or a change in control that might involve a premium price for holders of our common stock or otherwise be in their best interest. You should note, however, that any such an issuance must adhere to the requirements of the 1940 Act, Maryland law and any other limitations imposed by law.

The following is a general description of the terms of the preferred stock we may issue from time to time. Particular terms of any preferred stock we offer will be described in the prospectus supplement accompanying each preferred share offering.

The 1940 Act requires, among other things, that (i) immediately after issuance and before any dividend or other distribution is made with respect to our common stock and before any purchase of common stock is made, such preferred stock together with all other senior securities must not exceed an amount equal to 50% of our total assets after deducting the amount of such dividend, distribution or purchase price, as the case may be, (ii) the holders of shares of preferred stock, if any are issued, must be entitled as a class to elect two directors at all times and to elect a majority of the directors if dividends or other distribution on the preferred stock are in arrears by two years or more, and (iii) such shares be cumulative as to dividends and have a complete preference over our common stock to payment of their liquidation in event of dissolution. Some matters under the 1940 Act require the separate vote of the holders of any issued and outstanding preferred stock. For example, holders of preferred stock would vote separately from the holders of common stock on a proposal to cease operations as a business development company. We believe that the availability for issuance of preferred stock will provide us with increased flexibility in structuring future financings and acquisitions.

For any series of preferred stock that we may issue, our board of directors will determine and the articles supplementary and the prospectus supplement relating to such series will describe:

 

•

the designation and number of shares of such series;

 

•

the rate and time at which, and the preferences and conditions under which, any dividends or other distributions will be paid on shares of such series, as well as whether such dividends or other distributions are participating or non-participating;

 

•

any provisions relating to convertibility or exchangeability of the shares of such series, including adjustments to the conversion price of such series;

 

•

the rights and preferences, if any, of holders of shares of such series upon our liquidation, dissolution or winding up of our affairs;

 

•

the voting powers, if any, of the holders of shares of such series;

 

•

any provisions relating to the redemption of the shares of such series;

 

•

any limitations on our ability to pay dividends or make distributions on, or acquire or redeem, other securities while shares of such series are outstanding;

 

•

any conditions or restrictions on our ability to issue additional shares of such series or other securities;

 

•

if applicable, a discussion of certain U.S. federal income tax considerations; and

 

223

---

Table of Contents

Index to Financial Statements

•

any other relative powers, preferences and participating, optional or special rights of shares of such series, and the qualifications, limitations or restrictions thereof.

All shares of preferred stock that we may issue will be identical and of equal rank except as to the particular terms thereof that may be fixed by our board of directors, and all shares of each series of preferred stock will be identical and of equal rank except as to the dates from which dividends or other distributions, if any, thereon will be cumulative. To the extent we issue preferred stock, the payment of dividends to holders of our preferred stock will take priority over payment of dividends to our common stockholders.

 

224

---

Table of Contents

Index to Financial Statements

DESCRIPTION OF OUR SUBSCRIPTION RIGHTS

The following is a general description of the terms of the subscription rights we may issue from time to time. Particular terms of any subscription rights we offer will be described in the prospectus supplement relating to such subscription rights.

We may issue subscription rights to our stockholders to purchase common stock. Subscription rights may be issued independently or together with any other offered security and may or may not be transferable by the person purchasing or receiving the subscription rights. In connection with a subscription rights offering to our stockholders, we would distribute certificates evidencing the subscription rights and a prospectus supplement to our stockholders on the record date that we set for receiving subscription rights in such subscription rights offering.

Our stockholders will indirectly bear all of the expenses of the subscription rights offering, regardless of whether our stockholders exercise any subscription rights.

A prospectus supplement will describe the particular terms of any subscription rights we may issue, including the following:

 

•

the period of time the offering would remain open (which shall be open a minimum number of days such that all record holders would be eligible to participate in the offering and shall not be open longer than 120 days);

 

•

the title and aggregate number of such subscription rights;

 

•

the exercise price for such subscription rights (or method of calculation thereof);

 

•

the currency or currencies, including composite currencies, in which the price of such subscription rights may be payable;

 

•

if applicable, the designation and terms of the securities with which the subscription rights are issued and the number of subscription rights issued with each such security or each principal amount of such security;

 

•

the ratio of the offering (which, in the case of transferable rights, will require a minimum of three shares to be held of record before a person is entitled to purchase an additional share);

 

•

the number of such subscription rights issued to each stockholder;

 

•

the extent to which such subscription rights are transferable and the market on which they may be traded if they are transferable;

 

•

the date on which the right to exercise such subscription rights shall commence, and the date on which such right shall expire (subject to any extension);

 

•

if applicable, the minimum or maximum number of subscription rights that may be exercised at one time;

 

•

the extent to which such subscription rights include an over-subscription privilege with respect to unsubscribed securities and the terms of such over-subscription privilege;

 

•

any termination right we may have in connection with such subscription rights offering;

 

•

the terms of any rights to redeem, or call such subscription rights;

 

•

information with respect to book-entry procedures, if any;

 

•

the terms of the securities issuable upon exercise of the subscription rights;

 

•

the material terms of any standby underwriting, backstop or other purchase arrangement that we may enter into in connection with the subscription rights offering;

 

225

---

Table of Contents

Index to Financial Statements

•

if applicable, a discussion of certain U.S. federal income tax considerations applicable to the issuance or exercise of such subscription rights; and

 

•

any other terms of such subscription rights, including exercise, settlement and other procedures and limitations relating to the transfer and exercise of such subscription rights.

Each subscription right will entitle the holder of the subscription right to purchase for cash or other consideration such amount of shares of common stock at such subscription price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the subscription rights offered thereby. Subscription rights may be exercised as set forth in the prospectus supplement beginning on the date specified therein and continuing until the close of business on the expiration date for such subscription rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised subscription rights will become void.

Upon receipt of payment and the subscription rights certificate properly completed and duly executed at the corporate trust office of the subscription rights agent or any other office indicated in the prospectus supplement we will forward, as soon as practicable, the shares of common stock purchasable upon such exercise. If less than all of the rights represented by such subscription rights certificate are exercised, a new subscription certificate will be issued for the remaining rights. Prior to exercising their subscription rights, holders of subscription rights will not have any of the rights of holders of the securities purchasable upon such exercise. To the extent permissible under applicable law, we may determine to offer any unsubscribed offered securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, as set forth in the applicable prospectus supplement.

Under the 1940 Act, we may generally only offer subscription rights (other than rights to subscribe expiring not later than 120 days after their issuance and issued exclusively and ratably to a class or classes of our security holders) on the condition that (1) the subscription rights expire by their terms within ten years; (2) the exercise price is not less than the current market value at the date of issuance; (3) our stockholders authorize the proposal to issue such subscription rights, and a “required” majority of our Board of Directors approves of such issuance on the basis that the issuance is in the best interests of the Company and our stockholders; and (4) if the subscription rights are accompanied by other securities, the subscription rights are not separately transferable unless no class of such subscription rights and the securities accompanying them has been publicly distributed. A “required” majority of our Board of Directors is a vote of both a majority of our directors who have no financial interest in the transaction and a majority of the directors who are not interested persons of the company. The 1940 Act also provides that the amount of our voting securities that would result from the exercise of all outstanding warrants, options and subscription rights at the time of issuance may not exceed 25% of our outstanding voting securities.

For information regarding the dilutive impact of rights offerings, please see “Risk Factors—Risks Related to Our Securities” Your interest in us may be diluted if you do not fully exercise your subscription rights in any rights offering. In addition, if the subscription price is less than our NAV per share, then you will experience an immediate dilution of the aggregate NAV of your shares.”

 

226

---

Table of Contents

Index to Financial Statements

DESCRIPTION OF WARRANTS

The following is a general description of the terms of the warrants we may issue from time to time. Particular terms of any warrants we offer will be described in the prospectus supplement relating to such warrants and will be subject to compliance with the 1940 Act.

We may issue warrants to purchase shares of our common stock, preferred stock or debt securities. Such warrants may be issued independently or together with shares of common stock, preferred stock or debt securities and may be attached or separate from such securities. We will issue each series of warrants under a separate warrant agreement to be entered into between us and a warrant agent. The warrant agent will act solely as our agent and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants.

A prospectus supplement will describe the particular terms of any series of warrants we may issue, including the following:

 

•

the title and aggregate number of such warrants;

 

•

the price or prices at which such warrants will be issued;

 

•

the currency or currencies, including composite currencies, in which the price of such warrants may be payable;

 

•

if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;

 

•

in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which and the currency or currencies, including composite currencies, in which this principal amount of debt securities may be purchased upon such exercise;

 

•

in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon exercise of one warrant and the price at which and the currency or currencies, including composite currencies, in which these shares may be purchased upon such exercise;

 

•

the date on which the right to exercise such warrants shall commence and the date on which such right will expire (subject to any extension);

 

•

whether such warrants will be issued in registered form or bearer form;

 

•

if applicable, the minimum or maximum amount of such warrants that may be exercised at any one time;

 

•

if applicable, the date on and after which such warrants and the related securities will be separately transferable;

 

•

the terms of any rights to redeem, or call such warrants;

 

•

information with respect to book-entry procedures, if any;

 

•

the terms of the securities issuable upon exercise of the warrants;

 

•

if applicable, a discussion of certain U.S. federal income tax considerations; and

 

•

any other terms of such warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants.

We and the warrant agent may amend or supplement the warrant agreement for a series of warrants without the consent of the holders of the warrants issued thereunder to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders of the warrants.

 

227

---

Table of Contents

Index to Financial Statements

Each warrant will entitle the holder to purchase for cash such common stock or preferred stock at the exercise price or such principal amount of debt securities as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the warrants offered thereby. Warrants may be exercised as set forth in the prospectus supplement beginning on the date specified therein and continuing until the close of business on the expiration date set forth in the prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.

Upon receipt of payment and a warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the securities purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.

Prior to exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including, in the case of warrants to purchase debt securities, the right to receive principal, premium, if any, or interest payments, on the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture or, in the case of warrants to purchase common stock or preferred stock, the right to receive dividends or other distributions, if any, or payments upon our liquidation, dissolution or winding up or to exercise any voting rights.

Under the 1940 Act, we may generally only offer warrants provided that (i) the warrants expire by their terms within ten years, (ii) the exercise or conversion price is not less than the current market value at the date of issuance, (iii) our stockholders authorize the proposal to issue such warrants, and our board of directors approves such issuance on the basis that the issuance is in the best interests of the Company and its stockholders and (iv) if the warrants are accompanied by other securities, the warrants are not separately transferable unless no class of such warrants and the securities accompanying them has been publicly distributed. The 1940 Act also provides that the amount of our voting securities that would result from the exercise of all outstanding warrants, as well as options and rights, at the time of issuance may not exceed 25% of our outstanding voting securities.

 

228

---

Table of Contents

Index to Financial Statements

DESCRIPTION OF OUR DEBT SECURITIES

We may issue debt securities in one or more series. The specific terms of each series of debt securities will be described in this prospectus and in the particular prospectus supplement relating to that series. The prospectus supplement may or may not modify the general terms found in this prospectus and will be filed with the SEC. For a complete description of the terms of a particular series of debt securities, including any supplemental indenture, you should read both this prospectus and the prospectus supplement relating to that particular series.

As required by federal law for all bonds and notes of companies that are publicly offered, the debt securities are governed by a document called an “indenture.” An indenture is a contract between us and U.S. Bank National Association, a financial institution acting as trustee on your behalf, and is subject to and governed by the Trust Indenture Act of 1939, as amended. The trustee has two main roles. First, the trustee can enforce your rights against us if we default. There are some limitations on the extent to which the trustee acts on your behalf, described in the second paragraph under “Events of Default—Remedies if an Event of Default Occurs.” Second, the trustee performs certain administrative duties for us.

Because this section is a summary, it does not describe every aspect of the debt securities and the indenture. The following description summarizes the material provisions of the indenture. We urge you to read the indenture because it, and not this description, defines your rights as a holder of debt securities. For example, in this section, we use capitalized words to signify terms that are specifically defined in the indenture. We have filed the form of the indenture with the SEC. See “Available Information” for information on how to obtain a copy of the indenture.

A prospectus supplement, which will accompany this prospectus, will describe the particular terms of any series of debt securities being offered, including the following:

 

•

the designation or title of the series of debt securities;

 

•

the total principal amount of the series of debt securities;

 

•

the percentage of the principal amount at which the series of debt securities will be offered;

 

•

the date or dates on which principal will be payable;

 

•

the rate or rates (which may be either fixed or variable) and/or the method of determining such rate or rates of interest, if any;

 

•

the date or dates from which any interest will accrue, or the method of determining such date or dates, and the date or dates on which any interest will be payable;

 

•

the terms for redemption, extension or early repayment, if any;

 

•

the currencies in which the series of debt securities are issued and payable;

 

•

whether the amount of payments of principal, premium or interest, if any, on a series of debt securities will be determined with reference to an index, formula or other method (which could be based on one or more currencies, commodities, equity indices or other indices) and how these amounts will be determined;

 

•

the place or places, if any, other than or in addition to the City of New York, of payment, transfer, conversion and/or exchange of the debt securities;

 

•

the denominations in which the offered debt securities will be issued;

 

•

the provision for any sinking fund;

 

•

any restrictive covenants;

 

•

any Events of Default;

 

229

---

Table of Contents

Index to Financial Statements

•

whether the series of debt securities are issuable in certificated form;

 

•

any provisions for defeasance or covenant defeasance;

 

•

if applicable, U.S. federal income tax considerations relating to OID;

 

•

whether and under what circumstances we will pay additional amounts in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities rather than pay the additional amounts (and the terms of this option);

 

•

any provisions for convertibility or exchangeability of the debt securities into or for any other securities;

 

•

whether the debt securities are subject to subordination and the terms of such subordination;

 

•

the listing, if any, on a securities exchange; and

 

•

any other terms.

The debt securities may be secured or unsecured obligations. Unless the prospectus supplement states otherwise, principal (and premium, if any) and interest, if any, will be paid by us in immediately available funds.

We are permitted, under specified conditions, to issue multiple classes of indebtedness if our asset coverage, as defined in the 1940 Act, is at least equal to 200% immediately after each such issuance. In addition, while any indebtedness and other senior securities remain outstanding, we must make provisions to prohibit any distribution to our stockholders or the repurchase of such securities or shares unless we meet the applicable asset coverage ratios at the time of the distribution or repurchase. We may also borrow amounts up to 5% of the value of our total assets for temporary or emergency purposes without regard to asset coverage. For a discussion of the risks associated with leverage, see “Risk Factors—Risks Related to Our Business Structure.”

General

The indenture provides that any debt securities proposed to be sold under this prospectus and the attached prospectus supplement (“offered debt securities”) and any debt securities issuable upon the exercise of warrants or upon conversion or exchange of other offered securities (“underlying debt securities”), may be issued under the indenture in one or more series.

For purposes of this prospectus, any reference to the payment of principal of or premium or interest, if any, on debt securities will include additional amounts if required by the terms of the debt securities.

The indenture does not limit the amount of debt securities that may be issued thereunder from time to time. Debt securities issued under the indenture, when a single trustee is acting for all debt securities issued under the indenture, are called the “indenture securities.” The indenture also provides that there may be more than one trustee thereunder, each with respect to one or more different series of indenture securities. See “Resignation of Trustee” section below. At a time when two or more trustees are acting under the indenture, each with respect to only certain series, the term “indenture securities” means the one or more series of debt securities with respect to which each respective trustee is acting. In the event that there is more than one trustee under the indenture, the powers and trust obligations of each trustee described in this prospectus will extend only to the one or more series of indenture securities for which it is trustee. If two or more trustees are acting under the indenture, then the indenture securities for which each trustee is acting would be treated as if issued under separate indentures.

We refer you to the prospectus supplement for information with respect to any deletions from, modifications of or additions to the Events of Default or our covenants that are described below, including any addition of a covenant or other provision providing event risk or similar protection.

 

230

---

Table of Contents

Index to Financial Statements

We have the ability to issue indenture securities with terms different from those of indenture securities previously issued and, without the consent of the holders thereof, to reopen a previous issue of a series of indenture securities and issue additional indenture securities of that series unless the reopening was restricted when that series was created.

Conversion and Exchange

If any debt securities are convertible into or exchangeable for other securities, the prospectus supplement will explain the terms and conditions of the conversion or exchange, including the conversion price or exchange ratio (or the calculation method), the conversion or exchange period (or how the period will be determined), if conversion or exchange will be mandatory or at the option of the holder or us, provisions for adjusting the conversion price or the exchange ratio and provisions affecting conversion or exchange in the event of the redemption of the underlying debt securities. These terms may also include provisions under which the number or amount of other securities to be received by the holders of the debt securities upon conversion or exchange would be calculated according to the market price of the other securities as of a time stated in the prospectus supplement.

Issuance of Securities in Registered Form

We may issue the debt securities in registered form, in which case we may issue them either in book-entry form only or in “certificated” form. Debt securities issued in book-entry form will be represented by global securities. We expect that we will usually issue debt securities in book-entry only form represented by global securities.

Book-Entry Holders

We will issue registered debt securities in book-entry form only, unless we specify otherwise in the applicable prospectus supplement. This means debt securities will be represented by one or more global securities registered in the name of a depositary that will hold them on behalf of financial institutions that participate in the depositary’s book-entry system. These participating institutions, in turn, hold beneficial interests in the debt securities held by the depositary or its nominee. These institutions may hold these interests on behalf of themselves or customers.

Under the indenture, only the person in whose name a debt security is registered is recognized as the holder of that debt security. Consequently, for debt securities issued in book-entry form, we will recognize only the depositary as the holder of the debt securities and we will make all payments on the debt securities to the depositary. The depositary will then pass along the payments it receives to its participants, which in turn will pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the debt securities.

As a result, investors will not own debt securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary’s book-entry system or holds an interest through a participant. As long as the debt securities are represented by one or more global securities, investors will be indirect holders, and not holders, of the debt securities.

Street Name Holders

In the future, we may issue debt securities in certificated form or terminate a global security. In these cases, investors may choose to hold their debt securities in their own names or in “street name.” Debt securities held in street name are registered in the name of a bank, broker or other financial institution chosen by the investor, and the investor would hold a beneficial interest in those debt securities through the account he or she maintains at that institution.

 

231

---

Table of Contents

Index to Financial Statements

For debt securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the debt securities are registered as the holders of those debt securities and we will make all payments on those debt securities to them. These institutions will pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold debt securities in street name will be indirect holders, and not holders, of the debt securities.

Legal Holders

Our obligations, as well as the obligations of the applicable trustee and those of any third parties employed by us or the applicable trustee, run only to the legal holders of the debt securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a debt security or has no choice because we are issuing the debt securities only in book-entry form.

For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, if we want to obtain the approval of the holders for any purpose (for example, to amend an indenture or to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture), we would seek the approval only from the holders, and not the indirect holders, of the debt securities. Whether and how the holders contact the indirect holders is up to the holders.

When we refer to you, we mean those who invest in the debt securities being offered by this prospectus, whether they are the holders or only indirect holders of those debt securities. When we refer to your debt securities, we mean the debt securities in which you hold a direct or indirect interest.

Special Considerations for Indirect Holders

If you hold debt securities through a bank, broker or other financial institution, either in book-entry form or in street name, we urge you to check with that institution to find out:

 

•

how it handles securities payments and notices,

 

•

whether it imposes fees or charges,

 

•

how it would handle a request for the holders’ consent, if ever required,

 

•

whether and how you can instruct it to send you debt securities registered in your own name so you can be a holder, if that is permitted in the future for a particular series of debt securities,

 

•

how it would exercise rights under the debt securities if there were a default or other event triggering the need for holders to act to protect their interests, and

 

•

if the debt securities are in book-entry form, how the depositary’s rules and procedures will affect these matters.

Global Securities

As noted above, we usually will issue debt securities as registered securities in book-entry form only. A global security represents one or any other number of individual debt securities. Generally, all debt securities represented by the same global securities will have the same terms.

Each debt security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we

 

232

---

Table of Contents

Index to Financial Statements

select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all debt securities issued in book-entry form.

A global security may not be transferred to or registered in the name of anyone other than the depositary or its nominee, unless special termination situations arise. We describe those situations below under “Special Situations when a Global Security Will Be Terminated”. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all debt securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that has an account with the depositary. Thus, an investor whose security is represented by a global security will not be a holder of the debt security, but only an indirect holder of a beneficial interest in the global security.

Special Considerations for Global Securities

As an indirect holder, an investor’s rights relating to a global security will be governed by the account rules of the investor’s financial institution and of the depositary, as well as general laws relating to securities transfers. The depositary that holds the global security will be considered the holder of the debt securities represented by the global security.

If debt securities are issued only in the form of a global security, an investor should be aware of the following:

 

•

An investor cannot cause the debt securities to be registered in his or her name, and cannot obtain certificates for his or her interest in the debt securities, except in the special situations we describe below.

 

•

An investor will be an indirect holder and must look to his or her own bank or broker for payments on the debt securities and protection of his or her legal rights relating to the debt securities, as we describe under “Issuance of Securities in Registered Form” above.

 

•

An investor may not be able to sell interests in the debt securities to some insurance companies and other institutions that are required by law to own their securities in non-book-entry form.

 

•

An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the debt securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective.

 

•

The depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s interest in a global security. We and the trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way.

 

•

If we redeem less than all the debt securities of a particular series being redeemed, DTC’s practice is to determine by lot the amount to be redeemed from each of its participants holding that series.

 

•

An investor is required to give notice of exercise of any option to elect repayment of its debt securities, through its participant, to the applicable trustee and to deliver the related debt securities by causing its participant to transfer its interest in those debt securities, on DTC’s records, to the applicable trustee.

 

•

DTC requires that those who purchase and sell interests in a global security deposited in its book-entry system use immediately available funds. Your broker or bank may also require you to use immediately available funds when purchasing or selling interests in a global security.

 

233

---

Table of Contents

Index to Financial Statements

•

Financial institutions that participate in the depositary’s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the debt securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.

Special Situations when a Global Security will be Terminated

In a few special situations described below, a global security will be terminated and interests in it will be exchanged for certificates in non-book-entry form (certificated securities). After that exchange, the choice of whether to hold the certificated debt securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in a global security transferred on termination to their own names, so that they will be holders. We have described the rights of legal holders and street name investors under “Issuance of Securities in Registered Form” above.

The prospectus supplement may list situations for terminating a global security that would apply only to the particular series of debt securities covered by the prospectus supplement. If a global security is terminated, only the depositary, and not we or the applicable trustee, is responsible for deciding the names of the institutions in whose names the debt securities represented by the global security will be registered and, therefore, who will be the holders of those debt securities.

Payment and Paying Agents

We will pay interest to the person listed in the applicable trustee’s records as the owner of the debt security at the close of business on a particular day in advance of each due date for interest, even if that person no longer owns the debt security on the interest due date. That day, often approximately two weeks in advance of the interest due date, is called the “record date.” Because we will pay all the interest for an interest period to the holders on the record date, holders buying and selling debt securities must work out between themselves the appropriate purchase price. The most common manner is to adjust the sales price of the debt securities to prorate interest fairly between buyer and seller based on their respective ownership periods within the particular interest period. This prorated interest amount is called “accrued interest.”

Payments on Global Securities

We will make payments on a global security in accordance with the applicable policies of the depositary as in effect from time to time. Under those policies, we will make payments directly to the depositary, or its nominee, and not to any indirect holders who own beneficial interests in the global security. An indirect holder’s right to those payments will be governed by the rules and practices of the depositary and its participants.

Payments on Certificated Securities

We will make payments on a certificated debt security as follows. We will pay interest that is due on an interest payment date by check mailed on the interest payment date to the holder at his or her address shown on the trustee’s records as of the close of business on the regular record date. We will make all payments of principal and premium, if any, by check at the office of the applicable trustee in New York, New York and/or at other offices that may be specified in the prospectus supplement or in a notice to holders against surrender of the debt security.

Alternatively, if the holder asks us to do so, we will pay any amount that becomes due on the debt security by wire transfer of immediately available funds to an account at a bank in New York City, on the due date. To request payment by wire, the holder must give the applicable trustee or other paying agent appropriate transfer instructions at least 15 business days before the requested wire payment is due. In the case of any interest

 

234

---

Table of Contents

Index to Financial Statements

payment due on an interest payment date, the instructions must be given by the person who is the holder on the relevant regular record date. Any wire instructions, once properly given, will remain in effect unless and until new instructions are given in the manner described above.

Payment when Offices are Closed

If any payment is due on a debt security on a day that is not a business day, we will make the payment on the next day that is a business day. Payments made on the next business day in this situation will be treated under the indenture as if they were made on the original due date, except as otherwise indicated in the attached prospectus supplement. Such payment will not result in a default under any debt security or the indenture, and no interest will accrue on the payment amount from the original due date to the next day that is a business day.

Book-entry and other indirect holders should consult their banks or brokers for information on how they will receive payments on their debt securities.

Events of Default

You will have rights if an Event of Default occurs in respect of the debt securities of your series and is not cured, as described later in this subsection.

The term “Event of Default” in respect of the debt securities of your series means any of the following (unless the prospectus supplement relating to such debt securities states otherwise):

 

•

we do not pay the principal of, or any premium on, a debt security of the series on its due date, and do not cure this default within five days;

 

•

we do not pay interest on a debt security of the series when due, and such default is not cured within 30 days;

 

•

we do not deposit any sinking fund payment in respect of debt securities of the series on its due date, and do not cure this default within five days;

 

•

we remain in breach of a covenant in respect of debt securities of the series for 60 days after we receive a written notice of default stating we are in breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of debt securities of the series;

 

•

we file for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur and remain undischarged or unstayed for a period of 60 days;

 

•

on the last business day of each of 24 consecutive calendar months, we have an asset coverage of less than 100%; and

 

•

any other Event of Default in respect of debt securities of the series described in the applicable prospectus supplement occurs.

An Event of Default for a particular series of debt securities does not necessarily constitute an Event of Default for any other series of debt securities issued under the same or any other indenture. The trustee may withhold notice to the holders of debt securities of any default, except in the payment of principal, premium or interest, if it considers the withholding of notice to be in the best interests of the holders.

Remedies if an Event of Default Occurs

If an Event of Default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the debt securities of the affected series may declare the entire principal amount of all the debt securities of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. In certain circumstances, a declaration of acceleration of maturity may be canceled by the holders of a majority in principal amount of the debt securities of the affected series.

 

235

---

Table of Contents

Index to Financial Statements

The trustee is not required to take any action under the indenture at the request of any holders unless the holders offer the trustee reasonable protection from expenses and liability (called an “indemnity”). If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding debt securities of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising any right or remedy will be treated as a waiver of that right, remedy or Event of Default.

Before you are allowed to bypass your trustee and bring your own lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the debt securities, the following must occur:

 

•

the holder must give your trustee written notice that an Event of Default has occurred and remains uncured;

 

•

the holders of at least 25% in principal amount of all outstanding debt securities of the relevant series must make a written request that the trustee take action because of the default and must offer reasonable indemnity to the trustee against the cost and other liabilities of taking that action;

 

•

the trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity; and

 

•

the holders of a majority in principal amount of the debt securities must not have given the trustee a direction inconsistent with the above notice during that 60 day period.

However, you are entitled at any time to bring a lawsuit for the payment of money due on your debt securities on or after the due date.

Holders of a majority in principal amount of the debt securities of the affected series may waive any past defaults other than:

 

•

the payment of principal, any premium or interest; or

 

•

in respect of a covenant that cannot be modified or amended without the consent of each holder.

Book-entry and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and how to declare or cancel an acceleration of maturity.

Each year, we will furnish to each trustee a written statement of certain of our officers certifying that to their knowledge we are in compliance with the indenture and the debt securities, or else specifying any default.

Merger or Consolidation

Under the terms of the indenture, we are generally permitted to consolidate or merge with another entity. We may also be permitted to sell all or substantially all of our assets to another entity. However, unless the prospectus supplement relating to certain debt securities states otherwise, we may not take any of these actions unless all the following conditions are met:

 

•

where we merge out of existence or sell our assets, the resulting entity must agree to be legally responsible for our obligations under the debt securities;

 

•

immediately after giving effect to such transaction, no Default or Event of Default shall have happened and be continuing;

 

•

under the indenture, no merger or sale of assets may be made if as a result any of our property or assets or any property or assets of one of our subsidiaries, if any, would become subject to any mortgage, lien or other encumbrance unless either (a) the mortgage, lien or other encumbrance could be created

 

236

---

Table of Contents

Index to Financial Statements

•

pursuant to the limitation on liens covenant in the indenture without equally and ratably securing the indenture securities or (b) the indenture securities are secured equally and ratably with or prior to the debt secured by the mortgage, lien or other encumbrance;

 

•

we must deliver certain certificates and documents to the trustee; and

 

•

we must satisfy any other requirements specified in the prospectus supplement relating to a particular series of debt securities.

Modification or Waiver

There are three types of changes we can make to the indenture and the debt securities issued thereunder.

Changes Requiring Approval

First, there are changes that we cannot make to debt securities without specific approval of all of the holders. The following is a list of those types of changes:

 

•

change the stated maturity of the principal of or interest on a debt security;

 

•

reduce any amounts due on a debt security;

 

•

reduce the amount of principal payable upon acceleration of the maturity of a security following a default;

 

•

adversely affect any right of repayment at the holder’s option;

 

•

change the place (except as otherwise described in the prospectus or prospectus supplement) or currency of payment on a debt security;

 

•

impair your right to sue for payment;

 

•

adversely affect any right to convert or exchange a debt security in accordance with its terms;

 

•

modify the subordination provisions in the indenture in a manner that is adverse to holders of the debt securities;

 

•

reduce the percentage of holders of debt securities whose consent is needed to modify or amend the indenture;

 

•

reduce the percentage of holders of debt securities whose consent is needed to waive compliance with certain provisions of the indenture or to waive certain defaults;

 

•

modify any other aspect of the provisions of the indenture dealing with supplemental indentures, modification and waiver of past defaults, changes to the quorum or voting requirements or the waiver of certain covenants; and

 

•

change any obligation we have to pay additional amounts.

Changes Not Requiring Approval

The second type of change does not require any vote by the holders of the debt securities. This type is limited to clarifications and certain other changes that would not adversely affect holders of the outstanding debt securities in any material respect. We also do not need any approval to make any change that affects only debt securities to be issued under the indenture after the change takes effect.

Changes Requiring Majority Approval

Any other change to the indenture and the debt securities would require the following approval:

 

•

if the change affects only one series of debt securities, it must be approved by the holders of a majority in principal amount of that series; and

 

237

---

Table of Contents

Index to Financial Statements

•

if the change affects more than one series of debt securities issued under the same indenture, it must be approved by the holders of a majority in principal amount of all of the series affected by the change, with all affected series voting together as one class for this purpose.

The holders of a majority in principal amount of all of the series of debt securities issued under an indenture, voting together as one class for this purpose, may waive our compliance with some of our covenants in that indenture. However, we cannot obtain a waiver of a payment default or of any of the matters covered by the bullet points included above under “—Changes Requiring Approval.”

Further Details Concerning Voting

When taking a vote, we will use the following rules to decide how much principal to attribute to a debt security:

 

•

for OID securities, we will use the principal amount that would be due and payable on the voting date if the maturity of these debt securities were accelerated to that date because of a default;

 

•

for debt securities whose principal amount is not known (for example, because it is based on an index), we will use a special rule for that debt security described in the prospectus supplement; and

 

•

for debt securities denominated in one or more foreign currencies, we will use the U.S. dollar equivalent.

Debt securities will not be considered outstanding, and therefore not eligible to vote, if we have deposited or set aside in trust money for their payment or redemption. Debt securities will also not be eligible to vote if they have been fully defeased as described later under “Defeasance—Full Defeasance.”

We will generally be entitled to set any day as a record date for the purpose of determining the holders of outstanding indenture securities that are entitled to vote or take other action under the indenture. If we set a record date for a vote or other action to be taken by holders of one or more series, that vote or action may be taken only by persons who are holders of outstanding indenture securities of those series on the record date and must be taken within eleven months following the record date.

Book-entry and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the indenture or the debt securities or request a waiver.

Defeasance

The following provisions will be applicable to each series of debt securities unless we state in the applicable prospectus supplement that the provisions of covenant defeasance and full defeasance will not be applicable to that series.

Covenant Defeasance

Under current U.S. federal tax law, we can make the deposit described below and be released from some of the restrictive covenants in the indenture under which the particular series was issued. This is called “covenant defeasance.” In that event, you would lose the protection of those restrictive covenants but would gain the protection of having money and government securities set aside in trust to repay your debt securities. If applicable, you also would be released from the subordination provisions as described under the “Indenture Provisions—Subordination” section below. In order to achieve covenant defeasance, we must do the following:

 

•

if the debt securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates;

 

238

---

Table of Contents

Index to Financial Statements

•

we must deliver to the trustee a legal opinion of our counsel confirming that, under current U.S. federal income tax law, we may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity; and

 

•

we must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act, as amended, and a legal opinion and officers’ certificate stating that all conditions precedent to covenant defeasance have been complied with.

If we accomplish covenant defeasance, you can still look to us for repayment of the debt securities if there were a shortfall in the trust deposit or the trustee is prevented from making payment. For example, if one of the remaining Events of Default occurred (such as our bankruptcy) and the debt securities became immediately due and payable, there might be a shortfall. Depending on the event causing the default, you may not be able to obtain payment of the shortfall.

Full Defeasance

If there is a change in U.S. federal tax law, as described below, we can legally release ourselves from all payment and other obligations on the debt securities of a particular series (called “full defeasance”) if we put in place the following other arrangements for you to be repaid:

 

•

if the debt securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and United States government or United States government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates.

 

•

we must deliver to the trustee a legal opinion confirming that there has been a change in current U.S. federal tax law or an IRS ruling that allows us to make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity. Under current U.S. federal tax law, the deposit and our legal release from the debt securities would be treated as though we paid you your share of the cash and notes or bonds at the time the cash and notes or bonds were deposited in trust in exchange for your debt securities and you would recognize gain or loss on the debt securities at the time of the deposit;

 

•

we must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act, as amended, and a legal opinion and officers’ certificate stating that all conditions precedent to defeasance have been complied with;

 

•

Defeasance must not result in a breach of the indenture or any other material agreements; and

 

•

Satisfy the conditions for covenant defeasance contained in any supplemental indentures.

If we ever did accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment of the debt securities. You could not look to us for repayment in the unlikely event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever became bankrupt or insolvent. If applicable, you would also be released from the subordination provisions described later under “Indenture Provisions—Subordination.”

Form, Exchange and Transfer of Certificated Registered Securities

Holders may exchange their certificated securities, if any, for debt securities of smaller denominations or combined into fewer debt securities of larger denominations, as long as the total principal amount is not changed.

Holders may exchange or transfer their certificated securities, if any, at the office of their trustee. We have appointed the trustee to act as our agent for registering debt securities in the names of holders transferring debt securities. We may appoint another entity to perform these functions or perform them ourselves.

 

239

---

Table of Contents

Index to Financial Statements

Holders will not be required to pay a service charge to transfer or exchange their certificated securities, if any, but they may be required to pay any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange will be made only if our transfer agent is satisfied with the holder’s proof of legal ownership.

If we have designated additional transfer agents for your debt security, they will be named in your prospectus supplement. We may appoint additional transfer agents or cancel the appointment of any particular transfer agent. We may also approve a change in the office through which any transfer agent acts.

If any certificated securities of a particular series are redeemable and we redeem less than all the debt securities of that series, we may block the transfer or exchange of those debt securities during the period beginning 15 days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers or exchanges of any certificated securities selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any debt security that will be partially redeemed.

Resignation of Trustee

Each trustee may resign or be removed with respect to one or more series of indenture securities provided that a successor trustee is appointed to act with respect to these series. In the event that two or more persons are acting as trustee with respect to different series of indenture securities under the indenture, each of the trustees will be a trustee of a trust separate and apart from the trust administered by any other trustee.

Indenture Provisions—Subordination

Upon any distribution of our assets upon our dissolution, winding up, liquidation or reorganization, the payment of the principal of (and premium, if any) and interest, if any, on any indenture securities denominated as subordinated debt securities is to be subordinated to the extent provided in the indenture in right of payment to the prior payment in full of all senior indebtedness (as defined below), but our obligation to you to make payment of the principal of (and premium, if any) and interest, if any, on such subordinated debt securities will not otherwise be affected. In addition, no payment on account of principal (or premium, if any), sinking fund or interest, if any, may be made on such subordinated debt securities at any time unless full payment of all amounts due in respect of the principal (and premium, if any), sinking fund and interest on senior indebtedness has been made or duly provided for in money or money’s worth.

In the event that, notwithstanding the foregoing, any payment by us is received by the trustee in respect of subordinated debt securities or by the holders of any of such subordinated debt securities before all senior indebtedness is paid in full, the payment or distribution must be paid over to the holders of the senior indebtedness or on their behalf for application to the payment of all the senior indebtedness remaining unpaid until all the senior indebtedness has been paid in full, after giving effect to any concurrent payment or distribution to the holders of the senior indebtedness. Subject to the payment in full of all senior indebtedness upon this distribution by us, the holders of such subordinated debt securities will be subrogated to the rights of the holders of the senior indebtedness to the extent of payments made to the holders of the senior indebtedness out of the distributive share of such subordinated debt securities.

By reason of this subordination, in the event of a distribution of our assets upon our insolvency, certain of our senior creditors may recover more, ratably, than holders of any subordinated debt securities. The indenture provides that these subordination provisions will not apply to money and securities held in trust under the defeasance provisions of the indenture.

 

240

---

Table of Contents

Index to Financial Statements

Senior indebtedness is defined in the indenture as the principal of (and premium, if any) and unpaid interest on:

 

•

our indebtedness (including indebtedness of others guaranteed by us), whenever created, incurred, assumed or guaranteed, for money borrowed (other than indenture securities issued under the indenture and denominated as subordinated debt securities), unless in the instrument creating or evidencing the same or under which the same is outstanding it is provided that this indebtedness is not senior or prior in right of payment to the subordinated debt securities; and

 

•

renewals, extensions, modifications and refinancings of any of this indebtedness.

If this prospectus is being delivered in connection with the offering of a series of indenture securities denominated as subordinated debt securities, the accompanying prospectus supplement to this prospectus will set forth the approximate amount of our senior indebtedness outstanding as of a recent date.

Secured Indebtedness

Certain of our indebtedness, including certain series of indenture securities, may be secured. The prospectus supplement for each series of indenture securities will describe the terms of any security interest for such series and will indicate the approximate amount of our secured indebtedness as of a recent date. In the event of a distribution of our assets upon our insolvency, the holders of unsecured indenture securities may recover less, ratably, than holders of any of our secured indebtedness.

The Trustee under the Indenture

U.S. Bank National Association will serve as the trustee under the indenture.

Certain Considerations Relating to Foreign Currencies

Debt securities denominated or payable in foreign currencies may entail significant risks. These risks include the possibility of significant fluctuations in the foreign currency markets, the imposition or modification of foreign exchange controls and potential illiquidity in the secondary market. These risks will vary depending upon the currency or currencies involved and will be more fully described in the applicable prospectus supplement.

 

241

---

Table of Contents

Index to Financial Statements

PLAN OF DISTRIBUTION

We may offer, from time to time, in one or more offerings or series, up to $500,000,000 of our common stock, preferred stock, debt securities, subscription rights to purchase shares of our common stock or warrants representing rights to purchase shares of our common stock, preferred stock or debt securities, in one or more underwritten public offerings, at-the-market offerings to or through a market maker or into an existing trading market for the securities, on an exchange, or otherwise, negotiated transactions, block trades, best efforts, auctions or a combination of these methods. The holders of our common stock will indirectly bear any fees and expenses in connection with any such offerings. We may sell the securities through underwriters or dealers, directly to one or more purchasers, including existing stockholders in a rights offering, through agents or through a combination of any such methods of sale. Any underwriter or agent involved in the offer and sale of the securities will be named in the applicable prospectus supplement. A prospectus supplement or supplements will also describe the terms of the offering of the securities, including: the purchase price of the securities and the proceeds we will receive from the sale; any over-allotment options under which underwriters may purchase additional securities from us; any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation; any expenses we incur in connection with the sale of such securities; the public offering price; any discounts or concessions allowed or re-allowed or paid to dealers; and any securities exchange or market on which the securities may be listed. Only underwriters named in the applicable prospectus supplement will be underwriters of the securities offered by the applicable prospectus supplement.

The distribution of the securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at prevailing market prices at the time of sale, at prices related to such prevailing market prices, at negotiated prices, or at prices determined by an auction process, provided, however, that the offering price per share of our common stock, less any underwriting commissions or discounts, must equal or exceed the NAV per share of our common stock at the time of the offering except (1) in connection with a rights offering to our existing stockholders, (2) with the consent of the majority of our voting securities or (3) under such circumstances as the SEC may permit. The price at which securities may be distributed may represent a discount from prevailing market prices. Although we are not currently authorized to issue shares of our common stock at a price below our NAV per share, we may seek stockholder approval of this proposal again at a special meeting of stockholders or our next annual meeting of stockholders. Our Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share.

In connection with the sale of our securities, underwriters or agents may receive compensation from us or from purchasers of our securities, for whom they may act as agents, in the form of discounts, concessions or commissions. Underwriters may sell our securities to or through dealers and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of our securities may be deemed to be underwriters under the Securities Act, and any discounts and commissions they receive from us and any profit realized by them on the resale of our securities may be deemed to be underwriting discounts and commissions under the Securities Act. Any such underwriter or agent will be identified and any such compensation received from us will be described in the applicable prospectus supplement.

Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

 

242

---

Table of Contents

Index to Financial Statements

Any underwriters that are qualified market makers on the NYSE may engage in passive market making transactions in our common stock on the NYSE in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of our common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the applicable prospectus supplement. Unless the applicable prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.

Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no trading market, other than our common stock, which is traded on the NYSE. We may elect to list any other class or series of securities on any exchanges, but we are not obligated to do so. We cannot guarantee the liquidity of the trading markets for any securities.

Under agreements that we may enter, underwriters, dealers and agents who participate in the distribution of our securities may be entitled to indemnification by us against certain liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Underwriters, dealers and agents may engage in transactions with, or perform services for, us in the ordinary course of business.

If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase our securities from us pursuant to contracts providing for payment and delivery on a future date. Institutions with which such contracts may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and others, but in all cases such institutions must be approved by us. The obligations of any purchaser under any such contract will be subject to the condition that the purchase of our securities shall not at the time of delivery be prohibited under the laws of the jurisdiction to which such purchaser is subject. The underwriters and such other agents will not have any responsibility in respect of the validity or performance of such contracts. Such contracts will be subject only to those conditions set forth in the applicable prospectus supplement, and the applicable prospectus supplement will set forth the commission payable for solicitation of such contracts.

We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third parties in such sale transactions will be underwriters and, if not identified in this prospectus, will be identified in the applicable prospectus supplement.

In compliance with the guidelines of the Financial Industry Regulatory Authority, the maximum compensation to the underwriters or dealers in connection with the sale of our securities pursuant to this prospectus and the applicable prospectus supplement may not exceed 8% of the aggregate offering price of the securities as set forth on the cover page of the applicable prospectus supplement.

 

243

---

Table of Contents

Index to Financial Statements

In order to comply with the securities laws of certain states, if applicable, our securities offered hereby will be sold in such jurisdictions only through registered or licensed brokers or dealers.

BROKERAGE ALLOCATION AND OTHER PRACTICES

Because we generally acquire and dispose of our investments in privately negotiated transactions, we typically do not use brokers in the normal course of business. However, from time to time, we may work with brokers to sell positions we have acquired in the securities of publicly listed companies or to acquire positions (principally equity) in companies where we see a market opportunity to acquire such securities at attractive valuations. In cases where we do use a broker, we do not execute transactions through any particular broker or dealer, but will seek to obtain the best net results for the Company, taking into account such factors as price (including the applicable brokerage commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm and the firm’s risk and skill in positioning blocks of securities. While we generally seek reasonably competitive execution costs, we may not necessarily pay the lowest spread or commission available. Subject to applicable legal requirements, we may select a broker based partly upon brokerage or research services provided to us. In return for such services, we may pay a higher commission than other brokers would charge if we determine in good faith that such commission is reasonable in relation to the services provided.

CUSTODIAN, TRANSFER AND DIVIDEND PAYING AGENT AND REGISTRAR

Securities we hold in connection with our investments are held under a custody agreement with Union Bank of California. The address of the custodian is 475 Sansome Street, 15th Floor, San Francisco, California 94111. We have also entered into a custody agreement with U.S. Bank National Association, which is located at One Federal Street, Third Floor, Boston, Massachusetts 02110. The transfer agent and registrar for our common stock, American Stock Transfer & Trust Company, will act as our transfer agent, dividend paying and reinvestment agent and registrar. The principal business address of the transfer agent is 6201 15th Avenue, Brooklyn, New York 11219.

LEGAL MATTERS

Certain legal matters regarding the securities offered by this prospectus will be passed upon for us by Dechert LLP, Washington, D.C. Certain legal matters will be passed upon for underwriters, if any, by the counsel named in the prospectus supplement.

EXPERTS

The consolidated financial statements as of December 31, 2015 and December 31, 2014 and for each of the three years in the period ended December 31, 2015 and management’s assessment of the effectiveness of internal control over financial reporting (which is included in Management’s Report on Internal Control over Financial Reporting) as of December 31, 2015 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

 

244

---

Table of Contents

Index to Financial Statements

AVAILABLE INFORMATION

We have filed with the SEC a registration statement on Form N-2, together with all amendments and related exhibits, under the Securities Act, with respect to our securities offered by this prospectus. The registration statement contains additional information about us and our securities being offered by this prospectus.

We file annual, quarterly and current periodic reports, proxy statements and other information with the SEC under the Exchange Act. You may inspect and copy these reports, proxy statements and other information, as well as the registration statement of which this prospectus forms a part and the related exhibits and schedules, at the Public Reference Room of the SEC at 100 F Street, N.E., Washington, D.C. 20549-0102. You may obtain information on the operation of the Public Reference Room by calling the SEC at 202-551-8090. The SEC maintains an Internet website that contains reports, proxy and information statements and other information filed electronically by us with the SEC which are available on the SEC’s Internet website at http://www.sec.gov. Copies of these reports, proxy and information statements and other information may be obtained, after paying a duplicating fee, by electronic request at the following E-mail address: publicinfo@sec.gov, or by writing the SEC’s Public Reference Section, Washington, D.C. 20549-0102.

 

245

---

Table of Contents

Index to Financial Statements

INDEX TO FINANCIAL STATEMENTS

 

AUDITED FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm			F-2
Consolidated Statements of Assets and Liabilities as of December 31, 2015 and 2014			F-3
Consolidated Statements of Operations for the three years ended December 31, 2015			F-5
Consolidated Statements of Changes in Net Assets for the three years ended December 31, 2015			F-6
Consolidated Statements of Cash Flows for the three years ended December 31, 2015			F-7
Consolidated Schedule of Investments as of December 31, 2015			F-8
Consolidated Schedule of Investments as of December 31, 2014			F-24
Notes to Consolidated Financial Statements			F-41
Schedule of Investments in and Advances to Affiliates			F-82
UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Consolidated Statement of Assets and Liabilities as of March 31, 2016 and December 31, 2015 (unaudited)			F-83
Consolidated Statement of Operations for the three months ended March 31, 2016 and 2015 (unaudited)			F-85
Consolidated Statement of Changes in Net Assets for the three months ended March 31, 2016 and 2015 (unaudited)			F-86
Consolidated Statement of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited)			F-87
Consolidated Schedule of Investments as of March 31, 2016 (unaudited)			F-88
Consolidated Schedule of Investments as of December 31, 2015 (unaudited)			F-106
Notes to Consolidated Financial Statements (unaudited)			F-123
Schedule of Investments In and Advances to Affiliates			F-160

 

F-1

---

Table of Contents

Index to Financial Statements

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To Board of Directors and Shareholders of

Hercules Capital, Inc.

In our opinion, the accompanying consolidated statement of assets and liabilities, including the consolidated schedule of investments, and the related consolidated statements of operations, of changes in net assets, and of cash flows present fairly, in all material respects, the financial position of Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) and its subsidiaries at December 31, 2015 and 2014, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2015 in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion, the financial statement schedule listed in the accompanying index presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework 2013 issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013). The Company’s management is responsible for these financial statements and financial statement schedule, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing on page 109. Our responsibility is to express opinions on these financial statements, on the financial statement schedule, and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. Our procedures included confirmation of securities at December 31, 2015 by correspondence with the custodian, borrowers and brokers, and where replies were not received, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinions.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP

San Francisco, California

February 25, 2016

 

F-2

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES

(in thousands, except per share data)

 

		December 31, 2015				December 31, 2014
Assets
Investments:
Non-control/Non affiliate investments:
Debt investments (cost of $1,150,103 and $948,989, respectively)		$	1,109,196			$	922,306
Equity investments (cost of $50,305 and $34,626, respectively)			60,781				65,554
Warrant investments (cost of $38,131 and $36,184, respectively)			22,675				24,878
Total Non-control/Non-affiliate investments (cost of $1,238,539 and $1,019,799, respectively)			1,192,652				1,012,738
Affiliate investments:
Debt investments (cost of $2,200 and $2,993, respectively)			1,013				1,600
Equity investments (cost of $8,912 and $9,837, respectively)			6,661				6,179
Warrant investments (cost of $2,630 and $2,708, respectively)			312				220
Total Affiliate investments (cost of $13,742 and $15,538, respectively)			7,986				7,999
Total investments, at value (cost of $1,252,281 and $1,035,337, respectively)			1,200,638				1,020,737
Cash and cash equivalents			95,196				227,116
Restricted cash			9,191				12,660
Interest receivable			9,239				9,453
Other assets			20,497				29,257
Total assets		$	1,334,761			$	1,299,223
Liabilities
Accounts payable and accrued liabilities		$	17,241			$	14,101
Long-term Liabilities (Convertible Senior Notes)			17,522				17,345
Wells Facility			50,000				—
2017 Asset-Backed Notes			—				16,049
2021 Asset-Backed Notes			129,300				129,300
2019 Notes			110,364				170,364
2024 Notes			103,000				103,000
Long-Term SBA Debentures			190,200				190,200
Total liabilities		$	617,627			$	640,359
Commitments and Contingencies (Note 10)
Net assets consist of:
Common stock, par value			73				65
Capital in excess of par value			752,244				657,233
Unrealized depreciation on investments(1)			(52,808	)			(17,076	)
Accumulated realized gains on investments			27,993				14,079
Undistributed net investment income (Distributions in excess of net investment income)			(10,368	)			4,563
Total net assets		$	717,134			$	658,864
Total liabilities and net assets		$	1,334,761			$	1,299,223
Shares of common stock outstanding ($0.001 par value, 200,000,000 and 100,000,000 authorized, respectively)			72,118				64,715
Net asset value per share		$	9.94			$	10.18

 

(1)	Amounts includes $1.2 million in net unrealized depreciation on other assets and accrued liabilities, including escrow receivables, estimated taxes payable and Citigroup warrant participation agreement liabilities.

See notes to consolidated financial statements.

 

F-3

---

Table of Contents

Index to Financial Statements

The following table presents the assets and liabilities of our consolidated securitization trusts for the asset-backed notes (see Note 4), which are variable interest entities (“VIE”). The assets of our securitization VIEs can only be used to settle obligations of our consolidated securitization VIEs, these liabilities are only the obligations of our consolidated securitization VIEs, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statements of Assets and Liabilities above.

 

(Dollars in thousands)		December 31, 2015				December 31, 2014
Assets
Restricted Cash		$	9,191			$	12,660
Total investments, at value (cost of $258,748 and $296,314, respectively)			257,657				291,464
Total assets		$	266,848			$	304,124
Liabilities
Asset-Backed Notes		$	129,300			$	145,349
Total liabilities		$	129,300			$	145,349

See notes to consolidated financial statements.

 

F-4

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

 

		For the Year Ended December 31,
		2015				2014				2013
Investment income:
Interest income
Non-Control/Non-Affiliate investments		$	139,919			$	124,776			$	121,302
Affiliate investments			347				1,842				2,369
Total interest income			140,266				126,618				123,671
Fees
Non-Control/Non-Affiliate investments			16,865				17,013				16,016
Affiliate investments			1				34				26
Total fees			16,866				17,047				16,042
Total investment income			157,132				143,665				139,713
Operating expenses:
Interest			30,834				28,041				30,334
Loan fees			6,055				5,919				4,807
General and administrative			16,658				10,209				9,354
Employee Compensation:
Compensation and benefits			20,713				16,604				16,179
Stock-based compensation			9,370				9,561				5,974
Total employee compensation			30,083				26,165				22,153
Total operating expenses			83,630				70,334				66,648
Loss on debt extinguishment (Long-term Liabilities—Convertible Senior Notes)			(1	)			(1,581	)			—
Net investment income			73,501				71,750				73,065
Net realized gain on investments
Non-Control/Non-Affiliate investments			5,147				20,112				14,836
Total net realized gain on investments			5,147				20,112				14,836
Net change in unrealized appreciation (depreciation) on investments
Non-Control/Non-Affiliate investments			(36,839	)			(17,392	)			12,370
Affiliate investments			1,107				(3,282	)			(825	)
Total net unrealized appreciation (depreciation) on investments			(35,732	)			(20,674	)			11,545
Total net realized and unrealized gain (loss)			(30,585	)			(562	)			26,381
Net increase in net assets resulting from operations		$	42,916			$	71,188			$	99,446
Net investment income before investment gains and losses per common share:
Basic		$	1.04			$	1.13			$	1.22
Change in net assets resulting from operations per common share:
Basic		$	0.60			$	1.12			$	1.67
Diluted		$	0.59			$	1.10			$	1.63
Weighted average shares outstanding
Basic			69,479				61,862				58,838
Diluted			69,663				63,225				60,292
Dividends declared per common share:
Basic		$	1.24			$	1.24			$	1.11

See notes to consolidated financial statements.

 

F-5

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

(dollars and shares in thousands)

 

		Common Stock								Capital  in excess of par value				Unrealized Appreciation (Depreciation) on Investments				Accumulated Realized Gains (Losses) on Investments				Undistributed Net Investment Income/ (Distributions in Excess of Investment Income)				Provision for  Income Taxes  on Investment Gains				Net Assets
		Shares				Par Value
Balance at December 31, 2012			52,925			$	53			$	564,508			$	(7,947	)		$	(36,916	)		$	(3,388	)		$	(342	)		$	515,968
Net increase (decrease) in net assets resulting from operations			—				—				—				11,545				14,836				73,065				—				99,446
Public offering, net of offering expenses			8,050				8				95,529				—				—				—				—				95,537
Issuance of common stock due to stock option exercises			2,019				2				25,245				—				—				—				—				25,247
Retired shares from net issuance			(1,739	)			(2	)			(26,112	)			—				—				—				—				(26,114	)
Issuance of common stock under restricted stock plan			606				1				(1	)			—				—				—				—				—
Retired shares for restricted stock vesting			(183	)			—				(1,878	)			—				—				—				—				(1,878	)
Issuance of common stock as stock dividend			159				—				2,201				—				—				—				—				2,201
Dividends distributed			—				—				—				—				—				(66,454	)			—				(66,454	)
Stock-based compensation			—				—				6,054				—				—				—				—				6,054
Tax reclassification of stockholders’ equity in accordance with generally accepted accounting principles			—				—				(8,952	)			—				6,840				2,112				—				—
Balance at December 31, 2013			61,837			$	62			$	656,594			$	3,598			$	(15,240	)		$	5,335			$	(342	)		$	650,007
Net increase (decrease) in net assets resulting from operations			—			$	—			$	—			$	(20,674	)		$	20,112			$	71,750			$	—			$	71,188
Public offering, net of offering expenses			2,111				2				9,007				—				—				—				—				9,009
Issuance of common stock due to stock option exercises			354				—				3,955				—				—				—				—				3,955
Retired shares from net issuance			(277	)			—				(4,564	)			—				—				—				—				(4,564	)
Issuance of common stock under restricted stock plan			990				1				(1	)			—				—				—				—				—
Retired shares for restricted stock vesting			(397	)			—				(3,292	)			—				—				—				—				(3,292	)
Issuance of common stock as stock dividend			97				—				1,485				—				—				—				—				1,485
Dividends distributed			—				—				—				—				—				(78,562	)			—				(78,562	)
Stock-based compensation			—				—				9,638				—				—				—				—				9,638
Tax reclassification of stockholders’ equity in accordance with generally accepted accounting principles			—				—				(15,589	)			—				9,207				6,382				—				—
Balance at December 31, 2014			64,715			$	65			$	657,233			$	(17,076	)		$	14,079			$	4,905			$	(342	)		$	658,864
Net increase (decrease) in net assets resulting from operations			—			$	—			$	—			$	(35,732	)		$	5,147			$	73,501			$	—			$	42,916
Public offering, net of offering expenses			7,591				8				100,084				—				—				—				—				100,092
Acquisition of common stock under repurchase plan			(437	)			—				(4,644	)																			(4,644	)
Issuance of common stock due to stock option exercises			64				—				427				—				—				—				—				427
Retired shares from net issuance			(29	)			—				(423	)			—				—				—				—				(423	)
Issuance of common stock under restricted stock plan			676				1				(1	)			—				—				—				—				—
Retired shares for restricted stock vesting			(662	)			(1	)			(4,566	)			—				—				—				—				(4,567	)
Issuance of common stock as stock dividend			200				—				2,446				—				—				—				—				2,446
Dividends distributed			—				—				—				—				—				(87,438	)			—				(87,438	)
Stock-based compensation			—				—				9,461				—				—				—				—				9,461
Tax reclassification of stockholders’ equity in accordance with generally accepted accounting principles			—				—				(7,773	)			—				8,767				(994	)			—				—
Balance at December 31, 2015			72,118			$	73			$	752,244			$	(52,808	)		$	27,993			$	(10,026	)		$	(342	)		$	717,134

See notes to consolidated financial statements.

 

F-6

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

		For the Year Ended December 31,
		2015				2014				2013
Cash flows from operating activities:
Net increase in net assets resulting from operations		$	42,916			$	71,188			$	99,446
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchase of investments			(712,701	)			(623,232	)			(487,558	)
Principal and fee payments received on investments			509,593				503,003				477,535
Proceeds from the sale of investments			17,892				33,432				44,832
Net unrealized depreciation (appreciation) on investments			35,732				20,674				(11,545	)
Net realized gain on investments			(5,147	)			(20,112	)			(14,836	)
Accretion of paid-in-kind principal			(4,037	)			(2,549	)			(3,103	)
Accretion of loan discounts			(8,049	)			(9,792	)			(6,652	)
Accretion of loan discount on Convertible Senior Notes			246				843				1,083
Loss on debt extinguishment (Long-term Liabilities—Convertible Senior Notes)			1				1,581				—
Payment of loan discount on Convertible Senior Notes			(5	)			(4,195	)			—
Accretion of loan exit fees			(14,947	)			(11,541	)			(9,251	)
Change in deferred loan origination revenue			1,904				(281	)			1,409
Unearned fees related to unfunded commitments			(2,064	)			(259	)			(1,525	)
Amortization of debt fees and issuance costs			5,161				5,256				4,044
Depreciation			193				266				252
Stock-based compensation and amortization of restricted stock grants			9,461				9,638				6,054
Change in operating assets and liabilities:
Interest and fees receivable			213				(490	)			672
Prepaid expenses and other assets			4,826				1,351				926
Accounts payable			(639	)			271				54
Accrued liabilities			5,090				(1,583	)			1,757
Net cash provided by (used in) operating activities			(114,361	)			(26,531	)			103,594
Cash flows from investing activities:
Purchases of capital equipment			(187	)			(190	)			(311	)
Reduction of (investment in) restricted cash			3,469				(6,389	)			(6,271	)
Other long-term assets			—				25				—
Net cash provided by (used in) investing activities			3,282				(6,554	)			(6,582	)
Cash flows from financing activities:
Issuance of common stock, net			100,092				9,837				95,120
Repurchase of common stock, net			(4,645	)			—				—
Retirement of employee shares			(4,562	)			(3,901	)			(2,744	)
Dividends paid			(84,992	)			(77,076	)			(64,252	)
Issuance of 2024 Notes Payable			—				103,000				—
Issuance of 2021 Asset-Backed Notes			—				129,300				—
Repayments of 2017 Asset-Backed Notes			(16,049	)			(73,508	)			(39,743	)
Repayments of Long-Term SBA Debentures			—				(34,800	)			—
Repayments of 2019 Notes			(60,000	)			—				—
Borrowings of credit facilities			138,689				—				—
Repayments of credit facilities			(88,689	)			—				—
Cash paid for debt issuance costs			—				(6,669	)			—
Cash paid for redemption of Convertible Senior Notes			(65	)			(53,131	)			—
Fees paid for credit facilities and debentures			(620	)			(1,219	)			(19	)
Net cash used in financing activities			(20,841	)			(8,167	)			(11,638	)
Net increase (decrease) in cash and cash equivalents			(131,920	)			(41,252	)			85,374
Cash and cash equivalents at beginning of period			227,116				268,368				182,994
Cash and cash equivalents at end of period		$	95,196			$	227,116			$	268,368
Supplemental non-cash investing and financing activities:
Interest paid		$	30,527			$	25,738			$	25,245
Income taxes paid		$	973			$	133			$	85
Dividends Reinvested		$	2,446			$	1,485			$	2,201

See notes to consolidated financial statements.

 

F-7

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Debt Investments
Communications & Networking
1-5 Years Maturity
Avanti Communications Group(4)(9)		Communications & Networking		Senior Secured		October 2019		Interest rate FIXED 10.00%		$	10,000				$8,900				$7,812
OpenPeak, Inc.(7)		Communications & Networking		Senior Secured		April 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	12,370				9,134				2,444
SkyCross, Inc.(7)(12)(13)(14)		Communications & Networking		Senior Secured		January 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%, PIK Interest 5.00%		$	19,649				20,080				14,859
Spring Mobile Solutions, Inc.(13)		Communications & Networking		Senior Secured		January 2019		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	3,000				2,935				2,935
Subtotal: 1-5 Years Maturity															41,049				28,050
Subtotal: Communications & Networking (3.91%)*															41,049				28,050
Consumer & Business Products
Under 1 Year Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(14)		Consumer & Business Products		Senior Secured		June 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	308				308				308
Subtotal: Under 1 Year Maturity															308				308
1-5 Years Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(13)(14)		Consumer & Business Products		Senior Secured		December 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.50%		$	4,955				4,785				4,783
Miles, Inc. (p.k.a. Fluc, Inc.)(8)		Consumer & Business Products		Convertible Debt		March 2017		Interest rate FIXED 4.00%		$	100				100				—
Nasty Gal(13)(14)		Consumer & Business Products		Senior Secured		May 2019		Interest rate PRIME + 5.45% or Floor rate of 8.95%		$	15,000				14,876				14,876
The Neat Company(7)(12)(13)(14)		Consumer & Business Products		Senior Secured		September 2017		Interest rate PRIME + 7.75% or Floor rate of 11.00%, PIK Interest 1.00%		$	15,936				15,545				5,527
Subtotal: 1-5 Years Maturity															35,306				25,186
Subtotal: Consumer & Business Products (3.55%)*															35,614				25,494
Drug Delivery
1-5 Years Maturity
AcelRx Pharmaceuticals, Inc.(9)(10)(13)(14)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 3.85% or Floor rate of 9.10%		$	20,466				20,772				20,678
Agile Therapeutics, Inc.(10)(13)		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 4.75% or Floor rate of 9.00%		$	16,500				16,231				16,107
BIND Therapeutics, Inc.(13)(14)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 5.10% or Floor rate of 8.35%		$	15,000				15,119				15,044
BioQ Pharma Incorporated(10)(13)		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	10,000				10,180				10,066
		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 7.00% or Floor rate of 10.50%		$	3,000				2,962				2,962
Total BioQ Pharma Incorporated										$	13,000				13,142				13,028
Celator Pharmaceuticals, Inc.(10)(13)		Drug Delivery		Senior Secured		June 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	14,573				14,594				14,609
Celsion Corporation(10)(13)		Drug Delivery		Senior Secured		June 2017		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	6,346				6,501				6,544
Dance Biopharm, Inc.(13)(14)		Drug Delivery		Senior Secured		November 2017		Interest rate PRIME + 7.40% or Floor rate of 10.65%		$	2,705				2,776				2,757

 

See notes to consolidated financial statements.

 

F-8

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Edge Therapeutics, Inc.(10)(13)		Drug Delivery		Senior Secured		March 2018		Interest rate PRIME + 6.45% or Floor rate of 9.95%		$	5,466			$	5,431			$	5,455
Egalet Corporation(11)(13)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.15% or Floor rate of 9.40%		$	15,000				14,967				15,036
Neos Therapeutics, Inc.(10)(13)(14)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	10,000				10,000				10,007
		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	10,000				10,043				9,998
		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	5,000				4,977				4,957
Total Neos Therapeutics, Inc.										$	25,000				25,020				24,962
Pulmatrix Inc.(8)(10)(13)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	7,000				6,877				6,856
ZP Opco, Inc (p.k.a. Zosano Pharma)(10)(13)		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 2.70% or Floor rate of 7.95%		$	15,000				14,925				14,781
Subtotal: 1-5 Years Maturity															156,355				155,857
Subtotal: Drug Delivery (21.73%)*															156,355				155,857
Drug Discovery & Development
1-5 Years Maturity
Aveo Pharmaceuticals, Inc.(9)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 6.65% or Floor rate of 11.90%		$	10,000				10,076				9,944
Cerecor, Inc.(13)		Drug Discovery & Development		Senior Secured		August 2017		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	5,688				5,705				5,740
Cerulean Pharma, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		July 2018		Interest rate PRIME + 1.55% or Floor rate of 7.30%		$	21,000				21,132				21,109
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(10)(13)		Drug Discovery & Development		Senior Secured		December 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%		$	25,000				25,507				25,550
Epirus Biopharmaceuticals, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		April 2018		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	15,000				14,852				14,924
Genocea Biosciences, Inc.(10)(13)		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 3.75% or Floor rate of 7.25%		$	17,000				17,008				16,948
Immune Pharmaceuticals(10)(13)		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 6.50% or Floor rate of 10.00%		$	4,500				4,374				4,374
Insmed, Incorporated(10)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 4.75% or Floor rate of 9.25%		$	25,000				25,128				24,991
Mast Therapeutics, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 5.70% or Floor rate of 8.95%		$	15,000				14,808				14,808
Melinta Therapeutics(11)(13)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 3.75% or Floor rate of 8.25%		$	30,000				29,843				29,703
Merrimack Pharmaceuticals, Inc.(9)		Drug Discovery & Development		Senior Secured		December 2022		Interest rate FIXED 11.50%		$	25,000				25,000				25,000
Neothetics, Inc. (p.k.a. Lithera, Inc)(13)(14)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	10,000				9,966				9,940
Neuralstem, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		April 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	8,335				8,418				8,397
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(13)(14)		Drug Discovery & Development		Senior Secured		September 2020		Interest rate PRIME + 2.75% or Floor rate of 8.50%		$	20,000				19,828				19,828
uniQure B.V.(4)(9)(10)(13)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.00% or Floor rate of 10.25%		$	20,000				19,956				19,929
XOMA Corporation(9)(13)(14)		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 2.15% or Floor rate of 9.40%		$	20,000				19,974				19,815
Subtotal: 1-5 Years Maturity															271,575				271,000
Subtotal: Drug Discovery & Development (37.79%)*															271,575				271,000

 

See notes to consolidated financial statements.

 

F-9

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Electronics & Computer Hardware
1-5 Years Maturity
Persimmon Technologies(13)		Electronics & Computer Hardware		Senior Secured		June 2019		Interest rate PRIME + 7.50% or Floor rate of 11.00%		$	7,000			$	6,873			$	6,873
Subtotal: 1-5 Years Maturity															6,873				6,873
Subtotal: Electronics & Computer Hardware (0.96%)*															6,873				6,873
Sustainable and Renewable Technology
Under 1 Year Maturity
Agrivida, Inc.(13)(14)		Sustainable and Renewable Technology		Senior Secured		December 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	4,362				4,587				4,587
American Superconductor Corporation(10)(13)		Sustainable and Renewable Technology		Senior Secured		November 2016		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	3,667				4,106				4,106
Fluidic, Inc.(10)(13)		Sustainable and Renewable Technology		Senior Secured		March 2016		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	784				931				931
Polyera Corporation(13)(14)		Sustainable and Renewable Technology		Senior Secured		April 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	637				890				890
Stion Corporation(5)(13)		Sustainable and Renewable Technology		Senior Secured		March 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	2,200				2,200				1,013
Sungevity, Inc.(11)		Sustainable and Renewable Technology		Senior Secured		April 2016		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	20,000				20,000				20,000
Subtotal: Under 1 Year Maturity															32,714				31,527
1-5 Years Maturity
American Superconductor Corporation(10)(13)		Sustainable and Renewable Technology		Senior Secured		June 2017		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	1,500				1,496				1,484
Amyris, Inc.(9)(11)(13)		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	17,543				17,543				17,499
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	3,497				3,497				3,488
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	10,960				11,045				11,045
Total Amyris, Inc.										$	32,000				32,085				32,032
Modumetal, Inc.(13)		Sustainable and Renewable Technology		Senior Secured		March 2017		Interest rate PRIME + 8.70% or Floor rate of 11.95%		$	1,759				2,062				2,032
		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	7,061				7,101				7,080
Total Modumetal, Inc.										$	8,820				9,163				9,112
Polyera Corporation(13)		Sustainable and Renewable Technology		Senior Secured		January 2017		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	1,254				1,455				1,455
Proterra, Inc.(10)(13)		Sustainable and Renewable Technology		Senior Secured		December 2018		Interest rate PRIME + 6.95% or Floor rate of 10.20%		$	25,000				24,995				24,550

 

See notes to consolidated financial statements.

 

F-10

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Sungevity, Inc.(11)(13)		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	35,000			$	34,733			$	34,773
Tendril Networks(13)		Sustainable and Renewable Technology		Senior Secured		June 2019		Interest rate FIXED 7.25%		$	15,000				14,735				14,477
Subtotal: 1-5 Years Maturity															118,662				117,883
Subtotal: Sustainable and Renewable Technology (20.83%)*															151,376				149,410
Healthcare Services, Other
1-5 Years Maturity
Chromadex Corporation(13)(14)		Healthcare Services, Other		Senior Secured		April 2018		Interest rate PRIME + 6.10% or Floor rate of 9.35%		$	5,000				4,907				4,918
InstaMed Communications, LLC(13)(14)		Healthcare Services, Other		Senior Secured		February 2019		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	10,000				10,048				10,049
Subtotal: 1-5 Years Maturity															14,955				14,967
Subtotal: Healthcare Services, Other (2.09%)*															14,955				14,967
Information Services
Under 1 Year Maturity
Eccentex Corporation(13)(16)		Information Services		Senior Secured		May 2015		Interest rate PRIME + 7.00% or Floor rate of 10.25%		$	13				28				28
InXpo, Inc.(13)(14)		Information Services		Senior Secured		October 2016		Interest rate PRIME + 7.50% or Floor rate of 10.75%		$	1,589				1,624				1,624
Subtotal: Under 1 Year Maturity															1,652				1,652
Subtotal: Information Services (0.23%)*															1,652				1,652
Internet Consumer & Business Services
Under 1 Year Maturity
NetPlenish(7)(8)(14)		Internet Consumer & Business Services		Convertible Debt		September 2016		Interest rate FIXED 10.00%		$	381				373				—
		Internet Consumer & Business Services		Senior Secured		April 2016		Interest rate FIXED 10.00%		$	45				45				—
Total NetPlenish										$	426				418				—
Subtotal: Under 1 Year Maturity															418				—
1-5 Years Maturity
Aria Systems, Inc.(10)(12)		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 5.20% or Floor rate of 8.95%, PIK Interest 1.95%		$	18,101				17,850				17,673
		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 3.20% or Floor rate of 6.95%, PIK Interest 1.95%		$	2,021				1,995				1,972
Total Aria Systems, Inc.										$	20,122				19,845				19,645
One Planet Ops Inc. (p.k.a. Reply! Inc.)(7)(12)		Internet Consumer & Business Services		Senior Secured		March 2019		Interest rate PRIME + 4.25% or Floor rate of 7.50%		$	6,321				5,811				5,811
		Internet Consumer & Business Services		Senior Secured		March 2019		PIK Interest 2.00%		$	2,129				2,129				55
Total One Planet Ops Inc. (p.k.a. Reply! Inc.)										$	8,450				7,940				5,866

 

See notes to consolidated financial statements.

 

F-11

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
ReachLocal(13)		Internet Consumer & Business Services		Senior Secured		April 2018		Interest rate PRIME + 8.50% or Floor rate of 11.75%		$	25,000			$	24,868			$	24,769
Tapjoy, Inc.(11)(13)		Internet Consumer & Business Services		Senior Secured		July 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	20,000				19,598				19,514
Tectura Corporation(7)(12)(15)		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	6,468				6,468				4,851
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%		$	8,170				8,170				6,128
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	563				563				422
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	5,000				5,000				3,750
Total Tectura Corporation										$	20,201				20,201				15,151
Subtotal: 1-5 Years Maturity															92,452				84,945
Subtotal: Internet Consumer & Business Services (11.85%)*															92,870				84,945
Media/Content/Info
Under 1 Year Maturity
Zoom Media Group, Inc.		Media/Content/Info		Senior Secured		January 2016		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	5,060				5,060				5,060
Subtotal: Under 1 Year Maturity															5,060				5,060
1-5 Years Maturity
Machine Zone, Inc.(12)		Media/Content/Info		Senior Secured		May 2018		Interest rate PRIME + 2.50% or Floor rate of 6.75%, PIK Interest 3.00%		$	90,729				88,730				88,101
Subtotal: 1-5 Years Maturity															88,730				88,101
Subtotal: Media/Content/Info (12.99%)*															93,790				93,161
Medical Devices & Equipment
Under 1 Year Maturity
Medrobotics Corporation(13)(14)		Medical Devices & Equipment		Senior Secured		March 2016		Interest rate PRIME + 7.85% or Floor rate of 11.10%		$	576				735				735
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)(13)		Medical Devices & Equipment		Senior Secured		April 2016		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	292				700				700
Subtotal: Under 1 Year Maturity															1,435				1,435
1-5 Years Maturity
Amedica Corporation(8)(13)(14)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 9.20% or Floor rate of 12.45%		$	17,051				17,642				17,350
Aspire Bariatrics, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		October 2018		Interest rate PRIME + 4.00% or Floor rate of 9.25%		$	7,000				6,771				6,739
Avedro, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		June 2018		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	12,500				12,391				12,201
Flowonix Medical Incorporated(11)(13)		Medical Devices & Equipment		Senior Secured		May 2018		Interest rate PRIME + 6.50% or Floor rate of 10.00%		$	15,000				15,071				14,974
Gamma Medica, Inc.(10)(13)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	4,000				4,009				3,989

 

See notes to consolidated financial statements.

 

F-12

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
InspireMD, Inc.(4)(9)(13)		Medical Devices & Equipment		Senior Secured		February 2017		Interest rate PRIME + 5.00% or Floor rate of 10.50%		$	5,009			$	5,380			$	3,764
Quanterix Corporation(10)(13)		Medical Devices & Equipment		Senior Secured		February 2018		Interest rate PRIME + 2.75% or Floor rate of 8.00%		$	9,661				9,718				9,659
SynergEyes, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	4,263				4,516				4,464
Subtotal: 1-5 Years Maturity															75,498				73,140
Subtotal: Medical Devices & Equipment (10.40%)*															76,933				74,575
Semiconductors
Under 1 Year Maturity
Achronix Semiconductor Corporation(14)		Semiconductors		Senior Secured		July 2016		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	5,000				5,000				5,000
Subtotal: Under 1 Year Maturity															5,000				5,000
1-5 Years Maturity
Achronix Semiconductor Corporation(13)(14)		Semiconductors		Senior Secured		July 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	5,000				5,027				4,999
Aquantia Corporation		Semiconductors		Senior Secured		February 2017		Interest rate PRIME + 2.95% or Floor rate of 6.20%		$	5,001				5,001				5,001
Avnera Corporation(10)(13)		Semiconductors		Senior Secured		April 2018		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	7,500				7,498				7,568
Subtotal: 1-5 Years Maturity															17,526				17,568
Subtotal: Semiconductors (3.15%)*															22,526				22,568
Software
Under 1 Year Maturity
Clickfox, Inc.(13)(14)(16)		Software		Senior Secured		December 2015		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	3,300				3,465				3,465
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.)(12)(13)(14)		Software		Senior Secured		October 2016		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	1,335				1,350				875
Neos, Inc.(13)(14)		Software		Senior Secured		May 2016		Interest rate PRIME + 6.75% or Floor rate of 10.50%		$	729				895				895
Touchcommerce, Inc.(14)		Software		Senior Secured		August 2016		Interest rate PRIME + 2.25% or Floor rate of 6.50%		$	5,511				5,511				5,511
Subtotal: Under 1 Year Maturity															11,221				10,746
1-5 Years Maturity
Actifio, Inc.(12)		Software		Senior Secured		January 2019		Interest rate PRIME + 4.25% or Floor rate of 8.25%, PIK Interest 2.25%		$	30,263				30,019				29,712
Clickfox, Inc.(13)(14)		Software		Senior Secured		March 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	5,475				5,490				5,490
Druva, Inc.(10)(13)		Software		Senior Secured		March 2018		Interest rate PRIME + 4.60% or Floor rate of 7.85%		$	12,000				12,080				12,034
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.)(12)(13)(14)		Software		Senior Secured		March 2018		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	11,082				11,174				7,245
Message Systems, Inc.(14)		Software		Senior Secured		February 2019		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	17,500				17,103				17,013
		Software		Senior Secured		February 2017		Interest rate PRIME + 2.75% or Floor rate of 6.00%		$	1,618				1,618				1,616
Total Message Systems, Inc.										$	19,118				18,721				18,629

 

See notes to consolidated financial statements.

 

F-13

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
RedSeal Inc.(13)(14)		Software		Senior Secured		June 2017		Interest rate PRIME + 3.25% or Floor rate of 6.50%		$	3,000			$	3,000			$	2,987
		Software		Senior Secured		June 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	5,000				5,006				4,979
Total RedSeal Inc.										$	8,000				8,006				7,966
Soasta, Inc.(13)(14)		Software		Senior Secured		February 2018		Interest rate PRIME + 2.25% or Floor rate of 5.50%		$	3,500				3,432				3,419
		Software		Senior Secured		February 2018		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	15,000				14,699				14,646
Total Soasta, Inc.										$	18,500				18,131				18,065
Touchcommerce, Inc.(13)(14)		Software		Senior Secured		February 2018		Interest rate PRIME + 6.00% or Floor rate of 10.25%		$	12,000				11,853				11,721
Subtotal: 1-5 Years Maturity															115,474				110,862
Subtotal: Software (16.96%)*															126,695				121,608
Specialty Pharmaceuticals
Under 1 Year Maturity
Cranford Pharmaceuticals, LLC(10)(12)		Specialty Pharmaceuticals		Senior Secured		August 2016		Interest rate LIBOR + 8.25% or Floor rate of 9.50%		$	1,100				1,100				1,100
Subtotal: Under 1 Year Maturity															1,100				1,100
1-5 Years Maturity
Alimera Sciences, Inc.(10)(13)		Specialty Pharmaceuticals		Senior Secured		May 2018		Interest rate PRIME + 7.65% or Floor rate of 10.90%		$	35,000				34,296				34,309
Cranford Pharmaceuticals, LLC(10)(12)(13)(14)		Specialty Pharmaceuticals		Senior Secured		August 2017		Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%		$	10,041				10,164				10,235
Jaguar Animal Health, Inc.(10)(13)		Specialty Pharmaceuticals		Senior Secured		August 2018		Interest rate PRIME + 5.65% or Floor rate of 9.90%		$	6,000				6,009				6,009
Subtotal: 1-5 Years Maturity															50,469				50,553
Subtotal: Specialty Pharmaceuticals (7.20%)*															51,569				51,653
Surgical Devices
1-5 Years Maturity
Transmedics, Inc.(13)		Surgical Devices		Senior Secured		March 2019		Interest rate PRIME + 5.30% or Floor rate of 9.55%		$	8,500				8,471				8,396
Subtotal: 1-5 Years Maturity															8,471				8,396
Subtotal: Surgical Devices (1.17%)*															8,471				8,396
Total Debt Investments (154.81%)*															1,152,303				1,110,209

See notes to consolidated financial statements.

 

F-14

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Equity Investments
Biotechnology Tools
NuGEN Technologies, Inc.(14)		Biotechnology Tools		Equity		Preferred Series C			189,394			$	500			$	532
Subtotal: Biotechnology Tools (0.07%)*													500				532
Communications & Networking
GlowPoint, Inc.(3)		Communications & Networking		Equity		Common Stock			114,192				102				57
Peerless Network, Inc.		Communications & Networking		Equity		Preferred Series A			1,000,000				1,000				4,380
Subtotal: Communications & Networking (0.62%)*													1,102				4,437
Consumer & Business Products
Market Force Information, Inc.		Consumer & Business Products		Equity		Common Stock			480,261				—				217
		Consumer & Business Products		Equity		Preferred Series B-1			187,970				500				3
Total Market Force Information, Inc.									668,231				500				220
Subtotal: Consumer & Business Products (0.03%)*													500				220
Diagnostic
Singulex, Inc.		Diagnostic		Equity		Common Stock			937,998				750				304
Subtotal: Diagnostic (0.04%)*													750				304
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)		Drug Delivery		Equity		Common Stock			54,240				108				209
BioQ Pharma Incorporated(14)		Drug Delivery		Equity		Preferred Series D			165,000				500				660
Edge Therapeutics, Inc.(3)		Drug Delivery		Equity		Common Stock			157,190				1,000				1,965
Merrion Pharmaceuticals, Plc(3)(4)(9)		Drug Delivery		Equity		Common Stock			20,000				9				—
Neos Therapeutics, Inc.(3)(14)		Drug Delivery		Equity		Common Stock			125,000				1,500				1,790
Revance Therapeutics, Inc.(3)		Drug Delivery		Equity		Common Stock			22,765				557				778
Subtotal: Drug Delivery (0.75%)*													3,674				5,402
Drug Discovery & Development
Aveo Pharmaceuticals, Inc.(3)(9)(14)		Drug Discovery & Development		Equity		Common Stock			167,864				842				212
Cerecor, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			119,087				1,000				399
Cerulean Pharma, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			135,501				1,000				379
Dicerna Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Equity		Common Stock			142,858				1,000				1,695
Dynavax Technologies(3)(9)		Drug Discovery & Development		Equity		Common Stock			20,000				550				483
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			200,000				1,000				618
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			223,463				2,000				1,178
Inotek Pharmaceuticals Corporation(3)		Drug Discovery & Development		Equity		Common Stock			3,778				1,500				43
Insmed, Incorporated(3)		Drug Discovery & Development		Equity		Common Stock			70,771				1,000				1,284
Melinta Therapeutics		Drug Discovery & Development		Equity		Preferred Series 4			1,914,448				2,000				2,026
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)		Drug Discovery & Development		Equity		Common Stock			76,362				2,743				1,450
Subtotal: Drug Discovery & Development (1.36%)*													14,635				9,767

 

See notes to consolidated financial statements.

 

F-15

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Electronics & Computer Hardware
Identiv, Inc.(3)		Electronics & Computer Hardware		Equity		Common Stock			6,700			$	34			$	13
Subtotal: Electronics & Computer Hardware (0.00%)*													34				13
Sustainable and Renewable Technology
Glori Energy, Inc.(3)		Sustainable and Renewable Technology		Equity		Common Stock			18,208				165				6
Modumetal, Inc.		Sustainable and Renewable Technology		Equity		Preferred Series C			3,107,520				500				455
SCIEnergy, Inc.		Sustainable and Renewable Technology		Equity		Preferred Series 1			385,000				761				—
Sungevity, Inc.(14)		Sustainable and Renewable Technology		Equity		Preferred Series D			68,807,339				6,750				6,912
Subtotal: Sustainable and Renewable Technology (1.03%)*													8,176				7,373
Internet Consumer & Business Services
Blurb, Inc.(14)		Internet Consumer & Business Services		Equity		Preferred Series B			220,653				175				244
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Equity		Preferred Series C			230,030				250				264
		Internet Consumer & Business Services		Equity		Preferred Series D			198,677				250				249
Total Lightspeed POS, Inc.									428,707				500				513
Oportun (p.k.a. Progress Financial)		Internet Consumer & Business Services		Equity		Preferred Series G			218,351				250				349
		Internet Consumer & Business Services		Equity		Preferred Series H			87,802				250				248
Total Oportun (p.k.a. Progress Financial)									306,153				500				597
Philotic, Inc.		Internet Consumer & Business Services		Equity		Common Stock			9,023				93				—
RazorGator Interactive Group, Inc.		Internet Consumer & Business Services		Equity		Preferred Series AA			34,783				15				28
Taptera, Inc.		Internet Consumer & Business Services		Equity		Preferred Series B			454,545				150				99
Subtotal: Internet Consumer & Business Services (0.21%)*													1,433				1,481
Medical Devices & Equipment
AtriCure, Inc.(3)(14)		Medical Devices & Equipment		Equity		Common Stock			7,536				266				155
Flowonix Medical Incorporated		Medical Devices & Equipment		Equity		Preferred Series E			221,893				1,500				1,953
Gelesis, Inc.(14)		Medical Devices & Equipment		Equity		Common Stock			198,202				—				1,005
		Medical Devices & Equipment		Equity		Preferred Series A-1			191,210				425				1,051
		Medical Devices & Equipment		Equity		Preferred Series A-2			191,626				500				1,012
Total Gelesis, Inc.									581,038				925				3,068

 

See notes to consolidated financial statements.

 

F-16

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Medrobotics Corporation(14)		Medical Devices & Equipment		Equity		Preferred Series E			136,798			$	250			$	208
		Medical Devices & Equipment		Equity		Preferred Series F			73,971				155				189
		Medical Devices & Equipment		Equity		Preferred Series G			163,934				500				500
Total Medrobotics Corporation									374,703				905				897
Novasys Medical, Inc.		Medical Devices & Equipment		Equity		Preferred Series D-1			4,118,444				1,000				—
Optiscan Biomedical, Corp.(5)(14)		Medical Devices & Equipment		Equity		Preferred Series B			6,185,567				3,000				565
		Medical Devices & Equipment		Equity		Preferred Series C			1,927,309				655				169
		Medical Devices & Equipment		Equity		Preferred Series D			55,103,923				5,257				5,927
Total Optiscan Biomedical, Corp.									63,216,799				8,912				6,661
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Equity		Preferred Series 1			1,086,969				500				266
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.)		Medical Devices & Equipment		Equity		Preferred Series B			232,061				527				543
Subtotal: Medical Devices & Equipment (1.89%)*													14,535				13,543
Software
Box, Inc.(3)(14)		Software		Equity		Common Stock			1,287,347				5,653				17,957
CapLinked, Inc.		Software		Equity		Preferred Series A-3			53,614				51				79
Druva, Inc.		Software		Equity		Preferred Series 2			458,841				1,000				1,031
ForeScout Technologies, Inc.		Software		Equity		Preferred Series D			319,099				398				1,368
		Software		Equity		Preferred Series E			80,587				131				350
Total ForeScout Technologies, Inc.									399,686				529				1,718
HighRoads, Inc.		Software		Equity		Preferred Series B			190,170				307				—
NewVoiceMedia Limited(4)(9)		Software		Equity		Preferred Series E			669,173				963				1,016
WildTangent, Inc.(14)		Software		Equity		Preferred Series 3			100,000				402				190
Subtotal: Software (3.07%)*													8,905				21,991
Specialty Pharmaceuticals
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Equity		Preferred Series E			241,829				750				—
		Specialty Pharmaceuticals		Equity		Preferred Series E-1			26,955				—				—
		Specialty Pharmaceuticals		Equity		Preferred Series G			4,667,636				—				—
Total QuatRx Pharmaceuticals Company									4,936,420				750				—
Subtotal: Specialty Pharmaceuticals (0.00%)*													750				—
Surgical Devices
Gynesonics, Inc.(14)		Surgical Devices		Equity		Preferred Series B			219,298				250				32
		Surgical Devices		Equity		Preferred Series C			656,538				282				46
		Surgical Devices		Equity		Preferred Series D			1,991,157				712				637
		Surgical Devices		Equity		Preferred Series E			2,785,402				429				422
Total Gynesonics, Inc.									5,652,395				1,673				1,137
Transmedics, Inc.		Surgical Devices		Equity		Preferred Series B			88,961				1,100				154
		Surgical Devices		Equity		Preferred Series C			119,999				300				96
		Surgical Devices		Equity		Preferred Series D			260,000				650				521
		Surgical Devices		Equity		Preferred Series F			100,200				500				471
Total Transmedics, Inc.									569,160				2,550				1,242
Subtotal: Surgical Devices (0.33%)*													4,223				2,379
Total: Equity Investments (9.40%)*													59,217				67,442

 

See notes to consolidated financial statements.

 

F-17

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Warrant Investments
Biotechnology Tools
Labcyte, Inc.(14)		Biotechnology Tools		Warrant		Preferred Series C			1,127,624			$	323			$	187
Subtotal: Biotechnology Tools (0.03%)*													323				187
Communications & Networking
Intelepeer, Inc.(14)		Communications & Networking		Warrant		Common Stock			117,958				102				—
OpenPeak, Inc.		Communications & Networking		Warrant		Common Stock			108,982				149				—
PeerApp, Inc.		Communications & Networking		Warrant		Preferred Series B			298,779				61				62
Peerless Network, Inc.		Communications & Networking		Warrant		Preferred Series A			135,000				95				375
Ping Identity Corporation		Communications & Networking		Warrant		Preferred Series B			1,136,277				52				236
SkyCross, Inc.(14)		Communications & Networking		Warrant		Preferred Series F			9,762,777				394				—
Spring Mobile Solutions, Inc.		Communications & Networking		Warrant		Preferred Series D			2,834,375				418				53
Subtotal: Communications & Networking (0.10%)*													1,271				726
Consumer & Business Products
Antenna79 (p.k.a. Pong Research Corporation)(14)		Consumer & Business Products		Warrant		Preferred Series A			1,662,441				228				2
Intelligent Beauty, Inc.(14)		Consumer & Business Products		Warrant		Preferred Series B			190,234				230				214
IronPlanet, Inc.		Consumer & Business Products		Warrant		Preferred Series D			1,155,821				1,076				651
Market Force Information, Inc.		Consumer & Business Products		Warrant		Preferred Series A-1			150,212				24				10
Nasty Gal(14)		Consumer & Business Products		Warrant		Preferred Series C			845,194				23				20
The Neat Company(14)		Consumer & Business Products		Warrant		Preferred Series C-1			540,540				365				—
Subtotal: Consumer & Business Products (0.13%)*													1,946				897
Diagnostic
Navidea Biopharmaceuticals, Inc. (p.k.a. Neoprobe)(3)(14)		Diagnostic		Warrant		Common Stock			333,333				244				17
Subtotal: Diagnostic (0.00%)*													244				17
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)(14)		Drug Delivery		Warrant		Common Stock			176,730				786				238
Agile Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			180,274				730				680
BIND Therapeutics, Inc.(3)(14)		Drug Delivery		Warrant		Common Stock			152,586				488				6
BioQ Pharma Incorporated		Drug Delivery		Warrant		Common Stock			459,183				1				423
Celator Pharmaceuticals, Inc.(3)		Drug Delivery		Warrant		Common Stock			210,675				138				59
Celsion Corporation(3)		Drug Delivery		Warrant		Common Stock			194,986				428				20
Dance Biopharm, Inc.(14)		Drug Delivery		Warrant		Common Stock			43,813				74				55
Edge Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			78,595				390				417
Kaleo, Inc. (p.k.a. Intelliject, Inc.)		Drug Delivery		Warrant		Preferred Series B			82,500				594				1,217
Neos Therapeutics, Inc.(3)(14)		Drug Delivery		Warrant		Common Stock			70,833				285				275
Pulmatrix Inc.(3)		Drug Delivery		Warrant		Common Stock			25,150				116				12
ZP Opco, Inc (p.k.a. Zosano Pharma)(3)		Drug Delivery		Warrant		Common Stock			72,379				266				4
Subtotal: Drug Delivery (0.47%)*													4,296				3,406

 

See notes to consolidated financial statements.

 

F-18

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Drug Discovery & Development
ADMA Biologics, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			89,750			$	295			$	98
Anthera Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			40,178				984				—
Aveo Pharmaceuticals, Inc.(3)(9)		Drug Discovery & Development		Warrant		Common Stock			608,696				194				216
Cerecor, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			22,328				70				10
Cerulean Pharma, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			171,901				369				90
Chroma Therapeutics, Ltd.(4)(9)		Drug Discovery & Development		Warrant		Preferred Series D			325,261				490				—
Cleveland BioLabs, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			7,813				105				5
Concert Pharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			70,796				367				368
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(3)		Drug Discovery & Development		Warrant		Common Stock			292,398				165				59
Dicerna Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			200				28				—
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			64,194				276				55
Fortress Biotech, Inc. (p.k.a. Coronado Biosciences, Inc.)(3)		Drug Discovery & Development		Warrant		Common Stock			73,009				142				11
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			73,725				266				92
Immune Pharmaceuticals(3)		Drug Discovery & Development		Warrant		Common Stock			214,853				164				40
Mast Therapeutics, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			1,524,389				203				215
Melinta Therapeutics		Drug Discovery & Development		Warrant		Preferred Series 3			1,382,323				626				130
Nanotherapeutics, Inc.(14)		Drug Discovery & Development		Warrant		Common Stock			171,389				838				1,762
Neothetics, Inc. (p.k.a. Lithera, Inc)(3)(14)		Drug Discovery & Development		Warrant		Common Stock			46,838				266				2
Neuralstem, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			75,187				77				12
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)(14)		Drug Discovery & Development		Warrant		Common Stock			21,467				129				36
uniQure B.V.(3)(4)(9)		Drug Discovery & Development		Warrant		Common Stock			37,174				218				183
XOMA Corporation(3)(9)(14)		Drug Discovery & Development		Warrant		Common Stock			181,268				279				115
Subtotal: Drug Discovery & Development (0.49%)*													6,551				3,499
Electronics & Computer Hardware
Clustrix, Inc.		Electronics & Computer Hardware		Warrant		Common Stock			50,000				12				—
Persimmon Technologies		Electronics & Computer Hardware		Warrant		Preferred Series C			43,076				40				42
Subtotal: Electronics & Computer Hardware (0.01%)*													52				42

 

See notes to consolidated financial statements.

 

F-19

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Sustainable and Renewable Technology
Agrivida, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series D			471,327			$	120			$	38
Alphabet Energy, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A			86,329				82				159
American Superconductor Corporation(3)		Sustainable and Renewable Technology		Warrant		Common Stock			58,823				39				82
Brightsource Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series 1			116,667				104				6
Calera, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			44,529				513				—
EcoMotors, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series B			437,500				308				176
Fluidic, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series D			61,804				102				43
Fulcrum Bioenergy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series C-1			280,897				275				152
GreatPoint Energy, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series D-1			393,212				548				—
Polyera Corporation(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			311,609				338				10
Proterra, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series 4			397,931				37				50
SCIEnergy, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			530,811				181				—
		Sustainable and Renewable Technology		Warrant		Preferred Series 1			145,811				50				—
Total SCIEnergy, Inc.									676,622				231				—
Scifiniti (p.k.a. Integrated Photovoltaics, Inc.)(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A-1			390,000				82				48
Solexel, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			1,171,625				1,162				466
Stion Corporation(5)		Sustainable and Renewable Technology		Warrant		Preferred Series Seed			2,154				1,378				—
Sungevity, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			20,000,000				543				569
		Sustainable and Renewable Technology		Warrant		Preferred Series C			32,472,222				902				525
Total Sungevity, Inc.									52,472,222				1,445				1,094
TAS Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series AA			428,571				299				—
Tendril Networks		Sustainable and Renewable Technology		Warrant		Preferred Series 3-A			1,019,793				188				242
TPI Composites, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series B			160				273				85
Trilliant, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A			320,000				162				53
Subtotal: Sustainable and Renewable Technology (0.38%)*													7,686				2,704
Healthcare Services, Other
Chromadex Corporation(3)(14)		Healthcare Services, Other		Warrant		Common Stock			419,020				157				164
Subtotal: Healthcare Services, Other (0.02%)*													157				164
Information Services
Cha Cha Search, Inc.(14)		Information Services		Warrant		Preferred Series G			48,232				58				—
INMOBI Inc.(4)(9)		Information Services		Warrant		Common Stock			46,874				82				3
InXpo, Inc.(14)		Information Services		Warrant		Preferred Series C			648,400				98				2
		Information Services		Warrant		Preferred Series C-1			1,032,416				74				—
Total InXpo, Inc.									1,680,816				172				2
RichRelevance, Inc.(14)		Information Services		Warrant		Preferred Series E			112,612				98				—
Subtotal: Information Services (0.00%)*													410				5

 

See notes to consolidated financial statements.

 

F-20

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Internet Consumer & Business Services
Aria Systems, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series E			239,692			$	73			$	88
Blurb, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			234,280				636				148
CashStar, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C-2			727,272				130				34
Just Fabulous, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series B			206,184				1,102				1,104
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Warrant		Preferred Series C			245,610				20				82
Oportun (p.k.a. Progress Financial)		Internet Consumer & Business Services		Warrant		Preferred Series G			174,562				78				104
Prism Education Group, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series B			200,000				43				—
ReachLocal(3)		Internet Consumer & Business Services		Warrant		Common Stock			300,000				155				290
ShareThis, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			493,502				547				93
Tapjoy, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series D			748,670				316				8
Tectura Corporation		Internet Consumer & Business Services		Warrant		Preferred Series B-1			253,378				51				—
Subtotal: Internet Consumer & Business Services (0.27%)*													3,151				1,951
Media/Content/Info
Machine Zone, Inc.		Media/Content/Info		Warrant		Common Stock			143,626				1,802				2,086
Rhapsody International, Inc.(14)		Media/Content/Info		Warrant		Common Stock			715,755				384				218
Zoom Media Group, Inc.		Media/Content/Info		Warrant		Preferred Series A			1,204				348				23
Subtotal: Media/Content/Info (0.32%)*													2,534				2,327
Medical Devices & Equipment
Amedica Corporation(3)(14)		Medical Devices & Equipment		Warrant		Common Stock			1,548,387				459				31
Aspire Bariatrics, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series D			395,000				455				236
Avedro, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series AA			300,000				401				142
Flowonix Medical Incorporated		Medical Devices & Equipment		Warrant		Preferred Series E			110,947				203				428
Gamma Medica, Inc.		Medical Devices & Equipment		Warrant		Preferred Series A			357,500				170				144
Gelesis, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series A-1			74,784				78				262
InspireMD, Inc.(3)(4)(9)		Medical Devices & Equipment		Warrant		Common Stock			16,835				242				—
Medrobotics Corporation(14)		Medical Devices & Equipment		Warrant		Preferred Series E			455,539				370				244
NetBio, Inc.		Medical Devices & Equipment		Warrant		Common Stock			2,568				408				19
NinePoint Medical, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series A-1			587,840				170				119
Novasys Medical, Inc.		Medical Devices & Equipment		Warrant		Common Stock			109,449				2				—
		Medical Devices & Equipment		Warrant		Preferred Series D			526,840				125				—
		Medical Devices & Equipment		Warrant		Preferred Series D-1			53,607				6				—
Total Novasys Medical, Inc.									689,896				133				—

 

See notes to consolidated financial statements.

 

F-21

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Optiscan Biomedical, Corp.(5)(14)		Medical Devices & Equipment		Warrant		Preferred Series D			10,535,275			$	1,252			$	312
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Warrant		Common Stock			954				66				—
		Medical Devices & Equipment		Warrant		Preferred Series 1			1,632,084				676				63
Total Oraya Therapeutics, Inc.									1,633,038				742				63
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.)		Medical Devices & Equipment		Warrant		Preferred Series A			500,000				402				298
Quanterix Corporation		Medical Devices & Equipment		Warrant		Preferred Series C			115,618				156				60
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)		Medical Devices & Equipment		Warrant		Preferred Series A			6,464				188				—
Strata Skin Sciences, Inc. (p.k.a. MELA Sciences, Inc.)(3)		Medical Devices & Equipment		Warrant		Common Stock			69,320				402				—
ViewRay, Inc.(3)(14)		Medical Devices & Equipment		Warrant		Common Stock			128,231				333				84
Subtotal: Medical Devices & Equipment (0.34%)*													6,564				2,442
Semiconductors
Achronix Semiconductor Corporation(14)		Semiconductors		Warrant		Preferred Series C			360,000				160				27
		Semiconductors		Warrant		Preferred Series D-1			500,000				6				6
Total Achronix Semiconductor Corporation									860,000				166				33
Aquantia Corp.		Semiconductors		Warrant		Preferred Series G			196,831				4				39
Avnera Corporation		Semiconductors		Warrant		Preferred Series E			141,567				47				65
Subtotal: Semiconductors (0.02%)*													217				137
Software
Actifio, Inc.		Software		Warrant		Common Stock			73,584				249				210
Braxton Technologies, LLC		Software		Warrant		Preferred Series A			168,750				188				—
CareCloud Corporation(14)		Software		Warrant		Preferred Series B			413,433				258				625
Clickfox, Inc.(14)		Software		Warrant		Preferred Series B			1,038,563				330				362
		Software		Warrant		Preferred Series C			592,019				730				272
		Software		Warrant		Preferred Series C-A			46,109				13				16
Total Clickfox, Inc.									1,676,691				1,073				650
Hillcrest Laboratories, Inc.(14)		Software		Warrant		Preferred Series E			1,865,650				55				138
JumpStart Games, Inc. (p.k.a Knowledge Holdings, Inc.)(14)		Software		Warrant		Preferred Series E			614,333				16				—
Message Systems, Inc.(14)		Software		Warrant		Preferred Series B			408,011				334				497
Mobile Posse, Inc.(14)		Software		Warrant		Preferred Series C			396,430				130				59
Neos, Inc.(14)		Software		Warrant		Common Stock			221,150				22				113
NewVoiceMedia Limited(4)(9)		Software		Warrant		Preferred Series E			225,586				33				55
Poplicus, Inc.(14)		Software		Warrant		Preferred Series C			2,595,230				—				110
Soasta, Inc.(14)		Software		Warrant		Preferred Series E			410,800				691				561
Sonian, Inc.(14)		Software		Warrant		Preferred Series C			185,949				106				39
Touchcommerce, Inc.(14)		Software		Warrant		Preferred Series E			2,282,968				446				581
Subtotal: Software (0.51%)*													3,601				3,638
Specialty Pharmaceuticals
Alimera Sciences, Inc.(3)		Specialty Pharmaceuticals		Warrant		Common Stock			660,377				729				435
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Warrant		Preferred Series E			155,324				307				—
Subtotal: Specialty Pharmaceuticals (0.06%)*													1,036				435

 

See notes to consolidated financial statements.

 

F-22

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Surgical Devices
Gynesonics, Inc.(14)		Surgical Devices		Warrant		Preferred Series C			180,480			$	75			$	12
		Surgical Devices		Warrant		Preferred Series D			1,575,965				320				223
Total Gynesonics, Inc.									1,756,445				395				235
Transmedics, Inc.		Surgical Devices		Warrant		Preferred Series B			40,436				224				2
		Surgical Devices		Warrant		Preferred Series D			175,000				100				170
		Surgical Devices		Warrant		Preferred Series F			16,476				3				3
Total Transmedics, Inc.									231,912				327				175
Subtotal: Surgical Devices (0.06%)*													722				410
Total: Warrant Investments (3.21%)*													40,761				22,987
Total Investments (167.42%)*												$	1,252,281			$	1,200,638

  

 

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $29.3 million, $81.4 million and $52.1 million respectively. The tax cost of investments is $1.3 billion.

(3)

Except for warrants in 37 publicly traded companies and common stock in 20 publicly traded companies, all investments are restricted at December 31, 2015 and were valued at fair value as determined in good faith by the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Non-U.S. company or the company’s principal place of business is outside the United States.

(5)	Affiliate investment as defined under the Investment Company Act of 1940, as amended, in which Hercules owns at least 5% but not more than 25% of the company’s voting securities.

(6)	Control investment as defined under the Investment Company Act of 1940, as amended, in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. There were no control investments at December 31, 2015.

(7)

Debt is on non-accrual status at December 31, 2015, and is therefore considered non-income producing. Note that at December 31, 2015, only the PIK interest is on non-accrual for the Company’s debt investment in Skycross, Inc and only the $2.1 million PIK loan is on non-accrual for the Company’s debt investment in One Planet Ops Inc. (p.k.a. Reply! Inc.).

(8)	Denotes that all or a portion of the debt investment is convertible debt.

(9)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(10)	Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).

(11)	Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility.

(12)	Denotes that all or a portion of the debt investment principal includes accumulated PIK, or payment-in-kind, interest and is net of repayments.

(13)	Denotes that all or a portion of the debt investment includes an exit fee receivable. This fee ranges from 0.8% to 17.1% of the total debt commitment based on the contractual terms of our loan servicing agreements.

(14)	Denotes that all or a portion of the investment in this portfolio company is held by HT II or HT III, the Company’s wholly-owned SBIC subsidiaries.

(15)

The stated ‘Maturity Date’ for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company’s investment team and Investment Committee continue to closely monitor developments at the borrower company.

(16)	Repayment of debt investment is delinquent of the contractual maturity date as of December 31, 2015.

See notes to consolidated financial statements.

 

F-23

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Debt Investments
Biotechnology Tools
1-5 Years Maturity
Labcyte, Inc.(10)(12)(13)		Biotechnology Tools		Senior Secured		June 2016		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	2,695			$	2,869			$	2,869
Subtotal: 1-5 Years Maturity															2,869				2,869
Subtotal: Biotechnology Tools (0.44%)*															2,869				2,869
Communications & Networking
1-5 Years Maturity
OpenPeak, Inc.(10)(12)		Communications & Networking		Senior Secured		April 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	12,889				13,193				13,193
SkyCross, Inc.(12)(13)		Communications & Networking		Senior Secured		January 2018		Interest rate PRIME + 9.70% or Floor rate of 12.95%		$	22,000				21,580				20,149
Spring Mobile Solutions, Inc.(10)(12)		Communications & Networking		Senior Secured		November 2016		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	18,840				18,928				19,116
Subtotal: 1-5 Years Maturity															53,701				52,458
Subtotal: Communications & Networking (7.96%)*															53,701				52,458
Consumer & Business Products
1-5 Years Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(13)		Consumer & Business Products		Senior Secured		December 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	5,000				4,912				4,884
		Consumer & Business Products		Senior Secured		June 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	216				89				89
Total Antenna79 (p.k.a. Pong Research Corporation)										$	5,216				5,001				4,973
Fluc, Inc.(8)		Consumer & Business Products		Convertible Senior Note		March 2017		Interest rate FIXED 4.00%		$	100				100				100
IronPlanet, Inc.(12)		Consumer & Business Products		Senior Secured		November 2017		Interest rate PRIME + 6.20% or Floor rate of 9.45%		$	37,500				36,345				36,345
The Neat Company(11)(12)(13)		Consumer & Business Products		Senior Secured		September 2017		Interest rate PRIME + 7.75% or Floor rate of 11.00%, PIK Interest 1.00%		$	20,061				19,422				19,422
Subtotal: 1-5 Years Maturity															60,868				60,840
Subtotal: Consumer & Business Products (9.23%)*															60,868				60,840
Drug Delivery
Under 1 Year Maturity
Revance Therapeutics, Inc.(10)(12)		Drug Delivery		Senior Secured		March 2015		Interest rate PRIME + 6.60% or Floor rate of 9.85%		$	2,098				2,458				2,458
		Drug Delivery		Senior Secured		March 2015		Interest rate PRIME + 6.60% or Floor rate of 9.85%		$	210				246				246
Total Revance Therapeutics, Inc.										$	2,308				2,704				2,704
Subtotal: Under 1 Year Maturity															2,704				2,704
1-5 Years Maturity
AcelRx Pharmaceuticals, Inc.(9)(10)(12)(13)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 3.85% or Floor rate of 9.10%		$	25,000				24,831				24,969
BIND Therapeutics, Inc.(12)(13)		Drug Delivery		Senior Secured		September 2016		Interest rate PRIME + 7.00% or Floor rate of 10.25%		$	3,274				3,343				3,228
BioQuiddity Incorporated(12)		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	7,500				7,439				7,439
Celator Pharmaceuticals, Inc.(10)(12)		Drug Delivery		Senior Secured		June 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	10,000				9,927				9,899

See notes to consolidated financial statements.

 

F-24

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Celsion Corporation(10)(12)		Drug Delivery		Senior Secured		June 2017		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	10,000			$	9,858			$	10,027
Dance Biopharm, Inc.(12)(13)		Drug Delivery		Senior Secured		November 2017		Interest rate PRIME + 7.40% or Floor rate of 10.65%		$	3,905				3,871				3,864
Edge Therapeutics, Inc.(12)		Drug Delivery		Senior Secured		March 2018		Interest rate PRIME + 5.95% or Floor rate of 10.45%		$	3,000				2,847				2,847
Neos Therapeutics, Inc.(12)(13)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	5,000				4,916				4,916
		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 9.00%		$	10,000				10,010				10,063
Total Neos Therapeutics, Inc.										$	15,000				14,926				14,979
Zosano Pharma, Inc.(10)(12)		Drug Delivery		Senior Secured		June 2017		Interest rate PRIME + 6.80% or Floor rate of 12.05%		$	4,000				3,894				3,881
Subtotal: 1-5 Years Maturity															80,936				81,133
Subtotal: Drug Delivery (12.72%)*															83,640				83,837
Drug Discovery & Development
Under 1 Year Maturity
Aveo Pharmaceuticals, Inc.(9)(10)(12)(13)		Drug Discovery & Development		Senior Secured		December 2015		Interest rate PRIME + 7.15% or Floor rate of 11.90%		$	11,611				11,611				11,611
Concert Pharmaceuticals, Inc.(10)		Drug Discovery & Development		Senior Secured		October 2015		Interest rate PRIME + 3.25% or Floor rate of 8.50%		$	7,175				7,142				7,142
Subtotal: Under 1 Year Maturity															18,753				18,753
1-5 Years Maturity
ADMA Biologics, Inc.(10)(11)(12)		Drug Discovery & Development		Senior Secured		December 2017		Interest rate PRIME + 5.5% or Floor rate of 8.75%, PIK Interest 1.95%		$	5,000				4,879				4,933
		Drug Discovery & Development		Senior Secured		December 2017		Interest rate PRIME + 3.00% or Floor rate of 8.75%, PIK Interest 1.95%		$	10,153				10,032				10,144
Total ADMA Biologics, Inc.										$	15,153				14,911				15,077
Aveo Pharmaceuticals, Inc.(9)(10)(12)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 6.65% or Floor rate of 11.90%		$	10,000				9,766				9,766
Celladon Corporation(12)(13)		Drug Discovery & Development		Senior Secured		February 2018		Interest rate PRIME + 5.00% or Floor rate of 8.25%		$	10,000				10,022				10,022
Cempra, Inc.(10)(12)		Drug Discovery & Development		Senior Secured		April 2018		Interest rate PRIME + 6.30% or Floor rate of 9.55%		$	18,000				18,020				18,560
Cerecor Inc.(12)		Drug Discovery & Development		Senior Secured		August 2017		Interest rate PRIME + 6.30% or Floor rate of 9.55%		$	7,500				7,374				7,374
Cleveland BioLabs, Inc.(12)(13)		Drug Discovery & Development		Senior Secured		January 2017		Interest rate PRIME + 6.10% or Floor rate of 9.35%		$	1,883				1,883				1,920
CTI BioPharma Corp. (pka Cell Therapeutics, Inc.)(10)(12)		Drug Discovery & Development		Senior Secured		October 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	4,584				4,584				4,712
		Drug Discovery & Development		Senior Secured		October 2016		Interest rate PRIME + 9.00% or Floor rate of 12.25%		$	13,890				13,890				14,279
Total CTI BioPharma Corp. (pka Cell Therapeutics, Inc.)										$	18,474				18,474				18,991
Dynavax Technologies(9)(12)		Drug Discovery & Development		Senior Secured		July 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	10,000				9,897				9,897
Epirus Biopharmaceuticals, Inc.(12)		Drug Discovery & Development		Senior Secured		April 2018		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	7,500				7,308				7,308
Genocea Biosciences, Inc.(12)		Drug Discovery & Development		Senior Secured		July 2018		Interest rate PRIME + 2.25% or Floor rate of 7.25%		$	12,000				11,814				11,814
Insmed, Incorporated(10)(12)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 4.75% or Floor rate of 9.25%		$	25,000				24,854				24,854
Melinta Therapeutics(12)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.00% or Floor rate of 8.25%		$	20,000				19,272				19,272

 

See notes to consolidated financial statements.

 

F-25

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Merrimack Pharmaceuticals, Inc.(12)		Drug Discovery & Development		Senior Secured		November 2016		Interest rate PRIME + 5.30% or Floor rate of 10.55%		$	40,000			$	40,578			$	40,677
Neothetics, Inc. (pka Lithera, Inc)(12)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	10,000				9,751				9,697
Neuralstem, Inc.(12)(13)		Drug Discovery & Development		Senior Secured		April 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	9,489				9,333				9,333
uniQure B.V.(4)(9)(10)(12)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.00% or Floor rate of 10.25%		$	15,000				14,890				14,798
		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.25% or Floor rate of 10.25%		$	5,000				4,962				4,931
Total Uniqure B.V.										$	20,000				19,852				19,729
Subtotal: 1-5 Years Maturity															233,109				234,291
Subtotal: Drug Discovery & Development (38.41%)*															251,862				253,044
Electronics & Computer Hardware
1-5 Years Maturity
Plures Technologies, Inc.(7)(11)		Electronics & Computer Hardware		Senior Secured		October 2016		Interest rate LIBOR + 8.75% or Floor rate of 12.00%, PIK Interest 4.00%		$	267				180				—
Subtotal: 1-5 Years Maturity															180				—
Subtotal: Electronics & Computer Hardware (0.00%)*															180				—
Sustainable and Renewable Technology(16)
Under 1 Year Maturity
Glori Energy, Inc.(10)(12)		Sustainable and Renewable Technology		Senior Secured		June 2015		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	1,778				2,042				2,042
Scifiniti (pka Integrated Photovoltaics, Inc.)(13)		Sustainable and Renewable Technology		Senior Secured		February 2015		Interest rate PRIME + 7.38% or Floor rate of 10.63%		$	227				227				227
Stion Corporation(5)(12)		Sustainable and Renewable Technology		Senior Secured		February 2015		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	2,954				2,993				1,600
TAS Energy, Inc.(10)(12)		Sustainable and Renewable Technology		Senior Secured		December 2015		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	6,901				7,091				7,091
Subtotal: Under 1 Year Maturity															12,353				10,960
1-5 Years Maturity
Agrivida, Inc.(12)(13)		Sustainable and Renewable Technology		Senior Secured		December 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	4,921				5,013				4,923
American Superconductor Corporation(10)(12)		Sustainable and Renewable Technology		Senior Secured		March 2017		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	1,500				1,446				1,446
		Sustainable and Renewable Technology		Senior Secured		November 2016		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	7,667				7,847				7,847
Total American Superconductor Corporation										$	9,167				9,293				9,293
Amyris, Inc.(9)(12)		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	25,000				25,000				25,170
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	5,000				5,000				5,034
Total Amyris, Inc.										$	30,000				30,000				30,204

 

See notes to consolidated financial statements.

 

F-26

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Fluidic, Inc.(10)(12)		Sustainable and Renewable Technology		Senior Secured		March 2016		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	3,674			$	3,747			$	3,721
Modumetal, Inc.(12)		Sustainable and Renewable Technology		Senior Secured		March 2017		Interest rate PRIME + 8.70% or Floor rate of 11.95%		$	3,000				2,991				2,991
Polyera Corporation(12)(13)		Sustainable and Renewable Technology		Senior Secured		June 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	3,654				3,818				3,810
Subtotal: 1-5 Years Maturity															54,862				54,942
Subtotal: Sustainable and Renewable Technology (16) (10.00%)*															67,215				65,902
Healthcare Services, Other
1-5 Years Maturity
Chromadex Corporation(12)(13)		Healthcare Services, Other		Senior Secured		April 2018		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	2,500				2,407				2,407
InstaMed Communications, LLC(13)		Healthcare Services, Other		Senior Secured		March 2018		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	5,000				5,041				5,041
MDEverywhere, Inc.(10)(12)		Healthcare Services, Other		Senior Secured		January 2018		Interest rate LIBOR + 9.50% or Floor rate of 10.75%		$	3,000				2,962				2,962
Subtotal: 1-5 Years Maturity															10,410				10,410
Subtotal: Healthcare Services, Other (1.58%)*															10,410				10,410
Information Services
Under 1 Year Maturity
Eccentex Corporation(10)(12)		Information Services		Senior Secured		May 2015		Interest rate PRIME + 7.00% or Floor rate of 10.25%		$	204				218				184
Subtotal: Under 1 Year Maturity															218				184
1-5 Years Maturity
INMOBI Inc.(4)(9)(11)(12)		Information Services		Senior Secured		December 2016		Interest rate PRIME + 7.00% or Floor rate of 10.25%		$	9,612				9,283				9,283
		Information Services		Senior Secured		December 2017		Interest rate PRIME + 5.75% or Floor rate of 9.00%, PIK Interest 2.50%		$	15,013				14,820				14,820
Total INMOBI Inc.										$	24,625				24,103				24,103
InXpo, Inc.(12)(13)		Information Services		Senior Secured		July 2016		Interest rate PRIME + 7.75% or Floor rate of 10.75%		$	2,057				2,073				1,976
Subtotal: 1-5 Years Maturity															26,176				26,079
Subtotal: Information Services (3.99%)*															26,394				26,263
Internet Consumer & Business Services
Under 1 Year Maturity
Gazelle, Inc.(11)(13)		Internet Consumer & Business Services		Senior Secured		December 2015		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	1,231				1,231				1,231
NetPlenish(7)(8)(13)		Internet Consumer & Business Services		Convertible Senior Note		April 2015		Interest rate FIXED 10.00%		$	89				89				—
		Internet Consumer & Business Services		Senior Secured		September 2015		Interest rate FIXED 10.00%		$	381				373				—
Total NetPlenish										$	470				462				—
Reply! Inc.(10)(11)(12)		Internet Consumer & Business Services		Senior Secured		September 2015		Interest rate PRIME + 6.88% or Floor rate of 10.13%, PIK Interest 2.00%		$	7,615				7,757				4,322
		Internet Consumer & Business Services		Senior Secured		September 2015		Interest rate PRIME + 7.25% or Floor rate of 11.00%, PIK Interest 2.00%		$	1,680				1,749				955
Total Reply! Inc.										$	9,295				9,506				5,277

 

See notes to consolidated financial statements.

 

F-27

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Tectura Corporation(7)(11)(15)		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	563			$	563			$	121
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%		$	9,070				9,070				1,511
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	5,000				5,000				1,074
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	6,468				6,468				1,390
Total Tectura Corporation										$	21,101				21,101				4,096
Subtotal: Under 1 Year Maturity															32,300				10,604
1-5 Years Maturity
Education Dynamics, LLC(11)(13)		Internet Consumer & Business Services		Senior Secured		March 2016		Interest rate LIBOR + 12.5% or Floor rate of 12.50%, PIK Interest 1.50%		$	20,563				20,546				20,559
Gazelle, Inc.(11)(13)		Internet Consumer & Business Services		Senior Secured		July 2017		Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 2.50%		$	13,712				13,498				13,498
Just Fabulous, Inc.(10)(12)		Internet Consumer & Business Services		Senior Secured		February 2017		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	15,000				14,468				14,768
Lightspeed POS, Inc.(4)(9)(10)		Internet Consumer & Business Services		Senior Secured		May 2018		Interest rate PRIME + 3.25% or Floor rate of 6.50%		$	2,000				1,985				1,994
Reply! Inc.(10)(11)(12)		Internet Consumer & Business Services		Senior Secured		February 2016		Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 2.00%		$	2,721				2,658				1,548
Tapjoy, Inc.(12)		Internet Consumer & Business Services		Senior Secured		July 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	3,000				2,921				2,921
WaveMarket, Inc.(12)		Internet Consumer & Business Services		Senior Secured		March 2017		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	300				303				303
Subtotal: 1-5 Years Maturity															56,379				55,591
Subtotal: Internet Consumer & Business Services (10.05%)*															88,679				66,195
Media/Content/Info
Under 1 Year Maturity
Zoom Media Group, Inc.(10)(11)		Media/Content/ Info		Senior Secured		December 2015		Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 3.75%		$	2,510				2,466				2,466
		Media/Content/ Info		Senior Secured		December 2015		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	5,060				5,002				5,002
Total Zoom Media Group, Inc.										$	7,570				7,468				7,468
Subtotal: Under 1 Year Maturity															7,468				7,468
1-5 Years Maturity
Rhapsody International, Inc.(10)(11)(13)		Media/Content/ Info		Senior Secured		April 2018		Interest rate PRIME + 5.25% or Floor rate of 9.00%, PIK interest of 1.50%		$	20,206				19,750				19,579
Subtotal: 1-5 Years Maturity															19,750				19,579
Subtotal: Media/Content/Info (4.11%)*															27,218				27,047
Medical Devices & Equipment
Under 1 Year Maturity
Baxano Surgical, Inc.(7)(12)		Medical Devices & Equipment		Senior Secured		February 2015		Interest rate FIXED 12.50%		$	100				86				80
Home Dialysis Plus, Inc.(10)(12)		Medical Devices & Equipment		Senior Secured		September 2015		Interest rate FIXED 8.00%		$	500				500				500

 

See notes to consolidated financial statements.

 

F-28

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Oraya Therapeutics, Inc.(10)(11)(12)		Medical Devices & Equipment		Senior Secured		September 2015		Interest rate PRIME + 5.50% or Floor rate of 10.25%, PIK Interest 1.00%		$	6,174			$	6,146			$	6,146
Subtotal: Under 1 Year Maturity															6,732				6,726
1-5 Years Maturity
Amedica Corporation(8)(12)(13)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%		$	20,000				19,704				19,902
Avedro, Inc.(12)(13)		Medical Devices & Equipment		Senior Secured		December 2017		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	7,500				7,247				7,247
Baxano Surgical, Inc.(7)(12)		Medical Devices & Equipment		Senior Secured		March 2017		Interest rate PRIME + 7.75% or Floor rate of 12.50%		$	7,113				7,040				6,405
Flowonix Medical Incorporated(12)		Medical Devices & Equipment		Senior Secured		May 2018		Interest rate PRIME + 5.25% or Floor rate of 10.00%		$	15,000				14,675				14,675
Gamma Medica, Inc.(12)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	4,000				3,874				3,874
Home Dialysis Plus, Inc.(10)(12)		Medical Devices & Equipment		Senior Secured		October 2017		Interest rate PRIME + 6.35% or Floor rate of 9.60%		$	15,000				14,780				14,780
InspireMD, Inc.(4)(9)(10)(12)		Medical Devices & Equipment		Senior Secured		February 2017		Interest rate PRIME +7.25% or Floor rate of 10.50%		$	8,818				8,897				6,486
Medrobotics Corporation(12)(13)		Medical Devices & Equipment		Senior Secured		March 2016		Interest rate PRIME + 7.85% or Floor rate of 11.10%		$	2,680				2,765				2,755
nContact Surgical, Inc(12)		Medical Devices & Equipment		Senior Secured		November 2018		Interest rate PRIME + 9.25% or Floor rate of 9.25%		$	10,000				9,735				9,735
NetBio, Inc.(10)		Medical Devices & Equipment		Senior Secured		August 2017		Interest rate PRIME + 5.00% or Floor rate of 11.00%		$	4,870				4,669				4,718
NinePoint Medical, Inc.(12)(13)		Medical Devices & Equipment		Senior Secured		January 2016		Interest rate PRIME + 5.85% or Floor rate of 9.10%		$	3,241				3,357				3,342
Quanterix Corporation(10)(12)		Medical Devices & Equipment		Senior Secured		November 2017		Interest rate PRIME + 2.75% or Floor rate of 8.00%		$	5,000				4,930				4,911
SonaCare Medical, LLC (pka US HIFU, LLC)(10)(12)		Medical Devices & Equipment		Senior Secured		April 2016		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	875				1,200				1,209
SynergEyes, Inc.(12)(13)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	5,000				5,034				4,983
ViewRay, Inc.(11)(13)		Medical Devices & Equipment		Senior Secured		June 2017		Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 1.50%		$	15,220				14,920				14,973
Subtotal: 1-5 Years Maturity															122,827				119,995
Subtotal: Medical Devices & Equipment (19.23%)*															129,559				126,721
Semiconductors
Under 1 Year Maturity
Achronix Semiconductor Corporation		Semiconductors		Senior Secured		January 2015		Interest rate PRIME + 10.60% or Floor rate of 13.85%		$	95				95				95
Subtotal: Under 1 Year Maturity															95				95
1-5 Years Maturity
Avnera Corporation(10)(12)		Semiconductors		Senior Secured		April 2017		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	5,000				4,983				4,990
Subtotal: 1-5 Years Maturity															4,983				4,990
Subtotal: Semiconductors (0.77%)*															5,078				5,085
Software
Under 1 Year Maturity
CareCloud Corporation(12)(13)		Software		Senior Secured		July 2015		Interest rate PRIME + 1.40% or Floor rate of 4.65%		$	3,000				2,968				2,968
Clickfox, Inc.(12)(13)		Software		Senior Secured		July 2015		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	2,000				2,000				2,000

 

See notes to consolidated financial statements.

 

F-29

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Mobile Posse, Inc.(12)(13)		Software		Senior Secured		June 2015		Interest rate PRIME + 2.00% or Floor rate of 5.25%		$	1,000			$	993			$	988
Touchcommerce, Inc.(12)(13)		Software		Senior Secured		January 2015		Interest rate PRIME + 2.25% or Floor rate of 6.50%		$	3,811				3,811				3,805
Subtotal: Under 1 Year Maturity															9,772				9,761
1-5 Years Maturity
CareCloud Corporation(12)(13)		Software		Senior Secured		December 2017		Interest rate PRIME + 3.25% or Floor rate of 6.50%		$	208				204				201
		Software		Senior Secured		July 2017		Interest rate PRIME + 5.50% or Floor rate of 8.75%		$	10,000				9,839				9,740
		Software		Senior Secured		January 2018		Interest rate PRIME + 1.70% or Floor rate of 4.95%		$	3,000				2,929				2,884
Total CareCloud Corporation										$	13,208				12,972				12,825
Clickfox, Inc.(12)(13)		Software		Senior Secured		December 2017		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	6,000				6,010				5,948
JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.)(12)(13)		Software		Senior Secured		March 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	11,750				11,771				11,709
		Software		Senior Secured		October 2016		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	1,356				1,332				1,332
Total JumpStart Games, Inc. (p.k.a Knowledge Adventure, Inc.)										$	13,106				13,103				13,041
Mobile Posse, Inc.(12)(13)		Software		Senior Secured		December 2016		Interest rate PRIME + 7.50% or Floor rate of 10.75%		$	2,950				2,943				2,972
Neos Geosolutions, Inc.(12)(13)		Software		Senior Secured		May 2016		Interest rate PRIME + 5.75% or Floor rate of 10.50%		$	2,332				2,454				2,444
Poplicus, Inc.(12)(13)		Software		Senior Secured		June 2017		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	1,500				1,504				1,487
Soasta, Inc.(12)(13)		Software		Senior Secured		February 2018		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	15,000				14,367				14,367
		Software		Senior Secured		February 2018		Interest rate PRIME + 2.25% or Floor rate of 5.50%		$	3,500				3,353				3,353
Total Soasta, Inc.										$	18,500				17,720				17,720
Sonian, Inc.(12)(13)		Software		Senior Secured		July 2017		Interest rate PRIME + 7.00% or Floor rate of 10.25%		$	5,500				5,450				5,436
StrongView Systems, Inc.(12)		Software		Senior Secured		December 2017		Interest rate PRIME + 6.00% or Floor rate of 9.25%, PIK Interest 3.00%		$	10,000				9,779				9,779
Touchcommerce, Inc.(12)(13)		Software		Senior Secured		June 2017		Interest rate PRIME + 6.00% or Floor rate of 10.25%		$	5,000				4,903				4,953
Subtotal: 1-5 Years Maturity															76,838				76,605
Subtotal: Software (13.11%)*															86,610				86,366
Specialty Pharmaceuticals
Under 1 Year Maturity
Cranford Pharmaceuticals, LLC(11)(12)(13)		Specialty Pharmaceuticals		Senior Secured		August 2015		Interest rate LIBOR + 8.25% or Floor rate of 9.50%		$	2,000				1,977				1,986
Subtotal: Under 1 Year Maturity															1,977				1,986
1-5 Years Maturity
Alimera Sciences, Inc.(10)		Specialty Pharmaceuticals		Senior Secured		May 2018		Interest rate PRIME + 7.65% or Floor rate of 10.90%		$	35,000				34,138				33,429
Cranford Pharmaceuticals, LLC(11)(12)(13)		Specialty Pharmaceuticals		Senior Secured		February 2017		Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%		$	15,644				15,595				15,465
Subtotal: 1-5 Years Maturity															49,733				48,894
Subtotal: Specialty Pharmaceuticals (7.72%)*															51,710				50,880

 

See notes to consolidated financial statements.

 

F-30

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company

Sub-Industry

Type of Investment(1)

Maturity Date

Interest Rate and Floor

Principal Amount

Cost(2)

Value(3)

Surgical Devices

Under 1 Year Maturity

Transmedics, Inc.(10)(12)

Surgical Devices

Senior Secured

November 2015

Interest rate FIXED 12.95%

$6,061

$    5,989

$    5,989

Subtotal: Under 1 Year Maturity

5,989

5,989

Subtotal: Surgical Devices (0.91%)*

5,989

5,989

Total Debt Investments (140.23%)*

951,982

923,906

 

See notes to consolidated financial statements.

 

F-31

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Equity Investments
Biotechnology Tools
NuGEN Technologies, Inc.(13)		Biotechnology Tools		Equity		Preferred Series C			189,394			$	500			$	498
Subtotal: Biotechnology Tools (0.08%)*													500				498
Communications & Networking
GlowPoint, Inc.(3)		Communications & Networking		Equity		Common Stock			114,192				102				126
Peerless Network, Inc.		Communications & Networking		Equity		Preferred Series A			1,000,000				1,000				7,229
Subtotal: Communications & Networking (1.12%)*													1,102				7,355
Consumer & Business Products
Market Force Information, Inc.		Consumer & Business Products		Equity		Preferred Series B			187,970				500				317
Subtotal: Consumer & Business Products (0.05%)*													500				317
Diagnostic
Singulex, Inc.		Diagnostic		Equity		Common Stock			937,998				750				750
Subtotal: Diagnostic (0.11%)*													750				750
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)(13)		Drug Delivery		Equity		Common Stock			54,240				109				365
Merrion Pharmaceuticals, Plc(3)(4)(9)		Drug Delivery		Equity		Common Stock			20,000				9				—
Neos Therapeutics, Inc.(13)		Drug Delivery		Equity		Preferred Series C			300,000				1,500				1,635
Subtotal: Drug Delivery (0.30%)*													1,618				2,000
Drug Discovery & Development
Aveo Pharmaceuticals, Inc.(3)(9)(13)		Drug Discovery & Development		Equity		Common Stock			167,864				842				141
Celladon Corporation(3)(13)		Drug Discovery & Development		Equity		Common Stock			105,263				1,000				2,056
Cempra, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			97,931				458				2,303
Cerecor Inc.		Drug Discovery & Development		Equity		Preferred Series B			3,334,445				1,000				922
Dicerna Pharmaceuticals, Inc.(3)(13)		Drug Discovery & Development		Equity		Common Stock			142,858				1,000				2,353
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			223,463				2,000				1,262
Inotek Pharmaceuticals Corporation(14)		Drug Discovery & Development		Equity		Common Stock			4,523				1,500				—
Insmed, Incorporated(3)		Drug Discovery & Development		Equity		Common Stock			70,771				1,000				845
Paratek Pharmaceuticals, Inc. (p.k.a Transcept Pharmaceuticals, Inc.)(3)		Drug Discovery & Development		Equity		Common Stock			31,580				1,743				1,158
Subtotal: Drug Discovery & Development (1.68%)*													10,543				11,040
Electronics & Computer Hardware
Identiv, Inc.(3)		Electronics & Computer Hardware		Equity		Common Stock			49,097				247				682
Subtotal: Electronics & Computer Hardware (0.10%)*													247				682

 

See notes to consolidated financial statements.

 

F-32

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Sustainable and Renewable Technology(16)
Glori Energy, Inc.(3)		Sustainable and Renewable Technology		Equity		Common Stock			18,208			$	165			$	76
SCIEnergy, Inc.		Sustainable and Renewable Technology		Equity		Preferred Series 1			385,000				761				22
Subtotal: Sustainable and Renewable Technology(16) (0.01%)*													926				98
Information Services
Good Technology Corporation (pka Visto Corporation)(13)		Information Services		Equity		Common Stock			500,000				603				605
Subtotal: Information Services (0.09%)*													603				605
Internet Consumer & Business Services
Blurb, Inc.(13)		Internet Consumer & Business Services		Equity		Preferred Series B			220,653				175				265
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Equity		Preferred Series C			23,003				250				260
Philotic, Inc.		Internet Consumer & Business Services		Equity		Common Stock			9,023				93				—
Progress Financial		Internet Consumer & Business Services		Equity		Preferred Series G			218,351				250				233
Taptera, Inc.		Internet Consumer & Business Services		Equity		Preferred Series B			454,545				150				162
Subtotal: Internet Consumer & Business Services (0.14%)*													918				920
Media/Content/Info
Everyday Health, Inc. (pka Waterfront Media, Inc.)(3)		Media/Content/ Info		Equity		Common Stock			97,060				1,000				1,432
Subtotal: Media/Content/Info (0.22%)*													1,000				1,432
Medical Devices & Equipment
Flowonix Medical Incorporated		Medical Devices & Equipment		Equity		Preferred Series E			221,893				1,500				1,614
Gelesis, Inc.(5)(13)		Medical Devices & Equipment		Equity		LLC Interest			674,208				425				181
		Medical Devices & Equipment		Equity		LLC Interest			675,676				500				114
		Medical Devices & Equipment		Equity		LLC interests (Common)			674,208				—				31
Total Gelesis, Inc.									2,024,092				925				326
Medrobotics Corporation(13)		Medical Devices & Equipment		Equity		Preferred Series E			136,798				250				149
		Medical Devices & Equipment		Equity		Preferred Series F			73,971				155				167
Total Medrobotics Corporation									210,769				405				316

 

See notes to consolidated financial statements.

 

F-33

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Novasys Medical, Inc.		Medical Devices & Equipment		Equity		Preferred Series D-1			4,118,444			$	1,000			$	—
Optiscan Biomedical, Corp.(5)(13)		Medical Devices & Equipment		Equity		Preferred Series B			6,185,567				3,000				455
		Medical Devices & Equipment		Equity		Preferred Series C			1,927,309				655				138
		Medical Devices & Equipment		Equity		Preferred Series D			55,103,923				5,257				5,260
Total Optiscan Biomedical, Corp									63,216,799				8,912				5,853
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Equity		Preferred Series 1			1,086,969				500				—
Subtotal: Medical Devices & Equipment (1.23%)*													13,242				8,109
Software
Atrenta, Inc.		Software		Equity		Preferred Series C			1,196,845				986				1,745
		Software		Equity		Preferred Series D			635,513				508				1,109
Total Atrenta, Inc									1,832,358				1,494				2,854
Box, Inc.(13)(14)		Software		Equity		Preferred Series B			271,070				251				5,747
		Software		Equity		Preferred Series C			589,844				872				12,506
		Software		Equity		Preferred Series D			158,133				500				3,352
		Software		Equity		Preferred Series D-1			186,766				1,694				3,960
		Software		Equity		Preferred Series D-2			220,751				2,001				4,680
		Software		Equity		Preferred Series E			38,183				500				810
Total Box, Inc									1,464,747				5,818				31,055
CapLinked, Inc.		Software		Equity		Preferred Series A-3			53,614				51				79
ForeScout Technologies, Inc.		Software		Equity		Preferred Series D			319,099				398				519
HighRoads, Inc.		Software		Equity		Preferred Series B			190,170				307				228
WildTangent, Inc.(13)		Software		Equity		Preferred Series 3			100,000				402				228
Subtotal: Software (5.31%)*													8,470				34,963
Specialty Pharmaceuticals
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Equity		Preferred Series E			241,829				750				—
		Specialty Pharmaceuticals		Equity		Preferred Series E-1			26,955				—				—
		Specialty Pharmaceuticals		Equity		Preferred Series G			4,667,636				—				—
Total QuatRx Pharmaceuticals Company									4,936,420				750				—
Subtotal: Specialty Pharmaceuticals (0.00%)*													750				—
Surgical Devices
Gynesonics, Inc.(13)		Surgical Devices		Equity		Preferred Series B			219,298				250				101
		Surgical Devices		Equity		Preferred Series C			656,538				282				186
		Surgical Devices		Equity		Preferred Series D			1,991,157				712				1,073
Total Gynesonics, Inc.									2,866,993				1,244				1,360
Transmedics, Inc.		Surgical Devices		Equity		Preferred Series B			88,961				1,100				353
		Surgical Devices		Equity		Preferred Series C			119,999				300				180
		Surgical Devices		Equity		Preferred Series D			260,000				650				1,071
Total Transmedics, Inc.									468,960				2,050				1,604
Subtotal: Surgical Devices (0.45%)*													3,294				2,964
Total: Equity Investments (10.89%)*													44,463				71,733

 

See notes to consolidated financial statements.

 

F-34

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Warrant Investments
Biotechnology Tools
Labcyte, Inc.(13)		Biotechnology Tools		Warrant		Preferred Series C			1,127,624			$	323			$	354
Subtotal: Biotechnology Tools (0.05%)*													323				354
Communications & Networking
Intelepeer, Inc.(13)		Communications & Networking		Warrant		Preferred Series C			117,958				102				18
OpenPeak, Inc.		Communications & Networking		Warrant		Common Stock			108,982				149				104
PeerApp, Inc.		Communications & Networking		Warrant		Preferred Series B			298,779				61				45
Peerless Network, Inc.		Communications & Networking		Warrant		Preferred Series A			135,000				95				844
Ping Identity Corporation		Communications & Networking		Warrant		Preferred Series B			1,136,277				52				183
SkyCross, Inc.(13)		Communications & Networking		Warrant		Preferred Series F			9,762,777				394				—
Spring Mobile Solutions, Inc.		Communications & Networking		Warrant		Preferred Series D			2,834,375				418				426
Subtotal: Communications & Networking (0.25%)*													1,271				1,620
Consumer & Business Products
Antenna79 (p.k.a. Pong Research Corporation)(13)		Consumer & Business Products		Warrant		Preferred Series A			1,662,441				228				202
Intelligent Beauty, Inc.(13)		Consumer & Business Products		Warrant		Preferred Series B			190,234				230				327
IronPlanet, Inc.		Consumer & Business Products		Warrant		Preferred Series D			1,155,821				1,077				1,067
Market Force Information, Inc.		Consumer & Business Products		Warrant		Preferred Series A			99,286				24				21
The Neat Company(13)		Consumer & Business Products		Warrant		Preferred Series C-1			540,540				365				451
Subtotal: Consumer & Business Products (0.31%)*													1,924				2,068
Diagnostic
Navidea Biopharmaceuticals, Inc. (pka Neoprobe)(3)(13)		Diagnostic		Warrant		Common Stock			333,333				244				75
Subtotal: Diagnostic (0.01%)*													244				75
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)(13)		Drug Delivery		Warrant		Common Stock			176,730				786				420
Alexza Pharmaceuticals, Inc.(3)		Drug Delivery		Warrant		Common Stock			37,639				645				—
BIND Therapeutics, Inc.(3)(13)		Drug Delivery		Warrant		Common Stock			71,359				367				6
BioQuiddity Incorporated		Drug Delivery		Warrant		Common Stock			459,183				1				1
Celator Pharmaceuticals, Inc.(3)		Drug Delivery		Warrant		Common Stock			158,006				107				67
Celsion Corporation(3)		Drug Delivery		Warrant		Common Stock			194,986				428				248
Dance Biopharm, Inc.(13)		Drug Delivery		Warrant		Preferred Series A			97,701				74				109
Edge Therapeutics, Inc.		Drug Delivery		Warrant		Preferred Series C-1			107,526				390				217
Kaleo, Inc. (p.k.a. Intelliject, Inc.)		Drug Delivery		Warrant		Preferred Series B			82,500				594				1,108
Neos Therapeutics, Inc.(13)		Drug Delivery		Warrant		Preferred Series C			170,000				285				235
Revance Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			53,511				557				64
Zosano Pharma, Inc.(14)		Drug Delivery		Warrant		Common Stock			31,674				164				179
Subtotal: Drug Delivery (0.40%)*													4,398				2,654

 

See notes to consolidated financial statements.

 

F-35

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Drug Discovery & Development
ADMA Biologics, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			89,750			$	295			$	366
Anthera Pharmaceuticals, Inc.(3)(13)		Drug Discovery & Development		Warrant		Common Stock			40,178				984				—
Aveo Pharmaceuticals, Inc.(3)(9)(13)		Drug Discovery & Development		Warrant		Common Stock			608,696				194				107
Cerecor Inc.		Drug Discovery & Development		Warrant		Preferred Series B			625,208				70				47
Chroma Therapeutics, Ltd.(4)(9)		Drug Discovery & Development		Warrant		Preferred Series D			325,261				490				—
Cleveland BioLabs, Inc.(3)(13)		Drug Discovery & Development		Warrant		Common Stock			156,250				105				10
Concert Pharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			70,796				367				164
Coronado Biosciences, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			73,009				142				43
Dicerna Pharmaceuticals, Inc.(3)(13)		Drug Discovery & Development		Warrant		Common Stock			200				28				—
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			64,194				276				207
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			73,725				266				188
Horizon Pharma, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			3,735				52				4
Melinta Therapeutics		Drug Discovery & Development		Warrant		Preferred Series 3			1,151,936				604				590
Nanotherapeutics, Inc.(13)		Drug Discovery & Development		Warrant		Common Stock			171,389				838				1,421
Neothetics, Inc. (pka Lithera, Inc)(3)(13)		Drug Discovery & Development		Warrant		Common Stock			46,838				266				122
Neuralstem, Inc.(3)(13)		Drug Discovery & Development		Warrant		Common Stock			75,187				77				71
Paratek Pharmaceutcals, Inc. (p.k.a Transcept Pharmaceuticals, Inc)(3)		Drug Discovery & Development		Warrant		Common Stock			5,121				87				10
uniQure B.V.(3)(4)(9)		Drug Discovery & Development		Warrant		Common Stock			37,174				218				184
Subtotal: Drug Discovery & Development (0.54%)*													5,359				3,534
Electronics & Computer Hardware
Clustrix, Inc.		Electronics & Computer Hardware		Warrant		Common Stock			50,000				12				10
Subtotal: Electronics & Computer Hardware (0.00%)*													12				10
Sustainable and Renewable Technology(16)
Agrivida, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series D			471,327				120				186
Alphabet Energy, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series A			86,329				81				135
American Superconductor Corporation(3)		Sustainable and Renewable Technology		Warrant		Common Stock			588,235				39				40
Brightsource Energy, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series 1			174,999				780				213
Calera, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series C			44,529				513				—
EcoMotors, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series B			437,500				308				256
Fluidic, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series C			59,665				102				60
Fulcrum Bioenergy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series C-1			280,897				275				135

 

See notes to consolidated financial statements.

 

F-36

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
GreatPoint Energy, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series D-1			393,212			$	548			$	—
Polyera Corporation(13)		Sustainable and Renewable Technology		Warrant		Preferred Series C			161,575				69				228
SCIEnergy, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			530,811				181				—
		Sustainable and Renewable Technology		Warrant		Preferred Series 1			145,811				50				—
Total SCIEnergy, Inc.		Sustainable and Renewable Technology							676,622				231				—
Scifiniti (pka Integrated Photovoltaics, Inc.)(13)		Sustainable and Renewable Technology		Warrant		Preferred Series A-1			390,000				82				65
Solexel, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series C			1,171,625				1,162				666
Stion Corporation(5)		Sustainable and Renewable Technology		Warrant		Preferred Series Seed			2154				1,378				—
TAS Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series F			428,571				299				157
TPI Composites, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series B			160				273				107
Trilliant, Inc.(13)		Sustainable and Renewable Technology		Warrant		Preferred Series A			320,000				161				32
Subtotal: Sustainable and Renewable Technology(16) (0.35%)*													6,421				2,280
Healthcare Services, Other
Chromadex Corporation(3)(13)		Healthcare Services, Other		Warrant		Common Stock			419,020				156				106
MDEverywhere, Inc.		Healthcare Services, Other		Warrant		Common Stock			129				94				11
Subtotal: Healthcare Services, Other (0.02%)*													250				117
Information Services
Cha Cha Search, Inc.(13)		Information Services		Warrant		Preferred Series G			48,232				58				20
INMOBI Inc.(4)(9)		Information Services		Warrant		Common Stock			42,187				74				72
InXpo, Inc.(13)		Information Services		Warrant		Preferred Series C			648,400				98				26
		Information Services		Warrant		Preferred Series C-1			740,832				58				30
Total InXpo, Inc.									1,389,232				156				56
RichRelevance, Inc.(13)		Information Services		Warrant		Preferred Series E			112,612				98				—
Subtotal: Information Services (0.02%)*													386				148
Internet Consumer & Business Services
Blurb, Inc.(13)		Internet Consumer & Business Services		Warrant		Preferred Series B			218,684				299				79
		Internet Consumer & Business Services		Warrant		Preferred Series C			234,280				636				173
Total Blurb, Inc.									452,964				935				252
CashStar, Inc.(13)		Internet Consumer & Business Services		Warrant		Preferred Series C-2			727,272				130				83
Gazelle, Inc.(13)		Internet Consumer & Business Services		Warrant		Preferred Series A-1			991,288				158				185
Just Fabulous, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series B			206,184				1,101				1,490
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Warrant		Preferred Series C			24,561				20				60
Prism Education Group, Inc.(13)		Internet Consumer & Business Services		Warrant		Preferred Series B			200,000				43				—
Progress Financial		Internet Consumer & Business Services		Warrant		Preferred Series G			174,562				78				63
Reply! Inc.		Internet Consumer & Business Services		Warrant		Preferred Series B			137,225				320				—

 

See notes to consolidated financial statements.

 

F-37

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
ShareThis, Inc.(13)		Internet Consumer & Business Services		Warrant		Preferred Series C			493,502			$	547			$	282
Tapjoy, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series D			430,485				263				125
Tectura Corporation		Internet Consumer & Business Services		Warrant		Preferred Series B-1			253,378				51
Subtotal: Internet Consumer & Business Services (0.39%)*													3,646				2,540
Media/Content/Info
Mode Media Corporation(13)		Media/Content/Info		Warrant		Preferred Series D			407,457				482				—
Rhapsody International, Inc.(13)		Media/Content/Info		Warrant		Common Stock			715,755				385				358
Zoom Media Group, Inc.		Media/Content/Info		Warrant		Preferred Series A			1,204				348				382
Subtotal: Media/Content/Info (0.11%)*													1,215				740
Medical Devices & Equipment
Amedica Corporation(3)(13)		Medical Devices & Equipment		Warrant		Common Stock			516,129				459				—
Avedro, Inc.(13)		Medical Devices & Equipment		Warrant		Preferred Series D			1,308,451				401				553
Baxano Surgical, Inc.(3)		Medical Devices & Equipment		Warrant		Common Stock			882,353				439				—
Flowonix Medical Incorporated		Medical Devices & Equipment		Warrant		Preferred Series E			66,568				203				228
Gamma Medica, Inc.		Medical Devices & Equipment		Warrant		Preferred Series A			357,500				170				196
Gelesis, Inc.(5)(13)		Medical Devices & Equipment		Warrant		LLC Interest			263,688				78				1
Home Dialysis Plus, Inc.		Medical Devices & Equipment		Warrant		Preferred Series A			500,000				402				587
InspireMD, Inc.(3)(4)(9)		Medical Devices & Equipment		Warrant		Common Stock			168,351				242				12
Medrobotics Corporation(13)		Medical Devices & Equipment		Warrant		Preferred Series E			455,539				370				182
MELA Sciences, Inc.(3)		Medical Devices & Equipment		Warrant		Common Stock			69,320				401				1
nContact Surgical, Inc		Medical Devices & Equipment		Warrant		Preferred Series D-1			201,439				266				450
NetBio, Inc.		Medical Devices & Equipment		Warrant		Common Stock			2,568				408				60
NinePoint Medical, Inc.(13)		Medical Devices & Equipment		Warrant		Preferred Series A-1			587,840				170				204
Novasys Medical, Inc.		Medical Devices & Equipment		Warrant		Common Stock			109,449				2				—
		Medical Devices & Equipment		Warrant		Preferred Series D			526,840				125				—
		Medical Devices & Equipment		Warrant		Preferred Series D-1			53,607				6				—
Total Novasys Medical, Inc.									689,896				133				—
Optiscan Biomedical, Corp.(5)(13)		Medical Devices & Equipment		Warrant		Preferred Series D			10,535,275				1,252				219
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Warrant		Common Stock			954				66				—
		Medical Devices & Equipment		Warrant		Preferred Series 1			1,632,084				676				—
Total Oraya Therapeutics, Inc.									1,633,038				742				—
Quanterix Corporation		Medical Devices & Equipment		Warrant		Preferred Series C			69,371				104				164
SonaCare Medical, LLC (pka US HIFU, LLC)		Medical Devices & Equipment		Warrant		Preferred Series A			6,464				188				—
ViewRay, Inc.(13)		Medical Devices & Equipment		Warrant		Preferred Series C			312,500				333				359

 

See notes to consolidated financial statements.

 

F-38

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of  Investment(1)		Series		Shares				Cost(2)				Value(3)
Subtotal: Medical Devices & Equipment (0.49%)*												$	6,761			$	3,216
Semiconductors
Achronix Semiconductor Corporation		Semiconductors		Warrant		Preferred Series C			360,000				160				9
Avnera Corporation		Semiconductors		Warrant		Preferred Series E			102,958				14				32
Subtotal: Semiconductors (0.01%)*													174				41
Software
Atrenta, Inc.		Software		Warrant		Preferred Series D			392,670				120				359
Braxton Technologies, LLC		Software		Warrant		Preferred Series A			168,750				188				—
CareCloud Corporation(13)		Software		Warrant		Preferred Series B			413,433				258				482
Clickfox, Inc.(13)		Software		Warrant		Preferred Series B			1,038,563				330				783
		Software		Warrant		Preferred Series C			592,019				730				555
		Software		Warrant		Preferred Series C-A			46,109				14				35
Total Clickfox, Inc.									1,676,691				1,074				1,373
Daegis Inc. (pka Unify Corporation)(3)(13)		Software		Warrant		Common Stock			718,860				1,434				5
ForeScout Technologies, Inc.		Software		Warrant		Preferred Series E			80,587				41				74
Hillcrest Laboratories, Inc.(13)		Software		Warrant		Preferred Series E			1,865,650				54				106
JumpStart Games, Inc. (p.k.a Knowledge Holdings, Inc.)(13)		Software		Warrant		Preferred Series E			614,333				15				8
Mobile Posse, Inc.(13)		Software		Warrant		Preferred Series C			396,430				130				66
Neos Geosolutions, Inc.(13)		Software		Warrant		Preferred Series 3			221,150				22				—
NewVoiceMedia Limited(4)(9)		Software		Warrant		Preferred Series E			225,586				33				34
Soasta, Inc.(13)		Software		Warrant		Preferred Series E			410,800				691				1,014
Sonian, Inc.(13)		Software		Warrant		Preferred Series C			185,949				106				72
StrongView Systems, Inc.		Software		Warrant		Preferred Series C			551,470				169				218
SugarSync, Inc.(13)		Software		Warrant		Preferred Series CC			332,726				78				78
		Software		Warrant		Preferred Series DD			107,526				34				26
Total SugarSync, Inc.									440,252				112				104
Touchcommerce, Inc.(13)		Software		Warrant		Preferred Series E			992,595				252				164
White Sky, Inc.(13)		Software		Warrant		Preferred Series B-2			124,295				54				4
Subtotal: Software (0.62%)*													4,753				4,083
Specialty Pharmaceuticals
Alimera Sciences, Inc.(3)		Specialty Pharmaceuticals		Warrant		Common Stock			285,016				728				656
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Warrant		Preferred Series E			155,324				308				—
Subtotal: Specialty Pharmaceuticals (0.10%)*													1,036				656
Surgical Devices
Gynesonics, Inc.(13)		Surgical Devices		Warrant		Preferred Series C			180,480				74				48
		Surgical Devices		Warrant		Preferred Series D			1,575,965				320				562
Total Gynesonics, Inc.									1,756,445				394				610
Transmedics, Inc.		Surgical Devices		Warrant		Preferred Series B			40,436				225				—
		Surgical Devices		Warrant		Preferred Series D			175,000				100				352
Total Transmedics, Inc.									215,436				325				352
Subtotal: Surgical Devices (0.15%)*													719				962
Total Warrant Investments (3.81%)*													38,892				25,098
Total Investments (154.92%)*												$	1,035,337			$	1,020,737

 

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $46.1 million, $63.4 million and $17.3 million respectively. The tax cost of investments is $1.0 billion.

 

See notes to consolidated financial statements.

 

F-39

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

(FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2014

(dollars in thousands)

 

(3)

Except for warrants in twenty-nine publicly traded companies and common stock in thirteen publicly traded companies, all investments are restricted at December 31, 2014 and were valued at fair value as determined in good faith by the Audit Committee of the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Non-U.S. company or the company’s principal place of business is outside the United States.

(5)	Affiliate investment as defined under the Investment Company Act of 1940, as amended, in which Hercules owns at least 5% but not more than 25% of the company’s voting securities.

(6)	Control investment as defined under the Investment Company Act of 1940, as amended, in which Hercules owns at least 25% of the voting securities of the company or has greater than 50% representation on its board. There were no control investments at December 31, 2014.

(7)	Debt is on non-accrual status at December 31, 2014, and is therefore considered non-income producing.

(8)	Denotes that all or a portion of the debt investment is convertible senior debt.

(9)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(10)	Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitizations (as defined in Note 4).

(11)	Denotes that all or a portion of the debt investment principal includes accumulated PIK, or paid-in-kind, interest and is net of repayments.

(12)	Denotes that all or a portion of the debt investment includes an exit fee receivable.

(13)	Denotes that all or a portion of the investment in this portfolio company is held by HT II or HT III, the Company’s wholly-owned SBIC subsidiaries.

(14)	Subsequent to December 31, 2014, this company completed an initial public offering. Note that the December 31, 2014 fair value does not reflect any potential impact of the conversion of our preferred shares to common shares which may include reverse splits associated with the offering.

(15)

The stated ‘Maturity Date’ for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company’s investment team and Investment Committee continue to closely monitor developments at the borrower company.

(16)	In the Company’s quarterly and annual reports filed with the commission prior to this Annual Report on Form 10-K for the year ended December 31, 2014, the Company referred to this industry sector as “Energy Technology.”

 

See notes to consolidated financial statements.

 

F-40

---

Table of Contents

Index to Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Business and Basis of Presentation

Hercules Capital, Inc. (formerly Hercules Technology Growth Capital, Inc.; the “Company”) is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broadly diversified variety of technology, life sciences and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, McLean, VA, Santa Monica, CA, and Hartford, CT. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was taxed as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a regulated investment company, or RIC, under Subchapter M of the Code (see Note 5). As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 of the Accounting Standards Codification, as amended (“ASC”).

Hercules Technology II, L.P. (“HT II”), Hercules Technology III, L.P. (“HT III”), and Hercules Technology IV, L.P. (“HT IV”), are Delaware limited partnerships that were formed in January 2005, September 2009 and December 2010, respectively. HT II and HT III were licensed to operate as small business investment companies (“SBICs”) under the authority of the Small Business Administration (“SBA”) on September 27, 2006 and May 26, 2010, respectively. As SBICs, HT II and HT III are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. HT IV was formed in anticipation of receiving an additional SBIC license; however, the Company has not yet applied for such license, and HT IV currently has no material assets or liabilities. The Company also formed Hercules Technology SBIC Management, LLC, or (“HTM”), a limited liability company in November 2003. HTM is a wholly owned subsidiary of the Company and serves as the limited partner and general partner of HT II and HT III (see Note 4 to the Company’s consolidated financial statements).

HT II and HT III hold approximately $128.3 million and $310.8 million in assets, respectively, and they accounted for approximately 7.6% and 18.5% of the Company’s total assets, respectively, prior to consolidation at December 31, 2015.

The Company also established wholly owned subsidiaries, all of which are structured as Delaware corporations and limited liability companies, to hold portfolio companies organized as limited liability companies, or LLCs (or other forms of pass-through entities). By investing through these wholly owned subsidiaries, the Company is able to benefit from the tax treatment of these entities and create a tax structure that is more advantageous with respect to the Company’s RIC status.

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of the Company, its subsidiaries and its consolidated securitization VIEs. All inter-company accounts and transactions have been eliminated in consolidation. In accordance with Articles 6 and 10 of Regulation S-X under the Securities Act of 1933, as amended (the “Securities Act”), the Company does not consolidate portfolio company investments. It is not appropriate for an investment company to consolidate an investee that is not an investment company, rather an investment company’s interest in non-investment company investees should be measured at fair value in accordance with ASC 946.

 

F-41

---

Table of Contents

Index to Financial Statements

Financial statements prepared on a GAAP basis require management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries and all VIEs of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

As of the date of this report, the VIE consolidated by the Company is its securitization VIE formed in conjunction with the issuance of the Asset-Backed Notes (as defined herein) (See Note 4).

Reclassification

Certain balances from prior years have been reclassified in order to conform to the current year presentation.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At December 31, 2015, approximately 90.0% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board

 

F-42

---

Table of Contents

Index to Financial Statements

of Directors. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC 946 and measured in accordance with ASC 820. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy by the Company’s Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

The Company may from time to time engage an independent valuation firm to provide the Company with valuation assistance with respect to certain portfolio investments on a quarterly basis. The Company engages independent valuation firms on a discretionary basis. Specifically, on a quarterly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm.

The Company intends to continue to engage an independent valuation firm to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of services rendered by an independent valuation firm is at the discretion of the Board of Directors. The Company’s Board of Directors is ultimately and solely responsible for determining the fair value of the Company’s investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Company’s Board of Directors has approved a multi-step valuation process each quarter, as described below:

(1) the Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with the Company’s investment committee;

(3) the Audit Committee of the Board of Directors reviews the preliminary valuation of the investments in the portfolio as provided by the investment committee which incorporates the results of the independent valuation firm as appropriate; and

(4) the Board of Directors, upon the recommendation of the Audit Committee, discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the investment committee.

ASC 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels,

 

F-43

---

Table of Contents

Index to Financial Statements

defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of December 31, 2015 and as of December 31, 2014. The Company transfers investments in and out of Level 1, 2 and 3 securities as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period. During the year ended December 31, 2015, there were no transfers between Levels 1 or 2.

 

(in thousands) Description		Balance December 31, 2015				Quoted Prices In Active Markets For Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)
Senior Secured Debt		$	1,110,209			$	—			$	7,813			$	1,102,396
Preferred Stock			35,245				—				—				35,245
Common Stock			32,197				30,670				—				1,527
Warrants			22,987				—				4,422				18,565
Escrow Receivable(1)			2,967				—				—				2,967
Total		$	1,203,605			$	30,670			$	12,235			$	1,160,700

 

(in thousands) Description		Balance December 31, 2014				Quoted Prices In Active Markets For Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)
Senior Secured Debt		$	923,906			$	—			$	—			$	923,906
Preferred Stock			57,548				—				—				57,548
Common Stock			14,185				12,798				—				1,387
Warrants			25,098				—				3,175				21,923
Total		$	1,020,737			$	12,798			$	3,175			$	1,004,764

 

(1)	Note that escrow receivable has been added to the fair value leveling disclosure as of December 31, 2015. The Company had $3.6 million of escrow receivable as of December 31, 2014.

 

F-44

---

Table of Contents

Index to Financial Statements

The table below presents a reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the years ended December 31, 2015 and December 31, 2014.

 

(in thousands)		Balance January 1, 2015				Net Realized Gains (Losses)(1)				Net Change in Unrealized Appreciation (Depreciation)(2)				Purchases(5)				Sales				Repayments(6)				Gross Transfers into Level 3(3)				Gross Transfers out of Level 3(3)				Balance December  31, 2015
Senior Debt		$	923,906			$	(2,295	)		$	(12,930	)		$	699,555			$	—			$	(505,274	)		$	—			$	(566	)		$	1,102,396
Preferred Stock			57,548				2,598				(1,539	)			15,076				(4,542	)			—				685				(34,581	)			35,245
Common Stock			1,387				(298	)			743				—				(305	)			—				—				—				1,527
Warrants			21,923				(3,849	)			(4,749	)			5,311				1,220				—				—				(1,291	)			18,565
Escrow Receivable			3,598				71				—				511				(1,032	)			(181	)			—				—				2,967
Total		$	1,008,362			$	(3,773	)		$	(18,475	)		$	720,453			$	(4,659	)		$	(505,455	)		$	685			$	(36,438	)		$	1,160,700

 

(in thousands)		Balance January  1, 2014				Net Realized Gains  (Losses)(1)				Net Change in Unrealized Appreciation (Depreciation)(2)				Purchases(5)				Sales				Repayments(6)				Gross Transfers into Level 3(4)				Gross Transfers out of Level 3(4)				Balance December  31, 2014
Senior Debt		$	821,988			$	—			$	(14,182	)		$	615,596			$	—			$	(497,258	)		$	—			$	(2,238	)		$	923,906
Preferred Stock			35,554				(750	)			15,779				7,097				(503	)			—				2,007				(1,636	)			57,548
Common Stock			2,107				(130	)			601				—				(1,189	)			—				—				(2	)			1,387
Warrants			28,707				(48	)			(10,553	)			8,596				(2,503	)			—				—				(2,276	)			21,923
Total		$	888,356			$	(928	)		$	(8,355	)		$	631,289			$	(4,195	)		$	(497,258	)		$	2,007			$	(6,152	)		$	1,004,764

 

(1)	Included in net realized gains or losses in the accompanying Consolidated Statement of Operations.

(2)	Included in change in net unrealized appreciation (depreciation) in the accompanying Consolidated Statement of Operations.

(3)

Transfers out of Level 3 during the year ended December 31, 2015 relate to the initial public offerings of Box, Inc, ZP Opco, Inc. (p.k.a. Zosano Pharma, Inc), Neos Therapeutics, Edge Therapeutics Inc., ViewRay, Inc., and Cerecor, Inc. in addition to the exercise of warrants in both Forescout, Inc. and Atrenta, Inc. to preferred stock. Transfers into Level 3 during the year ended December 31, 2015 relate to the acquisition of preferred stock as a result of the exercise of warrants in both Forescout, Inc. and Atrenta, Inc and the conversion of debt to equity in Home Dialysis Plus and Gynesonics.

(4)

Transfers in/out of Level 3 during the year ended December 31, 2014 relate to the conversion of Paratek Pharmaceuticals, Inc., SCI Energy, Inc., Oraya Therapeutics, Inc., and Neuralstem, Inc. debt to equity, the exercise of warrants in Box, Inc and WildTangent, Inc. to equity, the conversion of warrants in Glori Energy, Inc. to equity in the company’s reverse public merger, the public merger of Paratek Pharmaceuticals, Inc. with Transcept Pharmaceuticals, Inc. and the initial public offerings of Concert Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Everyday Health, Inc., Neothetics, Inc., Revance Therapeutics, Inc., and UniQure BV.

(5)	Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period.

(6)	Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures.

For the year ended December 31, 2015, approximately $179,000 in net unrealized depreciation and $745,000 in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $13.7 million and $5.9 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

For the year ended December 31, 2014, approximately $15.0 million and $555,000 in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $14.2 million and $2.8 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

The following tables provide quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of December 31, 2015 and December 31, 2014. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The below table is not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements.

 

F-45

---

Table of Contents

Index to Financial Statements

The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.

 

Investment Type - Level Three Debt Investments		Fair Value at December 31, 2015 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(b)
Pharmaceuticals			$      72,981 406,590			Originated Within 6 Months Market Comparable Companies		Origination Yield Hypothetical Market Yield Premium/(Discount)		10.35% - 16.16% 9.55% - 16.75% (0.75%) - 0.00%		12.29% 12.67%
Technology			6,873 283,045   36,815			Originated Within 6 Months Market Comparable Companies   Liquidation(c)		Origination Yield Hypothetical Market Yield Premium/(Discount) Probability weighting of alternative outcomes		15.19% 6.57% - 23.26% (0.25%) -0.50% 10.00% - 100.00%		15.19% 13.22%
Sustainable and Renewable Technology			11,045 105,382   1,013			Originated Within 6 Months Market Comparable Companies   Liquidation(c)		Origination Yield Hypothetical Market Yield Premium/(Discount) Probability weighting of alternative outcomes		19.74% 10.62% - 27.31% 0.00% 100.00%		19.74% 15.91%
Medical Devices			80,53   3,764			Market Comparable Companies   Liquidation(c)		Hypothetical Market Yield Premium/(Discount) Probability weighting of alternative outcomes		11.65% - 19.90% 0.00% - 0.50% 50.00%		15.26%
Lower Middle Market			17,811 15,151			Originated Within 6 Months Liquidation(c)		Origination Yield Probability weighting of alternative outcomes		12.70% - 14.50% 25.00% - 75.00%		13.00%
						Debt Investments Where Fair Value Approximates Cost
			12,434			Imminent Payoffs(d)
			48,962			Debt Investments Maturing in Less than One Year
			$1,102,396			Total Level Three Debt Investments

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries note above as follows:

 

•

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development and Drug Delivery industries in the Consolidated Schedule of Investments.

 

•

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Consumer and Business Products, Information Services, and Communications and Networking industries in the Consolidated Schedule of Investments.

 

•

Sustainable and Renewable Technology, above, aligns with the Sustainable and Renewable Technology Industry in the Consolidated Schedule of Investments.

 

•

Medical Devices, above, is comprised of debt investments in the Surgical Devices and Medical Devices and Equipment industries in the Consolidated Schedule of Investments.

 

•

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services—Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Consolidated Schedule of Investments.

 

(b)	The weighted averages are calculated based on the fair market value of each investment.

 

(c)	The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

 

(d)	Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

 

F-46

---

Table of Contents

Index to Financial Statements

Investment Type -Level Three Debt Investments		Fair Value at December  31, 2014 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(b)
Pharmaceuticals			$117,229			Originated Within 6 Months		Origination Yield		10.34% - 16.52%		11.76%
			237,595			Market Comparable Companies		Hypothetical Market Yield		9.75% - 17.73%		10.62%
								Premium/(Discount)		(0.50%) - 1.00%
Medical Devices			60,332			Originated Within 6 Months		Origination Yield		12.14% - 16.56%		13.69%
			60,658			Market Comparable Companies		Hypothetical Market Yield		11.64% - 22.22%		12.19%
								Premium/(Discount)		0.00% - 1.00%
			12,970			Liquidation(c)		Probability weighting of alternative outcomes		50.00%
Technology			152,645			Originated Within 6 Months		Origination Yield		10.54% - 20.02%		14.08%
			80,835			Market Comparable Companies		Hypothetical Market Yield		6.95% - 15.50%		13.01%
								Premium/(Discount)		0.00% - 0.50%
			27,159			Liquidation(c)		Probability weighting of alternative outcomes		10.00% - 90.00%
Sustainable and Renewable Technology			4,437			Originated Within 6 Months		Origination Yield		13.85% - 21.57%		19.00%
			52,949			Market Comparable Companies		Hypothetical Market Yield		13.20% - 16.62%		15.41%
								Premium/(Discount)		0.00% - 1.50%
			1,600			Liquidation(c)		Probability weighting of alternative outcomes		100.00%
Lower Middle Market			2,962			Originated Within 6 Months		Origination Yield		14.04%		14.04%
			59,254			Market Comparable Companies		Hypothetical Market Yield		11.91% - 15.33%		13.98%
								Premium/(Discount)		0.00% - 0.50%
			4,096			Liquidation(c)		Probability weighting of alternative outcomes		45.00% - 55.00%
						Debt Investments Where Fair Value Approximates Amortized Cost
			9,318			Imminent Payoffs (d)
			39,867			Debt Investments Maturing in Less than One Year
			$923,906			Total Level Three Debt Investments

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries note above as follows:

 

•

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, Diagnostic and Biotechnology Tools industries in the Consolidated Schedule of Investments.

 

•

Medical Devices, above, is comprised of debt investments in the Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Consolidated Schedule of Investments.

 

•

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Consumer and Business Products, Information Services, and Communications and Networking industries in the Consolidated Schedule of Investments.

 

•

Sustainable and Renewable Technology, above, aligns with the Sustainable and Renewable Technology Industry in the Consolidated Schedule of Investments. In the Company’s quarterly and annual reports filed with the commission prior to this Annual Report on Form 10-K for the year ended December 31, 2014, the Company referred to this industry sector as “Energy Technology.”

 

•

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services—Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Consolidated Schedule of Investments.

 

(b)	The weighted averages are calculated based on the fair market value of each investment.

 

(c)	The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

 

(d)	Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

 

F-47

---

Table of Contents

Index to Financial Statements

Investment Type -Level Three Equity and Warrant Investments		Fair Value at December  31, 2015 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(e)
Equity Investments			$5,898			Market Comparable Companies		EBITDA Multiple(b)		3.3x - 19.5x		7.6x
								Revenue Multiple(b)		0.7x - 3.7x		2.1x
								Discount for Lack of Marketability(c)		14.31% - 25.11%		18.05%
								Average Industry Volatility(d)		37.72% - 109.64%		60.27%
								Risk-Free Interest Rate		0.61% - 1.09%		0.74%
								Estimated Time to Exit (in months)		10 - 26		15
			30,874			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 86.41%		65.40%
								Risk-Free Interest Rate		0.36% - 1.51%		0.80%
								Estimated Time to Exit (in months)		10 - 47		17
Warrant Investments			7,904			Market Comparable Companies		EBITDA Multiple(b)		5.1x - 57.9x		16.0x
								Revenue Multiple(b)		0.4x - 9.6x		3.0x
								Discount for Lack of Marketability(c)		10.09% - 31.37%		23.11%
								Average Industry Volatility(d)		39.51% - 73.36%		41.19%
								Risk-Free Interest Rate		0.32% - 1.51%		0.87%
								Estimated Time to Exit (in months)		4 - 47		23
			10,661			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 109.64%		64.31%
								Risk-Free Interest Rate		0.36% - 1.45%		0.85%
								Estimated Time to Exit (in months)		10 - 44		20
Total Level Three Warrant and Equity Investments			$55,337

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model (“OPM”) include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

(e)	Weighted averages are calculated based on the fair market value of each investment.

 

F-48

---

Table of Contents

Index to Financial Statements

Investment Type -Level Three Equity and Warrant Investments		Fair Value  at December 31, 2014 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(e)
Equity Investments			$12,249			Market Comparable Companies		EBITDA Multiple(b)		5.2x - 23.4x		8.5x
								Revenue Multiple(b)		0.9x - 3.6x		2.6x
								Discount for Lack of Marketability(c)		5.67% - 35.45%		15.95%
								Average Industry Volatility(d)		48.10% - 95.18%		62.78%
								Risk-Free Interest Rate		0.22% - 0.83%		0.24%
								Estimated Time to Exit (in months)		10 - 28		11
			46,686			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		38.95% - 84.30%		55.04%
								Risk-Free Interest Rate		0.10% - 1.32%		0.24%
								Estimated Time to Exit (in months)		6 - 43		10
Warrant Investments			9,725			Market Comparable Companies		EBITDA Multiple(b)		0.0x - 98.9x		16.6x
								Revenue Multiple(b)		0.3x - 15.7x		4.3x
								Discount for Lack of Marketability(c)		12.12% - 35.50%		22.14%
								Average Industry Volatility(d)		37.70% - 108.86%		67.23%
								Risk-Free Interest Rate		0.22% - 1.34%		0.75%
								Estimated Time to Exit (in months)		10 - 47		27
			12,198			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		32.85% - 99.81%		67.58%
								Risk-Free Interest Rate		0.21% - 2.95%		0.87%
								Estimated Time to Exit (in months)		10 - 48		28
Total Level Three Warrant and Equity Investments			$80,858

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model (“OPM”) include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

(e)	Weighted averages are calculated based on the fair market value of each investment.

Debt Investments

The Company follows the guidance set forth in ASC 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. In addition, the Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives. These investments are considered Level 2 assets.

 

F-49

---

Table of Contents

Index to Financial Statements

The Company applies a procedure for debt investments that assumes the sale of each investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to determine the change in market yields between inception of the debt security and the measurement date. Industry specific indices and other relevant market data are used to benchmark/assess market based movements.

Under this process, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated debt investments using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt security is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt security is greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Debt investments that are traded on a public exchange will be valued at the prevailing market price at period end.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes OPM. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically

 

F-50

---

Table of Contents

Index to Financial Statements

reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Portfolio Composition

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Generally, under the 1940 Act, the Company is deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more but less than 25% of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes the Company’s realized and unrealized gain and loss and changes in the Company’s unrealized appreciation and depreciation on affiliate investments for the years ended December 31, 2015, 2014, and 2013. The Company did not hold any Control investments at December 31, 2015, 2014 or 2013.

 

(in thousands)								Year Ended December 31, 2015
Portfolio Company		Type		Fair Value  at December 31, 2015				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation/ (Depreciation)				Realized Gain/(Loss)
Optiscan BioMedical, Corp.		Affiliate		$	6,973			$	—			$	901			$	—			$	—
Stion Corporation		Affiliate			1,013				348				206				—				—
Total				$	7,986			$	348			$	1,107			$	—			$	—

 

(in thousands)								Year Ended December 31, 2014
Portfolio Company		Type		Fair Value  at December 31, 2014				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation/ (Depreciation)				Realized Gain/(Loss)
Gelesis, Inc.		Affiliate		$	327			$	—			$	(146	)		$	—			$	—
Optiscan BioMedical, Corp.		Affiliate			6,072				—				(24	)			—				—
Stion Corporation		Affiliate			1,600				1,876				(3,112	)			—				—
Total				$	7,999			$	1,876			$	(3,282	)		$	—			$	—

 

(in thousands)								Year Ended December 31, 2013
Portfolio Company		Type		Fair Value  at December 31, 2013				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation/ (Depreciation)				Realized Gain/(Loss)
Gelesis, Inc.		Affiliate		$	473			$	—			$	(1,193	)		$	—			$	—
Optiscan BioMedical, Corp.		Affiliate			4,784				1,933				(225	)			—				—
Stion Corporation		Affiliate			5,724				462				593				—				—
Total				$	10,981			$	2,395			$	(825	)		$	—			$	—

During the year ended December 31, 2015, changes to the capitalization structure of the portfolio company Gelesis, Inc. reduced the Company’s investment below the threshold for classification as an affiliate investment.

 

F-51

---

Table of Contents

Index to Financial Statements

A summary of the composition of the Company’s investment portfolio as of December 31, 2015 and December 31, 2014 at fair value is shown as follows:

 

		December 31, 2015								December 31, 2014
(in thousands)		Investments at  Fair Value				Percentage of Total Portfolio				Investments at Fair Value				Percentage of Total Portfolio
Senior Secured Debt with Warrants		$	961,464				80.1	%		$	740,659				72.6	%
Senior Secured Debt			171,732				14.3	%			208,345				20.4	%
Preferred Stock			35,245				2.9	%			57,548				5.6	%
Common Stock			32,197				2.7	%			14,185				1.4	%
Total		$	1,200,638				100.0	%		$	1,020,737				100.0	%

The increase in common stock and the decrease in preferred stock is primarily due to the IPO of Box, Inc. on January 23, 2015 in which all of the Company’s preferred shares were converted to common stock in the public portfolio company. Any potential future gain is subject to the price of the shares when the Company exits the investment.

A summary of the Company’s investment portfolio, at value, by geographic location as of December 31, 2015 and December 31, 2014 is shown as follows:

 

		December 31, 2015								December 31, 2014
(in thousands)		Investments at Fair Value				Percentage of Total Portfolio				Investments at Fair Value				Percentage of Total Portfolio
United States		$	1,167,281				97.2	%		$	967,803				94.8	%
Netherlands			20,112				1.7	%			19,913				2.0	%
England			8,884				0.8	%			34				0.0	%
Israel			3,764				0.3	%			6,498				0.6	%
Canada			595				0.0	%			2,314				0.2	%
India			2				0.0	%			24,175				2.4	%
Total		$	1,200,638				100.0	%		$	1,020,737				100.0	%

The following table shows the fair value the Company’s portfolio by industry sector at December 31, 2015 and December 31, 2014:

 

		December 31, 2015								December 31, 2014
(in thousands)		Investments at Fair Value				Percentage of Total Portfolio				Investments at Fair Value				Percentage of Total Portfolio
Drug Discovery & Development		$	284,266				23.7	%		$	267,618				26.2	%
Drug Delivery			164,665				13.7	%			88,491				8.7	%
Sustainable and Renewable Technology			159,487				13.3	%			68,280				6.7	%
Software			147,237				12.3	%			125,412				12.3	%
Media/Content/Info			95,488				7.9	%			29,219				2.9	%
Medical Devices & Equipment			90,560				7.5	%			138,046				13.5	%
Internet Consumer & Business Services			88,377				7.4	%			69,655				6.8	%
Specialty Pharmaceuticals			52,088				4.3	%			51,536				5.0	%
Communications & Networking			33,213				2.8	%			61,433				6.0	%
Consumer & Business Products			26,611				2.2	%			63,225				6.2	%
Semiconductors			22,705				1.9	%			5,126				0.5	%
Healthcare Services, Other			15,131				1.3	%			10,527				1.0	%
Surgical Devices			11,185				0.9	%			9,915				1.0	%
Electronics & Computer Hardware			6,928				0.6	%			692				0.1	%
Information Services			1,657				0.1	%			27,016				2.6	%
Biotechnology Tools			719				0.1	%			3,721				0.4	%
Diagnostic			321				0.0	%			825				0.1	%
Total		$	1,200,638				100.0	%		$	1,020,737				100.0	%

No single portfolio investment represents more than 10% of the fair value of the investments as of December 31, 2015 and December 31, 2014.

 

F-52

---

Table of Contents

Index to Financial Statements

Portfolio Activity

During the year ended December 31, 2015, the Company funded investments in debt securities and equity investments totaling approximately $694.1 million and $18.6 million, respectively. During the year ended December 31, 2015, the Company converted approximately $566,000 of debt to equity in two portfolio companies. During the year ended December 31, 2015, the Company converted approximately $330,000 of warrants to equity in three portfolio companies.

During the year ended December 31, 2014, the Company funded investments in debt securities and equity investments totaling approximately $611.0 million and $10.3 million, respectively. The Company converted approximately $2.2 million of debt to equity in four portfolio companies in the year ended December 31, 2014.

During the year ended December 31, 2015, the Company recognized net realized gains of approximately $5.1 million on the portfolio. These net realized gains included gross realized gains of approximately $12.6 million primarily from the sale of investments in seven portfolio companies, including Box, Inc. ($3.2 million), Atrenta, Inc. ($2.6 million), Cempra, Inc. ($2.0 million), Celladon Corporation ($1.4 million), Egalet Corporation ($652,000), Everyday Health, Inc. ($387,000) and Identiv, Inc. ($304,000), and $1.5 million from subsequent recoveries received on two previously written-off debt investments. These gains were partially offset by gross realized losses of approximately $7.5 million primarily from the liquidation or write off of the Company’s investments in sixteen portfolio companies.

During the year ended December 31, 2014, the Company recognized net realized gains of approximately $20.1 million on the portfolio. These net realized gains included gross realized gains of approximately $24.0 million primarily from the sale of investments in seven portfolio companies including Acceleron Pharma, Inc., ($7.9 million), Merrimack Pharmaceuticals, Inc., ($4.3 million), Neuralstem, Inc., ($2.7 million), IPA Holdings, LLC., ($1.5 million), Cell Therapeutics, Inc., ($1.3 million), Trulia, Inc. ($1.0 million), and Portola Pharmaceuticals, Inc. ($700,000). These gains were partially offset by gross realized losses of approximately $3.9 million primarily from the liquidation of the Company’s investments in fifteen portfolio companies.

Investment Collateral

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. At December 31, 2015, approximately 39.7% of the Company’s portfolio company debt investments were secured by a first priority security in all of the assets of the portfolio company, including their intellectual property, 49.7% of the Company’s portfolio company debt investments were to portfolio companies that were prohibited from pledging or encumbering their intellectual property, or subject to a negative pledge, 7.9% of the Company’s portfolio company debt investments were secured by a second priority security interest in all of the portfolio company’s assets, other than intellectual property and 2.7% of the Company’s portfolio company debt investments were subordinated secured by all of the portfolio company’s assets, including intellectual property. At December 31, 2015 the Company had no equipment only liens on any of the Company’s portfolio companies.

Income Recognition

The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect that principal, interest, and other obligations due will be collected in full, management will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal and interest due has been paid or management

 

F-53

---

Table of Contents

Index to Financial Statements

believes the portfolio company has demonstrated the ability to repay the Company’s current and future contractual obligations. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, the Company may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

At December 31, 2015, the Company had five debt investments on non-accrual with a cumulative investment cost and fair value of approximately $47.4 million and $23.2 million, respectively, compared to four debt investments on non-accrual at December 31, 2014 with a cumulative investment cost and fair value of approximately $28.9 million and $10.6 million, respectively. In addition, at December 31, 2015, the Company had one debt investment with an investment cost and fair value of approximately $20.1 million and $14.9 million, respectively, for which only the PIK interest is on non-accrual. The increase in the cumulative cost and fair value of debt investments on non-accrual between December 31, 2015 and December 31, 2014 is the result of placing three new debt investments on non-accrual status during the period, offset by the liquidation of two debt investments that were on non-accrual at December 31, 2014. During the year ended December 31, 2015, the Company recognized a realized loss of approximately $180,000 on the write off of one debt investment that was on non-accrual at December 31, 2014. In addition, the Company recognized a realized loss of $1.2 million on the partial write off of one debt investment that is on non-accrual as of December 31, 2015.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the years ended December 31, 2015 and December 31, 2014.

Paid-In-Kind and End of Term Income

Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $4.7 million and $3.3 million in PIK income in the years ended December 31, 2015 and 2014, respectively.

In addition, the Company may also be entitled to an end-of-term payment that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At December 31, 2015, the Company had approximately $22.7 million in exit fees receivable, of which approximately $17.4 million was included as an offset to the cost basis of our current debt investments and approximately $5.3 million was deferred related to expired commitments. At December 31, 2014 the Company had approximately $19.3 million in exit fees receivable, of which approximately $8.4 million was included as an offset to the cost basis of our current debt investments and approximately $10.9 million was related to expired commitments.

To maintain the Company’s status as a RIC, PIK and end-of-term income must be paid out to stockholders in the form of dividends even though the cash has not yet been collected. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments.

Fee Income

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by us to portfolio companies and other third parties. Loan and commitment fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method.

 

F-54

---

Table of Contents

Index to Financial Statements

In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $26.1 million of unamortized fees at December 31, 2015, of which approximately $23.6 million was included as an offset to the cost basis of our current debt investments and approximately $2.5 million was deferred contingent upon the occurrence of a funding or milestone. At December 31, 2014 the Company had approximately $21.9 million of unamortized fees, of which approximately $17.4 million was included as an offset to the cost basis of our current debt investments and approximately $4.5 million was deferred contingent upon the occurrence of a funding or milestone.

The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fees, including prepayment penalties, fees related to select covenant default waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding.

Equity Offering Expenses

The Company’s offering costs are charged against the proceeds from equity offerings when received.

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing. Debt issuance costs are recognized as prepaid expenses and amortized over the life of the related debt instrument using the straight line method, which closely approximates the effective yield method. Prepaid financing costs, net of accumulated amortization, were as follows as of December 31, 2015 and December 31, 2014.

 

(in thousands)		December 31, 2015				December 31, 2014
SBA Debentures		$	3,371			$	4,038
2019 Notes			2,185				4,352
2024 Notes			2,872				3,205
2017 Asset-Backed Notes			—				506
2021 Asset-Backed Notes			2,305				3,207
Convertible Senior Notes			44				175
Wells Facility			669				794
Union Bank Facility			229				156
Total		$	11,675			$	16,433

Cash and Cash Equivalents

Cash and cash equivalents consists solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value.

Other Assets

Other Assets generally consists of prepaid expenses, deferred financing costs net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivable. The escrow receivable balance as of December 31, 2015 was approximately $3.0 million and was fair valued and held in accordance with ASC 820.

Stock Based Compensation

The Company has issued and may, from time to time, issue additional stock options and restricted stock to employees under the Company’s 2004 Equity Incentive Plan and Board members under the Company’s 2006

 

F-55

---

Table of Contents

Index to Financial Statements

Equity Incentive Plan. Management follows the guidelines set forth under ASC Topic 718, formally known as FAS 123R “Share-Based Payments” to account for stock options granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life.

Income Taxes

The Company operates to qualify to be taxed as a RIC under the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders in determining “taxable income.” Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by deductible expenses, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized.

As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company distributes dividends in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of the Company’s ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of the Company’s capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding years (the “Excise Tax Avoidance Requirements”). The Company will not be subject to excise taxes on amounts on which the Company is required to pay corporate income tax (such as retained net capital gains).

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and pay a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of dividends paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, dividends declared and paid by the Company in a taxable year may differ from taxable income for that taxable year as such dividends may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

The Company intends to distribute approximately $8.2 million of spillover earnings from ordinary income for the taxable year ended December 31, 2015 to the Company’s shareholders in 2016. The Company distributed 100% of its spillover from long term capital gains for the taxable year ended December 31, 2014 to the Company’s shareholders in 2015.

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and net realized securities gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

Earnings Per Share (“EPS”)

Basic EPS is calculated by dividing net earnings applicable to common shareholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and

 

F-56

---

Table of Contents

Index to Financial Statements

restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock.

Comprehensive Income

The Company reports all changes in comprehensive income in the Consolidated Statement of Operations. Comprehensive income is equal to net increase in net assets resulting from operations.

Dividends

Dividends and distributions to common stockholders are approved by the Board of Directors on a quarterly basis and the dividend payable is recorded on the ex-dividend date.

The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company’s Board of Directors authorizes, and the Company declares a cash dividend, then the Company’s stockholders who have not “opted out” of the Company’s dividend reinvestment plan will have their cash dividend automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash dividends. During 2015, 2014, and 2013, the Company issued approximately 199,894, 96,976, and 159,000 shares, respectively, of common stock to shareholders in connection with the dividend reinvestment plan.

Segments

The Company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Recent Accounting Pronouncements

In February 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-02, “Consolidation (Topic 810)—Amendments to the Consolidation Analysis”. The new guidance applies to entities in all industries and provides a new scope exception to registered money market funds and similar unregistered money market funds. It makes targeted amendments to the current consolidation guidance and ends the deferral granted to investment companies from applying the VIE guidance. The Company currently consolidates all VIEs of which it is the primary beneficiary, thus the Company does not anticipates a material impact from adopting this standard on its financial statements. ASU 2015-02 is effective for public business entities for annual reporting periods beginning after December 15, 2015.

In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”, which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability and in August 2015, the FASB issued ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the application of ASU 2015-03 to debt issuance costs associated with line-of-credit arrangements and allows presentation of debt issuance costs on these instruments as assets that are amortized over the term of the instrument. Adoption of these standards will result in the presentation of the Company’s SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes net of the associated debt issuance costs for each instrument in the liabilities section on the Consolidated Statement of Assets and Liabilities. There will be no changes to the

 

F-57

---

Table of Contents

Index to Financial Statements

accounting or presentation of the Wells Facility as debt issuance costs are amortized over the term of the line of credit. ASU 2015-03 and ASU 2015-15 are effective for interim and annual reporting periods in fiscal years that begin after December 15, 2015.

3. Fair Value of Financial Instruments

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The Company believes that the carrying amounts of its financial instruments, consisting of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The Convertible Senior Notes, the April 2019 Notes, the September 2019 Notes (together with the April 2019 Notes, the “2019 Notes”), the 2024 Notes, 2021 Asset-Backed Notes, and the SBA debentures, as each term is defined herein, as sources of liquidity remain a strategic advantage due to their flexible structure, long-term duration, and low fixed interest rates. At December 31, 2015, the April 2019 Notes were trading on the New York Stock Exchange (“NYSE”) for $25.42 per share at par value, the September 2019 Notes were trading on the NYSE for $25.23 per share at par value and the 2024 Notes were trading on the NYSE for $25.34 per share at par value. The par value at underwriting for each of these notes was $25.00 per share. Based on market quotations on or around December 31, 2015, the Convertible Senior Notes were quoted for 1.110 per dollar at par value and the 2021 Asset-Backed Notes were quoted for 0.996 per dollar at par value. Calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms, the fair value of the SBA debentures would be approximately $194.1 million, compared to the carrying amount of $190.2 million as of December 31, 2015. The fair value of the outstanding borrowings under the Wells Facility at December 31, 2015 is equal to its transaction price as the Company renegotiated the terms of the agreement with Wells Fargo Capital Finance, LLC in December 2015.

See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in Note 2.

The liabilities of the Company are recorded at amortized cost and not at fair value on the Consolidated Statement of Assets and Liabilities. The following tables provide additional information about the fair value and level in the fair value hierarchy of the Company’s liabilities at December 31, 2015 and December 31, 2014.

 

(in thousands) Description(1)		December 31, 2015				Identical Assets (Level 1)				Observable Inputs (Level 2)				Unobservable Inputs (Level  3)
Convertible Senior Notes		$	19,540			$	—			$	19,540			$	—
Wells Facility			50,000				—				—				50,000
2021 Asset-Backed Notes			128,775				—				128,775				—
April 2019 Notes			65,573				—				65,573				—
September 2019 Notes			46,297				—				46,297				—
2024 Notes			104,401				—				104,401				—
SBA Debentures			194,121				—				—				194,121
Total		$	608,707			$	—			$	364,586			$	244,121

 

(in thousands) Description		December 31, 2014				Identical Assets (Level 1)				Observable Inputs (Level 2)				Unobservable Inputs (Level  3)
Convertible Senior Notes		$	22,799			$	—			$	22,799			$	—
2017 Asset-Backed Notes			22,068				—				—				22,068
2021 Asset-Backed Notes			129,300				—				129,300				—
April 2019 Notes			86,450				—				86,450				—
September 2019 Notes			88,073				—				88,073				—
2024 Notes			104,071				—				104,071				—
SBA Debentures			191,779				—				—				191,779
Total		$	644,540			$	—			$	430,693			$	213,847

 

(1)	As of April 16, 2015, the 2017 Asset-Backed Notes were fully repaid.

 

F-58

---

Table of Contents

Index to Financial Statements

4. Borrowings

Outstanding Borrowings

At December 31, 2015 and December 31, 2014, the Company had the following available borrowings and outstanding borrowings:

 

		December 31, 2015								December 31, 2014
(in thousands)		Total Available				Carrying  Value(1)				Total Available				Carrying  Value(1)
SBA Debentures(2)		$	190,200			$	190,200			$	190,200			$	190,200
2019 Notes			110,364				110,364				170,364				170,364
2024 Notes			103,000				103,000				103,000				103,000
2017 Asset-Backed Notes			—				—				16,049				16,049
2021 Asset-Backed Notes			129,300				129,300				129,300				129,300
Convertible Senior Notes(3)			17,604				17,522				17,674				17,345
Wells Facility(4)			75,000				50,000				75,000				—
Union Bank Facility(4)			75,000				—				75,000				—
Total		$	700,468			$	600,386			$	776,587			$	626,258

 

(1)	Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding.

(2)	At both December 31, 2015 and December 31, 2014, the total available borrowings under the SBA debentures were $190.2 million, of which $41.2 million was available in HT II and $149.0 million was available in HT III.

(3)

During the year ended December 31, 2015, holders of approximately $70,000 of the Company’s Convertible Senior Notes exercised their conversion rights. The balance at December 31, 2015 represents the remaining aggregate principal amount outstanding of the Convertible Senior Notes less the remaining unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total remaining unaccreted discount for the Convertible Senior Notes was approximately $82,000 at December 31, 2015 and $329,000 at December 31, 2014.

(4)	Availability subject to the Company meeting the borrowing base requirements.

Long-Term SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. Under the Small Business Investment Company Act and current SBA policy applicable to SBICs, a SBIC can have outstanding at any time SBA guaranteed debentures up to twice the amount of its regulatory capital. With the Company’s net investment of $44.0 million in HT II as of December 31, 2015, HT II has the capacity to issue a total of $41.2 million of SBA guaranteed debentures, subject to SBA approval, of which $41.2 million was outstanding as of December 31, 2015. As of December 31, 2015, HT II has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of December 31, 2015, the Company held investments in HT II in 32 companies with a fair value of approximately $79.5 million, accounting for approximately 6.6% of the Company’s total portfolio. HT II held approximately $128.3 million in assets and accounted for approximately 7.6% of the Company’s total assets prior to consolidation at December 31, 2015.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With the Company’s net investment of $74.5 million in HT III as of December 31, 2015, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, subject to SBA approval, of which $149.0 million was outstanding as of December 31, 2015. As of December 31, 2015, HT III has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of December 31, 2015, the Company held investments in HT III in 44 companies with a fair value of approximately $255.9 million, accounting for approximately 21.3% of the Company’s total portfolio. HT III held approximately $310.8 million in assets and accounted for approximately 18.5% of the Company’s total assets prior to consolidation at December 31, 2015.

 

F-59

---

Table of Contents

Index to Financial Statements

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $19.5 million and have average annual fully taxed net income not exceeding $6.5 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through the Company’s wholly-owned subsidiaries HT II and HT III, the Company plans to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to the Company if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect the Company because HT II and HT III are the Company’s wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of December 31, 2015 as a result of having sufficient capital as defined under the SBA regulations.

The rates of borrowings under various draws from the SBA beginning in March 2009 are set semiannually in March and September and range from 2.25% to 4.62% excluding annual fees. Interest payments on SBA debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of March 2009, the initial maturity of SBA debentures will occur in March 2019. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees on other debentures have been set at 0.906%. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.515%. The rates of borrowings on the Company’s SBA debentures range from 3.05% to 5.53% when including these annual fees.

The average amount of debentures outstanding for the year ended December 31, 2015 for HT II was approximately $41.2 million with an average interest rate of approximately 4.52%. The average amount of debentures outstanding for the year ended December 31, 2015 for HT III was approximately $149.0 million with an average interest rate of approximately 3.43%.

For the years ended December 31, 2015 and 2014, the components of interest expense and related fees and cash paid for interest expense for the SBA debentures are as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	6,969			$	7,328
Amortization of debt issuance cost (loan fees)			667				1,036
Total interest expense and fees		$	7,636			$	8,364
Cash paid for interest expense and fees		$	6,942			$	8,042

As of December 31, 2015, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $350.0 million, subject to periodic adjustments by the SBA. In aggregate, at

 

F-60

---

Table of Contents

Index to Financial Statements

December 31, 2015, with the Company’s net investment of $118.5 million, HT II and HT III have the capacity to issue a total of $190.2 million of SBA-guaranteed debentures, subject to SBA approval. At December 31, 2015, the Company has issued $190.2 million in SBA-guaranteed debentures in the Company’s SBIC subsidiaries.

The Company reported the following SBA debentures outstanding on its Consolidated Statement of Assets and Liabilities as of December 31, 2015 and December 31, 2014:

 

(in thousands) Issuance/Pooling Date		Maturity Date		Interest  Rate(1)				December 31, 2015				December 31, 2014
SBA Debentures:
March 25, 2009		March 1, 2019			5.53	%		$	18,400			$	18,400
September 23, 2009		September 1, 2019			4.64	%			3,400				3,400
September 22, 2010		September 1, 2020			3.62	%			6,500				6,500
September 22, 2010		September 1, 2020			3.50	%			22,900				22,900
March 29, 2011		March 1, 2021			4.37	%			28,750				28,750
September 21, 2011		September 1, 2021			3.16	%			25,000				25,000
March 21, 2012		March 1, 2022			3.28	%			25,000				25,000
March 21, 2012		March 1, 2022			3.05	%			11,250				11,250
September 19, 2012		September 1, 2022			3.05	%			24,250				24,250
March 27, 2013		March 1, 2023			3.16	%			24,750				24,750
Total SBA Debentures								$	190,200			$	190,200

 

(1)	Interest rate includes annual charge

2019 Notes

On March 6, 2012, the Company and U.S. Bank National Association (the “2019 Trustee”) entered into an indenture (the “Base Indenture”). On April 17, 2012, the Company and the 2019 Trustee entered into the First Supplemental Indenture to the Base Indenture (the “First Supplemental Indenture”), dated April 17, 2012, relating to the Company’s issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

In July 2012, the Company reopened the Company’s April 2019 Notes and issued an additional $41.5 million in aggregate principal amount of April 2019 Notes, which included the exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

On September 24, 2012, the Company and the 2019 Trustee, entered into the Second Supplemental Indenture to the Base Indenture (the “Second Supplemental Indenture”), dated as of September 24, 2012, relating to the Company’s issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% notes due 2019 (the “September 2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

In October 2012, the underwriters exercised their over-allotment option for an additional $10.9 million of the September 2019 Notes, bringing the total amount of the September 2019 Notes issued to approximately $85.9 million in aggregate principal outstanding.

In April 2015, the Company redeemed $20.0 million of the $84.5 million issued and outstanding aggregate principal amount of April 2019 Notes, as previously approved by the Board of Directors. In December 2015, the Company redeemed $40.0 million of the $85.9 million issued and outstanding aggregate principal amount of September 2019 Notes, as previously approved by the Board of Directors.

 

F-61

---

Table of Contents

Index to Financial Statements

As of December 31, 2015 and December 31, 2014, the 2019 Notes payable is comprised of:

 

(in thousands)		December 31, 2015				December 31, 2014
April 2019 Notes		$	64,490			$	84,490
September 2019 Notes			45,874				85,874
Carrying Value of 2019 Notes		$	110,364			$	170,364

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the NYSE under the trading symbol “HTGZ.”

The April 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grant security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring the Company’s compliance with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the 2019 Trustee if the Company should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the First Supplemental Indenture. The Base Indenture provides for customary events of default and further provides that the 2019 Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The April 2019 Notes were sold pursuant to an underwriting agreement dated April 11, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the NYSE under the trading symbol “HTGY.”

 

F-62

---

Table of Contents

Index to Financial Statements

The September 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the 2019 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the Second Supplemental Indenture. The Base Indenture provides for customary events of default and further provides that the 2019 Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The September 2019 Notes were sold pursuant to an underwriting agreement dated September 19, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

For the years ended December 31, 2015 and 2014, the components of interest expense and related fees and cash paid for interest expense for the 2019 Notes are as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	10,899			$	11,926
Amortization of debt issuance cost (loan fees)			2,167				967
Total interest expense and fees		$	13,066			$	12,893
Cash paid for interest expense and fees		$	11,132			$	11,926

As of December 31, 2015, the Company was in compliance with the terms of the Base Indenture, and respective supplemental indentures thereto, governing the April 2019 Notes and September 2019 Notes.

2024 Notes

On July 14, 2014, the Company and U.S. Bank, N.A. (the “2024 Trustee”), entered into the Third Supplemental Indenture (the “Third Supplemental Indenture”) to the Base Indenture between the Company and the 2024 Trustee, dated July 14, 2014, relating to the Company’s issuance, offer and sale of $100.0 million aggregate principal amount of 2024 Notes. On August 6, 2014, the underwriters issued notification to exercise their over-allotment option for an additional $3.0 million in aggregate principal amount of the 2024 Notes. The sale of the 2024 Notes generated net proceeds of approximately $99.9 million.

The 2024 Notes will mature on July 30, 2024 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after July 30, 2017, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The 2024 Notes bear

 

F-63

---

Table of Contents

Index to Financial Statements

interest at a rate of 6.25% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2014, and trade on the NYSE under the trading symbol “HTGX.”

The 2024 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2024 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the Third Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the Third Supplemental Indenture. The Base Indenture, as supplemented by the Third Supplemental Indenture, also contains certain reporting requirements, including a requirement that the Company provide financial information to the holders of the 2024 Notes and the 2024 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. The Base Indenture provides for customary events of default and further provides that the 2024 Trustee or the holders of 25% in aggregate principal amount of the outstanding 2024 Notes in a series may declare such 2024 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period. As of December 31, 2015, the Company was in compliance with the terms of the Base Indenture as supplemented by the Third Supplemental Indenture.

At both December 31, 2015 and December 31, 2014, the 2024 Notes had an outstanding principal balance of $103.0 million.

For the years ended December 31, 2015 and 2014, the components of interest expense and related fees and cash paid for interest expense for the 2024 Notes are as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	6,437			$	2,955
Amortization of debt issuance cost (loan fees)			333				153
Total interest expense and fees		$	6,770			$	3,108
Cash paid for interest expense and fees		$	6,437			$	1,887

2017 Asset-Backed Notes

On December 19, 2012, the Company completed a $230.7 million term debt securitization in connection with which an affiliate of the Company made an offer of $129.3 million in aggregate principal amount of fixed-rate asset-backed notes (the “2017 Asset-Backed Notes”), which were rated A2(sf) by Moody’s Investors Service, Inc. The 2017 Asset-Backed Notes were sold by Hercules Capital Funding Trust 2012-1 pursuant to a note purchase agreement, dated as of December 12, 2012, by and among the Company, Hercules Capital Funding 2012-1, LLC as trust depositor (the “2012 Trust Depositor”), Hercules Capital Funding Trust 2012-1 as issuer (the “2012 Securitization Issuer”), and Guggenheim Securities, LLC, as initial purchaser, and were backed by a pool of senior loans made to certain of the Company’s portfolio companies and secured by certain assets of those portfolio companies and serviced by the Company.

As part of this transaction, the Company entered into a sale and contribution agreement with the 2012 Trust Depositor under which the Company has agreed to sell or have contributed to the 2012 Trust Depositor certain

 

F-64

---

Table of Contents

Index to Financial Statements

senior loans made to certain of the Company’s portfolio companies (the “2012 Loans”). The Company made customary representations, warranties and covenants in the sale and contribution agreement with respect to the 2012 Loans as of the date of their transfer to the 2012 Trust Depositor.

At December 31, 2014, the 2017 Asset-Backed Notes had an outstanding principal balance of $16.0 million. In February 2015, changes in the payment schedule of obligors in the 2017 Asset-Backed Notes collateral pool triggered a rapid amortization event in accordance with the sale and servicing agreement for the 2017 Asset-Backed Notes. Due to this event, the 2017 Asset-Backed Notes were fully repaid as of April 16, 2015.

Interest on the 2017 Asset-Backed Notes was paid, to the extent of funds available, at a fixed rate of 3.32% per annum. For the years ended December 31, 2015 and 2014, the components of interest expense and related fees and cash paid for interest expense for the 2017 Asset-Backed Notes are as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	141			$	1,628
Amortization of debt issuance cost (loan fees)			506				2,180
Total interest expense and fees		$	647			$	3,808
Cash paid for interest expense and fees		$	—			$	—

Under the terms of the 2017 Asset Backed Notes, the Company is required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2017 Asset-Backed Notes. The Company segregated these funds and classified them as restricted cash. There was approximately $1.2 million of restricted cash as of December 31, 2014, funded through interest collections. As the 2017 Asset-Backed Notes were fully repaid as of April 16, 2015 there were no funds segregated as restricted cash related to the 2017 Asset-Backed Notes at December 31, 2015.

2021 Asset-Backed Notes

On November 13, 2014, the Company completed a $237.4 million term debt securitization in connection with which an affiliate of the Company made an offer of $129.3 million in aggregate principal amount of fixed-rate asset-backed notes (the “2021 Asset-Backed Notes”), which were rated A(sf) by Kroll Bond Rating Agency, Inc. (“KBRA”). The 2021 Asset-Backed Notes were sold by Hercules Capital Funding Trust 2014-1 pursuant to a note purchase agreement, dated as of November 13, 2014, by and among the Company, Hercules Capital Funding 2014-1, LLC as trust depositor (the “2014 Trust Depositor”), Hercules Capital Funding Trust 2014-1 as issuer (the “2014 Securitization Issuer”), and Guggenheim Securities, LLC, as initial purchaser, and are backed by a pool of senior loans made to certain of the Company’s portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has an 18-month reinvestment period during which time principal collections may be reinvested into additional eligible loans. Interest on the 2021 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.524% per annum. The 2021 Asset-Backed Notes have a stated maturity of April 16, 2021.

As part of this transaction, the Company entered into a sale and contribution agreement with the 2014 Trust Depositor under which the Company has agreed to sell or have contributed to the 2014 Trust Depositor certain senior loans made to certain of the Company’s portfolio companies (the “2014 Loans”). The Company has made customary representations, warranties and covenants in the sale and contribution agreement with respect to the 2014 Loans as of the date of their transfer to the 2014 Trust Depositor.

In connection with the issuance and sale of the 2021 Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the note purchase agreement. The 2021 Asset-Backed Notes are secured obligations of the 2014 Securitization Issuer and are non-recourse to the Company. The 2014

 

F-65

---

Table of Contents

Index to Financial Statements

Securitization Issuer also entered into an indenture governing the 2021 Asset-Backed Notes, which includes customary representations, warranties and covenants. The 2021 Asset-Backed Notes were sold without being registered under the Securities Act (A) in the United States to “qualified institutional buyers” as defined in Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rules 501(A)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” as defined in Sec. 2(a)(51) of the 1940 Act and pursuant to an exemption under the Securities Act and (B) to non-U.S. purchasers acquiring interest in the 2021 Asset-Backed Notes outside the United States in accordance with Regulation S under the Securities Act. The 2014 Securitization Issuer is not registered under the 1940 Act in reliance on an exemption provide by Section 3(c)(7) thereof and Rule 3a-7 thereunder. In addition, the 2014 Trust Depositor entered into an amended and restated trust agreement in respect of the 2014 Securitization Issuer, which includes customary representation, warranties and covenants.

The 2014 Loans are serviced by the Company pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. The Company performs certain servicing and administrative functions with respect to the 2014 Loans. The Company is entitled to receive a monthly fee from the 2014 Securitization Issuer for servicing the 2014 Loans. This servicing fee is equal to the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including October 5, 2014 through and including December 5, 2014 over 360) of 2.00% and the aggregate outstanding principal balance of the 2014 Loans plus collections on deposit in the 2014 Securitization Issuer’s collections account, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including October 5, 2014, to the close of business on December 5, 2014).

The Company also serves as administrator to the 2014 Securitization Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At both December 31, 2015 and December 31, 2014, the 2021 Asset-Backed Notes had an outstanding principal balance of $129.3 million.

For the years ended December 31, 2015 and 2014, the components of interest expense and related fees and cash paid for interest expense for the 2021 Asset-Backed Notes are as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	4,557			$	608
Amortization of debt issuance cost (loan fees)			902				117
Total interest expense and fees		$	5,459			$	725
Cash paid for interest expense and fees		$	4,557			$	418

Under the terms of the 2021 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2021 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. There was approximately $9.2 million and $11.5 million of restricted cash as of December 31, 2015 and December 31, 2014, respectively, funded through interest collections.

Convertible Senior Notes

In April 2011, the Company issued $75.0 million in aggregate principal amount of 6.00% convertible senior notes due 2016 (the “Convertible Senior Notes”). During the year ended December 31, 2015, holders of approximately $70,000 of the Company’s Convertible Senior Notes exercised their conversion rights. As of

 

F-66

---

Table of Contents

Index to Financial Statements

December 31, 2015, the carrying value of the Convertible Senior Notes, comprised of the aggregate principal amount outstanding less the remaining unaccreted discount initially recorded upon issuance of the Convertible Senior Notes, is approximately $17.5 million.

The Convertible Senior Notes mature on April 15, 2016, unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are the Company’s senior unsecured obligations and rank senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding October 15, 2015, holders could convert their Convertible Senior Notes only under certain circumstances set forth in the indenture governing the Convertible Senior Notes. On or after October 15, 2015, until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at the Company’s election, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. The conversion rate was initially 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the conversion rate is increased for converting holders. As of December 31, 2015, the conversion rate was 90.6580 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $11.03 per share of common stock).

The Company may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require the Company to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

The Convertible Senior Notes are accounted for in accordance with ASC Subtopic 470-20 (previously FASB Staff Position No. APB 14- 1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)”). In accounting for the Convertible Senior Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes was recorded in “capital in excess of par value” in the Consolidated Statement of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 8.1%.

Upon meeting the stock trading price conversion requirement as set forth in the indenture governing the Convertible Senior Notes, dated April 15, 2011, between the Company and U.S. Bank National Association, during the three months ended June 30, 2014, September 30, 2014 and December 31, 2014, the Convertible Senior Notes became convertible on July 1, 2014 and continued to be convertible during each of the three months ended September 30, 2014, December 31, 2014 and March 31, 2015, respectively. During this period and as of December 31, 2015, approximately $57.4 million of the Convertible Senior Notes were converted and were settled with a combination of cash equal to the outstanding principal amount of the Convertible Senior Notes and

 

F-67

---

Table of Contents

Index to Financial Statements

approximately 1.5 million shares of the Company’s common stock, or $24.3 million. By not meeting the stock trading price conversion requirement during the three months ended March 31, 2015, June 30, 2015, or September 30, 2015 the Convertible Senior Notes were not convertible for the period between April 1, 2015 and October 14, 2015. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time as described above.

The Company recorded a loss on extinguishment of debt for the proportionate amount of unamortized debt issuance costs and original issue discount on Notes converted during the period. The loss was partially offset by a gain in the amount of the difference between the outstanding principal balance of the converted notes and the fair value of the debt instrument. The net loss on extinguishment of debt the Company recorded for the years ended December 31, 2015 and 2014 was approximately $1,000 and $1.6 million, respectively. The loss on extinguishment of debt was classified as a component of net investment income in the Company’s Consolidated Statement of Operations.

As of December 31, 2015 and December 31, 2014, the components of the carrying value of the Convertible Senior Notes were as follows:

 

(in thousands)		December 31, 2015				December 31, 2014
Principal amount of debt		$	17,604			$	17,674
Original issue discount, net of accretion			(82	)			(329	)
Carrying value of Convertible Senior Debt		$	17,522			$	17,345

For the years ended December 31, 2015 and 2014, the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	1,007			$	2,753
Accretion of original issue discount			246				843
Amortization of debt issuance cost (loan fees)			131				450
Total interest expense and fees		$	1,384			$	4,046
Cash paid for interest expense and fees		$	1,057			$	3,465

The estimated effective interest rate of the debt component of the Convertible Senior Notes, equal to the stated interest of 6.0% plus the accretion of the original issue discount, was approximately 8.1% for the years ended December 31, 2015 and December 31, 2014. Interest expense decreased by approximately $1.7 million during the year ended December 31, 2015 from the year ended December 31, 2014, due to Convertible Senior Notes settled in the period. As of December 31, 2015, the Company is in compliance with the terms of the indentures governing the Convertible Senior Notes.

Wells Facility

On June 29, 2015, the Company, through a special purpose wholly-owned subsidiary, Hercules Funding II LLC (“Hercules Funding II”), entered into an Amended and Restated Loan and Security Agreement (the “Wells Facility”) with Wells Fargo Capital Finance, LLC, as a lender and as the arranger and the administrative agent, and the lenders party thereto from time to time. The Wells Facility amends, restates, and otherwise replaces the Loan and Security Agreement, which was originally entered into on August 25, 2008, with Wells Fargo Capital Finance, LLC, and had been amended from time to time. The Wells Facility was amended and restated to, among other things, consolidate prior amendments and update certain provisions to reflect current operations and personnel of the Company and Hercules Funding II. Many other terms and provisions of the Wells Facility remain the same or substantially similar to the terms and provisions of the original Wells Facility.

 

F-68

---

Table of Contents

Index to Financial Statements

On December 16, 2015, the Company entered into an amendment to the Wells Facility that extended the revolving credit availability period and maturity date of the facility. As amended, the revolving credit availability period ends on August 1, 2018 and the Wells Facility matures on August 2, 2019, unless terminated sooner in accordance with its terms.

Under the Wells Facility, Wells Fargo Capital Finance, LLC has made commitments of $75.0 million. The Wells Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the facility; however, there can be no assurances that additional lenders will join the Wells Facility. Borrowings under the Wells Facility generally bear interest at a rate per annum equal to LIBOR plus 3.25%, and the Wells Facility has an advance rate of 50% against eligible debt investments. The Wells Facility is secured by all of the assets of Hercules Funding II. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% depending on the average monthly outstanding balance under the facility relative to the maximum amount of commitments at such time. For the years ended December 31, 2015 and 2014, this non-use fee was approximately $294,000 and $380,000, respectively.

The Wells Facility also includes various financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding II, including covenants relating to certain changes of control of the Company and Hercules Funding II. Among other things, these covenants also require the Company to maintain certain financial ratios, including a maximum debt to worth ratio, minimum interest coverage ratio, minimum portfolio funding liquidity, and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $500.0 million plus 90% of the cumulative amount of equity raised after June 30, 2014. As of December 31, 2015, the minimum tangible net worth covenant has increased to $590.4 million as a result of the March 2015 follow-on public offering of 7.6 million shares of common stock for total net proceeds of approximately $100.1 million. The Wells Facility provides for customary events of default, including, without limitation, with respect to payment defaults, breach of representations and covenants, certain key person provisions, cross acceleration provisions to certain other debt, lien and judgment limitations, and bankruptcy.

On June 20, 2011 the Company paid $1.1 million in structuring fees in connection with the original Wells Facility. In connection with an amendment to the original Wells Facility in August 2014, the Company paid an additional $750,000 in structuring fees and in connection with the amendment in December 2015, the Company paid an additional $188,000 in structuring fees. These fees are being amortized through the end of the term of the Wells Facility.

The Company had aggregate draws of $138.7 million on the available facility during the year ended December 31, 2015 offset by repayments of $88.7 million. At December 31, 2015 there was $50.0 million of borrowings outstanding on this facility. At December 31, 2014 there were no borrowings outstanding on this facility.

For the years ended December 31, 2015 and 2014, the components of interest expense and related fees and cash paid for interest expense for the Wells Facility are as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Interest expense		$	578			$	—
Amortization of debt issuance cost (loan fees)			361				198
Total interest expense and fees		$	939			$	198
Cash paid for interest expense and fees		$	402			$	—

 

F-69

---

Table of Contents

Index to Financial Statements

Union Bank Facility

The Company has a $75.0 million revolving senior secured credit facility (the “Union Bank Facility”) with MUFG Union Bank, N.A. (“MUFG Union Bank”). The Company originally entered into the Union Bank Facility on February 10, 2010 but, following several amendments, amended and restated the Union Bank Facility on August 14, 2014. The amendment and restatement extends the maturity date of the Union Bank Facility to August 1, 2017, increases the size of the Union Bank Facility to $75.0 million from $30.0 million, and adjusts the interest rate for LIBOR borrowings under the Union Bank Facility. The Company further amended the Union Bank Facility in November 2015 but the amendment did not result in any material changes to the facility.

LIBOR-based borrowings by the Company under the Union Bank Facility will bear interest at a rate per annum equal to LIBOR plus 2.25% with no floor, whereas previously the Company paid a per annum interest rate on such borrowings equal to LIBOR plus 2.50% with a floor of 4.00%. Other borrowings by the Company under the Union Bank Facility, which are based on a reference rate instead of LIBOR, will continue to bear interest at a rate per annum equal to the reference rate (which is the greater of the federal funds rate plus 1.00% and a periodically announced MUFG Union Bank index rate) plus the greater of (i) 4.00% minus the reference rate and (ii) 1.00%. The Company continues to have the option of determining which type of borrowing to request under the Union Bank Facility. Subject to certain conditions, the amendment also removes a previous ceiling on the amount of certain unsecured indebtedness that the Company may incur.

The Union Bank Facility contains an accordion feature, pursuant to which the Company may increase the size of the Union Bank Facility to an aggregate principal amount of $300.0 million by bringing in additional lenders, subject to the approval of MUFG Union Bank and other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility to increase available borrowings.

The Union Bank Facility requires the payment of a non-use fee of 0.50% annually. For the years ended December 31, 2015 and 2014, this non-use fee was approximately $380,000 and $240,000, respectively. The amount that the Company may borrow under the Union Bank Facility is determined by applying an advance rate to eligible loans. The Union Bank Facility generally requires payment of monthly interest on loans based on a reference rate and at the end of a one, two, or three-month period, as applicable, for loans based on LIBOR. All outstanding principal is due upon maturity.

The Union Bank Facility is collateralized by debt investments in the Company’s portfolio companies, and includes an advance rate equal to 50.0% of eligible debt investments placed in the collateral pool.

The Company has various financial and operating covenants required by the Union Bank Facility. These covenants require, among other things, that the Company maintain certain financial ratios, including liquidity, asset coverage, and debt service coverage, and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $550.0 million plus 90% of the amount of net cash proceeds received from the sale of common stock after June 30, 2014. As of December 31, 2015, the minimum tangible net worth covenant has increased to $640.1 million as a result of the March 2015 follow-on public offering of 7.6 million shares of common stock for total net proceeds of approximately $100.1 million. The Union Bank Facility provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control.

At December 31, 2015 there were no borrowings outstanding on the Union Bank Facility.

Citibank Credit Facility

The Company, through Hercules Funding Trust I, an affiliated statutory trust, had a securitized credit facility (the “Citibank Credit Facility”) with Citigroup Global Markets Realty Corp. (“Citigroup”), which expired under normal terms. During the first quarter of 2009, the Company paid off all principal and interest owed under

 

F-70

---

Table of Contents

Index to Financial Statements

the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of debt investments and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, the Company granted to Citigroup a 10% participation in all warrants held as collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the year ended December 31, 2015, the Company reduced its realized gain by approximately $143,000 for Citigroup’s participation in the realized gain from the acquisition proceeds the Company received on equity exercised from warrants that were included in the collateral pool. The Company recorded an increase in participation liability and a decrease in unrealized appreciation by a net amount of approximately $11,000 primarily due to appreciation of fair value on the pool of warrants collateralized under the warrant participation agreement offset by the acquisition proceeds the Company received on its Atrenta, Inc. equity investment. The remaining value of their participation right on unrealized gains in the related equity investments is approximately $111,000 as of December 31, 2015 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, the Company has paid Citigroup approximately $2.2 million under the warrant participation agreement thereby reducing realized gains by this amount. The Company will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between February 2016 and January 2017.

5. Income Taxes

The Company intends to operate so as to qualify to be taxed as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of taxable income and gains distributed to stockholders.

To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount at least equal 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, to its stockholders. We, among other things, have made and intend to continue to make the requisite distributions to our stockholders, which will generally relieve us from U.S. federal income taxes. However, depending on the level of taxable income earned in a taxable year, we may choose to carry forward taxable income in excess of current taxable year dividend distributions into the next taxable year and pay a 4% excise tax on such taxable income, as required. To the extent that we determine that our estimated current year annual taxable income will be in excess of estimated current taxable year distributions, we will accrue excise tax, if any, on estimated excess taxable income as taxable income is earned.

 

F-71

---

Table of Contents

Index to Financial Statements

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary in nature. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. During the year ended December 31, 2015 and 2014, the Company reclassified for book purposes amounts arising from permanent book/tax differences primarily related to accelerated revenue recognition for income tax purposes, respectively, as follows:

 

		Year Ended December 31,
(in thousands)		2015				2014
Undistributed net investment income (distributions in excess of investment income)		$	(994	)		$	6,382
Accumulated realized gains		$	8,767			$	9,207
Additional paid-in capital		$	(7,773	)		$	(15,589	)

For income tax purposes, distributions paid to shareholders are reported as ordinary income, return of capital, long-term capital gains or a combination thereof. The tax character of distributions paid for the year ended December 31, 2015 was ordinary income in the amount of $70.6 million and long term capital gains in the amount of $15.3 million. The tax character of distributions paid for the year ended December 31, 2014 was ordinary income in the amount of $73.2 million.

The aggregate gross unrealized appreciation of the Company’s investments over cost for federal income tax purposes was $29.3 million and $46.1 million as of December 31, 2015 and 2014, respectively. The aggregate gross unrealized depreciation of the Company’s investments under cost for federal income tax purposes was $81.4 million and $63.4 million as of December 31, 2015 and 2014, respectively. The net unrealized depreciation over cost for federal income tax purposes was $52.1 million and $17.3 million as of December 31, 2015 and 2014, respectively. The aggregate cost of securities for federal income tax purposes was $1.3 billion and $1.0 billion as of December 31, 2015 and 2014, respectively.

At December 31, 2015 and 2014, the components of distributable earnings on a tax basis detailed below differ from the amounts reflected in the Company’s Consolidated Statements of Assets and Liabilities by temporary book/tax differences primarily arising from the treatment of loan related yield enhancements.

 

		Year Ended December 31,
(in thousands)		2015				2014
Accumulated Capital Gains		$	7,962			$	16,663
Other Temporary Differences			4,117				1,795
Undistributed Ordinary Income			236				—
Unrealized Depreciation			(47,498	)			(16,891	)
Components of Distributable Earnings		$	(35,183	)		$	1,567

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision for income taxes.

Based on an analysis of the Company’s tax position, there are no uncertain tax positions that met the recognition or measurement criteria. The Company is currently not undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2012- 2014 federal tax years for the Company remain subject to examination by the IRS. The 2011-2014 state tax years for the Company remain subject to examination by the state taxing authorities.

 

F-72

---

Table of Contents

Index to Financial Statements

6. Shareholders’ Equity

On August 16, 2013, the Company entered into an “At-The-Market” (“ATM”) equity distribution agreement (the “Equity Distribution Agreement”) with JMP Securities LLC (“JMP”). The Equity Distribution Agreement provides that the Company may offer and sell up to 8.0 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the year ended December 31, 2014, the Company sold 650,000 shares of common stock for total accumulated net proceeds of approximately $9.5 million, all of which is accretive to net asset value. The Company has not sold any shares of common stock under this agreement during the year ended December 31, 2015. The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of December 31, 2015, approximately 7.35 million shares remain available for issuance and sale under the equity distribution agreement.

On February 24, 2015, the Board of Directors authorized a stock repurchase plan permitting the Company to repurchase up to $50.0 million of its common stock. This plan expired on August 24, 2015. On August 27, 2015, the Board of Directors authorized a replacement stock repurchase plan permitting the Company to repurchase up to $50.0 million of its common stock. The Company may repurchase shares of its common stock in the open market, including block purchases, at prices that may be above or below the net asset value as reported in the most recently published financial statements. The Company expects that the share repurchase program will be in effect until August 23, 2016, or until the approved dollar amount has been used to repurchase shares. During the year ended December 31, 2015, the Company repurchased 437,006 shares of its common stock at an average price per share of $10.61 per share and a total cost of approximately $4.6 million. As of December 31, 2015, approximately $45.4 million of common stock remains eligible for repurchase under the stock repurchase plan. See “Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities” for further information on the repurchases made during the period. See “Note 14— Subsequent Events.”

The Company anticipates that the manner, timing, and amount of any share purchases will be determined by management based upon the evaluation of market conditions, stock price, and additional factors in accordance with regulatory requirements. Pursuant to the 1940 Act, the Company is required to notify shareholders when such a program is initiated or implemented. The repurchase program does not require the Company to acquire any specific number of shares and may be extended, modified, or discontinued at any time.

On March 27, 2015, the Company raised approximately $100.1 million, after deducting offering expenses, in a public offering of 7,590,000 shares of its common stock.

At the 2015 Annual Meeting of Stockholders on July 7, 2015, the Company’s common stockholders approved a proposal to allow the Company to issue common stock at a discount from its then current net asset value (“NAV”) per share, which is effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of stockholders. In connection with the receipt of such stockholder approval, the Company will limit the number of shares that it issues at a price below NAV pursuant to this authorization so that the aggregate dilutive effect on the Company’s then outstanding shares will not exceed 20%. The Company’s Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share. During the year ended December 31, 2015, the Company has not issued common stock at a discount to NAV.

The Company has issued stock options for common stock subject to future issuance, of which 622,171 and 695,672 were outstanding at December 31, 2015 and December 31, 2014, respectively.

 

F-73

---

Table of Contents

Index to Financial Statements

7. Equity Incentive Plan

The Company and its stockholders have authorized and adopted the 2004 Equity Incentive Plan (the “2004 Plan”) for purposes of attracting and retaining the services of its executive officers and key employees. Under the 2004 Plan, the Company is authorized to issue 7.0 million shares of common stock. On June 1, 2011, stockholders approved an amended and restated plan and provided an increase of 1.0 million shares, authorizing the Company to issue 8.0 million shares of common stock under the 2004 Plan. At the Company’s 2015 Annual Meeting of stockholders on July 7, 2015, the Company’s stockholders voted to approve an amendment to the 2004 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 4.0 million shares.

The Company and its stockholders have authorized and adopted the 2006 Non-Employee Director Plan (the “2006 Plan” and, together with the 2004 Plan, the “Plans”) for purposes of attracting and retaining the services of its Board of Directors. Under the 2006 Plan, the Company is authorized to issue 1.0 million shares of common stock. The Company filed an exemptive relief request with the Securities and Exchange Commission (“SEC”) to allow options to be issued under the 2006 Plan which was approved on October 10, 2007.

On June 21, 2007, the stockholders approved amendments to the 2004 Plan and the 2006 Plan allowing for the grant of restricted stock. The amended Plans limit the combined maximum amount of restricted stock that may be issued under both Plans to 10% of the outstanding shares of the Company’s stock on the effective date of the Plans plus 10% of the number of shares of stock issued or delivered by the Company during the terms of the Plans. The amendments further specify that no one person shall be granted awards of restricted stock relating to more than 25% of the shares available for issuance under the 2004 Plan. Further, the amount of voting securities that would result from the exercise of all of the Company’s outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 25% of its outstanding voting securities, except that if the amount of voting securities that would result from such exercise of all of the Company’s outstanding warrants, options and rights issued to the Company’s directors, officers and employees, together with any restricted stock issued pursuant to the Plans, would exceed 15% of the Company’s outstanding voting securities, then the total amount of voting securities that would result from the exercise of all outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 20% of the Company’s outstanding voting securities.

A summary of the restricted stock activity under the Company’s 2006 and 2004 Plans for each of the three periods ended December 31 2015, 2014, and 2013 is as follows:

 

		2006 Plan				2004 Plan
Outstanding at December 31, 2012			36,668				1,819,041
Granted			—				607,001
Cancelled			—				(30,264	)
Outstanding at December 31, 2013			36,668				2,395,778
Granted			8,333				981,550
Cancelled			—				(152,277	)
Outstanding at December 31, 2014			45,001				3,225,051
Granted			19,999				656,341
Cancelled			—				(312,564	)
Outstanding at December 31, 2015			65,000				3,568,828

In 2015, 2014, and 2013, the Company granted approximately 676,340, 989,883 and 607,001 shares, respectively, of restricted stock pursuant to the Plans. All restricted stock grants under the 2004 Plan made prior to March 4, 2013 will continue to vest on a monthly basis following their one year anniversary over the succeeding 36 months. During 2012, the Compensation Committee adopted a policy that provided for awards with different vesting schedules for short and long-term awards. Under the 2004 Plan, restricted stock awarded subsequent to March 3, 2013 will vest subject to continued employment based on two vesting schedules: short-term awards vest one-half on the one year anniversary of the date of the grant and quarterly over the succeeding

 

F-74

---

Table of Contents

Index to Financial Statements

12 months, and long-term awards vest one-fourth on the one year anniversary of the date of grant and quarterly over the succeeding 36 months. No restricted stock was granted pursuant to the 2004 Plan prior to 2009. See “Note 14 —Subsequent Events.”

The Company determined that the fair value of restricted stock granted under the 2006 and 2004 Plans during the years ended December 31, 2015, 2014, and 2013 was approximately $9.2 million, $13.7 million and $7.7 million, respectively based on the grant date close price and vesting period of each grant. During the years ended December 31, 2015, 2014, and 2013 the Company expensed approximately $9.2 million, $9.2 million and $5.6 million of compensation expense related to restricted stock, respectively. As of December 31, 2015, there was approximately $8.4 million of total unrecognized compensation costs related to restricted stock. These costs are expected to be recognized over a weighted average period of 1.77 years.

The following table summarizes the activities for the Company’s unvested restricted stock for the years ended December 31, 2015, 2014, and 2013:

 

		Unvested Restricted Stock Awards
		Restricted Stock Awards				Weighted Average Grant  Date Fair Value
Unvested at December 31, 2012			899,789			$	10.73
Granted			607,001			$	12.72
Vested			(440,629	)		$	10.59
Forfeited			(30,264	)		$	11.24
Unvested at December 31, 2013			1,035,897			$	11.94
Granted			989,883			$	13.82
Vested			(570,723	)		$	12.00
Forfeited			(152,277	)		$	12.82
Unvested at December 31, 2014			1,302,780			$	13.23
Granted			676,340			$	13.67
Vested			(816,484	)		$	13.26
Forfeited			(312,564	)		$	13.16
Unvested at December 31, 2015			850,072			$	13.59

The SEC, through an exemptive order granted on June 22, 2010, approved amendments to the Plans which allow participants to elect to have the Company withhold shares of the Company’s common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”). The exemptive order also permits the holders of restricted stock to elect to have the Company withhold shares of the Company’s stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual can make a cash payment at the time of option exercise or to pay taxes on restricted stock.

 

F-75

---

Table of Contents

Index to Financial Statements

The following table summarizes the common stock options activities under the Company’s 2006 and 2004 Plans for each of the three periods ended December 31 2015, 2014, and 2013:

 

		Common Stock Options				Weighted Average Exercise Price
Shares Outstanding at December 31, 2012			2,574,749			$	12.00
Granted			443,500			$	14.51
Exercised			(2,003,988	)		$	12.38
Forfeited			(115,338	)		$	10.38
Expired			(65,000	)		$	13.30
Shares Outstanding at December 31, 2013			833,923			$	12.53
Granted			426,000			$	15.54
Exercised			(353,547	)		$	10.76
Forfeited			(208,344	)		$	14.80
Expired			(2,360	)		$	13.78
Shares Outstanding at December 31, 2014			695,672			$	14.58
Granted			163,500			$	12.68
Exercised			(36,331	)		$	10.81
Forfeited			(190,006	)		$	14.83
Expired			(10,664	)		$	13.21
Shares Outstanding at December 31, 2015			622,171			$	14.25
Shares Expected to Vest at December 31, 2015			471,057			$	14.25

The following table summarizes stock options outstanding and exercisable at December 31, 2015:

 

(Dollars in thousands, except exercise price)		Options outstanding																Options exercisable
Range of exercise prices		Number of shares				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value				Weighted Average Exercise Price				Number of shares				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value				Weighted Average Exercise Price
$9.25 - $14.02			213,644				6.36			$	151,114			$	12.06				59,643				3.81			$	86,279			$	10.76
$14.60 - $16.34			408,527				5.44				—			$	15.40				230,874				5.11				—			$	15.36
$9.25 - $16.34			622,171				5.76			$	151,114			$	14.25				290,517				4.84			$	86,279			$	14.42

Options generally vest 33% one year after the date of grant and ratably over the succeeding 24 months. All options may be exercised for a period ending seven years after the date of grant. At December 31, 2015, options for approximately 290,517 shares were exercisable at a weighted average exercise price of approximately $14.42 per share with weighted average of remaining contractual term of 4.84 years.

The Company determined that the fair value of options granted under the 2006 and 2004 Plans during the years ended December 31, 2015, 2014, and 2013 was approximately $57,000, $211,000 and $1.1 million, respectively. During the years ended December 31, 2015, 2014, and 2013, approximately $265,000, $395,000 and $422,000, of share-based cost due to stock option grants was expensed, respectively. As of December 31, 2015, there was $232,000 of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 1.25 years.

The fair value of options granted is based upon a Black Scholes option pricing model using the assumptions in the following table for each of the three periods ended December 31, 2015, 2014, and 2013 is as follows:

 

		Year Ended December 31,
		2015				2014				2013
Expected Volatility			18.94	%			19.90	%			46.90	%
Expected Dividends			10	%			10	%			10	%
Expected term (in years)			4.5				4.5				4.5
Risk-free rate			1.08% - 1.70	%			1.21% - 1.66	%			0.56% - 1.63	%

 

F-76

---

Table of Contents

Index to Financial Statements

8. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:

 

		Year Ended December 31,
(in thousands, except per share data)		2015				2014				2013
Numerator
Net increase in net assets resulting from operations		$	42,916			$	71,188			$	99,446
Less: Dividends declared-common and restricted shares			(87,438	)			(78,562	)			(66,454	)
Undistributed earnings			(44,522	)			(7,374	)			32,992
Undistributed earnings-common shares			(44,522	)			(7,374	)			32,992
Add: Dividend declared-common shares			85,959				76,953				65,123
Numerator for basic and diluted change in net assets per common share		$	41,437			$	69,579			$	98,115
Denominator
Basic weighted average common shares outstanding			69,479				61,862				58,838
Common shares issuable			184				1,363				1,454
Weighted average common shares outstanding assuming dilution			69,663				63,225				60,292
Change in net assets per common share
Basic		$	0.60			$	1.12			$	1.67
Diluted		$	0.59			$	1.10			$	1.63

In the table above, unvested share-based payment awards that have non-forfeitable rights to dividends or dividend equivalents are treated as participating securities for calculating earnings per share.

For the purpose of calculating diluted earnings per share for year ended December 31, 2015, the dilutive effect of the Convertible Senior Notes under the treasury stock method is included in this calculation because the Company’s share price was greater than the conversion price in effect ($11.03 as of December 31, 2015 and $11.36 as of December 31, 2014) for the Convertible Senior Notes for such period.

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti-dilutive shares. For the years ended December 31, 2015, 2014, and 2013, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, was approximately 627,483, 727,733 and 1,835,880 shares, respectively.

Effective as of April 6, 2015, the Company amended its charter to increase the number of shares of common stock it is authorized to issue from 100 million to 200 million. The Company effected the increase in authorized shares by filing Articles of Amendment with the State Department of Assessments and Taxation of Maryland. At December 31, 2015, the Company was authorized to issue 200 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

 

F-77

---

Table of Contents

Index to Financial Statements

9. Financial Highlights

Following is a schedule of financial highlights for the three years ended December 31, 2015.

 

		Year Ended December 31,
		2015				2014				2013
Per share data(1):
Net asset value at beginning of period		$	10.18			$	10.51			$	9.75
Net investment income			1.06				1.16				1.24
Net realized gain on investments			0.07				0.32				0.25
Net unrealized appreciation (depreciation) on investments			(0.51	)			(0.33	)			0.20
Total from investment operations			0.62				1.15				1.69
Net increase (decrease) in net assets from capital share transactions(1)			0.26				(0.37	)			0.10
Distributions of net investment income(6)			(1.26	)			(1.27	)			(1.13	)
Stock-based compensation expense included in investment income(2)			0.14				0.16				0.10
Net asset value at end of period		$	9.94			$	10.18			$	10.51
Ratios and supplemental data:
Per share market value at end of period		$	12.19			$	14.88			$	16.40
Total return(3)			(9.70	%)			(1.75	%)			58.49	%
Shares outstanding at end of period			72,118				64,715				61,837
Weighted average number of common shares outstanding			69,479				61,862				58,838
Net assets at end of period		$	717,134			$	658,864			$	650,007
Ratio of total expense to average net assets(4)			11.55	%			10.97	%			11.06	%
Ratio of net investment income before investment gains and losses to average net assets(4)			10.15	%			10.94	%			12.12	%
Portfolio turnover rate(5)			46.34	%			56.15	%			56.05	%
Average debt outstanding		$	615,198			$	535,127			$	580,053
Weighted average debt per common share		$	8.85			$	8.65			$	9.86

 

(1)	All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date.

(2)	Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC 718, net investment income includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital.

(3)

The total return for the years ended December 31, 2015, 2014 and 2013 equals the change in the ending market value over the beginning of the period price per share plus dividends paid per share during the period, divided by the beginning price assuming the dividend is reinvested on the date of the distribution.

(4)	All ratios are calculated based on weighted average net assets for the relevant period.

(5)	The portfolio turnover rate for the years ended December 31, 2015, 2014 and 2013 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period.

(6)	Includes dividends on unvested shares.

10. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to the Company’s portfolio companies. A portion of these unfunded contractual commitments as of December 31, 2015 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the Company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At December 31, 2015, the Company had approximately $75.4 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones. In addition, the Company had approximately $40.5 million of unavailable commitments to portfolio companies due to milestone and other covenant restrictions.

 

F-78

---

Table of Contents

Index to Financial Statements

The Company also had approximately $86.0 million of non-binding term sheets outstanding at December 31, 2015. Non-binding outstanding term sheets are subject to completion of the Company’s due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. Not all non-binding term sheets are expected to close and do not necessarily represent the Company’s future cash requirements.

The fair value of the Company’s unfunded commitments are considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to a market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

Certain premises are leased under agreements which expire at various dates through March 2020. Total rent expense amounted to approximately $1.7 million, $1.6 million and $1.1 million, during the years ended December 31, 2015, 2014, and 2013, respectively. The following table shows the Company’s contractual obligations as of December 31, 2015:

 

		Payments due by period (in thousands)
Contractual Obligations(1)(2)		Total				Less than 1 year				1 - 3 years				3 - 5 years				After 5 years
Borrowings(3) (4)		$	600,386			$	17,522			$	129,300			$	211,564			$	242,000
Operating Lease Obligations(5)			4,843				1,624				2,924				295				—
Total		$	605,229			$	19,146			$	132,224			$	211,859			$	242,000

 

(1)	Excludes commitments to extend credit to the Company’s portfolio companies.

(2)	The Company also has a warrant participation agreement with Citigroup. See Note 4 to the Company’s consolidated financial statements.

(3)

Includes $190.2 million in borrowings under the SBA debentures, $110.4 million of the 2019 Notes, $103.0 million of the 2024 Notes, $129.3 million in aggregate principal amount of the 2021 Asset-Backed Notes, $17.5 million of the Convertible Senior Notes and $50.0 million in outstanding borrowings on the Wells Facility as of December 31, 2015.

(4)

Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding. The aggregate principal amount outstanding of the Convertible Senior Notes is $17.6 million less the remaining unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total remaining unaccreted discount for the Convertible Senior Notes was $82,000 at December 31, 2015.

(5)	Long-Term facility leases.

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

11. Indemnification

The Company has entered into indemnification agreements with its directors. The indemnification agreements are intended to provide the Company’s directors the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that the Company shall indemnify the director who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act.

The Company and its executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by the Company to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

 

F-79

---

Table of Contents

Index to Financial Statements

12. Concentrations of Credit Risk

The Company’s customers are primarily privately held companies and public companies which are active in the drug discovery and development, sustainable and renewable technology, internet consumer and business services, medical devices and equipment, software, drug delivery, information services, communications and networking, healthcare services, specialty pharmaceuticals, surgical devices, electronics and computer hardware, media/content/info, biotechnology tools, semiconductors, consumer and business products and diagnostic industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.

Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrant or other equity-related interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies.

For the years ended December 31, 2015 and December 31, 2014, the Company’s ten largest portfolio companies represented approximately 32.1% and 28.6% of the total fair value of the Company’s investments in portfolio companies, respectively. At December 31, 2015 and December 31, 2014, the Company had two and three investments, respectively, that represented 5% or more of the Company’s net assets. At December 31, 2015, the Company had four equity investments representing approximately 53.2% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. At December 31, 2014, the Company had three equity investments which represented approximately 61.5% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of such investments.

13. Selected Quarterly Data (Unaudited)

The following tables set forth certain quarterly financial information for each of the last eight quarters ended December 31, 2015. This information was derived from the Company’s unaudited consolidated financial statements. Results for any quarter are not necessarily indicative of results for the full year or for any further quarter.

 

		Quarter Ended
(in thousands, except per share data)		March 31, 2015				June 30, 2015				September 30, 2015				December 31, 2015
Total investment income		$	32,494			$	38,126			$	47,132			$	39,380
Net investment income before investment gains and losses			12,993				16,781				23,590				20,137
Net increase (decrease) in net assets resulting from operations			21,919				2,752				4,075				14,170
Change in net assets per common share (basic)		$	0.33			$	0.03			$	0.05			$	0.20
		Quarter Ended
		March 31, 2014				June 30, 2014				September 30, 2014				December 31, 2014
Total investment income		$	35,770			$	34,001			$	37,019			$	36,875
Net investment income before investment gains and losses			18,304				18,551				18,995				15,899
Net increase (decrease) in net assets resulting from operations			22,185				13,191				15,177				20,635
Change in net assets per common share (basic)		$	0.36			$	0.21			$	0.24			$	0.32

14. Subsequent Events

Dividend Declaration

On February 17, 2016 the Board of Directors declared a cash dividend of $0.31 per share to be paid on March 14, 2016 to shareholders of record as of March 7, 2016. This dividend would represent the Company’s forty-second consecutive dividend declaration since the Company’s initial public offering, bringing the total cumulative dividend declared to date to $11.54 per share.

 

F-80

---

Table of Contents

Index to Financial Statements

Corporate Rebranding

On February 25, 2016, the Company changed its name to “Hercules Capital, Inc.”, from “Hercules Technology Growth Capital, Inc.” The Company will continue to trade on the New York Stock Exchange under the “HTGC” ticker symbol.

Share Repurchase Program

On February 24, 2015, the Board of Directors approved a $50.0 million open market share repurchase program and on February 17, 2016, the Board of Directors extended the program until August 23, 2016. The Company may repurchase shares of its common stock in the open market, including block purchases, at prices that may be above or below the net asset value as reported in our then most recently published financial statements. The Company expects that the share repurchase program will be in effect until August 23, 2016, or until the approved dollar amount has been used to repurchase shares. Subsequent to December 31, 2015 and as of February 22, 2016, the Company repurchased 449,588 shares of its common stock at an average price per share of $10.64 per share and a total cost of approximately $4.8 million. As of February 22, 2016, approximately $40.6 million of common stock remains eligible for repurchase under the stock repurchase plan.

Restricted Stock Award Grants

In January 2016, the Company granted approximately 536,250 restricted stock awards pursuant to the Plans.

Portfolio Company Developments

As of February 22, 2016, the Company held warrants or equity positions in three companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings. All three companies filed confidentially under the Jumpstart Our Business Startups Act of 2012. There can be no assurance that these companies will complete their initial public offerings in a timely manner or at all.

 

F-81

---

Table of Contents

Index to Financial Statements

Schedule 12-14

HERCULES CAPITAL, INC.

(FORMERLY HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)

SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of and for the year ended December 31, 2015

(in thousands)

 

Portfolio Company		Investment(1)		Amount of Interest Credited to Income(2)				As of December 31, 2014 Fair Value(5)				Gross Additions(3)				Gross Reductions(4)				As of December 31, 2015 Fair Value
Affiliate Investments
Optiscan BioMedical, Corp.		Preferred Stock		$	—			$	5,853			$	808			$	—			$	6,661
		Preferred Warrants			—				219				93				—				312
Stion Corporation		Senior Debt			347				1,600				—				(587	)			1,013
Total Control and Affiliate Investments				$	347			$	7,672			$	901			$	(587	)		$	7,986

 

(1)	Stock and warrants are generally non-income producing and restricted. The principal amount for debt is shown in the Consolidated Schedule of Investments as of December 31, 2015.

(2)	Represents the total amount of interest or dividends credited to income for the year an investment was an affiliate or control investment.

(3)

Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation.

(4)

Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation.

(5)

Note that as of December 31, 2014, Gelesis was classified as an affiliate investment on Consolidated Statement of Assets and Liabilities. During the year ended December 31, 2015, changes to the capitalization structure of the portfolio company occurred that reduced the Company’s investment below the threshold for classification as an affiliate investment. As such the investment has been removed from this disclosure.

 

F-82

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(unaudited)

(dollars in thousands, except per share data)

 

		March 31, 2016				December 31, 2015
Assets
Investments:
Non-control/Non-affiliate investments:
Debt investments (cost of $1,239,601 and $1,150,103, respectively)		$	1,204,136			$	1,109,196
Equity investments (cost of $51,208 and $50,305, respectively)			55,837				60,781
Warrant investments (cost of $39,789 and $38,131, respectively)			23,240				22,675
Total Non-control/Non-affiliate investments (cost of $1,330,598 and $1,238,539, respectively)			1,283,213				1,192,652
Affiliate investments:
Debt investments (cost of $2,185 and $2,200, respectively)			1,537				1,013
Equity investments (cost of $8,912 and $8,912, respectively)			6,304				6,661
Warrant investments (cost of $2,630 and $2,630, respectively)			256				312
Total Affiliate investments (cost of $13,727 and $13,742, respectively)			8,097				7,986
Total investments, at value (cost of $1,344,325 and $1,252,281, respectively)			1,291,310				1,200,638
Cash and cash equivalents			13,478				95,196
Restricted cash			3,646				9,191
Interest receivable			10,993				9,239
Other assets			12,388				9,720
Total assets		$	1,331,815			$	1,323,984
Liabilities
Accounts payable and accrued liabilities		$	12,086			$	17,241
Long-Term Liabilities (Convertible Senior Notes), net (principal of $17,604 and $17,604, respectively)(1)			17,572				17,478
Wells Facility			61,003				50,000
2021 Asset-Backed Notes, net (principal of $129,300 and $129,300, respectively)(1)			127,227				126,995
2019 Notes, net (principal of $110,364 and $110,364, respectively)(1)			108,339				108,179
2024 Notes, net (principal of $103,000 and $103,000, respectively)(1)			100,211				100,128
Long-Term SBA Debentures, net (principal of $190,200 and $190,200, respectively)(1)			186,997				186,829
Total liabilities		$	613,435			$	606,850
Net assets consist of:
Common stock, par value			74				73
Capital in excess of par value			761,565				752,244
Unrealized depreciation on investments(2)			(54,142	)			(52,808	)
Accumulated realized gains on investments			23,525				27,993
Undistributed net investment income (Distributions in excess of net investment income)			(12,642	)			(10,368	)
Total net assets		$	718,380			$	717,134
Total liabilities and net assets		$	1,331,815			$	1,323,984
Shares of common stock outstanding ($0.001 par value, 200,000,000 and 100,000,000 authorized, respectively)			73,230				72,118
Net asset value per share		$	9.81			$	9.94

 

(1)

The Company’s SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes, as each term is defined herein, are presented net of the associated debt issuance costs for each instrument. See “Note 2—Summary of Significant Accounting Policies” and “Note 4 – Borrowings”.

(2)	Amounts include $1.1 million and $1.2 million, respectively, in net unrealized depreciation on other assets and accrued liabilities, including escrow receivables, estimated taxes payable and Citigroup warrant participation agreement liabilities.

See notes to consolidated financial statements.

 

F-83

---

Table of Contents

Index to Financial Statements

The following table presents the assets and liabilities of our consolidated securitization trust for the 2021 Asset-Backed Notes (see Note 4), which is a variable interest entity (“VIE”). The assets of our securitization VIE can only be used to settle obligations of our consolidated securitization VIE, these liabilities are only the obligations of our consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statement of Assets and Liabilities above.

 

(Dollars in thousands)		March 31, 2016				December 31, 2015
Assets
Restricted Cash		$	3,646			$	9,191
Total investments, at value (cost of $265,038 and $258,748, respectively)			264,469				257,657
Total assets		$	268,115			$	266,848
Liabilities
2021 Asset-Backed Notes, net (principal of $129,300 and $129,300, respectively)(1)		$	127,227			$	126,995
Total liabilities		$	127,227			$	126,995

 

(1)	The Company’s SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes, as each term is defined herein, are presented net of the associated debt issuance costs for each instrument. See “Note 2—Summary of Significant Accounting Policies” and “Note 4—Borrowings”.

 

 

See notes to consolidated financial statements.

 

F-84

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENT OF OPERATIONS

(unaudited)

(in thousands, except per share data)

 

		Three Months Ended March 31,
		2016				2015
Investment income:
Interest income
Non-control/Non-affiliate investments		$	36,409			$	30,459
Affiliate investments			65				100
Total interest income			36,474				30,559
Fees
Non-control/Non-affiliate investments			2,465				1,934
Affiliate investments			—				1
Total fees			2,465				1,935
Total investment income			38,939				32,494
Operating expenses:
Interest			7,018				7,854
Loan fees			988				1,513
General and administrative			3,580				3,618
Employee compensation:
Compensation and benefits			4,685				3,796
Stock-based compensation			2,571				2,719
Total employee compensation			7,256				6,515
Total operating expenses			18,842				19,500
Loss on debt extinguishment (Long-Term Liabilities—Convertible Senior Notes)			—				(1	)
Net investment income			20,097				12,993
Net realized gain (loss) on investments
Non-control/Non-affiliate investments			(4,468	)			3,312
Total net realized gain (loss) on investments			(4,468	)			3,312
Net change in unrealized appreciation (depreciation) on investments
Non-control/Non-affiliate investments			(1,460	)			3,301
Affiliate investments			126				2,313
Total net unrealized appreciation (depreciation) on investments			(1,334	)			5,614
Total net realized and unrealized gain (loss)			(5,802	)			8,926
Net increase in net assets resulting from operations		$	14,295			$	21,919
Net investment income before investment gains and losses per common share:
Basic		$	0.28			$	0.20
Change in net assets resulting from operations per common share:
Basic		$	0.20			$	0.33
Diluted		$	0.20			$	0.33
Weighted average shares outstanding
Basic			71,172				63,783
Diluted			71,199				64,163
Dividends declared per common share:
Basic		$	0.31			$	0.31

See notes to consolidated financial statements.

 

F-85

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS

(unaudited)

(dollars and shares in thousands)

 

		Common Stock								Capital in excess of par value				Unrealized Appreciation (Depreciation) on Investments				Accumulated Realized Gains (Losses) on Investments				Undistributed Net Investment Income/ (Distributions in Excess of Investment Income)				Provision for Income Taxes on Investment Gains				Net Assets
		Shares				Par Value
Balance at December 31, 2014			64,715			$	65			$	657,233			$	(17,076	)		$	14,079			$	4,905			$	(342	)		$	658,864
Net increase (decrease) in net assets resulting from operations			—				—				—				5,614				3,312				12,993				—				21,919
Public offering, net of offering expenses			7,591				8				100,084				—				—				—				—				100,092
Issuance of common stock due to stock option exercises			34				—				406				—				—				—				—				406
Retired shares from net issuance			(27	)			—				(401	)			—				—				—				—				(401	)
Issuance of common stock under restricted stock plan			580				—				—				—				—				—				—				—
Retired shares for restricted stock vesting			(42	)			—				(591	)			—				—				—				—				(591	)
Issuance of common stock as stock dividend			40				—				562				—				—				—				—				562
Dividends distributed			—				—				—				—				—				(20,266	)			—				(20,266	)
Stock-based compensation			—				—				2,741				—				—				—				—				2,741
Balance at March 31, 2015			72,891			$	73			$	760,034			$	(11,462	)		$	17,391			$	(2,368	)		$	(342	)		$	763,326
Balance at December 31, 2015			72,118			$	73			$	752,244			$	(52,808	)		$	27,993			$	(10,026	)		$	(342	)		$	717,134
Net increase (decrease) in net assets resulting from operations			—				—				—				(1,334	)			(4,468	)			20,097				—				14,295
Public offering, net of offering expenses			1,109				1				12,403				—				—				—				—				12,404
Acquisition of common stock under repurchase plan			(449	)			—				(4,789	)			—				—				—				—				(4,789	)
Issuance of common stock under restricted stock plan			538				—				—				—				—				—				—				—
Retired shares for restricted stock vesting			(129	)			—				(1,385	)			—				—				—				—				(1,385	)
Issuance of common stock as stock dividend			43				—				496				—				—				—				—				496
Dividends distributed			—				—				—				—				—				(22,371	)			—				(22,371	)
Stock-based compensation			—				—				2,596				—				—				—				—				2,596
Balance at March 31, 2016			73,230			$	74			$	761,565			$	(54,142	)		$	23,525			$	(12,300	)		$	(342	)		$	718,380

 

See notes to consolidated financial statements.

 

F-86

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

(unaudited)

(dollars in thousands)

 

		For the Three Months Ended March 31,
		2016				2015
Cash flows from operating activities:
Net increase in net assets resulting from operations		$	14,295			$	21,919
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchase of investments			(170,921	)			(209,387	)
Principal and fee payments received on investments			77,808				75,368
Proceeds from the sale of investments			4,636				7,001
Net unrealized depreciation (appreciation) on investments			1,334				(5,614	)
Net realized loss (gain) on investments			4,468				(3,312	)
Accretion of paid-in-kind principal			(1,535	)			(665	)
Accretion of loan discounts			(1,863	)			(1,356	)
Accretion of loan discount on Convertible Senior Notes			61				62
Loss on debt extinguishment (Long-Term Liabilities—Convertible Senior Notes)			—				1
Payment of loan discount on Convertible Senior Notes			—				(2	)
Accretion of loan exit fees			(5,231	)			(2,767	)
Change in deferred loan origination revenue			655				1,540
Unearned fees related to unfunded commitments			(87	)			527
Amortization of debt fees and issuance costs			785				1,288
Depreciation			56				58
Stock-based compensation and amortization of restricted stock grants			2,596				2,741
Change in operating assets and liabilities:
Interest and fees receivable			(1,753	)			351
Prepaid expenses and other assets			(2,540	)			2,674
Accounts payable			(88	)			(504	)
Accrued liabilities			(5,029	)			(3,978	)
Net cash used in operating activities			(82,353	)			(114,055	)
Cash flows from investing activities:
Purchases of capital equipment			(127	)			(42	)
Reduction of (investments in) restricted cash			5,545				(9,289	)
Net cash provided by (used in) investing activities			5,418				(9,331	)
Cash flows from financing activities:
Issuance of common stock, net			12,404				100,092
Repurchase of common stock, net			(4,789	)			—
Retirement of employee shares			(1,385	)			(586	)
Dividends paid			(21,875	)			(19,704	)
Repayments of 2017 Asset-Backed Notes			—				(11,846	)
Borrowings of credit facilities			106,666				—
Repayments of credit facilities			(95,663	)			—
Cash paid for redemption of Convertible Senior Notes			—				(30	)
Fees paid for credit facilities and debentures			(141	)			100
Net cash provided by (used in) financing activities			(4,783	)			68,026
Net decrease in cash and cash equivalents			(81,718	)			(55,360	)
Cash and cash equivalents at beginning of period			95,196				227,116
Cash and cash equivalents at end of period		$	13,478			$	171,756
Supplemental non-cash investing and financing activities:
Dividends Reinvested		$	496			$	562

See notes to consolidated financial statements.

 

F-87

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Debt Investments
Biotechnology Tools
1-5 Years Maturity
Exicure, Inc.(11)(13)		Biotechnology Tools		Senior Secured		September 2019		Interest rate PRIME + 6.45% or Floor rate of 9.95%		$	6,000			$	5,862			$	5,862
Subtotal: 1-5 Years Maturity															5,862				5,862
Subtotal: Biotechnology Tools (0.82%)*															5,862				5,862
Communications & Networking
1-5 Years Maturity
Avanti Communications Group(4)(9)		Communications & Networking		Senior Secured		October 2019		Interest rate FIXED 10.00%		$	7,500				6,693				5,475
OpenPeak, Inc.(7)		Communications & Networking		Senior Secured		April 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	12,370				9,134				4,379
SkyCross, Inc.(7)(12)(13)(14)		Communications & Networking		Senior Secured		January 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%, PIK Interest 5.00%		$	19,674				20,529				7,050
Spring Mobile Solutions, Inc.(13)		Communications & Networking		Senior Secured		January 2019		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	3,000				2,959				2,959
Subtotal: 1-5 Years Maturity															39,315				19,863
Subtotal: Communications & Networking (2.76%)*															39,315				19,863
Consumer & Business Products
Under 1 Year Maturity
Antenna79 (p.k.a. Pong Research Corporation)(14)		Consumer & Business Products		Senior Secured		June 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	158				158				158
Miles, Inc. (p.k.a. Fluc, Inc.)(8)		Consumer & Business Products		Convertible Debt		March 2017		Interest rate FIXED 4.00%		$	100				100				—
Subtotal: Under 1 Year Maturity															258				158
1-5 Years Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(13)(14)		Consumer & Business Products		Senior Secured		December 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.50%		$	4,433				4,359				4,359
Nasty Gal(13)(14)		Consumer & Business Products		Senior Secured		May 2019		Interest rate PRIME + 5.45% or Floor rate of 8.95%		$	15,000				14,996				14,723
Second Time Around (Simplify Holdings, LLC)(13)(14)		Consumer & Business Products		Senior Secured		February 2019		Interest rate PRIME + 7.25% or Floor rate of 10.75%		$	2,500				2,477				2,477
Subtotal: 1-5 Years Maturity															21,832				21,559
Subtotal: Consumer & Business Products (3.02%)*															22,090				21,717

 

See notes to consolidated financial statements.

 

F-88

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Drug Delivery
1-5 Years Maturity
AcelRx Pharmaceuticals, Inc.(9)(10)(13)(14)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 3.85% or Floor rate of 9.10%		$	20,466			$	20,914			$	20,892
Agile Therapeutics, Inc.(10)(13)		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 4.75% or Floor rate of 9.00%		$	16,500				16,347				16,304
BIND Therapeutics, Inc.(13)(14)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 5.10% or Floor rate of 8.35%		$	13,691				13,919				13,754
BioQ Pharma Incorporated(10)(13)		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	10,000				10,237				10,174
		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 7.00% or Floor rate of 10.50%		$	3,000				2,983				2,983
Total BioQ Pharma Incorporated										$	13,000				13,220				13,157
Celator Pharmaceuticals, Inc.(10)(13)		Drug Delivery		Senior Secured		June 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	13,276				13,349				13,510
Celsion Corporation(10)(13)		Drug Delivery		Senior Secured		June 2017		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	5,364				5,575				5,603
Dance Biopharm, Inc.(13)(14)		Drug Delivery		Senior Secured		November 2017		Interest rate PRIME + 7.40% or Floor rate of 10.65%		$	2,384				2,475				1,380
Edge Therapeutics, Inc.(10)(13)		Drug Delivery		Senior Secured		March 2018		Interest rate PRIME + 5.45% or Floor rate of 9.95%		$	4,919				4,915				4,942
Egalet Corporation(11)(13)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.15% or Floor rate of 9.40%		$	15,000				15,059				15,170
Neos Therapeutics, Inc.(10)(13)(14)		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 9.00%		$	10,000				10,000				10,063
		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 10.50%		$	10,000				10,109				10,123
		Drug Delivery		Senior Secured		October 2017		Interest rate FIXED 9.00%		$	5,000				5,017				5,027
Total Neos Therapeutics, Inc.										$	25,000				25,126				25,213
Pulmatrix Inc.(8)(10)(13)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	7,000				6,924				6,935
ZP Opco, Inc (p.k.a. Zosano Pharma)(10)(13)		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 2.70% or Floor rate of 7.95%		$	15,000				14,996				14,936
Subtotal: 1-5 Years Maturity															152,819				151,796
Subtotal: Drug Delivery (21.13%)*															152,819				151,796
Drug Discovery & Development
1-5 Years Maturity
Aveo Pharmaceuticals, Inc.(9)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 6.65% or Floor rate of 11.90%		$	10,000				10,149				10,067
Bellicum Pharmaceuticals, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		March 2020		Interest rate PRIME + 5.85% or Floor rate of 9.35%		$	15,000				14,893				14,893

 

See notes to consolidated financial statements.

 

F-89

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Brickell Biotech, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		September 2019		Interest rate PRIME + 5.70% or Floor rate of 9.20%		$	7,500			$	7,321			$	7,321
Cerecor, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		August 2017		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	4,884				4,928				4,980
Cerulean Pharma, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		July 2018		Interest rate PRIME + 1.55% or Floor rate of 7.30%		$	19,072				19,432				19,454
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(10)(13)		Drug Discovery & Development		Senior Secured		December 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%		$	25,000				25,607				25,778
CytRx Corporation(10)(13)(14)		Drug Discovery & Development		Senior Secured		February 2020		Interest rate PRIME + 6.00% or Floor rate of 9.50%		$	25,000				24,436				24,436
Epirus Biopharmaceuticals, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		April 2018		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	15,000				14,944				15,061
Genocea Biosciences, Inc.(10)(13)		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 2.25% or Floor rate of 7.25%		$	17,000				17,081				17,147
Immune Pharmaceuticals(10)(13)		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 4.75% or Floor rate of 10.00%		$	4,500				4,429				4,388
Insmed, Incorporated(10)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 4.75% or Floor rate of 9.25%		$	25,000				24,776				24,764
Mast Therapeutics, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 5.70% or Floor rate of 8.95%		$	15,000				14,890				14,920
Melinta Therapeutics(11)(13)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 3.75% or Floor rate of 8.25%		$	30,000				30,010				30,013
Merrimack Pharmaceuticals, Inc.(9)		Drug Discovery & Development		Senior Secured		December 2022		Interest rate FIXED 11.50%		$	25,000				25,000				25,000
Neothetics, Inc. (p.k.a. Lithera, Inc)(13)(14)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	4,000				4,132				4,137
Neuralstem, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		April 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	7,235				7,364				7,341
Paratek Pharmaceuticals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(13)(14)		Drug Discovery & Development		Senior Secured		September 2020		Interest rate PRIME + 2.75% or Floor rate of 8.50%		$	20,000				19,893				19,890
uniQure B.V.(4)(9)(10)(13)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.00% or Floor rate of 10.25%		$	20,000				20,002				20,053
XOMA Corporation(9)(13)(14)		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 2.15% or Floor rate of 9.40%		$	20,000				20,129				20,067
Subtotal: 1-5 Years Maturity															309,416				309,710
Subtotal: Drug Discovery & Development (43.11%)*															309,416				309,710

 

See notes to consolidated financial statements.

 

F-90

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Electronics & Computer Hardware
1-5 Years Maturity
Persimmon Technologies(11)(13)		Electronics & Computer Hardware		Senior Secured		June 2019		Interest rate PRIME + 7.50% or Floor rate of 11.00%		$	7,000			$	6,928			$	6,855
Subtotal: 1-5 Years Maturity															6,928				6,855
Subtotal: Electronics & Computer Hardware (0.95%)*															6,928				6,855
Healthcare Services, Other
1-5 Years Maturity
Chromadex Corporation(13)(14)		Healthcare Services, Other		Senior Secured		April 2018		Interest rate PRIME + 6.10% or Floor rate of 9.35%		$	5,000				4,952				4,977
InstaMed Communications, LLC(13)(14)		Healthcare Services, Other		Senior Secured		February 2019		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	10,000				10,127				10,111
Subtotal: 1-5 Years Maturity															15,079				15,088
Subtotal: Healthcare Services, Other (2.10%)*															15,079				15,088
Information Services
Under 1 Year Maturity
InXpo, Inc.(13)(14)		Information Services		Senior Secured		October 2016		Interest rate PRIME + 7.50% or Floor rate of 10.75%		$	1,247				1,304				1,304
Subtotal: Under 1 Year Maturity															1,304				1,304
Subtotal: Information Services (0.18%)*															1,304				1,304
Internet Consumer & Business Services
Under 1 Year Maturity
NetPlenish(7)(8)(14)		Internet Consumer & Business Services		Convertible Debt		September 2016		Interest rate FIXED 10.00%		$	381				373				—
		Internet Consumer & Business Services		Senior Secured		April 2016		Interest rate FIXED 10.00%		$	44				44				—
Total NetPlenish										$	425				417				—
Subtotal: Under 1 Year Maturity															417				—
1-5 Years Maturity
Aria Systems, Inc.(10)(12)		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 3.20% or Floor rate of 6.95%, PIK Interest 1.95%		$	2,031				2,008				1,983
		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 5.20% or Floor rate of 8.95%, PIK Interest 1.95%		$	18,191				17,962				17,767
Total Aria Systems, Inc.										$	20,222				19,970				19,750
CloudOne, Inc.(13)		Internet Consumer & Business Services		Senior Secured		April 2019		Interest rate PRIME + 6.35% or Floor rate of 9.85%		$	5,000				4,927				4,927

 

See notes to consolidated financial statements.

 

F-91

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
LogicSource(13)(14)		Internet Consumer & Business Services		Senior Secured		October 2019		Interest rate PRIME + 6.25% or Floor rate of 9.75%		$	8,500				$  8,371			$	8,371
One Planet Ops Inc. (p.k.a. Reply! Inc.)		Internet Consumer & Business Services		Senior Secured		March 2019		Interest rate PRIME + 4.25% or Floor rate of 7.50%		$	6,168				5,725				5,262
ReachLocal(13)		Internet Consumer & Business Services		Senior Secured		April 2018		Interest rate PRIME + 8.50% or Floor rate of 11.75%		$	25,000				25,147				25,007
Tapjoy, Inc.(11)(13)		Internet Consumer & Business Services		Senior Secured		July 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	20,000				19,653				19,555
Tectura Corporation(7)(12)(15)		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	6,468				6,468				5,175
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%		$	7,670				7,670				6,136
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	563				563				450
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	5,000				5,000				4,000
Total Tectura Corporation										$	19,701				19,701				15,761
Subtotal: 1-5 Years Maturity															103,494				98,633
Subtotal: Internet Consumer & Business Services (13.73%)*															103,911				98,633
Media/Content/Info
1-5 Years Maturity
Machine Zone, Inc.(12)		Media/Content/ Info		Senior Secured		May 2018		Interest rate PRIME + 2.50% or Floor rate of 6.75%, PIK Interest 3.00%		$	101,437				99,395				98,647
WP Technology, Inc. (Wattpad, Inc.)(4)(9)(13)		Media/Content/ Info		Senior Secured		April 2020		Interest rate PRIME + 4.75% or Floor rate of 8.25%		$	5,000				4,943				4,943
Subtotal: 1-5 Years Maturity															104,338				103,590
Subtotal: Media/Content/Info (14.42%)*															104,338				103,590
Medical Devices & Equipment
Under 1 Year Maturity
InspireMD, Inc.(4)(9)(13)		Medical Devices & Equipment		Senior Secured		February 2017		Interest rate PRIME + 5.00% or Floor rate of 10.50%		$	3,992				4,412				3,730
Optiscan Biomedical, Corp.(5)(8)(14)		Medical Devices & Equipment		Convertible Debt		December 2016		Interest Rate FIXED 8.00%		$	431				431				431
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)(13)		Medical Devices & Equipment		Senior Secured		April 2016		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	73				481				481
Subtotal: Under 1 Year Maturity															5,324				4,642

 

See notes to consolidated financial statements.

 

F-92

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
1-5 Years Maturity
Amedica Corporation(8)(13)(14)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 9.20% or Floor rate of 12.45%		$	15,218			$	16,015			$	15,753
Aspire Bariatrics, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		October 2018		Interest rate PRIME + 4.00% or Floor rate of 9.25%		$	7,000				6,860				6,827
Avedro, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		June 2018		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	11,761				11,688				11,675
Flowonix Medical Incorporated(11)(13)		Medical Devices & Equipment		Senior Secured		May 2018		Interest rate PRIME + 4.75% or Floor rate of 10.00%		$	15,000				15,179				15,092
Gamma Medica, Inc.(10)(13)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	2,500				2,567				2,549
Micell Technologies, Inc.(11)(13)		Medical Devices & Equipment		Senior Secured		August 2019		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	8,500				8,253				8,253
Quanta Fluid Solutions(4)(9)(13)		Medical Devices & Equipment		Senior Secured		April 2020		Interest rate PRIME + 8.05% or Floor rate of 11.55%		$	12,500				12,351				12,351
Quanterix Corporation(10)(13)		Medical Devices & Equipment		Senior Secured		February 2018		Interest rate PRIME + 2.75% or Floor rate of 8.00%		$	12,661				12,757				12,707
SynergEyes, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	3,804				4,104				4,036
Subtotal: 1-5 Years Maturity															89,774				89,243
Subtotal: Medical Devices & Equipment (13.07%)*															95,098				93,885
Semiconductors
Under 1 Year Maturity
Achronix Semiconductor Corporation(14)		Semiconductors		Senior Secured		July 2016		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	4,260				4,260				4,260
Subtotal: Under 1 Year Maturity															4,260				4,260
1-5 Years Maturity
Achronix Semiconductor Corporation(13)(14)		Semiconductors		Senior Secured		July 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	4,710				4,787				4,728
Avnera Corporation(10)(13)		Semiconductors		Senior Secured		April 2018		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	7,500				7,527				7,596
Subtotal: 1-5 Years Maturity															12,314				12,324
Subtotal: Semiconductors (2.31%)*															16,574				16,584
Software
Under 1 Year Maturity
Clickfox, Inc.(14)(16)		Software		Senior Secured		March 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	2,600				2,600				2,600
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.) (12)(13)(14)		Software		Senior Secured		October 2016		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	1,483				1,444				815
Message Systems, Inc.(14)		Software		Senior Secured		February 2017		Interest rate PRIME + 2.75% or Floor rate of 6.00%		$	318				318				318
Neos, Inc.(13)(14)		Software		Senior Secured		May 2016		Interest rate PRIME + 6.75% or Floor rate of 10.50%		$	446				616				616
Touchcommerce, Inc.(14)		Software		Senior Secured		August 2016		Interest rate PRIME + 2.25% or Floor rate of 6.50%		$	6,000				6,000				6,000
Subtotal: Under 1 Year Maturity															10,978				10,349

 

See notes to consolidated financial statements.

 

F-93

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
1-5 Years Maturity
Actifio, Inc.(12)(13)		Software		Senior Secured		January 2019		Interest rate PRIME + 4.25% or Floor rate of 8.25%, PIK Interest 2.25%		$	30,434				$30,216			$	29,898
		Software		Senior Secured		January 2019		Interest rate PRIME + 4.75% or Floor rate of 8.75%, PIK Interest 2.50%		$	10,000				9,533				9,533
Total Actifio, Inc.										$	40,434				39,749				39,431
Clickfox, Inc. (13)(14)		Software		Senior Secured		March 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	4,935				4,988				4,979
Druva, Inc.(10)(13)		Software		Senior Secured		March 2018		Interest rate PRIME + 4.60% or Floor rate of 7.85%		$	12,000				12,173				12,113
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.) (12)(13)(14)		Software		Senior Secured		March 2018		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	12,308				11,640				6,568
Message Systems, Inc.(14)		Software		Senior Secured		February 2019		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	17,500				17,141				16,960
OneLogin, Inc.(12)(14)		Software		Senior Secured		August 2019		Interest rate PRIME + 6.45% or Floor rate of 9.95%, PIK Interest 3.25%		$	13,033				12,880				12,880
RedSeal Inc.(13)(14)		Software		Senior Secured		June 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	5,000				5,038				4,992
Signpost, Inc.(12)(13)(14)		Software		Senior Secured		February 2020		Interest rate PRIME + 4.15% or Floor rate of 8.15%, PIK Interest 1.75%		$	15,035				14,609				14,609
Touchcommerce, Inc.(13)(14)		Software		Senior Secured		February 2018		Interest rate PRIME + 6.00% or Floor rate of 10.25%		$	12,000				11,957				11,872
Subtotal: 1-5 Years Maturity															130,175				124,404
Subtotal: Software (18.76%)*															141,153				134,753
Specialty Pharmaceuticals
Under 1 Year Maturity
Cranford Pharmaceuticals, LLC(14)		Specialty Pharmaceuticals		Senior Secured		August 2016		Interest rate LIBOR + 8.25% or Floor rate of 9.50%		$	1,100				1,100				1,100
Subtotal: Under 1 Year Maturity															1,100				1,100
1-5 Years Maturity
Alimera Sciences, Inc.(10)(13)		Specialty Pharmaceuticals		Senior Secured		May 2018		Interest rate PRIME + 7.65% or Floor rate of 10.90%		$	35,000				34,137				34,090
Cranford Pharmaceuticals, LLC(10)(12)(13)(14)		Specialty Pharmaceuticals		Senior Secured		August 2017		Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%		$	8,874				9,071				9,071
Jaguar Animal Health, Inc.(10)(13)		Specialty Pharmaceuticals		Senior Secured		August 2018		Interest rate PRIME + 5.65% or Floor rate of 9.90%		$	5,821				5,897				5,842
Subtotal: 1-5 Years Maturity															49,105				49,003
Subtotal: Specialty Pharmaceuticals (6.97%)*															50,205				50,103

 

See notes to consolidated financial statements.

 

F-94

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Surgical Devices
1-5 Years Maturity
Transmedics, Inc.(13)		Surgical Devices		Senior Secured		March 2019		Interest rate PRIME + 5.30% or Floor rate of 9.55%		$	8,500				$  8,491			$	8,428
Subtotal: 1-5 Years Maturity															8,491				8,428
Subtotal: Surgical Devices (1.17%)*															8,491				8,428
Sustainable and Renewable Technology
Under 1 Year Maturity
Agrivida, Inc.(13)(14)		Sustainable and Renewable Technology		Senior Secured		December 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	3,786				4,034				4,034
American Superconductor Corporation(10)(13)		Sustainable and Renewable Technology		Senior Secured		November 2016		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	2,667				3,135				3,135
Amyris, Inc.(9)(11)(13)		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	17,543				17,543				17,543
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	3,497				3,497				3,497
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	10,960				11,224				11,224
Total Amyris, Inc.										$	32,000				32,264				32,264
Modumetal, Inc.(11)(13)		Sustainable and Renewable Technology		Senior Secured		March 2017		Interest rate PRIME + 8.70% or Floor rate of 11.95%		$	1,429				1,805				1,805
Stion Corporation (5)(13)		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	1,754				1,754				1,106
Subtotal: Under 1 Year Maturity															42,992				42,344
1-5 Years Maturity
American Superconductor Corporation(10)(13)		Sustainable and Renewable Technology		Senior Secured		June 2017		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	1,500				1,509				1,500
Modumetal, Inc.(11)(13)		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	6,170				6,415				6,362
Proterra, Inc.(10)(13)		Sustainable and Renewable Technology		Senior Secured		December 2018		Interest rate PRIME + 6.95% or Floor rate of 10.20%		$	25,000				25,140				24,592
Rive Technology, Inc.(13)(14)		Sustainable and Renewable Technology		Senior Secured		January 2019		Interest rate PRIME + 6.20% or Floor rate of 9.45%		$	7,500				7,450				7,450
Sungevity, Inc.(11)(13)(14)		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	35,000				35,969				35,879

 

See notes to consolidated financial statements.

 

F-95

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	20,000			$	20,000			$	19,975
Total Sungevity, Inc.										$	55,000				55,969				55,854
Tendril Networks(11)(13)		Sustainable and Renewable Technology		Senior Secured		June 2019		Interest rate FIXED 7.25%		$	15,000				14,908				14,580
Verdezyne, Inc.(13)(14)		Sustainable and Renewable Technology		Senior Secured		April 2019		Interest rate PRIME + 8.25% or Floor rate of 11.75%		$	15,000				14,820				14,820
Subtotal: 1-5 Years Maturity															126,211				125,158
Subtotal: Sustainable and Renewable Technology (23.32%)*															169,203				167,502
Total Debt Investments (167.83%)*															1,241,786				1,205,673

 

See notes to consolidated financial statements.

 

F-96

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Equity Investments
Biotechnology Tools
NuGEN Technologies, Inc.(14)		Biotechnology Tools		Equity		Preferred Series C			189,394			$	500			$	538
Subtotal: Biotechnology Tools (0.07%)*													500				538
Communications & Networking
GlowPoint, Inc.(3)		Communications & Networking		Equity		Common Stock			114,192				102				45
Peerless Network, Inc.		Communications & Networking		Equity		Preferred Series A			1,000,000				1,000				4,304
Ping Identity Corporation		Communications & Networking		Equity		Preferred Series B			684,004				52				391
Subtotal: Communications & Networking (0.66%)*													1,154				4,740
Consumer & Business Products
Market Force Information, Inc.		Consumer & Business Products		Equity		Common Stock			480,261				—				192
		Consumer & Business Products		Equity		Preferred Series B-1			187,970				500				3
Total Market Force Information, Inc.									668,231				500				195
Subtotal: Consumer & Business Products (0.03%)*													500				195
Diagnostic
Singulex, Inc.		Diagnostic		Equity		Common Stock			937,998				750				60
Subtotal: Diagnostic (0.01%)*													750				60
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)		Drug Delivery		Equity		Common Stock			54,240				108				168
BioQ Pharma Incorporated(14)		Drug Delivery		Equity		Preferred Series D			165,000				500				650
Edge Therapeutics, Inc.(3)		Drug Delivery		Equity		Common Stock			157,190				1,000				1,438
Merrion Pharmaceuticals, Plc(3)(4)(9)		Drug Delivery		Equity		Common Stock			20,000				9				—
Neos Therapeutics, Inc.(3)(14)		Drug Delivery		Equity		Common Stock			125,000				1,500				1,349
Revance Therapeutics, Inc.(3)		Drug Delivery		Equity		Common Stock			22,765				557				397
Subtotal: Drug Delivery (0.56%)*													3,674				4,002
Drug Discovery & Development
Aveo Pharmaceuticals, Inc.(3)(9)(14)		Drug Discovery & Development		Equity		Common Stock			167,864				842				153
Cerecor, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			119,087				1,000				444
Cerulean Pharma, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			135,501				1,000				367
Dicerna Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Equity		Common Stock			142,858				1,000				766
Dynavax Technologies(3)(9)		Drug Discovery & Development		Equity		Common Stock			20,000				550				385
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			200,000				1,000				538
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			223,463				2,000				1,730
Inotek Pharmaceuticals Corporation(3)		Drug Discovery & Development		Equity		Common Stock			3,778				1,500				28
Insmed, Incorporated(3)		Drug Discovery & Development		Equity		Common Stock			70,771				1,000				897
Melinta Therapeutics		Drug Discovery & Development		Equity		Preferred Series 4			1,914,448				2,000				2,040

 

See notes to consolidated financial statements.

 

F-97

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)		Drug Discovery & Development		Equity		Common Stock			76,362			$	2,744			$	1,158
Subtotal: Drug Discovery & Development (1.18%)*													14,636				8,506
Electronics & Computer Hardware
Identiv, Inc.(3)		Electronics & Computer Hardware		Equity		Common Stock			6,700				34				14
Subtotal: Electronics & Computer Hardware (0.00%)*													34				14
Internet Consumer & Business Services
Blurb, Inc.(14)		Internet Consumer & Business Services		Equity		Preferred Series B			220,653				175				223
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Equity		Preferred Series C			230,030				250				254
		Internet Consumer & Business Services		Equity		Preferred Series D			198,677				250				241
Total Lightspeed POS, Inc.									428,707				500				495
Oportun (p.k.a. Progress Financial)		Internet Consumer & Business Services		Equity		Preferred Series G			218,351				250				374
		Internet Consumer & Business Services		Equity		Preferred Series H			87,802				250				245
Total Oportun (p.k.a. Progress Financial)									306,153				500				619
Philotic, Inc.		Internet Consumer & Business Services		Equity		Common Stock			9,023				93				—
RazorGator Interactive Group, Inc.		Internet Consumer & Business Services		Equity		Preferred Series AA			34,783				15				28
Subtotal: Internet Consumer & Business Services (0.19%)*													1,283				1,365
Medical Devices & Equipment
AtriCure, Inc.(3)(14)		Medical Devices & Equipment		Equity		Common Stock			7,536				266				116
Flowonix Medical Incorporated		Medical Devices & Equipment		Equity		Preferred Series E			221,893				1,500				1,913
Gelesis, Inc.(14)		Medical Devices & Equipment		Equity		Common Stock			198,202				—				815
		Medical Devices & Equipment		Equity		Preferred Series A-1			191,210				425				859
		Medical Devices & Equipment		Equity		Preferred Series A-2			191,626				500				823
Total Gelesis, Inc.									581,038				925				2,497
Medrobotics Corporation(14)		Medical Devices & Equipment		Equity		Preferred Series E			136,798				250				207
		Medical Devices & Equipment		Equity		Preferred Series F			73,971				155				192
		Medical Devices & Equipment		Equity		Preferred Series G			163,934				500				504
Total Medrobotics Corporation									374,703				905				903
Novasys Medical, Inc.		Medical Devices & Equipment		Equity		Preferred Series D-1			4,118,444				1,000				—
Optiscan Biomedical, Corp.(5)(14)		Medical Devices & Equipment		Equity		Preferred Series B			6,185,567				3,000				520
		Medical Devices & Equipment		Equity		Preferred Series C			1,927,309				655				156
		Medical Devices & Equipment		Equity		Preferred Series D			55,103,923				5,257				5,628
Total Optiscan Biomedical, Corp.									63,216,799				8,912				6,304

 

See notes to consolidated financial statements.

 

F-98

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Equity		Preferred Series 1			1,086,969			$	500			$	267
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.)		Medical Devices & Equipment		Equity		Preferred Series B			232,061				527				503
Quanterix Corporation		Medical Devices & Equipment		Equity		Preferred Series D			272,479				1,000				1,216
Subtotal: Medical Devices & Equipment (1.91%)*													15,535				13,719
Software
Box, Inc.(3)(14)		Software		Equity		Common Stock			1,287,347				5,654				15,532
CapLinked, Inc.		Software		Equity		Preferred Series A-3			53,614				50				82
Druva, Inc.		Software		Equity		Preferred Series 2			458,841				1,000				1,056
ForeScout Technologies, Inc.		Software		Equity		Preferred Series D			319,099				398				1,363
		Software		Equity		Preferred Series E			80,587				131				348
Total ForeScout Technologies, Inc.									399,686				529				1,711
HighRoads, Inc.		Software		Equity		Preferred Series B			190,170				307				—
NewVoiceMedia Limited(4)(9)		Software		Equity		Preferred Series E			669,173				963				699
WildTangent, Inc.(14)		Software		Equity		Preferred Series 3			100,000				402				171
Subtotal: Software (2.68%)*													8,905				19,251
Specialty Pharmaceuticals
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Equity		Preferred Series E			241,829				750				—
		Specialty Pharmaceuticals		Equity		Preferred Series E-1			26,955				—				—
		Specialty Pharmaceuticals		Equity		Preferred Series G			4,667,636				—				—
Total QuatRx Pharmaceuticals Company									4,936,420				750				—
Subtotal: Specialty Pharmaceuticals (0.00%)*													750				—
Surgical Devices
Gynesonics, Inc.(14)		Surgical Devices		Equity		Preferred Series B			219,298				250				26
		Surgical Devices		Equity		Preferred Series C			656,538				282				36
		Surgical Devices		Equity		Preferred Series D			1,991,157				712				602
		Surgical Devices		Equity		Preferred Series E			2,785,402				429				390
Total Gynesonics, Inc.									5,652,395				1,673				1,054
Transmedics, Inc.		Surgical Devices		Equity		Preferred Series B			88,961				1,100				105
		Surgical Devices		Equity		Preferred Series C			119,999				300				59
		Surgical Devices		Equity		Preferred Series D			260,000				650				427
		Surgical Devices		Equity		Preferred Series F			100,200				500				470
Total Transmedics, Inc.									569,160				2,550				1,061
Subtotal: Surgical Devices (0.29%)*													4,223				2,115
Sustainable and Renewable Technology
Glori Energy, Inc.(3)		Sustainable and Renewable Technology		Equity		Common Stock			18,208				165				4
Modumetal, Inc.		Sustainable and Renewable Technology		Equity		Preferred Series C			3,107,520				500				483
SCIEnergy, Inc.		Sustainable and Renewable Technology		Equity		Common Stock			19,250				761				—
Sungevity, Inc.(14)		Sustainable and Renewable Technology		Equity		Preferred Series D			68,807,339				6,750				7,149
Subtotal: Sustainable and Renewable Technology (1.06%)*													8,176				7,636
Total: Equity Investments (8.65%)*													60,120				62,141

 

See notes to consolidated financial statements.

 

F-99

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Warrant Investments
Biotechnology Tools
Exicure, Inc.		Biotechnology Tools		Warrant		Preferred Series C			104,348			$	107			$	109
Labcyte, Inc.(14)		Biotechnology Tools		Warrant		Preferred Series C			1,127,624				323				181
Subtotal: Biotechnology Tools (0.04%)*													430				290
Communications & Networking
Intelepeer, Inc.(14)		Communications & Networking		Warrant		Common Stock			117,958				102				—
OpenPeak, Inc.		Communications & Networking		Warrant		Common Stock			108,982				149				—
PeerApp, Inc.		Communications & Networking		Warrant		Preferred Series B			298,779				61				37
Peerless Network, Inc.		Communications & Networking		Warrant		Preferred Series A			135,000				95				360
SkyCross, Inc.(14)		Communications & Networking		Warrant		Preferred Series F			9,762,777				394				—
Spring Mobile Solutions, Inc.		Communications & Networking		Warrant		Preferred Series D			2,834,375				418				55
Subtotal: Communications & Networking (0.06%)*													1,219				452
Consumer & Business Products
Antenna79 (p.k.a. Pong Research Corporation)(14)		Consumer & Business Products		Warrant		Preferred Series A			1,662,441				228				—
Intelligent Beauty, Inc.(14)		Consumer & Business Products		Warrant		Preferred Series B			190,234				230				281
IronPlanet, Inc.		Consumer & Business Products		Warrant		Preferred Series D			1,155,821				1,076				805
Nasty Gal(14)		Consumer & Business Products		Warrant		Preferred Series C			845,194				23				18
The Neat Company(14)		Consumer & Business Products		Warrant		Preferred Series C-1			540,540				365				—
Subtotal: Consumer & Business Products (0.15%)*													1,922				1,104
Diagnostic
Navidea Biopharmaceuticals, Inc. (p.k.a. Neoprobe)(3)(14)		Diagnostic		Warrant		Common Stock			333,333				244				4
Subtotal: Diagnostic (0.00%)*													244				4
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)(14)		Drug Delivery		Warrant		Common Stock			176,730				785				154
Agile Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			180,274				730				204
BIND Therapeutics, Inc.(3)(14)		Drug Delivery		Warrant		Common Stock			152,586				488				5
BioQ Pharma Incorporated		Drug Delivery		Warrant		Common Stock			459,183				1				354
Celsion Corporation(3)		Drug Delivery		Warrant		Common Stock			194,986				428				10
Dance Biopharm, Inc.(14)		Drug Delivery		Warrant		Common Stock			43,813				74				—
Edge Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			78,595				390				228
Kaleo, Inc. (p.k.a. Intelliject, Inc.)		Drug Delivery		Warrant		Preferred Series B			82,500				594				877
Neos Therapeutics, Inc.(3)(14)		Drug Delivery		Warrant		Common Stock			70,833				285				122
Pulmatrix Inc.(3)		Drug Delivery		Warrant		Common Stock			25,150				116				2
ZP Opco, Inc (p.k.a. Zosano Pharma)(3)		Drug Delivery		Warrant		Common Stock			72,379				266				2
Subtotal: Drug Delivery (0.27%)*													4,157				1,958
Drug Discovery & Development
ADMA Biologics, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			89,750				295				123

 

See notes to consolidated financial statements.

 

F-100

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Anthera Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			40,178			$	984			$	—
Aveo Pharmaceuticals, Inc.(3)(9)(14)		Drug Discovery & Development		Warrant		Common Stock			608,696				194				117
Brickell Biotech, Inc.		Drug Discovery & Development		Warrant		Preferred Series C			26,086				119				125
Cerecor, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			22,328				70				11
Cerulean Pharma, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			171,901				369				9
Chroma Therapeutics, Ltd.(4)(9)		Drug Discovery & Development		Warrant		Preferred Series D			325,261				490				—
Cleveland BioLabs, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			7,813				105				2
Concert Pharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			70,796				367				158
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(3)		Drug Discovery & Development		Warrant		Common Stock			292,398				165				20
CytRx Corporation(3)(14)		Drug Discovery & Development		Warrant		Common Stock			634,146				416				773
Dicerna Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			200				28				—
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			64,194				276				42
Fortress Biotech, Inc. (p.k.a. Coronado Biosciences, Inc.)(3)		Drug Discovery & Development		Warrant		Common Stock			73,009				142				15
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			73,725				266				219
Immune Pharmaceuticals(3)		Drug Discovery & Development		Warrant		Common Stock			214,853				164				13
Mast Therapeutics, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			2,272,724				203				185
Melinta Therapeutics		Drug Discovery & Development		Warrant		Preferred Series 3			1,382,323				626				100
Nanotherapeutics, Inc.(14)		Drug Discovery & Development		Warrant		Common Stock			171,389				838				1,035
Neothetics, Inc. (p.k.a. Lithera, Inc)(3)(14)		Drug Discovery & Development		Warrant		Common Stock			46,838				266				8
Neuralstem, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			75,187				77				10
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)(14)		Drug Discovery & Development		Warrant		Common Stock			21,467				129				20
uniQure B.V.(3)(4)(9)		Drug Discovery & Development		Warrant		Common Stock			37,174				218				105
XOMA Corporation(3)(9)(14)		Drug Discovery & Development		Warrant		Common Stock			181,268				279				53
Subtotal: Drug Discovery & Development (0.44%)*													7,086				3,143
Electronics & Computer Hardware
Clustrix, Inc.		Electronics & Computer Hardware		Warrant		Common Stock			50,000				12				—
Persimmon Technologies		Electronics & Computer Hardware		Warrant		Preferred Series C			43,076				40				67
Subtotal: Electronics & Computer Hardware (0.01%)*													52				67
Healthcare Services, Other
Chromadex Corporation(3)(9)(14)		Healthcare Services, Other		Warrant		Common Stock			419,020				157				201
Subtotal: Healthcare Services, Other (0.03%)*													157				201

 

See notes to consolidated financial statements.

 

F-101

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Information Services
Cha Cha Search, Inc.(14)		Information Services		Warrant		Preferred Series G			48,232			$	58			$	—
INMOBI Inc.(4)(9)		Information Services		Warrant		Common Stock			46,874				82				—
InXpo, Inc.(14)		Information Services		Warrant		Preferred Series C			648,400				98				2
		Information Services		Warrant		Preferred Series C-1			1,165,183				74				2
Total InXpo, Inc.									1,813,583				172				4
RichRelevance, Inc.(14)		Information Services		Warrant		Preferred Series E			112,612				98				—
Subtotal: Information Services (0.00%)*													410				4
Internet Consumer & Business Services
Aria Systems, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series E			239,692				73				74
Blurb, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			234,280				636				130
CashStar, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C-2			727,272				130				37
CloudOne, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series E			968,992				19				19
Just Fabulous, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series B			206,184				1,102				1,417
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Warrant		Preferred Series C			245,610				20				67
LogicSource(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			79,625				30				55
Oportun (p.k.a. Progress Financial)		Internet Consumer & Business Services		Warrant		Preferred Series G			174,562				78				134
Prism Education Group, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series B			200,000				43				—
ReachLocal(3)		Internet Consumer & Business Services		Warrant		Common Stock			300,000				155				315
ShareThis, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			493,502				547				127
Tapjoy, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series D			748,670				316				198
Tectura Corporation		Internet Consumer & Business Services		Warrant		Preferred Series B-1			253,378				51				—
Subtotal: Internet Consumer & Business Services (0.36%)*													3,200				2,573
Media/Content/Info
Machine Zone, Inc.		Media/Content/Info		Warrant		Common Stock			155,271				1,959				2,822
Rhapsody International, Inc.(14)		Media/Content/Info		Warrant		Common Stock			715,755				384				221
WP Technology, Inc. (Wattpad, Inc.)(4)		Media/Content/Info		Warrant		Common Stock			127,909				1				1
Zoom Media Group, Inc.		Media/Content/Info		Warrant		Preferred Series A			1,204				348				18
Subtotal: Media/Content/Info (0.43%)*													2,692				3,062
Medical Devices & Equipment
Amedica Corporation(3)(14)		Medical Devices & Equipment		Warrant		Common Stock			103,225				459				65
Aspire Bariatrics, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series D			395,000				455				220
Avedro, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series AA			300,000				401				128
Flowonix Medical Incorporated		Medical Devices & Equipment		Warrant		Preferred Series E			110,947				203				450
Gamma Medica, Inc.		Medical Devices & Equipment		Warrant		Preferred Series A			357,500				170				183

 

See notes to consolidated financial statements.

 

F-102

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Gelesis, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series A-1			74,784			$	78			$	336
InspireMD, Inc.(3)(4)(9)		Medical Devices & Equipment		Warrant		Common Stock			16,835				242				—
Medrobotics Corporation(14)		Medical Devices & Equipment		Warrant		Preferred Series E			455,539				370				232
Micell Technologies, Inc.		Medical Devices & Equipment		Warrant		Preferred Series D-2			84,955				262				280
NetBio, Inc.		Medical Devices & Equipment		Warrant		Common Stock			2,568				408				17
NinePoint Medical, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series A-1			587,840				170				67
Novasys Medical, Inc.		Medical Devices & Equipment		Warrant		Common Stock			109,449				2				—
		Medical Devices & Equipment		Warrant		Preferred Series D			526,840				125				—
		Medical Devices & Equipment		Warrant		Preferred Series D-1			53,607				6				—
Total Novasys Medical, Inc.									689,896				133				—
Optiscan Biomedical, Corp.(5)(14)		Medical Devices & Equipment		Warrant		Preferred Series D			10,535,275				1,252				256
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Warrant		Common Stock			954				66				—
		Medical Devices & Equipment		Warrant		Preferred Series 1			1,632,084				676				57
Total Oraya Therapeutics, Inc.									1,633,038				742				313
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.)		Medical Devices & Equipment		Warrant		Preferred Series A			500,000				402				243
Quanterix Corporation		Medical Devices & Equipment		Warrant		Preferred Series C			173,428				180				144
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)		Medical Devices & Equipment		Warrant		Preferred Series A			6,464				188				—
Strata Skin Sciences, Inc. (p.k.a. MELA Sciences, Inc.)(3)		Medical Devices & Equipment		Warrant		Common Stock			69,320				402				—
ViewRay, Inc.(3)(14)		Medical Devices & Equipment		Warrant		Common Stock			128,231				333				30
Subtotal: Medical Devices & Equipment (0.38%)*													6,850				2,708
Semiconductors
Achronix Semiconductor Corporation(14)		Semiconductors		Warrant		Preferred Series C			360,000				160				18
		Semiconductors		Warrant		Preferred Series D-1			500,000				6				4
Total Achronix Semiconductor Corporation									860,000				166				22
Aquantia Corp.		Semiconductors		Warrant		Preferred Series G			196,831				4				38
Avnera Corporation		Semiconductors		Warrant		Preferred Series E			141,567				47				67
Subtotal: Semiconductors (0.02%)*													217				127
Software
Actifio, Inc.		Software		Warrant		Common Stock			73,584				249				190
		Software		Warrant		Preferred Series F			31,673				343				343
Total Actifio, Inc.									105,257				592				533
Braxton Technologies, LLC		Software		Warrant		Preferred Series A			168,750				188				—
CareCloud Corporation(14)		Software		Warrant		Preferred Series B			413,433				258				609
Clickfox, Inc.(14)		Software		Warrant		Preferred Series B			1,038,563				330				193
		Software		Warrant		Preferred Series C			592,019				730				161
		Software		Warrant		Preferred Series C-A			46,109				13				9
Total Clickfox, Inc.									1,676,691				1,073				363

 

See notes to consolidated financial statements.

 

F-103

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Hillcrest Laboratories, Inc.(14)		Software		Warrant		Preferred Series E			1,865,650			$	55			$	183
JumpStart Games, Inc. (p.k.a Knowledge Holdings, Inc.)(14)		Software		Warrant		Preferred Series E			614,333				16				—
Message Systems, Inc.(14)		Software		Warrant		Preferred Series C			503,718				334				434
Mobile Posse, Inc.(14)		Software		Warrant		Preferred Series C			396,430				130				80
Neos, Inc.(14)		Software		Warrant		Common Stock			221,150				22				110
NewVoiceMedia Limited(4)(9)		Software		Warrant		Preferred Series E			225,586				33				28
OneLogin, Inc.(14)		Software		Warrant		Common Stock			228,972				150				148
Poplicus, Inc.(14)		Software		Warrant		Preferred Series C			2,595,230				—				98
Signpost, Inc.(14)		Software		Warrant		Preferred Series C			324,005				314				305
Soasta, Inc.(14)		Software		Warrant		Preferred Series E			410,800				691				273
Sonian, Inc.(14)		Software		Warrant		Preferred Series C			185,949				106				26
Touchcommerce, Inc.(14)		Software		Warrant		Preferred Series E			2,282,968				446				575
Subtotal: Software (0.52%)*													4,408				3,765
Specialty Pharmaceuticals
Alimera Sciences, Inc.(3)		Specialty Pharmaceuticals		Warrant		Common Stock			862,069				729				313
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Warrant		Preferred Series E			155,324				307				—
Subtotal: Specialty Pharmaceuticals (0.04%)*													1,036				313
Surgical Devices
Gynesonics, Inc.(14)		Surgical Devices		Warrant		Preferred Series C			180,480				75				8
		Surgical Devices		Warrant		Preferred Series D			1,575,965				320				200
Total Gynesonics, Inc.									1,756,445				395				208
Transmedics, Inc.		Surgical Devices		Warrant		Preferred Series B			40,436				224				—
		Surgical Devices		Warrant		Preferred Series D			175,000				100				121
		Surgical Devices		Warrant		Preferred Series F			16,476				3				2
Total Transmedics, Inc.									231,912				327				123
Subtotal: Surgical Devices (0.05%)*													722				331
Sustainable and Renewable Technology
Agrivida, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series D			471,327				120				79
Alphabet Energy, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A			86,329				82				149
American Superconductor Corporation(3)		Sustainable and Renewable Technology		Warrant		Common Stock			58,823				39				103
Brightsource Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series 1			116,667				104				7
Calera, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			44,529				513				—
EcoMotors, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series B			437,500				308				134
Fluidic, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series D			61,804				102				38
Fulcrum Bioenergy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series C-1			280,897				275				207
GreatPoint Energy, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series D-1			393,212				548				—
Polyera Corporation(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			311,609				338				12
Proterra, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series 4			397,931				37				55
Rive Technology, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series E			234,477				12				24

 

See notes to consolidated financial statements.

 

F-104

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2016

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
SCIEnergy, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			530,811			$	181			$	—
		Sustainable and Renewable Technology		Warrant		Preferred Series 2-A			6,229				50				—
Total SCIEnergy, Inc.									537,040				231				—
Solexel, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			1,171,625				1,162				649
Stion Corporation(5)		Sustainable and Renewable Technology		Warrant		Preferred Series Seed			2,154				1,378				—
Sungevity, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			20,000,000				543				763
		Sustainable and Renewable Technology		Warrant		Preferred Series C			32,472,222				902				807
Total Sungevity, Inc.									52,472,222				1,445				1,570
TAS Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series AA			428,571				299				—
Tendril Networks		Sustainable and Renewable Technology		Warrant		Preferred Series 3-A			1,019,793				189				208
TPI Composites, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series B			160				273				108
Trilliant, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A			320,000				162				51
Subtotal: Sustainable and Renewable Technology (0.47%)*													7,617				3,394
Total: Warrant Investments (3.27%)*													42,419				23,496
Total Investments (179.75%)*												$	1,344,325			$	1,291,310

 

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $24.3 million, $77.2 million and $52.9 million respectively. The tax cost of investments is $1.3 billion.

(3)

Except for warrants in 37 publicly traded companies and common stock in 20 publicly traded companies, all investments are restricted at March 31, 2016 and were valued at fair value as determined in good faith by the Company’s board of directors (the “Board of Directors”). No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Non-U.S. company or the company’s principal place of business is outside the United States.

(5)	Affiliate investment as defined under the Investment Company Act of 1940, as amended, (the “1940 Act”) in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.

(6)	Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. There were no control investments at March 31, 2016.

(7)	Debt is on non-accrual status at March 31, 2016, and is therefore considered non-income producing.

(8)	Denotes that all or a portion of the debt investment is convertible debt.

(9)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(10)	Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).

(11)	Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility (as defined in Note 4).

(12)	Denotes that all or a portion of the debt investment principal includes accumulated PIK, or payment-in-kind, interest and is net of repayments.

(13)	Denotes that all or a portion of the debt investment includes an exit fee receivable. This fee ranges from 1.0% to 19.4% of the total debt commitment based on the contractual terms of our loan servicing agreements.

(14)	Denotes that all or a portion of the investment in this portfolio company is held by Hercules Technology II, L.P., or HT II, or Hercules Technology III, L.P., or HT III, the Company’s wholly-owned SBIC subsidiaries.

(15)

The stated ‘maturity date’ for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company’s investment team and Investment Committee continue to closely monitor developments at the borrower company.

(16)	Repayment of debt investment is delinquent of the contractual maturity date.

 

See notes to consolidated financial statements.

 

F-105

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Debt Investments
Communications & Networking
1-5 Years Maturity
Avanti Communications Group(4)(9)		Communications & Networking		Senior Secured		October 2019		Interest rate FIXED 10.00%		$	10,000			$	8,900			$	7,812
OpenPeak, Inc.(7)		Communications & Networking		Senior Secured		April 2017		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	12,370				9,134				2,444
SkyCross, Inc.(7)(12)(13)(14)		Communications & Networking		Senior Secured		January 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%, PIK Interest 5.00%		$	19,649				20,080				14,859
Spring Mobile Solutions, Inc.(13)		Communications & Networking		Senior Secured		January 2019		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	3,000				2,935				2,935
Subtotal: 1-5 Years Maturity															41,049				28,050
Subtotal: Communications & Networking (3.91%)*															41,049				28,050
Consumer & Business Products
Under 1 Year Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(14)		Consumer & Business Products		Senior Secured		June 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	308				308				308
Subtotal: Under 1 Year Maturity															308				308
1-5 Years Maturity
Antenna79 (p.k.a. Pong Research Corporation)(12)(13)(14)		Consumer & Business Products		Senior Secured		December 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.50%		$	4,955				4,785				4,783
Miles, Inc. (p.k.a. Fluc, Inc.)(8)		Consumer & Business Products		Convertible Debt		March 2017		Interest rate FIXED 4.00%		$	100				100				—
Nasty Gal(13)(14)		Consumer & Business Products		Senior Secured		May 2019		Interest rate PRIME + 5.45% or Floor rate of 8.95%		$	15,000				14,876				14,876
The Neat Company(7)(12)(13)(14)		Consumer & Business Products		Senior Secured		September 2017		Interest rate PRIME + 7.75% or Floor rate of 11.00%, PIK Interest 1.00%		$	15,936				15,545				5,527
Subtotal: 1-5 Years Maturity															35,306				25,186
Subtotal: Consumer & Business Products (3.55%)*															35,614				25,494
Drug Delivery
1-5 Years Maturity
AcelRx Pharmaceuticals, Inc.(9)(10)(13)(14)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 3.85% or Floor rate of 9.10%		$	20,466			$	20,772			$	20,678
Agile Therapeutics, Inc.(10)(13)		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 4.75% or Floor rate of 9.00%		$	16,500				16,231				16,107
BIND Therapeutics, Inc.(13)(14)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 5.10% or Floor rate of 8.35%		$	15,000				15,119				15,044
BioQ Pharma Incorporated(10)(13)		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	10,000				10,180				10,066
		Drug Delivery		Senior Secured		May 2018		Interest rate PRIME + 7.00% or Floor rate of 10.50%		$	3,000				2,962				2,962
Total BioQ Pharma Incorporated										$	13,000				13,142				13,028
Celator Pharmaceuticals, Inc.(10)(13)		Drug Delivery		Senior Secured		June 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	14,573				14,594				14,609
Celsion Corporation(10)(13)		Drug Delivery		Senior Secured		June 2017		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	6,346				6,501				6,544
Dance Biopharm, Inc.(13)(14)		Drug Delivery		Senior Secured		November 2017		Interest rate PRIME + 7.40% or Floor rate of 10.65%		$	2,705				2,776				2,757
Edge Therapeutics, Inc.(10)(13)		Drug Delivery		Senior Secured		March 2018		Interest rate PRIME + 6.45% or Floor rate of 9.95%		$	5,466				5,431				5,455

 

See notes to consolidated financial statements.

 

F-106

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Egalet Corporation(11)(13)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.15% or Floor rate of 9.40%		$	15,000			$	14,967			$	15,036
Neos Therapeutics, Inc.(10)(13)(14)		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	10,000				10,000				10,007
		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	10,000				10,043				9,998
		Drug Delivery		Senior Secured		October 2017		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	5,000				4,977				4,957
Total Neos Therapeutics, Inc.										$	25,000				25,020				24,962
Pulmatrix Inc.(8)(10)(13)		Drug Delivery		Senior Secured		July 2018		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	7,000				6,877				6,856
ZP Opco, Inc (p.k.a. Zosano Pharma)(10)(13)		Drug Delivery		Senior Secured		December 2018		Interest rate PRIME + 2.70% or Floor rate of 7.95%		$	15,000				14,925				14,781
Subtotal: 1-5 Years Maturity															156,355				155,857
Subtotal: Drug Delivery (21.73%)*															156,355				155,857
Drug Discovery & Development
1-5 Years Maturity
Aveo Pharmaceuticals, Inc.(9)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 6.65% or Floor rate of 11.90%		$	10,000				10,076				9,944
Cerecor, Inc.(13)		Drug Discovery & Development		Senior Secured		August 2017		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	5,688				5,705				5,740
Cerulean Pharma, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		July 2018		Interest rate PRIME + 1.55% or Floor rate of 7.30%		$	21,000				21,132				21,109
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(10)(13)		Drug Discovery & Development		Senior Secured		December 2018		Interest rate PRIME + 7.70% or Floor rate of 10.95%		$	25,000				25,507				25,550
Epirus Biopharmaceuticals, Inc.(11)(13)		Drug Discovery & Development		Senior Secured		April 2018		Interest rate PRIME + 4.70% or Floor rate of 7.95%		$	15,000				14,852				14,924
Genocea Biosciences, Inc.(10)(13)		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 3.75% or Floor rate of 7.25%		$	17,000				17,008				16,948
Immune Pharmaceuticals(10)(13)		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 6.50% or Floor rate of 10.00%		$	4,500				4,374				4,374
Insmed, Incorporated(10)(13)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 4.75% or Floor rate of 9.25%		$	25,000				25,128				24,991
Mast Therapeutics, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		January 2019		Interest rate PRIME + 5.70% or Floor rate of 8.95%		$	15,000				14,808				14,808
Melinta Therapeutics(11)(13)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 3.75% or Floor rate of 8.25%		$	30,000				29,843				29,703
Merrimack Pharmaceuticals, Inc.(9)		Drug Discovery & Development		Senior Secured		December 2022		Interest rate FIXED 11.50%		$	25,000				25,000				25,000
Neothetics, Inc. (p.k.a. Lithera, Inc)(13)(14)		Drug Discovery & Development		Senior Secured		January 2018		Interest rate PRIME + 5.75% or Floor rate of 9.00%		$	10,000				9,966				9,940
Neuralstem, Inc.(13)(14)		Drug Discovery & Development		Senior Secured		April 2017		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	8,335				8,418				8,397
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(13)(14)		Drug Discovery & Development		Senior Secured		September 2020		Interest rate PRIME + 2.75% or Floor rate of 8.50%		$	20,000				19,828				19,828
uniQure B.V.(4)(9)(10)(13)		Drug Discovery & Development		Senior Secured		June 2018		Interest rate PRIME + 5.00% or Floor rate of 10.25%		$	20,000				19,956				19,929
XOMA Corporation(9)(13)(14)		Drug Discovery & Development		Senior Secured		September 2018		Interest rate PRIME + 2.15% or Floor rate of 9.40%		$	20,000				19,974				19,815
Subtotal: 1-5 Years Maturity															271,575				271,000
Subtotal: Drug Discovery & Development (37.79%)*															271,575				271,000

 

See notes to consolidated financial statements.

 

F-107

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Electronics & Computer Hardware
1-5 Years Maturity
Persimmon Technologies(13)		Electronics & Computer Hardware		Senior Secured		June 2019		Interest rate PRIME + 7.50% or Floor rate of 11.00%		$	7,000			$	6,873			$	6,873
Subtotal: 1-5 Years Maturity															6,873				6,873
Subtotal: Electronics & Computer Hardware (0.96%)*															6,873				6,873
Sustainable and Renewable Technology
Under 1 Year Maturity
Agrivida, Inc.(13)(14)		Sustainable and Renewable Technology		Senior Secured		December 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	4,362				4,587				4,587
American Superconductor Corporation(10)(13)		Sustainable and Renewable Technology		Senior Secured		November 2016		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	3,667				4,106				4,106
Fluidic, Inc.(10)(13)		Sustainable and Renewable Technology		Senior Secured		March 2016		Interest rate PRIME + 8.00% or Floor rate of 11.25%		$	784				931				931
Polyera Corporation(13)(14)		Sustainable and Renewable Technology		Senior Secured		April 2016		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	637				890				890
Stion Corporation(5)(13)		Sustainable and Renewable Technology		Senior Secured		March 2016		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	2,200				2,200				1,013
Sungevity, Inc.(11)		Sustainable and Renewable Technology		Senior Secured		April 2016		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	20,000				20,000				20,000
Subtotal: Under 1 Year Maturity															32,714				31,527
1-5 Years Maturity
American Superconductor Corporation(10)(13)		Sustainable and Renewable Technology		Senior Secured		June 2017		Interest rate PRIME + 7.25% or Floor rate of 11.00%		$	1,500				1,496				1,484
Amyris, Inc.(9)(11)(13)		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	17,543				17,543				17,499
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	3,497				3,497				3,488
		Sustainable and Renewable Technology		Senior Secured		February 2017		Interest rate PRIME + 6.25% or Floor rate of 9.50%		$	10,960				11,045				11,045
Total Amyris, Inc.										$	32,000				32,085				32,032
Modumetal, Inc.(13)		Sustainable and Renewable Technology		Senior Secured		March 2017		Interest rate PRIME + 8.70% or Floor rate of 11.95%		$	1,759				2,062				2,032
		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	7,061				7,101				7,080
Total Modumetal, Inc.										$	8,820				9,163				9,112
Polyera Corporation(13)		Sustainable and Renewable Technology		Senior Secured		January 2017		Interest rate PRIME + 6.70% or Floor rate of 9.95%		$	1,254				1,455				1,455
Proterra, Inc.(10)(13)		Sustainable and Renewable Technology		Senior Secured		December 2018		Interest rate PRIME + 6.95% or Floor rate of 10.20%		$	25,000				24,995				24,550

 

See notes to consolidated financial statements.

 

F-108

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Sungevity, Inc.(11)(13)		Sustainable and Renewable Technology		Senior Secured		October 2017		Interest rate PRIME + 3.70% or Floor rate of 6.95%		$	35,000			$	34,733			$	34,773
Tendril Networks(13)		Sustainable and Renewable Technology		Senior Secured		June 2019		Interest rate FIXED 7.25%		$	15,000				14,735				14,477
Subtotal: 1-5 Years Maturity															118,662				117,883
Subtotal: Sustainable and Renewable Technology (20.83%)*															151,376				149,410
Healthcare Services, Other
1-5 Years Maturity
Chromadex Corporation(13)(14)		Healthcare Services, Other		Senior Secured		April 2018		Interest rate PRIME + 6.10% or Floor rate of 9.35%		$	5,000				4,907				4,918
InstaMed Communications, LLC(13)(14)		Healthcare Services, Other		Senior Secured		February 2019		Interest rate PRIME + 6.75% or Floor rate of 10.00%		$	10,000				10,048				10,049
Subtotal: 1-5 Years Maturity															14,955				14,967
Subtotal: Healthcare Services, Other (2.09%)*															14,955				14,967
Information Services
Under 1 Year Maturity
Eccentex Corporation(13)(16)		Information Services		Senior Secured		May 2015		Interest rate PRIME + 7.00% or Floor rate of 10.25%		$	13				28				28
InXpo, Inc.(13)(14)		Information Services		Senior Secured		October 2016		Interest rate PRIME + 7.50% or Floor rate of 10.75%		$	1,589				1,624				1,624
Subtotal: Under 1 Year Maturity															1,652				1,652
Subtotal: Information Services (0.23%)*															1,652				1,652
Internet Consumer & Business Services
Under 1 Year Maturity
NetPlenish(7)(8)(14)		Internet Consumer & Business Services		Convertible Debt		September 2016		Interest rate FIXED 10.00%		$	381				373				—
		Internet Consumer & Business Services		Senior Secured		April 2016		Interest rate FIXED 10.00%		$	45				45				—
Total NetPlenish										$	426				418				—
Subtotal: Under 1 Year Maturity															418				—
1-5 Years Maturity
Aria Systems, Inc.(10)(12)		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 5.20% or Floor rate of 8.95%, PIK Interest 1.95%		$	18,101				17,850				17,673
		Internet Consumer & Business Services		Senior Secured		June 2019		Interest rate PRIME + 3.20% or Floor rate of 6.95%, PIK Interest 1.95%		$	2,021				1,995				1,972
Total Aria Systems, Inc.										$	20,122				19,845				19,645
One Planet Ops Inc. (p.k.a. Reply! Inc.)(7)(12)		Internet Consumer & Business Services		Senior Secured		March 2019		Interest rate PRIME + 4.25% or Floor rate of 7.50%		$	6,321				5,811				5,811
		Internet Consumer & Business Services		Senior Secured		March 2019		PIK Interest 2.00%		$	2,129				2,129				55
Total One Planet Ops Inc. (p.k.a. Reply! Inc.)										$	8,450				7,940				5,866

 

See notes to consolidated financial statements.

 

F-109

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
ReachLocal(13)		Internet Consumer & Business Services		Senior Secured		April 2018		Interest rate PRIME + 8.50% or Floor rate of 11.75%		$	25,000			$	24,868			$	24,769
Tapjoy, Inc.(11)(13)		Internet Consumer & Business Services		Senior Secured		July 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	20,000				19,598				19,514
Tectura Corporation(7)(12)(15)		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	6,468				6,468				4,851
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%		$	8,170				8,170				6,128
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	563				563				422
		Internet Consumer & Business Services		Senior Secured		May 2014		Interest rate LIBOR + 10.00% or Floor rate of 13.00%		$	5,000				5,000				3,750
Total Tectura Corporation										$	20,201				20,201				15,151
Subtotal: 1-5 Years Maturity															92,452				84,945
Subtotal: Internet Consumer & Business Services (11.85%)*															92,870				84,945
Media/Content/Info
Under 1 Year Maturity
Zoom Media Group, Inc.		Media/Content/Info		Senior Secured		January 2016		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	5,060				5,060				5,060
Subtotal: Under 1 Year Maturity															5,060				5,060
1-5 Years Maturity
Machine Zone, Inc.(12)		Media/Content/Info		Senior Secured		May 2018		Interest rate PRIME + 2.50% or Floor rate of 6.75%, PIK Interest 3.00%		$	90,729				88,730				88,101
Subtotal: 1-5 Years Maturity															88,730				88,101
Subtotal: Media/Content/Info (12.99%)*															93,790				93,161
Medical Devices & Equipment
Under 1 Year Maturity
Medrobotics Corporation(13)(14)		Medical Devices & Equipment		Senior Secured		March 2016		Interest rate PRIME + 7.85% or Floor rate of 11.10%		$	576				735				735
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)(13)		Medical Devices & Equipment		Senior Secured		April 2016		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	292				700				700
Subtotal: Under 1 Year Maturity															1,435				1,435
1-5 Years Maturity
Amedica Corporation(8)(13)(14)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 9.20% or Floor rate of 12.45%		$	17,051				17,642				17,350
Aspire Bariatrics, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		October 2018		Interest rate PRIME + 4.00% or Floor rate of 9.25%		$	7,000				6,771				6,739
Avedro, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		June 2018		Interest rate PRIME + 6.00% or Floor rate of 9.25%		$	12,500				12,391				12,201
Flowonix Medical Incorporated(11)(13)		Medical Devices & Equipment		Senior Secured		May 2018		Interest rate PRIME + 6.50% or Floor rate of 10.00%		$	15,000				15,071				14,974
Gamma Medica, Inc.(10)(13)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 6.50% or Floor rate of 9.75%		$	4,000				4,009				3,989
InspireMD, Inc.(4)(9)(13)		Medical Devices & Equipment		Senior Secured		February 2017		Interest rate PRIME + 5.00% or Floor rate of 10.50%		$	5,009				5,380				3,764

 

See notes to consolidated financial statements.

 

F-110

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Quanterix Corporation(10)(13)		Medical Devices & Equipment		Senior Secured		February 2018		Interest rate PRIME + 2.75% or Floor rate of 8.00%		$	9,661			$	9,718			$	9,659
SynergEyes, Inc.(13)(14)		Medical Devices & Equipment		Senior Secured		January 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	4,263				4,516				4,464
Subtotal: 1-5 Years Maturity															75,498				73,140
Subtotal: Medical Devices & Equipment (10.40%)*															76,933				74,575
Semiconductors
Under 1 Year Maturity
Achronix Semiconductor Corporation(14)		Semiconductors		Senior Secured		July 2016		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	5,000				5,000				5,000
Subtotal: Under 1 Year Maturity															5,000				5,000
1-5 Years Maturity
Achronix Semiconductor Corporation(13)(14)		Semiconductors		Senior Secured		July 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	5,000				5,027				4,999
Aquantia Corporation		Semiconductors		Senior Secured		February 2017		Interest rate PRIME + 2.95% or Floor rate of 6.20%		$	5,001				5,001				5,001
Avnera Corporation(10)(13)		Semiconductors		Senior Secured		April 2018		Interest rate PRIME + 5.25% or Floor rate of 8.50%		$	7,500				7,498				7,568
Subtotal: 1-5 Years Maturity															17,526				17,568
Subtotal: Semiconductors (3.15%)*															22,526				22,568
Software
Under 1 Year Maturity
Clickfox, Inc.(13)(14)(16)		Software		Senior Secured		December 2015		Interest rate PRIME + 8.75% or Floor rate of 12.00%		$	3,300				3,465				3,465
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.)(12)(13)(14)		Software		Senior Secured		October 2016		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	1,335				1,350				875
Neos, Inc.(13)(14)		Software		Senior Secured		May 2016		Interest rate PRIME + 6.75% or Floor rate of 10.50%		$	729				895				895
Touchcommerce, Inc.(14)		Software		Senior Secured		August 2016		Interest rate PRIME + 2.25% or Floor rate of 6.50%		$	5,511				5,511				5,511
Subtotal: Under 1 Year Maturity															11,221				10,746
1-5 Years Maturity
Actifio, Inc.(12)		Software		Senior Secured		January 2019		Interest rate PRIME + 4.25% or Floor rate of 8.25%, PIK Interest 2.25%		$	30,263				30,019				29,712
Clickfox, Inc.(13)(14)		Software		Senior Secured		March 2018		Interest rate PRIME + 8.25% or Floor rate of 11.50%		$	5,475				5,490				5,490
Druva, Inc.(10)(13)		Software		Senior Secured		March 2018		Interest rate PRIME + 4.60% or Floor rate of 7.85%		$	12,000				12,080				12,034
JumpStart Games, Inc. (p.k.a. Knowledge Adventure, Inc.)(12)(13)(14)		Software		Senior Secured		March 2018		Interest rate FIXED 5.75%, PIK Interest 10.75%		$	11,082				11,174				7,245
Message Systems, Inc.(14)		Software		Senior Secured		February 2019		Interest rate PRIME + 7.25% or Floor rate of 10.50%		$	17,500				17,103				17,013
		Software		Senior Secured		February 2017		Interest rate PRIME + 2.75% or Floor rate of 6.00%		$	1,618				1,618				1,616
Total Message Systems, Inc.										$	19,118				18,721				18,629
RedSeal Inc.(13)(14)		Software		Senior Secured		June 2017		Interest rate PRIME + 3.25% or Floor rate of 6.50%		$	3,000				3,000				2,987
		Software		Senior Secured		June 2018		Interest rate PRIME + 7.75% or Floor rate of 11.00%		$	5,000				5,006				4,979
Total RedSeal Inc.										$	8,000				8,006				7,966

 

See notes to consolidated financial statements.

 

F-111

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Maturity Date		Interest Rate and Floor		Principal Amount				Cost(2)				Value(3)
Soasta, Inc.(13)(14)		Software		Senior Secured		February 2018		Interest rate PRIME + 2.25% or Floor rate of 5.50%		$	3,500				$3,432			$	3,419
		Software		Senior Secured		February 2018		Interest rate PRIME + 4.75% or Floor rate of 8.00%		$	15,000				14,699				14,646
Total Soasta, Inc.										$	18,500				18,131				18,065
Touchcommerce, Inc.(13)(14)		Software		Senior Secured		February 2018		Interest rate PRIME + 6.00% or Floor rate of 10.25%		$	12,000				11,853				11,721
Subtotal: 1-5 Years Maturity															115,474				110,862
Subtotal: Software (16.96%)*															126,695				121,608
Specialty Pharmaceuticals
Under 1 Year Maturity
Cranford Pharmaceuticals, LLC(10)(12)		Specialty Pharmaceuticals		Senior Secured		August 2016		Interest rate LIBOR + 8.25% or Floor rate of 9.50%		$	1,100				1,100				1,100
Subtotal: Under 1 Year Maturity															1,100				1,100
1-5 Years Maturity
Alimera Sciences, Inc.(10)(13)		Specialty Pharmaceuticals		Senior Secured		May 2018		Interest rate PRIME + 7.65% or Floor rate of 10.90%		$	35,000				34,296				34,309
Cranford Pharmaceuticals, LLC(10)(12)(13)(14)		Specialty Pharmaceuticals		Senior Secured		August 2017		Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%		$	10,041				10,164				10,235
Jaguar Animal Health, Inc.(10)(13)		Specialty Pharmaceuticals		Senior Secured		August 2018		Interest rate PRIME + 5.65% or Floor rate of 9.90%		$	6,000				6,009				6,009
Subtotal: 1-5 Years Maturity															50,469				50,553
Subtotal: Specialty Pharmaceuticals (7.20%)*															51,569				51,653
Surgical Devices
1-5 Years Maturity
Transmedics, Inc.(13)		Surgical Devices		Senior Secured		March 2019		Interest rate PRIME + 5.30% or Floor rate of 9.55%		$	8,500				8,471				8,396
Subtotal: 1-5 Years Maturity															8,471				8,396
Subtotal: Surgical Devices (1.17%)*															8,471				8,396
Total Debt Investments (154.81%)*															1,152,303				1,110,209

 

See notes to consolidated financial statements.

 

F-112

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Equity Investments
Biotechnology Tools
NuGEN Technologies, Inc.(14)		Biotechnology Tools		Equity		Preferred Series C			189,394			$	500			$	532
Subtotal: Biotechnology Tools (0.07%)*													500				532
Communications & Networking
GlowPoint, Inc.(3)		Communications & Networking		Equity		Common Stock			114,192				102				57
Peerless Network, Inc.		Communications & Networking		Equity		Preferred Series A			1,000,000				1,000				4,380
Subtotal: Communications & Networking (0.62%)*													1,102				4,437
Consumer & Business Products
Market Force Information, Inc.		Consumer & Business Products		Equity		Common Stock			480,261				—				217
		Consumer & Business Products		Equity		Preferred Series B-1			187,970				500				3
Total Market Force Information, Inc.									668,231				500				220
Subtotal: Consumer & Business Products (0.03%)*													500				220
Diagnostic
Singulex, Inc.		Diagnostic		Equity		Common Stock			937,998				750				304
Subtotal: Diagnostic (0.04%)*													750				304
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)		Drug Delivery		Equity		Common Stock			54,240				108				209
BioQ Pharma Incorporated(14)		Drug Delivery		Equity		Preferred Series D			165,000				500				660
Edge Therapeutics, Inc.(3)		Drug Delivery		Equity		Common Stock			157,190				1,000				1,965
Merrion Pharmaceuticals, Plc(3)(4)(9)		Drug Delivery		Equity		Common Stock			20,000				9				—
Neos Therapeutics, Inc.(3)(14)		Drug Delivery		Equity		Common Stock			125,000				1,500				1,790
Revance Therapeutics, Inc.(3)		Drug Delivery		Equity		Common Stock			22,765				557				778
Subtotal: Drug Delivery (0.75%)*													3,674				5,402
Drug Discovery & Development
Aveo Pharmaceuticals, Inc.(3)(9)(14)		Drug Discovery & Development		Equity		Common Stock			167,864				842				212
Cerecor, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			119,087				1,000				399
Cerulean Pharma, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			135,501				1,000				379
Dicerna Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Equity		Common Stock			142,858				1,000				1,695
Dynavax Technologies(3)(9)		Drug Discovery & Development		Equity		Common Stock			20,000				550				483
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			200,000				1,000				618
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Equity		Common Stock			223,463				2,000				1,178
Inotek Pharmaceuticals Corporation(3)		Drug Discovery & Development		Equity		Common Stock			3,778				1,500				43

 

See notes to consolidated financial statements.

 

F-113

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Insmed, Incorporated(3)		Drug Discovery & Development		Equity		Common Stock			70,771			$	1,000			$	1,284
Melinta Therapeutics		Drug Discovery & Development		Equity		Preferred Series 4			1,914,448				2,000				2,026
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)		Drug Discovery & Development		Equity		Common Stock			76,362				2,743				1,450
Subtotal: Drug Discovery & Development (1.36%)*													14,635				9,767
Electronics & Computer Hardware
Identiv, Inc.(3)		Electronics & Computer Hardware		Equity		Common Stock			6,700				34				13
Subtotal: Electronics & Computer Hardware (0.00%)*													34				13
Sustainable and Renewable Technology
Glori Energy, Inc.(3)		Sustainable and Renewable Technology		Equity		Common Stock			18,208				165				6
Modumetal, Inc.		Sustainable and Renewable Technology		Equity		Preferred Series C			3,107,520				500				455
SCIEnergy, Inc.		Sustainable and Renewable Technology		Equity		Preferred Series 1			385,000				761				—
Sungevity, Inc.(14)		Sustainable and Renewable Technology		Equity		Preferred Series D			68,807,339				6,750				6,912
Subtotal: Sustainable and Renewable Technology (1.03%)*													8,176				7,373
Internet Consumer & Business Services
Blurb, Inc.(14)		Internet Consumer & Business Services		Equity		Preferred Series B			220,653				175				244
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Equity		Preferred Series C			230,030				250				264
		Internet Consumer & Business Services		Equity		Preferred Series D			198,677				250				249
Total Lightspeed POS, Inc.									428,707				500				513
Oportun (p.k.a. Progress Financial)		Internet Consumer & Business Services		Equity		Preferred Series G			218,351				250				349
		Internet Consumer & Business Services		Equity		Preferred Series H			87,802				250				248
Total Oportun (p.k.a. Progress Financial)									306,153				500				597
Philotic, Inc.		Internet Consumer & Business Services		Equity		Common Stock			9,023				93				—
RazorGator Interactive Group, Inc.		Internet Consumer & Business Services		Equity		Preferred Series AA			34,783				15				28
Taptera, Inc.		Internet Consumer & Business Services		Equity		Preferred Series B			454,545				150				99
Subtotal: Internet Consumer & Business Services (0.21%)*													1,433				1,481
Medical Devices & Equipment
AtriCure, Inc.(3)(14)		Medical Devices & Equipment		Equity		Common Stock			7,536				266				155
Flowonix Medical Incorporated		Medical Devices & Equipment		Equity		Preferred Series E			221,893				1,500				1,953

 

See notes to consolidated financial statements.

 

F-114

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Gelesis, Inc. (14)		Medical Devices & Equipment		Equity		Common Stock			198,202			$	—			$	1,005
		Medical Devices & Equipment		Equity		Preferred Series A-1			191,210				425				1,051
		Medical Devices & Equipment		Equity		Preferred Series A-2			191,626				500				1,012
Total Gelesis, Inc.									581,038				925				3,068
Medrobotics Corporation(14)		Medical Devices & Equipment		Equity		Preferred Series E			136,798				250				208
		Medical Devices & Equipment		Equity		Preferred Series F			73,971				155				189
		Medical Devices & Equipment		Equity		Preferred Series G			163,934				500				500
Total Medrobotics Corporation									374,703				905				897
Novasys Medical, Inc.		Medical Devices & Equipment		Equity		Preferred Series D-1			4,118,444				1,000				—
Optiscan Biomedical, Corp.(5)(14)		Medical Devices & Equipment		Equity		Preferred Series B			6,185,567				3,000				565
		Medical Devices & Equipment		Equity		Preferred Series C			1,927,309				655				169
		Medical Devices & Equipment		Equity		Preferred Series D			55,103,923				5,257				5,927
Total Optiscan Biomedical, Corp.									63,216,799				8,912				6,661
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Equity		Preferred Series 1			1,086,969				500				266
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.)		Medical Devices & Equipment		Equity		Preferred Series B			232,061				527				543
Subtotal: Medical Devices & Equipment (1.89%)*													14,535				13,543
Software
Box, Inc.(3)(14)		Software		Equity		Common Stock			1,287,347				5,653				17,957
CapLinked, Inc.		Software		Equity		Preferred Series A-3			53,614				51				79
Druva, Inc.		Software		Equity		Preferred Series 2			458,841				1,000				1,031
ForeScout Technologies, Inc.		Software		Equity		Preferred Series D			319,099				398				1,368
		Software		Equity		Preferred Series E			80,587				131				350
Total ForeScout Technologies, Inc.									399,686				529				1,718
HighRoads, Inc.		Software		Equity		Preferred Series B			190,170				307				—
NewVoiceMedia Limited(4)(9)		Software		Equity		Preferred Series E			669,173				963				1,016
WildTangent, Inc.(14)		Software		Equity		Preferred Series 3			100,000				402				190
Subtotal: Software (3.07%)*													8,905				21,991
Specialty Pharmaceuticals
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Equity		Preferred Series E			241,829				750				—
		Specialty Pharmaceuticals		Equity		Preferred Series E-1			26,955				—				—
		Specialty Pharmaceuticals		Equity		Preferred Series G			4,667,636				—				—
Total QuatRx Pharmaceuticals Company									4,936,420				750				—
Subtotal: Specialty Pharmaceuticals (0.00%)*													750				—

 

See notes to consolidated financial statements.

 

F-115

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Surgical Devices
Gynesonics, Inc.(14)		Surgical Devices		Equity		Preferred Series B			219,298			$	250			$	32
		Surgical Devices		Equity		Preferred Series C			656,538				282				46
		Surgical Devices		Equity		Preferred Series D			1,991,157				712				637
		Surgical Devices		Equity		Preferred Series E			2,785,402				429				422
Total Gynesonics, Inc.									5,652,395				1,673				1,137
Transmedics, Inc.		Surgical Devices		Equity		Preferred Series B			88,961				1,100				154
		Surgical Devices		Equity		Preferred Series C			119,999				300				96
		Surgical Devices		Equity		Preferred Series D			260,000				650				521
		Surgical Devices		Equity		Preferred Series F			100,200				500				471
Total Transmedics, Inc.									569,160				2,550				1,242
Subtotal: Surgical Devices (0.33%)*													4,223				2,379
Total: Equity Investments (9.40%)*													59,217				67,442
Warrant Investments
Biotechnology Tools
Labcyte, Inc.(14)		Biotechnology Tools		Warrant		Preferred Series C			1,127,624				323				187
Subtotal: Biotechnology Tools (0.03%)*													323				187
Communications & Networking
Intelepeer, Inc.(14)		Communications & Networking		Warrant		Common Stock			117,958				102				—
OpenPeak, Inc.		Communications & Networking		Warrant		Common Stock			108,982				149				—
PeerApp, Inc.		Communications & Networking		Warrant		Preferred Series B			298,779				61				62
Peerless Network, Inc.		Communications & Networking		Warrant		Preferred Series A			135,000				95				375
Ping Identity Corporation		Communications & Networking		Warrant		Preferred Series B			1,136,277				52				236
SkyCross, Inc.(14)		Communications & Networking		Warrant		Preferred Series F			9,762,777				394				—
Spring Mobile Solutions, Inc.		Communications & Networking		Warrant		Preferred Series D			2,834,375				418				53
Subtotal: Communications & Networking (0.10%)*													1,271				726
Consumer & Business Products
Antenna 79 (p.k.a. Pong Research Corporation)(14)		Consumer & Business Products		Warrant		Preferred Series A			1,662,441				228				2
Intelligent Beauty, Inc.(14)		Consumer & Business Products		Warrant		Preferred Series B			190,234				230				214
IronPlanet, Inc.		Consumer & Business Products		Warrant		Preferred Series D			1,155,821				1,076				651
Market Force Information, Inc.		Consumer & Business Products		Warrant		Preferred Series A-1			150,212				24				10
Nasty Gal(14)		Consumer & Business Products		Warrant		Preferred Series C			845,194				23				20
The Neat Company(14)		Consumer & Business Products		Warrant		Preferred Series C-1			540,540				365				—
Subtotal: Consumer & Business Products (0.13%)*													1,946				897

 

See notes to consolidated financial statements.

 

F-116

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Diagnostic
Navidea Biopharmaceuticals, Inc. (p.k.a. Neoprobe)(3)(14)		Diagnostic		Warrant		Common Stock			333,333			$	244			$	17
Subtotal: Diagnostic (0.00%)*													244				17
Drug Delivery
AcelRx Pharmaceuticals, Inc.(3)(9)(14)		Drug Delivery		Warrant		Common Stock			176,730				786				238
Agile Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			180,274				730				680
BIND Therapeutics, Inc.(3)(14)		Drug Delivery		Warrant		Common Stock			152,586				488				6
BioQ Pharma Incorporated		Drug Delivery		Warrant		Common Stock			459,183				1				423
Celator Pharmaceuticals, Inc.(3)		Drug Delivery		Warrant		Common Stock			210,675				138				59
Celsion Corporation(3)		Drug Delivery		Warrant		Common Stock			194,986				428				20
Dance Biopharm, Inc.(14)		Drug Delivery		Warrant		Common Stock			43,813				74				55
Edge Therapeutics, Inc.(3)		Drug Delivery		Warrant		Common Stock			78,595				390				417
Kaleo, Inc. (p.k.a. Intelliject, Inc.)		Drug Delivery		Warrant		Preferred Series B			82,500				594				1,217
Neos Therapeutics, Inc.(3)(14)		Drug Delivery		Warrant		Common Stock			70,833				285				275
Pulmatrix Inc.(3)		Drug Delivery		Warrant		Common Stock			25,150				116				12
ZP Opco, Inc (p.k.a. Zosano Pharma)(3)		Drug Delivery		Warrant		Common Stock			72,379				266				4
Subtotal: Drug Delivery (0.47%)*													4,296				3,406
Drug Discovery & Development
ADMA Biologics, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			89,750				295				98
Anthera Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			40,178				984				—
Aveo Pharmaceuticals, Inc.(3)(9)		Drug Discovery & Development		Warrant		Common Stock			608,696				194				216
Cerecor, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			22,328				70				10
Cerulean Pharma, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			171,901				369				90
Chroma Therapeutics, Ltd.(4)(9)		Drug Discovery & Development		Warrant		Preferred Series D			325,261				490				—
Cleveland BioLabs, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			7,813				105				5
Concert Pharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			70,796				367				368
CTI BioPharma Corp. (p.k.a. Cell Therapeutics, Inc.)(3)		Drug Discovery & Development		Warrant		Common Stock			292,398				165				59
Dicerna Pharmaceuticals, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			200				28				—
Epirus Biopharmaceuticals, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			64,194				276				55
Fortress Biotech, Inc. (p.k.a. Coronado Biosciences, Inc.)(3)		Drug Discovery & Development		Warrant		Common Stock			73,009				142				11
Genocea Biosciences, Inc.(3)		Drug Discovery & Development		Warrant		Common Stock			73,725				266				92
Immune Pharmaceuticals(3)		Drug Discovery & Development		Warrant		Common Stock			214,853				164				40
Mast Therapeutics, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			1,524,389				203				215

 

See notes to consolidated financial statements.

 

F-117

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Melinta Therapeutics		Drug Discovery & Development		Warrant		Preferred Series 3			1,382,323			$	626			$	130
Nanotherapeutics, Inc.(14)		Drug Discovery & Development		Warrant		Common Stock			171,389				838				1,762
Neothetics, Inc. (p.k.a. Lithera, Inc)(3)(14)		Drug Discovery & Development		Warrant		Common Stock			46,838				266				2
Neuralstem, Inc.(3)(14)		Drug Discovery & Development		Warrant		Common Stock			75,187				77				12
Paratek Pharmaceutcals, Inc. (p.k.a. Transcept Pharmaceuticals, Inc.)(3)(14)		Drug Discovery & Development		Warrant		Common Stock			21,467				129				36
uniQure B.V.(3)(4)(9)		Drug Discovery & Development		Warrant		Common Stock			37,174				218				183
XOMA Corporation(3)(9)(14)		Drug Discovery & Development		Warrant		Common Stock			181,268				279				115
Subtotal: Drug Discovery & Development (0.49%)*													6,551				3,499
Electronics & Computer Hardware
Clustrix, Inc.		Electronics & Computer Hardware		Warrant		Common Stock			50,000				12				—
Persimmon Technologies		Electronics & Computer Hardware		Warrant		Preferred Series C			43,076				40				42
Subtotal: Electronics & Computer Hardware (0.01%)*													52				42
Sustainable and Renewable Technology
Agrivida, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series D			471,327				120				38
Alphabet Energy, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A			86,329				82				159
American Superconductor Corporation(3)		Sustainable and Renewable Technology		Warrant		Common Stock			58,823				39				82
Brightsource Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series 1			116,667				104				6
Calera, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			44,529				513				—
EcoMotors, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series B			437,500				308				176
Fluidic, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series D			61,804				102				43
Fulcrum Bioenergy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series C-1			280,897				275				152
GreatPoint Energy, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series D-1			393,212				548				—
Polyera Corporation(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			311,609				338				10
Proterra, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series 4			397,931				37				50
SCIEnergy, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			530,811				181				—
		Sustainable and Renewable Technology		Warrant		Preferred Series 1			145,811				50				—
Total SCIEnergy, Inc.									676,622				231				—

 

See notes to consolidated financial statements.

 

F-118

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Scifiniti (p.k.a. Integrated Photovoltaics, Inc.)(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A-1			390,000			$	82			$	48
Solexel, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series C			1,171,625				1,162				466
Stion Corporation(5)		Sustainable and Renewable Technology		Warrant		Preferred Series Seed			2,154				1,378				—
Sungevity, Inc.		Sustainable and Renewable Technology		Warrant		Common Stock			20,000,000				543				569
		Sustainable and Renewable Technology		Warrant		Preferred Series C			32,472,222				902				525
Total Sungevity, Inc.									52,472,222				1,445				1,094
TAS Energy, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series AA			428,571				299				—
Tendril Networks		Sustainable and Renewable Technology		Warrant		Preferred Series 3-A			1,019,793				188				242
TPI Composites, Inc.		Sustainable and Renewable Technology		Warrant		Preferred Series B			160				273				85
Trilliant, Inc.(14)		Sustainable and Renewable Technology		Warrant		Preferred Series A			320,000				162				53
Subtotal: Sustainable and Renewable Technology (0.38%)*													7,686				2,704
Healthcare Services, Other
Chromadex Corporation(3)(14)		Healthcare Services, Other		Warrant		Common Stock			419,020				157				164
Subtotal: Healthcare Services, Other (0.02%)*													157				164
Information Services
Cha Cha Search, Inc.(14)		Information Services		Warrant		Preferred Series G			48,232				58				—
INMOBI Inc.(4)(9)		Information Services		Warrant		Common Stock			46,874				82				3
InXpo, Inc.(14)		Information Services		Warrant		Preferred Series C			648,400				98				2
		Information Services		Warrant		Preferred Series C-1			1,032,416				74				—
Total InXpo, Inc.									1,680,816				172				2
RichRelevance, Inc.(14)		Information Services		Warrant		Preferred Series E			112,612				98				—
Subtotal: Information Services (0.00%)*													410				5
Internet Consumer & Business Services
Aria Systems, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series E			239,692				73				88
Blurb, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			234,280				636				148
CashStar, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C-2			727,272				130				34
Just Fabulous, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series B			206,184				1,102				1,104
Lightspeed POS, Inc.(4)(9)		Internet Consumer & Business Services		Warrant		Preferred Series C			245,610				20				82
Oportun (p.k.a. Progress Financial)		Internet Consumer & Business Services		Warrant		Preferred Series G			174,562				78				104
Prism Education Group, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series B			200,000				43				—

 

See notes to consolidated financial statements.

 

F-119

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
ReachLocal(3)		Internet Consumer & Business Services		Warrant		Common Stock			300,000			$	155			$	290
ShareThis, Inc.(14)		Internet Consumer & Business Services		Warrant		Preferred Series C			493,502				547				93
Tapjoy, Inc.		Internet Consumer & Business Services		Warrant		Preferred Series D			748,670				316				8
Tectura Corporation		Internet Consumer & Business Services		Warrant		Preferred Series B-1			253,378				51				—
Subtotal: Internet Consumer & Business Services (0.27%)*													3,151				1,951
Media/Content/Info
Machine Zone, Inc.		Media/Content/Info		Warrant		Common Stock			143,626				1,802				2,086
Rhapsody International, Inc.(14)		Media/Content/Info		Warrant		Common Stock			715,755				384				218
Zoom Media Group, Inc.		Media/Content/Info		Warrant		Preferred Series A			1,204				348				23
Subtotal: Media/Content/Info (0.32%)*													2,534				2,327
Medical Devices & Equipment
Amedica Corporation(3)(14)		Medical Devices & Equipment		Warrant		Common Stock			1,548,387				459				31
Aspire Bariatrics, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series D			395,000				455				236
Avedro, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series AA			300,000				401				142
Flowonix Medical Incorporated		Medical Devices & Equipment		Warrant		Preferred Series E			110,947				203				428
Gamma Medica, Inc.		Medical Devices & Equipment		Warrant		Preferred Series A			357,500				170				144
Gelesis, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series A-1			74,784				78				262
InspireMD, Inc.(3)(4)(9)		Medical Devices & Equipment		Warrant		Common Stock			16,835				242				—
Medrobotics Corporation(14)		Medical Devices & Equipment		Warrant		Preferred Series E			455,539				370				244
NetBio, Inc.		Medical Devices & Equipment		Warrant		Common Stock			2,568				408				19
NinePoint Medical, Inc.(14)		Medical Devices & Equipment		Warrant		Preferred Series A-1			587,840				170				119
Novasys Medical, Inc.		Medical Devices & Equipment		Warrant		Common Stock			109,449				2				—
		Medical Devices & Equipment		Warrant		Preferred Series D			526,840				125				—
		Medical Devices & Equipment		Warrant		Preferred Series D-1			53,607				6				—
Total Novasys Medical, Inc.									689,896				133				—
Optiscan Biomedical, Corp.(5)(14)		Medical Devices & Equipment		Warrant		Preferred Series D			10,535,275				1,252				312
Oraya Therapeutics, Inc.		Medical Devices & Equipment		Warrant		Common Stock			954				66				—
		Medical Devices & Equipment		Warrant		Preferred Series 1			1,632,084				676				63
Total Oraya Therapeutics, Inc.									1,633,038				742				63

 

See notes to consolidated financial statements.

 

F-120

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Outset Medical, Inc. (p.k.a. Home Dialysis Plus, Inc.)		Medical Devices & Equipment		Warrant		Preferred Series A			500,000			$	402			$	298
Quanterix Corporation		Medical Devices & Equipment		Warrant		Preferred Series C			115,618				156				60
SonaCare Medical, LLC (p.k.a. US HIFU, LLC)		Medical Devices & Equipment		Warrant		Preferred Series A			6,464				188				—
Strata Skin Sciences, Inc. (p.k.a. MELA Sciences, Inc.)(3)		Medical Devices & Equipment		Warrant		Common Stock			69,320				402				—
ViewRay, Inc.(3)(14)		Medical Devices & Equipment		Warrant		Common Stock			128,231				333				84
Subtotal: Medical Devices & Equipment (0.34%)*													6,564				2,442
Semiconductors
Achronix Semiconductor Corporation(14)		Semiconductors		Warrant		Preferred Series C			360,000				160				27
		Semiconductors		Warrant		Preferred Series D-1			500,000				6				6
Total Achronix Semiconductor Corporation									860,000				166				33
Aquantia Corp.		Semiconductors		Warrant		Preferred Series G			196,831				4				39
Avnera Corporation		Semiconductors		Warrant		Preferred Series E			141,567				47				65
Subtotal: Semiconductors (0.02%)*													217				137
Software
Actifio, Inc.		Software		Warrant		Common Stock			73,584				249				210
Braxton Technologies, LLC		Software		Warrant		Preferred Series A			168,750				188				—
CareCloud Corporation(14)		Software		Warrant		Preferred Series B			413,433				258				625
Clickfox, Inc.(14)		Software		Warrant		Preferred Series B			1,038,563				330				362
		Software		Warrant		Preferred Series C			592,019				730				272
		Software		Warrant		Preferred Series C-A			46,109				13				16
Total Clickfox, Inc.									1,676,691				1,073				650
Hillcrest Laboratories, Inc.(14)		Software		Warrant		Preferred Series E			1,865,650				55				138
JumpStart Games, Inc. (p.k.a Knowledge Holdings, Inc.)(14)		Software		Warrant		Preferred Series E			614,333				16				—
Message Systems, Inc.(14)		Software		Warrant		Preferred Series B			408,011				334				497
Mobile Posse, Inc.(14)		Software		Warrant		Preferred Series C			396,430				130				59
Neos, Inc.(14)		Software		Warrant		Common Stock			221,150				22				113
NewVoiceMedia Limited(4)(9)		Software		Warrant		Preferred Series E			225,586				33				55
Poplicus, Inc.(14)		Software		Warrant		Preferred Series C			2,595,230				—				110
Soasta, Inc.(14)		Software		Warrant		Preferred Series E			410,800				691				561
Sonian, Inc.(14)		Software		Warrant		Preferred Series C			185,949				106				39
Touchcommerce, Inc.(14)		Software		Warrant		Preferred Series E			2,282,968				446				581
Subtotal: Software (0.51%)*													3,601				3,638
Specialty Pharmaceuticals
Alimera Sciences, Inc.(3)		Specialty Pharmaceuticals		Warrant		Common Stock			660,377				729				435
QuatRx Pharmaceuticals Company		Specialty Pharmaceuticals		Warrant		Preferred Series E			155,324				307				—
Subtotal: Specialty Pharmaceuticals (0.06%)*													1,036				435

 

See notes to consolidated financial statements.

 

F-121

---

Table of Contents

Index to Financial Statements

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2015

(unaudited)

(dollars in thousands)

 

Portfolio Company		Sub-Industry		Type of Investment(1)		Series		Shares				Cost(2)				Value(3)
Surgical Devices
Gynesonics, Inc.(14)		Surgical Devices		Warrant		Preferred Series C			180,480			$	75			$	12
		Surgical Devices		Warrant		Preferred Series D			1,575,965				320				223
Total Gynesonics, Inc.									1,756,445				395				235
Transmedics, Inc.		Surgical Devices		Warrant		Preferred Series B			40,436				224				2
		Surgical Devices		Warrant		Preferred Series D			175,000				100				170
		Surgical Devices		Warrant		Preferred Series F			16,476				3				3
Total Transmedics, Inc.									231,912				327				175
Subtotal: Surgical Devices (0.06%)*													722				410
Total: Warrant Investments (3.21%)*													40,761				22,987
Total Investments (167.42%)*												$	1,252,281			$	1,200,638

  

 

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $29.3 million, $81.4 million and $52.1 million respectively. The tax cost of investments is $1.3 billion.

(3)

Except for warrants in 37 publicly traded companies and common stock in 20 publicly traded companies, all investments are restricted at December 31, 2015 and were valued at fair value as determined in good faith by the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Non-U.S. company or the company’s principal place of business is outside the United States.

(5)	Affiliate investment as defined under the 1940 Act in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.

(6)	Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. There were no control investments at December 31, 2015.

(7)

Debt is on non-accrual status at December 31, 2015, and is therefore considered non-income producing. Note that at December 31, 2015, only the PIK interest is on non-accrual for the Company’s debt investment in Skycross, Inc and only the $2.1 million PIK loan is on non-accrual for the Company’s debt investment in One Planet Ops Inc. (p.k.a. Reply! Inc.).

(8)	Denotes that all or a portion of the debt investment is convertible senior debt.

(9)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(10)	Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitizations.

(11)	Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility.

(12)	Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.

(13)	Denotes that all or a portion of the debt investment includes an exit fee receivable. This fee ranges from 0.8% to 17.1% of the total debt commitment based on the contractual terms of our loan servicing agreements.

(14)	Denotes that all or a portion of the investment in this portfolio company is held by HT II or HT III, the Company’s wholly-owned SBIC subsidiaries.

(15)

The stated ‘maturity date’ for the Tectura assets reflects the last extension of the forbearance period on these loans. The borrower loans remain outstanding and management is continuing to work with the borrower to satisfy the obligations. The Company’s investment team and Investment Committee continue to closely monitor developments at the borrower company.

(16)	Repayment of debt investment is delinquent of the contractual maturity date.

See notes to consolidated financial statements.

 

F-122

---

Table of Contents

Index to Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business and Basis of Presentation

Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, McLean, VA, Santa Monica, CA., and Hartford, CT. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was taxed as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a regulated investment company, or RIC, under Subchapter M of the Code (see Note 5). As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 (“Financial Services – Investment Companies”) of the Accounting Standards Codification, as amended (“ASC”).

Hercules Technology II, L.P. (“HT II”), Hercules Technology III, L.P. (“HT III”), and Hercules Technology IV, L.P. (“HT IV”), are Delaware limited partnerships that were formed in January 2005, September 2009 and December 2010, respectively. HT II and HT III were licensed to operate as small business investment companies (“SBICs”) under the authority of the Small Business Administration (“SBA”) on September 27, 2006 and May 26, 2010, respectively. As SBICs, HT II and HT III are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. HT IV was formed in anticipation of receiving an additional SBIC license; however, the Company has not yet applied for such license, and HT IV currently has no material assets or liabilities. The Company also formed Hercules Technology SBIC Management, LLC, or (“HTM”), a limited liability company in November 2003. HTM is a wholly owned subsidiary of the Company and serves as the limited partner and general partner of HT II and HT III (see Note 4 to the Company’s consolidated financial statements).

HT II and HT III hold approximately $111.6 million and $289.1 million in assets, respectively, and they accounted for approximately 6.6% and 17.1% of the Company’s total assets, respectively, prior to consolidation at March 31, 2016.

The Company also established wholly owned subsidiaries, all of which are structured as Delaware corporations and limited liability companies, to hold portfolio companies organized as limited liability companies, or LLCs (or other forms of pass-through entities). By investing through these wholly owned subsidiaries, the Company is able to benefit from the tax treatment of these entities and create a tax structure that is more advantageous with respect to the Company’s RIC status. These taxable subsidies are consolidated for U.S. GAAP financial reporting purposes, and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and recorded at fair value. The taxable subsidiaries are not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments

The consolidated financial statements include the accounts of the Company, its subsidiaries and its consolidated securitization VIE. All significant inter-company accounts and transactions have been eliminated in consolidation. In accordance with Article 6 and 10 of Regulation S-X the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company does not consolidate portfolio company investments. It is not appropriate for an investment company to consolidate a portfolio company that is not an investment company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC 946.

 

F-123

---

Table of Contents

Index to Financial Statements

The accompanying consolidated interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X under the Exchange Act. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the period ended December 31, 2015. The year-end Consolidated Statement of Assets and Liabilities data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.

Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries and all VIEs of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

As of the date of this report, the VIE consolidated by the Company is its securitization VIE formed in conjunction with the issuance of the 2021 Asset-Backed Notes (as defined herein). See “Note 4 – Borrowings”.

 

F-124

---

Table of Contents

Index to Financial Statements

Reclassification

Certain balances from prior years have been reclassified in order to conform to the current year presentation.

Change in Accounting Principle

As of January 1, 2016, the Company adopted Accounting Standards Update (“ASU”) 2015-03 “Simplifying the Presentation of Debt Issuance Costs” and ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which require debt issuance costs to be presented on the balance sheet as a direct deduction from the associated debt liability, except for debt issuance costs associated with line-of-credit arrangements. Adoption of these standards results in the reclassification of debt issuance costs from Other Assets and the presentation of the Company’s SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes net of the associated debt issuance costs for each instrument in the liabilities section on the Consolidated Statement of Assets and Liabilities. In addition, the comparative Consolidated Statement of Assets and Liabilities as of December 31, 2015 has been adjusted to apply the change in accounting principle retrospectively. Specifically, the presentation of the Company’s Other Assets, SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes line items were adjusted by the amount of unamortized debt issuance costs for each instrument. There is no impact to the Company’s Consolidated Statement of Operations. In addition, there is no change to the presentation of the Wells Facility as debt issuance costs are presented separately as an asset on the Consolidated Statement of Assets and Liabilities.

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the straight line method, which closely approximates the effective yield method. In accordance with ASU 2015-03 debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statement of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements. Debt issuance costs, net of accumulated amortization, were as follows as of March 31, 2016 and December 31, 2015.

 

(in thousands)		March 31, 2016				December 31, 2015
SBA Debentures		$	3,203			$	3,371
2019 Notes			2,025				2,185
2024 Notes			2,789				2,872
2021 Asset-Backed Notes			2,073				2,305
Convertible Senior Notes			12				44
Wells Facility(1)			737				669
Union Bank Facility(1)			190				229
Total		$	11,029			$	11,675

 

(1)	As the Wells Facility and Union Bank Facility are line-of-credit arrangements, the debt issuance costs associated with these instruments are presented separately as an asset on the Consolidated Statement of Assets and Liabilities in accordance with ASU 2015-15.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At March 31, 2016, approximately 97.0% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC 946 and measured in accordance with ASC 820 (“Fair Value Measurements”). The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable

 

F-125

---

Table of Contents

Index to Financial Statements

technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy by the Company’s Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

The Company may from time to time engage an independent valuation firm to provide the Company with valuation assistance with respect to certain portfolio investments on a quarterly basis. The Company engages independent valuation firms on a discretionary basis. Specifically, on a quarterly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm.

The Company intends to continue to engage an independent valuation firm to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of services rendered by an independent valuation firm is at the discretion of the Board of Directors. The Company’s Board of Directors is ultimately, and solely, responsible for determining the fair value of the Company’s investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Company’s Board of Directors has approved a multi-step valuation process each quarter, as described below:

(1) the Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with the Company’s investment committee;

(3) the Audit Committee of the Board of Directors reviews the preliminary valuation of the investments in the portfolio as provided by the investment committee, which incorporates the results of the independent valuation firm as appropriate; and

(4) the Board of Directors, upon the recommendation of the Audit Committee, discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the investment committee.

ASC 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

 

F-126

---

Table of Contents

Index to Financial Statements

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publically held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2016 and as of December 31, 2015. The Company transfers investments in and out of Level 1, 2 and 3 securities as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period. During the three months ended March 31, 2016, there were no transfers between Levels 1 or 2.

 

(in thousands) Description		Balance March 31, 2016				Quoted Prices  In Active Markets For Identical Assets (Level 1)				Significant Other  Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)
Senior Secured Debt		$	1,205,673			$	—			$	5,475			$	1,200,198
Preferred Stock			35,542				—				—				35,542
Common Stock			26,599				25,531				—				1,068
Warrants			23,496				—				3,641				19,855
Escrow Receivable			2,967				—				—				2,967
Total		$	1,294,277			$	25,531			$	9,116			$	1,259,630
(in thousands) Description		Balance December  31, 2015				Quoted Prices In Active Markets For Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)
Senior Secured Debt		$	1,110,209			$	—			$	7,813			$	1,102,396
Preferred Stock			35,245				—				—				35,245
Common Stock			32,197				30,670				—				1,527
Warrants			22,987				—				4,422				18,565
Escrow Receivable			2,967				—				—				2,967
Total		$	1,203,605			$	30,670			$	12,235			$	1,160,700

 

F-127

---

Table of Contents

Index to Financial Statements

The table below presents a reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three months ended March 31, 2016 and the year ended December 31, 2015.

 

(in thousands)		Balance January  1, 2016				Net Realized Gains (Losses)(1)				Net Change in Unrealized Appreciation (Depreciation)(2)				Purchases(5)				Sales				Repayments(6)				Gross Transfers into Level 3(3)				Gross Transfers out of Level 3(3)				Balance March  31, 2016
Senior Debt		$	1,102,396			$	(6,451	)		$	6,112			$	175,552			$	—			$	(77,411	)		$	—			$	—			$	1,200,198
Preferred Stock			35,245				(150	)			156				1,000				—				—				52				(761	)			35,542
Common Stock			1,527				—				(1,220	)			—				—				—				761				—				1,068
Warrants			18,565				(106	)			(91	)			1,539				—				—				—				(52	)			19,855
Escrow Receivable			2,967				—				—				—				—				—				—				—				2,967
Total		$	1,160,700			$	(6,707	)		$	4,957			$	178,091			$	—			$	(77,411	)		$	813			$	(813	)		$	1,259,630

 

(in thousands)		Balance January  1, 2015				Net Realized Gains (Losses)(1)				Net Change in Unrealized Appreciation (Depreciation)(2)				Purchases(5)				Sales				Repayments(6)				Gross Transfers into Level 3(4)				Gross Transfers out of Level 3(4)				Balance December  31, 2015
Senior Debt		$	923,906			$	(2,295	)		$	(12,930	)		$	699,555			$	—			$	(505,274	)		$	—			$	(566	)		$	1,102,396
Preferred Stock			57,548				2,598				(1,539	)			15,076				(4,542	)			—				685				(34,581	)			35,245
Common Stock			1,387				(298	)			743				—				(305	)			—				—				—				1,527
Warrants			21,923				(3,849	)			(4,749	)			5,311				1,220				—				—				(1,291	)			18,565
Escrow Receivable			3,598				71				—				511				(1,032	)			(181	)			—				—				2,967
Total		$	1,008,362			$	(3,773	)		$	(18,475	)		$	720,453			$	(4,659	)		$	(505,455	)		$	685			$	(36,438	)		$	1,160,700

 

(1)	Included in net realized gains or losses in the accompanying Consolidated Statement of Operations.

(2)	Included in change in net unrealized appreciation (depreciation) in the accompanying Consolidated Statement of Operations.

(3)

Transfers out of Level 3 during the three months ended March 31, 2016 relate to the exercise of warrants in Ping Identity Corporation to preferred stock and the conversion of the Company’s preferred shares to common shares in SCIEnergy, Inc. Transfers into Level 3 during the three months ended March 31, 2016 relate to the acquisition of preferred stock as a result of the exercise of warrants in Ping Identity Corporation and the conversion of the Company’s preferred shares to common shares in SCIEnergy, Inc..

(4)

Transfers out of Level 3 during the year ended December 31, 2015 relate to the initial public offerings, or IPOs of Box, Inc., ZP Opco, Inc. (p.k.a. Zosano Pharma, Inc), Neos Therapeutics, Edge Therapeutics Inc., ViewRay, Inc., and Cerecor, Inc. in addition to the exercise of warrants in both Forescout, Inc. and Atrenta, Inc. to preferred stock. Transfers into Level 3 during the year ended December 31, 2015 relate to the acquisition of preferred stock as a result of the exercise of warrants in both Forescout, Inc. and Atrenta, Inc and the conversion of debt to equity in Home Dialysis Plus and Gynesonics.

(5)	Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period.

(6)	Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures.

For the three months ended March 31, 2016, approximately $104,000 in net unrealized appreciation and $1.2 million in net unrealized depreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $6.1 million in net unrealized depreciation and $45,000 in net unrealized appreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

For the year ended December 31, 2015, approximately $179,000 in net unrealized depreciation and $745,000 in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $13.7 million and $5.9 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

The following tables provide quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of March 31, 2016 and December 31, 2015. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy the Company may also use other valuation techniques and methodologies when determining the Company’s fair value

 

F-128

---

Table of Contents

Index to Financial Statements

measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements.

The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.

 

Investment Type -Level Three Debt Investments		Fair Value at March 31, 2016 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(b)
Pharmaceuticals			$92,845			Originated Within 6 Months		Origination Yield		12.00% - 14.48%		13.15%
			430,402			Market Comparable Companies		Hypothetical Market Yield		8.86% - 16.81%		12.39%
								Premium/(Discount)		(0.75%) - 1.00%
Technology			55,262			Originated Within 6 Months		Origination Yield		11.00% - 15.73%		13.78%
			273,064			Market Comparable Companies		Hypothetical Market Yield		10.75% - 17.85%		13.38%
								Premium/(Discount)		(0.50%) - 0.50%
			28,591			Liquidation(c)		Probability weighting of alternative outcomes		5.00% - 100.00%
Sustainable and Renewable Technology			22,270			Originated Within 6 Months		Origination Yield		12.74% - 16.13%		15.00%
			102,890			Market Comparable Companies		Hypothetical Market Yield		7.54% - 25.68%		17.60%
								Premium/(Discount)		(0.50%) - 0.00%
			1,106			Liquidation(c)		Probability weighting of alternative outcomes		100.00%
Medical Devices			8,253			Originated Within 6 Months		Origination Yield		15.34%		15.34%
			77,067			Market Comparable Companies		Hypothetical Market Yield		10.73% - 19.86%		14.67%
								Premium/(Discount)		0.00% - 0.50%
			5,110			Liquidation(c)		Probability weighting of alternative outcomes		25.00% - 75.00%
Lower Middle Market			5,436			Originated Within 6 Months		Origination Yield		13.61% - 14.50%		14.10%
			14,723			Market Comparable Companies		Hypothetical Market Yield		13.78%		13.78%
								Premium/(Discount)		0.25%
			15,761			Liquidation(c)		Probability weighting of alternative outcomes		20.00% - 60.00%
						Debt Investments Where Fair Value Approximates Cost
			14,074			Imminent Payoffs(d)
			53,344			Debt Investments Maturing in Less than One Year
			$1,200,198			Total Level Three Debt Investments

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:

 

•

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery and Biotechnology Tools industries in the Consolidated Schedule of Investments.

 

•

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Consumer and Business Products, Information Services, and Communications and Networking industries in the Consolidated Schedule of Investments.

 

•

Sustainable and Renewable Technology, above, aligns with the Sustainable and Renewable Technology Industry in the Consolidated Schedule of Investments.

 

•

Medical Devices, above, is comprised of debt investments in the Surgical Devices and Medical Devices and Equipment industries in the Consolidated Schedule of Investments.

 

•

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services—Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Consolidated Schedule of Investments.

 

(b)	The weighted averages are calculated based on the fair market value of each investment.

(c)	The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

(d)	Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

 

F-129

---

Table of Contents

Index to Financial Statements

Investment Type -Level Three Debt Investments		Fair Value  at December 31, 2015 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(b)
Pharmaceuticals			$72,981 406,590			Originated Within 6 Months Market Comparable Companies		Origination Yield Hypothetical Market Yield Premium/(Discount)		10.35% - 16.16% 9.55% - 16.75% (0.75%) - 0.00%		12.29% 12.67%
Technology			6,873 283,045   36,815			Originated Within 6 Months Market Comparable Companies   Liquidation(c)		Origination Yield Hypothetical Market Yield Premium/(Discount) Probability weighting of alternative outcomes		15.19% 6.57% - 23.26% (0.25% - 0.50%) 10.00% - 100.00%		15.19% 13.22%
Sustainable and Renewable Technology			11,045 105,382   1,013			Originated Within 6 Months Market Comparable Companies   Liquidation(c)		Origination Yield Hypothetical Market Yield Premium/(Discount) Probability weighting of alternative outcomes		19.74% 10.62% - 27.31% 0.00% 100.00%		19.74% 15.91%
Medical Devices			80,530   3,764			Market Comparable Companies   Liquidation(c)		Hypothetical Market Yield Premium/(Discount) Probability weighting of alternative outcomes		11.65% - 19.90% 0.00% - 0.50% 50.00%		15.26%
Lower Middle Market			17,811 15,151			Originated Within 6 Months Liquidation(c)		Origination Yield Probability weighting of alternative outcomes		12.70% - 14.50% 25.00% - 75.00%		13.00%
						Debt Investments Where Fair Value Approximates Cost
			12,434			Imminent Payoffs(d)
			48,962			Debt Investments Maturing in Less than One Year
			$1,102,396			Total Level Three Debt Investments

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:

 

•

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development and Drug Delivery industries in the Consolidated Schedule of Investments.

 

•

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Consumer and Business Products, Information Services, and Communications and Networking industries in the Consolidated Schedule of Investments.

 

•

Sustainable and Renewable Technology, above, aligns with the Sustainable and Renewable Technology Industry in the Consolidated Schedule of Investments.

 

•

Medical Devices, above, is comprised of debt investments in the Surgical Devices and Medical Devices and Equipment industries in the Consolidated Schedule of Investments.

 

•

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services—Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Consolidated Schedule of Investments.

 

(b)	The weighted averages are calculated based on the fair market value of each investment.

(c)	The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

(d)	Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

 

F-130

---

Table of Contents

Index to Financial Statements

Investment Type -Level Three Equity and Warrant Investments		Fair Value  at March 31, 2016 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(e)
Equity Investments			$5,518			Market Comparable Companies		EBITDA Multiple(b)		4.3x - 20.8x		7.5x
								Revenue Multiple(b)		0.7x - 3.8x		2.0x
								Discount for Lack of Marketability(c)		15.08% - 26.98%		17.22%
								Average Industry Volatility(d)		40.32% - 111.12%		64.44%
								Risk-Free Interest Rate		0.56% - 0.74%		0.60%
								Estimated Time to Exit (in months)		10 - 23		12
			31,092			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 82.81%		66.30%
								Risk-Free Interest Rate		0.54% - 1.36%		0.72%
								Estimated Time to Exit (in months)		10 - 47		17
Warrant Investments			9,115			Market Comparable Companies		EBITDA Multiple(b)		5.4x - 50.0x		11.3x
								Revenue Multiple(b)		0.5x - 7.3x		1.9x
								Discount for Lack of Marketability(c)		15.15% -  32.23%		20.70%
								Average Industry Volatility(d)		36.84% - 98.38%		56.47%
								Risk-Free Interest Rate		0.54% - 1.11%		0.59%
								Estimated Time to Exit (in months)		10 - 50		16
			10,740			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 111.12%		65.82%
								Risk-Free Interest Rate		0.44% - 1.43%		0.78%
								Estimated Time to Exit (in months)		7 - 47		21
Total Level Three Warrant and Equity Investments			$56,465

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model (“OPM”) include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

(e)	Weighted averages are calculated based on the fair market value of each investment.

 

F-131

---

Table of Contents

Index to Financial Statements

Investment Type -Level Three Equity and Warrant Investments		Fair Value at December 31, 2015 (in thousands)				Valuation Techniques/ Methodologies		Unobservable Input(a)		Range		Weighted Average(e)
Equity Investments			$5,898			Market Comparable Companies		EBITDA Multiple(b)		3.3x - 19.5x		7.6x
								Revenue Multiple(b)		0.7x - 3.7x		2.1x
								Discount for Lack of Marketability(c)		14.31% - 25.11%		18.05%
								Average Industry Volatility(d)		37.72% - 109.64%		60.27%
								Risk-Free Interest Rate		0.61% - 1.09%		0.74%
								Estimated Time to Exit (in months)		10 - 26		15
			30,874			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 86.41%		65.40%
								Risk-Free Interest Rate		0.36% - 1.51%		0.80%
								Estimated Time to Exit (in months)		10 - 47		17
Warrant Investments			7,904			Market Comparable Companies		EBITDA Multiple(b)		5.1x - 57.9x		16.0x
								Revenue Multiple (b)		0.4x - 9.6x		3.0x
								Discount for Lack of Marketability(c)		10.09% - 31.37%		23.11%
								Average Industry Volatility(d)		39.51% - 73.36%		41.19%
								Risk-Free Interest Rate		0.32% - 1.51%		0.87%
								Estimated Time to Exit (in months)		4 - 47		23
			10,661			Market Adjusted OPM Backsolve		Average Industry Volatility(d)		28.52% - 109.64%		64.31%
								Risk-Free Interest Rate		0.36% - 1.45%		0.85%
								Estimated Time to Exit (in months)		10 - 44		20
Total Level Three Warrant and Equity Investments			$55,337

 

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes OPM include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

(e)	Weighted averages are calculated based on the fair market value of each investment.

Debt Investments

The Company follows the guidance set forth in ASC 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. In addition, the Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives. These investments are considered Level 2 assets.

 

F-132

---

Table of Contents

Index to Financial Statements

In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued to principal as earned. The Company then applies the valuation methods as set forth below.

The Company applies a procedure for debt investments that assumes the sale of each investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to determine the change in market yields between inception of the debt security and the measurement date. Industry specific indices and other relevant market data are used to benchmark/assess market based movements.

Under this process, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated debt investments using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt security is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt security is greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Debt investments that are traded on a public exchange will be valued at the prevailing market price at period end.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes OPM. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market

 

F-133

---

Table of Contents

Index to Financial Statements

conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Portfolio Composition

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes the Company’s realized and unrealized gain and loss and changes in our unrealized appreciation and depreciation on affiliate investments for the three months ended March 31, 2016 and 2015. The Company did not hold any Control investments at either March 31, 2016 or 2015.

 

(in thousands)										For the Three Months Ended March 31, 2016
Portfolio Company		Type				Fair Value at March  31, 2016				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation / (Depreciation)				Realized Gain/(Loss)
Optiscan BioMedical, Corp.			Affiliate			$	6,991			$	7			$	(413	)		$	—			$	—
Stion Corporation			Affiliate				1,106				58				539				—				—
Total						$	8,097			$	65			$	126			$	—			$	—
(in thousands)										For the Three Months Ended March 31, 2015
Portfolio Company		Type				Fair Value at March 31, 2015				Investment Income				Net Change in Unrealized Appreciation/ (Depreciation)				Reversal of Unrealized Appreciation / (Depreciation)				Realized Gain/(Loss)
Gelesis, Inc.			Affiliate			$	2,414			$	—			$	2,087			$	—			$	—
Optiscan BioMedical, Corp.			Affiliate				6,768				—				695				—				—
Stion Corporation			Affiliate				1,600				101				(469	)			—				—
Total						$	10,782			$	101			$	2,313			$	—			$	—

As of December 31, 2015, changes to the capitalization structure of the portfolio company Gelesis, Inc. reduced the Company’s investment below the threshold for classification as an affiliate investment.

 

F-134

---

Table of Contents

Index to Financial Statements

The following table shows the fair value of the Company’s portfolio of investments by asset class as of March 31, 2016 and December 31, 2015:

 

		March 31, 2016								December 31, 2015
(in thousands)		Investments at Fair  Value				Percentage of Total  Portfolio				Investments at Fair  Value				Percentage of Total  Portfolio
Senior Secured Debt with Warrants		$	1,007,751				78.0	%		$	961,464				80.1	%
Senior Secured Debt			221,418				17.1	%			171,732				14.3	%
Preferred Stock			35,542				2.8	%			35,245				2.9	%
Common Stock			26,599				2.1	%			32,197				2.7	%
Total		$	1,291,310				100.0	%		$	1,200,638				100.0	%

A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2016 and December 31, 2015 is shown as follows:

 

		March 31, 2016								December 31, 2015
(in thousands)		Investments at Fair Value				Percentage of Total  Portfolio				Investments at Fair Value				Percentage of Total  Portfolio
United States		$	1,243,362				96.3	%		$	1,167,281				97.2	%
Netherlands			20,158				1.6	%			20,112				1.7	%
England			18,553				1.4	%			8,884				0.8	%
Canada			5,507				0.4	%			595				0.0	%
Israel			3,730				0.3	%			3,764				0.3	%
India			—				0.0	%			2				0.0	%
Total		$	1,291,310				100.0	%		$	1,200,638				100.0	%

The following table shows the fair value of the Company’s portfolio by industry sector at March 31, 2016 and December 31, 2015:

 

		March 31, 2016								December 31, 2015
(in thousands)		Investments at Fair Value				Percentage of Total  Portfolio				Investments at Fair Value				Percentage of Total  Portfolio
Drug Discovery & Development		$	321,359				24.9	%		$	284,266				23.7	%
Sustainable and Renewable Technology			178,532				13.8	%			159,487				13.3	%
Software			157,769				12.2	%			147,237				12.3	%
Drug Delivery			157,756				12.2	%			164,665				13.7	%
Medical Devices & Equipment			110,312				8.6	%			90,560				7.5	%
Media/Content/Info			106,652				8.3	%			95,488				7.9	%
Internet Consumer & Business Services			102,571				8.0	%			88,377				7.4	%
Specialty Pharmaceuticals			50,416				3.9	%			52,088				4.3	%
Communications & Networking			25,055				1.9	%			33,213				2.8	%
Consumer & Business Products			23,016				1.8	%			26,611				2.2	%
Semiconductors			16,711				1.3	%			22,705				1.9	%
Healthcare Services, Other			15,289				1.2	%			15,131				1.3	%
Surgical Devices			10,874				0.8	%			11,185				0.9	%
Electronics & Computer Hardware			6,936				0.5	%			6,928				0.6	%
Biotechnology Tools			6,690				0.5	%			719				0.1	%
Information Services			1,308				0.1	%			1,657				0.1	%
Diagnostic			64				0.0	%			321				0.0	%
Total		$	1,291,310				100.0	%		$	1,200,638				100.0	%

No single portfolio investment represents more than 10% of the fair value of the investments as of March 31, 2016 and December 31, 2015.

Portfolio Activity

During the three months ended March 31, 2016, the Company funded and or restructured investments in debt securities totaling approximately $169.9 million. During the three months ended March 31, 2016, the Company funded equity investments totaling approximately $1.0 million.

 

F-135

---

Table of Contents

Index to Financial Statements

During the three months ended March 31, 2015, the Company funded and or restructured investments in debt securities totaling approximately $207.0 million. During the three months ended March 31, 2015, the Company funded equity investments totaling approximately $2.4 million.

During the three months ended March 31, 2016, the Company recognized net realized losses of approximately $4.5 million. During the three months ended March 31, 2016, the Company recorded gross realized gains of approximately $2.8 million primarily from the sale of investments in two portfolio companies, including Celator Pharmaceuticals, Inc. ($1.5 million) and the sale of options on Box, Inc. ($1.1 million). These gains were offset by gross realized losses of approximately $7.3 million primarily from the liquidation or write off of the Company’s investment in six portfolio companies, including the settlement of our outstanding debt investment in The Neat Company ($6.2 million).

During the three months ended March 31, 2015, the Company recognized net realized gains of approximately $3.3 million. During the three months ended March 31, 2015, the Company recorded gross realized gains of approximately $4.3 million primarily from the sale of investments in four portfolio companies, including Cempra, Inc. ($2.0 million), Celladon Corporation ($1.4 million), Everyday Health, Inc. ($387,000) and Identiv, Inc. ($304,000). These gains were partially offset by gross realized losses of approximately $1.0 million from the liquidation of the Company’s investments in three portfolio companies.

Investment Collateral

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. At March 31, 2016, approximately 91.8% of the Company’s debt investments were in a senior secured first lien position, with 40.4% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property; 48.1% secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property, or subject to a negative pledge; and 3.3% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, with a second lien on the portfolio company’s cash and accounts receivable. The remaining 8.2% of the Company’s debt investments were secured by a second priority security interest in all of the portfolio company’s assets, other than intellectual property. At March 31, 2016 the Company had no equipment only liens on material investments in the Company’s portfolio companies.

Income Recognition

The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect that principal, interest and other obligations due will be collected in full, the Company will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal and interest due has been paid or the Company believes the portfolio company has demonstrated the ability to repay the Company’s current and future contractual obligations. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, the Company may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

At March 31, 2016, the Company had four debt investments on non-accrual with a cumulative investment cost and approximate fair value of $49.8 million and $27.2 million, respectively. At December 31, 2015, the Company had five debt investments on non-accrual with cumulative investment cost and fair value of approximately $47.4 million and $23.2 million, respectively. In addition, at December 31, 2015, the Company

 

F-136

---

Table of Contents

Index to Financial Statements

had one debt investment with an investment cost and fair value of approximately $20.1 million and $14.9 million, respectively, for which only the PIK interest is on non-accrual. During the three months ended March 31, 2016, the Company recognized a realized loss of approximately $6.2 million on the settlement of one debt investment that was on non-accrual at December 31, 2015. In addition, the Company recognized a realized loss of $430,000 on the partial write off of one debt investment that was on non-accrual as of December 31, 2015.

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by us to portfolio companies and other third parties. Loan and commitment fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $26.8 million of unamortized fees at March 31, 2016, of which approximately $24.3 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $2.5 million was deferred contingent upon the occurrence of a funding or milestone. At December 31, 2015 the Company had approximately $26.1 million of unamortized fees, of which approximately $23.6 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $2.5 million was deferred contingent upon the occurrence of a funding or milestone.

The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fees, including prepayment penalties, fees related to select covenant default waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding.

In addition, the Company may also be entitled to an end-of-term payment that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At March 31, 2016 the Company had approximately $26.0 million in exit fees receivable, of which approximately $20.8 million was included as a component of the cost basis of the Company’s current debt investments and approximately $5.2 million was a deferred receivable related to expired commitments. At December 31, 2015 the Company had approximately $22.7 million in exit fees receivable, of which approximately $17.4 million was included a component of the cost basis of the Company’s current debt investments and approximately $5.3 million was a deferred receivable related to expired commitments.

The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $1.7 million and $907,000 in PIK income during the three months ended March 31, 2016 and 2015, respectively.

To maintain the Company’s status as a RIC, PIK and end-of-term income must be paid out to stockholders in the form of dividends even though the Company has not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three months ended March 31, 2016 and 2015.

 

F-137

---

Table of Contents

Index to Financial Statements

3. Fair Value of Financial Instruments

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The Company believes that the carrying amounts of its financial instruments, consisting of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The Convertible Senior Notes, the April 2019 Notes, the September 2019 Notes (together with the April 2019 Notes, the “2019 Notes”), the 2024 Notes, the 2021 Asset-Backed Notes, and the SBA debentures, provide a strategic advantage as sources of liquidity due to their flexible structure, long-term duration, and low fixed interest rates. At March 31, 2016, the April 2019 Notes were trading on the New York Stock Exchange, or NYSE, for $25.59 per share at par value, the September 2019 Notes were trading on the NYSE for $25.32 per share at par value and the 2024 Notes were trading on the NYSE for $25.12 per share at par value. The par value at underwriting for each of these notes was $25.00 per share. Based on market quotations on or around March 31, 2016, the Convertible Senior Notes were quoted for 1.086 per dollar at par value and the 2021 Asset-Backed Notes were quoted for 0.991 per dollar at par value. Calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms, the fair value of the SBA debentures would be approximately $196.7 million, compared to the carrying amount of $190.2 million as of March 31, 2016. The fair value of the outstanding borrowings under the Wells Facility at March 31, 2016 is equal to its transaction price as the Company added Alostar Bank of Commerce as an additional lender to the agreement with Wells Fargo Capital Finance, LLC at the same terms in March 2016.

See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in Note 2.

The liabilities of the Company are recorded at amortized cost and not at fair value on the Consolidated Statement of Assets and Liabilities. The following tables provide additional information about the fair value and level in the fair value hierarchy of the Company’s liabilities at March 31, 2016 and December 31, 2015:

 

(in thousands) Description		March 31, 2016				Identical Assets (Level 1)				Observable Inputs (Level 2)				Unobservable Inputs (Level 3)
Convertible Senior Notes		$	19,111			$	—			$	19,111			$	—
Wells Facility			61,003				—				—				61,003
2021 Asset-Backed Notes			128,169				—				128,169				—
April 2019 Notes			66,012				—				66,012				—
September 2019 Notes			46,462				—				46,462				—
2024 Notes			103,494				—				103,494				—
SBA Debentures			196,692				—				—				196,692
Total		$	620,943			$	—			$	363,248			$	257,695

 

(in thousands) Description		December 31, 2015				Identical Assets (Level 1)				Observable Inputs (Level 2)				Unobservable Inputs (Level 3)
Convertible Senior Notes		$	19,540			$	—			$	19,540			$	—
Wells Facility			50,000				—				—				50,000
2021 Asset-Backed Notes			128,775				—				128,775				—
April 2019 Notes			65,573				—				65,573				—
September 2019 Notes			46,297				—				46,297				—
2024 Notes			104,401				—				104,401				—
SBA Debentures			194,121				—				—				194,121
Total		$	608,707			$	—			$	364,586			$	244,121

 

F-138

---

Table of Contents

Index to Financial Statements

4. Borrowings

Outstanding Borrowings

At March 31, 2016 and December 31, 2015, the Company had the following available borrowings and outstanding borrowings:

 

		March 31, 2016												December 31, 2015
(in thousands)		Total Available				Principal				Carrying Value(1)				Total Available				Principal				Carrying Value(1)
SBA Debentures(2)		$	190,200			$	190,200			$	186,997			$	190,200			$	190,200			$	186,829
2019 Notes			110,364				110,364				108,339				110,364				110,364				108,179
2024 Notes			103,000				103,000				100,211				103,000				103,000				100,128
2021 Asset-Backed Notes			129,300				129,300				127,227				129,300				129,300				126,995
Convertible Senior Notes			17,604				17,604				17,572				17,604				17,604				17,478
Wells Facility(3)			95,000				61,003				61,003				75,000				50,000				50,000
Union Bank Facility(3)			75,000				—				—				75,000				—				—
Total		$	720,468			$	611,471			$	601,349			$	700,468			$	600,468			$	589,609

 

(1)

Except for the Wells Facility and Union Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted discount, if any, associated with the loan as of the balance sheet date. See “Note 2—Summary of Significant Accounting Policies” for the amount of debt issuance cost associated with each borrowing.

(2)	At both March 31, 2016 and December 31, 2015, the total available borrowings under the SBA debentures were $190.2 million, of which $41.2 million was available in HT II and $149.0 million was available in HT III.

(3)	Availability subject to the Company meeting the borrowing base requirements.

Long-Term SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. Under the Small Business Investment Company Act and current SBA policy applicable to SBICs, a SBIC can have outstanding at any time SBA guaranteed debentures up to twice the amount of its regulatory capital. With the Company’s net investment of $44.0 million in HT II as of March 31, 2016, HT II has the capacity to issue a total of $41.2 million of SBA guaranteed debentures, subject to SBA approval, of which $41.2 million was outstanding as of March 31, 2016. As of March 31, 2016, HT II has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2016 the Company held investments in HT II in 35 companies with a fair value of approximately $98.7 million, accounting for approximately 7.6% of the Company’s total portfolio at March 31, 2016. HT II held approximately $111.6 million in assets and accounted for approximately 6.6% of the Company’s total assets prior to consolidation at March 31, 2016.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With the Company’s net investment of $74.5 million in HT III as of March 31, 2016, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, of which $149.0 million was outstanding as of March 31, 2016. As of March 31, 2016, HT III has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2016, the Company held investments in HT III in 49 companies with a fair value of approximately $272.5 million, accounting for approximately 21.1% of the Company’s total portfolio at March 31, 2016. HT III held approximately $289.1 million in assets and accounted for approximately 17.1% of the Company’s total assets prior to consolidation at March 31, 2016.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $19.5 million and have average annual fully taxed net income not exceeding $6.5 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual

 

F-139

---

Table of Contents

Index to Financial Statements

fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through the Company’s wholly-owned subsidiaries HT II and HT III, the Company plans to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to the Company if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect the Company because HT II and HT III are the Company’s wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2016 as a result of having sufficient capital as defined under the SBA regulations.

The rates of borrowings under various draws from the SBA beginning in March 2009 are set semiannually in March and September and range from 2.25% to 4.62% excluding annual fees. Interest payments on SBA debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of March 2009, the initial maturity of SBA debentures will occur in March 2019. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees on other debentures have been set at 0.906%. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.515%. The rates of borrowings on the Company’s SBA debentures range from 3.05% to 5.53% when including these annual fees.

The average amount of debentures outstanding for the three months ended March 31, 2016 for HT II was approximately $41.2 million with an average interest rate of approximately 4.52%. The average amount of debentures outstanding for the three months ended March 31, 2016 for HT III was approximately $149.0 million with an average interest rate of approximately 3.43%.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the SBA debentures are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,738			$	1,718
Amortization of debt issuance cost (loan fees)			168				165
Total interest expense and fees		$	1,906			$	1,883
Cash paid for interest expense and fees		$	3,461			$	3,442

As of March 31, 2016, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $350.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2016, with the Company’s net investment of $118.5 million, HT II and HT III have the capacity to issue a total of $190.2 million of SBA-guaranteed debentures, subject to SBA approval. At March 31, 2016, the Company has issued $190.2 million in SBA-guaranteed debentures in the Company’s SBIC subsidiaries.

 

F-140

---

Table of Contents

Index to Financial Statements

The Company reported the following SBA debentures outstanding principal balances as of March 31, 2016 and December 31, 2015:

 

(in thousands) Issuance/Pooling Date		Maturity Date		Interest  Rate(1)				March 31, 2016				December 31, 2015
SBA Debentures:
March 25, 2009		March 1, 2019			5.53	%		$	18,400			$	18,400
September 23, 2009		September 1, 2019			4.64	%			3,400				3,400
September 22, 2010		September 1, 2020			3.62	%			6,500				6,500
September 22, 2010		September 1, 2020			3.50	%			22,900				22,900
March 29, 2011		March 1, 2021			4.37	%			28,750				28,750
September 21, 2011		September 1, 2021			3.16	%			25,000				25,000
March 21, 2012		March 1, 2022			3.28	%			25,000				25,000
March 21, 2012		March 1, 2022			3.05	%			11,250				11,250
September 19, 2012		September 1, 2022			3.05	%			24,250				24,250
March 27, 2013		March 1, 2023			3.16	%			24,750				24,750
Total SBA Debentures								$	190,200			$	190,200

 

(1)	Interest rate includes annual charge

2019 Notes

On March 6, 2012, the Company and U.S. Bank National Association (the “2019 Trustee”) entered into an indenture (the “Base Indenture”). On April 17, 2012, the Company and the 2019 Trustee entered into the First Supplemental Indenture to the Base Indenture (the “First Supplemental Indenture”), dated April 17, 2012, relating to the Company’s issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

In July 2012, the Company reopened the Company’s April 2019 Notes and issued an additional $41.5 million in aggregate principal amount of April 2019 Notes, which included the exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

On September 24, 2012, the Company and the 2019 Trustee, entered into the Second Supplemental Indenture to the Base Indenture (the “Second Supplemental Indenture”), dated as of September 24, 2012, relating to the Company’s issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% notes due 2019 (the “September 2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

In October 2012, the underwriters exercised their over-allotment option for an additional $10.9 million of the September 2019 Notes, bringing the total amount of the September 2019 Notes issued to approximately $85.9 million in aggregate principal outstanding.

In April 2015, the Company redeemed $20.0 million of the $84.5 million issued and outstanding aggregate principal amount of April 2019 Notes, as previously approved by the Board of Directors. In December 2015 the Company redeemed $40.0 million of the $85.9 million issued and outstanding aggregate principal amount of September 2019 Notes, as previously approved by the Board of Directors.

As of March 31, 2016 and December 31, 2015, the 2019 Notes payable outstanding principal balance consists of:

 

(in thousands)		March 31, 2016				December 31, 2015
April 2019 Notes		$	64,490			$	64,490
September 2019 Notes			45,874				45,874
Total 2019 Notes Principal Outstanding		$	110,364			$	110,364

 

F-141

---

Table of Contents

Index to Financial Statements

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the NYSE under the trading symbol “HTGZ.”

The April 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grant security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring the Company’s compliance with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the 2019 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the First Supplemental Indenture. The Base Indenture provides for customary events of default and further provides that the 2019 Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The April 2019 Notes were sold pursuant to an underwriting agreement dated April 11, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the NYSE under the trading symbol “HTGY.”

The September 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

 

F-142

---

Table of Contents

Index to Financial Statements

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the 2019 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the Second Supplemental Indenture. The Base Indenture provides for customary events of default and further provides that the 2019 Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The September 2019 Notes were sold pursuant to an underwriting agreement dated September 19, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the April 2019 Notes and September 2019 Notes are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,932			$	2,981
Amortization of debt issuance cost (loan fees)			160				240
Total interest expense and fees		$	2,092			$	3,221
Cash paid for interest expense and fees		$	1,932			$	2,981

As of March 31, 2016, the Company was in compliance with the terms of the Base Indenture, and respective supplemental indentures thereto, governing the April 2019 Notes and September 2019 Notes.

2024 Notes

On July 14, 2014, the Company and U.S. Bank, N.A. (the “2024 Trustee”), entered into the Third Supplemental Indenture (the “Third Supplemental Indenture”) to the Base Indenture between the Company and the 2024 Trustee, dated July 14, 2014, relating to the Company’s issuance, offer and sale of $100.0 million aggregate principal amount of 2024 Notes. On August 6, 2014, the underwriters issued notification to exercise their over-allotment option for an additional $3.0 million in aggregate principal amount of the 2024 Notes. The sale of the 2024 Notes generated net proceeds of approximately $99.9 million.

The 2024 Notes will mature on July 30, 2024 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after July 30, 2017, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The 2024 Notes bear interest at a rate of 6.25% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2014, and trade on the NYSE under the trading symbol “HTGX.”

The 2024 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2024 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries.

 

F-143

---

Table of Contents

Index to Financial Statements

The Base Indenture, as supplemented by the Third Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act and to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) of the 1940 Act as modified by Section 61(a)(1) of the 1940 Act. These covenants are subject to important limitations and exceptions that are described in the Base Indenture, as supplemented by the Third Supplemental Indenture. The Base Indenture, as supplemented by the Third Supplemental Indenture, also contains certain reporting requirements, including a requirement that the Company provide financial information to the holders of the 2024 Notes and the 2024 Trustee if the Company should no longer be subject to the reporting requirements under the Exchange Act. The Base Indenture provides for customary events of default and further provides that the 2024 Trustee or the holders of 25% in aggregate principal amount of the outstanding 2024 Notes in a series may declare such 2024 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period. As of March 31, 2016, the Company was in compliance with the terms of the Base Indenture as supplemented by the Third Supplemental Indenture.

At both March 31, 2016 and December 31, 2015, the 2024 Notes had an outstanding principal balance of $103.0 million. See “Note 12—Subsequent Events”.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the 2024 Notes are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,609			$	1,609
Amortization of debt issuance cost (loan fees)			83				83
Total interest expense and fees		$	1,692			$	1,692
Cash paid for interest expense and fees		$	1,609			$	1,609

2021 Asset-Backed Notes

On November 13, 2014, the Company completed a $237.4 million term debt securitization in connection with which an affiliate of the Company made an offer of $129.3 million in aggregate principal amount of fixed rate asset-backed notes (the “2021 Asset-Backed Notes”), which were rated A(sf) by Kroll Bond Rating Agency, Inc. (“KBRA”). The 2021 Asset-Backed Notes were sold by Hercules Capital Funding Trust 2014-1 pursuant to a note purchase agreement, dated as of November 13, 2014, by and among the Company, Hercules Capital Funding 2014-1, LLC as trust depositor (the “2014 Trust Depositor”), Hercules Capital Funding Trust 2014-1 as issuer (the “2014 Securitization Issuer”), and Guggenheim Securities, LLC, as initial purchaser, and are backed by a pool of senior loans made to certain of the Company’s portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has an 18-month reinvestment period during which time principal collections may be reinvested into additional eligible loans. Interest on the 2021 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.524% per annum. The 2021 Asset-Backed Notes have a stated maturity of April 16, 2021.

As part of this transaction, the Company entered into a sale and contribution agreement with the 2014 Trust Depositor under which the Company has agreed to sell or have contributed to the 2014 Trust Depositor certain senior loans made to certain of the Company’s portfolio companies (the “2014 Loans”). The Company has made customary representations, warranties and covenants in the sale and contribution agreement with respect to the 2014 Loans as of the date of their transfer to the 2014 Trust Depositor.

In connection with the issuance and sale of the 2021 Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the note purchase agreement. The 2021 Asset-Backed Notes are secured obligations of the 2014 Securitization Issuer and are non-recourse to the Company. The 2014

 

F-144

---

Table of Contents

Index to Financial Statements

Securitization Issuer also entered into an indenture governing the 2021 Asset-Backed Notes, which includes customary representations, warranties and covenants. The 2021 Asset-Backed Notes were sold without being registered under the Securities Act of 1933, as amended, (the “Securities Act”) (A) in the United States to “qualified institutional buyers” as defined in Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rules 501(a)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” as defined in Sec. 2 (a)(51)(A) of the 1940 Act and pursuant to an exemption under the Securities Act and (B) to non-U.S. purchasers acquiring interest in the 2021 Asset-Backed Notes outside the United States in accordance with Regulation S under the Securities Act. The 2014 Securitization Issuer is not registered under the 1940 Act in reliance on an exemption provided by Section 3(c)(7) thereof and Rule 3a-7 thereunder. In addition, the 2014 Trust Depositor entered into an amended and restated trust agreement in respect of the 2014 Securitization Issuer, which includes customary representation, warranties and covenants.

The 2014 Loans are serviced by the Company pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. The Company performs certain servicing and administrative functions with respect to the 2014 Loans. The Company is entitled to receive a monthly fee from the 2014 Securitization Issuer for servicing the 2014 Loans. This servicing fee is equal to the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including October 5, 2014 through and including December 5, 2014 over 360) of 2.00% and the aggregate outstanding principal balance of the 2014 Loans plus collections on deposit in the 2014 Securitization Issuer’s collections account, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including October 5, 2014, to the close of business on December 5, 2014).The Company also serves as administrator to the 2014 Securitization Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At both March 31, 2016 and December 31, 2015, the 2021 Asset-Backed Notes had an outstanding principal balance of $129.3 million.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the 2021 Asset-Backed Notes are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	1,139			$	1,139
Amortization of debt issuance cost (loan fees)			232				222
Total interest expense and fees		$	1,371			$	1,361
Cash paid for interest expense and fees		$	1,139			$	1,139

Under the terms of the 2021 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2021 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. There was approximately $3.6 million and $9.2 million of restricted cash as of March 31, 2016 and December 31, 2015, respectively, funded through interest collections.

Convertible Senior Notes

In April 2011, the Company issued $75.0 million in aggregate principal amount of 6.00% convertible senior notes due 2016 (the “Convertible Senior Notes”). As of March 31, 2016, the outstanding principal balance of the Convertible Senior Notes is $17.6 million and the carrying value, comprised of the aggregate principal amount outstanding less the remaining unamortized debt issuance costs associated with the borrowing and the remaining unaccreted discount initially recorded upon issuance of the Convertible Senior Notes, is approximately $17.6 million.

 

F-145

---

Table of Contents

Index to Financial Statements

The Convertible Senior Notes mature on April 15, 2016, unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are the Company’s senior unsecured obligations and rank senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding October 15, 2015, holders could convert their Convertible Senior Notes only under certain circumstances set forth in the indenture governing the Convertible Senior Notes. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at the Company’s election, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. The conversion rate was initially 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate is subject to adjustment in some events but is not adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the conversion rate is increased for converting holders. As of March 31, 2016, the conversion rate was 91.3937 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $10.94 per share of common stock).

The Company may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require the Company to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

The Convertible Senior Notes are accounted for in accordance with ASC Subtopic 470-20 (“Debt Instruments with Conversion and Other Options”). In accounting for the Convertible Senior Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes was recorded in “capital in excess of par value” in the Consolidated Statement of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 8.1%.

Upon meeting the stock trading price conversion requirement as set forth in the indenture governing the Convertible Senior Notes, dated April 15, 2011, between the Company and U.S. Bank National Association, during the three months ended June 30, 2014, September 30, 2014 and December 31, 2014, the Convertible Senior Notes became convertible on July 1, 2014 and continued to be convertible during each of the three months ended September 30, 2014, December 31, 2014 and March 31, 2015, respectively. During this period and as of March 31, 2016, approximately $57.4 million of the Convertible Senior Notes were converted and were settled with a combination of cash equal to the outstanding principal amount of the converted notes and approximately 1.5 million shares of the Company’s common stock, or $24.3 million. By not meeting the stock trading price conversion requirement during the three months ended March 31, 2015, June 30, 2015, or September 30, 2015 the Convertible Senior Notes were not convertible for the period between April 1, 2015 and October 14, 2015. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time as described above. See “Note 12—Subsequent Events”.

 

F-146

---

Table of Contents

Index to Financial Statements

The Company recorded a loss on extinguishment of debt for the proportionate amount of unamortized debt issuance costs and original issue discount. The loss was partially offset by a gain in the amount of the difference between the outstanding principal balance of the Convertible Senior Notes and the fair value of the debt instrument. The net loss on extinguishment of debt the Company recorded for the year ended December 31, 2015 was $1,000. The Company did not record a loss on extinguishment of debt in the three months ended March 31, 2016. The loss on extinguishment of debt was classified as a component of net investment income in the Company’s Consolidated Statement of Operations.

As of March 31, 2016 and December 31, 2015, the components of the carrying value of the Convertible Senior Notes were as follows:

 

(in thousands)		March 31, 2016				December 31, 2015
Principal amount of debt		$	17,604			$	17,604
Unamortized debt issuance cost			(12	)			(44	)
Original issue discount, net of accretion			(20	)			(82	)
Carrying value of Convertible Senior Notes		$	17,572			$	17,478

For the three months ended March 31, 2016 and 2015, the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	264			$	215
Accretion of original issue discount			61				62
Amortization of debt issuance cost (loan fees)			32				33
Total interest expense and fees		$	357			$	310
Cash paid for interest expense and fees		$	—			$	—

The estimated effective interest rate of the debt component of the Convertible Senior Notes, equal to the stated interest of 6.0% plus the accretion of the original issue discount, was approximately 8.1% for the three months ended March 31, 2016 and 2015. As of March 31, 2016, the Company is in compliance with the terms of the indentures governing the Convertible Senior Notes.

Wells Facility

On June 29, 2015, the Company, through a special purpose wholly-owned subsidiary, Hercules Funding II LLC (“Hercules Funding II”), entered into an Amended and Restated Loan and Security Agreement (the “Wells Facility”) with Wells Fargo Capital Finance, LLC, as a lender and as the arranger and the administrative agent, and the lenders party thereto from time to time. The Wells Facility amends, restates, and otherwise replaces the Loan and Security Agreement, which was originally entered into on August 25, 2008, with Wells Fargo Capital Finance, LLC, and had been amended from time to time. The Wells Facility was amended and restated to, among other things, consolidate prior amendments and update certain provisions to reflect current operations and personnel of the Company and Hercules Funding II. Many other terms and provisions of the Wells Facility remain the same or substantially similar to the terms and provisions of the original Wells Facility.

On December 16, 2015, the Company entered into an amendment to the Wells Facility that extended the revolving credit availability period and maturity date of the facility. As amended, the revolving credit availability period ends on August 1, 2018 and the Wells Facility matures on August 2, 2019, unless terminated sooner in accordance with its terms.

On March 8, 2016, the Company entered into a further amendment to the Wells Facility that amended the minimum interest coverage ratio covenant and added Alostar Bank of Commerce as a lender of the facility, expanding the available commitment to $95.0 million under the accordion feature. See “Note 12—Subsequent Events”.

 

F-147

---

Table of Contents

Index to Financial Statements

Under the Wells Facility, Wells Fargo Capital Finance, LLC has made commitments of $75.0 million and Alostar Bank of Commerce has made commitments of $20.0 million. The Wells Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the facility; however, there can be no assurances that additional lenders will join the Wells Facility. Borrowings under the Wells Facility generally bear interest at a rate per annum equal to LIBOR plus 3.25%, and the Wells Facility has an advance rate of 50% against eligible debt investments. The Wells Facility is secured by all of the assets of Hercules Funding II. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% depending on the average monthly outstanding balance under the facility relative to the maximum amount of commitments at such time. For the three months ended March 31, 2016, this non-use fee was approximately $66,000. For the three months ended March 31, 2015, this non-use fee was approximately $94,000.

The Wells Facility also includes various financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding II, including covenants relating to certain changes of control of the Company and Hercules Funding II. Among other things, these covenants also require the Company to maintain certain financial ratios, including a maximum debt to worth ratio, minimum interest coverage ratio, minimum portfolio funding liquidity, and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $500.0 million plus 90% of the cumulative amount of equity raised after June 30, 2014. As of March 31, 2016, the minimum tangible net worth covenant has increased to $601.9 million as a result of the March 2015 follow-on public offering of 7.6 million shares of common stock for total gross proceeds of approximately $100.4 million and the 1.1 million shares of common stock issued under the At-The-Market (“ATM”) equity distribution agreement with JMP Securities (“JMP”) for gross proceeds of $12.8 million during the three months ended March 31, 2016. The Wells Facility provides for customary events of default, including, without limitation, with respect to payment defaults, breach of representations and covenants, certain key person provisions, cross acceleration provisions to certain other debt, lien and judgment limitations, and bankruptcy.

On June 20, 2011 the Company paid $1.1 million in structuring fees in connection with the original Wells Facility. In connection with an amendment to the original Wells Facility in August 2014, the Company paid an additional $750,000 in structuring fees and in connection with the amendment in December 2015, the Company paid an additional $188,000 in structuring fees. These fees are being amortized through the end of the term of the Wells Facility.

The Company had aggregate draws of $106.7 million on the available facility during the three months ended March 31, 2016 offset by repayments of $95.7 million. At March 31, 2016 and December 31, 2015 there was $61.0 million and $50.0 million, respectively, of borrowings outstanding on this facility.

For the three months ended March 31, 2016 and 2015, the components of interest expense and related fees and cash paid for interest expense for the Wells Facility are as follows:

 

		Three Months Ended March 31,
(in thousands)		2016				2015
Interest expense		$	275			$	—
Amortization of debt issuance cost (loan fees)			104				86
Total interest expense and fees		$	379			$	86
Cash paid for interest expense and fees		$	244			$	—

Union Bank Facility

The Company has a $75.0 million revolving senior secured credit facility (the “Union Bank Facility”) with MUFG Union Bank, N.A. (“MUFG Union Bank”). The Company originally entered into the Union Bank Facility on February 10, 2010 but, following several amendments, amended and restated the Union Bank Facility on

 

F-148

---

Table of Contents

Index to Financial Statements

August 14, 2014. The amendment and restatement extends the maturity date of the Union Bank Facility to August 1, 2017, increases the size of the Union Bank Facility to $75.0 million from $30.0 million, and adjusts the interest rate for LIBOR borrowings under the Union Bank Facility. The Company further amended the Union Bank Facility in November 2015 but the amendment did not result in any material changes to the facility.

LIBOR-based borrowings by the Company under the Union Bank Facility will bear interest at a rate per annum equal to LIBOR plus 2.25% with no floor, whereas previously the Company paid a per annum interest rate on such borrowings equal to LIBOR plus 2.50% with a floor of 4.00%. Other borrowings by the Company under the Union Bank Facility, which are based on a reference rate instead of LIBOR, will continue to bear interest at a rate per annum equal to the reference rate (which is the greater of the federal funds rate plus 1.00% and a periodically announced MUFG Union Bank index rate) plus the greater of (i) 4.00% minus the reference rate and (ii) 1.00%. The Company continues to have the option of determining which type of borrowing to request under the Union Bank Facility. Subject to certain conditions, the amendment also removes a previous ceiling on the amount of certain unsecured indebtedness that the Company may incur.

The Union Bank Facility contains an accordion feature, pursuant to which the Company may increase the size of the Union Bank Facility to an aggregate principal amount of $300.0 million by bringing in additional lenders, subject to the approval of MUFG Union Bank and other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility to increase available borrowings.

The Union Bank Facility requires the payment of a non-use fee of 0.50% annually. For the three months ended March 31, 2016, this non-use fee was approximately $95,000. For the three months ended March 31, 2015, this non-use fee was approximately $94,000. The amount that the Company may borrow under the Union Bank Facility is determined by applying an advance rate to eligible loans. The Union Bank Facility generally requires payment of monthly interest on loans based on a reference rate and at the end of a one, two, or three-month period, as applicable, for loans based on LIBOR. All outstanding principal is due upon maturity.

The Union Bank Facility is collateralized by debt investments in the Company’s portfolio companies, and includes an advance rate equal to 50.0% of eligible debt investments placed in the collateral pool.

The Company has various financial and operating covenants required by the Union Bank Facility. These covenants require, among other things, that the Company maintain certain financial ratios, including liquidity, asset coverage, and debt service coverage, and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $550.0 million plus 90% of the amount of net cash proceeds received from the sale of common stock after June 30, 2014. As of March 31, 2016, the minimum tangible net worth covenant has increased to $651.2 million as a result of the March 2015 follow-on public offering of 7.6 million shares of common stock for total net proceeds of approximately $100.1 million and the 1.1 million shares of common stock issued under the ATM equity distribution agreement with JMP for net proceeds of $12.4 million during the three months ended March 31, 2016. The Union Bank Facility provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control.

At March 31, 2016 there were no borrowings outstanding on the Union Bank Facility.

Citibank Credit Facility

The Company, through Hercules Funding Trust I, an affiliated statutory trust, had a securitized credit facility (the “Citibank Credit Facility”) with Citigroup Global Markets Realty Corp. (“Citigroup”), which expired under normal terms. During the first quarter of 2009, the Company paid off all principal and interest owed under the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of debt investments and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, the Company granted to Citigroup a 10% participation in all warrants held as

 

F-149

---

Table of Contents

Index to Financial Statements

collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three months ended March 31, 2016, the Company recorded a decrease in participation liability and an increase in unrealized appreciation by a net amount of approximately $1,000 primarily due to depreciation of fair value on the pool of warrants collateralized under the warrant participation. The remaining value of Citigroup’s participation right on unrealized gains in the related equity investments is approximately $110,000 as of March 31, 2016 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, the Company has paid Citigroup approximately $2.2 million under the warrant participation agreement thereby reducing realized gains by this amount. The Company will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between April 2016 and January 2017.

5. Income taxes

The Company intends to operate so as to qualify to be taxed as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of taxable income and gains distributed as dividends to stockholders. Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized.

To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, to its stockholders. The amount to be paid out as a dividend is determined by the Board of Directors each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividends declared, however, a portion of the total amount of the Company’s dividends for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders.

During the three months ended March 31, 2016, the Company declared a distribution of $0.31 per share. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s taxable year based upon its taxable income for the full taxable year and distributions paid for the full taxable year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full taxable year. If the Company had determined the tax attributes of our distributions taxable year-to-date as of March 31, 2016, 100% would be from our current and accumulated earnings and profits. However there can be no certainty to shareholders that this determination is representative of what the tax attributes of its 2016 distributions to shareholders will actually be.

As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company distributes dividends in a timely manner to our shareholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of the Company’s ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of the Company’s capital gain net income for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years (the “Excise Tax Avoidance Requirements”). The Company will not be subject to excise taxes on amounts on which the Company is required to pay corporate income tax (such as retained net capital gains).

 

F-150

---

Table of Contents

Index to Financial Statements

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and pay a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of dividends paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, dividends declared and paid by the Company in a taxable year may differ from taxable income for that taxable year as such dividends may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

The Company has taxable subsidiaries which are designed to hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidies are consolidated for U.S. GAAP financial reporting purposes and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements, and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by the taxable subsidiaries would be taxed at normal corporate tax rates based on its taxable income.

Taxable income for the three months ended March 31, 2016 was approximately $21.7 million or $0.30 per share. Taxable net realized losses for the same period was $3.7 million or approximately $0.05 per share. Taxable income for the three months ended March 31, 2015 was approximately $16.3 million or $0.26 per share. Taxable net realized losses for the same period were $2.6 million or approximately $0.04 per share.

The Company intends to distribute approximately $8.2 million of spillover earnings from ordinary income from the year ended December 31, 2015 to the Company’s shareholders in 2016.

6. Shareholders’ Equity

On August 16, 2013, the Company entered into an ATM equity distribution agreement (the “Equity Distribution Agreement”) with JMP and on March 7, 2016, the Company renewed the Equity Distribution Agreement. The Equity Distribution Agreement provides that the Company may offer and sell up to 8.0 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended March 31, 2016 the Company sold 1.1 million shares of common stock for total accumulated net proceeds of approximately $12.4 million. The Company did not sell any shares under the program during the year ended December 31, 2015. The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2016 approximately 6.2 million shares remain available for issuance and sale under the equity distribution agreement. See “Note 12—Subsequent Events”.

On February 24, 2015, the Company’s Board of Directors authorized a stock repurchase plan permitting the Company to repurchase up to $50.0 million of its common stock. This plan expired on August 24, 2015. On August 27, 2015, the Company’s Board of Directors authorized a replacement stock repurchase plan permitting the Company to repurchase up to $50.0 million of its common stock and on February 17, 2016 the Board of Directors extended the program until August 23, 2016. The Company may repurchase shares of its common stock in the open market, including block purchases, at prices that may be above or below the net asset value as reported in the most recently published financial statements. The Company expects that the share repurchase

 

F-151

---

Table of Contents

Index to Financial Statements

program will be in effect until August 23, 2016, or until the approved dollar amount has been used to repurchase shares. During the three months ended March 31, 2016 the Company repurchased 449,588 shares of its common stock at an average price per share of $10.64 per share and a total cost of approximately $4.8 million. As of March 31, 2016 approximately $40.6 million of common stock remains eligible for repurchase under the stock repurchase plan. See “Item 2. Unregistered Sales of Equity Securities and Use of Proceeds” for further information on the repurchases made during the period.

The Company anticipates that the manner, timing, and amount of any share purchases will be determined by management based upon the evaluation of market conditions, stock price, and additional factors in accordance with regulatory requirements. Pursuant to the 1940 Act, the Company is required to notify shareholders when such a program is initiated or implemented. The repurchase program does not require the Company to acquire any specific number of shares and may be extended, modified, or discontinued at any time.

On March 27, 2015, the Company raised approximately $100.1 million, after deducting offering expenses, in a public offering of 7,590,000 shares of its common stock.

At the 2015 Annual Meeting of Stockholders on July 7, 2015, the Company’s common stockholders approved a proposal to allow the Company to issue common stock at a discount from its then current net asset value (“NAV”) per share, which is effective for a period expiring on the earlier of July 7, 2016 or the 2016 annual meeting of stockholders. In connection with the receipt of such stockholder approval, the Company will limit the number of shares that it issues at a price below NAV pursuant to this authorization so that the aggregate dilutive effect on the Company’s then outstanding shares will not exceed 20%. The Company’s Board of Directors, subject to its fiduciary duties and regulatory requirements, has the discretion to determine the amount of the discount, and as a result, the discount could be up to 100% of NAV per share. During the three months ended March 31, 2016 the Company has not issued common stock at a discount to NAV. The Company did not issue common stock at a discount to NAV during the year ended December 31, 2015.

The Company has issued stock options for common stock subject to future issuance, of which 695,838 and 622,171 were outstanding at March 31, 2016 and December 31, 2015, respectively.

7. Equity Incentive Plan

The Company and its stockholders have authorized and adopted the 2004 Equity Incentive Plan (the “2004 Plan”) for purposes of attracting and retaining the services of its executive officers and key employees. Under the 2004 Plan, the Company is authorized to issue 7.0 million shares of common stock. On June 1, 2011, stockholders approved an amended and restated plan and provided an increase of 1.0 million shares, authorizing the Company to issue 8.0 million shares of common stock under the 2004 Plan. At the Company’s 2015 Annual Meeting of stockholders on July 7, 2015, the Company’s stockholders voted to approve an amendment to the 2004 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 4.0 million shares.

The Company and its stockholders have authorized and adopted the 2006 Non-Employee Director Plan (the “2006 Plan” and, together with the 2004 Plan, the “Plans”) for purposes of attracting and retaining the services of its Board of Directors. Under the 2006 Plan, the Company is authorized to issue 1.0 million shares of common stock. The Company filed an exemptive relief request with the Securities and Exchange Commission (“SEC”) to allow options to be issued under the 2006 Plan which was approved on October 10, 2007.

On June 21, 2007, the stockholders approved amendments to the 2004 Plan and the 2006 Plan allowing for the grant of restricted stock. The amended Plans limit the combined maximum amount of restricted stock that may be issued under both Plans to 10% of the outstanding shares of the Company’s stock on the effective date of the Plans plus 10% of the number of shares of stock issued or delivered by the Company during the terms of the Plans. The amendments further specify that no one person shall be granted awards of restricted stock relating to

 

F-152

---

Table of Contents

Index to Financial Statements

more than 25% of the shares available for issuance under the 2004 Plan. Further, the amount of voting securities that would result from the exercise of all of the Company’s outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 25% of its outstanding voting securities, except that if the amount of voting securities that would result from such exercise of all of the Company’s outstanding warrants, options and rights issued to the Company’s directors, officers and employees, together with any restricted stock issued pursuant to the Plans, would exceed 15% of the Company’s outstanding voting securities, then the total amount of voting securities that would result from the exercise of all outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 20% of the Company’s outstanding voting securities.

The following table summarizes the common stock options activities for the three months ended March 31, 2016 and 2015:

 

		Three Months Ended March 31,
		2016								2015
		Common Stock Options				Weighted Average Exercise Price				Common Stock Options				Weighted Average Exercise Price
Outstanding at December 31,			622,171			$	14.25				695,672			$	14.58
Granted			124,000			$	11.29				68,500			$	14.10
Exercised			—			$	—				(34,664	)		$	10.69
Forfeited			(45,890	)		$	14.23				(141,280	)		$	14.71
Expired			(4,443	)		$	16.34				(2,499	)		$	11.01
Outstanding at March 31,			695,838			$	13.71				585,729			$	14.74
Shares Expected to Vest at March 31,			367,032			$	13.71				438,472			$	14.74

The following table summarizes common stock options outstanding and exercisable at March 31, 2016:

 

(Dollars in thousands, except exercise price)		Options Outstanding																Options Exercisable
Range of exercise prices		Number of shares				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value				Weighted Average Exercise Price				Number of shares				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value				Weighted Average Exercise Price
$9.25 - $14.02			302,644				6.38			$	214,703			$	11.52				67,890				3.84			$	75,893			$	11.15
$14.60 - $16.34			393,194				4.82				—			$	15.40				260,916				4.35				—			$	15.33
$9.25 - $16.34			695,838				5.50			$	214,703			$	13.71				328,806				4.25			$	75,893			$	14.47

Options generally vest 33% one year after the date of grant and ratably over the succeeding 24 months.

All options may be exercised for a period ending seven years after the date of grant. At March 31, 2016 options for 328,806 shares were exercisable at a weighted average exercise price of approximately $14.47 per share with a weighted average remaining contractual term of 4.25 years.

The Company determined that the fair value of options granted under the 2006 and 2004 Plans during the three months ended March 31, 2016 and 2015 was approximately $39,000 and $27,000, respectively. During the three months ended March 31, 2016 and 2015, approximately $51,000 and $67,000 of share-based cost due to stock option grants was expensed, respectively. As of March 31, 2016 there was approximately $181,000 of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average remaining vesting period of 1.42 years.

The Company follows ASC 718 (“Compensation—Stock Compensation”) to account for stock options granted. Under ASC 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the

 

F-153

---

Table of Contents

Index to Financial Statements

appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life. The fair value of options granted is based upon a Black Scholes option pricing model using the assumptions in the following table for the three months ended March 31, 2016 and 2015:

 

		Three Months Ended March 31,
		2016				2015
Expected Volatility			18.94	%			18.94	%
Expected Dividends			10	%			10	%
Expected term (in years)			4.5				4.5
Risk-free rate			1.04%-1.63	%			1.08%-1.57	%

During the three months ended March 31, 2016 and 2015 the Company granted 538,250 shares and 579,833 shares, respectively, of restricted stock pursuant to the Plans. The Company determined that the fair value of restricted stock granted under the 2006 and 2004 Plans during the three months ended March 31, 2016 and 2015 was approximately $6.5 million and $8.1 million, respectively. During the three months ended March 31, 2016 and 2015, the Company expensed approximately $2.5 million and $2.7 million of compensation expense related to restricted stock, respectively. As of March 31, 2016, there was approximately $12.2 million of total unrecognized compensation costs related to restricted stock. These costs are expected to be recognized over a weighted average remaining vesting period of 2.27 years.

The following table summarizes the activities for the Company’s unvested restricted stock for the three months ended March 31, 2016 and 2015:

 

		Three Months Ended March 31,
		2016								2015
		Restricted Stock Awards				Weighted Average Grant  Date Fair Value				Restricted Stock Awards				Weighted Average Grant  Date Fair Value
Unvested at December 31,			850,072			$	13.59				1,302,780			$	13.23
Granted			538,250			$	12.00				579,833			$	14.02
Vested			(285,155	)		$	13.65				(102,042	)		$	12.01
Forfeited			(7,138	)		$	14.02				(1,438	)		$	12.88
Unvested at March 31,			1,096,029			$	12.79				1,779,133			$	13.56

The SEC, through an exemptive order granted on June 22, 2010, approved amendments to the Plans which allow participants to elect to have the Company withhold shares of the Company’s common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”). The exemptive order also permits the holders of restricted stock to elect to have the Company withhold shares of the Company’s stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual can make a cash payment at the time of option exercise or to pay taxes on restricted stock.

 

F-154

---

Table of Contents

Index to Financial Statements

8. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:

 

		Three Months Ended March 31,
(in thousands, except per share data)		2016				2015
Numerator
Net increase in net assets resulting from operations		$	14,295			$	21,919
Less: Dividends declared-common and restricted shares			(22,371	)			(20,266	)
Undistributed (distributions in excess of) earnings			(8,076	)			1,653
Undistributed (distributions in excess of) earnings-common shares			(8,076	)			1,653
Add: Dividend declared-common shares			21,975				19,712
Numerator for basic and diluted change in net assets per common share		$	13,899			$	21,365
Denominator
Basic weighted average common shares outstanding			71,172				63,783
Common shares issuable			27				380
Weighted average common shares outstanding assuming dilution			71,199				64,163
Change in net assets per common share
Basic		$	0.20			$	0.33
Diluted		$	0.20			$	0.33

In the table above, unvested share-based payment awards that have non-forfeitable rights to dividends or dividend equivalents are treated as participating securities for calculating earnings per share.

For the purpose of calculating diluted earnings per share for the three months ended March 31, 2016 and 2015, the dilutive effect of the Convertible Senior Notes under the treasury stock method is included in this calculation because the Company’s share price was greater than the conversion price in effect ($10.94 as of March 31, 2016 and $11.28 as of March 31, 2015) for the Convertible Senior Notes for such periods.

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti-dilutive shares. For the three months ended March 31, 2016 and 2015, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, was approximately 717,679 shares and 652,102 shares, respectively.

At March 31, 2016, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

 

F-155

---

Table of Contents

Index to Financial Statements

9. Financial Highlights

Following is a schedule of financial highlights for the three months ended March 31, 2016 and 2015:

 

		Three Months Ended March 31,
		2016				2015
Per share data(1):
Net asset value at beginning of period		$	9.94			$	10.18
Net investment income			0.28				0.20
Net realized gain on investments			(0.06	)			0.05
Net unrealized appreciation (depreciation) on investments			(0.02	)			0.09
Total from investment operations			0.20				0.34
Net increase (decrease) in net assets from capital share transactions(1)			(0.06	)			0.23
Distributions of net investment income(6)			(0.31	)			(0.32	)
Stock-based compensation expense included in investment income(2)			0.04				0.04
Net asset value at end of period		$	9.81			$	10.47
Ratios and supplemental data:
Per share market value at end of period		$	12.01			$	13.48
Total return(3)			1.18	%			(7.35	%)
Shares outstanding at end of period			73,230				72,891
Weighted average number of common shares outstanding			71,172				63,783
Net assets at end of period		$	718,380			$	763,326
Ratio of total expense to average net assets(4)			10.47	%			11.73	%
Ratio of net investment income before investment gains and losses to average net assets(4)			11.17	%			7.82	%
Portfolio turnover rate (5)			7.16	%			7.64	%
Average debt outstanding		$	578,406			$	624,132
Weighted average debt per common share		$	8.13			$	9.79

 

(1)	All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date.

(2)	Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC 718, net investment income includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital.

(3)

The total return for the three months ended March 31, 2016 and 2015 equals the change in the ending market value over the beginning of the period price per share plus dividends paid per share during the period, divided by the beginning price assuming the dividend is reinvested on the date of the distribution. As such, the total return is not annualized.

(4)	All ratios are calculated based on weighted average net assets for the relevant period and are annualized.

(5)	The portfolio turnover rate for the three months ended March 31, 2016 and 2015 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.

(6)	Includes dividends on unvested shares.

10. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to the Company’s portfolio companies. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the Company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At March 31, 2016, the Company had approximately $64.6 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones. In addition, the Company had approximately $98.0 million of unavailable commitments to portfolio companies due to milestone and other covenant restrictions.

 

F-156

---

Table of Contents

Index to Financial Statements

The Company also had approximately $60.5 million of non-binding term sheets outstanding at March 31, 2016. Non-binding outstanding term sheets are subject to completion of the Company’s due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of the Company’s unfunded commitments are considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to a market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

Certain premises are leased under agreements which expire at various dates through March 2020. Total rent expense amounted to approximately $436,000 during the three months ended March 31, 2016. Total rent expense amounted to approximately $408,000 during the same period ended March 31, 2015. The Company’s contractual obligations as of March 31, 2016 include:

 

		Payments due by period (in thousands)
Contractual Obligations(1)(2)		Total				Less than 1 year				1 - 3 years				3 - 5 years				After 5 years
Borrowings(3)(4)		$	611,471			$	17,604			$	147,700			$	232,917			$	213,250
Operating Lease Obligations(5)			4,427				1,598				2,593				236				—
Total		$	615,898			$	19,202			$	150,293			$	233,153			$	213,250

 

(1)	Excludes commitments to extend credit to the Company’s portfolio companies.

(2)	The Company also has a warrant participation agreement with Citigroup. See Note 4 to the Company’s consolidated financial statements.

(3)

Includes $190.2 million in principal outstanding under the SBA debentures, $110.4 million of the 2019 Notes, $103.0 million of the 2024 Notes, $129.3 million of the 2021 Asset-Backed Notes, $17.6 million of the Convertible Senior Note, and $61.0 million under the Wells Facility as of March 31, 2016.

(4)	Amounts represent future principal repayments and not the carrying value of each liability. See Note 4 to the Company’s consolidated financial statements.

(5)	Long-term facility leases.

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

11. Recent Accounting Pronouncements

In February 2015, the FASB issued ASU 2015-02, “Consolidation (Topic 810)—Amendments to the Consolidation Analysis”. The new guidance applies to entities in all industries and provides a new scope exception to registered money market funds and similar unregistered money market funds. It makes targeted amendments to the current consolidation guidance and ends the deferral granted to investment companies from applying the VIE guidance. There is not a material impact from adopting this standard on the Company’s financial statements. The Company has adopted this standard for the three months ended March 31, 2016.

In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”, which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability and in August 2015, the FASB issued ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the application of ASU

 

F-157

---

Table of Contents

Index to Financial Statements

2015-03 to debt issuance costs associated with line-of-credit arrangements and allows presentation of debt issuance costs on these instruments as assets that are amortized over the term of the instrument. Adoption of these standards results in the reclassification of debt issuance costs from Other Assets and the presentation of the Company’s SBA Debentures, 2019 Notes, 2024 Notes, 2021 Asset-Backed Notes, and Convertible Senior Notes net of the associated debt issuance costs for each instrument in the liabilities section on the Consolidated Statement of Assets and Liabilities. There is no impact to the Company’s Consolidated Statement of Operations. In addition, there is no change to the presentation of the Wells Facility as debt issuance costs are presented separately as an asset on the Consolidated Statement of Assets and Liabilities. The Company has adopted this standard for the three months ended March 31, 2016. Refer to “Note 2—Summary of Significant Accounting Policies”.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which, among other things, requires that (i) all equity investments, other than equity-method investments, in unconsolidated entities generally be measured at fair value through earnings and (ii) an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. Additionally, the ASU changes the disclosure requirements for financial instruments. ASU 2016-01 is effective for annual reporting periods, and the interim periods within those periods, beginning after December 15, 2017. Early adoption is permitted for certain provisions. The Company is currently evaluating the impact that ASU 2016-01 will have on its consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which, among other things, requires recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Additionally the ASU requires the classification of all cash payments on leases within operating activities in the Consolidated Statement of Cash Flows. ASU 2016-02 is effective for annual reporting periods, and the interim periods within those periods, beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-02 will have on its consolidated financial statements and disclosures.

In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which, among other things, simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods, and the interim periods within those periods, beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-09 will have on its consolidated financial statements and disclosures.

12. Subsequent Events

Dividend Declaration

On April 27, 2016 the Board of Directors declared a cash dividend of $0.31 per share to be paid on May 23, 2016 to shareholders of record as of May 16, 2016. This dividend represents the Company’s forty-third consecutive dividend declaration since the Company’s IPO, bringing the total cumulative dividend declared to date to $11.85 per share.

Convertible Senior Notes

The Convertible Senior Notes were convertible into shares of the Company’s common stock beginning October 15, 2015 until the close of business on the scheduled trading day immediately preceding the April 15, 2016 maturity date. Subsequent to March 31, 2016, approximately $17.4 million of the Convertible Senior Notes were converted pursuant to the conversion procedures as set forth in the indenture governing the Convertible

 

F-158

---

Table of Contents

Index to Financial Statements

Senior Notes and were settled in April 2016 with a combination of cash equal to the outstanding principal amount of the converted notes and approximately 137,854 shares of the Company’s common stock. The remaining Convertible Senior Notes outstanding were fully repaid at maturity on April 15, 2016.

Wells Facility

On April 7, 2016, the Company entered into a further amendment to the Wells Facility that amended the concentration limits on eligible assets in the collateral pool and added Everbank Commercial Finance, Inc. as a lender of the facility, expanding the available commitment to $120.0 million under the accordion feature.

2024 Notes

On May 2, 2016, the Company closed an underwritten public offering of an additional $72.9 million in aggregate principal amount of its 6.25% unsecured notes due 2024 (the “Additional 2024 Notes”). The $72.9 million in aggregate principal amount includes $65.4 million from the initial offering and $7.5 million as a result of underwriters exercising a portion of their option to purchase up to an additional $9.8 million in aggregate principal to cover overallotments. The Additional 2024 Notes constitute a further issuance of, rank equally in right of payment with, and form a single series with the $103.0 million in aggregate principal amount of the 6.25% unsecured notes due 2024 that the Company initially issued on July 14, 2014 (the “Existing 2024 Notes”).

The Existing 2024 Notes currently trade on the NYSE under the symbol “HTGX” and it is anticipated that the additional $74.8 million in aggregate principal amount of the Additional 2024 Notes will trade under the same symbol. The Existing 2024 Notes and the Additional 2024 Notes will mature on July 30, 2024, and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after July 30, 2017. The Additional 2024 Notes will bear interest at a rate of 6.25% per year payable quarterly on January 30, April 30, July 30 and October 30, of each year, beginning July 30, 2016. The Company intends to invest the net proceeds of this public offering to fund investments in debt and equity securities in accordance with its investment objective and for other general corporate purposes.

ATM Issuances

Subsequent to March 31, 2016 and as of May 2, 2016, the Company sold 331,000 shares of common stock for total accumulated net proceeds of approximately $4.0 million under its ATM equity distribution agreement with JMP. As of May 2, 2016 approximately 5.9 million shares remain available for issuance and sale under the equity distribution agreement.

Credit Rating

On April 26, 2016, Standard and Poor’s assigned a BBB- credit rating to the Company’s 2024 Notes and 2019 Notes.

Portfolio Company Developments

As of May 2, 2016, the Company held warrants or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings. All four companies filed confidentially under the Jumpstart Our Business Startups Act. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely matter or at all.

On May 2, 2016, Bind Therapeutics, Inc. (“BIND”), a portfolio company, filed for Voluntary Chapter 11 Bankruptcy Protection in the District of Delaware. In that filing, BIND claims it will pursue strategic and financial alternatives to continue as a going concern and that their cash and assets exceed the loan amount due to Hercules Capital. The Company’s agreements with BIND have affirmative and negative covenants and events of defaults customary for a senior secured lending transaction of this nature. As of the date of these financial statements, the Company believes that BIND has the ability to meet its Secured Obligations and given that BIND is current on all payments, the Company has left our investment in BIND on accrual status.

 

F-159

---

Table of Contents

Index to Financial Statements

Schedule 12-14

HERCULES CAPITAL, INC.

SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of and for the Three Months Ended March 31, 2016

(in thousands)

 

Portfolio Company		Investment(1)		Amount of Interest Credited to Income(2)				As of December 31, 2015 Fair Value				Gross Additions(3)				Gross Reductions(4)				Net Change in Unrealized Appreciation/ (Depreciation)				As of March 31, 2016 Fair Value
Affiliate Investments
Optiscan BioMedical, Corp.		Senior Debt		$	7			$	—			$	431			$	—			$	—			$	431
		Preferred Stock			—				6,661				—				—				(357	)			6,304
		Preferred Warrants			—				312				—				—				(56	)			256
Stion Corporation		Senior Debt			58				1,013				—				(446	)			539				1,106
Total Control and Affiliate Investments				$	65			$	7,986			$	431			$	(446	)		$	126			$	8,097

 

(1)	Stock and warrants are generally non-income producing and restricted. The principal amount for debt is shown in the Consolidated Schedule of Investments as of March 31, 2016

(2)	Represents the total amount of interest or dividends credited to income for the year an investment was an affiliate or control investment.

(3)	Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.

(4)	Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities.

 

F-160

---

Table of Contents

Index to Financial Statements

 

 

---

Table of Contents

Index to Financial Statements

PART C—OTHER INFORMATION

Item 25. Financial Statements and Exhibits

1. Financial Statements

The following financial statements of Hercules Capital, Inc. (the “Company” or the “Registrant”) are included in this registration statement in “Part A—Information Required in a Prospectus”:

 

AUDITED FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firm			F-2
Consolidated Statements of Assets and Liabilities as of December 31, 2015 and 2014			F-3
Consolidated Statements of Operations for the three years ended December 31, 2015			F-5
Consolidated Statements of Changes in Net Assets for the three years ended December 31, 2015			F-6
Consolidated Statements of Cash Flows for the three years ended December 31, 2015			F-7
Consolidated Schedule of Investments as of December 31, 2015			F-8
Consolidated Schedule of Investments as of December 31, 2014			F-24
Notes to Consolidated Financial Statements			F-41
Schedule 12-14 Investments In and Advances to Affiliates			F-82
UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Consolidated Statements of Assets and Liabilities as of March 31, 2016 (unaudited) and December  31, 2015			F-83
Consolidated Statements of Operations for the three month periods ended March  31, 2016 and 2015 (unaudited)			F-85
Consolidated Statements of Changes in Net Assets for the three month periods ended March  31, 2016 and 2015 (unaudited)			F-86
Consolidated Statements of Cash Flows for the three month periods ended March 31, 2016 and 2015 (unaudited)			F-87
Consolidated Schedule of Investments as of March 31, 2016 (unaudited)			F-88
Consolidated Schedule of Investments as of December 31, 2015 (unaudited)			F-106
Notes to Consolidated Financial Statements (unaudited)			F-123
Schedule 12-14 Investments In and Advances to Affiliates			F-160

2. Exhibits

 

Exhibit Number		Description
a.1		Articles of Amendment and Restatement.(2)
a.2		Articles of Amendment, dated March 6, 2007.(10)
a.3		Articles of Amendment, dated April 5, 2011.(21)
a.4		Articles of Amendment, dated April 3, 2015.(43)
a.5		Articles of Amendment, dated February 23, 2016.(49)
b.1		Amended and Restated Bylaws.(49)
d.1		Specimen certificate of the Company’s common stock, par value $.001 per share.(50)
d.2		Form of Indenture and related exhibits(24)
d.3		Form of Warrant Agreement(24)
d.4		Form of Subscription Agent Agreement(24)

 

C-1

---

Table of Contents

Index to Financial Statements

Exhibit Number		Description
d.5		Form of Subscription Certificate(24)
d.6		Statement of Eligibility of Trustee on Form T-1(45)
d.7		Indenture, dated March 6, 2012 between the Registrant and U.S. Bank National Association.(25)
d.8		First Supplemental Indenture, dated April 17, 2012 between the Registrant and U.S. Bank, National Association.(25)
d.9		Second Supplemental Indenture, dated as of September 24, 2012, between the Registrant and U.S. Bank, National Association.(28)
d.10		Third Supplemental Indenture, dated as of July 14, 2014, between the Registrant and U.S. Bank, National Association.(39)
d.11		Form of 7.00% Senior Note due 2019, dated as of April 17, 2012 (Existing April 2019 Note) (included as part of Exhibit (d)(8)).(25)
d.12		Form of 7.00% Senior Note due 2019, dated as of July 6, 2012 (Additional April 2019 Note).(26)
d.13		Form of 7.00% Senior Note due 2019, dated as of July 12, 2012 (Over-Allotment April 2019 Note).(27)
d.14		Form of 7.00% Senior Note due 2019, dated as of September 24, 2012 (September 2019 Note) (included as part of Exhibit (d)(9)).(28)
d.15		Form of 7.00% Senior Note due 2019, dated as of October 2, 2012 (Over-Allotment September 2019 Note).(29)
d.16		Form of 7.00% Senior Note due 2019, dated as of October 17, 2012 (Over-Allotment II September 2019 Note).(33)
d.17		Form of 6.25% Note due 2024, dated July 14, 2014 (July 2024 Note) (included as part of Exhibit (d)(10)).(39)
d.18		Form of 6.25% Note due 2024, dated August 11, 2014 (Over-Allotment July 2024 Note).(40)
d.19		Form of 6.25% Note due 2024, dated May 2, 2016.(54)
e		Form of Dividend Reinvestment Plan.(3)
f.1		Credit Agreement dated as of April 12, 2005 between Hercules Technology Growth Capital, Inc. and Alcmene Funding, L.L.C.(2)
f.2		Pledge and Security Agreement dated as of April 12, 2005 between Hercules Technology Growth Capital, Inc. and Alcmene Funding, L.L.C.(2)
f.3		First Amendment to Credit and Pledge Security Agreement dated August 1, 2005 between Hercules Technology Growth Capital, Inc. and Alcmene Funding L.L.C.(4)
f.4		Loan Sale Agreement between Hercules Funding LLC and Hercules Technology Growth Capital, Inc. dated as of August 1, 2005.(4)
f.5		Sale and Servicing Agreement among Hercules Funding Trust I, Hercules Funding LLC, Hercules Technology Growth Capital, Inc., U.S. Bank National Association and Lyon Financial Services, Inc. dated as of August 1, 2005.(4)
f.6		Indenture between Hercules Funding Trust I and U.S. Bank National Association dated as of August 1, 2005.(4)

 

C-2

---

Table of Contents

Index to Financial Statements

Exhibit Number		Description
f.7		Note Purchase Agreement among Hercules Funding Trust I, Hercules Funding I LLC, Hercules Technology Growth Capital, Inc. and Citigroup Global Markets Realty Corp. dated as of August 1, 2005.(4)
f.8		Second Amendment to Credit and Pledge Security Agreement by and among Hercules Technology Growth Capital, Inc. and Alcmene Funding, L.L.C., as lender and administrative agent for the lenders, dated March 6, 2006.(5)
f.9		First Omnibus Amendment by and among Hercules Funding Trust I, Hercules Funding I, LLC, Hercules Technology Growth Capital, Inc., U.S. Bank National Association, Lyon Financial Services, Inc. and Citigroup Global Markets Realty Corp. dated March 6, 2006.(5)
f.10		Intercreditor Agreement among Hercules Technology Growth Capital, Inc., Alcmene Funding, L.L.C. and Citigroup Global Markets Realty Corp. dated as of March 6, 2006.(5)
f.11		Warrant Participation Agreement between the Company and Citigroup Global Markets Realty Corp. dated as of August 1, 2005.(6)
f.12		Second Amendment to Warrant Participation Agreement dated as of October 16, 2006.(6)
f.13		Third Amendment to Sale and Servicing Agreement among Hercules Funding Trust I, Hercules Funding LLC, Hercules Technology Growth Capital, Inc., U.S. Bank National Association and Lyon Financial Services, Inc., dated as of July 28, 2006.(7)
f.14		Second Omnibus Amendment by and among Hercules Funding Trust I, Hercules Funding I, LLC, Hercules Technology Growth Capital, Inc., U.S. Bank National Association, Lyon Financial Services, Inc. and Citigroup Global Markets Realty Corp. dated December 6, 2006.(8)
f.15		Fifth Amendment to Sale and Servicing Agreement by and among Hercules Funding Trust I, Hercules Funding I, LLC, Hercules Technology Growth Capital, Inc., U.S. Bank National Association, Lyon Financial Services, Inc. and Citigroup Global Markets Realty Corp. dated March 30, 2007.(11)
f.16		Amended and Restated Sale and Servicing Agreement by and among Hercules Funding Trust I, Hercules Funding I LLC, the Company, U.S. Bank National Association, Lyon Financial Services, Inc., Citigroup Global Markets Inc., and Deutsche Bank AG dated as of May 2, 2007.(12)
f.17		Fourth Amendment to the Warrant Participation Agreement by and among Hercules Technology Growth Capital, Inc. and Citigroup Global Markets Realty Corp., dated as of May 2, 2007.(13)
f.18		Amended and Restated Note Purchase Agreement by and among Hercules Funding Trust I, Hercules Funding I LLC, Hercules Technology Growth Capital, Inc. and Citigroup Global Markets, Inc. dated as of May 2, 2007.(13)
f.19		First Amendment to Amended and Restated Note Purchase Agreement by and among Hercules Funding Trust I, Hercules Funding I LLC, Hercules Technology Growth Capital, Inc. and Citigroup Global Markets, Inc. dated as of May 7, 2008.(15)
f.20		Second Amendment to Amended and Restated Sale and Servicing Agreement by and among Hercules Funding Trust I, Hercules Funding I LLC, Hercules Technology Growth Capital, Inc., U.S. Bank National Association, Lyon Financial Services, Inc., Citigroup Global Markets Inc., and Deutsche Bank AG dated as of May 7, 2008.(15)
f.21		Form of SBA Debenture.(16)
f.22		Sale and Servicing Agreement among Hercules Funding II LLC, the Company, Lyon Financial Services, Inc., and Wells Fargo Foothill, LLC, dated as of August 25, 2008.(17)

 

C-3

---

Table of Contents

Index to Financial Statements

Exhibit Number		Description
f.23		Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Foothill, LLC, dated as of August 25, 2008.(17)
f.24		First Amendment to Loan and Security Agreement by and among Hercules Funding II, LLC and Wells Fargo Foothill, LLC, dated as of April 30, 2009.(18)
f.25		Second Amendment to Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of June 20, 2011.(23)
f.26		Third Amendment to Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of August 1, 2012.(31)
f.27		Fifth Amendment to Loan and Security Agreement by and among Hercules Funding II, LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of August 8, 2014.(41)
f.28		Seventh Amendment to Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of May 6, 2015.(44)
f.29		Amended and Restated Loan and Security Agreement by and among Hercules Funding II, LLC, the Lenders thereto and Wells Fargo Capital Finance, LLC, dated as of June 29, 2015.(48)
f.30		First Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of December 16, 2015.(48)
f.31		Second Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of March 8, 2016.( 51)
f.32		Third Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), dated as of April 7, 2016.(53)
f.33		Amended and Restated Sales and Servicing Agreement among Hercules Funding II, LLC, Hercules Technology Growth Capital, Inc. and Wells Fargo Capital Finance, LLC, dated as of June 29, 2015.(47)
f.34		Indenture between Hercules Technology Growth Capital, Inc. and U.S. Bank National Association, dated as of April 15, 2011.(22)
f.35		Form of Note under the Indenture dated as of April 15, 2011 (included as part of Exhibit (f)(34)).(22)
f.36		Indenture by and between Hercules Capital Funding Trust 2012-1 and U.S. Bank National Association, dated as of December 19, 2012.(34)
f.37		Amended and Restated Trust Agreement by and between Hercules Capital Funding 2012-1 LLC and Wilmington Trust, National Association, dated as of December 19, 2012.(34)
f.38		Sale and Servicing Agreement by and between Hercules Capital Funding 2012-1 LLC, Hercules Capital Funding Trust 2012-1 LLC, Hercules Technology Growth Capital, Inc. and U.S. Bank National Association, dated as of December 19, 2012.(34)
f.39		Sale and Contribution Agreement by and between Hercules Technology Growth Capital, Inc. and Hercules Capital Funding 2012-1 LLC, dated as of December 19, 2012.(34)
f.48		Note Purchase Agreement by and between the Hercules Technology Growth Capital, Inc., Hercules Capital Funding 2012-1 LLC, as Trust Depositor, Hercules Capital Funding Trust 2012-1, as Issuer, and Guggenheim Securities, LLC, as Initial Purchaser, dated as of December 12, 2012.(34)

 

C-4

---

Table of Contents

Index to Financial Statements

Exhibit Number		Description
f.40		Administration Agreement by and between Hercules Capital Funding Trust 2012-1LLC, Hercules Technology Growth Capital, Inc, Wilmington Trust, National Association, and U.S. Bank National Association, dated as of December 19, 2012.(34)
f.41		Indenture by and among Hercules Capital Funding Trust 2014-1 and U.S. Bank National Association, dated as of November 13, 2014.(42)
f.42		Amended and Restated Trust Agreement by and among Hercules Capital Funding 2014-1 LLC and Wilmington Trust, National Association, dated as of November 13, 2014.(42)
f.43		Sale and Servicing Agreement by and among Hercules Capital Funding Trust 2014-1, Hercules Technology Growth Capital, Inc., Hercules Capital Funding 2014-1 LLC and U.S. Bank National Association, dated as of November 13, 2014.(42)
f.53		Sale and Contribution Agreement by and among Hercules Technology Growth Capital, Inc. and Hercules Capital Funding 2014-1 LLC, dated as of November 13, 2014.(42)
f.44		Note Purchase Agreement among Hercules Technology Growth Capital, Inc., Hercules Capital Funding 2014-1 LLC, Hercules Capital Funding Trust 2014-1 and Guggenheim Securities, LLC, dated as of November 4, 2014.(42)
f.45		Administration Agreement among Hercules Technology Growth Capital, Inc., Hercules Capital Funding Trust 2014-1, Wilmington Trust National Association and U.S. Bank National Association, dated November 13, 2014.(42)
f.46		Loan and Security Agreement by and among Hercules Funding III, LLC, as borrower, MUFG Union Bank, N.A., as the arranger and administrative agent, and the lenders party thereto from time to time, dated as of May 5, 2016.(55)
f.47		Sale and Servicing Agreement by and among Hercules Funding III LLC, as borrower, Hercules Capital, Inc., as originator and servicer, and MUFG Union Bank, N.A., as agent, dated as of May 5, 2016.(56)
h.1		Form of Equity Underwriting Agreement.(45)
h.2		Form of Debt Underwriting Agreement.(45)
h.3		Amended and Restated Equity Distribution Agreement, dated as of March 7, 2016, by and among the Registrant and JMP Securities LLC.(52)
i.1		Hercules Technology Growth Capital, Inc. 2004 Equity Incentive Plan (2015 Amendment and Restatement).(35)
i.2		Hercules Technology Growth Capital, Inc. 2006 Non-Employee Director Plan (2007 Amendment and Restatement).(14)
i.3		Form of Incentive Stock Option Award under the 2004 Equity Incentive Plan.(2)
i.4		Form of Nonstatutory Stock Option Award under the 2004 Equity Incentive Plan.(2)
i.5		Form of Restricted Stock Award under the 2004 Equity Incentive Plan.(16)
j		Form of Custody Agreement between the Company and Union Bank of California.(2)
k.1		Form of Registrar Transfer Agency and Service Agreement between the Company and American Stock Transfer & Trust Company.(2)
k.2		Warrant Agreement dated June 22, 2004 between the Company and American Stock Transfer & Trust Company, as warrant agent.(1)

 

C-5

---

Table of Contents

Index to Financial Statements

Exhibit Number		Description
k.3		Lease Agreement dated June 13, 2006 between the Company and 400 Hamilton Associates.(9)
k.4		Form of Indemnification Agreement.(43)
1.1*		Opinion of Dechert LLP.
n.1*		Consent of PricewaterhouseCoopers LLP.
n.2		Report of PricewaterhouseCoopers LLP.(56)
n.3*		Consent of Dechert LLP (included in Exhibit l.1)
p.1		Subscription Agreement dated February 2, 2004 between the Company and the subscribers named therein.(2)
p.2		Subscription Agreement by and among the Company and the subscribers named therein, dated as of March 2, 2006.(5)
r		Code of Ethics.(2)
s.1		Form of Prospectus Supplement For Common Stock Offerings.(45)
s.2		Form of Prospectus Supplement For Preferred Stock Offerings.(45)
s.3		Form of Prospectus Supplement For Debt Offerings.(45)
s.4		Form of Prospectus Supplement For Rights Offerings.(45)
s.5		Form of Prospectus Supplement For Warrant Offerings.(45)
s.6		Form of Prospectus For At-the-Market Offerings.(45)
99.1*		Statement of Computation of Ratios of Earnings to Fixed Charges.

 

*	Filed herewith.

**	To be Filed by amendment.

(1)	Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on February 22, 2005.

(2)	Previously filed as part of Pre-Effective Amendment No. 1, as filed on May 17, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company.

(3)	Previously filed as part of Post-Effective Amendment No. 1, as filed on June 10, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company.

(4)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on August 5, 2005.

(5)	Previously filed as part of Post-Effective Amendment No. 3, as filed on March 9, 2006 (File No. 333-126604) to the Registration Statement on Form N-2 of the Company.

(6)	Previously filed as part of the Pre-Effective Amendment No. 1, as filed on October 17, 2006 (File No. 333-136918) to the Registration Statement on Form N-2 of the Company.

(7)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed August 3, 2006.

(8)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on December 6, 2006.

(9)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on August 1, 2006.

(10)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed March 9, 2007.

(11)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed April 3, 2007.

(12)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed May 4, 2007.

(13)	Previously filed as part of the Pre-Effective Amendment No. 1, as filed May 15, 2007 (File No. 333-141828), to the Registration Statement on Form N-2 of the Company.

(14)	Previously filed as part of the Securities to be Offered to Employees in Employee Benefit Plans on Form S-8, as filed October, 2, 2007.

(15)	Previously filed as part of the Pre-Effective Amendment No. 2, as filed June 5, 2008 (File No. 333-150403), to the Registration Statement on Form N-2 of the Company.

(16)	Previously filed as part of the Annual Report on Form 10-K of the Company, as filed on March 16, 2009.

(17)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on August 27, 2008.

(18)	Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on May 11, 2009.

(19)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 17, 2010.

(20)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on November 4, 2011.

(21)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2011.

(22)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 18, 2011.

(23)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on June 24, 2011.

(24)	Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on February 8, 2012 (File No. 333-179431).

 

C-6

---

Table of Contents

Index to Financial Statements

(25)	Previously filed as part of Post-Effective Amendment No. 1, as filed on April 17, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(26)	Previously filed as part of Post-Effective Amendment No. 2, as filed on July 6, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(27)	Previously filed as part of Post-Effective Amendment No. 3, as filed on July 12, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(28)	Previously filed as part of Post-Effective Amendment No. 5, as filed on September 24, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(29)	Previously filed as part of Post-Effective Amendment No. 7, as filed on October 2, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(30)	Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on May 8, 2012.

(31)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on August 2, 2012.

(32)	Previously filed as part of Post-Effective Amendment No. 4, as filed on September 19, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(33)	Previously filed as part of Post-Effective Amendment No. 8, as filed on October 17, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.

(34)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on December 20, 2012.

(35)	Previously filed as part of the Securities to be Offered to Employees in Employee Benefit Plans on Form S-8, as filed on August 28, 2015.

(36)	Previously filed as part of Post-Effective Amendment No. 1, as filed on August 16, 2013 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.

(37)	Previously filed as part of the Annual Report on Form 10-K of the Company, as filed on February 27, 2014.

(38)	Previously filed as part of Post-Effective Amendment No. 4, as filed on July 11, 2014 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.

(39)	Previously filed as part of Post-Effective Amendment No. 5, as filed on July 14, 2014 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.

(40)	Previously filed as part of Post-Effective Amendment No. 6, as filed on August 11, 2014 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.

(41)	Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on November 6, 2014.

(42)	Previously filed as part of Post-Effective Amendment No. 8, as filed on March 25, 2015 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.

(43)	Previously filed as part of the Registration Statement on Form N-2, as filed on April 20, 2015 (File No. 333-203511).

(44)	Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on May 7, 2015.

(45)	Previously filed as part of Pre-Effective Amendment No. 1 to the Registration Statement on Form N-2, as filed on June 8, 2015 (File No 333-203511).

(46)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on November 13, 2015.

(47)	Previously filed as part of the current report on Form 8-K of the Company, as filed on June 30, 2015.

(48)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on December 18, 2015.

(49)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 25, 2016.

(50)	Previously filed as part of the Annual Report on Form 10-K of the Company, as filed on February 25, 2016.

(51)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 8, 2016.

(52)	Previously filed as part of Post-Effective Amendment No. 2 to the Registration Statement on Form N-2, as filed on March 22, 2016 (File No 333-203511).

(53)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2016.

(54)	Previously filed as part of Post-Effective Amendment No. 3 to the Registration Statement on Form N-2, as filed on May 2, 2016 (File No 333-203511).

(55)	Previously filed as part of the Current Report on Form 8-K of the Company, as filed on May 10, 2016.

(56)	Previously filed as part of Post-Effective Amendment No. 1 to the Registration Statement on Form N-2, as filed on March 7, 2016 (File No. 333-203511).

Item 26. Marketing Arrangements

The information contained under the heading “Plan of Distribution” of the prospectus is incorporated herein by reference, and any information concerning any underwriters will be contained in any prospectus supplement if any, accompanying this prospectus.

 

C-7

---

Table of Contents

Index to Financial Statements

Item 27. Other Expenses of Issuance and Distribution

The following table sets forth the estimated expenses payable by us in connection with the offering (excluding placement fees):

 

		Amount
SEC registration fee		$	58,100	*
FINRA filing fee			47,510
NYSE listing fee			136,190
Accounting fees and expenses			108,000
Legal fees and expenses			310,000
Printing expenses			65,000
Miscellaneous			5,200
Total		$	730,000

 

Note: Except the SEC registration fee and the FINRA filing fee, all listed amounts are estimates.

 

*	This amount has been offset against filing fees associated with unsold securities registered under a previous registration statement.

Item 28. Persons Controlled by or Under Common Control

Hercules Technology SBIC Management, LLC is a wholly owned subsidiary of the Company. Hercules Technology SBIC Management, LLC is the general partner of Hercules Technology II, L.P., Hercules Technology III, LP and Hercules Technology IV, LP. The Company owns substantially all of the limited partnership interests in Hercules Technology II, L.P. Hercules Technology III, L.P., Hercules Technology IV, L.P. Hercules Funding II LLC, Hercules Funding III LLC, Achilles Technology Management Co., Inc, Hercules Technology Management Co. II, Inc., Hercules Technology Management Co. III, Inc., Hercules Technology Management Co. V, Inc., Hercules Technology I, LLC, Hercules Technology II, LLC, Hydra Ventures LLC, Hercules Capital Funding Trust 2014-1 and Hercules Capital Funding 2014-1 LLC are wholly owned subsidiaries of the Company. Accordingly, the Company may be deemed to control, directly or indirectly, the following entities:

 

Name		Jurisdiction of Organization
Hercules Technology II, L.P.		Delaware
Hercules Technology III, L.P.		Delaware
Hercules Technology IV, L.P.		Delaware
Hercules Technology SBIC Management, LLC		Delaware
Hercules Funding II, LLC		Delaware
Hercules Funding III, LLC		Delaware
Achilles Technology Management Co, Inc.		Delaware
Hercules Technology Management Co II, Inc.		Delaware
Hercules Technology Management Co III, Inc.		Delaware
Hercules Technology Management Co V, Inc.		Delaware
Hercules Technology I, LLC		Delaware
Hercules Technology II LLC		Delaware
Hydra Ventures LLC		Delaware
Hercules Capital Funding Trust 2014-1		Delaware
Hercules Capital Funding 2014-1 LLC		Delaware

All of the entities are included in the Company’s consolidated financial statements as of March 31, 2016.

 

C-8

---

Table of Contents

Index to Financial Statements

Item 29. Number of Holder of Securities

The following table sets forth the approximate number of shareholders of the Company’s common stock as of May 26, 2016:

 

Title of Class		Number of Record Holders
Common stock, par value $.001 per share			44,200

Item 30. Indemnification

Maryland law permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (a) actual receipt of an improper benefit or profit in money, property or services or (b) active and deliberate dishonesty established by a final judgment as being material to the cause of action. The Registrant’s charter contains such a provision which eliminates directors’ and officers’ liability to the maximum extent permitted by Maryland law, subject to the requirements of the 1940 Act.

The Registrant’s charter authorizes the Registrant, to the maximum extent permitted by Maryland law and subject to the requirements of the 1940 Act, to obligate itself to indemnify any present or former director or officer or any individual who, while a director or officer of the Registrant and at its request, serves or has served another corporation, real estate investment trust, partnership, joint venture, trust, employee benefit plan or other enterprise as a director, officer, partner or trustee, from and against any claim or liability to which that person may become subject or which that person may incur by reason of his or her service in any such capacity and, under certain circumstances and provided certain conditions have been met, to pay or reimburse their reasonable expenses in advance of final disposition of a proceeding. The Registrant’s bylaws obligate the Registrant, to the maximum extent permitted by Maryland law and subject to the requirements of the 1940 Act, to indemnify any present or former director or officer or any individual who, while a director or officer of the Registrant and at its request, serves or has served another corporation, real estate investment trust, partnership, joint venture, trust, employee benefit plan or other enterprise as a director, officer, partner or trustee and who is made, or threatened to be made, a party to the proceeding by reason of his or her service in any such capacity from and against any claim or liability to which that person may become subject or which that person may incur by reason of his or her service in any such capacity and, under certain circumstances and provided certain conditions have been met, to pay or reimburse their reasonable expenses in advance of final disposition of a proceeding. The charter and bylaws also permit the Registrant to indemnify and, under certain circumstances and provided certain conditions have been met, advance expenses to any person who served a predecessor of the Registrant in any of the capacities described above and any of the Registrant’s employees or agents or any employees or agents of its predecessor. In accordance with the 1940 Act, the Registrant will not indemnify any person for any liability to which such person would be subject by reason of such person’s willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his office. Additionally, the Registrant will not indemnify any person with respect to any matter as to which such person shall have been finally adjudicated in any proceeding not to have acted in good faith in the reasonable belief that their action was in the best interests of the Registrant.

Maryland law requires a corporation (unless its charter provides otherwise, which the Registrant’s charter does not) to indemnify a director or officer who has been successful, on the merits or otherwise, in the defense of any proceeding to which he or she is made, or threatened to be made, a party by reason of his or her service in that capacity. Maryland law permits a corporation to indemnify its present and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they may be made, or threatened to be made, a party by reason of their service in those or other capacities unless it is established that (a) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (1) was committed in bad faith or (2) was the result of active and deliberate dishonesty, (b) the director or officer actually received an improper personal

 

C-9

---

Table of Contents

Index to Financial Statements

benefit in money, property or services or (c) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. However, under Maryland law, a Maryland corporation may not indemnify for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal benefit was improperly received, unless in either case a court orders indemnification, and then only for expenses. In addition, Maryland law permits a corporation to advance reasonable expenses to a director or officer upon the corporation’s receipt of (a) a written affirmation by the director or officer of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification by the corporation and (b) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately determined that the standard of conduct was not met.

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the Company pursuant to the provisions described above, or otherwise, the Company has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person in the successful defense of an action, suit or proceeding) is asserted by a director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The Company carries liability insurance for the benefit of its directors and officers (other than with respect to claims resulting from the willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his or her office) on a claims-made basis of up to $3,000,000, subject to a $250,000 retention and the other terms thereof.

The Company has agreed to indemnify the underwriters against specified liabilities for actions taken in their capacities as such, including liabilities under the Securities Act of 1933, as amended.

Item 31. Business and Other Connections of Investment Advisor

Not applicable.

Item 32. Location of Accounts and Records

The Company maintains at its principal office, 400 Hamilton Avenue Suite 310 Palo Alto, CA 94301, physical possession of each account, book or other document required to be maintained by Section 31(a) of the 1940 Act and the rules thereunder.

Item 33. Management Services

Not applicable.

Item 34. Undertakings

The Registrant undertakes:

 

1.

to suspend the offering of shares until the prospectus is amended if (a) subsequent to the effective date of its registration statement, the NAV declines more than ten percent from its NAV as of the effective date of the registration statement or (b) the NAV increases to an amount greater than the net proceeds (if applicable) as stated in the prospectus.

 

2.

Not applicable.

 

C-10

---

Table of Contents

Index to Financial Statements

3.

Not applicable.

 

4.

 

a.

to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

i.

to include any prospectus required by Section 10(a)(3) of the Securities Act;

 

ii.

to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

 

iii.

to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

 

b.

that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial bona fide offering thereof;

 

c.

to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering;

 

d.

that, for the purpose of determining liability under the Securities Act to any purchaser, if the Registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 497(b), (c), (d) or (e) under the Securities Act as part of a registration statement relating to an offering, other than prospectus filed in reliance on Rule 430A under the Securities Act, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness, provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supercede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use;

 

e.

that for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to the purchaser:

 

i.

any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 497 under the Securities Act;

 

ii.

the portion of any advertisement pursuant to Rule 482 under the Securities Act relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and

 

iii.

any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

 

f.

to file a post-effective amendment to the registration statement, and to suspend any offers or sales pursuant the registration statement until such post-effective amendment has been declared

 

C-11

---

Table of Contents

Index to Financial Statements

effective under the Securities Act, in the event the shares of the Registrant are trading below its NAV per share and either (a) the Registrant receives, or has been advised by its independent registered accounting firm that it will receive, an audit report reflecting substantial doubt regarding the Registrant’s ability to continue as a going concern or (b) the Registrant has concluded that a fundamental change has occurred in its financial position or results of operations; and

 

5.

Not applicable.

 

6.

Not applicable.

 

C-12

---

Table of Contents

Index to Financial Statements

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 5 to the Registration Statement on Form N-2 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, and State of California, on the 3^rd day of June, 2016.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/S/    MANUEL A. HENRIQUEZ         Manuel A. Henriquez		Chairman of the Board, President and Chief Executive Officer (principal executive officer)		June 3, 2016
/S/    MARK HARRIS         Mark Harris		Chief Financial Officer (principal financial and accounting officer)		June 3, 2016
/S/    ALLYN C. WOODWARD, JR.         Allyn C. Woodward, Jr.		Director		June 3, 2016
/S/    ROBERT P. BADAVAS         Robert P. Badavas		Director		June 3, 2016
/S/    THOMAS J. FALLON         Thomas J. Fallon		Director		June 3, 2016
/S/    SUSANNE D. LYONS         Susanne D. Lyons		Director		June 3, 2016
/S/    JOSEPH F. HOFFMAN Joseph F. Hoffman		Director		June 3, 2016
/S/    RODNEY A. FERGUSON         Rodney A. Ferguson		Director		June 3, 2016

---

Table of Contents

Index to Financial Statements

EXHIBIT INDEX

 

Exhibit Number		Description
l.1*		Opinion of Dechert LLP.
n.1*		Consent of PricewaterhouseCoopers LLP.
99.1*		Statement of Computation of Ratios to Earnings of Fixed Charges.

 

*	Filed herewith.